{
  "category": "Anatomic Pathology",
  "subject": {
    "name": "Molecular",
    "url": "https://app.pathprimer.com/curriculum/25f506d5-2976-43d8-9ea7-1e5035a5d53d",
    "lessons": {
      "Cytogenetics/FISH": {
        "name": "Cytogenetics/FISH",
        "url": "https://app.pathprimer.com/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
        "topics": {
          "Cytogenetics and FISH": {
            "name": "Cytogenetics and FISH",
            "url": "https://app.pathprimer.com/document/b10bcf0e-42e3-4b0c-9963-bd965f43c3cb/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "Cytogenetics": {
                "History": [
                  {
                    "text": "Historic early explorations1882: German cytologist Walther Flemming published book describing whole process of mitosis; introduced Aniline staining to observe chromosomes during cell division1888: German anatomist Wilhelm von Waldeyer-Hartz introduced term chromosome1902-1903: Walter Sutton and Theodor Boveri proposed chromosomal theory of inheritance1924: Grigory Andreevich Levitsky coined term karyotype1959: American pathologist Peter Nowell and research fellow David Hungerford detected tiny chromosome from 2 patients with chronic myeloid leukemia (CML) known as Philadelphia chromosome1st chromosomal abnormality linked to human neoplasm",
                    "sub_points": [
                      "1882: German cytologist Walther Flemming published book describing whole process of mitosis; introduced Aniline staining to observe chromosomes during cell division",
                      "1888: German anatomist Wilhelm von Waldeyer-Hartz introduced term chromosome",
                      "1902-1903: Walter Sutton and Theodor Boveri proposed chromosomal theory of inheritance",
                      "1924: Grigory Andreevich Levitsky coined term karyotype",
                      "1959: American pathologist Peter Nowell and research fellow David Hungerford detected tiny chromosome from 2 patients with chronic myeloid leukemia (CML) known as Philadelphia chromosome1st chromosomal abnormality linked to human neoplasm",
                      "1st chromosomal abnormality linked to human neoplasm"
                    ]
                  },
                  {
                    "text": "Technical advances1952: T.C. Hsu discovers that hypotonic solution allows for better separation of chromosomesSerendipitous laboratory error had substituted hypotonic for isotonic solution1956: Joe Hin Tjio and Albert Levan introduces perfect method for arresting cells in metaphase by using colchicinePermits correct identification of human chromosome number as 461960: Peter Nowell discovers that phytohemagglutinin stimulates lymphocytes to divide in cultureAllows karyotypes to be produced from normal peripheral blood specimens1968: Torbjorn Caspersson produced 1st chromosome banding pattern using quinacrine mustard (Q banding)Allows chromosomes and chromosomal regions to be easily identified1971: Margery Wayne Shaw pioneers Giemsa bandingSimpler preparation than fluorescent Q banding; opened era of widespread chromosome analysis1972: Janet Rowley discovered that Ph chromosome in CML resulted from translocation between long arms of chromosome 9 and 22This finding established cancer as genetic disease1990s: Optical mapping of genome was originally developed by David Schwartz and his lab at NYUMethod has since been integral to assembly process of many large-scale sequencing projectsOptical genome mapping (OGM) addresses limitations of existing cytogenetic techniquesOffers higher resolution than karyotyping in detecting large-scale structural variants",
                    "sub_points": [
                      "1952: T.C. Hsu discovers that hypotonic solution allows for better separation of chromosomesSerendipitous laboratory error had substituted hypotonic for isotonic solution",
                      "Serendipitous laboratory error had substituted hypotonic for isotonic solution",
                      "1956: Joe Hin Tjio and Albert Levan introduces perfect method for arresting cells in metaphase by using colchicinePermits correct identification of human chromosome number as 46",
                      "Permits correct identification of human chromosome number as 46",
                      "1960: Peter Nowell discovers that phytohemagglutinin stimulates lymphocytes to divide in cultureAllows karyotypes to be produced from normal peripheral blood specimens",
                      "Allows karyotypes to be produced from normal peripheral blood specimens",
                      "1968: Torbjorn Caspersson produced 1st chromosome banding pattern using quinacrine mustard (Q banding)Allows chromosomes and chromosomal regions to be easily identified",
                      "Allows chromosomes and chromosomal regions to be easily identified",
                      "1971: Margery Wayne Shaw pioneers Giemsa bandingSimpler preparation than fluorescent Q banding; opened era of widespread chromosome analysis",
                      "Simpler preparation than fluorescent Q banding; opened era of widespread chromosome analysis",
                      "1972: Janet Rowley discovered that Ph chromosome in CML resulted from translocation between long arms of chromosome 9 and 22This finding established cancer as genetic disease",
                      "This finding established cancer as genetic disease",
                      "1990s: Optical mapping of genome was originally developed by David Schwartz and his lab at NYUMethod has since been integral to assembly process of many large-scale sequencing projectsOptical genome mapping (OGM) addresses limitations of existing cytogenetic techniquesOffers higher resolution than karyotyping in detecting large-scale structural variants",
                      "Method has since been integral to assembly process of many large-scale sequencing projects",
                      "Optical genome mapping (OGM) addresses limitations of existing cytogenetic techniquesOffers higher resolution than karyotyping in detecting large-scale structural variants",
                      "Offers higher resolution than karyotyping in detecting large-scale structural variants"
                    ]
                  }
                ],
                "Sample Requirements": [
                  {
                    "text": "Living cells are absolutely required for chromosome analysisCells must be made to divide in culture for successful karyotyping",
                    "sub_points": [
                      "Cells must be made to divide in culture for successful karyotyping"
                    ]
                  }
                ],
                "Technical Procedure": [
                  {
                    "text": "Living cells are allowed to divide in cultureSpecific mitogens may be required, depending on specimen type and information desired from studyStem cells, blasts, and many malignant cells have capacity to divide autonomouslyTerminally differentiated cells (B cells, T cells, and plasma cells) may need stimulation from additional chemicals &/or interleukins in order to divide",
                    "sub_points": [
                      "Specific mitogens may be required, depending on specimen type and information desired from studyStem cells, blasts, and many malignant cells have capacity to divide autonomouslyTerminally differentiated cells (B cells, T cells, and plasma cells) may need stimulation from additional chemicals &/or interleukins in order to divide",
                      "Stem cells, blasts, and many malignant cells have capacity to divide autonomously",
                      "Terminally differentiated cells (B cells, T cells, and plasma cells) may need stimulation from additional chemicals &/or interleukins in order to divide"
                    ]
                  },
                  {
                    "text": "Colchicine is added to cultureInhibits formation of mitotic spindleDividing cells can no longer progress past metaphaseChromosomes remain in bundled and visible format during this state of \"metaphase arrest\"",
                    "sub_points": [
                      "Inhibits formation of mitotic spindle",
                      "Dividing cells can no longer progress past metaphase",
                      "Chromosomes remain in bundled and visible format during this state of \"metaphase arrest\""
                    ]
                  },
                  {
                    "text": "Hypotonic solution is added to cultureCauses water to enter cell and nucleus, which enhances spreading of chromosomes",
                    "sub_points": [
                      "Causes water to enter cell and nucleus, which enhances spreading of chromosomes"
                    ]
                  },
                  {
                    "text": "Cells are fixed in swollen stateUsing modified Carnoy solution (3:1 methanol:glacial acetic acid)",
                    "sub_points": [
                      "Using modified Carnoy solution (3:1 methanol:glacial acetic acid)"
                    ]
                  },
                  {
                    "text": "Cells are dropped onto glass slides and stainedIn situ cultures may also be prepared in similar fashion",
                    "sub_points": [
                      "In situ cultures may also be prepared in similar fashion"
                    ]
                  },
                  {
                    "text": "Band resolutionNumber of bands visible depends on sample type and preparationMore visible bands yield higher resolution study with greater sensitivityAt 450 band resolution (i.e., 450 bands visible in complete karyotype), each band contains ~ 6 Mb of DNAAt 850 band resolution, each band would contain ~ 3 Mb of DNAG-banding visual resolution on karyotype is ~ 5-10 Mb in routine practiceAbnormalities smaller than this limit will not be detected",
                    "sub_points": [
                      "Number of bands visible depends on sample type and preparationMore visible bands yield higher resolution study with greater sensitivityAt 450 band resolution (i.e., 450 bands visible in complete karyotype), each band contains ~ 6 Mb of DNAAt 850 band resolution, each band would contain ~ 3 Mb of DNA",
                      "More visible bands yield higher resolution study with greater sensitivity",
                      "At 450 band resolution (i.e., 450 bands visible in complete karyotype), each band contains ~ 6 Mb of DNA",
                      "At 850 band resolution, each band would contain ~ 3 Mb of DNA",
                      "G-banding visual resolution on karyotype is ~ 5-10 Mb in routine practiceAbnormalities smaller than this limit will not be detected",
                      "Abnormalities smaller than this limit will not be detected"
                    ]
                  },
                  {
                    "text": "Metaphases are analyzed under light microscope20 metaphases are analyzed in typical case",
                    "sub_points": [
                      "20 metaphases are analyzed in typical case"
                    ]
                  }
                ],
                "Analysis and Nomenclature": [
                  {
                    "text": "Follows International System for Human Cytogenetic Nomenclature (ISCN) guidelines"
                  },
                  {
                    "text": "Chromosomal armsCentromere divides each chromosome in short (p) and long (q) arms",
                    "sub_points": [
                      "Centromere divides each chromosome in short (p) and long (q) arms"
                    ]
                  },
                  {
                    "text": "Chromosomal regionsDivided into regions, bands, and subbandse.g., 9q34 refers to chromosome 9, long arm, region 3, band 4Said aloud as 9 q three four, not 9 q thirty-fourIf bands are further divided into subbands, decimal point is used (e.g., 1p31.1)",
                    "sub_points": [
                      "Divided into regions, bands, and subbands",
                      "e.g., 9q34 refers to chromosome 9, long arm, region 3, band 4Said aloud as 9 q three four, not 9 q thirty-fourIf bands are further divided into subbands, decimal point is used (e.g., 1p31.1)",
                      "Said aloud as 9 q three four, not 9 q thirty-four",
                      "If bands are further divided into subbands, decimal point is used (e.g., 1p31.1)"
                    ]
                  },
                  {
                    "text": "Karyotype descriptionsNumber of chromosomes present is listed 1st, followed by commaNext, sex chromosomes present are listed, followed by commaFinally, any structural &/or numerical abnormalities are listedIf ≥ 2 cell lines are present, they are listed individually, separated by \"/\", and number of counted cells in each cell line is listed in bracketsTerm idem can be used to indicate abnormalities that 2nd cell line shares with 1st",
                    "sub_points": [
                      "Number of chromosomes present is listed 1st, followed by comma",
                      "Next, sex chromosomes present are listed, followed by comma",
                      "Finally, any structural &/or numerical abnormalities are listed",
                      "If ≥ 2 cell lines are present, they are listed individually, separated by \"/\", and number of counted cells in each cell line is listed in bracketsTerm idem can be used to indicate abnormalities that 2nd cell line shares with 1st",
                      "Term idem can be used to indicate abnormalities that 2nd cell line shares with 1st"
                    ]
                  },
                  {
                    "text": "Specific terms for structural abnormalitiesDeletion (del)Part of chromosome is lostInsertion (ins)Part of 1 chromosome is inserted into different areaInversion (inv)Inverted in orientation relative to reference sequenceParacentric inversion affects only 1 chromosomal armPericentric inversion involves both p and q arms and thus includes centromere in inverted segmentTranslocation (t)Exchange of chromosomal regions between 2 different chromosomesDerivative chromosome (der)Structurally rearranged chromosomeMarker chromosome (mar)Abnormal chromosome that cannot be identifiedRing chromosome (r)Circular configuration with chromosome ends fused",
                    "sub_points": [
                      "Deletion (del)Part of chromosome is lost",
                      "Part of chromosome is lost",
                      "Insertion (ins)Part of 1 chromosome is inserted into different area",
                      "Part of 1 chromosome is inserted into different area",
                      "Inversion (inv)Inverted in orientation relative to reference sequenceParacentric inversion affects only 1 chromosomal armPericentric inversion involves both p and q arms and thus includes centromere in inverted segment",
                      "Inverted in orientation relative to reference sequence",
                      "Paracentric inversion affects only 1 chromosomal arm",
                      "Pericentric inversion involves both p and q arms and thus includes centromere in inverted segment",
                      "Translocation (t)Exchange of chromosomal regions between 2 different chromosomes",
                      "Exchange of chromosomal regions between 2 different chromosomes",
                      "Derivative chromosome (der)Structurally rearranged chromosome",
                      "Structurally rearranged chromosome",
                      "Marker chromosome (mar)Abnormal chromosome that cannot be identified",
                      "Abnormal chromosome that cannot be identified",
                      "Ring chromosome (r)Circular configuration with chromosome ends fused",
                      "Circular configuration with chromosome ends fused"
                    ]
                  },
                  {
                    "text": "Criteria for clonalityNot every abnormality seen in analysis is considered clonalRandom genetic errors may occur during cell cultureChromosomes may spread too far during preparation, leading to artifactual \"loss\" of chromosomesClone is defined as2 cells that share same abnormality, if abnormality is chromosome gain or structural abnormality3 cells that share same loss of chromosome",
                    "sub_points": [
                      "Not every abnormality seen in analysis is considered clonalRandom genetic errors may occur during cell cultureChromosomes may spread too far during preparation, leading to artifactual \"loss\" of chromosomes",
                      "Random genetic errors may occur during cell culture",
                      "Chromosomes may spread too far during preparation, leading to artifactual \"loss\" of chromosomes",
                      "Clone is defined as2 cells that share same abnormality, if abnormality is chromosome gain or structural abnormality3 cells that share same loss of chromosome",
                      "2 cells that share same abnormality, if abnormality is chromosome gain or structural abnormality",
                      "3 cells that share same loss of chromosome"
                    ]
                  }
                ],
                "Key Types of Clinical Findings": [
                  {
                    "text": "AneuploidyGains or losses of whole chromosomese.g., Down syndrome, trisomy 21",
                    "sub_points": [
                      "Gains or losses of whole chromosomes",
                      "e.g., Down syndrome, trisomy 21"
                    ]
                  },
                  {
                    "text": "Translocationse.g., t(9;22)(q34.1;q11.2)Exchange of chromosomal material between chromosomes 9 and 22 with breakpoints at designated bands on long arms of eachResults inBCR::ABL1fusion seen in CML and subset of B-lymphoblastic leukemia/lymphoma",
                    "sub_points": [
                      "e.g., t(9;22)(q34.1;q11.2)Exchange of chromosomal material between chromosomes 9 and 22 with breakpoints at designated bands on long arms of eachResults inBCR::ABL1fusion seen in CML and subset of B-lymphoblastic leukemia/lymphoma",
                      "Exchange of chromosomal material between chromosomes 9 and 22 with breakpoints at designated bands on long arms of each",
                      "Results inBCR::ABL1fusion seen in CML and subset of B-lymphoblastic leukemia/lymphoma"
                    ]
                  }
                ],
                "Clinical Utility of Cancer Cytogenetics": [
                  {
                    "text": "For diagnosisEstablish neoplastic diagnosis due to presence of clonee.g., monosomy 7 may permit confident diagnosis of myelodysplastic syndromeEstablish specific subtype of neoplasm due to cytogenetic abnormality characteristic of that neoplasme.g., t(8;21)(q21.3;q22.1) permits diagnosis of specific subtype of acute myeloid leukemia",
                    "sub_points": [
                      "Establish neoplastic diagnosis due to presence of clonee.g., monosomy 7 may permit confident diagnosis of myelodysplastic syndrome",
                      "e.g., monosomy 7 may permit confident diagnosis of myelodysplastic syndrome",
                      "Establish specific subtype of neoplasm due to cytogenetic abnormality characteristic of that neoplasme.g., t(8;21)(q21.3;q22.1) permits diagnosis of specific subtype of acute myeloid leukemia",
                      "e.g., t(8;21)(q21.3;q22.1) permits diagnosis of specific subtype of acute myeloid leukemia"
                    ]
                  },
                  {
                    "text": "For prognosisDetermine likely behavior of neoplasm based on cytogenetic abnormalitiese.g., presence of 17p deletion in chronic lymphocytic leukemia is associated with aggressive disease course",
                    "sub_points": [
                      "Determine likely behavior of neoplasm based on cytogenetic abnormalitiese.g., presence of 17p deletion in chronic lymphocytic leukemia is associated with aggressive disease course",
                      "e.g., presence of 17p deletion in chronic lymphocytic leukemia is associated with aggressive disease course"
                    ]
                  },
                  {
                    "text": "Identifying residual diseaseTrack presence of neoplasm over time based on presence of previously established clonal abnormalities",
                    "sub_points": [
                      "Track presence of neoplasm over time based on presence of previously established clonal abnormalities"
                    ]
                  },
                  {
                    "text": "Identifying clonal evolutionDetect acquisition of additional cytogenetic abnormalities over time in neoplasm, which may be linked to more aggressive behavior",
                    "sub_points": [
                      "Detect acquisition of additional cytogenetic abnormalities over time in neoplasm, which may be linked to more aggressive behavior"
                    ]
                  }
                ]
              },
              "Fluorescence In Situ Hybridization": {
                "History": [
                  {
                    "text": "Radiolabeled probes were cumbersome and dangerous"
                  },
                  {
                    "text": "In 1980, fluorescently labeled probe was 1st usedLimited by dim fluorescent signal of early probes",
                    "sub_points": [
                      "Limited by dim fluorescent signal of early probes"
                    ]
                  },
                  {
                    "text": "By early 1990s, improved probe labeling technology allowed routine detection of target nucleic acids"
                  }
                ],
                "Sample Requirements for FISH": [
                  {
                    "text": "In contrast to chromosome analysis, FISH can be performed on nondividing (interphase) cells, includingFixed cells, paraffin-embedded tissue sections, air-dried smears, touch preparations, or cytospin preparations",
                    "sub_points": [
                      "Fixed cells, paraffin-embedded tissue sections, air-dried smears, touch preparations, or cytospin preparations"
                    ]
                  },
                  {
                    "text": "May also be performed on metaphase cells"
                  }
                ],
                "Technical Procedure": [
                  {
                    "text": "PretreatmentIncludes dehydration of slide with graded ethanol series",
                    "sub_points": [
                      "Includes dehydration of slide with graded ethanol series"
                    ]
                  },
                  {
                    "text": "Codenaturation and hybridizationFluorescently labeled probe specific to DNA target sequence is appliedSlide is heated to denature double-stranded DNASlide is incubated for 14-20 hours at temperature permitting hybridization of probe to target DNA",
                    "sub_points": [
                      "Fluorescently labeled probe specific to DNA target sequence is applied",
                      "Slide is heated to denature double-stranded DNA",
                      "Slide is incubated for 14-20 hours at temperature permitting hybridization of probe to target DNA"
                    ]
                  },
                  {
                    "text": "Final slide preparationExcess probe is washed awayMounting medium with DAPI counterstain is appliedDAPI stains DNA at fluorescent wavelength different from that of probePermits visualization of nuclei under fluorescent microscope",
                    "sub_points": [
                      "Excess probe is washed away",
                      "Mounting medium with DAPI counterstain is appliedDAPI stains DNA at fluorescent wavelength different from that of probePermits visualization of nuclei under fluorescent microscope",
                      "DAPI stains DNA at fluorescent wavelength different from that of probe",
                      "Permits visualization of nuclei under fluorescent microscope"
                    ]
                  }
                ],
                "Key Probe Strategies": [
                  {
                    "text": "Numerical chromosome enumeration probesHybridize near centromeric region of chromosomeDetects presence or absence of specific chromosome",
                    "sub_points": [
                      "Hybridize near centromeric region of chromosome",
                      "Detects presence or absence of specific chromosome"
                    ]
                  },
                  {
                    "text": "Dual-color, dual-fusion probesUsed to detect specific translocations2 genes involved in translocations are labeled in different colors (typically red and green)Translocation will result in 2 fused signalsFused signal often appear yellowPresence of 2 fusion signals in cell is highly specific for translocation in question",
                    "sub_points": [
                      "Used to detect specific translocations2 genes involved in translocations are labeled in different colors (typically red and green)Translocation will result in 2 fused signalsFused signal often appear yellowPresence of 2 fusion signals in cell is highly specific for translocation in question",
                      "2 genes involved in translocations are labeled in different colors (typically red and green)",
                      "Translocation will result in 2 fused signalsFused signal often appear yellow",
                      "Fused signal often appear yellow",
                      "Presence of 2 fusion signals in cell is highly specific for translocation in question"
                    ]
                  },
                  {
                    "text": "Break-apart probesUsed if only 1 gene involved in translocation is knownRed and green probes are labeled on either end of geneIf there is translocation, red and green signals will become separatedPartner gene cannot be identified by this approach",
                    "sub_points": [
                      "Used if only 1 gene involved in translocation is known",
                      "Red and green probes are labeled on either end of geneIf there is translocation, red and green signals will become separatedPartner gene cannot be identified by this approach",
                      "If there is translocation, red and green signals will become separated",
                      "Partner gene cannot be identified by this approach"
                    ]
                  }
                ],
                "Nomenclature": [
                  {
                    "text": "Follows International System for Human Cytogenetic Nomenclature (ISCN) guidelines"
                  },
                  {
                    "text": "Interphase FISH is indicated by \"nuc ish\"Followed by locus designation for probe, \"x,\" and number of signals seenIf signals have become juxtaposed (as with dual-fusion probe), this is indicated with \"con\" followed by, in brackets, number of cells in which abnormality was seene.g., FISH in typical new diagnosis of CML could be written as \"nuc ish(ABL1x3),(BCRx3),(ABL1 con BCRx2)[162/200]\"",
                    "sub_points": [
                      "Followed by locus designation for probe, \"x,\" and number of signals seen",
                      "If signals have become juxtaposed (as with dual-fusion probe), this is indicated with \"con\" followed by, in brackets, number of cells in which abnormality was seen",
                      "e.g., FISH in typical new diagnosis of CML could be written as \"nuc ish(ABL1x3),(BCRx3),(ABL1 con BCRx2)[162/200]\""
                    ]
                  },
                  {
                    "text": "Cases are classified as positive or negative based on established laboratory-specific cutoffs"
                  }
                ],
                "Clinical Utility of FISH": [
                  {
                    "text": "For diagnosise.g., rapid diagnosis of APL by detection ofPML::RARAfusion",
                    "sub_points": [
                      "e.g., rapid diagnosis of APL by detection ofPML::RARAfusion"
                    ]
                  },
                  {
                    "text": "For prognosise.g., detection ofTP53deletion in chronic lymphocytic leukemia",
                    "sub_points": [
                      "e.g., detection ofTP53deletion in chronic lymphocytic leukemia"
                    ]
                  },
                  {
                    "text": "Detection of residual diseaseRequires known FISH detectable abnormality",
                    "sub_points": [
                      "Requires known FISH detectable abnormality"
                    ]
                  },
                  {
                    "text": "Noninvasive detection of fetal aneuploidySuccessfully performed on fetal nucleated RBCs isolated from maternal blood",
                    "sub_points": [
                      "Successfully performed on fetal nucleated RBCs isolated from maternal blood"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Diffuse Large B-Cell Lymphoma": {
            "name": "Diffuse Large B-Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/8071b759-b1df-4c59-b705-42d7b28d8d2c/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) (ICC and WHO)Biologically heterogeneous neoplasms composed of large B cells",
                    "sub_points": [
                      "Biologically heterogeneous neoplasms composed of large B cells"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Prognosis affected by extent of disease, molecular genetics, and proliferation rate"
                  },
                  {
                    "text": "DLBCL may result from progression of low-grade B-cell lymphoma or arise de novo"
                  }
                ],
                "Macroscopic": [
                  {
                    "text": "Lymphadenopathy"
                  },
                  {
                    "text": "Mass lesions in extranodal sites"
                  }
                ],
                "Molecular": [
                  {
                    "text": "FISH and conventional cytogeneticsStratifies DLBCL, NOS into prognostic groupsPoor prognostic groups have more complex geneticsTP53mutations may confer worse prognosis",
                    "sub_points": [
                      "Stratifies DLBCL, NOS into prognostic groups",
                      "Poor prognostic groups have more complex genetics",
                      "TP53mutations may confer worse prognosis"
                    ]
                  },
                  {
                    "text": "Molecular subtypes of DLBCL, NOSGerminal center B-cell (GCB) subtypeActivated B-cell (ABC) subtype",
                    "sub_points": [
                      "Germinal center B-cell (GCB) subtype",
                      "Activated B-cell (ABC) subtype"
                    ]
                  },
                  {
                    "text": "No current consensus for mutational subtypes"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Neoplastic lymphocytes with nuclear size ≥ macrophage nucleus or 2x size of mature normal lymphocyte"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunohistochemical features of DLBCL subtypes (Hans scheme most common)GCB subtype: CD10(+), BCL6(+), MUM1(-)Non-GCB (ABC-like) subtype: CD10(-), BCL6(+/-), MUM1(+)GCB has better prognosis that ABC subtype",
                    "sub_points": [
                      "GCB subtype: CD10(+), BCL6(+), MUM1(-)",
                      "Non-GCB (ABC-like) subtype: CD10(-), BCL6(+/-), MUM1(+)GCB has better prognosis that ABC subtype",
                      "GCB has better prognosis that ABC subtype"
                    ]
                  },
                  {
                    "text": "Double-expressor DLBCL (poor prognosis)Expresses MYC (≥ 40% of cells) and BCL2 (≥ 50% of cells)",
                    "sub_points": [
                      "Expresses MYC (≥ 40% of cells) and BCL2 (≥ 50% of cells)"
                    ]
                  },
                  {
                    "text": "CD5 expression may portend worse prognosis"
                  },
                  {
                    "text": "CD30 expression is potential target for therapy"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "DLBCL, NOS: Biologically heterogeneous neoplasm composed of large B cells with nuclear size ≥ macrophage nucleus or 2x size of mature small lymphocyte"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "No known causative infectious agents, but some cases are associated with Epstein-Barr virus (EBV) and hepatitis C"
                  }
                ],
                "Immunodeficiency": [
                  {
                    "text": "Increases incidence of DLBCLCommon immune dysfunctions associated with DLBCL includes HIV infection, iatrogenic immunosuppression, congenital immune dysfunction",
                    "sub_points": [
                      "Common immune dysfunctions associated with DLBCL includes HIV infection, iatrogenic immunosuppression, congenital immune dysfunction"
                    ]
                  }
                ],
                "Classification": [
                  {
                    "text": "International Consensus Classification (ICC) and World Health Organization (WHO) 5th edition diagnoses are similar"
                  },
                  {
                    "text": "Divided into morphologic variants, immunophenotypic, and molecular subgroupsMorphologic variantsCentroblasticImmunoblasticAnaplasticOther rare morphologic variantsCell of origin subtypes by immunophenotypingGerminal center B cell (GCB)-likeNon-GCB [activated B cell (ABC)]-likeCell of origin subtypes by gene expression profilingGCB subtype (50-60%)ABC subtypeOthers (those that do not fit GCB or ABC)",
                    "sub_points": [
                      "Morphologic variantsCentroblasticImmunoblasticAnaplasticOther rare morphologic variants",
                      "Centroblastic",
                      "Immunoblastic",
                      "Anaplastic",
                      "Other rare morphologic variants",
                      "Cell of origin subtypes by immunophenotypingGerminal center B cell (GCB)-likeNon-GCB [activated B cell (ABC)]-like",
                      "Germinal center B cell (GCB)-like",
                      "Non-GCB [activated B cell (ABC)]-like",
                      "Cell of origin subtypes by gene expression profilingGCB subtype (50-60%)ABC subtypeOthers (those that do not fit GCB or ABC)",
                      "GCB subtype (50-60%)",
                      "ABC subtype",
                      "Others (those that do not fit GCB or ABC)"
                    ]
                  },
                  {
                    "text": "Other lymphoma of large B cellsT-cell/histiocyte-rich large B-cell lymphomaPrimary mediastinal (thymic) large B-cell lymphomaIntravascular large B-cell lymphomaDLBCL associated with chronic inflammationLymphomatoid granulomatosisALK(+) large B-cell lymphomaPlasmablastic lymphomaHHV8(+) diffuse large B-cell lymphomaPrimary effusion lymphomaPrimary DLBCL of CNSPrimary cutaneous DLBCL, leg typeEBV(+) diffuse large B-cell lymphoma, NOSLarge B-cell lymphoma withIRF4rearrangement",
                    "sub_points": [
                      "T-cell/histiocyte-rich large B-cell lymphoma",
                      "Primary mediastinal (thymic) large B-cell lymphoma",
                      "Intravascular large B-cell lymphoma",
                      "DLBCL associated with chronic inflammation",
                      "Lymphomatoid granulomatosis",
                      "ALK(+) large B-cell lymphoma",
                      "Plasmablastic lymphoma",
                      "HHV8(+) diffuse large B-cell lymphoma",
                      "Primary effusion lymphoma",
                      "Primary DLBCL of CNS",
                      "Primary cutaneous DLBCL, leg type",
                      "EBV(+) diffuse large B-cell lymphoma, NOS",
                      "Large B-cell lymphoma withIRF4rearrangement"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Older adults primarily affectedMedian: 7th decade, though children and young adults can be affected",
                    "sub_points": [
                      "Median: 7th decade, though children and young adults can be affected"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Enlarging lymph nodes or extranodal mass"
                  },
                  {
                    "text": "Frequent B symptoms"
                  },
                  {
                    "text": "DLBCL may represent transformation from low-grade B-cell lymphoma"
                  }
                ],
                "Treatment": [],
                "Adjuvant therapy": [
                  {
                    "text": "Stem cell transplant in cases with certain genetic findings, such asMYCtranslocations"
                  }
                ],
                "Drugs": [
                  {
                    "text": "R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy is primary treatment"
                  },
                  {
                    "text": "Less cytotoxic targeted therapies are being developed; bortezomib has efficacy in relapsed DLBCL and ABC subtypes"
                  }
                ],
                "Radiation": [
                  {
                    "text": "Radiation may be used in limited-stage disease and specific subtypes"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "International Prognostic Index (IPI) used for prognosticationClinical variables, including disease stage and patient age, are considered in prognostication",
                    "sub_points": [
                      "Clinical variables, including disease stage and patient age, are considered in prognostication"
                    ]
                  },
                  {
                    "text": "Morphologic variants have not shown prognostic differences"
                  },
                  {
                    "text": "Overall 5-year survival ranges from 25-75% depending on prognostic factors"
                  },
                  {
                    "text": "No single aberrant gene is responsible for diverse nature of DLBCL, NOS"
                  },
                  {
                    "text": "Unfavorable prognostic factorsABC by gene expression profilingHigh Ki-67 expression (> 80%)Non-GCB (ABC-like) subtype as determined by immunohistochemistryHigh expression of MYC may portend poor prognosis, but reports varyConcurrent BCL2 and MYC expression (double expressors) may show poor prognosisTP53mutations or loss show worse prognosisCDKN2Amutationsand trisomy 3 are associated with decreased survival in ABC subtypeDecreased CD8(+) tumor-infiltrating T cells or overexpression of PDL1 may confer worse prognosis",
                    "sub_points": [
                      "ABC by gene expression profiling",
                      "High Ki-67 expression (> 80%)",
                      "Non-GCB (ABC-like) subtype as determined by immunohistochemistry",
                      "High expression of MYC may portend poor prognosis, but reports vary",
                      "Concurrent BCL2 and MYC expression (double expressors) may show poor prognosis",
                      "TP53mutations or loss show worse prognosis",
                      "CDKN2Amutationsand trisomy 3 are associated with decreased survival in ABC subtype",
                      "Decreased CD8(+) tumor-infiltrating T cells or overexpression of PDL1 may confer worse prognosis"
                    ]
                  },
                  {
                    "text": "Double-/triple-hit B-cell lymphomas are now classified as separate category of high-grade B-cell lymphoma (HGBCL)HGBCL with rearrangements ofMYCandBCL2(ICC)HGBCL with rearrangement ofMYCandBCL6(ICC)DLBCL/HGBCL withMYCandBCL2rearrangements (WHO-HAEM5)",
                    "sub_points": [
                      "HGBCL with rearrangements ofMYCandBCL2(ICC)",
                      "HGBCL with rearrangement ofMYCandBCL6(ICC)",
                      "DLBCL/HGBCL withMYCandBCL2rearrangements (WHO-HAEM5)"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Enlarged lymph nodes or extranodal mass lesions"
                  }
                ]
              },
              "MOLECULAR": {
                "Cytogenetics": [
                  {
                    "text": "Used for detection of numerical and structural chromosomal abnormalitiesIdentifies common translocation involvingIGH,MYC, andBCL6,among othersBCL6translocations account for most common cytogenetic abnormality in DLBCLOccur most commonly in ABC subtype of DLBCL",
                    "sub_points": [
                      "Identifies common translocation involvingIGH,MYC, andBCL6,among others",
                      "BCL6translocations account for most common cytogenetic abnormality in DLBCLOccur most commonly in ABC subtype of DLBCL",
                      "Occur most commonly in ABC subtype of DLBCL"
                    ]
                  }
                ],
                "Fluorescence In Situ Hybridization": [
                  {
                    "text": "Routinely performed to detect translocations in DLBCLCommonly used probes includeMYC,BCL2, andBCL6IsolatedMYCrearrangement in 5-15% of DLBCLMolecular studies for mutations common to DLBCL help exclude Burkitt lymphoma (BL)FISH break-apart probe strategy is commonly usedFISH targeted probes are used if identification of partner fused gene indicated",
                    "sub_points": [
                      "Commonly used probes includeMYC,BCL2, andBCL6IsolatedMYCrearrangement in 5-15% of DLBCLMolecular studies for mutations common to DLBCL help exclude Burkitt lymphoma (BL)",
                      "IsolatedMYCrearrangement in 5-15% of DLBCL",
                      "Molecular studies for mutations common to DLBCL help exclude Burkitt lymphoma (BL)",
                      "FISH break-apart probe strategy is commonly used",
                      "FISH targeted probes are used if identification of partner fused gene indicated"
                    ]
                  },
                  {
                    "text": "FISH panel that includeMYC,BCL2, andBCL6probes helps to separate DLBCL, NOS from so-called double-/triple-hit lymphomasDouble-/triple-hit lymphomas are now classified as high-grade B-cell lymphoma with rearrangements ofMYCandBCL2(ICC)Poor prognosis with resistance to therapyDLCBL withMYCandBCL6rearrangements appear to show clinical behavior between DLBCL and HGBCL but are classified as HGBCL withMYCandBCL6rearrangements (ICC)",
                    "sub_points": [
                      "Double-/triple-hit lymphomas are now classified as high-grade B-cell lymphoma with rearrangements ofMYCandBCL2(ICC)Poor prognosis with resistance to therapy",
                      "Poor prognosis with resistance to therapy",
                      "DLCBL withMYCandBCL6rearrangements appear to show clinical behavior between DLBCL and HGBCL but are classified as HGBCL withMYCandBCL6rearrangements (ICC)"
                    ]
                  },
                  {
                    "text": "IRF4andIGHrearrangements in large B-cell lymphomaCytogenetically cryptic translocationFISH assay should be done to detect this rearrangement in suspected casesDetected in distinct category of non-Hodgkin lymphoma designated as large B-cell lymphoma withIRF4rearrangementOccurs in children and younger ageAssociated with favorable outcome after treatment",
                    "sub_points": [
                      "Cytogenetically cryptic translocation",
                      "FISH assay should be done to detect this rearrangement in suspected cases",
                      "Detected in distinct category of non-Hodgkin lymphoma designated as large B-cell lymphoma withIRF4rearrangement",
                      "Occurs in children and younger age",
                      "Associated with favorable outcome after treatment"
                    ]
                  }
                ],
                "Polymerase Chain Reaction": [
                  {
                    "text": "Detects clonalIGHrearrangement in DLBCL"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Mutated genes implicated in oncogenesis of DLBCLBCL6,MYC,PAX5,PIM1,PIM2,SOCS1,BACH2,CIITA, andTCL1A",
                    "sub_points": [
                      "BCL6,MYC,PAX5,PIM1,PIM2,SOCS1,BACH2,CIITA, andTCL1A"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Used for prognostication"
                  },
                  {
                    "text": "Stratifies DLBCL into 3 subtypesGCB subtype: 55%ABC subtype: 35%Other subtype not fitting GCB or ABC: 10%",
                    "sub_points": [
                      "GCB subtype: 55%",
                      "ABC subtype: 35%",
                      "Other subtype not fitting GCB or ABC: 10%"
                    ]
                  }
                ],
                "MicroRNA Expression": [
                  {
                    "text": "Global microRNA expression profilingHas been used for prognosticationCan separate DLBCL of GCB-like from ABC-like subtype",
                    "sub_points": [
                      "Has been used for prognostication",
                      "Can separate DLBCL of GCB-like from ABC-like subtype"
                    ]
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "Confirms distinct genotype in ABC-like, GCB-like, and primary mediastinal LBCLMany mutations discovered have yet to be linked to prognosisNo current consensus for classification using mutational subgroups",
                    "sub_points": [
                      "Many mutations discovered have yet to be linked to prognosis",
                      "No current consensus for classification using mutational subgroups"
                    ]
                  },
                  {
                    "text": "Some genetic alterations are shared between GCB and ABC subtypes of DLBCL"
                  },
                  {
                    "text": "MutatedTP53may confer poor prognosis"
                  },
                  {
                    "text": "Other mutated genes implicated to have adverse prognostic impactB2M,CD58,CREBBP,EP300,KMT2D(MLL2),MEF2B,FOXO1, andBCL6",
                    "sub_points": [
                      "B2M,CD58,CREBBP,EP300,KMT2D(MLL2),MEF2B,FOXO1, andBCL6"
                    ]
                  },
                  {
                    "text": "Some mutated gene profile may differ in GCB subtype vs. ABC subtype of DLBCLMutations in NF-κB and B-cell receptor signaling pathways are more common in ABC-like and includeCD79B,CARD11,MYD88,PRDM1,PIM1, andTNFAIP3Mutations in gene involving histone methylation are more common in GCB-like and includeKMT2D(MLL2),EZH2,CREBBP,GNA13,MEF2B,B2M, andTNFRSF14",
                    "sub_points": [
                      "Mutations in NF-κB and B-cell receptor signaling pathways are more common in ABC-like and includeCD79B,CARD11,MYD88,PRDM1,PIM1, andTNFAIP3",
                      "CD79B,CARD11,MYD88,PRDM1,PIM1, andTNFAIP3",
                      "Mutations in gene involving histone methylation are more common in GCB-like and includeKMT2D(MLL2),EZH2,CREBBP,GNA13,MEF2B,B2M, andTNFRSF14",
                      "KMT2D(MLL2),EZH2,CREBBP,GNA13,MEF2B,B2M, andTNFRSF14"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Large lymphoid cells with heterogeneous morphology depending on subtype"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Large B cells with nuclear size ≥ macrophage nucleus or 2x size of mature normal lymphocyte"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Positive for pan B-cell markers: CD20, CD19, CD22, CD79A, PAX5Rituximab can greatly reduce expression of CD20, so may require alternate B-cell markerAlternate B-cell marker is required to assess B-cell lineage",
                    "sub_points": [
                      "Rituximab can greatly reduce expression of CD20, so may require alternate B-cell markerAlternate B-cell marker is required to assess B-cell lineage",
                      "Alternate B-cell marker is required to assess B-cell lineage"
                    ]
                  },
                  {
                    "text": "Nonpan B-cell lineage markers typically included in diagnostic work up of DLBCLCD3, CD5, CD10, BCL2, cyclin-D1, BCL6, MUM1, κ, and λ",
                    "sub_points": [
                      "CD3, CD5, CD10, BCL2, cyclin-D1, BCL6, MUM1, κ, and λ"
                    ]
                  },
                  {
                    "text": "Additional helpful diagnostic and prognostic markers recommended to be included in IHC panelKi-67, MYC, CD138, ALK, HHV8, FOXP1, and CD30",
                    "sub_points": [
                      "Ki-67, MYC, CD138, ALK, HHV8, FOXP1, and CD30"
                    ]
                  },
                  {
                    "text": "Germinal center-associated markersCD10, BCL6, LMO2, HGAL, and GCET1",
                    "sub_points": [
                      "CD10, BCL6, LMO2, HGAL, and GCET1"
                    ]
                  },
                  {
                    "text": "Several published algorithmic schemes to distinguish GCB- vs. ABC-like DLBCL subtypes and non-GCB type, includingHans, Choi, Visco-Young, Nyman, and TallyHans algorithm most commonly usedGCB subtype CD10(+), BCL6(+/-), and MUM1(-)ABC (non-GCB) subtype CD10(-), MUM1(+), and BCL6(+/-)",
                    "sub_points": [
                      "Hans, Choi, Visco-Young, Nyman, and Tally",
                      "Hans algorithm most commonly usedGCB subtype CD10(+), BCL6(+/-), and MUM1(-)ABC (non-GCB) subtype CD10(-), MUM1(+), and BCL6(+/-)",
                      "GCB subtype CD10(+), BCL6(+/-), and MUM1(-)",
                      "ABC (non-GCB) subtype CD10(-), MUM1(+), and BCL6(+/-)"
                    ]
                  },
                  {
                    "text": "MYC expressionDetected in 30-50% of DLBCLHigher than rate ofMYCrearrangementsMay confer worse prognosis but is not useful surrogate forMYCrearrangements",
                    "sub_points": [
                      "Detected in 30-50% of DLBCLHigher than rate ofMYCrearrangementsMay confer worse prognosis but is not useful surrogate forMYCrearrangements",
                      "Higher than rate ofMYCrearrangements",
                      "May confer worse prognosis but is not useful surrogate forMYCrearrangements"
                    ]
                  },
                  {
                    "text": "Expression of BCL2 and MYC (so-called \"double expressor\") worse prognosis"
                  },
                  {
                    "text": "Expression of CD5 may confer worse prognosis"
                  },
                  {
                    "text": "Ki-67> 80% Ki-67 proliferation index may be poor prognostic indicatorPoor prognosis in high Ki-67 proliferation index may only be applicable in DLBCL in older patients and in ABC-like subtypes",
                    "sub_points": [
                      "> 80% Ki-67 proliferation index may be poor prognostic indicatorPoor prognosis in high Ki-67 proliferation index may only be applicable in DLBCL in older patients and in ABC-like subtypes",
                      "Poor prognosis in high Ki-67 proliferation index may only be applicable in DLBCL in older patients and in ABC-like subtypes"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Used for immunophenotyping of lymphomaCommonly used antibody panel for suspected DLBCL cases include CD20, CD19, CD3, CD5, CD10, κ, and λMore specific and prognostic marker are done on paraffin-embedded tissue sections",
                    "sub_points": [
                      "Commonly used antibody panel for suspected DLBCL cases include CD20, CD19, CD3, CD5, CD10, κ, and λ",
                      "More specific and prognostic marker are done on paraffin-embedded tissue sections"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBER can be (+)Seen most often in immune-suppressed and older individualsMay indicate worse prognosisIf EBER(+), diagnosis is reclassified as EBV(+) DLBCL except in WHO well-defined lymphoma categories that are EBV associated, includingLymphomatoid granulomatosisPlasmablastic lymphomaDLBCL associated with chronic inflammationEBV(+) mucocutaneous ulcer",
                    "sub_points": [
                      "Seen most often in immune-suppressed and older individuals",
                      "May indicate worse prognosis",
                      "If EBER(+), diagnosis is reclassified as EBV(+) DLBCL except in WHO well-defined lymphoma categories that are EBV associated, includingLymphomatoid granulomatosisPlasmablastic lymphomaDLBCL associated with chronic inflammationEBV(+) mucocutaneous ulcer",
                      "Lymphomatoid granulomatosis",
                      "Plasmablastic lymphoma",
                      "DLBCL associated with chronic inflammation",
                      "EBV(+) mucocutaneous ulcer"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Burkitt Lymphoma": [
                  {
                    "text": "Highly aggressive but curable lymphoma of germinal center-derived B cells"
                  },
                  {
                    "text": "Monotonous, medium-sized cells with numerous histiocytes and mitoses"
                  },
                  {
                    "text": "MYCrearrangement by FISH or karyotyping is hallmark"
                  },
                  {
                    "text": "CD20(+), CD10(+), BCL6(+), BCL2(-) or weakly (+)"
                  },
                  {
                    "text": "Ki-67 shows virtually 100% rate"
                  },
                  {
                    "text": "EBER(+) in > 90% of endemic BL"
                  },
                  {
                    "text": "EBER(+) in ~ 20-30% of sporadic BL and in 30-40% of immunodeficiency-associated cases"
                  },
                  {
                    "text": "Morphology in conjunction with near 100% proliferation index and lack or weak expression of BCL2 helps to distinguish BL from DLBCL"
                  }
                ],
                "High-Grade B-Cell Lymphoma": [
                  {
                    "text": "Heterogeneous group of aggressive lymphomasHGBCL withMYCandBCL2rearrangementsHGBCL withMYCandBCL6rearrangementsLBCL (HGBCL-WHO) with 11q aberrationsHGBCL, NOSDLBCL with blastoid morphologyExcludes lymphoblastic leukemia/lymphoma and blastoid mantle cell lymphoma",
                    "sub_points": [
                      "HGBCL withMYCandBCL2rearrangements",
                      "HGBCL withMYCandBCL6rearrangements",
                      "LBCL (HGBCL-WHO) with 11q aberrations",
                      "HGBCL, NOSDLBCL with blastoid morphologyExcludes lymphoblastic leukemia/lymphoma and blastoid mantle cell lymphoma",
                      "DLBCL with blastoid morphology",
                      "Excludes lymphoblastic leukemia/lymphoma and blastoid mantle cell lymphoma"
                    ]
                  },
                  {
                    "text": "Worse prognosis than DLBCL with resistance to therapy"
                  }
                ],
                "Plasma Cell Neoplasm/Plasma Cell Myeloma": [
                  {
                    "text": "Plasma cell myeloma with plasmablastic transformation may look similar to plasmablastic lymphoma (PBL), specific type of DLBCL"
                  },
                  {
                    "text": "Plasma cell myeloma may resemble immunoblasts"
                  },
                  {
                    "text": "CD56 positivity should raise suspicion of plasma cell myeloma, but other markers may be similar to plasmablastic lymphomaCD38(+), CD138(+), CD20(-), MUM1(+), CD45(-)",
                    "sub_points": [
                      "CD38(+), CD138(+), CD20(-), MUM1(+), CD45(-)"
                    ]
                  },
                  {
                    "text": "EBER negativity in PCM helps differentiate from PBL"
                  },
                  {
                    "text": "Ki-67 often lower in PCM than PBL"
                  }
                ],
                "Anaplastic Large Cell Lymphoma": [
                  {
                    "text": "Usually has very pleomorphic cells but some are monomorphic, which can be confused with DLBCL"
                  },
                  {
                    "text": "Can be confused with anaplastic variant of DLBCL, but CD20 is (-)"
                  },
                  {
                    "text": "CD45 variable; T-cell antigens variable, but usually 1 or more will be (+)"
                  },
                  {
                    "text": "ALK(+) in ALK(+) ALCL category; clonalIGHrearrangement in DLBCL; clonalTRGandTRBrearrangement in ALCL"
                  }
                ],
                "Mediastinal Gray Zone Lymphoma": [
                  {
                    "text": "Associated with mediastinal disease, especially primary mediastinal large B-cell lymphoma"
                  },
                  {
                    "text": "B-cell markers often aberrantly expressed in conjunction with expression of Hodgkin markers"
                  },
                  {
                    "text": "BOB1/OCT2 can help to differentiate from DLBCLOne or other or both should be (-) in classic Hodgkin lymphomaBoth typically (+) in DLBCL",
                    "sub_points": [
                      "One or other or both should be (-) in classic Hodgkin lymphoma",
                      "Both typically (+) in DLBCL"
                    ]
                  }
                ],
                "Myeloid Sarcoma": [
                  {
                    "text": "Can be very difficult to differentiate from DLBCL on morphology"
                  },
                  {
                    "text": "MPO(+), CD34(+/-), CD68(+), CD163(+), CD117(+)"
                  },
                  {
                    "text": "May be solitary mass but often in bone marrow and peripheral blood"
                  }
                ],
                "Histiocytic Sarcoma": [
                  {
                    "text": "Malignant neoplasm composed of neoplastic histiocytes"
                  },
                  {
                    "text": "Sometimes associated with other lymphomas, including DLBCL"
                  },
                  {
                    "text": "CD163(+), CD45(+), CD68(+), CD20(-), CD3(-)"
                  },
                  {
                    "text": "ClonalIGHrearrangement may be sometimes detected by PCR in HS"
                  }
                ],
                "Malignant Melanoma": [
                  {
                    "text": "Large, malignant-appearing cells"
                  },
                  {
                    "text": "IHC should differentiate from DLBCL"
                  },
                  {
                    "text": "Malignant cells in melanoma are S100(+), HMB-45(+), tyrosinase (+), Melan-A (+), SOX10(+)"
                  }
                ],
                "Poorly Differentiated Epithelioid Neoplasms": [
                  {
                    "text": "May be difficult to morphologically differentiate from DLBCL on H&E"
                  },
                  {
                    "text": "Carcinomas are cytokeratin (+), EMA(+), CD45(-)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Pheochromocytoma/Paraganglioma": {
            "name": "Pheochromocytoma/Paraganglioma",
            "url": "https://app.pathprimer.com/document/4078bbc1-c681-45a8-a920-92aafec38e71/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Identification of patients with hereditary pheochromocytoma involves clinical assessment, biochemical testing, and pathology leading to directed genetic testing"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Majority of pheochromocytomas appear to arise sporadicallyMany sporadic tumors have no known somatic driver mutationNF1inactivation somatic mutation is most common mutation, found in > 25% of sporadic casesUp to 1/3 of sporadic cases have no known genetic driver mutation",
                    "sub_points": [
                      "Many sporadic tumors have no known somatic driver mutation",
                      "NF1inactivation somatic mutation is most common mutation, found in > 25% of sporadic cases",
                      "Up to 1/3 of sporadic cases have no known genetic driver mutation"
                    ]
                  },
                  {
                    "text": "> 40% of PPGL hereditary; at least 10 known susceptibility genesRET,VHL,NF1,SDHA,SDHB,SDHC,SDHD,SDHAF2,KIF1B,TMEM127, andMAX",
                    "sub_points": [
                      "RET,VHL,NF1,SDHA,SDHB,SDHC,SDHD,SDHAF2,KIF1B,TMEM127, andMAX"
                    ]
                  },
                  {
                    "text": "SDHBmutation associated with extraabdominal location, high probability of metastasis, and poor prognosis"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Classic pattern is small nests (zellballen) of neuroendocrine cells with interspersed small blood vessels"
                  },
                  {
                    "text": "Numerous variant and combined patterns exist, including diffuse growth, large zellballen, spindle cells, cell cords"
                  },
                  {
                    "text": "Sustentacular cells variably present, best seen with IHC"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "IHC for SDHB and SDHA can triage patients for appropriate genetic testing"
                  },
                  {
                    "text": "Generic neuroendocrine markers chromogranin (CgA or CgB) and synaptophysin usually positive in chief cells; keratins usually negative"
                  },
                  {
                    "text": "Positive for TYH, DBH, GATA3, INSM1, chromogranin A, and synaptophysin"
                  },
                  {
                    "text": "Sustentacular cells stain for S100 and SOX10"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Pheochromocytoma (PCC)"
                  },
                  {
                    "text": "Paraganglioma (PGL)"
                  },
                  {
                    "text": "Pheochromocytoma/paraganglioma (PPGL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Intraadrenal PGL"
                  },
                  {
                    "text": "Adrenal sympathetic PGL"
                  }
                ],
                "Definitions": [
                  {
                    "text": "PCC: Neuroendocrine neoplasm derived from neural crest cells that arises from adrenal medulla chromaffin cells"
                  },
                  {
                    "text": "PGL: Neuroendocrine neoplasm derived from neural crest progenitor cells that arises from extraadrenal sympathetic or parasympathetic paragangliaSympathetic (sympathoadrenal) PGL arises in vicinity of sympathetic chains and along sympathetic nerve branches in pelvic organs and retroperitoneumParasympathetic PGL [head and neck PGL (HNP)] arises mainly from branches of vagus and glossopharyngeal nerves in head and neck, sometimes mediastinumPCC is intraadrenal sympathetic PGL",
                    "sub_points": [
                      "Sympathetic (sympathoadrenal) PGL arises in vicinity of sympathetic chains and along sympathetic nerve branches in pelvic organs and retroperitoneum",
                      "Parasympathetic PGL [head and neck PGL (HNP)] arises mainly from branches of vagus and glossopharyngeal nerves in head and neck, sometimes mediastinum",
                      "PCC is intraadrenal sympathetic PGL"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Developmental Anomaly": [
                  {
                    "text": "Normal paraganglia, from which PPGL arise, consist of neural crest-derived neuroendocrine cells associated with sympathetic and parasympathetic nervesAdrenal medulla and organ of Zuckerkandl are major sympathetic paraganglia; others are microscopicCarotid bodies are major parasympathetic paraganglia; others are microscopic",
                    "sub_points": [
                      "Adrenal medulla and organ of Zuckerkandl are major sympathetic paraganglia; others are microscopic",
                      "Carotid bodies are major parasympathetic paraganglia; others are microscopic"
                    ]
                  }
                ],
                "Environmental Influences": [
                  {
                    "text": "High-altitude PGL in people living in some mountainous areasMostly carotid PGL",
                    "sub_points": [
                      "Mostly carotid PGL"
                    ]
                  }
                ],
                "Hereditary Influences": [
                  {
                    "text": "> 40% of adults and up to 80% of children with PPGL have hereditary susceptibility gene germline mutation"
                  },
                  {
                    "text": "Highest inheritable proportion of any known human tumorAt least 18 known susceptibility genes, includingRET,SDHA,SDHB,SDHC,SDHD,SDHAF2,NF1,VHL, andTMEM127Hereditary PPGL often found after other stigmata point to hereditary tumor syndrome (usually MEN2, VHL, NF1)Variants of some hereditary syndromes can cause only PPGL (VHL type 2C)Mutations of some genes (e.g.,TMEM127) cause hereditary but nonsyndromic PPGLMultiple tumors or tumors presenting in children suggest hereditary diseaseTumors withRETorNF1mutations almost always intraadrenalSDHD-andSDHAF2-related PGL show parent of origin-dependent expressionTumor development only with paternal inheritance",
                    "sub_points": [
                      "At least 18 known susceptibility genes, includingRET,SDHA,SDHB,SDHC,SDHD,SDHAF2,NF1,VHL, andTMEM127",
                      "RET,SDHA,SDHB,SDHC,SDHD,SDHAF2,NF1,VHL, andTMEM127",
                      "Hereditary PPGL often found after other stigmata point to hereditary tumor syndrome (usually MEN2, VHL, NF1)",
                      "Variants of some hereditary syndromes can cause only PPGL (VHL type 2C)",
                      "Mutations of some genes (e.g.,TMEM127) cause hereditary but nonsyndromic PPGL",
                      "Multiple tumors or tumors presenting in children suggest hereditary disease",
                      "Tumors withRETorNF1mutations almost always intraadrenal",
                      "SDHD-andSDHAF2-related PGL show parent of origin-dependent expressionTumor development only with paternal inheritance",
                      "Tumor development only with paternal inheritance"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence is ~ 0.6 cases per 100,000 person-years"
                  },
                  {
                    "text": "Age at diagnosis: 50-60 years in most cases; ~ 20% occur in children"
                  }
                ],
                "Site": [
                  {
                    "text": "~ 98% of sympathetic PGL located in abdomen or pelvis; 90% are intraadrenal (PCC)"
                  },
                  {
                    "text": "Most parasympathetic PGL are carotid, jugulotympanic, or vagal"
                  }
                ],
                "Presentation": [
                  {
                    "text": "< 25% present with classic triad of headache, palpitations, and diaphoresis"
                  },
                  {
                    "text": "Many are discovered incidentally on imaging for other work-up or surveillance of germline mutation positive patients"
                  },
                  {
                    "text": "Sympathoadrenal PPGLs may show signs and symptoms of catecholamine excessTumors withSDHBmutation are more likely than other sympathoadrenal PPGL to be clinically silent",
                    "sub_points": [
                      "Tumors withSDHBmutation are more likely than other sympathoadrenal PPGL to be clinically silent"
                    ]
                  },
                  {
                    "text": "Parasympathetic PGL are usually clinically silent mass lesions"
                  },
                  {
                    "text": "Sporadic tumors typically solitary, usually in adults"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Plasma metanephrine, normetanephrine, and 3-methoxytyramine more sensitive than corresponding catecholamines for tumor detection"
                  },
                  {
                    "text": "Succinatemutaion analysis"
                  },
                  {
                    "text": "PCC can be adrenergic or noradrenergic; extraadrenal PGL is almost always noradrenergic; HNP can lack ability for catecholamine biosynthesis"
                  },
                  {
                    "text": "Genotype affects biochemical functionNoradrenergic PCC raises suspicion of von Hippel-Lindau (VHL) syndrome",
                    "sub_points": [
                      "Noradrenergic PCC raises suspicion of von Hippel-Lindau (VHL) syndrome"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Complete surgical excision with adrenergic blockade"
                  },
                  {
                    "text": "Metastatic disease treatment includes surgery, ablation, chemotherapy, and radionuclide therapy"
                  },
                  {
                    "text": "Molecular targeted therapy undergoing clinical trialsTyrosine kinase inhibitorsHIFA2 inhibitorsCheckpoint inhibitor immunotherapy",
                    "sub_points": [
                      "Tyrosine kinase inhibitors",
                      "HIFA2 inhibitors",
                      "Checkpoint inhibitor immunotherapy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Overall survival for patients with PPGL is 63% at 5 years"
                  },
                  {
                    "text": "Most patients with metastases die from complications of excess catecholamines or destructive local growth"
                  }
                ],
                "Malignancy": [
                  {
                    "text": "WHO 2017 states that all PPGL should be considered malignant"
                  },
                  {
                    "text": "Metastatic diseaseRisk of metastasis and prognosis vary with tumor location and genotype~ 10% metastasis for PCC; > 20% for PGLBest predictor of metastasis is presence ofSDHBmutation (43%)Metastatic tumors withSDHBmutation have worst prognosisMust be to sites where normal paraganglia are not present to avoid confusion with new primary tumorCurrently, no established histologic criteria to predict whether primary PPGL will metastasizeMost accepted adverse histologic findings include high proliferative rate, comedonecrosis and diffuse growth patternMetastases can develop years or decades after resection of primary tumor",
                    "sub_points": [
                      "Risk of metastasis and prognosis vary with tumor location and genotype~ 10% metastasis for PCC; > 20% for PGLBest predictor of metastasis is presence ofSDHBmutation (43%)Metastatic tumors withSDHBmutation have worst prognosis",
                      "~ 10% metastasis for PCC; > 20% for PGL",
                      "Best predictor of metastasis is presence ofSDHBmutation (43%)Metastatic tumors withSDHBmutation have worst prognosis",
                      "Metastatic tumors withSDHBmutation have worst prognosis",
                      "Must be to sites where normal paraganglia are not present to avoid confusion with new primary tumor",
                      "Currently, no established histologic criteria to predict whether primary PPGL will metastasizeMost accepted adverse histologic findings include high proliferative rate, comedonecrosis and diffuse growth pattern",
                      "Most accepted adverse histologic findings include high proliferative rate, comedonecrosis and diffuse growth pattern",
                      "Metastases can develop years or decades after resection of primary tumor"
                    ]
                  },
                  {
                    "text": "All patients must receive lifelong follow-up"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Circumscribed, unencapsulated; ~ 3-5 cm, can be > 10 cm"
                  },
                  {
                    "text": "Cut surface usually pink-gray to tanDistinguishes PCC from yellow-gold color of most adrenal cortical tumors",
                    "sub_points": [
                      "Distinguishes PCC from yellow-gold color of most adrenal cortical tumors"
                    ]
                  },
                  {
                    "text": "Occasional tumors show patchy or diffuse brown pigmentation"
                  },
                  {
                    "text": "Cystic degeneration and necrosis sometimes present"
                  },
                  {
                    "text": "Sample for micronodules in uninvolved adrenal tissueMay represent synchronous microPCC associated with hereditary disease",
                    "sub_points": [
                      "May represent synchronous microPCC associated with hereditary disease"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "Sporadic PPGL": [
                  {
                    "text": "Majority of PCC appear to arise sporadically"
                  },
                  {
                    "text": "Up to 1/3 of sporadic cases have no known genetic driver mutation"
                  },
                  {
                    "text": "NF1inactivation mutation is most common somatic mutation seen in > 25% of sporadic tumors"
                  },
                  {
                    "text": "Germline mutations in known susceptibility genes may be seen in up to 16% of sporadic-appearing casesChanges in copy number of hereditary susceptibility genes may be present",
                    "sub_points": [
                      "Changes in copy number of hereditary susceptibility genes may be present"
                    ]
                  }
                ],
                "Hereditary PPGL": [
                  {
                    "text": "Identification of multiple susceptibility genes demonstrated extensive tumor genetic heterogeneity"
                  },
                  {
                    "text": "Most striking feature is genetic diversity≥ 10 susceptibility genes now established",
                    "sub_points": [
                      "≥ 10 susceptibility genes now established"
                    ]
                  },
                  {
                    "text": "Most attributable to mutations inRET,VHL,NF1,SDHA,SDHB,SDHC,SDHD,SDHAF2,KIF1B,TMEM127, andMAXOccult germline mutations of susceptibility genes common in patients with apparently sporadic tumors",
                    "sub_points": [
                      "Occult germline mutations of susceptibility genes common in patients with apparently sporadic tumors"
                    ]
                  },
                  {
                    "text": "Mutations in SDH family of genes account for up to 80% of familial PPGL aggregations~ 30% of pediatric tumors> 40% of malignant tumors",
                    "sub_points": [
                      "~ 30% of pediatric tumors",
                      "> 40% of malignant tumors"
                    ]
                  },
                  {
                    "text": "Multiple endocrine neoplasia type 2 (MEN2)Autosomal dominant syndrome caused by mutation inRETprotooncogeneActivatingRETmutations predispose to PCCOften recurrent and bilateral in 50-80% of cases",
                    "sub_points": [
                      "Autosomal dominant syndrome caused by mutation inRETprotooncogene",
                      "ActivatingRETmutations predispose to PCCOften recurrent and bilateral in 50-80% of cases",
                      "Often recurrent and bilateral in 50-80% of cases"
                    ]
                  },
                  {
                    "text": "Familial PPGL syndromesPGL syndromes encompass group of inherited syndromes that involve mutations in genes that encode components of succinate dehydrogenase (SDH) mitochondrial enzyme complex 2SDH is composed of 4 subunits: A, B, C, and DGermline mutations in SDH family of genes give rise to familial PPGL syndrome, sometimes only referred to as familial PGLPGL1, PGL2, PGL3, and PGL4 caused by mutations inSDHD,SDHAF2,SDHC, andSDHB, respectivelyHead and neck PGL commonSDHA-related PGL rare and caused by loss-of-function mutation inSDHA",
                    "sub_points": [
                      "PGL syndromes encompass group of inherited syndromes that involve mutations in genes that encode components of succinate dehydrogenase (SDH) mitochondrial enzyme complex 2SDH is composed of 4 subunits: A, B, C, and D",
                      "SDH is composed of 4 subunits: A, B, C, and D",
                      "Germline mutations in SDH family of genes give rise to familial PPGL syndrome, sometimes only referred to as familial PGLPGL1, PGL2, PGL3, and PGL4 caused by mutations inSDHD,SDHAF2,SDHC, andSDHB, respectivelyHead and neck PGL commonSDHA-related PGL rare and caused by loss-of-function mutation inSDHA",
                      "PGL1, PGL2, PGL3, and PGL4 caused by mutations inSDHD,SDHAF2,SDHC, andSDHB, respectively",
                      "Head and neck PGL common",
                      "SDHA-related PGL rare and caused by loss-of-function mutation inSDHA"
                    ]
                  },
                  {
                    "text": "Carney triadMean age of presentation of PPGL is 28 yearsOnly 16% present with PCC",
                    "sub_points": [
                      "Mean age of presentation of PPGL is 28 yearsOnly 16% present with PCC",
                      "Only 16% present with PCC"
                    ]
                  },
                  {
                    "text": "VHL syndromeAutosomal dominant, caused by mutation ofVHL~ 10-26% of VHL patients develop PPGL, but risk varies between different familiesMean age of onset of PCC in VHL is ~ 30 years",
                    "sub_points": [
                      "Autosomal dominant, caused by mutation ofVHL",
                      "~ 10-26% of VHL patients develop PPGL, but risk varies between different families",
                      "Mean age of onset of PCC in VHL is ~ 30 years"
                    ]
                  },
                  {
                    "text": "Neurofibromatosis type 1 (NF1)Autosomal dominant, caused byNF1mutationPCC occur in 20-50% of individuals with NF1 and hypertensionNF1-associated PPGL typically has characteristics similar to those of sporadic tumors with relatively late mean age of onset and ~ 10% risk of malignancyGangliocytic duodenal PGL may also occur~ 84% of PCC are unilateral",
                    "sub_points": [
                      "Autosomal dominant, caused byNF1mutation",
                      "PCC occur in 20-50% of individuals with NF1 and hypertension",
                      "NF1-associated PPGL typically has characteristics similar to those of sporadic tumors with relatively late mean age of onset and ~ 10% risk of malignancy",
                      "Gangliocytic duodenal PGL may also occur",
                      "~ 84% of PCC are unilateral"
                    ]
                  },
                  {
                    "text": "Carney-Stratakis dyadInherited predisposition to gastrointestinal stromal tumor (GIST) and PGL caused by inactivating germline mutations inSDHB,SDHC, orSDHDOnly rare cases reported to be associated with PCC",
                    "sub_points": [
                      "Inherited predisposition to gastrointestinal stromal tumor (GIST) and PGL caused by inactivating germline mutations inSDHB,SDHC, orSDHD",
                      "Only rare cases reported to be associated with PCC"
                    ]
                  },
                  {
                    "text": "Recently identified hereditary forms of PPGL involve transmembrane-encoding gene,TMEM127, andMAXNo specific syndrome has been described forTMEM127MAXmutations occur in families with PCC, but no specific syndrome has been described yet",
                    "sub_points": [
                      "No specific syndrome has been described forTMEM127",
                      "MAXmutations occur in families with PCC, but no specific syndrome has been described yet"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "The Cancer Genome Atlas has classified PPGL into 3 molecular clusters"
                  },
                  {
                    "text": "Cluster I: Mutations disrupt hypoxia-signaling pathwaysKrebs cycle/VHL/EPAS1-relatedGenes includeVHL, SDHx, andFH",
                    "sub_points": [
                      "Krebs cycle/VHL/EPAS1-related",
                      "Genes includeVHL, SDHx, andFH"
                    ]
                  },
                  {
                    "text": "Cluster II: Mutations disrupt kinase-signaling pathwaysGenes includeRET,NF1,TMEM127, andMAX",
                    "sub_points": [
                      "Genes includeRET,NF1,TMEM127, andMAX"
                    ]
                  },
                  {
                    "text": "Cluster III: Mutations affect WNT-signaling pathwayMAML3oncogene fusions andCSDE1mutations in sporadic adult PCC",
                    "sub_points": [
                      "MAML3oncogene fusions andCSDE1mutations in sporadic adult PCC"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Wide architectural and cytologic variation"
                  },
                  {
                    "text": "Classic pattern is small nests (zellballen) of neuroendocrine cells (chief cells) with interspersed small blood vessels"
                  },
                  {
                    "text": "Numerous variant and combined patterns exist, including diffuse growth, large zellballen, spindle cells, cell cords"
                  },
                  {
                    "text": "Sustentacular cells variably present, best seen with IHCPossibly nonneoplastic cell type induced or attracted by tumor-derived factors",
                    "sub_points": [
                      "Possibly nonneoplastic cell type induced or attracted by tumor-derived factors"
                    ]
                  },
                  {
                    "text": "Cavernous blood vessels sometimes prominent, especially in HNP"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Tumor cells resemble normal chromaffin cells, vesicular nuclei, inconspicuous or large nucleoli"
                  },
                  {
                    "text": "Nuclear pseudoinclusions, embracing cells, extracellular hyaline globules variably present"
                  },
                  {
                    "text": "Basophilic, amphophilic, or clear cytoplasm"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Positive for TYH, DBH, GATA3, INSM1, chromogranin A and synaptophysinParasympathetic PGL can be negative for chromogranin A and positive for chromogranin BTYH expression correlates with catecholamine synthesis; can be negative, especially in parasympathetic PGLElevated metanephrine after resection of TYH(-) PGL suggests 2nd primary, not metastasis",
                    "sub_points": [
                      "Parasympathetic PGL can be negative for chromogranin A and positive for chromogranin B",
                      "TYH expression correlates with catecholamine synthesis; can be negative, especially in parasympathetic PGLElevated metanephrine after resection of TYH(-) PGL suggests 2nd primary, not metastasis",
                      "Elevated metanephrine after resection of TYH(-) PGL suggests 2nd primary, not metastasis"
                    ]
                  },
                  {
                    "text": "Sustentacular cells positive for S100 and SOX10"
                  },
                  {
                    "text": "Ki-67 proliferative index essential reporting criteriaEstablished risk factor for development of metastasesReported as % positive tumor cells in 10 HPF within hotspot area",
                    "sub_points": [
                      "Established risk factor for development of metastases",
                      "Reported as % positive tumor cells in 10 HPF within hotspot area"
                    ]
                  },
                  {
                    "text": "Molecular markers for germline mutation screeningSDHB, SDHA for SDHx mutationsSDHB protein lost in PPGL withSDHA,SDHB,SDHC, orSDHDmutationsSDHA protein lost only whenSDHAis mutatedSustentacular and endothelial cells serve as intrinsic positive controls for SDHBFH for fumarate hydratase mutations",
                    "sub_points": [
                      "SDHB, SDHA for SDHx mutationsSDHB protein lost in PPGL withSDHA,SDHB,SDHC, orSDHDmutationsSDHA protein lost only whenSDHAis mutatedSustentacular and endothelial cells serve as intrinsic positive controls for SDHB",
                      "SDHB protein lost in PPGL withSDHA,SDHB,SDHC, orSDHDmutations",
                      "SDHA protein lost only whenSDHAis mutated",
                      "Sustentacular and endothelial cells serve as intrinsic positive controls for SDHB",
                      "FH for fumarate hydratase mutations"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Germline testing with genetics consultation in appropriate clinical context"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Adrenal Cortical Carcinoma": [
                  {
                    "text": "Positive for Melan A, SF1"
                  },
                  {
                    "text": "Negative for chromogranin, TYH, GATA3"
                  },
                  {
                    "text": "Synaptophysin and inhibin positive in both cortical and medullary tumors; do not use in this differential diagnosis"
                  }
                ],
                "Other Neuroendocrine Tumors": [
                  {
                    "text": "Neuroendocrine carcinomas and carcinoids, pancreatic endocrine tumors, medullary thyroid carcinoma"
                  },
                  {
                    "text": "Keratins are usually positive"
                  }
                ],
                "Hepatocellular Carcinomas": [
                  {
                    "text": "Absence of neuroendocrine markers, presence of keratins &/or tissue-specific markers"
                  }
                ],
                "Renal Cell Carcinoma": [
                  {
                    "text": "Absence of neuroendocrine markers, presence of keratins &/or CD10, RCC, and other tissue-specific markers"
                  }
                ],
                "Alveolar Soft Part Sarcomas": [
                  {
                    "text": "Absence of neuroendocrine markers, presence of soft tissue-specific marker TFE3"
                  }
                ],
                "Glomus Tumors and Glomangiomas": [
                  {
                    "text": "Location: Outside adrenal"
                  },
                  {
                    "text": "Presence of neuroendocrine markers, S100, GFAP"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "PDGFRA,PDGFRB, andFGFR1Rearrangements": {
            "name": "PDGFRA,PDGFRB, andFGFR1Rearrangements",
            "url": "https://app.pathprimer.com/document/97b0a67f-0f1d-497c-842a-f7eaf2ffed01/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "Terminology": {
                "Definitions": [
                  {
                    "text": "PDGFRAHGNC name: Platelet-derived growth factor receptor, alpha polypeptideHGNC ID: 8803Chromosomal location: 4q12",
                    "sub_points": [
                      "HGNC name: Platelet-derived growth factor receptor, alpha polypeptide",
                      "HGNC ID: 8803",
                      "Chromosomal location: 4q12"
                    ]
                  },
                  {
                    "text": "PDGFRBHGNC name: Platelet-derived growth factor receptor, beta polypeptideHGNC ID: 8804Chromosomal location: 5q33.1",
                    "sub_points": [
                      "HGNC name: Platelet-derived growth factor receptor, beta polypeptide",
                      "HGNC ID: 8804",
                      "Chromosomal location: 5q33.1"
                    ]
                  },
                  {
                    "text": "FGFR1HGNC name: Fibroblast growth factor receptor 1HGNC ID: 3688Chromosomal location: 8p11.23-p11.22",
                    "sub_points": [
                      "HGNC name: Fibroblast growth factor receptor 1",
                      "HGNC ID: 3688",
                      "Chromosomal location: 8p11.23-p11.22"
                    ]
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Fusion Gene Formation": [
                  {
                    "text": "PDGFRA,PDGFRB, andFGFR1encode tyrosine kinases"
                  },
                  {
                    "text": "Rearrangements generate fusion genes leading to abnormal kinase signaling"
                  }
                ]
              },
              "Clinical Implications": {
                "General Clinical Implications": [
                  {
                    "text": "Rearrangements of these genes are diagnostic of WHO 2008 entities \"myeloid and lymphoid neoplasms with eosinophilia and abnormalities ofPDGFRA,PDGFRB, orFGFR1\""
                  }
                ],
                "PDGFRARearrangement": [
                  {
                    "text": "Diagnostic feature of \"myeloid and lymphoid neoplasms withPDGFRArearrangement\" (WHO 2008)"
                  },
                  {
                    "text": "Note thatPDGFRAmutations (rather than rearrangements), which may be seen in diverse neoplasms, are not encompassed by WHO diagnosis"
                  }
                ],
                "PDGFRBRearrangement": [
                  {
                    "text": "Diagnostic feature of \"myeloid neoplasms withPDGFRBrearrangement\" (WHO 2008)Note thatPDGFRBrearrangements are now described in lymphoblastic leukemia/lymphoma (i.e., despite absence of \"lymphoid\" from WHO 2008 specific description)",
                    "sub_points": [
                      "Note thatPDGFRBrearrangements are now described in lymphoblastic leukemia/lymphoma (i.e., despite absence of \"lymphoid\" from WHO 2008 specific description)"
                    ]
                  }
                ],
                "FGFR1Rearrangement": [
                  {
                    "text": "Diagnostic feature of \"myeloid and lymphoid neoplasms withFGFR1abnormalities\" (WHO 2008)"
                  }
                ],
                "Clinical Presentation": [
                  {
                    "text": "EosinophiliaCharacteristically present in these neoplasms, but may not be seen in all cases",
                    "sub_points": [
                      "Characteristically present in these neoplasms, but may not be seen in all cases"
                    ]
                  },
                  {
                    "text": "Variable disease phenotypeIncludes presentation with features ofChronic eosinophilic leukemiaAcute myeloid leukemiaLymphoblastic leukemia/lymphomaChronic myelomonocytic leukemiaMixed phenotype acute leukemiaOther myeloid or immature lymphoid neoplasms",
                    "sub_points": [
                      "Includes presentation with features ofChronic eosinophilic leukemiaAcute myeloid leukemiaLymphoblastic leukemia/lymphomaChronic myelomonocytic leukemiaMixed phenotype acute leukemiaOther myeloid or immature lymphoid neoplasms",
                      "Chronic eosinophilic leukemia",
                      "Acute myeloid leukemia",
                      "Lymphoblastic leukemia/lymphoma",
                      "Chronic myelomonocytic leukemia",
                      "Mixed phenotype acute leukemia",
                      "Other myeloid or immature lymphoid neoplasms"
                    ]
                  },
                  {
                    "text": "Gene-defined entitiesRegardless of clinical presentation, presence ofPDGFRA,PDGFRB, orFGFR1rearrangement is key diagnostic finding",
                    "sub_points": [
                      "Regardless of clinical presentation, presence ofPDGFRA,PDGFRB, orFGFR1rearrangement is key diagnostic finding"
                    ]
                  }
                ]
              },
              "Testing for PDGFRA,PDGFRB, and FGFR1 Rearrangements": {
                "Karyotype vs. FISH/RT-PCR": [
                  {
                    "text": "Karyotype willnotdetect typicalPDGFRArearrangementFISH or RT-PCR is necessary for this purpose",
                    "sub_points": [
                      "FISH or RT-PCR is necessary for this purpose"
                    ]
                  },
                  {
                    "text": "Karyotype will detect typicalPDGFRBandFGFR1translocationsFISH is indicated to confirm these rearrangements",
                    "sub_points": [
                      "FISH is indicated to confirm these rearrangements"
                    ]
                  }
                ]
              },
              "Detection of PDGFRA Rearrangement": {
                "CommonFIP1L1-PDGFRAFusion": [
                  {
                    "text": "Fusion ofPDGFRAwithFIP1L1is characteristic type ofPDGFRArearrangementFIP1L1HGNC name: Factor interacting with PAPOLA and CPSF1HGNC ID: 19124",
                    "sub_points": [
                      "FIP1L1HGNC name: Factor interacting with PAPOLA and CPSF1HGNC ID: 19124",
                      "HGNC name: Factor interacting with PAPOLA and CPSF1",
                      "HGNC ID: 19124"
                    ]
                  },
                  {
                    "text": "This rearrangement occurs due to small interstitial deletion at 4q12Because of small size of deletion, this change isnotvisible on routine karyotypingThus, FISH or RT-PCR is necessary to identify rearrangementBoth are clinically available",
                    "sub_points": [
                      "Because of small size of deletion, this change isnotvisible on routine karyotyping",
                      "Thus, FISH or RT-PCR is necessary to identify rearrangementBoth are clinically available",
                      "Both are clinically available"
                    ]
                  },
                  {
                    "text": "1 popular FISH strategy uses 3 probes, 1 of which hybridizes at or nearCHIC2(in deleted region), with the others flankingPDGFRAandFIP1L1CHIC2HGNC name: Cysteine-rich hydrophobic domain 2HGNC ID: 1935",
                    "sub_points": [
                      "CHIC2HGNC name: Cysteine-rich hydrophobic domain 2HGNC ID: 1935",
                      "HGNC name: Cysteine-rich hydrophobic domain 2",
                      "HGNC ID: 1935"
                    ]
                  },
                  {
                    "text": "Probe pattern for negative case is tricolor fusion signal, indicating presence ofPDGFRA,CHIC2, andFIP1L1in same vicinity"
                  },
                  {
                    "text": "Probe pattern for positive case is fusion ofPDGFRA- andFIP1L1-specific signals only, without interveningCHIC2-specific signalIndicates deletion of region betweenPDGFRAandFIP1L1with loss ofCHIC2, resulting in fusion betweenPDGFRAandFIP1L1Though this test is sometimes referred to colloquially as \"CHIC2deletion,\"CHIC2is in fact an irrelevant bystander in formation of pathogenicFIP1L1-PDGFRAfusion",
                    "sub_points": [
                      "Indicates deletion of region betweenPDGFRAandFIP1L1with loss ofCHIC2, resulting in fusion betweenPDGFRAandFIP1L1Though this test is sometimes referred to colloquially as \"CHIC2deletion,\"CHIC2is in fact an irrelevant bystander in formation of pathogenicFIP1L1-PDGFRAfusion",
                      "Though this test is sometimes referred to colloquially as \"CHIC2deletion,\"CHIC2is in fact an irrelevant bystander in formation of pathogenicFIP1L1-PDGFRAfusion"
                    ]
                  }
                ],
                "Other RarePDGFRARearrangements": [
                  {
                    "text": "Rare translocations involvingPDGFRAhave also been described with other partner genesKIF5B(10p11.22)CDK5RAP2(9q33.3)STRN(2p22.2)ETV6(12p13)BCR(22q11.23)",
                    "sub_points": [
                      "KIF5B(10p11.22)",
                      "CDK5RAP2(9q33.3)",
                      "STRN(2p22.2)",
                      "ETV6(12p13)",
                      "BCR(22q11.23)"
                    ]
                  },
                  {
                    "text": "These reciprocal translocations are typically detected on routine karyotypingWould also generally give rise to abnormal variant FISH patterns with tricolorFIP1L1/CHIC2/PDGFRAprobe set",
                    "sub_points": [
                      "Would also generally give rise to abnormal variant FISH patterns with tricolorFIP1L1/CHIC2/PDGFRAprobe set"
                    ]
                  },
                  {
                    "text": "RT-PCR for specificFIP1L1-PDGFRAfusion would be negative in the case of these alternative partners"
                  }
                ]
              },
              "Detection of PDGFRB Rearrangement": {
                "CommonETV6-PDGFRBFusion": [
                  {
                    "text": "Fusion ofPDGFRBwithETV6(12p13) is the most common type ofPDGFRBrearrangement"
                  }
                ],
                "AlternativePDGFRBRearrangements": [
                  {
                    "text": "> 19 alternative reciprocal translocation partners are also seen"
                  }
                ],
                "Karyotyping forPDGFRBRearrangements": [
                  {
                    "text": "PDGFRBrearrangements are typically detected on routine karyotyping"
                  },
                  {
                    "text": "Of note, not all t(5;12)(q31~33;p13) translocations involvePDGFRB&/orETV6FISH is therefore recommended to confirm presence ofPDGFRBrearrangement in cases with 5q31~33 abnormality",
                    "sub_points": [
                      "FISH is therefore recommended to confirm presence ofPDGFRBrearrangement in cases with 5q31~33 abnormality"
                    ]
                  }
                ],
                "FISH forPDGFRBRearrangements": [
                  {
                    "text": "Breakapart probe strategy is commonly employedUseful for confirming presence ofPDGFRBrearrangement",
                    "sub_points": [
                      "Useful for confirming presence ofPDGFRBrearrangement"
                    ]
                  },
                  {
                    "text": "Very rare cases of karyotypically crypticPDGFRBrearrangements (detectable only by FISH) are also described"
                  }
                ]
              },
              "Detection of FGFR1 Rearrangement": {
                "Karyotyping forFGFR1Rearrangement": [
                  {
                    "text": "Most common translocation is withZMYM2(HGNC ID: 12989, previously known asZNF198) at 13q11-q12"
                  },
                  {
                    "text": "At least 13 other reciprocal translocation partner genes have also been described forFGFR1However, not all 8p11 translocations involveFGFR1In particular,KAT6A(HGNC: 13013, previously known asMYST3) at 8p11 is also rearranged in some myeloid neoplasmsThus, FISH may be indicated for confirmation",
                    "sub_points": [
                      "However, not all 8p11 translocations involveFGFR1In particular,KAT6A(HGNC: 13013, previously known asMYST3) at 8p11 is also rearranged in some myeloid neoplasmsThus, FISH may be indicated for confirmation",
                      "In particular,KAT6A(HGNC: 13013, previously known asMYST3) at 8p11 is also rearranged in some myeloid neoplasms",
                      "Thus, FISH may be indicated for confirmation"
                    ]
                  }
                ],
                "FISH forFGFR1Rearrangement": [
                  {
                    "text": "Breakapart probe strategy is commonly employed"
                  },
                  {
                    "text": "Useful for confirming presence ofFGFR1rearrangement in cases with 8p11 abnormality"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Overview of Acute Myeloid Leukemia": {
            "name": "Overview of Acute Myeloid Leukemia",
            "url": "https://app.pathprimer.com/document/851a1de6-aabc-4734-b1dd-8b8ebc107e17/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "World Health Organization classification, 5th edition (WHO-HAEM5)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Acute myelogenous leukemia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic stem cell proliferation encompassing heterogeneous group of genetically distinct neoplasms"
                  }
                ],
                "WHO-HAEM5 and ICC": [
                  {
                    "text": "AML with recurrent genetic abnormalities in both ICC and WHO-HAEM5Both ICC and WHO-HAEM5 require blasts ≥ 20% in following categoriesAML withBCR::ABL1AML with myelodysplasia-related cytogenetic abnormalitiesAML with myelodysplasia-related gene mutationAML, NOS (ICC)/ AML defined by differentiation (WHO-HAEM5)ICC category of AML with mutatedTP53requires ≥ 20% blasts as wellIn addition, WHO-HAEM5 requires ≥ 20% blasts for AML withCEBPAmutationNo blasts cutoff in WHO-HAEM5 for remaining AML subtypes with recurrent genetic abnormalitiesICC requires ≥ 10% bone marrow blasts for AML with recurrent genetic abnormalities except for AML withBCR::ABL1and AML withTP53AML defined by differentiation in WHO-HAEM5 designated as AML, NOS in ICC",
                    "sub_points": [
                      "Both ICC and WHO-HAEM5 require blasts ≥ 20% in following categoriesAML withBCR::ABL1AML with myelodysplasia-related cytogenetic abnormalitiesAML with myelodysplasia-related gene mutationAML, NOS (ICC)/ AML defined by differentiation (WHO-HAEM5)",
                      "AML withBCR::ABL1",
                      "AML with myelodysplasia-related cytogenetic abnormalities",
                      "AML with myelodysplasia-related gene mutation",
                      "AML, NOS (ICC)/ AML defined by differentiation (WHO-HAEM5)",
                      "ICC category of AML with mutatedTP53requires ≥ 20% blasts as well",
                      "In addition, WHO-HAEM5 requires ≥ 20% blasts for AML withCEBPAmutation",
                      "No blasts cutoff in WHO-HAEM5 for remaining AML subtypes with recurrent genetic abnormalities",
                      "ICC requires ≥ 10% bone marrow blasts for AML with recurrent genetic abnormalities except for AML withBCR::ABL1and AML withTP53",
                      "AML defined by differentiation in WHO-HAEM5 designated as AML, NOS in ICC"
                    ]
                  }
                ],
                "Common Examples of AML With Recurrent Genetic Abnormalities": [
                  {
                    "text": "AML withBCR::ABL1fusionIncluded in AML with recurrent genetic abnormalities in both classificationsDefined as de novo AML withBCR::ABL1fusion at initial diagnostic presentation and lack of subsequent evidence of chronic myeloid leukemia (CML)Compared with myeloid blast phase of CML, AML withBCR::ABL1frequently presents with higher percentage of blasts, lower basophils, and lower incidence of splenomegaly≥ 20% blasts required by both ICC and WHO-HAEM5May have concurrentNPM1mutationRecognition important due to availability of targeted kinase inhibitors",
                    "sub_points": [
                      "Included in AML with recurrent genetic abnormalities in both classifications",
                      "Defined as de novo AML withBCR::ABL1fusion at initial diagnostic presentation and lack of subsequent evidence of chronic myeloid leukemia (CML)",
                      "Compared with myeloid blast phase of CML, AML withBCR::ABL1frequently presents with higher percentage of blasts, lower basophils, and lower incidence of splenomegaly",
                      "≥ 20% blasts required by both ICC and WHO-HAEM5",
                      "May have concurrentNPM1mutation",
                      "Recognition important due to availability of targeted kinase inhibitors"
                    ]
                  },
                  {
                    "text": "AML with mutatedNPM1Remains unchanged in both WHO-HAEM5 and ICCUsually seen in normal karyotype~ 10% of cases show chromosomal abnormalities, including +8 and del(9q)Rare cooccurrence ofTP53mutation may be seenShould still be classified asNPM1-mutated AML but annotatingTP53mutationMultilineage dysplasia present in ~ 23% of de novoNPM1-mutated AMLNo prognostic significance in absence of prior myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) or MDS-related cytogenetic abnormalitiesImpact of secondary-type myelodysplasia-related gene mutations on outcome remains controversialFavorable prognosis in absence ofFLT3ITDNPM1mutation in secondary AMLLack favorable prognosis seen inNPM1-mutated de novo AML cases",
                    "sub_points": [
                      "Remains unchanged in both WHO-HAEM5 and ICC",
                      "Usually seen in normal karyotype~ 10% of cases show chromosomal abnormalities, including +8 and del(9q)",
                      "~ 10% of cases show chromosomal abnormalities, including +8 and del(9q)",
                      "Rare cooccurrence ofTP53mutation may be seenShould still be classified asNPM1-mutated AML but annotatingTP53mutation",
                      "Should still be classified asNPM1-mutated AML but annotatingTP53mutation",
                      "Multilineage dysplasia present in ~ 23% of de novoNPM1-mutated AMLNo prognostic significance in absence of prior myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) or MDS-related cytogenetic abnormalitiesImpact of secondary-type myelodysplasia-related gene mutations on outcome remains controversial",
                      "No prognostic significance in absence of prior myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) or MDS-related cytogenetic abnormalities",
                      "Impact of secondary-type myelodysplasia-related gene mutations on outcome remains controversial",
                      "Favorable prognosis in absence ofFLT3ITD",
                      "NPM1mutation in secondary AMLLack favorable prognosis seen inNPM1-mutated de novo AML cases",
                      "Lack favorable prognosis seen inNPM1-mutated de novo AML cases"
                    ]
                  },
                  {
                    "text": "AML with inframe basic leucine zipper region (bZIP)CEBPAmutation (ICC)Only inframe mutations involving bZIP confer favorable outcome irrespective of occurrence as biallelic or monoallelic> 10% blasts required for diagnosisFrequent comutation ofGATA2is seenConcurrent cytogenetic abnormalities are uncommonMultilineage dysplasia maybe present in subset of casesNo prognostic significance in absence of MDS-related cytogenetic abnormalities",
                    "sub_points": [
                      "Only inframe mutations involving bZIP confer favorable outcome irrespective of occurrence as biallelic or monoallelic",
                      "> 10% blasts required for diagnosis",
                      "Frequent comutation ofGATA2is seen",
                      "Concurrent cytogenetic abnormalities are uncommon",
                      "Multilineage dysplasia maybe present in subset of casesNo prognostic significance in absence of MDS-related cytogenetic abnormalities",
                      "No prognostic significance in absence of MDS-related cytogenetic abnormalities"
                    ]
                  },
                  {
                    "text": "AML withCEBPAmutation (WHO-HAEM5)Requires presence of biallelic mutations inCEBPAor single mutation located in bZIP region20% blasts required for diagnosis",
                    "sub_points": [
                      "Requires presence of biallelic mutations inCEBPAor single mutation located in bZIP region20% blasts required for diagnosis",
                      "20% blasts required for diagnosis"
                    ]
                  },
                  {
                    "text": "AML with mutatedTP53(ICC)New distinct entity in ICC but not recognized in WHO-HAEM5TP53pathogenic mutation at VAF of ≥ 10% required ± loss of theTP53wildtype alleleRegarded as poor prognostic leukemia",
                    "sub_points": [
                      "New distinct entity in ICC but not recognized in WHO-HAEM5",
                      "TP53pathogenic mutation at VAF of ≥ 10% required ± loss of theTP53wildtype allele",
                      "Regarded as poor prognostic leukemia"
                    ]
                  },
                  {
                    "text": "AML with myelodysplasia-related gene mutation (ICC)Corresponds to AML, myelodysplasia-related of WHO-HAEM5Associated mutated genes includeASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1, andZRSR2≥ 20% blasts required by both classificationsPoor risk category of AML",
                    "sub_points": [
                      "Corresponds to AML, myelodysplasia-related of WHO-HAEM5",
                      "Associated mutated genes includeASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1, andZRSR2≥ 20% blasts required by both classificationsPoor risk category of AML",
                      "ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1, andZRSR2",
                      "≥ 20% blasts required by both classifications",
                      "Poor risk category of AML"
                    ]
                  },
                  {
                    "text": "AML with myelodysplasia-related cytogenetic abnormalities (ICC)Corresponds to AML, myelodysplasia-related in WHO-HAEM5Associated cytogenetic abnormalities includeComplex karyotype or del(5)q/t(5q)/add(5q), -7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p)/del(17p), and del(20q), idic(X)(q13)≥ 20% blasts required by both classifications",
                    "sub_points": [
                      "Corresponds to AML, myelodysplasia-related in WHO-HAEM5",
                      "Associated cytogenetic abnormalities includeComplex karyotype or del(5)q/t(5q)/add(5q), -7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p)/del(17p), and del(20q), idic(X)(q13)",
                      "Complex karyotype or del(5)q/t(5q)/add(5q), -7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p)/del(17p), and del(20q), idic(X)(q13)",
                      "≥ 20% blasts required by both classifications"
                    ]
                  }
                ],
                "Familial AML With Germline Predisposition": [
                  {
                    "text": "Included under separate hematologic neoplasms with germline predisposition"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "All ages affectedMedian: 63 years",
                    "sub_points": [
                      "Median: 63 years"
                    ]
                  },
                  {
                    "text": "Overall, proportion of acute leukemias that are AML increases with age~ 80% of adult acute leukemias are myeloid",
                    "sub_points": [
                      "~ 80% of adult acute leukemias are myeloid"
                    ]
                  },
                  {
                    "text": "Some AML subtypes are more prevalent in older adultsAML with myelodysplasia-related gene mutations or myelodysplasia-related cytogenetic abnormalities",
                    "sub_points": [
                      "AML with myelodysplasia-related gene mutations or myelodysplasia-related cytogenetic abnormalities"
                    ]
                  },
                  {
                    "text": "Some AML subtypes are more prevalent in younger age groupsAML with recurring genetic abnormality [e.g., t(15;17)/PML::RARA, t(8;21)/RUNX1::RUNX1T1, inv(16)/t(16;16)/CBFB::MYH11, t(9;11)/MLLT3::KMT2A]AML with t(1;22)/RBM15::MRTFAoccurs in infants and children < 3 years of ageRare occurrence in young adults have also been reported",
                    "sub_points": [
                      "AML with recurring genetic abnormality [e.g., t(15;17)/PML::RARA, t(8;21)/RUNX1::RUNX1T1, inv(16)/t(16;16)/CBFB::MYH11, t(9;11)/MLLT3::KMT2A]",
                      "AML with t(1;22)/RBM15::MRTFAoccurs in infants and children < 3 years of ageRare occurrence in young adults have also been reported",
                      "Rare occurrence in young adults have also been reported"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "Age-adjusted incidence: 3.4 cases per 100,000 individuals"
                  },
                  {
                    "text": "~ 20,000 new cases in USA each year"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Variable clinical courseClinically aggressive disease in most casesAcute promyelocytic leukemia (APL) can be curedRare cases may regress spontaneouslyNeonatal AML with t(8;16)/KAT6A::CREBBP",
                    "sub_points": [
                      "Clinically aggressive disease in most cases",
                      "Acute promyelocytic leukemia (APL) can be cured",
                      "Rare cases may regress spontaneouslyNeonatal AML with t(8;16)/KAT6A::CREBBP",
                      "Neonatal AML with t(8;16)/KAT6A::CREBBP"
                    ]
                  },
                  {
                    "text": "Prognosis of unfavorable AML subtypes remains poor in older patients and those who are not eligible for allogeneic stem cell transplant"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "De novo AML Development": [
                  {
                    "text": "Somatic driver mutationsSerial acquisition of somatic mutations in hematopoietic stem cells (HSC)",
                    "sub_points": [
                      "Serial acquisition of somatic mutations in hematopoietic stem cells (HSC)"
                    ]
                  },
                  {
                    "text": "Down syndrome (sporadic)10-20x increased risk for AML> 500x increased risk for acute megakaryoblastic leukemia",
                    "sub_points": [
                      "10-20x increased risk for AML",
                      "> 500x increased risk for acute megakaryoblastic leukemia"
                    ]
                  }
                ],
                "Familial Predisposition Syndromes": [
                  {
                    "text": "Inherited bone marrow (BM) failure syndromesFanconi anemia (FA), dyskeratosis congenita, Diamond-Blackfan anemia, severe congenital neutropenia, Shwachman-Diamond syndrome",
                    "sub_points": [
                      "Fanconi anemia (FA), dyskeratosis congenita, Diamond-Blackfan anemia, severe congenital neutropenia, Shwachman-Diamond syndrome"
                    ]
                  },
                  {
                    "text": "Familial platelet disorder with propensity to AML, familial AML with mutated CEBPA, familial AML withGATA2mutations"
                  }
                ],
                "Environmental Exposures": [
                  {
                    "text": "Radiation, benzene, cytotoxic therapy"
                  }
                ],
                "Progression of Underlying Hematopoietic Neoplasm": [
                  {
                    "text": "MDS, MPN, and MDS/MPN overlap neoplasmsSecondary to acquisition of additional genetic mutations",
                    "sub_points": [
                      "Secondary to acquisition of additional genetic mutations"
                    ]
                  }
                ],
                "Pathogenesis of Leukemogenesis": [
                  {
                    "text": "Accumulation of multiple genetic hits"
                  },
                  {
                    "text": "Class I and II mutationsClass I: Proproliferative signale.g.,FLT3,JAK2,KITClass II: Impairment of cellular maturatione.g.,PML::RARA,CEBPA,RUNX1::RUNX1T1",
                    "sub_points": [
                      "Class I: Proproliferative signale.g.,FLT3,JAK2,KIT",
                      "e.g.,FLT3,JAK2,KIT",
                      "Class II: Impairment of cellular maturatione.g.,PML::RARA,CEBPA,RUNX1::RUNX1T1",
                      "e.g.,PML::RARA,CEBPA,RUNX1::RUNX1T1"
                    ]
                  },
                  {
                    "text": "Complex interplay of genetic events contributes to AML pathogenesisAML genome shows fewer mutations compared to other cancersAt least 1 potential driver mutation is detected in each de novo AML based on The Cancer Genome Atlas (TCGA) published dataVirtually all AML cases show at least 1 nonsynonymous mutations in 1 of 9 gene categories, includingTranscription factor fusions,NPM1, tumor suppressor genes, DNA methylation-related genes, signaling genes, chromatin modifying genes, myeloid transcription factor genes, and spliceosome complex genesExamples of well-established mutated genes relevant to AML pathogenesis includeFLT3,NPM1,CEBPA, RUNX1,IDH1, andIDH2",
                    "sub_points": [
                      "AML genome shows fewer mutations compared to other cancersAt least 1 potential driver mutation is detected in each de novo AML based on The Cancer Genome Atlas (TCGA) published data",
                      "At least 1 potential driver mutation is detected in each de novo AML based on The Cancer Genome Atlas (TCGA) published data",
                      "Virtually all AML cases show at least 1 nonsynonymous mutations in 1 of 9 gene categories, includingTranscription factor fusions,NPM1, tumor suppressor genes, DNA methylation-related genes, signaling genes, chromatin modifying genes, myeloid transcription factor genes, and spliceosome complex genes",
                      "Transcription factor fusions,NPM1, tumor suppressor genes, DNA methylation-related genes, signaling genes, chromatin modifying genes, myeloid transcription factor genes, and spliceosome complex genes",
                      "Examples of well-established mutated genes relevant to AML pathogenesis includeFLT3,NPM1,CEBPA, RUNX1,IDH1, andIDH2",
                      "FLT3,NPM1,CEBPA, RUNX1,IDH1, andIDH2"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Symptoms related to BM failureFatigue (anemia), bleeding (thrombocytopenia), infection (neutropenia)",
                    "sub_points": [
                      "Fatigue (anemia), bleeding (thrombocytopenia), infection (neutropenia)"
                    ]
                  },
                  {
                    "text": "Extramedullary involvementSkin lesions, gingival hyperplasia, myeloid sarcomas",
                    "sub_points": [
                      "Skin lesions, gingival hyperplasia, myeloid sarcomas"
                    ]
                  }
                ],
                "Clinical Risk Factors": [],
                "Prognostic factors and risk": [
                  {
                    "text": "Cytogenetics and molecular genetics"
                  },
                  {
                    "text": "Prior chemotherapy &/or radiation"
                  },
                  {
                    "text": "Underlying hematopoietic neoplasm, e.g., MDS"
                  },
                  {
                    "text": "Increasing age (> 60 years), performance status"
                  },
                  {
                    "text": "Elevated LDH"
                  }
                ],
                "Treatment of AML": [
                  {
                    "text": "Initial assessment to determine if patient is candidate for intensive induction chemotherapyTreatment-related mortality (TRM) after intensive chemotherapy is usually among older patients (> 65 years)However, age is not most important predictor of TRMTRM rate is declining with improved supportive care and better health status in older patientsAge alone should not be decisive factor to guide therapyMedically fit older patients may benefit from intensive therapyAdditional factors to be considered in decision making for intensive treatment include performance status, significant comorbidities, and presence or absence of adverse cytogenetics/molecular genetics",
                    "sub_points": [
                      "Treatment-related mortality (TRM) after intensive chemotherapy is usually among older patients (> 65 years)However, age is not most important predictor of TRMTRM rate is declining with improved supportive care and better health status in older patientsAge alone should not be decisive factor to guide therapyMedically fit older patients may benefit from intensive therapy",
                      "However, age is not most important predictor of TRM",
                      "TRM rate is declining with improved supportive care and better health status in older patients",
                      "Age alone should not be decisive factor to guide therapy",
                      "Medically fit older patients may benefit from intensive therapy",
                      "Additional factors to be considered in decision making for intensive treatment include performance status, significant comorbidities, and presence or absence of adverse cytogenetics/molecular genetics"
                    ]
                  },
                  {
                    "text": "Intensive induction therapy3 days of anthracycline and 7 days of cytarabine (also called \"7+3\" regimen)40-60% complete remission in patients ≥ 60 years old",
                    "sub_points": [
                      "3 days of anthracycline and 7 days of cytarabine (also called \"7+3\" regimen)40-60% complete remission in patients ≥ 60 years old",
                      "40-60% complete remission in patients ≥ 60 years old"
                    ]
                  },
                  {
                    "text": "FDA-approved targeted therapiesFLT3inhibitorsMidostaurin is 1st FDA-approvedFLT3-targeted therapy in AMLAddition of midostaurin to chemotherapy has shown increased complete remission rate in clinical trialsPatients withFLT3ITD orFLT3TKD mutation benefit from intensive chemotherapy plus midostaurinIDH2inhibitorsEnasidenib is oralIDH2inhibitor approved by FDAIDH2mutation is required prior to administrationAlternative treatment option for patients with relapsed/refractory AML who are not eligible or not tolerant of intensive therapyOption for patients ≥ 60 years of age withIDH2mutations who are not candidates for intensive therapyEnasidenib adverse effectsThrombocytopenia, hyperbilirubinemia, nausea, fatigueIDH differentiation syndrome in 10% of patients; can be fatalHumanized anti-CD33 antibody (gemtuzumab ozogamicin)Reasonable treatment option in certain AML patientsNewly diagnosed CD33(+) AML in adultsRelapsed/refractory CD33(+) AML in adultsTreatment of AML in pediatric patients ≥ 2 years of ageInduction and consolidation option for patients ≤ 60 years of age with CD33(+) AML of either favorable or intermediate risk or core-binding factor leukemia withoutKITmutation, per NCCN guidelinesMore data may still be needed to find its ideal place in AML therapy",
                    "sub_points": [
                      "FLT3inhibitorsMidostaurin is 1st FDA-approvedFLT3-targeted therapy in AMLAddition of midostaurin to chemotherapy has shown increased complete remission rate in clinical trialsPatients withFLT3ITD orFLT3TKD mutation benefit from intensive chemotherapy plus midostaurin",
                      "Midostaurin is 1st FDA-approvedFLT3-targeted therapy in AML",
                      "Addition of midostaurin to chemotherapy has shown increased complete remission rate in clinical trials",
                      "Patients withFLT3ITD orFLT3TKD mutation benefit from intensive chemotherapy plus midostaurin",
                      "IDH2inhibitorsEnasidenib is oralIDH2inhibitor approved by FDAIDH2mutation is required prior to administrationAlternative treatment option for patients with relapsed/refractory AML who are not eligible or not tolerant of intensive therapyOption for patients ≥ 60 years of age withIDH2mutations who are not candidates for intensive therapyEnasidenib adverse effectsThrombocytopenia, hyperbilirubinemia, nausea, fatigueIDH differentiation syndrome in 10% of patients; can be fatal",
                      "Enasidenib is oralIDH2inhibitor approved by FDA",
                      "IDH2mutation is required prior to administration",
                      "Alternative treatment option for patients with relapsed/refractory AML who are not eligible or not tolerant of intensive therapy",
                      "Option for patients ≥ 60 years of age withIDH2mutations who are not candidates for intensive therapy",
                      "Enasidenib adverse effectsThrombocytopenia, hyperbilirubinemia, nausea, fatigueIDH differentiation syndrome in 10% of patients; can be fatal",
                      "Thrombocytopenia, hyperbilirubinemia, nausea, fatigue",
                      "IDH differentiation syndrome in 10% of patients; can be fatal",
                      "Humanized anti-CD33 antibody (gemtuzumab ozogamicin)Reasonable treatment option in certain AML patientsNewly diagnosed CD33(+) AML in adultsRelapsed/refractory CD33(+) AML in adultsTreatment of AML in pediatric patients ≥ 2 years of ageInduction and consolidation option for patients ≤ 60 years of age with CD33(+) AML of either favorable or intermediate risk or core-binding factor leukemia withoutKITmutation, per NCCN guidelinesMore data may still be needed to find its ideal place in AML therapy",
                      "Reasonable treatment option in certain AML patientsNewly diagnosed CD33(+) AML in adultsRelapsed/refractory CD33(+) AML in adultsTreatment of AML in pediatric patients ≥ 2 years of ageInduction and consolidation option for patients ≤ 60 years of age with CD33(+) AML of either favorable or intermediate risk or core-binding factor leukemia withoutKITmutation, per NCCN guidelines",
                      "Newly diagnosed CD33(+) AML in adults",
                      "Relapsed/refractory CD33(+) AML in adults",
                      "Treatment of AML in pediatric patients ≥ 2 years of age",
                      "Induction and consolidation option for patients ≤ 60 years of age with CD33(+) AML of either favorable or intermediate risk or core-binding factor leukemia withoutKITmutation, per NCCN guidelines",
                      "More data may still be needed to find its ideal place in AML therapy"
                    ]
                  },
                  {
                    "text": "Other agents in active clinical trialsGuadecitabine (hypomethylating agent)Being studied in phase I and II clinical trialsLonger half-life compared to decitabineCurrently under further evaluation in clinical trialsAdditional phase I study of guadecitabine plus atezolizumab is underwayBCL2 inhibitor (venetoclax)Promising results in phase I/II trial in combination with low-dose cytarabineIDH1inhibitorsIvosidenib is 1stIDH1inhibitor for patients withIDH1-mutated AMLImmunotherapy (checkpoint inhibitors)Modest results with PD1 or PDL1 inhibitors in AMLMore promising results in combination with hypomethylating agents or cytotoxic chemotherapy",
                    "sub_points": [
                      "Guadecitabine (hypomethylating agent)Being studied in phase I and II clinical trialsLonger half-life compared to decitabineCurrently under further evaluation in clinical trialsAdditional phase I study of guadecitabine plus atezolizumab is underway",
                      "Being studied in phase I and II clinical trials",
                      "Longer half-life compared to decitabine",
                      "Currently under further evaluation in clinical trials",
                      "Additional phase I study of guadecitabine plus atezolizumab is underway",
                      "BCL2 inhibitor (venetoclax)Promising results in phase I/II trial in combination with low-dose cytarabine",
                      "Promising results in phase I/II trial in combination with low-dose cytarabine",
                      "IDH1inhibitorsIvosidenib is 1stIDH1inhibitor for patients withIDH1-mutated AML",
                      "Ivosidenib is 1stIDH1inhibitor for patients withIDH1-mutated AML",
                      "Immunotherapy (checkpoint inhibitors)Modest results with PD1 or PDL1 inhibitors in AMLMore promising results in combination with hypomethylating agents or cytotoxic chemotherapy",
                      "Modest results with PD1 or PDL1 inhibitors in AML",
                      "More promising results in combination with hypomethylating agents or cytotoxic chemotherapy"
                    ]
                  },
                  {
                    "text": "Intensive chemotherapy followed by autologous transplantationOne randomized study showed better RFS and similar OS to conventional consolidation chemotherapy",
                    "sub_points": [
                      "One randomized study showed better RFS and similar OS to conventional consolidation chemotherapy"
                    ]
                  },
                  {
                    "text": "Maintenance therapyNot part of standard AML treatmentNo convincing evidence of benefit",
                    "sub_points": [
                      "Not part of standard AML treatment",
                      "No convincing evidence of benefit"
                    ]
                  },
                  {
                    "text": "Allogeneic HSC transplantationOnly curative option in patients with primary refractive disease",
                    "sub_points": [
                      "Only curative option in patients with primary refractive disease"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Required Elements": [
                  {
                    "text": "Peripheral blood (PB) &/or BM microscopic examination"
                  },
                  {
                    "text": "Flow cytometry"
                  },
                  {
                    "text": "Cytogenetics"
                  },
                  {
                    "text": "Complete and accurate clinical historyPrior therapy, prior hematologic neoplasm",
                    "sub_points": [
                      "Prior therapy, prior hematologic neoplasm"
                    ]
                  },
                  {
                    "text": "Additional elements to be considered on case-by-case basisCytochemistryFISH when karyotyping is inadequate or cytogenetically cryptic abnormality suspected",
                    "sub_points": [
                      "Cytochemistry",
                      "FISH when karyotyping is inadequate or cytogenetically cryptic abnormality suspected"
                    ]
                  },
                  {
                    "text": "Molecular geneticsFLT3,NPM1,CEBPAmutational analysis requiredUpfront gene panel mutational analysis by next-generation sequencing recommended, includingASXL1,BCOR,BRINP3,CALR,CBL,CSF3R,DNMT3A,EZH2,FLT3,IDH1,IDH2,JAK2,KIT,KRAS,NPM1,NRAS,PHF6,PTPN11,RAD21,RUNX1,SETBP1,SF3B1,SMC1A,SMC3,SRSF2,STAG2,TET2,TP53,U2AF1,WT1, andZRSR2",
                    "sub_points": [
                      "FLT3,NPM1,CEBPAmutational analysis required",
                      "Upfront gene panel mutational analysis by next-generation sequencing recommended, includingASXL1,BCOR,BRINP3,CALR,CBL,CSF3R,DNMT3A,EZH2,FLT3,IDH1,IDH2,JAK2,KIT,KRAS,NPM1,NRAS,PHF6,PTPN11,RAD21,RUNX1,SETBP1,SF3B1,SMC1A,SMC3,SRSF2,STAG2,TET2,TP53,U2AF1,WT1, andZRSR2",
                      "ASXL1,BCOR,BRINP3,CALR,CBL,CSF3R,DNMT3A,EZH2,FLT3,IDH1,IDH2,JAK2,KIT,KRAS,NPM1,NRAS,PHF6,PTPN11,RAD21,RUNX1,SETBP1,SF3B1,SMC1A,SMC3,SRSF2,STAG2,TET2,TP53,U2AF1,WT1, andZRSR2"
                    ]
                  }
                ]
              },
              "Molecular Pathology": {
                "Cytogenetics": [
                  {
                    "text": "~ 50% of AML cases show chromosomal abnormalities"
                  },
                  {
                    "text": "Favorable risk groupAML with t(15;17), t(8;21), inv(16) or t(16;16) cytogenetic abnormalities",
                    "sub_points": [
                      "AML with t(15;17), t(8;21), inv(16) or t(16;16) cytogenetic abnormalities"
                    ]
                  },
                  {
                    "text": "Unfavorable riskComplex cytogenetics (≥ 3), 3q abnormalities, inv(3), del(5q), -5, t(9;22), -17, 11q23 rearrangements excluding 9;11 abnormalities",
                    "sub_points": [
                      "Complex cytogenetics (≥ 3), 3q abnormalities, inv(3), del(5q), -5, t(9;22), -17, 11q23 rearrangements excluding 9;11 abnormalities"
                    ]
                  }
                ],
                "Acquired Gene Alterations": [
                  {
                    "text": "FLT3ITD mutationsDetected in ~ 20% of AML casesLeads to constitutive activation of FLT3 receptor kinaseAssociated with poor prognosis and resistance to standard chemotherapyTesting is recommended in all newly diagnosed AML cases for prognostic and therapeutic decisionsFLT3ITD mutations are not stable over course of diseaseNot useful for disease monitoring",
                    "sub_points": [
                      "Detected in ~ 20% of AML cases",
                      "Leads to constitutive activation of FLT3 receptor kinase",
                      "Associated with poor prognosis and resistance to standard chemotherapy",
                      "Testing is recommended in all newly diagnosed AML cases for prognostic and therapeutic decisions",
                      "FLT3ITD mutations are not stable over course of diseaseNot useful for disease monitoring",
                      "Not useful for disease monitoring"
                    ]
                  },
                  {
                    "text": "FLT3TKD mutationsTesting is recommended forFLT3-targeted therapy",
                    "sub_points": [
                      "Testing is recommended forFLT3-targeted therapy"
                    ]
                  },
                  {
                    "text": "NPM1mutationsPresent in ~ 30% of AMLMore common in cytogenetically normal AML (50-60%)Associated with good prognosis in absence ofFLT3ITD mutationsAre stable over course of diseaseUseful marker for minimal residual disease detection",
                    "sub_points": [
                      "Present in ~ 30% of AML",
                      "More common in cytogenetically normal AML (50-60%)",
                      "Associated with good prognosis in absence ofFLT3ITD mutations",
                      "Are stable over course of diseaseUseful marker for minimal residual disease detection",
                      "Useful marker for minimal residual disease detection"
                    ]
                  },
                  {
                    "text": "CEBPAmutationsCCAAT enhancer binding protein α (CEBPA) gene encodes bZIP transcription factorCEBPAmutations detected in ~ 10% of AMLMostly in normal cytogenetic AMLs and in AML with 9q deletionMutations can be single (50% of mutated case), double (usually biallelic), or homozygousOnly inframe bZIPCEBPAmutations are associated with favorable prognosis per ICC",
                    "sub_points": [
                      "CCAAT enhancer binding protein α (CEBPA) gene encodes bZIP transcription factor",
                      "CEBPAmutations detected in ~ 10% of AML",
                      "Mostly in normal cytogenetic AMLs and in AML with 9q deletion",
                      "Mutations can be single (50% of mutated case), double (usually biallelic), or homozygousOnly inframe bZIPCEBPAmutations are associated with favorable prognosis per ICC",
                      "Only inframe bZIPCEBPAmutations are associated with favorable prognosis per ICC"
                    ]
                  },
                  {
                    "text": "RUNX1mutationsTranscription factor that belongs to core-binding factor αMutations reported in 6-10% of cytogenetically normal AMLRUNX1-mutated AML has unfavorable prognosis with resistance to chemotherapyUseful as marker for disease monitoring",
                    "sub_points": [
                      "Transcription factor that belongs to core-binding factor α",
                      "Mutations reported in 6-10% of cytogenetically normal AML",
                      "RUNX1-mutated AML has unfavorable prognosis with resistance to chemotherapyUseful as marker for disease monitoring",
                      "Useful as marker for disease monitoring"
                    ]
                  },
                  {
                    "text": "TET2mutationsTET2catalyzes conversion of 5-methylcytosine to 5-hydroxymethylcytosineMutations may alter crucial step in DNA methylation and HSC functionsMutations are inactivating type and include deletion, missense, nonsense, and frameshiftDetected in ~ 8% of AML, mostly in cytogenetically normal casesPrognostic significance in AML is not entirely clearControversial in published data in different studies",
                    "sub_points": [
                      "TET2catalyzes conversion of 5-methylcytosine to 5-hydroxymethylcytosineMutations may alter crucial step in DNA methylation and HSC functionsMutations are inactivating type and include deletion, missense, nonsense, and frameshift",
                      "Mutations may alter crucial step in DNA methylation and HSC functions",
                      "Mutations are inactivating type and include deletion, missense, nonsense, and frameshift",
                      "Detected in ~ 8% of AML, mostly in cytogenetically normal cases",
                      "Prognostic significance in AML is not entirely clearControversial in published data in different studies",
                      "Controversial in published data in different studies"
                    ]
                  },
                  {
                    "text": "IDH1andIDH2mutationsEncode cytoplasmic isocitrate dehydrogenase 1 and mitochondrial isocitrate dehydrogenase 2, respectivelyDetected in ~ 7-8% of AML, mostly in cytogenetically normal casesAppear to be associated withNPM1mutationsIDH1mutations appear to be mutually exclusive withTET2mutationsIDH1andIDH2mutations are largely absent in AML with recurrent chromosomal translocationsPrognostic significance ofIDH1andIDH2mutations in AML is controversialFavorable prognosis inIDH1- orIDH2-mutated AML with mutatedNPM1and wildtypeFLT3IDH1-andIDH2-targeted therapies available",
                    "sub_points": [
                      "Encode cytoplasmic isocitrate dehydrogenase 1 and mitochondrial isocitrate dehydrogenase 2, respectively",
                      "Detected in ~ 7-8% of AML, mostly in cytogenetically normal cases",
                      "Appear to be associated withNPM1mutations",
                      "IDH1mutations appear to be mutually exclusive withTET2mutations",
                      "IDH1andIDH2mutations are largely absent in AML with recurrent chromosomal translocations",
                      "Prognostic significance ofIDH1andIDH2mutations in AML is controversialFavorable prognosis inIDH1- orIDH2-mutated AML with mutatedNPM1and wildtypeFLT3",
                      "Favorable prognosis inIDH1- orIDH2-mutated AML with mutatedNPM1and wildtypeFLT3",
                      "IDH1-andIDH2-targeted therapies available"
                    ]
                  },
                  {
                    "text": "DNMT3AmutationsEncodes enzyme that catalyze transfer of methyl group to 5' position of cytosine at CpG dinucleotidesOccur in ~ 20% of cytogenetically normal AMLTypically associated with intermediate cytogenetic profile",
                    "sub_points": [
                      "Encodes enzyme that catalyze transfer of methyl group to 5' position of cytosine at CpG dinucleotides",
                      "Occur in ~ 20% of cytogenetically normal AML",
                      "Typically associated with intermediate cytogenetic profile"
                    ]
                  },
                  {
                    "text": "ASXL1mutationsOccur in ~ 6% of AMLAssociated with adverse prognosis and overall shorter survivalMutations also occur in other hematologic malignancies, including MDS, CML, CMML, and ALL",
                    "sub_points": [
                      "Occur in ~ 6% of AML",
                      "Associated with adverse prognosis and overall shorter survival",
                      "Mutations also occur in other hematologic malignancies, including MDS, CML, CMML, and ALL"
                    ]
                  },
                  {
                    "text": "Many other low-frequency mutations occur in AML"
                  }
                ],
                "Familial AML Gene Mutations": [
                  {
                    "text": "FamilialCEBPA-mutated AMLNear-complete penetrance for AML developmentMost individuals inherit frameshift mutationSubsequent 2nd mutation in normalCEBPAallele is key cooperating mutation in most cases~ 1% of sporadic AML could be attributed to familial AML withCEBPAmutation",
                    "sub_points": [
                      "Near-complete penetrance for AML development",
                      "Most individuals inherit frameshift mutation",
                      "Subsequent 2nd mutation in normalCEBPAallele is key cooperating mutation in most cases",
                      "~ 1% of sporadic AML could be attributed to familial AML withCEBPAmutation"
                    ]
                  },
                  {
                    "text": "FamilialGATA2-mutated AMLSame mutations lead to different clinical syndromesNo genotype-phenotype correlation",
                    "sub_points": [
                      "Same mutations lead to different clinical syndromesNo genotype-phenotype correlation",
                      "No genotype-phenotype correlation"
                    ]
                  },
                  {
                    "text": "Familial platelet disorder with propensity to MDS/AMLMonoallelicRUNX1mutationMissense, nonsense, frameshift, insertion, deletion and rarely translocation can occurProgression to MDS/AML requires 2nd-hit mutations",
                    "sub_points": [
                      "MonoallelicRUNX1mutationMissense, nonsense, frameshift, insertion, deletion and rarely translocation can occur",
                      "Missense, nonsense, frameshift, insertion, deletion and rarely translocation can occur",
                      "Progression to MDS/AML requires 2nd-hit mutations"
                    ]
                  },
                  {
                    "text": "Other mutated genes associated with familial AML includeSRP72,DKC1,DIDO1,DDX41,ETV6,TERT,TERC,ANKRD26, andTP53",
                    "sub_points": [
                      "SRP72,DKC1,DIDO1,DDX41,ETV6,TERT,TERC,ANKRD26, andTP53"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blasts and Blast Equivalents": [
                  {
                    "text": "MyeloblastsCytoplasmic azurophilic granules, Auer rods",
                    "sub_points": [
                      "Cytoplasmic azurophilic granules, Auer rods"
                    ]
                  },
                  {
                    "text": "MonoblastsVery fine cytoplasmic azurophilic granules; abundant blue-gray cytoplasm",
                    "sub_points": [
                      "Very fine cytoplasmic azurophilic granules; abundant blue-gray cytoplasm"
                    ]
                  },
                  {
                    "text": "MegakaryoblastsMay see cytoplasmic blebbing/shedding, but not specific",
                    "sub_points": [
                      "May see cytoplasmic blebbing/shedding, but not specific"
                    ]
                  },
                  {
                    "text": "Promyelocytes in APLSingle or bilobed nuclei, hypo- or hypergranular cytoplasm, may see cytoplasm packed with Auer rods",
                    "sub_points": [
                      "Single or bilobed nuclei, hypo- or hypergranular cytoplasm, may see cytoplasm packed with Auer rods"
                    ]
                  }
                ],
                "Peripheral Blood": [
                  {
                    "text": "Cytopenias"
                  },
                  {
                    "text": "Circulating blasts/blast equivalents"
                  },
                  {
                    "text": "Assess erythrocytes for evidence of disseminated intravascular coagulation"
                  }
                ],
                "Bone Marrow Aspirate": [
                  {
                    "text": "RequirementsWell-stained, adequate specimenIf fibrotic or dry tap, assess touch preparations",
                    "sub_points": [
                      "Well-stained, adequate specimen",
                      "If fibrotic or dry tap, assess touch preparations"
                    ]
                  },
                  {
                    "text": "Enumerate blasts and assess for dysplasia"
                  },
                  {
                    "text": "Assess for increased/abnormal-appearing mast cellsMastocytosis may be concurrent",
                    "sub_points": [
                      "Mastocytosis may be concurrent"
                    ]
                  }
                ],
                "Bone Marrow Core Biopsy": [
                  {
                    "text": "Identify blastsUtilize immunohistochemistry if neededNot all blasts are CD34(+), particularly APL blasts, megakaryocytic, monocytic, and erythroid blastsImmunohistochemistry not as sensitive as flow cytometry",
                    "sub_points": [
                      "Utilize immunohistochemistry if neededNot all blasts are CD34(+), particularly APL blasts, megakaryocytic, monocytic, and erythroid blastsImmunohistochemistry not as sensitive as flow cytometry",
                      "Not all blasts are CD34(+), particularly APL blasts, megakaryocytic, monocytic, and erythroid blasts",
                      "Immunohistochemistry not as sensitive as flow cytometry"
                    ]
                  },
                  {
                    "text": "Assess megakaryocytic dysplasia"
                  },
                  {
                    "text": "Evaluate for associated concurrent neoplasm"
                  }
                ],
                "Specialized Testing": [
                  {
                    "text": "Cytochemical stainsMPOIf positive, confirms myeloid lineageIf negative, does not exclude myeloid lineage~ 5% of acute monoblastic leukemias may show scattered MPO(+) granulesNSEIf positive, confirms monocytic lineageIf negative, does not exclude monocytic lineage",
                    "sub_points": [
                      "MPOIf positive, confirms myeloid lineageIf negative, does not exclude myeloid lineage~ 5% of acute monoblastic leukemias may show scattered MPO(+) granules",
                      "If positive, confirms myeloid lineage",
                      "If negative, does not exclude myeloid lineage",
                      "~ 5% of acute monoblastic leukemias may show scattered MPO(+) granules",
                      "NSEIf positive, confirms monocytic lineageIf negative, does not exclude monocytic lineage",
                      "If positive, confirms monocytic lineage",
                      "If negative, does not exclude monocytic lineage"
                    ]
                  },
                  {
                    "text": "Flow cytometryShould be performed in all new cases of AMLEstablishes lineageEstablishes phenotype \"fingerprint\" for future monitoringBlast markersCD34: Not all blasts are CD34(+)CD117: Also stains pronormoblasts, mast cellsTdT: Stains subset of AMLMyeloid markersMPO, CD13, CD33Monocytic markersCD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)Megakaryocytic markersCD31, CD41, CD42b, CD61Erythroid markersGlycophorin A, hemoglobin A, CD71 (not specific), e-cadherin (expressed in erythroblasts and normoblasts)",
                    "sub_points": [
                      "Should be performed in all new cases of AML",
                      "Establishes lineage",
                      "Establishes phenotype \"fingerprint\" for future monitoring",
                      "Blast markersCD34: Not all blasts are CD34(+)CD117: Also stains pronormoblasts, mast cellsTdT: Stains subset of AML",
                      "CD34: Not all blasts are CD34(+)",
                      "CD117: Also stains pronormoblasts, mast cells",
                      "TdT: Stains subset of AML",
                      "Myeloid markersMPO, CD13, CD33",
                      "MPO, CD13, CD33",
                      "Monocytic markersCD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)",
                      "CD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)",
                      "Megakaryocytic markersCD31, CD41, CD42b, CD61",
                      "CD31, CD41, CD42b, CD61",
                      "Erythroid markersGlycophorin A, hemoglobin A, CD71 (not specific), e-cadherin (expressed in erythroblasts and normoblasts)",
                      "Glycophorin A, hemoglobin A, CD71 (not specific), e-cadherin (expressed in erythroblasts and normoblasts)"
                    ]
                  },
                  {
                    "text": "IHCUseful if flow cytometry inadequate or not performedIn general, fewer antibodies are available compared with flow cytometrySome are unique to IHC, howeverCD68: Myeloid and monocyticLysozyme: MonocyticCD31, CD42b: Megakaryocytic lineage",
                    "sub_points": [
                      "Useful if flow cytometry inadequate or not performed",
                      "In general, fewer antibodies are available compared with flow cytometrySome are unique to IHC, howeverCD68: Myeloid and monocyticLysozyme: MonocyticCD31, CD42b: Megakaryocytic lineage",
                      "Some are unique to IHC, however",
                      "CD68: Myeloid and monocytic",
                      "Lysozyme: Monocytic",
                      "CD31, CD42b: Megakaryocytic lineage"
                    ]
                  },
                  {
                    "text": "CytogeneticsShould be performed in all new cases of AMLSubmit in sodium heparin anticoagulantDiagnostic: e.g., AML with recurring genetic abnormalityPrognostic: Favorable, intermediate, and unfavorable risk groups",
                    "sub_points": [
                      "Should be performed in all new cases of AML",
                      "Submit in sodium heparin anticoagulant",
                      "Diagnostic: e.g., AML with recurring genetic abnormality",
                      "Prognostic: Favorable, intermediate, and unfavorable risk groups"
                    ]
                  },
                  {
                    "text": "FISHPerform as needed, depending on morphologic suspicion and cytogenetic findings",
                    "sub_points": [
                      "Perform as needed, depending on morphologic suspicion and cytogenetic findings"
                    ]
                  },
                  {
                    "text": "Molecular geneticsFLT3,NPM1, andCEBPAmutationsUpfront AML-associated gene panel mutation analysis by next-generation sequencing recommended",
                    "sub_points": [
                      "FLT3,NPM1, andCEBPAmutations",
                      "Upfront AML-associated gene panel mutation analysis by next-generation sequencing recommended"
                    ]
                  }
                ],
                "Monitoring of Measurable Residual Disease": [
                  {
                    "text": "Multiparameter flow cytometryMust distinguish AML cells from normal hematopoietic cells",
                    "sub_points": [
                      "Must distinguish AML cells from normal hematopoietic cells"
                    ]
                  },
                  {
                    "text": "Molecular measurable residual disease (MRD) testingInclude quantitative PCR (qPCR) and next-generation sequencingLeukemia-related abnormalities suitable for qPCR includeNPM1,BCR::ABL1,CBFB::MYH11,RUNX1::RUNX1T1,KMT2A::MLLT3,PML::RARA, and othersShould reach limit of detection at least 10⁻³",
                    "sub_points": [
                      "Include quantitative PCR (qPCR) and next-generation sequencing",
                      "Leukemia-related abnormalities suitable for qPCR includeNPM1,BCR::ABL1,CBFB::MYH11,RUNX1::RUNX1T1,KMT2A::MLLT3,PML::RARA, and others",
                      "Should reach limit of detection at least 10⁻³"
                    ]
                  },
                  {
                    "text": "Mutations consistent with clonal hematopoiesis (e.g.,ASXL1,DNMT3A,TET2) should not be considered as MRD"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Granulocyte Colony-Stimulating Factor Administration": [
                  {
                    "text": "Blasts may account for ≥ 20% in hypocellular specimen"
                  },
                  {
                    "text": "Nonclonal transient phenomenon"
                  }
                ],
                "Blast Phase of Preexisting Myeloid Neoplasms": [
                  {
                    "text": "Clinical history help to separate from de novo AML"
                  }
                ]
              },
              "Recommended Diagnostic Work-Up": {
                "Morphologic Examination": [
                  {
                    "text": "Blood smear review with differential count on at least 200 nucleated cells"
                  },
                  {
                    "text": "BM aspirate review with differential count on at least 500 nucleated cells"
                  },
                  {
                    "text": "≥ 10% myeloblasts is now required to establish diagnosis of AML in several AML categories in ICC, includingAPL withPML::RARAAML with t(8;21);RUNX1::RUNX1T1AML with inv(16)/t(16;16);CBFB::MYH11",
                    "sub_points": [
                      "APL withPML::RARA",
                      "AML with t(8;21);RUNX1::RUNX1T1",
                      "AML with inv(16)/t(16;16);CBFB::MYH11"
                    ]
                  },
                  {
                    "text": "Promonocytes are counted as blast equivalent"
                  },
                  {
                    "text": "Abnormal promyelocytes in APL are counted as blast equivalent"
                  }
                ],
                "Cytochemistry": [
                  {
                    "text": "MPOVery helpful in rapid presumptive diagnosis of hypogranular variant of APL in morphologically suspicious cases",
                    "sub_points": [
                      "Very helpful in rapid presumptive diagnosis of hypogranular variant of APL in morphologically suspicious cases"
                    ]
                  },
                  {
                    "text": "NSEHelpful to assess for monocytic differentiation in blast population",
                    "sub_points": [
                      "Helpful to assess for monocytic differentiation in blast population"
                    ]
                  }
                ],
                "Flow Cytometric Immunophenotyping": [
                  {
                    "text": "CD34, CD117, CD33, CD13, and HLA-DR expressed in majority of AMLCD34 and HLA-DR typically absent in APL",
                    "sub_points": [
                      "CD34 and HLA-DR typically absent in APL"
                    ]
                  }
                ],
                "Myeloid Lineage-Specific Markers": [
                  {
                    "text": "Myeloid granulocytic lineage markersMPO (as determined by flow cytometry, immunohistochemistry, or cytochemistry)Expression of at least 2 of following for monocytic differentiation: CD11c, CD14, CD64, lysozyme, esterase",
                    "sub_points": [
                      "MPO (as determined by flow cytometry, immunohistochemistry, or cytochemistry)",
                      "Expression of at least 2 of following for monocytic differentiation: CD11c, CD14, CD64, lysozyme, esterase"
                    ]
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "Remains mandatory in diagnostic work-up of all suspected AML casesSeveral additional chromosomal translocations and inversions are currently included as \"AML with recurrent genetic abnormalities\"Other balanced and several unbalanced abnormalities are included among \"AML with myelodysplasia-related cytogenetic abnormalities\"",
                    "sub_points": [
                      "Several additional chromosomal translocations and inversions are currently included as \"AML with recurrent genetic abnormalities\"",
                      "Other balanced and several unbalanced abnormalities are included among \"AML with myelodysplasia-related cytogenetic abnormalities\""
                    ]
                  }
                ],
                "FISH": [
                  {
                    "text": "Can be performed as option if cytogenetic analysis failsRecurrent rearrangements, such asPML::RARA,RUNX1::RUNX1T1, andCBFB::MYH11Loss of chromosome 5q, 7q, 17p",
                    "sub_points": [
                      "Recurrent rearrangements, such asPML::RARA,RUNX1::RUNX1T1, andCBFB::MYH11",
                      "Loss of chromosome 5q, 7q, 17p"
                    ]
                  }
                ],
                "Molecular Genetic Testing": [
                  {
                    "text": "NPM1,FLT3,CEBPAmutations required for classificationShould be tested to assess for AML categories defined by these genes mutationsAML with mutatedNPM1Presence of multilineage dysplasia in absence of MDS-related cytogenetic abnormalities has no prognostic significance in de novo AML with mutatedNPM1AML withCEBPAmutationPresence of multilineage dysplasia in absence of MDS-related cytogenetic abnormalities has no prognostic significance in de novo AML with inframe bZIP mutation ofCEBPAFLT3ITD andFLT3tyrosine kinase domain (TKD) mutationsReportFLT3ITD mutant-to-wild type allelic ratioCalculated by ratio of area under curve of mutatedFLT3ITD divided by area under curve of wildtypeFLT3TP53andASXL1mutational analysis highly recommendedBoth have been associated with poor prognosis",
                    "sub_points": [
                      "Should be tested to assess for AML categories defined by these genes mutationsAML with mutatedNPM1Presence of multilineage dysplasia in absence of MDS-related cytogenetic abnormalities has no prognostic significance in de novo AML with mutatedNPM1AML withCEBPAmutationPresence of multilineage dysplasia in absence of MDS-related cytogenetic abnormalities has no prognostic significance in de novo AML with inframe bZIP mutation ofCEBPA",
                      "AML with mutatedNPM1Presence of multilineage dysplasia in absence of MDS-related cytogenetic abnormalities has no prognostic significance in de novo AML with mutatedNPM1",
                      "Presence of multilineage dysplasia in absence of MDS-related cytogenetic abnormalities has no prognostic significance in de novo AML with mutatedNPM1",
                      "AML withCEBPAmutationPresence of multilineage dysplasia in absence of MDS-related cytogenetic abnormalities has no prognostic significance in de novo AML with inframe bZIP mutation ofCEBPA",
                      "Presence of multilineage dysplasia in absence of MDS-related cytogenetic abnormalities has no prognostic significance in de novo AML with inframe bZIP mutation ofCEBPA",
                      "FLT3ITD andFLT3tyrosine kinase domain (TKD) mutationsReportFLT3ITD mutant-to-wild type allelic ratioCalculated by ratio of area under curve of mutatedFLT3ITD divided by area under curve of wildtypeFLT3",
                      "ReportFLT3ITD mutant-to-wild type allelic ratioCalculated by ratio of area under curve of mutatedFLT3ITD divided by area under curve of wildtypeFLT3",
                      "Calculated by ratio of area under curve of mutatedFLT3ITD divided by area under curve of wildtypeFLT3",
                      "TP53andASXL1mutational analysis highly recommendedBoth have been associated with poor prognosis",
                      "Both have been associated with poor prognosis"
                    ]
                  },
                  {
                    "text": "Myeloid gene panelExpanded myeloid gene panel is replacing single gene testing although only few molecular markers are informative in current clinical practiceGenes commonly assessed in myeloid gene panel in many academic centers include but are not limited toASXL1,TP53,RUNX1,DNMT3A,NPM1,CEBPA,FLT3,JAK2,CALR,MPL,IDH1,IDH2,KIT,TET2,CSF3R,SF3B1,SRSF2,SETBP1,U2AF1,EZH2,WT1,KRAS, andNRAS",
                    "sub_points": [
                      "Expanded myeloid gene panel is replacing single gene testing although only few molecular markers are informative in current clinical practice",
                      "Genes commonly assessed in myeloid gene panel in many academic centers include but are not limited toASXL1,TP53,RUNX1,DNMT3A,NPM1,CEBPA,FLT3,JAK2,CALR,MPL,IDH1,IDH2,KIT,TET2,CSF3R,SF3B1,SRSF2,SETBP1,U2AF1,EZH2,WT1,KRAS, andNRAS",
                      "ASXL1,TP53,RUNX1,DNMT3A,NPM1,CEBPA,FLT3,JAK2,CALR,MPL,IDH1,IDH2,KIT,TET2,CSF3R,SF3B1,SRSF2,SETBP1,U2AF1,EZH2,WT1,KRAS, andNRAS"
                    ]
                  },
                  {
                    "text": "Generate integrated report to incorporate all diagnostic and prognostic work-up"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Muscle Sarcomas": {
            "name": "Muscle Sarcomas",
            "url": "https://app.pathprimer.com/document/cda37433-6413-460d-8942-4dac8f58ea22/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Sarcomas phenotypically showing differentiation to smooth muscle or skeletal muscle"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Leiomyosarcoma": [
                  {
                    "text": "SporadicMost common typeComplex genetic alterations with fairly consistent findings",
                    "sub_points": [
                      "Most common type",
                      "Complex genetic alterations with fairly consistent findings"
                    ]
                  },
                  {
                    "text": "Syndrome associatedLi-Fraumeni syndrome: Mutation inTP53Hereditary leiomyomatosis and renal cell cancer (HLRCC)Germline loss of function of fumarate hydratase (FH) (1q)",
                    "sub_points": [
                      "Li-Fraumeni syndrome: Mutation inTP53",
                      "Hereditary leiomyomatosis and renal cell cancer (HLRCC)Germline loss of function of fumarate hydratase (FH) (1q)",
                      "Germline loss of function of fumarate hydratase (FH) (1q)"
                    ]
                  },
                  {
                    "text": "Epstein-Barr virus (EBV) associationAlmost always occurs in setting of immunosuppressionRare cause of leiomyosarcoma (LMS) and leiomyomaUsually excellent prognosis",
                    "sub_points": [
                      "Almost always occurs in setting of immunosuppression",
                      "Rare cause of leiomyosarcoma (LMS) and leiomyoma",
                      "Usually excellent prognosis"
                    ]
                  }
                ],
                "Alveolar Rhabdomyosarcoma": [
                  {
                    "text": "SpecificFOXO1translocations are driver event in at least 90%"
                  },
                  {
                    "text": "Additional rare fusions also reported:PAX3::FOXO4/NCOA1/INO80DorFOXO1::FGFR1"
                  }
                ],
                "Embryonal Rhabdomyosarcoma": [
                  {
                    "text": "SporadicComplex genetic alterations with some relatively consistent findings",
                    "sub_points": [
                      "Complex genetic alterations with some relatively consistent findings"
                    ]
                  },
                  {
                    "text": "Syndrome associatedNeurofibromatosis type 1 (NF1)Rhabdomyosarcoma (RMS) develops in 1.5-6% of NF1 patientsLi-Fraumeni syndromeRMS in setting ofTP53germline mutation often show diffuse anaplasiaHereditary retinoblastoma syndromeGermlineRB1mutationBeckwith-Wiedemann syndromeMethylation abnormalities ofGF2andH19at 11P locusGenes at this site also important in sporadic embryonal RMS (ERMS)",
                    "sub_points": [
                      "Neurofibromatosis type 1 (NF1)Rhabdomyosarcoma (RMS) develops in 1.5-6% of NF1 patients",
                      "Rhabdomyosarcoma (RMS) develops in 1.5-6% of NF1 patients",
                      "Li-Fraumeni syndromeRMS in setting ofTP53germline mutation often show diffuse anaplasia",
                      "RMS in setting ofTP53germline mutation often show diffuse anaplasia",
                      "Hereditary retinoblastoma syndromeGermlineRB1mutation",
                      "GermlineRB1mutation",
                      "Beckwith-Wiedemann syndromeMethylation abnormalities ofGF2andH19at 11P locusGenes at this site also important in sporadic embryonal RMS (ERMS)",
                      "Methylation abnormalities ofGF2andH19at 11P locus",
                      "Genes at this site also important in sporadic embryonal RMS (ERMS)"
                    ]
                  },
                  {
                    "text": "May rarely arise from germ cell tumor of testis, ovary, or mediastinum"
                  }
                ],
                "Spindle Cell/Sclerosing Rhabdomyosarcoma": [
                  {
                    "text": "3 groups of specific genetic alterations"
                  }
                ],
                "Pleomorphic Rhabdomyosarcoma": [
                  {
                    "text": "Complex genetic alterations"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "LMSAge: Middle-aged to older adults most commonlySexF > M for retroperitoneal and large vessel tumorsM > F for deep soft tissue tumorsM = F for superficial tumorsLocationRetroperitoneum most common siteUterine and other müllerian sitesLarge vessel-associated tumors include inferior vena cava and its branches > large leg veins > othersDeep soft tissues of extremities account for 10-15% of extremity sarcomasDermal and subcutaneous tumors occur most commonly on extremitiesMay also occur as primary bone sarcoma",
                    "sub_points": [
                      "Age: Middle-aged to older adults most commonly",
                      "SexF > M for retroperitoneal and large vessel tumorsM > F for deep soft tissue tumorsM = F for superficial tumors",
                      "F > M for retroperitoneal and large vessel tumors",
                      "M > F for deep soft tissue tumors",
                      "M = F for superficial tumors",
                      "LocationRetroperitoneum most common siteUterine and other müllerian sitesLarge vessel-associated tumors include inferior vena cava and its branches > large leg veins > othersDeep soft tissues of extremities account for 10-15% of extremity sarcomasDermal and subcutaneous tumors occur most commonly on extremitiesMay also occur as primary bone sarcoma",
                      "Retroperitoneum most common site",
                      "Uterine and other müllerian sites",
                      "Large vessel-associated tumors include inferior vena cava and its branches > large leg veins > others",
                      "Deep soft tissues of extremities account for 10-15% of extremity sarcomas",
                      "Dermal and subcutaneous tumors occur most commonly on extremities",
                      "May also occur as primary bone sarcoma"
                    ]
                  },
                  {
                    "text": "Alveolar RMS (ARMS)Age: Adolescents to young adults most commonlySex: M = FLocationExtremities (most common location) > trunk/pelvis > retroperitoneumHead and neck; most commonly nasopharynx, sinuses, or parameningealRare patients present with diffuse bone marrow involvement and no known primary site",
                    "sub_points": [
                      "Age: Adolescents to young adults most commonly",
                      "Sex: M = F",
                      "LocationExtremities (most common location) > trunk/pelvis > retroperitoneumHead and neck; most commonly nasopharynx, sinuses, or parameningealRare patients present with diffuse bone marrow involvement and no known primary site",
                      "Extremities (most common location) > trunk/pelvis > retroperitoneum",
                      "Head and neck; most commonly nasopharynx, sinuses, or parameningeal",
                      "Rare patients present with diffuse bone marrow involvement and no known primary site"
                    ]
                  },
                  {
                    "text": "ERMSAge: Children < 10 years most commonlySex: M (slightly) > FLocationHead and neck = genitourinary region (~ 85% of cases) > trunk/extremities (~ 9% of cases) > other visceral locations",
                    "sub_points": [
                      "Age: Children < 10 years most commonly",
                      "Sex: M (slightly) > F",
                      "LocationHead and neck = genitourinary region (~ 85% of cases) > trunk/extremities (~ 9% of cases) > other visceral locations",
                      "Head and neck = genitourinary region (~ 85% of cases) > trunk/extremities (~ 9% of cases) > other visceral locations"
                    ]
                  },
                  {
                    "text": "Spindle cell/sclerosing RMSAgeBimodal distribution in children and adultsCases in infants (< 1 year) show specific genetic alterations and usually nonaggressive behaviorSexM > F ~ 6:1 for adult groupLocationHead and neck: Most common location for spindle cell examples in adults withMYOD1-mutant tumorsParatesticular soft tissues: Most common site for non-EWSR1/FUS::TFCP2spindle cell examples in childrenExtremities: Most common site for sclerosing examplesRarely may occur elsewhere: Retroperitoneum and viscera or craniofacial bones forEWSR1/FUS::TFCP2cases",
                    "sub_points": [
                      "AgeBimodal distribution in children and adultsCases in infants (< 1 year) show specific genetic alterations and usually nonaggressive behavior",
                      "Bimodal distribution in children and adults",
                      "Cases in infants (< 1 year) show specific genetic alterations and usually nonaggressive behavior",
                      "SexM > F ~ 6:1 for adult group",
                      "M > F ~ 6:1 for adult group",
                      "LocationHead and neck: Most common location for spindle cell examples in adults withMYOD1-mutant tumorsParatesticular soft tissues: Most common site for non-EWSR1/FUS::TFCP2spindle cell examples in childrenExtremities: Most common site for sclerosing examplesRarely may occur elsewhere: Retroperitoneum and viscera or craniofacial bones forEWSR1/FUS::TFCP2cases",
                      "Head and neck: Most common location for spindle cell examples in adults withMYOD1-mutant tumors",
                      "Paratesticular soft tissues: Most common site for non-EWSR1/FUS::TFCP2spindle cell examples in children",
                      "Extremities: Most common site for sclerosing examples",
                      "Rarely may occur elsewhere: Retroperitoneum and viscera or craniofacial bones forEWSR1/FUS::TFCP2cases"
                    ]
                  },
                  {
                    "text": "Pleomorphic RMSAge: Middle-aged to older adultsSex: M > FLocationExtremities (especially lower) > trunk > abdomen/retroperitoneum > paratesticular > head and neckRarely reported at other sites, such as uterus",
                    "sub_points": [
                      "Age: Middle-aged to older adults",
                      "Sex: M > F",
                      "LocationExtremities (especially lower) > trunk > abdomen/retroperitoneum > paratesticular > head and neckRarely reported at other sites, such as uterus",
                      "Extremities (especially lower) > trunk > abdomen/retroperitoneum > paratesticular > head and neck",
                      "Rarely reported at other sites, such as uterus"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Surgery ± radiation for local controlComplete surgical excision may be curative in small stage I tumors",
                    "sub_points": [
                      "Complete surgical excision may be curative in small stage I tumors"
                    ]
                  },
                  {
                    "text": "Chemotherapy used for higher stage tumors with surgery ± radiation"
                  },
                  {
                    "text": "New therapies under study: PARP inhibitors + cytotoxic agents, MEK inhibitors + IGFR1 inhibitors, HDAC inhibitors, and novel cytotoxic agents"
                  },
                  {
                    "text": "Specific treatment regimen may be driven by genetic findings rather than morphology in future"
                  }
                ],
                "Outcome": [
                  {
                    "text": "Muscle sarcomas in adults tend to behave more aggressively than most other sarcomas"
                  },
                  {
                    "text": "Stage is best predictor of outcome"
                  },
                  {
                    "text": "Many genetic markers are reportedly prognosticBut none have been prospectively validated in large series except for ARMS translocations",
                    "sub_points": [
                      "But none have been prospectively validated in large series except for ARMS translocations"
                    ]
                  },
                  {
                    "text": "LMSDermal tumors do not metastasize unless invading subcutaneous fatExtremity tumorsLarger tumor size (> 5 cm), deep location, and grade > 1 are adverse prognostic factorsRetroperitoneal tumorsNearly all patients succumb to disease due to recurrences &/or metastasesTumors associated with large vesselsGenerally poor prognosisEBV-related LMSFavorable prognosis (only 5% death rate)",
                    "sub_points": [
                      "Dermal tumors do not metastasize unless invading subcutaneous fat",
                      "Extremity tumorsLarger tumor size (> 5 cm), deep location, and grade > 1 are adverse prognostic factors",
                      "Larger tumor size (> 5 cm), deep location, and grade > 1 are adverse prognostic factors",
                      "Retroperitoneal tumorsNearly all patients succumb to disease due to recurrences &/or metastases",
                      "Nearly all patients succumb to disease due to recurrences &/or metastases",
                      "Tumors associated with large vesselsGenerally poor prognosis",
                      "Generally poor prognosis",
                      "EBV-related LMSFavorable prognosis (only 5% death rate)",
                      "Favorable prognosis (only 5% death rate)"
                    ]
                  },
                  {
                    "text": "ARMSARMS generally behave worse than similarly staged ERMSPAX7::FOXO1tumors behave better thanPAX3::FOXO1tumors",
                    "sub_points": [
                      "ARMS generally behave worse than similarly staged ERMSPAX7::FOXO1tumors behave better thanPAX3::FOXO1tumors",
                      "PAX7::FOXO1tumors behave better thanPAX3::FOXO1tumors"
                    ]
                  },
                  {
                    "text": "ERMSAge is factor: Prognosis better for young children (to 9 years) > older children > adultsPrognosis also varies by histologic variantBotryoid ERMS has relatively good prognosisAnaplastic ERMS has worse prognosisPrognosis also varies by siteOrbital and paratesticular better than extremity and parameningeal tumors",
                    "sub_points": [
                      "Age is factor: Prognosis better for young children (to 9 years) > older children > adults",
                      "Prognosis also varies by histologic variantBotryoid ERMS has relatively good prognosisAnaplastic ERMS has worse prognosis",
                      "Botryoid ERMS has relatively good prognosis",
                      "Anaplastic ERMS has worse prognosis",
                      "Prognosis also varies by siteOrbital and paratesticular better than extremity and parameningeal tumors",
                      "Orbital and paratesticular better than extremity and parameningeal tumors"
                    ]
                  },
                  {
                    "text": "Spindle cell/sclerosing RMSAge: Prognosis better in children than in adultsHowever, pediatric cases withMYOD1mutations behave as aggressively as adult cases withMYOD1mutationsCongenital/infantile type withNCOA2orVGLL2rearrangements has high overall 5-year survivalEWSR1/FUS::TFCP2fusion-positive RMS: Behaves aggressively",
                    "sub_points": [
                      "Age: Prognosis better in children than in adultsHowever, pediatric cases withMYOD1mutations behave as aggressively as adult cases withMYOD1mutationsCongenital/infantile type withNCOA2orVGLL2rearrangements has high overall 5-year survivalEWSR1/FUS::TFCP2fusion-positive RMS: Behaves aggressively",
                      "However, pediatric cases withMYOD1mutations behave as aggressively as adult cases withMYOD1mutations",
                      "Congenital/infantile type withNCOA2orVGLL2rearrangements has high overall 5-year survival",
                      "EWSR1/FUS::TFCP2fusion-positive RMS: Behaves aggressively"
                    ]
                  },
                  {
                    "text": "Pleomorphic RMSPoor prognosis with metastatic rate of ~ 50%",
                    "sub_points": [
                      "Poor prognosis with metastatic rate of ~ 50%"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Leiomyosarcoma": [
                  {
                    "text": "ArchitectureConventional subtypeLong, sweeping fascicles intersecting at 90° anglesRagged cytoplasmic clearing reminiscent of contraction bands in normal smooth muscleMyxoid subtypeGray-blue myxoid matrix reduces cellularity and can obscure fascicular architectureOther variants: Inflammatory, osteoclastic giant-cell rich, pleomorphic, epithelioidEpithelioid subtype grows as solid sheetsHigher grade tumors often have zones of fibrosis and geographic necrosis",
                    "sub_points": [
                      "Conventional subtypeLong, sweeping fascicles intersecting at 90° anglesRagged cytoplasmic clearing reminiscent of contraction bands in normal smooth muscle",
                      "Long, sweeping fascicles intersecting at 90° angles",
                      "Ragged cytoplasmic clearing reminiscent of contraction bands in normal smooth muscle",
                      "Myxoid subtypeGray-blue myxoid matrix reduces cellularity and can obscure fascicular architecture",
                      "Gray-blue myxoid matrix reduces cellularity and can obscure fascicular architecture",
                      "Other variants: Inflammatory, osteoclastic giant-cell rich, pleomorphic, epithelioidEpithelioid subtype grows as solid sheets",
                      "Epithelioid subtype grows as solid sheets",
                      "Higher grade tumors often have zones of fibrosis and geographic necrosis"
                    ]
                  },
                  {
                    "text": "Cell morphologyConventional subtypeEosinophilic plump spindle cells with cigar-shaped or train car-shaped nucleiNuclear pleomorphism increases with gradeMyxoid subtypePlump spindle cells, similar to those in conventional subtype, but also may include polygonal or stellate cellsEpithelioid subtypeLarge, round epithelioid tumor cells with vesicular nuclei and macronucleoliUsually mixed with conventional areasPleomorphic (poorly differentiated) subtypeNonspecific, high-grade, poorly differentiated areas with marked cellular and nuclear pleomorphismUsually mixed with conventional areas",
                    "sub_points": [
                      "Conventional subtypeEosinophilic plump spindle cells with cigar-shaped or train car-shaped nucleiNuclear pleomorphism increases with grade",
                      "Eosinophilic plump spindle cells with cigar-shaped or train car-shaped nuclei",
                      "Nuclear pleomorphism increases with grade",
                      "Myxoid subtypePlump spindle cells, similar to those in conventional subtype, but also may include polygonal or stellate cells",
                      "Plump spindle cells, similar to those in conventional subtype, but also may include polygonal or stellate cells",
                      "Epithelioid subtypeLarge, round epithelioid tumor cells with vesicular nuclei and macronucleoliUsually mixed with conventional areas",
                      "Large, round epithelioid tumor cells with vesicular nuclei and macronucleoli",
                      "Usually mixed with conventional areas",
                      "Pleomorphic (poorly differentiated) subtypeNonspecific, high-grade, poorly differentiated areas with marked cellular and nuclear pleomorphismUsually mixed with conventional areas",
                      "Nonspecific, high-grade, poorly differentiated areas with marked cellular and nuclear pleomorphism",
                      "Usually mixed with conventional areas"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHCMuscle markers positive: SMA, desmin, MSA, caldesmonNegative markers: MYOD1 and myogenin, except in rare cases of mixed LMS/RMSPositivity for at least 2 muscle markers is more supportive of diagnosis than just 1, because other tumor types may express SMA, MSA, or desmin",
                    "sub_points": [
                      "IHCMuscle markers positive: SMA, desmin, MSA, caldesmonNegative markers: MYOD1 and myogenin, except in rare cases of mixed LMS/RMSPositivity for at least 2 muscle markers is more supportive of diagnosis than just 1, because other tumor types may express SMA, MSA, or desmin",
                      "Muscle markers positive: SMA, desmin, MSA, caldesmon",
                      "Negative markers: MYOD1 and myogenin, except in rare cases of mixed LMS/RMS",
                      "Positivity for at least 2 muscle markers is more supportive of diagnosis than just 1, because other tumor types may express SMA, MSA, or desmin"
                    ]
                  }
                ],
                "Alveolar Rhabdomyosarcoma": [
                  {
                    "text": "ArchitectureConventional subtypeAlveolar-like spaces created by tumor cells falling off into central space, leaving single layer of attached lining cellsSolid subtypeSolid sheets or nests separated by dense, fibrous stroma",
                    "sub_points": [
                      "Conventional subtypeAlveolar-like spaces created by tumor cells falling off into central space, leaving single layer of attached lining cells",
                      "Alveolar-like spaces created by tumor cells falling off into central space, leaving single layer of attached lining cells",
                      "Solid subtypeSolid sheets or nests separated by dense, fibrous stroma",
                      "Solid sheets or nests separated by dense, fibrous stroma"
                    ]
                  },
                  {
                    "text": "Cell morphologyMedium-sized round cells with high N:C ratioSpindle cells or clear cells may rarely be present\"Wreath cells\" = tumor giant cells with peripheral ring of nucleiRelatively common and clue to diagnosisRhabdomyoblastsEosinophilic cells ± cross striations = more differentiated tumor cells",
                    "sub_points": [
                      "Medium-sized round cells with high N:C ratio",
                      "Spindle cells or clear cells may rarely be present",
                      "\"Wreath cells\" = tumor giant cells with peripheral ring of nucleiRelatively common and clue to diagnosis",
                      "Relatively common and clue to diagnosis",
                      "RhabdomyoblastsEosinophilic cells ± cross striations = more differentiated tumor cells",
                      "Eosinophilic cells ± cross striations = more differentiated tumor cells"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHCMuscle markers: Myogenin (usually diffusely strongly positive), MYOD1 in more differentiated rhabdomyoblasts; CD56, desmin also positiveOther markers uncommonly positive: Keratins, chromogranin, synaptophysinFISH for specific translocationsBreak-apart probe forFOXO1positive in ~ 90% of cases withFOXO1translocations",
                    "sub_points": [
                      "IHCMuscle markers: Myogenin (usually diffusely strongly positive), MYOD1 in more differentiated rhabdomyoblasts; CD56, desmin also positiveOther markers uncommonly positive: Keratins, chromogranin, synaptophysin",
                      "Muscle markers: Myogenin (usually diffusely strongly positive), MYOD1 in more differentiated rhabdomyoblasts; CD56, desmin also positive",
                      "Other markers uncommonly positive: Keratins, chromogranin, synaptophysin",
                      "FISH for specific translocationsBreak-apart probe forFOXO1positive in ~ 90% of cases withFOXO1translocations",
                      "Break-apart probe forFOXO1positive in ~ 90% of cases withFOXO1translocations"
                    ]
                  }
                ],
                "Embryonal Rhabdomyosarcoma": [
                  {
                    "text": "ArchitectureConventional subtypeAlternating hypercellular and hypocellular areas often with myxoid backgroundCellular fascicles and sheetsBotryoid subtypeCambium layer: Band of hypercellular tumor running under epithelial surfaceLobules usually myxoid and sparsely cellularDense pattern subtypeMimics solid-type ARMSSolid sheets of round blue cellsAnaplastic subtypeDiffuse or focal distribution of markedly pleomorphic tumor cells",
                    "sub_points": [
                      "Conventional subtypeAlternating hypercellular and hypocellular areas often with myxoid backgroundCellular fascicles and sheets",
                      "Alternating hypercellular and hypocellular areas often with myxoid background",
                      "Cellular fascicles and sheets",
                      "Botryoid subtypeCambium layer: Band of hypercellular tumor running under epithelial surfaceLobules usually myxoid and sparsely cellular",
                      "Cambium layer: Band of hypercellular tumor running under epithelial surface",
                      "Lobules usually myxoid and sparsely cellular",
                      "Dense pattern subtypeMimics solid-type ARMSSolid sheets of round blue cells",
                      "Mimics solid-type ARMS",
                      "Solid sheets of round blue cells",
                      "Anaplastic subtypeDiffuse or focal distribution of markedly pleomorphic tumor cells",
                      "Diffuse or focal distribution of markedly pleomorphic tumor cells"
                    ]
                  },
                  {
                    "text": "Cell morphologyConventional and botryoid ERMSRound to ovoid to stellate, less differentiated cellsCells showing more myogenic features, including brightly eosinophilic cytoplasm ± cross striationsDense pattern subtypePredominantly primitive round blue cells packed tightly togetherAnaplastic ERMSMarkedly pleomorphic with irregular enlarged and multilobated, hyperchromatic nuclei and coarse chromatinMitoses (including atypical forms) commonConventional cells also often present",
                    "sub_points": [
                      "Conventional and botryoid ERMSRound to ovoid to stellate, less differentiated cellsCells showing more myogenic features, including brightly eosinophilic cytoplasm ± cross striations",
                      "Round to ovoid to stellate, less differentiated cells",
                      "Cells showing more myogenic features, including brightly eosinophilic cytoplasm ± cross striations",
                      "Dense pattern subtypePredominantly primitive round blue cells packed tightly together",
                      "Predominantly primitive round blue cells packed tightly together",
                      "Anaplastic ERMSMarkedly pleomorphic with irregular enlarged and multilobated, hyperchromatic nuclei and coarse chromatinMitoses (including atypical forms) commonConventional cells also often present",
                      "Markedly pleomorphic with irregular enlarged and multilobated, hyperchromatic nuclei and coarse chromatin",
                      "Mitoses (including atypical forms) common",
                      "Conventional cells also often present"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHCMuscle markers usually show patchy positivity for myogenin in contrast to ARMS, which almost always shows diffuse strong reactivity; CD56, desmin also positive; MYOD1 in more differentiated tumor cells; SMA sometimes positiveOther markers: Membranous expression of CD99 in some cases; cytoplasmic expression of WT1 in some cases; rarely keratins, S100, and NFPFISH:FOXO1is intact by break-apart probe testing",
                    "sub_points": [
                      "IHCMuscle markers usually show patchy positivity for myogenin in contrast to ARMS, which almost always shows diffuse strong reactivity; CD56, desmin also positive; MYOD1 in more differentiated tumor cells; SMA sometimes positiveOther markers: Membranous expression of CD99 in some cases; cytoplasmic expression of WT1 in some cases; rarely keratins, S100, and NFP",
                      "Muscle markers usually show patchy positivity for myogenin in contrast to ARMS, which almost always shows diffuse strong reactivity; CD56, desmin also positive; MYOD1 in more differentiated tumor cells; SMA sometimes positive",
                      "Other markers: Membranous expression of CD99 in some cases; cytoplasmic expression of WT1 in some cases; rarely keratins, S100, and NFP",
                      "FISH:FOXO1is intact by break-apart probe testing"
                    ]
                  }
                ],
                "Spindle Cell/Sclerosing Rhabdomyosarcoma": [
                  {
                    "text": "ArchitectureCongenital/infantile group: Crowded fascicles of spindled cells ± fibrotic background ± areas of conventional ERMSAdult group: Fascicles of spindled cells often with dense, collagenized background, sometimes imparting clefted pseudovascular appearanceEWSR1/FUS::TFCP2RMS group: Sheets and fascicles of spindled and epithelioid tumor cells",
                    "sub_points": [
                      "Congenital/infantile group: Crowded fascicles of spindled cells ± fibrotic background ± areas of conventional ERMS",
                      "Adult group: Fascicles of spindled cells often with dense, collagenized background, sometimes imparting clefted pseudovascular appearance",
                      "EWSR1/FUS::TFCP2RMS group: Sheets and fascicles of spindled and epithelioid tumor cells"
                    ]
                  },
                  {
                    "text": "Cell morphologySpindled cells are plump to elongate with vesicular to hyperchromatic spindled nucleiEpithelioid cells also present inEWSR1/FUS::TFCP2RMSPrimitive (blastic) cells &/or more differentiated rhabdomyoblasts may be presentPleomorphic cells may be presentEspecially in adult cases",
                    "sub_points": [
                      "Spindled cells are plump to elongate with vesicular to hyperchromatic spindled nucleiEpithelioid cells also present inEWSR1/FUS::TFCP2RMS",
                      "Epithelioid cells also present inEWSR1/FUS::TFCP2RMS",
                      "Primitive (blastic) cells &/or more differentiated rhabdomyoblasts may be present",
                      "Pleomorphic cells may be presentEspecially in adult cases",
                      "Especially in adult cases"
                    ]
                  },
                  {
                    "text": "Ancillary studiesIHCMuscle markers: Myogenin often only focally positive in scattered cells; desmin and (often) SMA positiveOther markers: EMA and keratins may be positive (keratins and ALK usually positive inEWSR1/FUS::TFCP2RMS)ISHCongenital/infantile type may show specificNCOA2orVGLL2rearrangementsTFCP2rearrangements inEWSR1/FUS::TFCP2RMSPCR/Sanger sequencing or next-generation sequencingAdult group:MYOD1mutations",
                    "sub_points": [
                      "IHCMuscle markers: Myogenin often only focally positive in scattered cells; desmin and (often) SMA positiveOther markers: EMA and keratins may be positive (keratins and ALK usually positive inEWSR1/FUS::TFCP2RMS)",
                      "Muscle markers: Myogenin often only focally positive in scattered cells; desmin and (often) SMA positive",
                      "Other markers: EMA and keratins may be positive (keratins and ALK usually positive inEWSR1/FUS::TFCP2RMS)",
                      "ISHCongenital/infantile type may show specificNCOA2orVGLL2rearrangementsTFCP2rearrangements inEWSR1/FUS::TFCP2RMS",
                      "Congenital/infantile type may show specificNCOA2orVGLL2rearrangements",
                      "TFCP2rearrangements inEWSR1/FUS::TFCP2RMS",
                      "PCR/Sanger sequencing or next-generation sequencingAdult group:MYOD1mutations",
                      "Adult group:MYOD1mutations"
                    ]
                  }
                ],
                "Pleomorphic Rhabdomyosarcoma": [
                  {
                    "text": "ArchitectureSheets and fascicles of pleomorphic cells",
                    "sub_points": [
                      "Sheets and fascicles of pleomorphic cells"
                    ]
                  },
                  {
                    "text": "Cell morphologyPleomorphic spindled tumor cells with irregular, hyperchromatic nucleiTumor giant cellsFew cells may have marked cytoplasmic eosinophilia, suggesting diagnosisHigh mitotic rate with atypical mitotic figuresDifferentiated rhabdomyoblasts with cross striations are usually absent",
                    "sub_points": [
                      "Pleomorphic spindled tumor cells with irregular, hyperchromatic nuclei",
                      "Tumor giant cells",
                      "Few cells may have marked cytoplasmic eosinophilia, suggesting diagnosis",
                      "High mitotic rate with atypical mitotic figures",
                      "Differentiated rhabdomyoblasts with cross striations are usually absent"
                    ]
                  },
                  {
                    "text": "Ancillary studiesDesmin positive; reactivity for myogenin may be focal; MYOD1 usually negative",
                    "sub_points": [
                      "Desmin positive; reactivity for myogenin may be focal; MYOD1 usually negative"
                    ]
                  }
                ]
              },
              "Genetic Findings": {
                "Leiomyosarcoma": [
                  {
                    "text": "KaryotypeComplex aneuploid karyotype found in majority of cases",
                    "sub_points": [
                      "Complex aneuploid karyotype found in majority of cases"
                    ]
                  },
                  {
                    "text": "Chromosomal microarrayCopy number losses > gainsSpecific gain or loss is usually seen in ≤ 20% of cases, except for 13q loss (~ 60% of cases)Copy number gains: 1q12-q31, 17pCopy number losses: 1p36, 1q41-qter, 2p15-pter, 3p21-23, 8p21-pter, 9p21, 10q23-qter, 11q22-qter, 13q12-q14, 13q32-qter, 9p21, 16q, 18p11Losses at 1p36 and 8p21-pter may increase risk of metastasis",
                    "sub_points": [
                      "Copy number losses > gains",
                      "Specific gain or loss is usually seen in ≤ 20% of cases, except for 13q loss (~ 60% of cases)",
                      "Copy number gains: 1q12-q31, 17p",
                      "Copy number losses: 1p36, 1q41-qter, 2p15-pter, 3p21-23, 8p21-pter, 9p21, 10q23-qter, 11q22-qter, 13q12-q14, 13q32-qter, 9p21, 16q, 18p11Losses at 1p36 and 8p21-pter may increase risk of metastasis",
                      "Losses at 1p36 and 8p21-pter may increase risk of metastasis"
                    ]
                  },
                  {
                    "text": "Major genes alteredTP53: Mutated or lost (~ 90%)RB1:Lost (~ 95%)CDKN2A: Lost or hypermethylatedInactivation may independently impart worse prognosisPTEN: Lost or inactivating mutation (~ 60%); rarely gain-of-function mutationMYOCD: Amplified in 70%ATRX: Loss of expression in ~ 33%DMD: Mutated in ~ 50%",
                    "sub_points": [
                      "TP53: Mutated or lost (~ 90%)",
                      "RB1:Lost (~ 95%)",
                      "CDKN2A: Lost or hypermethylatedInactivation may independently impart worse prognosis",
                      "Inactivation may independently impart worse prognosis",
                      "PTEN: Lost or inactivating mutation (~ 60%); rarely gain-of-function mutation",
                      "MYOCD: Amplified in 70%",
                      "ATRX: Loss of expression in ~ 33%",
                      "DMD: Mutated in ~ 50%"
                    ]
                  },
                  {
                    "text": "Major pathways dysregulatedCell cyclePI3K/AKT pathwayTelomere maintenanceAlternative lengthening of telomeres (ALT) found in ~ 60% of casesMuscle development pathwaysCell assembly and organization pathwaysDNA replication, recombination, and repair pathwaysCD44/AKT pathway",
                    "sub_points": [
                      "Cell cycle",
                      "PI3K/AKT pathway",
                      "Telomere maintenanceAlternative lengthening of telomeres (ALT) found in ~ 60% of cases",
                      "Alternative lengthening of telomeres (ALT) found in ~ 60% of cases",
                      "Muscle development pathways",
                      "Cell assembly and organization pathways",
                      "DNA replication, recombination, and repair pathways",
                      "CD44/AKT pathway"
                    ]
                  },
                  {
                    "text": "Gene expression profiling results identify distinct subsets of LMSTranscriptionally distinctive subsets vary by investigator4 studies each divided LMS into 3 subsets based on differential gene expressionProposed subsets were not independently prognosticMost recent attempt at transcriptional subtyping divided LMS into sets based on gene expression in distinct smooth muscle tumor cell lineagesDedifferentiated, abdominal, abdominal or extremity, gynecologicSRCoverexpressed in most LMSLMS of retroperitoneum may have distinct gene expression profile compared to LMS of other sites (based on results of 2 studies)",
                    "sub_points": [
                      "Transcriptionally distinctive subsets vary by investigator4 studies each divided LMS into 3 subsets based on differential gene expressionProposed subsets were not independently prognosticMost recent attempt at transcriptional subtyping divided LMS into sets based on gene expression in distinct smooth muscle tumor cell lineagesDedifferentiated, abdominal, abdominal or extremity, gynecologic",
                      "4 studies each divided LMS into 3 subsets based on differential gene expressionProposed subsets were not independently prognostic",
                      "Proposed subsets were not independently prognostic",
                      "Most recent attempt at transcriptional subtyping divided LMS into sets based on gene expression in distinct smooth muscle tumor cell lineagesDedifferentiated, abdominal, abdominal or extremity, gynecologic",
                      "Dedifferentiated, abdominal, abdominal or extremity, gynecologic",
                      "SRCoverexpressed in most LMS",
                      "LMS of retroperitoneum may have distinct gene expression profile compared to LMS of other sites (based on results of 2 studies)"
                    ]
                  },
                  {
                    "text": "EpigeneticsmiRNAs upregulated that are involved in smooth muscle differentiation and in mesenchymal stem cell proliferation",
                    "sub_points": [
                      "miRNAs upregulated that are involved in smooth muscle differentiation and in mesenchymal stem cell proliferation"
                    ]
                  }
                ],
                "Alveolar Rhabdomyosarcoma": [
                  {
                    "text": "~ 90% of ARMS contain specific gene fusion as driver event"
                  },
                  {
                    "text": "Fusion genest(2;13);PAX3::FOXO1Accounts for ~ 65-75% of fusion-positive ARMSt(1;13);PAX7::FOXO1Accounts for ~ 20-25% of fusion-positive ARMSOther rare fusions reported include eitherPAX3orFOXO1with novel partnersFusion proteins act as potent and highly expressed transcriptional activators that affectProliferation pathwaysApoptosis pathwaysMyogenic differentiationMotility pathways",
                    "sub_points": [
                      "t(2;13);PAX3::FOXO1Accounts for ~ 65-75% of fusion-positive ARMS",
                      "Accounts for ~ 65-75% of fusion-positive ARMS",
                      "t(1;13);PAX7::FOXO1Accounts for ~ 20-25% of fusion-positive ARMS",
                      "Accounts for ~ 20-25% of fusion-positive ARMS",
                      "Other rare fusions reported include eitherPAX3orFOXO1with novel partners",
                      "Fusion proteins act as potent and highly expressed transcriptional activators that affectProliferation pathwaysApoptosis pathwaysMyogenic differentiationMotility pathways",
                      "Proliferation pathways",
                      "Apoptosis pathways",
                      "Myogenic differentiation",
                      "Motility pathways"
                    ]
                  },
                  {
                    "text": "KaryotypeTranslocations can be identified in karyotype in most casesTetraploid karyotype found in few cases",
                    "sub_points": [
                      "Translocations can be identified in karyotype in most cases",
                      "Tetraploid karyotype found in few cases"
                    ]
                  },
                  {
                    "text": "Chromosomal microarrayShares some of copy number losses with ERMS but generally at lower frequencyCommonly amplified sites include 1p36, 2p24, 12q13-q14, 13q14, 13q31ARMS has higher rate of amplifications than ERMS13q14 and 13q31 amplified preferentially inPAX7::FOXO1cases12q13-q15 amplified preferentially inPAX3::FOXO1cases",
                    "sub_points": [
                      "Shares some of copy number losses with ERMS but generally at lower frequency",
                      "Commonly amplified sites include 1p36, 2p24, 12q13-q14, 13q14, 13q31ARMS has higher rate of amplifications than ERMS13q14 and 13q31 amplified preferentially inPAX7::FOXO1cases12q13-q15 amplified preferentially inPAX3::FOXO1cases",
                      "ARMS has higher rate of amplifications than ERMS",
                      "13q14 and 13q31 amplified preferentially inPAX7::FOXO1cases",
                      "12q13-q15 amplified preferentially inPAX3::FOXO1cases"
                    ]
                  },
                  {
                    "text": "Additional genes altered beyond fusion genesFew genes are mutated in ARMS compared to ~ 30% of ERMS casesFibroblast growth factors overexpressed or upregulatedMYCandMYCNoverexpressedGenes close toPAXcommonly altered:NRAS,KRAS,FGFR4,PIK3CA,CTNNB1,FBXW7, andBCORALKoverexpressed in most casesSMARCA4overexpressed in most cases",
                    "sub_points": [
                      "Few genes are mutated in ARMS compared to ~ 30% of ERMS cases",
                      "Fibroblast growth factors overexpressed or upregulated",
                      "MYCandMYCNoverexpressed",
                      "Genes close toPAXcommonly altered:NRAS,KRAS,FGFR4,PIK3CA,CTNNB1,FBXW7, andBCOR",
                      "ALKoverexpressed in most cases",
                      "SMARCA4overexpressed in most cases"
                    ]
                  },
                  {
                    "text": "Epigenetic alterations include overexpression ofPRC2, which hypermethylates histone H3"
                  }
                ],
                "Embryonal Rhabdomyosarcoma": [
                  {
                    "text": "KaryotypeComplex aneuploid karyotype found in most casesMild hyperdiploidy in subset (tetraploidy is rare)",
                    "sub_points": [
                      "Complex aneuploid karyotype found in most cases",
                      "Mild hyperdiploidy in subset (tetraploidy is rare)"
                    ]
                  },
                  {
                    "text": "Chromosomal microarrayNone of gains or losses are universalCopy number gains: 1q, 8q (8 gains in ~ 70%), 19q, 20q most commonCopy number losses: 3 or part of 3 (most common), 9, 10Amplification of 12q13-15Most common site of allelic loss: 11p15.5",
                    "sub_points": [
                      "None of gains or losses are universal",
                      "Copy number gains: 1q, 8q (8 gains in ~ 70%), 19q, 20q most common",
                      "Copy number losses: 3 or part of 3 (most common), 9, 10",
                      "Amplification of 12q13-15",
                      "Most common site of allelic loss: 11p15.5"
                    ]
                  },
                  {
                    "text": "Major genes altered or differentially expressedInactivation of tumor suppressor gene at 11p15.5GenesRAS pathway genes: Mutated in ~ 50% of cases (NRAS,KRAS,HRAS,FGFR4,NF1,PIK3CA)Other mutated genes:TP53(~ 10%),BCOR(~ 15%),DICER1(especially in RMS of female genital tract)Genes amplified:MYCN,CDK4Fibroblast growth factors often overexpressedSNAI2highly overexpressedSNAIL family transcription factor: Acts as oncogene to inhibit MYOD-driven differentiation and instead promote tumor growthRepresses expression of myogenic differentiation regulators:MYOD1,MYOG,MEFfamily TEFs, andCDKN1ASIX1highly overexpressedSIXfamily transcription factor: Acts as oncogene to inhibit muscle cell differentiation at early point in cell differentiation",
                    "sub_points": [
                      "Inactivation of tumor suppressor gene at 11p15.5",
                      "GenesRAS pathway genes: Mutated in ~ 50% of cases (NRAS,KRAS,HRAS,FGFR4,NF1,PIK3CA)Other mutated genes:TP53(~ 10%),BCOR(~ 15%),DICER1(especially in RMS of female genital tract)Genes amplified:MYCN,CDK4",
                      "RAS pathway genes: Mutated in ~ 50% of cases (NRAS,KRAS,HRAS,FGFR4,NF1,PIK3CA)",
                      "Other mutated genes:TP53(~ 10%),BCOR(~ 15%),DICER1(especially in RMS of female genital tract)",
                      "Genes amplified:MYCN,CDK4",
                      "Fibroblast growth factors often overexpressed",
                      "SNAI2highly overexpressedSNAIL family transcription factor: Acts as oncogene to inhibit MYOD-driven differentiation and instead promote tumor growthRepresses expression of myogenic differentiation regulators:MYOD1,MYOG,MEFfamily TEFs, andCDKN1A",
                      "SNAIL family transcription factor: Acts as oncogene to inhibit MYOD-driven differentiation and instead promote tumor growth",
                      "Represses expression of myogenic differentiation regulators:MYOD1,MYOG,MEFfamily TEFs, andCDKN1A",
                      "SIX1highly overexpressedSIXfamily transcription factor: Acts as oncogene to inhibit muscle cell differentiation at early point in cell differentiation",
                      "SIXfamily transcription factor: Acts as oncogene to inhibit muscle cell differentiation at early point in cell differentiation"
                    ]
                  },
                  {
                    "text": "Major pathways dysregulated: PI3K/AKT and other downstream pathways of FGF and IGF signaling and WNT/β-catenin signaling"
                  },
                  {
                    "text": "Epigenetic alterations are distinct from those in ARMSEpigenetic changes in both ARMS and ERMS include hypermethylation of various tumor suppressor and cell differentiation genes",
                    "sub_points": [
                      "Epigenetic changes in both ARMS and ERMS include hypermethylation of various tumor suppressor and cell differentiation genes"
                    ]
                  }
                ],
                "Spindle Cell/Sclerosing Rhabdomyosarcoma": [
                  {
                    "text": "3 genetic groups now recognized"
                  },
                  {
                    "text": "Spindle cell/sclerosing RMS adult groupMost common in adolescents → adultsComplex aneuploid karyotype, including gains and losses of whole and partial chromosomesGenes alteredMYOD1mutations in ~ 60%PIK3CAmutations in ~ 30%DualMYOD1andPIK3CAmutations appear to correlate with sclerosing morphology",
                    "sub_points": [
                      "Most common in adolescents → adults",
                      "Complex aneuploid karyotype, including gains and losses of whole and partial chromosomes",
                      "Genes alteredMYOD1mutations in ~ 60%PIK3CAmutations in ~ 30%DualMYOD1andPIK3CAmutations appear to correlate with sclerosing morphology",
                      "MYOD1mutations in ~ 60%",
                      "PIK3CAmutations in ~ 30%DualMYOD1andPIK3CAmutations appear to correlate with sclerosing morphology",
                      "DualMYOD1andPIK3CAmutations appear to correlate with sclerosing morphology"
                    ]
                  },
                  {
                    "text": "Congenital/infantile groupMost cases show specific rearrangementNCOA2fusionst(8;11);TEAD1::NCOA2t(6;8)(p21;q13);SRF::NCOA2t(6;8)(q22'q13);VGLL2::NCOA2AdditionalVGLL2(6q22) rearrangementt(6;6);VGLL2::CITED2Chromosome 6q22-23 breaks and inverts, resulting in fusion of 3'CITED2to 5'VGLL2Normal role ofNCOA2: Transcriptional coactivator for nuclear hormone receptors, including vitamin D, thyroid, steroid, and retinoid receptorsForms pathogenic fusions in some cases of acute myeloid leukemia, acute lymphoblastic leukemia, and most cases of mesenchymal chondrosarcoma (fusing withHEY1)Normal roles ofTEAD1,SRF,VGLL2: Help control skeletal muscle-specific gene transcription",
                    "sub_points": [
                      "Most cases show specific rearrangement",
                      "NCOA2fusionst(8;11);TEAD1::NCOA2t(6;8)(p21;q13);SRF::NCOA2t(6;8)(q22'q13);VGLL2::NCOA2",
                      "t(8;11);TEAD1::NCOA2",
                      "t(6;8)(p21;q13);SRF::NCOA2",
                      "t(6;8)(q22'q13);VGLL2::NCOA2",
                      "AdditionalVGLL2(6q22) rearrangementt(6;6);VGLL2::CITED2Chromosome 6q22-23 breaks and inverts, resulting in fusion of 3'CITED2to 5'VGLL2",
                      "t(6;6);VGLL2::CITED2Chromosome 6q22-23 breaks and inverts, resulting in fusion of 3'CITED2to 5'VGLL2",
                      "Chromosome 6q22-23 breaks and inverts, resulting in fusion of 3'CITED2to 5'VGLL2",
                      "Normal role ofNCOA2: Transcriptional coactivator for nuclear hormone receptors, including vitamin D, thyroid, steroid, and retinoid receptorsForms pathogenic fusions in some cases of acute myeloid leukemia, acute lymphoblastic leukemia, and most cases of mesenchymal chondrosarcoma (fusing withHEY1)",
                      "Forms pathogenic fusions in some cases of acute myeloid leukemia, acute lymphoblastic leukemia, and most cases of mesenchymal chondrosarcoma (fusing withHEY1)",
                      "Normal roles ofTEAD1,SRF,VGLL2: Help control skeletal muscle-specific gene transcription"
                    ]
                  },
                  {
                    "text": "EWSR1/FUS::TFCP2groupOccurs in all age groupsMost commonly craniofacial bones (intraosseous)MEIS1::NCOA2cases: Included withEWSR1/FUS::TFCP2cases as aggressive, intraosseous RMS",
                    "sub_points": [
                      "Occurs in all age groups",
                      "Most commonly craniofacial bones (intraosseous)",
                      "MEIS1::NCOA2cases: Included withEWSR1/FUS::TFCP2cases as aggressive, intraosseous RMS"
                    ]
                  }
                ],
                "Pleomorphic Rhabdomyosarcoma": [
                  {
                    "text": "KaryotypeOnly few cases studiedComplex aneuploid karyotype: Most commonly loss of chromosomes 2,13,14,15,16, and 19",
                    "sub_points": [
                      "Only few cases studied",
                      "Complex aneuploid karyotype: Most commonly loss of chromosomes 2,13,14,15,16, and 19"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "DDx for Leiomyosarcoma": [
                  {
                    "text": "Other fascicular spindle cell sarcomasMalignant peripheral nerve sheath tumorNegative muscle markers except malignant triton tumor, which also expresses neural markers, such as patchy S100 and SOX10Low-grade myofibroblastic sarcomaUsually desmin negativeSynovial sarcomaNegative muscle markers; positive for TLE1; positive for t(X;18)Fibrosarcoma arising in dermatofibrosarcoma protuberansMay have lower grade areas present; usually negative for 2 muscle markers; positive for t(17;22)",
                    "sub_points": [
                      "Malignant peripheral nerve sheath tumorNegative muscle markers except malignant triton tumor, which also expresses neural markers, such as patchy S100 and SOX10",
                      "Negative muscle markers except malignant triton tumor, which also expresses neural markers, such as patchy S100 and SOX10",
                      "Low-grade myofibroblastic sarcomaUsually desmin negative",
                      "Usually desmin negative",
                      "Synovial sarcomaNegative muscle markers; positive for TLE1; positive for t(X;18)",
                      "Negative muscle markers; positive for TLE1; positive for t(X;18)",
                      "Fibrosarcoma arising in dermatofibrosarcoma protuberansMay have lower grade areas present; usually negative for 2 muscle markers; positive for t(17;22)",
                      "May have lower grade areas present; usually negative for 2 muscle markers; positive for t(17;22)"
                    ]
                  },
                  {
                    "text": "Desmoplastic or spindle cell melanomaMay show reactivity for melanoma markers, almost always negative for muscle markers",
                    "sub_points": [
                      "May show reactivity for melanoma markers, almost always negative for muscle markers"
                    ]
                  }
                ],
                "DDx for Alveolar Rhabdomyosarcoma and Dense Pattern Embryonal Rhabdomyosarcoma": [
                  {
                    "text": "Other small round blue cell tumorsEwing sarcoma family of tumorsLacks rhabdomyoblasts; positive forEWSR1orFUSfusionsMetastatic Wilms tumorBiphasic or triphasic in many cases; lacks rhabdomyoblasts, WT1 nuclear positivity by IHCMetastatic neuroblastomaNeurofibrillary matrix and rosettes often present; lacks muscle marker expression",
                    "sub_points": [
                      "Ewing sarcoma family of tumorsLacks rhabdomyoblasts; positive forEWSR1orFUSfusions",
                      "Lacks rhabdomyoblasts; positive forEWSR1orFUSfusions",
                      "Metastatic Wilms tumorBiphasic or triphasic in many cases; lacks rhabdomyoblasts, WT1 nuclear positivity by IHC",
                      "Biphasic or triphasic in many cases; lacks rhabdomyoblasts, WT1 nuclear positivity by IHC",
                      "Metastatic neuroblastomaNeurofibrillary matrix and rosettes often present; lacks muscle marker expression",
                      "Neurofibrillary matrix and rosettes often present; lacks muscle marker expression"
                    ]
                  }
                ],
                "DDx for Embryonal Rhabdomyosarcoma": [
                  {
                    "text": "Pediatric spindle cell tumorsCongenital fibrosarcomaMay have multiple histologic patterns, lacks muscle markers; positive for t(12;15)(p13;q25)Inflammatory myofibroblastic tumorMore prominent inflammation, usually ALK positive (in children)",
                    "sub_points": [
                      "Congenital fibrosarcomaMay have multiple histologic patterns, lacks muscle markers; positive for t(12;15)(p13;q25)",
                      "May have multiple histologic patterns, lacks muscle markers; positive for t(12;15)(p13;q25)",
                      "Inflammatory myofibroblastic tumorMore prominent inflammation, usually ALK positive (in children)",
                      "More prominent inflammation, usually ALK positive (in children)"
                    ]
                  }
                ],
                "DDx for Spindle Cell/Sclerosing Rhabdomyosarcoma": [
                  {
                    "text": "Includes those for LMS"
                  },
                  {
                    "text": "Osteosarcoma: True osteoid and malignant osteoblasts present; positive for SATB2"
                  }
                ],
                "DDx for Pleomorphic Rhabdomyosarcoma": [
                  {
                    "text": "Pleomorphic undifferentiated sarcoma: Lacks rhabdomyoblasts and lacks skeletal muscle marker expression"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Tumor Suppressor Genes": {
            "name": "Tumor Suppressor Genes",
            "url": "https://app.pathprimer.com/document/8addae1e-ae29-4610-98fd-c0528908b3fa/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "Etiology/Pathogenesis": {
                "Oncogenesis": [
                  {
                    "text": "Cancer is often a multistep process during which cells acquire a series of mutationsMutations lead to decreased tumor suppressor gene function &/or increased proto-oncogene functionResults in uncontrolled growth and failure to respond to signals that normally lead to cell death (apoptosis)Rapid growth and uncontrolled cell division may lead to abnormal chromosome segregation and additional changes (genetic instability) in chromosome number (aneuploidy)",
                    "sub_points": [
                      "Mutations lead to decreased tumor suppressor gene function &/or increased proto-oncogene function",
                      "Results in uncontrolled growth and failure to respond to signals that normally lead to cell death (apoptosis)",
                      "Rapid growth and uncontrolled cell division may lead to abnormal chromosome segregation and additional changes (genetic instability) in chromosome number (aneuploidy)"
                    ]
                  },
                  {
                    "text": "Proto-oncogenesAn oncogene is the mutated version of a proto-oncogeneCause normal cells to become cancerous when mutatedMutations are typically dominant in nature> 40 different human proto-oncogenes are known~ 14 proto-oncogenes are associated with high propensity for cancerOncogenes arise as result of mutations that increase expression level or activity of a proto-oncogenePoint mutations, deletions, or insertions in promoter region of proto-oncogene may lead to increased transcriptionGene amplification events leading to extrachromosomal copies of proto-oncogeneChromosomal translocation events that relocate proto-oncogene to new chromosomal site that leads to overexpressionChromosomal translocations that lead to fusion between proto-oncogene and 2nd gene, which produces fusion protein with oncogenic activityIncreased production of these proteins leads to increased cell division, decreased cell differentiation, and inhibition of cell deathThese characteristics define cancer cellsOncogenes are therefore important targets for cancer therapy",
                    "sub_points": [
                      "An oncogene is the mutated version of a proto-oncogene",
                      "Cause normal cells to become cancerous when mutatedMutations are typically dominant in nature",
                      "Mutations are typically dominant in nature",
                      "> 40 different human proto-oncogenes are known~ 14 proto-oncogenes are associated with high propensity for cancer",
                      "~ 14 proto-oncogenes are associated with high propensity for cancer",
                      "Oncogenes arise as result of mutations that increase expression level or activity of a proto-oncogenePoint mutations, deletions, or insertions in promoter region of proto-oncogene may lead to increased transcriptionGene amplification events leading to extrachromosomal copies of proto-oncogeneChromosomal translocation events that relocate proto-oncogene to new chromosomal site that leads to overexpressionChromosomal translocations that lead to fusion between proto-oncogene and 2nd gene, which produces fusion protein with oncogenic activity",
                      "Point mutations, deletions, or insertions in promoter region of proto-oncogene may lead to increased transcription",
                      "Gene amplification events leading to extrachromosomal copies of proto-oncogene",
                      "Chromosomal translocation events that relocate proto-oncogene to new chromosomal site that leads to overexpression",
                      "Chromosomal translocations that lead to fusion between proto-oncogene and 2nd gene, which produces fusion protein with oncogenic activity",
                      "Increased production of these proteins leads to increased cell division, decreased cell differentiation, and inhibition of cell deathThese characteristics define cancer cellsOncogenes are therefore important targets for cancer therapy",
                      "These characteristics define cancer cells",
                      "Oncogenes are therefore important targets for cancer therapy"
                    ]
                  },
                  {
                    "text": "Tumor suppressor genesEncode for proteins that repress cell cycle or promote apoptosisSome genes are involved in DNA repair processesRoles may includeRepression of genes essential for continuation of cell cycleCoupling of cell cycle to presence of DNA damageProapoptotic signaling if DNA damage cannot be repairedCell adhesion proteins that help prevent tumor cells from metastasizingDNA repair proteins (e.g., DNA mismatch repair proteins,MEN1-andBRCA1-/BRCA2-encoded proteins)Mutations within tumor suppressor genes result in a loss-of-function (recessive in nature)Loss of heterozygosity and \"two-hit\" hypothesisFirst proposed by geneticist Alfred Knudson in 1971Both tumor suppressor genes must be mutated in order for a particular cell to become cancerous (\"two-hit\" hypothesis)Loss of heterozygosity is a phrase often used to describe process that leads to \"second hit\" and results in loss of remaining functional copy of tumor suppressor geneMutations are oftenPoint mutations or small deletions that disrupt protein functionChromosomal deletions or breaks that delete tumor suppressor geneSomatic recombination during which normal gene copy is replaced with a mutant copyAt least 30 different tumor suppressor genes have been identified",
                    "sub_points": [
                      "Encode for proteins that repress cell cycle or promote apoptosis",
                      "Some genes are involved in DNA repair processes",
                      "Roles may includeRepression of genes essential for continuation of cell cycleCoupling of cell cycle to presence of DNA damageProapoptotic signaling if DNA damage cannot be repairedCell adhesion proteins that help prevent tumor cells from metastasizingDNA repair proteins (e.g., DNA mismatch repair proteins,MEN1-andBRCA1-/BRCA2-encoded proteins)",
                      "Repression of genes essential for continuation of cell cycle",
                      "Coupling of cell cycle to presence of DNA damage",
                      "Proapoptotic signaling if DNA damage cannot be repaired",
                      "Cell adhesion proteins that help prevent tumor cells from metastasizing",
                      "DNA repair proteins (e.g., DNA mismatch repair proteins,MEN1-andBRCA1-/BRCA2-encoded proteins)",
                      "Mutations within tumor suppressor genes result in a loss-of-function (recessive in nature)",
                      "Loss of heterozygosity and \"two-hit\" hypothesisFirst proposed by geneticist Alfred Knudson in 1971Both tumor suppressor genes must be mutated in order for a particular cell to become cancerous (\"two-hit\" hypothesis)Loss of heterozygosity is a phrase often used to describe process that leads to \"second hit\" and results in loss of remaining functional copy of tumor suppressor gene",
                      "First proposed by geneticist Alfred Knudson in 1971",
                      "Both tumor suppressor genes must be mutated in order for a particular cell to become cancerous (\"two-hit\" hypothesis)",
                      "Loss of heterozygosity is a phrase often used to describe process that leads to \"second hit\" and results in loss of remaining functional copy of tumor suppressor gene",
                      "Mutations are oftenPoint mutations or small deletions that disrupt protein functionChromosomal deletions or breaks that delete tumor suppressor geneSomatic recombination during which normal gene copy is replaced with a mutant copy",
                      "Point mutations or small deletions that disrupt protein function",
                      "Chromosomal deletions or breaks that delete tumor suppressor gene",
                      "Somatic recombination during which normal gene copy is replaced with a mutant copy",
                      "At least 30 different tumor suppressor genes have been identified"
                    ]
                  }
                ]
              },
              "Terminology, Definitions, and Concepts": {
                "Introduction": [
                  {
                    "text": "Mutation is thought to imply deleterious genetic sequence variationThis definition is likely overly simplistic, as not all mutations have deleterious effect",
                    "sub_points": [
                      "This definition is likely overly simplistic, as not all mutations have deleterious effect"
                    ]
                  },
                  {
                    "text": "DNA sequence can be altered in various waysChange in actual sequence (sequence variation)Change in amount of given sequence (copy number variation)Change in position (i.e., inversion and translocation)",
                    "sub_points": [
                      "Change in actual sequence (sequence variation)",
                      "Change in amount of given sequence (copy number variation)",
                      "Change in position (i.e., inversion and translocation)"
                    ]
                  },
                  {
                    "text": "Gene mutations/sequence alterations have varying effects, depending on where they occur and whether they alter protein functionGenetic changes that affect 3rd base in codon are less likely to result in incorporation of incorrect amino acid and therefore rarely alter gene code/protein function",
                    "sub_points": [
                      "Genetic changes that affect 3rd base in codon are less likely to result in incorporation of incorrect amino acid and therefore rarely alter gene code/protein function"
                    ]
                  },
                  {
                    "text": "Genotype vs. phenotypeGenotype refers to genetic information as it exists in the form of nucleic acidsPhenotype refers to how encoded proteins function to create outwardly observable characteristicsGenotypic alterations may or may not result in alterations in phenotype",
                    "sub_points": [
                      "Genotype refers to genetic information as it exists in the form of nucleic acids",
                      "Phenotype refers to how encoded proteins function to create outwardly observable characteristics",
                      "Genotypic alterations may or may not result in alterations in phenotype"
                    ]
                  },
                  {
                    "text": "Somatic mutationsAcquired mutation that is not inherited from parent and also not passed to offspring",
                    "sub_points": [
                      "Acquired mutation that is not inherited from parent and also not passed to offspring"
                    ]
                  },
                  {
                    "text": "Germline mutationsHeritable genetic variation/mutation in germ cell (eggs or sperm) lineagePassed on from parent to offspringReferred to as constitutional mutations in offspring",
                    "sub_points": [
                      "Heritable genetic variation/mutation in germ cell (eggs or sperm) lineage",
                      "Passed on from parent to offspringReferred to as constitutional mutations in offspring",
                      "Referred to as constitutional mutations in offspring"
                    ]
                  },
                  {
                    "text": "Driver mutationsSubset of cancer mutations that provide selective advantage to tumor (e.g.,EGFR, EML4-ALK)Contribute to tumor's growth, progression, and survival (clonal expansion)Cancer cells rely more heavily on driver mutations than other mutations that are often termed passenger mutationsMore often targets of directed therapy",
                    "sub_points": [
                      "Subset of cancer mutations that provide selective advantage to tumor (e.g.,EGFR, EML4-ALK)",
                      "Contribute to tumor's growth, progression, and survival (clonal expansion)",
                      "Cancer cells rely more heavily on driver mutations than other mutations that are often termed passenger mutations",
                      "More often targets of directed therapy"
                    ]
                  },
                  {
                    "text": "Passenger mutationsTypically comprise larger subset of acquired somatic mutations that are not as important to tumor growth and survivalMay be associated with clonal expansion because they occur in same genome as driver mutationsReferred to as \"hitchhiker\" in evolutionary biology",
                    "sub_points": [
                      "Typically comprise larger subset of acquired somatic mutations that are not as important to tumor growth and survival",
                      "May be associated with clonal expansion because they occur in same genome as driver mutations",
                      "Referred to as \"hitchhiker\" in evolutionary biology"
                    ]
                  },
                  {
                    "text": "Polymorphism vs. gene mutationsNumerous single-nucleotide polymorphisms (SNPs; pronounced snips) have been identified in human genome1 in every 300 nucleotides in human genome is considered polymorphic (i.e., < 1 nucleotide being common in a population)In most cases, SNP has 2 alternative forms (alleles) (i.e., A or G at specified nucleotide position)Conceptually, both SNPs and mutations represent variation in genetic sequenceArbitrary threshold of 1% frequency is widely accepted in making distinction between SNP (polymorphism with frequency of > 1%) and mutation (polymorphism with frequency < 1%)Frequency is thought to be indicative of stability of polymorphism in a populationHigh-frequency SNP alleles are not thought to have major consequential phenotypic effects",
                    "sub_points": [
                      "Numerous single-nucleotide polymorphisms (SNPs; pronounced snips) have been identified in human genome",
                      "1 in every 300 nucleotides in human genome is considered polymorphic (i.e., < 1 nucleotide being common in a population)",
                      "In most cases, SNP has 2 alternative forms (alleles) (i.e., A or G at specified nucleotide position)",
                      "Conceptually, both SNPs and mutations represent variation in genetic sequence",
                      "Arbitrary threshold of 1% frequency is widely accepted in making distinction between SNP (polymorphism with frequency of > 1%) and mutation (polymorphism with frequency < 1%)Frequency is thought to be indicative of stability of polymorphism in a populationHigh-frequency SNP alleles are not thought to have major consequential phenotypic effects",
                      "Frequency is thought to be indicative of stability of polymorphism in a population",
                      "High-frequency SNP alleles are not thought to have major consequential phenotypic effects"
                    ]
                  }
                ],
                "Types of Mutations": [
                  {
                    "text": "Missense mutation/substitutionChange in 1 DNA base pairResults in substitution of 1 amino acid for anotherMay or may not alter protein functionDepends on degree of similarity between amino acids",
                    "sub_points": [
                      "Change in 1 DNA base pair",
                      "Results in substitution of 1 amino acid for another",
                      "May or may not alter protein functionDepends on degree of similarity between amino acids",
                      "Depends on degree of similarity between amino acids"
                    ]
                  },
                  {
                    "text": "Nonsense mutation/substitutionChange in 1 DNA base pairResults in substitution of 1 amino acid for stop codonResults in premature termination of translation and truncated protein that may function improperly or not at all",
                    "sub_points": [
                      "Change in 1 DNA base pair",
                      "Results in substitution of 1 amino acid for stop codon",
                      "Results in premature termination of translation and truncated protein that may function improperly or not at all"
                    ]
                  },
                  {
                    "text": "InsertionAddition of ≥ 1 base to original DNA sequenceIncreases number of DNA bases in geneProtein encoded by gene may not function properly",
                    "sub_points": [
                      "Addition of ≥ 1 base to original DNA sequence",
                      "Increases number of DNA bases in gene",
                      "Protein encoded by gene may not function properly"
                    ]
                  },
                  {
                    "text": "DeletionChange in number of DNA bases by removing piece of DNASmall deletions may remove 1 or a few base pairs within geneLarger deletions can remove entire gene or several adjacent genesDeleted DNA may alter function of resulting protein(s)",
                    "sub_points": [
                      "Change in number of DNA bases by removing piece of DNA",
                      "Small deletions may remove 1 or a few base pairs within gene",
                      "Larger deletions can remove entire gene or several adjacent genes",
                      "Deleted DNA may alter function of resulting protein(s)"
                    ]
                  },
                  {
                    "text": "DuplicationPiece of DNA abnormally copied 1 or more timesMay alter function of resulting protein",
                    "sub_points": [
                      "Piece of DNA abnormally copied 1 or more times",
                      "May alter function of resulting protein"
                    ]
                  },
                  {
                    "text": "FrameshiftAddition or loss of DNA bases that result in change in gene's reading frameReading frame consists of groups of 3 bases (codon) that each code for 1 amino acidShifts grouping of these bases and changes overall amino acid code/sequenceResulting protein is usually nonfunctionalInsertions, deletions, and duplications can all result in frameshift mutationMay result in premature termination if stop codon is formed downstream from mutation",
                    "sub_points": [
                      "Addition or loss of DNA bases that result in change in gene's reading frameReading frame consists of groups of 3 bases (codon) that each code for 1 amino acid",
                      "Reading frame consists of groups of 3 bases (codon) that each code for 1 amino acid",
                      "Shifts grouping of these bases and changes overall amino acid code/sequence",
                      "Resulting protein is usually nonfunctionalInsertions, deletions, and duplications can all result in frameshift mutation",
                      "Insertions, deletions, and duplications can all result in frameshift mutation",
                      "May result in premature termination if stop codon is formed downstream from mutation"
                    ]
                  },
                  {
                    "text": "Repeat expansionShort DNA sequences that are repeated a number of times in a rowe.g., trinucleotide repeat is repeated 3-base pair sequence (e.g., CGT) and tetranucleotide repeat is a repeat of 4-base pair sequence (e.g., CGGT)Increases number of times DNA sequence is repeatedMany genes contain these repeats without any alteration in protein functionWhen repeats exceed \"normal\" range, protein may function improperly or not at all",
                    "sub_points": [
                      "Short DNA sequences that are repeated a number of times in a rowe.g., trinucleotide repeat is repeated 3-base pair sequence (e.g., CGT) and tetranucleotide repeat is a repeat of 4-base pair sequence (e.g., CGGT)",
                      "e.g., trinucleotide repeat is repeated 3-base pair sequence (e.g., CGT) and tetranucleotide repeat is a repeat of 4-base pair sequence (e.g., CGGT)",
                      "Increases number of times DNA sequence is repeated",
                      "Many genes contain these repeats without any alteration in protein function",
                      "When repeats exceed \"normal\" range, protein may function improperly or not at all"
                    ]
                  },
                  {
                    "text": "ConversionSequence change where range of nucleotides are replaced by sequence from elsewhere in genomeAllelic gene conversion occurs during meiotic recombination",
                    "sub_points": [
                      "Sequence change where range of nucleotides are replaced by sequence from elsewhere in genome",
                      "Allelic gene conversion occurs during meiotic recombination"
                    ]
                  },
                  {
                    "text": "Deletion/insertion (indel)Sequence change where ≥ 1 nucleotide is replaced by ≥ 1 other nucleotideIf only 1 nucleotide is replaced by single other nucleotide, this should be referred to as substitution",
                    "sub_points": [
                      "Sequence change where ≥ 1 nucleotide is replaced by ≥ 1 other nucleotide",
                      "If only 1 nucleotide is replaced by single other nucleotide, this should be referred to as substitution"
                    ]
                  },
                  {
                    "text": "TranslocationChromosome rearrangement between parts of nonhomologous chromosomes2 chromosomes break, with fragments joining together at \"breakpoints\"Reciprocal translocation should include description of 1st and 2nd junctionse.g., t(4;X) and t(X;4)",
                    "sub_points": [
                      "Chromosome rearrangement between parts of nonhomologous chromosomes",
                      "2 chromosomes break, with fragments joining together at \"breakpoints\"",
                      "Reciprocal translocation should include description of 1st and 2nd junctionse.g., t(4;X) and t(X;4)",
                      "e.g., t(4;X) and t(X;4)"
                    ]
                  },
                  {
                    "text": "TranspositionSeries or range of nucleotides moves from 1 position to another in genome or sequence (i.e., deletion at 1 position is combined with insertion of deleted sequence at another position)",
                    "sub_points": [
                      "Series or range of nucleotides moves from 1 position to another in genome or sequence (i.e., deletion at 1 position is combined with insertion of deleted sequence at another position)"
                    ]
                  }
                ]
              },
              "Nomenclature": {
                "Introduction": [
                  {
                    "text": "Consistent and uniform use of nomenclature in management of DNA sequence data is critical for accurate and concise communication of test results and genetic risk assessment"
                  },
                  {
                    "text": "Unique letter designationsUpper-case nucleotide symbols are used when describing DNA (i.e., A, G, C, T)Lower-case nucleotide symbols are used when describing RNA (i.e., a, g, c, u)3- or 1-letter amino acid codes are used when describing protein/amino acid sequence change (e.g., GLU and E)\"X\" refers to stop codon",
                    "sub_points": [
                      "Upper-case nucleotide symbols are used when describing DNA (i.e., A, G, C, T)",
                      "Lower-case nucleotide symbols are used when describing RNA (i.e., a, g, c, u)",
                      "3- or 1-letter amino acid codes are used when describing protein/amino acid sequence change (e.g., GLU and E)\"X\" refers to stop codon",
                      "\"X\" refers to stop codon"
                    ]
                  },
                  {
                    "text": "Letter designations used to refer to reference sequenceCoding DNA: c.Genomic DNA: g.Mitochondrial DNA: m.RNA: r.Noncoding RNA: n.Protein: p.",
                    "sub_points": [
                      "Coding DNA: c.",
                      "Genomic DNA: g.",
                      "Mitochondrial DNA: m.",
                      "RNA: r.",
                      "Noncoding RNA: n.",
                      "Protein: p."
                    ]
                  },
                  {
                    "text": "Symbols used to describe changes\">\" indicates substitution at DNA level\"_\" indicates range of affected residues, separating 1st and last residue affected\"del\" indicates deletion\"dup\" indicates duplication\"ins\" indicates insertion\"inv\" indicates inversion\"con\" indicates conversion\"[ ]\" enclose changes from single allele\"( )\" is used when exact position of change is not known; range of uncertainty is described as precisely as possible and listed between parentheses",
                    "sub_points": [
                      "\">\" indicates substitution at DNA level",
                      "\"_\" indicates range of affected residues, separating 1st and last residue affected",
                      "\"del\" indicates deletion",
                      "\"dup\" indicates duplication",
                      "\"ins\" indicates insertion",
                      "\"inv\" indicates inversion",
                      "\"con\" indicates conversion",
                      "\"[ ]\" enclose changes from single allele",
                      "\"( )\" is used when exact position of change is not known; range of uncertainty is described as precisely as possible and listed between parentheses"
                    ]
                  },
                  {
                    "text": "Nucleotide numberingCoding DNA reference sequence (c.)Nucleotide 1 is the A of ATG-translation initiation codonThere is no nucleotide 0Nucleotide 5' of ATG-translation initiation codon is -1, the previous -2, etc.Intronic nucleotidesBeginning of intron is denoted by number of last exon in preceding exon followed by plus sign and position of intronic nucleotides (e.g., c.89+1G)End of intron is denoted by number of 1st nucleotide of following exon, followed by minus sign preceding upstream intronic nucleotide position (c.89-1T)In middle of intron, plus sign will change to minus sign using these rulesGenomic reference sequenceNumbering is arbitrary and starts with 1 at 1st nucleotide of database reference file+, -, or other signs are not used",
                    "sub_points": [
                      "Coding DNA reference sequence (c.)Nucleotide 1 is the A of ATG-translation initiation codonThere is no nucleotide 0Nucleotide 5' of ATG-translation initiation codon is -1, the previous -2, etc.",
                      "Nucleotide 1 is the A of ATG-translation initiation codon",
                      "There is no nucleotide 0",
                      "Nucleotide 5' of ATG-translation initiation codon is -1, the previous -2, etc.",
                      "Intronic nucleotidesBeginning of intron is denoted by number of last exon in preceding exon followed by plus sign and position of intronic nucleotides (e.g., c.89+1G)End of intron is denoted by number of 1st nucleotide of following exon, followed by minus sign preceding upstream intronic nucleotide position (c.89-1T)In middle of intron, plus sign will change to minus sign using these rules",
                      "Beginning of intron is denoted by number of last exon in preceding exon followed by plus sign and position of intronic nucleotides (e.g., c.89+1G)",
                      "End of intron is denoted by number of 1st nucleotide of following exon, followed by minus sign preceding upstream intronic nucleotide position (c.89-1T)",
                      "In middle of intron, plus sign will change to minus sign using these rules",
                      "Genomic reference sequenceNumbering is arbitrary and starts with 1 at 1st nucleotide of database reference file+, -, or other signs are not used",
                      "Numbering is arbitrary and starts with 1 at 1st nucleotide of database reference file",
                      "+, -, or other signs are not used"
                    ]
                  }
                ],
                "Nomenclature Examples": [
                  {
                    "text": "SubstitutionDesignated by \">\"Examplesc.546A>T describes an A to T substitution at nucleotide position 546p.Gln78His describes glutamine to histidine substitution at amino-acid residue 78\">\" not used when describing substitution at protein level",
                    "sub_points": [
                      "Designated by \">\"",
                      "Examplesc.546A>T describes an A to T substitution at nucleotide position 546p.Gln78His describes glutamine to histidine substitution at amino-acid residue 78\">\" not used when describing substitution at protein level",
                      "c.546A>T describes an A to T substitution at nucleotide position 546",
                      "p.Gln78His describes glutamine to histidine substitution at amino-acid residue 78",
                      "\">\" not used when describing substitution at protein level"
                    ]
                  },
                  {
                    "text": "DeletionDesignated by \"del\"Range of deletion indicated by \"_\"Examplesc.546delT, or c.546del describes deletion of T at nucleotide position 546c.586_591del or c.586_591delTGGTCA, or c.586_591del6 describes deletion of 6 nucleotides (TGGTCA) starting at nucleotide position 586 to and ending at position 591",
                    "sub_points": [
                      "Designated by \"del\"",
                      "Range of deletion indicated by \"_\"",
                      "Examplesc.546delT, or c.546del describes deletion of T at nucleotide position 546c.586_591del or c.586_591delTGGTCA, or c.586_591del6 describes deletion of 6 nucleotides (TGGTCA) starting at nucleotide position 586 to and ending at position 591",
                      "c.546delT, or c.546del describes deletion of T at nucleotide position 546",
                      "c.586_591del or c.586_591delTGGTCA, or c.586_591del6 describes deletion of 6 nucleotides (TGGTCA) starting at nucleotide position 586 to and ending at position 591"
                    ]
                  },
                  {
                    "text": "DuplicationDesignated by \"dup\"Range of duplication indicated by \"_\"Examplesc.546dupT, or c.546dup describes duplication of a nucleotide (T) at position 546c.586_591dup, or c.586_591dupTGGTCA or c.586_591dup6 describe a duplication of 6 nucleotides (TGGTCA) starting at nucleotide position 586 and ending at position 591Duplications should not be described as insertions",
                    "sub_points": [
                      "Designated by \"dup\"",
                      "Range of duplication indicated by \"_\"",
                      "Examplesc.546dupT, or c.546dup describes duplication of a nucleotide (T) at position 546c.586_591dup, or c.586_591dupTGGTCA or c.586_591dup6 describe a duplication of 6 nucleotides (TGGTCA) starting at nucleotide position 586 and ending at position 591",
                      "c.546dupT, or c.546dup describes duplication of a nucleotide (T) at position 546",
                      "c.586_591dup, or c.586_591dupTGGTCA or c.586_591dup6 describe a duplication of 6 nucleotides (TGGTCA) starting at nucleotide position 586 and ending at position 591",
                      "Duplications should not be described as insertions"
                    ]
                  },
                  {
                    "text": "InsertionDesignated by \"ins\"Range of insertion is designated by \"_\"Provide inserted sequenceExamplesc.547_548insT describes insertion of nucleotide T between nucleotides at positions 547 and 548c.1087_1088insTGACGT describes insertion of 6 nucleotides (TGACGT) that occurs between nucleotides at positions 1087 and 1088When insertion is large, inserted sequence can be submitted to database and database accession and version number can be written",
                    "sub_points": [
                      "Designated by \"ins\"",
                      "Range of insertion is designated by \"_\"",
                      "Provide inserted sequence",
                      "Examplesc.547_548insT describes insertion of nucleotide T between nucleotides at positions 547 and 548c.1087_1088insTGACGT describes insertion of 6 nucleotides (TGACGT) that occurs between nucleotides at positions 1087 and 1088",
                      "c.547_548insT describes insertion of nucleotide T between nucleotides at positions 547 and 548",
                      "c.1087_1088insTGACGT describes insertion of 6 nucleotides (TGACGT) that occurs between nucleotides at positions 1087 and 1088",
                      "When insertion is large, inserted sequence can be submitted to database and database accession and version number can be written"
                    ]
                  },
                  {
                    "text": "InversionDesignated by \"inv\"Range of inversion is designated by \"_\"Examplec.547_2032inv 1486 describes sequence of 1,486 nucleotides from nucleotide position 547 to 2032 have been inverted",
                    "sub_points": [
                      "Designated by \"inv\"",
                      "Range of inversion is designated by \"_\"",
                      "Examplec.547_2032inv 1486 describes sequence of 1,486 nucleotides from nucleotide position 547 to 2032 have been inverted",
                      "c.547_2032inv 1486 describes sequence of 1,486 nucleotides from nucleotide position 547 to 2032 have been inverted"
                    ]
                  },
                  {
                    "text": "ConversionDesignated by \"con\" after indication of 1st and last nucleotides affected by conversion, followed by description of origin of new nucleotidesRange of conversion is designated by \"_\"Examplec.547_658con918_1029 describes conversion replacing nucleotide sequence at position 547 to 658 with new nucleotide sequence originating from position 918 to 1029g.123_678conNG_012232.1:g.9456_10011 describes conversion replacing nucleotides 123 to 678 with nucleotides 9456 to 10011 from sequence as present in GenBank file NG_012232.1",
                    "sub_points": [
                      "Designated by \"con\" after indication of 1st and last nucleotides affected by conversion, followed by description of origin of new nucleotides",
                      "Range of conversion is designated by \"_\"",
                      "Examplec.547_658con918_1029 describes conversion replacing nucleotide sequence at position 547 to 658 with new nucleotide sequence originating from position 918 to 1029g.123_678conNG_012232.1:g.9456_10011 describes conversion replacing nucleotides 123 to 678 with nucleotides 9456 to 10011 from sequence as present in GenBank file NG_012232.1",
                      "c.547_658con918_1029 describes conversion replacing nucleotide sequence at position 547 to 658 with new nucleotide sequence originating from position 918 to 1029",
                      "g.123_678conNG_012232.1:g.9456_10011 describes conversion replacing nucleotides 123 to 678 with nucleotides 9456 to 10011 from sequence as present in GenBank file NG_012232.1"
                    ]
                  },
                  {
                    "text": "TranslocationDesignated by \"t\"Range indicated by \"_\"Example: t(X;4)(p21.2;q35) (c.857+101_857+102)",
                    "sub_points": [
                      "Designated by \"t\"",
                      "Range indicated by \"_\"",
                      "Example: t(X;4)(p21.2;q35) (c.857+101_857+102)"
                    ]
                  },
                  {
                    "text": "Repeated sequencesThe following format is used when describing repeated sequences: \"Position of 1st repeat unit_[number of repeats]\"Examplesg.123_124[4] describes location of 1st unit of the variable sequence (nucleotide position 123 to 124) with number in brackets describing number of repeats present in alleleAlternatively, g.123TG[4] describes a repeating sequence of TG that repeats 4 times where 1st unit (TG) is present at nucleotide position 123_124 in genomic reference sequence",
                    "sub_points": [
                      "The following format is used when describing repeated sequences: \"Position of 1st repeat unit_[number of repeats]\"",
                      "Examplesg.123_124[4] describes location of 1st unit of the variable sequence (nucleotide position 123 to 124) with number in brackets describing number of repeats present in alleleAlternatively, g.123TG[4] describes a repeating sequence of TG that repeats 4 times where 1st unit (TG) is present at nucleotide position 123_124 in genomic reference sequence",
                      "g.123_124[4] describes location of 1st unit of the variable sequence (nucleotide position 123 to 124) with number in brackets describing number of repeats present in allele",
                      "Alternatively, g.123TG[4] describes a repeating sequence of TG that repeats 4 times where 1st unit (TG) is present at nucleotide position 123_124 in genomic reference sequence"
                    ]
                  },
                  {
                    "text": "SNPDatabase SNP entries designated by \"rs\"Examples: rs2306220: A>G; g.78654 C>G",
                    "sub_points": [
                      "Database SNP entries designated by \"rs\"",
                      "Examples: rs2306220: A>G; g.78654 C>G"
                    ]
                  },
                  {
                    "text": "Deletion/insertionCommonly designated as \"indel\" but may also be designated as \"delins\"Range indicated by \"_\"Examplec.1166_1177delinsAGT describes deletion that extends from nucleotide position 1166 to 1177 with nucleotides AGT inserted in place of deleted sequence",
                    "sub_points": [
                      "Commonly designated as \"indel\" but may also be designated as \"delins\"",
                      "Range indicated by \"_\"",
                      "Examplec.1166_1177delinsAGT describes deletion that extends from nucleotide position 1166 to 1177 with nucleotides AGT inserted in place of deleted sequence",
                      "c.1166_1177delinsAGT describes deletion that extends from nucleotide position 1166 to 1177 with nucleotides AGT inserted in place of deleted sequence"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Papillary Renal Cell Carcinoma": {
            "name": "Papillary Renal Cell Carcinoma",
            "url": "https://app.pathprimer.com/document/05f33dd4-5b7d-4884-bb7b-c05331968dd2/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Most cases are sporadic"
                  },
                  {
                    "text": "Familial cases in hereditary papillary renal cell carcinoma (PRCC) syndrome"
                  },
                  {
                    "text": "Subclassification into type 1 and type 2 tumors no longer recommended, according to WHO 5th edition"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Sporadic cases commonly have trisomy 7, trisomy 17, loss of Y chromosome"
                  },
                  {
                    "text": "Significantly mutated genes includeMET,CDKN2A,SETD2,NF2,KDM6A,SMARCB1,FAT1,BAP1,PBRM1,STAG2,NFE2L2, andTP53"
                  },
                  {
                    "text": "Formerly type 1 tumors typically have alteredMETstatus (~ 80%) by mutation, splice variant, or fusion"
                  },
                  {
                    "text": "Formerly type 2 tumors are genetically heterogeneous"
                  },
                  {
                    "text": "Altered cancer-associated pathways include chromatin remodeling and Hippo signaling pathways"
                  },
                  {
                    "text": "Mutations or promoter hypermethylation ofCDKN2Aassociated with poor prognosis"
                  },
                  {
                    "text": "Activation of or mutations in NRF2-ARE pathway genes"
                  },
                  {
                    "text": "High-grade tumors have alterations inTERTpromoter andARID1Amutations"
                  },
                  {
                    "text": "TP53mutations associated with poor survival"
                  },
                  {
                    "text": "Distinct subgroup has CpG island methylator phenotype (CIMP) that is associated with poor survival"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Papillary architecture with fibrovascular coresTypically lined by single layer of tumor cells",
                    "sub_points": [
                      "Typically lined by single layer of tumor cells"
                    ]
                  },
                  {
                    "text": "Graded according to WHO/International Society of Urological Pathology (ISUP) grading system based on nucleolar prominence"
                  },
                  {
                    "text": "Sarcomatoid change present in ~ 5% of cases"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Positive for pancytokeratin, EMA, cytokeratin 7, CD10, AMACR (P504S), PAX2, PAX8, and RCCma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Papillary renal cell carcinoma (PRCC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Malignant epithelial neoplasm of kidney with papillary architecture thought to arise from proximal nephron"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Accounts for 10-15% of renal cell carcinomas"
                  },
                  {
                    "text": "2nd most common type of renal cell carcinoma"
                  },
                  {
                    "text": "Subclassification into type 1 and type 2 tumors no longer recommended according to WHO 5th edition"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most cases are sporadic"
                  },
                  {
                    "text": "Mean age: 52-66 years"
                  },
                  {
                    "text": "Familial casesHereditary PRCCAutosomal dominant inheritanceTumors are typically multiple and bilateralCaused by activating germline mutations in tyrosine kinase domain ofMEToncogene located at 7q31",
                    "sub_points": [
                      "Hereditary PRCCAutosomal dominant inheritanceTumors are typically multiple and bilateralCaused by activating germline mutations in tyrosine kinase domain ofMEToncogene located at 7q31",
                      "Autosomal dominant inheritance",
                      "Tumors are typically multiple and bilateral",
                      "Caused by activating germline mutations in tyrosine kinase domain ofMEToncogene located at 7q31"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Partial nephrectomy (nephron-sparing surgery) or radical nephrectomy"
                  },
                  {
                    "text": "Ablative techniques, including radiofrequency ablation or cryoablation for nonsurgical candidates"
                  },
                  {
                    "text": "For systemic diseaseTyrosine kinase inhibitorsmTOR inhibitorsMonoclonal antibodies against immune checkpoint inhibitors PD-1, PD-L1, CTLA-4",
                    "sub_points": [
                      "Tyrosine kinase inhibitors",
                      "mTOR inhibitors",
                      "Monoclonal antibodies against immune checkpoint inhibitors PD-1, PD-L1, CTLA-4"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Depends on grade, stage, and presence or absence of sarcomatoid change"
                  }
                ]
              },
              "MOLECULAR": {
                "Molecular Genetics": [
                  {
                    "text": "Heterogeneous molecular alterations"
                  },
                  {
                    "text": "Sporadic cases commonly have trisomy 7, trisomy 17, loss of Y chromosome"
                  },
                  {
                    "text": "Often gains of chromosomes 3, 8, 12, 16, and 20"
                  },
                  {
                    "text": "Losses of chromosomes 1p, 4q, 6q, 9p, 11p, 13q, 14q, 18, 21q, and X"
                  },
                  {
                    "text": "Significantly mutated genes identified by whole-genome sequencingMET,CDKN2A,SETD2,NF2,KDM6A,SMARCB1,FAT1,BAP1,PBRM1,STAG2,NFE2L2,TP53TFE3andTFEBfusions in ~ 10% of cases",
                    "sub_points": [
                      "MET,CDKN2A,SETD2,NF2,KDM6A,SMARCB1,FAT1,BAP1,PBRM1,STAG2,NFE2L2,TP53",
                      "TFE3andTFEBfusions in ~ 10% of cases"
                    ]
                  },
                  {
                    "text": "Type 1 and type 2 PRCC characterized by different molecular alterationsIncludes distinct differences in mRNA, miRNA, and lncRNA clusters",
                    "sub_points": [
                      "Includes distinct differences in mRNA, miRNA, and lncRNA clusters"
                    ]
                  },
                  {
                    "text": "Formerly type 1 tumors~ 80% have alteredMETstatus, either by mutation (~ 15%), splice variant, or fusion",
                    "sub_points": [
                      "~ 80% have alteredMETstatus, either by mutation (~ 15%), splice variant, or fusion"
                    ]
                  },
                  {
                    "text": "Formerly type 2 tumors are genetically heterogeneous"
                  },
                  {
                    "text": "Altered cancer-associated pathways include chromatin remodeling and Hippo signaling pathways"
                  },
                  {
                    "text": "Mutations inSETD2,BAP1,PBRM1located on chromosome 3p"
                  },
                  {
                    "text": "Mutations or promoter hypermethylation ofCDKN2Aassociated with poor prognosis"
                  },
                  {
                    "text": "Activation of or mutations in NRF2-ARE pathway genes (NFE2L2,CUL3,KEAP1,SIRT1) in aggressive tumorsMutations in key genes of this pathway lead to constitutive activation of NRF2 transcription factor responsible for cell proliferation under oxidative stress",
                    "sub_points": [
                      "Mutations in key genes of this pathway lead to constitutive activation of NRF2 transcription factor responsible for cell proliferation under oxidative stress"
                    ]
                  },
                  {
                    "text": "High-grade tumors have alterations inTERTpromoter andARID1Amutations"
                  },
                  {
                    "text": "TP53mutations associated with poor survival"
                  },
                  {
                    "text": "Distinct subgroup has CpG island methylator phenotype (CIMP) that is associated with poor survivalSome of these cases also haveFHmutation",
                    "sub_points": [
                      "Some of these cases also haveFHmutation"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Papillary architecture with fibrovascular coresTypically lined by single layer of tumor cells",
                    "sub_points": [
                      "Typically lined by single layer of tumor cells"
                    ]
                  },
                  {
                    "text": "Tubular, solid, and glomeruloid areas may be seen"
                  },
                  {
                    "text": "Papillary fronds typically lined by single layer of tumor cells"
                  },
                  {
                    "text": "Fibrovascular cores often contain collections of foamy macrophages"
                  },
                  {
                    "text": "Necrosis may be present"
                  },
                  {
                    "text": "Sarcomatoid change present in ~ 5% of cases"
                  },
                  {
                    "text": "Graded according to WHO/International Society of Urological Pathology (ISUP) grading system based on nucleolar prominenceType 1 PRCCPapillae usually thin and delicate, often shortNeoplastic cells have modest to scant amphophilic cytoplasmSmall round to ovoid nuclei with inconspicuous nucleoliType 1 PRCC morphology characteristic of tumors occurring in familial setting of hereditary PRCCType 2 PRCCPapillary fronds often with dense and fibrous fibrovascular coresNeoplastic cells have abundant eosinophilic cytoplasmLarge, round nuclei with varying degrees of nuclear pseudostratificationTypically with prominent nucleoliNucleolar grade significantly higher in type 2 tumors compared to type 1",
                    "sub_points": [
                      "Type 1 PRCCPapillae usually thin and delicate, often shortNeoplastic cells have modest to scant amphophilic cytoplasmSmall round to ovoid nuclei with inconspicuous nucleoliType 1 PRCC morphology characteristic of tumors occurring in familial setting of hereditary PRCC",
                      "Papillae usually thin and delicate, often short",
                      "Neoplastic cells have modest to scant amphophilic cytoplasm",
                      "Small round to ovoid nuclei with inconspicuous nucleoli",
                      "Type 1 PRCC morphology characteristic of tumors occurring in familial setting of hereditary PRCC",
                      "Type 2 PRCCPapillary fronds often with dense and fibrous fibrovascular coresNeoplastic cells have abundant eosinophilic cytoplasmLarge, round nuclei with varying degrees of nuclear pseudostratificationTypically with prominent nucleoliNucleolar grade significantly higher in type 2 tumors compared to type 1",
                      "Papillary fronds often with dense and fibrous fibrovascular cores",
                      "Neoplastic cells have abundant eosinophilic cytoplasm",
                      "Large, round nuclei with varying degrees of nuclear pseudostratification",
                      "Typically with prominent nucleoli",
                      "Nucleolar grade significantly higher in type 2 tumors compared to type 1"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Positive for pancytokeratin, EMA, cytokeratin 7, CD10, AMACR (P504S), PAX2, PAX8, and RCCma"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Clear Cell Papillary Renal Cell Carcinoma": [
                  {
                    "text": "Tumor cells have clear cytoplasm with apical alignment of low-grade nuclei"
                  },
                  {
                    "text": "Negative for AMACR and CD10"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Southern Blot Analysis of Antigen Receptor Genes": {
            "name": "Southern Blot Analysis of Antigen Receptor Genes",
            "url": "https://app.pathprimer.com/document/c60e935d-d697-4be4-b2f3-d8762f3bb20a/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Southern blot (SB)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Analysis of restriction fragment length polymorphism"
                  },
                  {
                    "text": "Transfer of electrophoretically separated DNA fragments to filter membrane followed by detection of DNA fragment of interest by specific probe hybridizationTechnique of transfer of DNA fragments onto filter membrane invented by Edwin Southern in 1973",
                    "sub_points": [
                      "Technique of transfer of DNA fragments onto filter membrane invented by Edwin Southern in 1973"
                    ]
                  },
                  {
                    "text": "SB technique was extensively used in past for analysis of clonality in non-Hodgkin lymphomas"
                  },
                  {
                    "text": "Currently, PCR has replaced SB in assessment of clonality in non-Hodgkin lymphomas"
                  }
                ]
              },
              "Steps in Southern Blot Analysis": {
                "DNA Preparation": [
                  {
                    "text": "Extraction and purification of intact genomic DNA from fresh specimen~ 10 μg of DNA is required for routine SB analysisCan use as little as 200 ng if high concentration of gene of interest present, such as in plasmid DNA",
                    "sub_points": [
                      "~ 10 μg of DNA is required for routine SB analysisCan use as little as 200 ng if high concentration of gene of interest present, such as in plasmid DNA",
                      "Can use as little as 200 ng if high concentration of gene of interest present, such as in plasmid DNA"
                    ]
                  }
                ],
                "DNA Digestion": [
                  {
                    "text": "Restriction enzymes are used to cut intact DNARestriction enzymes are bacterial-derivedCut DNA at specific sequences known as restriction sitesRestriction sites are typically short sequences of 4-8 bpRestriction sites are frequently palindromesIdentical sequence on both strands when read from 5' to 3' on both strandsExample of palindrome restriction site recognized by enzyme EcoRI: GAATTC",
                    "sub_points": [
                      "Restriction enzymes are bacterial-derived",
                      "Cut DNA at specific sequences known as restriction sitesRestriction sites are typically short sequences of 4-8 bpRestriction sites are frequently palindromesIdentical sequence on both strands when read from 5' to 3' on both strandsExample of palindrome restriction site recognized by enzyme EcoRI: GAATTC",
                      "Restriction sites are typically short sequences of 4-8 bp",
                      "Restriction sites are frequently palindromesIdentical sequence on both strands when read from 5' to 3' on both strandsExample of palindrome restriction site recognized by enzyme EcoRI: GAATTC",
                      "Identical sequence on both strands when read from 5' to 3' on both strands",
                      "Example of palindrome restriction site recognized by enzyme EcoRI: GAATTC"
                    ]
                  },
                  {
                    "text": "DNA fragments produced by specific restriction enzyme produce reproducible set of DNA fragments"
                  },
                  {
                    "text": "Mutations, indels, or rearrangements may alter size of DNA fragments produced within geneAlterations in size pattern of DNA fragments called RFLP",
                    "sub_points": [
                      "Alterations in size pattern of DNA fragments called RFLP"
                    ]
                  }
                ],
                "Gel Electrophoresis of DNA Fragments": [
                  {
                    "text": "Agarose gel functions as sieve that allows separation of DNA fragments"
                  },
                  {
                    "text": "Negatively charged DNA fragments facilitate their movement through electric field"
                  },
                  {
                    "text": "DNA fragments are fractionated according to their sizes"
                  },
                  {
                    "text": "Gel should be adequately covered by buffer"
                  },
                  {
                    "text": "High voltage should be avoided to prevent melting of agarose gel"
                  },
                  {
                    "text": "Fragments ranging from 200 bp to 20 kb are typically separated on agarose gel"
                  },
                  {
                    "text": "Analysis of DNA fragments > 20 kb should be done by pulsed-field electrophoresis"
                  },
                  {
                    "text": "Fragments < 200 bp can be reliably analyzed using polyacrylamide gel"
                  }
                ],
                "Transfer of DNA onto Nylon or Nitrocellulose Membrane": [
                  {
                    "text": "Diluted solution of hydrochloric acid is applied to gel before transfer to hydrolyze larger DNA fragments"
                  },
                  {
                    "text": "DNA must be denatured before transferTreatment of gel with alkaline denatures DNA",
                    "sub_points": [
                      "Treatment of gel with alkaline denatures DNA"
                    ]
                  },
                  {
                    "text": "Upward capillary action of buffer transfers DNA fragments from gel onto nylon or nitrocellulose membrane"
                  }
                ],
                "Stabilization of Transferred DNA on Membrane": [
                  {
                    "text": "DNA must be stabilized on membrane before probe hybridizationTransferred DNA will firmly adhere to and be stabilized on membrane after baking membrane at 80° C in oven for ~ 2 hoursDNA can also be stabilized by exposing nylon membrane to UV lightUV light induces crosslink between nucleic acids and amine groups on membrane",
                    "sub_points": [
                      "Transferred DNA will firmly adhere to and be stabilized on membrane after baking membrane at 80° C in oven for ~ 2 hours",
                      "DNA can also be stabilized by exposing nylon membrane to UV lightUV light induces crosslink between nucleic acids and amine groups on membrane",
                      "UV light induces crosslink between nucleic acids and amine groups on membrane"
                    ]
                  }
                ],
                "DNA Hybridization": [
                  {
                    "text": "Hybridization probesSingle-stranded specific DNA fragment complementary to target DNA on membraneProbe is labeled with isotopic 32P or nonisotopic systems, such as chemiluminescenceMembrane is washed after completion of hybridization to remove unused and nonspecifically bound probes",
                    "sub_points": [
                      "Single-stranded specific DNA fragment complementary to target DNA on membrane",
                      "Probe is labeled with isotopic 32P or nonisotopic systems, such as chemiluminescence",
                      "Membrane is washed after completion of hybridization to remove unused and nonspecifically bound probes"
                    ]
                  }
                ],
                "Interpretation of Southern Blot Analysis of Antigen Receptor Genes": [
                  {
                    "text": "Radioactive hybridized probes are visualized after exposure to x-ray film and appear as dark bands"
                  },
                  {
                    "text": "For analysis of antigen receptor genes (ARGs), patient's DNA sample is digested in parallel with germline DNA sample"
                  },
                  {
                    "text": "Locations of bands in patient's sample are compared to germline DNA bandsPolyclonal or reactive lymphoid populationNumerous different VDJ rearrangements present, but individual rearrangements are too small to be detected as visible nongermline bandsMonoclonal B-cell or T-cell populationAll neoplastic cells are derived from single transformed cellIdentical gene rearrangements are present in all neoplastic cellsRestriction fragments containing identical gene rearrangements are detected as novel (nongermline) band(s)Presence of nongermline bands in patient's sample indicate monoclonal ARG rearrangementNongermline bands are often of lower molecular sizes compared to germline bandsNongermline bands are sometimes of higher molecular sizes compared to germline bandsKnown DNA polymorphic region in EcoRI restriction digest existsThus, presence of nongermline band in only EcoRI restriction digest must not be interpreted as evidence for clonality",
                    "sub_points": [
                      "Polyclonal or reactive lymphoid populationNumerous different VDJ rearrangements present, but individual rearrangements are too small to be detected as visible nongermline bands",
                      "Numerous different VDJ rearrangements present, but individual rearrangements are too small to be detected as visible nongermline bands",
                      "Monoclonal B-cell or T-cell populationAll neoplastic cells are derived from single transformed cellIdentical gene rearrangements are present in all neoplastic cellsRestriction fragments containing identical gene rearrangements are detected as novel (nongermline) band(s)Presence of nongermline bands in patient's sample indicate monoclonal ARG rearrangement",
                      "All neoplastic cells are derived from single transformed cell",
                      "Identical gene rearrangements are present in all neoplastic cells",
                      "Restriction fragments containing identical gene rearrangements are detected as novel (nongermline) band(s)",
                      "Presence of nongermline bands in patient's sample indicate monoclonal ARG rearrangement",
                      "Nongermline bands are often of lower molecular sizes compared to germline bands",
                      "Nongermline bands are sometimes of higher molecular sizes compared to germline bands",
                      "Known DNA polymorphic region in EcoRI restriction digest existsThus, presence of nongermline band in only EcoRI restriction digest must not be interpreted as evidence for clonality",
                      "Thus, presence of nongermline band in only EcoRI restriction digest must not be interpreted as evidence for clonality"
                    ]
                  },
                  {
                    "text": "At least 2 nongermline bands in 1 digest or 1 nongermline band in 2 different digests are required to establish diagnosis of clonal T-cell receptor β (TRB) gene rearrangement"
                  }
                ],
                "Southern Blot vs. PCR in Assessment of Clonality in Lymphoid Proliferations": [
                  {
                    "text": "Advantages of SB in assessment of clonalityConsidered to be gold standard for assessment of clonality in lymphoid neoplasmsFewer false-negative results compared with PCR",
                    "sub_points": [
                      "Considered to be gold standard for assessment of clonality in lymphoid neoplasms",
                      "Fewer false-negative results compared with PCR"
                    ]
                  },
                  {
                    "text": "Disadvantages of SB in assessment of clonalityRequires relatively large amounts of fresh, intact DNALower sensitivity (~ 5%) compared to PCR, which has much higher sensitivityHigh cost and labor intensiveLong turnaround time of ~ 10-14 days",
                    "sub_points": [
                      "Requires relatively large amounts of fresh, intact DNA",
                      "Lower sensitivity (~ 5%) compared to PCR, which has much higher sensitivity",
                      "High cost and labor intensive",
                      "Long turnaround time of ~ 10-14 days"
                    ]
                  }
                ],
                "Other Applications of RFLP Analysis": [
                  {
                    "text": "DNA fingerprintingAnalysis of variable number of tandem repeats (VNTRs)VNTRs are repeat sequences of 20-100 bpEach individual has unique numbers of VNTRs at single locusRestriction fragments produce unique pattern in given individualAnalysis of VNTRs on samples collected as evidence at crime scene identifies suspects",
                    "sub_points": [
                      "Analysis of variable number of tandem repeats (VNTRs)VNTRs are repeat sequences of 20-100 bpEach individual has unique numbers of VNTRs at single locusRestriction fragments produce unique pattern in given individual",
                      "VNTRs are repeat sequences of 20-100 bp",
                      "Each individual has unique numbers of VNTRs at single locus",
                      "Restriction fragments produce unique pattern in given individual",
                      "Analysis of VNTRs on samples collected as evidence at crime scene identifies suspects"
                    ]
                  },
                  {
                    "text": "PaternityAnalysis of VNTRs loci to determine paternity",
                    "sub_points": [
                      "Analysis of VNTRs loci to determine paternity"
                    ]
                  },
                  {
                    "text": "Genetic diversityAnalysis of RFLP to study evolution and migration of wild lifeAlso used to study breeding patterns in animal population",
                    "sub_points": [
                      "Analysis of RFLP to study evolution and migration of wild life",
                      "Also used to study breeding patterns in animal population"
                    ]
                  },
                  {
                    "text": "Genome mapping and genetic disease analysis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "FISH forERBB2(HER2) Amplifications": {
            "name": "FISH forERBB2(HER2) Amplifications",
            "url": "https://app.pathprimer.com/document/aa188b5f-08b0-4567-a998-0223691f72be/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name:erb-b2 receptor tyrosine kinase 2a.k.a. HER2Terminology used extensively and interchangeably",
                    "sub_points": [
                      "a.k.a. HER2Terminology used extensively and interchangeably",
                      "Terminology used extensively and interchangeably"
                    ]
                  },
                  {
                    "text": "Official symbol: ERBB2"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "ERBB2amplification in breast cancer~ 30% of invasive breast cancerCorrelates with poor prognosisImportant to evaluate for anti-ERBB2 therapy",
                    "sub_points": [
                      "~ 30% of invasive breast cancer",
                      "Correlates with poor prognosis",
                      "Important to evaluate for anti-ERBB2 therapy"
                    ]
                  },
                  {
                    "text": "Other malignancies withERBB2amplificationsGastric and gastroesophageal carcinoma (9-38%), colorectal cancer (~ 3% and 5-15% in RAS/RAF-negative tumors), gallbladder (5-10%), cholangiocarcinoma (5-15%), uterine serous carcinoma (25-30%), invasive bladder cancer (~ 9%)",
                    "sub_points": [
                      "Gastric and gastroesophageal carcinoma (9-38%), colorectal cancer (~ 3% and 5-15% in RAS/RAF-negative tumors), gallbladder (5-10%), cholangiocarcinoma (5-15%), uterine serous carcinoma (25-30%), invasive bladder cancer (~ 9%)"
                    ]
                  },
                  {
                    "text": "Malignancies with reported low frequency ofERBB2(HER2) amplificationCervical, testicular, non-small cell lung and other epithelial-derived tumors",
                    "sub_points": [
                      "Cervical, testicular, non-small cell lung and other epithelial-derived tumors"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "NormalERBB2Function": [
                  {
                    "text": "Part of epidermal growth factor receptor (EGFR) family"
                  },
                  {
                    "text": "Tyrosine kinase receptor involved in growth signaling"
                  },
                  {
                    "text": "No known ligand-binding domain of its ownBinds to other EGFR family members to form heterodimer",
                    "sub_points": [
                      "Binds to other EGFR family members to form heterodimer"
                    ]
                  }
                ],
                "Overexpression ofERBB2in Cancer": [
                  {
                    "text": "Usually result of gene amplification"
                  },
                  {
                    "text": "Can lead to oncogenic transformation"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Treatment": [
                  {
                    "text": "Patients with amplifiedERBB2or 3+ IHC-positive tumors can benefit fromERBB2-targeted specific therapiesTrastuzumab (Herceptin)Monoclonal antibody againstERBB2Significantly improves outcome inERBB2(+) cancers",
                    "sub_points": [
                      "Trastuzumab (Herceptin)Monoclonal antibody againstERBB2Significantly improves outcome inERBB2(+) cancers",
                      "Monoclonal antibody againstERBB2",
                      "Significantly improves outcome inERBB2(+) cancers"
                    ]
                  },
                  {
                    "text": "New indication for trastuzumab-deruxtecanBased on DESTINY-Breast04 phase III trialPatients with nonamplifiedERBB2by FISH and 1+ or 2+ IHC-positive breast cancer treated with trastuzumab-deruxtecan showed significant improvement in survivalPatients with IHC 0 score were not included in trial and thus not eligible",
                    "sub_points": [
                      "Based on DESTINY-Breast04 phase III trial",
                      "Patients with nonamplifiedERBB2by FISH and 1+ or 2+ IHC-positive breast cancer treated with trastuzumab-deruxtecan showed significant improvement in survival",
                      "Patients with IHC 0 score were not included in trial and thus not eligible"
                    ]
                  }
                ],
                "Guidelines": [
                  {
                    "text": "2018 American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) recommendations to determineERBB2status for all newly diagnosed invasive breast cancer and subsequent metastatic diseaseIHC or ISH methods acceptableIf results are equivocal, reflex testing using alternate method should be performedTesting must be performed in CAP-accredited laboratoryPreferably use FDA-approved IHC, brightfield ISH, or FISHOptimal specimen handlingSlice at 5- to 10-mm intervalsFix in 10% neutral buffered formalin for 6-72 hoursResults important to determine appropriate therapyAnti-ERBB2 therapy shouldnotbe used with negative or equivocal results or while waiting for result",
                    "sub_points": [
                      "IHC or ISH methods acceptableIf results are equivocal, reflex testing using alternate method should be performed",
                      "If results are equivocal, reflex testing using alternate method should be performed",
                      "Testing must be performed in CAP-accredited laboratoryPreferably use FDA-approved IHC, brightfield ISH, or FISH",
                      "Preferably use FDA-approved IHC, brightfield ISH, or FISH",
                      "Optimal specimen handlingSlice at 5- to 10-mm intervalsFix in 10% neutral buffered formalin for 6-72 hours",
                      "Slice at 5- to 10-mm intervals",
                      "Fix in 10% neutral buffered formalin for 6-72 hours",
                      "Results important to determine appropriate therapyAnti-ERBB2 therapy shouldnotbe used with negative or equivocal results or while waiting for result",
                      "Anti-ERBB2 therapy shouldnotbe used with negative or equivocal results or while waiting for result"
                    ]
                  },
                  {
                    "text": "2023 ASCO-CAP guideline update2018 ASCO-CAP recommendations forERBB2testing are affirmedAcknowledges new indication for trastuzumab-deruxtecanRecommends pathologists make best practice efforts to distinguish IHC 0 from 1+ resultsRecommends adding comment provided by ASCO-CAP to all HER2 test reports",
                    "sub_points": [
                      "2018 ASCO-CAP recommendations forERBB2testing are affirmed",
                      "Acknowledges new indication for trastuzumab-deruxtecanRecommends pathologists make best practice efforts to distinguish IHC 0 from 1+ resultsRecommends adding comment provided by ASCO-CAP to all HER2 test reports",
                      "Recommends pathologists make best practice efforts to distinguish IHC 0 from 1+ results",
                      "Recommends adding comment provided by ASCO-CAP to all HER2 test reports"
                    ]
                  },
                  {
                    "text": "National Comprehensive Cancer Network (NCCN)ERBB2testing recommendations for patients with followingMetastatic colorectal cancer with noRAS/RAFmutationsAdvanced gastroesophageal or gastric adenocarcinomaUnresectable or metastatic gallbladder cancer or cholangiocarcinomaAdvanced-stage or recurrent serous endometrial carcinoma or carcinosarcoma",
                    "sub_points": [
                      "Metastatic colorectal cancer with noRAS/RAFmutations",
                      "Advanced gastroesophageal or gastric adenocarcinoma",
                      "Unresectable or metastatic gallbladder cancer or cholangiocarcinoma",
                      "Advanced-stage or recurrent serous endometrial carcinoma or carcinosarcoma"
                    ]
                  }
                ]
              },
              "Predictive Cancer Testing Summary": {
                "Test Interpretation": [
                  {
                    "text": "ERBB2 IHC on tumor tissueGraded from 0-3+0 = no staining, or incomplete/barely perceptible in ≤ 10% of tumor cellsInterpreted as negative1+ = barely perceptible, incomplete membrane staining in > 10% of tumor cellsInterpreted as negative2+ = weak to moderate complete membrane staining in > 10% of tumor cellsInterpreted as equivocal2+ criteria were redefined in 2018 ASCO/CAP updateReflex to ISH using same specimenorwith new specimen can repeat IHC or reflex to ISH3+ = complete, intense membrane staining in > 10% cellsInterpreted as positive",
                    "sub_points": [
                      "Graded from 0-3+",
                      "0 = no staining, or incomplete/barely perceptible in ≤ 10% of tumor cellsInterpreted as negative",
                      "Interpreted as negative",
                      "1+ = barely perceptible, incomplete membrane staining in > 10% of tumor cellsInterpreted as negative",
                      "Interpreted as negative",
                      "2+ = weak to moderate complete membrane staining in > 10% of tumor cellsInterpreted as equivocal2+ criteria were redefined in 2018 ASCO/CAP updateReflex to ISH using same specimenorwith new specimen can repeat IHC or reflex to ISH",
                      "Interpreted as equivocal",
                      "2+ criteria were redefined in 2018 ASCO/CAP update",
                      "Reflex to ISH using same specimenorwith new specimen can repeat IHC or reflex to ISH",
                      "3+ = complete, intense membrane staining in > 10% cellsInterpreted as positive",
                      "Interpreted as positive"
                    ]
                  },
                  {
                    "text": "ERBB2FISH reflex testing should be performed on IHC 2+ (equivocal) casesSingle-probe assays (ERBB2only) require average of ≥ 6 signals per cell to be called positiveDual-signal assay (ERBB2/CEP17) requires ratio > 2.0 to be deemed positive resultIf ratio is < 2.0 butERBB2signal number is still > 6, this is also considered positiveIf ratio is < 2.0 with ERBB2 copy number between 4.0 and 6.0, this is considered equivocal and requires reflex testing to alternate method",
                    "sub_points": [
                      "Single-probe assays (ERBB2only) require average of ≥ 6 signals per cell to be called positive",
                      "Dual-signal assay (ERBB2/CEP17) requires ratio > 2.0 to be deemed positive resultIf ratio is < 2.0 butERBB2signal number is still > 6, this is also considered positiveIf ratio is < 2.0 with ERBB2 copy number between 4.0 and 6.0, this is considered equivocal and requires reflex testing to alternate method",
                      "If ratio is < 2.0 butERBB2signal number is still > 6, this is also considered positive",
                      "If ratio is < 2.0 with ERBB2 copy number between 4.0 and 6.0, this is considered equivocal and requires reflex testing to alternate method"
                    ]
                  }
                ],
                "Pathology Review of Concurrent H&E": [
                  {
                    "text": "Important to avoid inclusion of adjacent in situ carcinoma lesions during FISH read"
                  }
                ],
                "General Issues": [
                  {
                    "text": "Repeat testing should be performedOn relapse in patients with previouslyERBB2(-) tumorsOn excision specimen in patients withERBB2(-) core needle biopsy specimen",
                    "sub_points": [
                      "On relapse in patients with previouslyERBB2(-) tumors",
                      "On excision specimen in patients withERBB2(-) core needle biopsy specimen"
                    ]
                  },
                  {
                    "text": "Testing must be reported asindeterminateif technical issues preclude diagnosisInadequate specimen handlingSignificant artifacts, including crush and edge artifactsFailed analytical testing demonstrated by failed controlsReport as indeterminate and request another specimen",
                    "sub_points": [
                      "Inadequate specimen handling",
                      "Significant artifacts, including crush and edge artifacts",
                      "Failed analytical testing demonstrated by failed controls",
                      "Report as indeterminate and request another specimen"
                    ]
                  }
                ]
              },
              "FISH Method for ERBB2 Amplification": {
                "Methodology": [
                  {
                    "text": "Paraffin-embedded, formalin-fixed tumor tissue sections"
                  },
                  {
                    "text": "Fluorescent DNA probe binds to sequence inERBB2region at 17q12"
                  },
                  {
                    "text": "Used with chromosome 17 centromeric probe (CEP17)"
                  },
                  {
                    "text": "Ratio ofERBB2signals to CEP17 signals is calculated"
                  },
                  {
                    "text": "Chromogenic ISH (CISH) is alternativeCan correlate better with morphology",
                    "sub_points": [
                      "Can correlate better with morphology"
                    ]
                  }
                ],
                "Single-Probe ISH Assay": [
                  {
                    "text": "Positive if ≥ 6.0 signals/cell"
                  },
                  {
                    "text": "If ≥ 4.0 but < 6.0 signals per cell, need concurrent IHC evaluationPositive if IHC 3+ or dual-probe ISH group 1Negative if IHC 0-2+ or dual-probe ISH group 5",
                    "sub_points": [
                      "Positive if IHC 3+ or dual-probe ISH group 1",
                      "Negative if IHC 0-2+ or dual-probe ISH group 5"
                    ]
                  },
                  {
                    "text": "If < 4.0 signals/cell, considered negative"
                  }
                ],
                "Dual-Probe ISH Assay": [
                  {
                    "text": "HER2:CEP17 ratio ≥ 2.0Group 1: AverageHER2copy number ≥ 4.0 signals/cellConsidered ISH positive andHER2(+)Group 2: AverageHER2copy number < 4.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results are obtained, this is consideredHER2(-) with comment (unclear benefit of trastuzumab in small sample size clinical trial)If IHC is 0-2+, consideredHER2(-)If IHC is 3+, consideredHER2(+)",
                    "sub_points": [
                      "Group 1: AverageHER2copy number ≥ 4.0 signals/cellConsidered ISH positive andHER2(+)",
                      "Considered ISH positive andHER2(+)",
                      "Group 2: AverageHER2copy number < 4.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results are obtained, this is consideredHER2(-) with comment (unclear benefit of trastuzumab in small sample size clinical trial)If IHC is 0-2+, consideredHER2(-)If IHC is 3+, consideredHER2(+)",
                      "Reflex back to IHC from same tissue",
                      "If IHC is 2+, recount ISHIf same ISH results are obtained, this is consideredHER2(-) with comment (unclear benefit of trastuzumab in small sample size clinical trial)",
                      "If same ISH results are obtained, this is consideredHER2(-) with comment (unclear benefit of trastuzumab in small sample size clinical trial)",
                      "If IHC is 0-2+, consideredHER2(-)",
                      "If IHC is 3+, consideredHER2(+)"
                    ]
                  },
                  {
                    "text": "HER2:CEP17 ratio < 2.0Group 3: AverageHER2copy number ≥ 6.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results obtained, consideredHER2(+)If IHC is 0-1+, consideredHER2(-)If IHC is 2-3+, consideredHER2(+)Group 4: AverageHER2copy number ≥ 4.0 and < 6.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results are obtained, consideredHER2(-) with comment (unclear benefit of trastuzumab)If IHC is 0-2+, consideredHER2(-)If IHC is 3+, consideredHER2(+)Group 5: AverageHER2copy number < 4.0 signals/cellConsidered ISH negative andHER2(-)",
                    "sub_points": [
                      "Group 3: AverageHER2copy number ≥ 6.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results obtained, consideredHER2(+)If IHC is 0-1+, consideredHER2(-)If IHC is 2-3+, consideredHER2(+)",
                      "Reflex back to IHC from same tissue",
                      "If IHC is 2+, recount ISHIf same ISH results obtained, consideredHER2(+)",
                      "If same ISH results obtained, consideredHER2(+)",
                      "If IHC is 0-1+, consideredHER2(-)",
                      "If IHC is 2-3+, consideredHER2(+)",
                      "Group 4: AverageHER2copy number ≥ 4.0 and < 6.0 signals/cellReflex back to IHC from same tissueIf IHC is 2+, recount ISHIf same ISH results are obtained, consideredHER2(-) with comment (unclear benefit of trastuzumab)If IHC is 0-2+, consideredHER2(-)If IHC is 3+, consideredHER2(+)",
                      "Reflex back to IHC from same tissue",
                      "If IHC is 2+, recount ISHIf same ISH results are obtained, consideredHER2(-) with comment (unclear benefit of trastuzumab)",
                      "If same ISH results are obtained, consideredHER2(-) with comment (unclear benefit of trastuzumab)",
                      "If IHC is 0-2+, consideredHER2(-)",
                      "If IHC is 3+, consideredHER2(+)",
                      "Group 5: AverageHER2copy number < 4.0 signals/cellConsidered ISH negative andHER2(-)",
                      "Considered ISH negative andHER2(-)"
                    ]
                  }
                ],
                "Alternate Patterns": [
                  {
                    "text": "Aneuploidy"
                  },
                  {
                    "text": "Monosomy 17~ 2% incidenceCEP17 signals are < 1.4 copies per cellIfERBB2signals are at same/similar number (ratio still < 2.0), these are reported as nonamplified",
                    "sub_points": [
                      "~ 2% incidence",
                      "CEP17 signals are < 1.4 copies per cell",
                      "IfERBB2signals are at same/similar number (ratio still < 2.0), these are reported as nonamplified"
                    ]
                  },
                  {
                    "text": "Heterogeneity1 group of tumor cells shows amplification, while another region does not; both groups should be reported with ratio calculated for each",
                    "sub_points": [
                      "1 group of tumor cells shows amplification, while another region does not; both groups should be reported with ratio calculated for each"
                    ]
                  },
                  {
                    "text": "High-signal numbers for both CEP17 andERBB2Interpretation may depend on patternIf colocalized (fused \"yellow\" signal), may indicate amplification of both and should be reported as such, even though ratio appears normalIf not colocalized (increased numbers but clearly distinct), meaning is unclear, but according to current guidelines, if ratios are normal, these should be reported as nonamplified",
                    "sub_points": [
                      "Interpretation may depend on patternIf colocalized (fused \"yellow\" signal), may indicate amplification of both and should be reported as such, even though ratio appears normalIf not colocalized (increased numbers but clearly distinct), meaning is unclear, but according to current guidelines, if ratios are normal, these should be reported as nonamplified",
                      "If colocalized (fused \"yellow\" signal), may indicate amplification of both and should be reported as such, even though ratio appears normal",
                      "If not colocalized (increased numbers but clearly distinct), meaning is unclear, but according to current guidelines, if ratios are normal, these should be reported as nonamplified"
                    ]
                  }
                ]
              },
              "Other Methods for Evaluation of ERBB2 Status": {
                "Quantitative Real-Time PCR": [
                  {
                    "text": "Emerging alternate method can be used in cases (~ 5%) where FISH fails"
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "For cases with limited available diagnostic tissue or when patient is unable to undergo traditional biopsy"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Papillary Thyroid Carcinoma": {
            "name": "Papillary Thyroid Carcinoma",
            "url": "https://app.pathprimer.com/document/6596e9dc-2bdf-4553-9ed3-bc7a613fff93/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Papillary thyroid carcinoma (PTC)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most common subtype of thyroid cancer (85-90%)"
                  },
                  {
                    "text": "Female predominance"
                  },
                  {
                    "text": "Strong association with radiation exposure"
                  },
                  {
                    "text": "Most cases present as nodule"
                  },
                  {
                    "text": "Frequent metastasis to cervical lymph nodes"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Gene mutationsBRAFmutations60-80% of classic PTC> 90% of tall cell variantp.V600E most common variantRAS mutationsStrong association with follicular variant (25-45%)< 10% in classic PTCTERTpromoter mutations in 5-15%",
                    "sub_points": [
                      "BRAFmutations60-80% of classic PTC> 90% of tall cell variantp.V600E most common variant",
                      "60-80% of classic PTC",
                      "> 90% of tall cell variant",
                      "p.V600E most common variant",
                      "RAS mutationsStrong association with follicular variant (25-45%)< 10% in classic PTC",
                      "Strong association with follicular variant (25-45%)",
                      "< 10% in classic PTC",
                      "TERTpromoter mutations in 5-15%"
                    ]
                  },
                  {
                    "text": "Gene rearrangementsRETin up to 25%PAX8::PPARGfusion in up to 10% in follicular variantsNTRK1andNTRK3in < 5%ALKin < 5%",
                    "sub_points": [
                      "RETin up to 25%",
                      "PAX8::PPARGfusion in up to 10% in follicular variants",
                      "NTRK1andNTRK3in < 5%",
                      "ALKin < 5%"
                    ]
                  },
                  {
                    "text": "miRNA dysregulationmiR-146b, miR-221, and miR-222",
                    "sub_points": [
                      "miR-146b, miR-221, and miR-222"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Papillary growth"
                  },
                  {
                    "text": "Characteristic nuclear featuresGround-glass nucleiNuclear pseudoinclusionsNuclear grooves",
                    "sub_points": [
                      "Ground-glass nuclei",
                      "Nuclear pseudoinclusions",
                      "Nuclear grooves"
                    ]
                  },
                  {
                    "text": "Psammoma bodies"
                  },
                  {
                    "text": "Several histologic subtypes"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Papillary thyroid carcinoma (PTC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Most common type of thyroid carcinoma, typically characterized by papillary architecture and well-defined cytological features, includingCharacteristic empty-appearing nucleiLongitudinal nuclear groovesPsammoma bodies in some cases",
                    "sub_points": [
                      "Characteristic empty-appearing nuclei",
                      "Longitudinal nuclear grooves",
                      "Psammoma bodies in some cases"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Strong association with radiation exposure"
                  }
                ],
                "Cell of Origin": [
                  {
                    "text": "Follicular cells of thyroid gland"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Most common type of thyroid cancer (~ 85-90%)"
                  },
                  {
                    "text": "Incidence relatively higher in areas of high iodine intake"
                  }
                ],
                "Sex": [
                  {
                    "text": "F:M = 4:1"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most cases present as thyroid nodule"
                  },
                  {
                    "text": "Worrisome symptoms and signs at presentationRapid increase in sizeDyspnea, dysphagia, or hoarsenessFirmness, lack of mobility, or large sizePresence of lymphadenopathy",
                    "sub_points": [
                      "Rapid increase in size",
                      "Dyspnea, dysphagia, or hoarseness",
                      "Firmness, lack of mobility, or large size",
                      "Presence of lymphadenopathy"
                    ]
                  },
                  {
                    "text": "May also be found incidentally in thyroid tissue removed for other conditions"
                  },
                  {
                    "text": "Regional lymph node metastasis usually presents at diagnosis in ~ 50% of PTC"
                  },
                  {
                    "text": "Distant metastases are uncommonLung is most common site of metastasis",
                    "sub_points": [
                      "Lung is most common site of metastasis"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "SurgeryComplete or partial thyroidectomy ± neck dissection",
                    "sub_points": [
                      "Complete or partial thyroidectomy ± neck dissection"
                    ]
                  },
                  {
                    "text": "Radioiodine therapy"
                  },
                  {
                    "text": "Targeted therapiesTyrosine kinase inhibitorsTargetingBRAF&/orRETsignaling pathwaysMainly considered in patients with aggressive disease or with distant metastasis and for tumors refractory to conventional therapies",
                    "sub_points": [
                      "Tyrosine kinase inhibitorsTargetingBRAF&/orRETsignaling pathwaysMainly considered in patients with aggressive disease or with distant metastasis and for tumors refractory to conventional therapies",
                      "TargetingBRAF&/orRETsignaling pathways",
                      "Mainly considered in patients with aggressive disease or with distant metastasis and for tumors refractory to conventional therapies"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "In general, well-differentiated tumors have very good prognosis90-95% overall survival",
                    "sub_points": [
                      "90-95% overall survival"
                    ]
                  },
                  {
                    "text": "Males and patients > 45 years of age tend to have more aggressive disease"
                  },
                  {
                    "text": "Regional lymph node metastasis has no significant impact on long-term prognosis"
                  },
                  {
                    "text": "Distant metastasis is predictor of poor outcome"
                  },
                  {
                    "text": "Prognostic impacts ofBRAFor other gene mutations are controversial"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Tumor size ranges from microscopic to large"
                  },
                  {
                    "text": "Most tumors are solid, whitish, firm, and clearly invasive"
                  },
                  {
                    "text": "< 10% are encapsulated"
                  },
                  {
                    "text": "Cystic changes seen in ~ 10% of PTC"
                  },
                  {
                    "text": "Calcifications may be present"
                  }
                ]
              },
              "MOLECULAR": {
                "Cytogenetics": [
                  {
                    "text": "Diploid or near-diploid chromosomal DNA contentAneuploidy or complex karyotypes usually associated with high-grade features",
                    "sub_points": [
                      "Aneuploidy or complex karyotypes usually associated with high-grade features"
                    ]
                  },
                  {
                    "text": "Low rate of loss of heterozygosity"
                  }
                ],
                "MAPK-Related Gene Alterations": [
                  {
                    "text": "BRAFmutationsBRAFV600E mutation has been strongly associated with papillary phenotypeSeen in ~ 60-80% of classic variantSeen in > 90% of tall cell variantSeen in ~ 10% of encapsulated follicular variant of PTC (EFV-PTC)c.1799T>A results in valine to glutamate substitution in codon 600 (p.V600E)Accounts for 98% ofBRAFmutationsBRAFmutation has been associated with aggressive behavior and poor outcome in some studies",
                    "sub_points": [
                      "BRAFV600E mutation has been strongly associated with papillary phenotypeSeen in ~ 60-80% of classic variantSeen in > 90% of tall cell variantSeen in ~ 10% of encapsulated follicular variant of PTC (EFV-PTC)",
                      "Seen in ~ 60-80% of classic variant",
                      "Seen in > 90% of tall cell variant",
                      "Seen in ~ 10% of encapsulated follicular variant of PTC (EFV-PTC)",
                      "c.1799T>A results in valine to glutamate substitution in codon 600 (p.V600E)Accounts for 98% ofBRAFmutations",
                      "Accounts for 98% ofBRAFmutations",
                      "BRAFmutation has been associated with aggressive behavior and poor outcome in some studies"
                    ]
                  },
                  {
                    "text": "KRAS,NRAS, andHRASmutationsStrong association with invasive encapsulated follicular variant of PTC (25-45%)< 10% in classic PTCMutations inBRAF,NRAS,HRAS, andKRASare essentially mutually exclusive",
                    "sub_points": [
                      "Strong association with invasive encapsulated follicular variant of PTC (25-45%)",
                      "< 10% in classic PTC",
                      "Mutations inBRAF,NRAS,HRAS, andKRASare essentially mutually exclusive"
                    ]
                  }
                ],
                "Other Gene Mutations": [
                  {
                    "text": "TERTpromoter mutationsPresent in 5-15% in most seriesp.C228T is most common mutationCan coexist withBRAFV600E mutationsAssociated with poor prognosis",
                    "sub_points": [
                      "Present in 5-15% in most series",
                      "p.C228T is most common mutation",
                      "Can coexist withBRAFV600E mutations",
                      "Associated with poor prognosis"
                    ]
                  },
                  {
                    "text": "Low-frequency gene mutationsOther low-frequency (< 5%) somatic mutations includeHRAS,KRAS,MEK1,EIF1AX,PPM1D,CHEK2,MED12, andRBM10",
                    "sub_points": [
                      "Other low-frequency (< 5%) somatic mutations includeHRAS,KRAS,MEK1,EIF1AX,PPM1D,CHEK2,MED12, andRBM10",
                      "HRAS,KRAS,MEK1,EIF1AX,PPM1D,CHEK2,MED12, andRBM10"
                    ]
                  }
                ],
                "Gene Fusions": [
                  {
                    "text": "RETrearrangements16 different partner genes are reportedFusion of tyrosine kinase domain ofREToncogene (10q11.21) to 5' portion of partner genesPresent in 5-25% of PTCStrong association with radiation-related PTCCommon in tumors from children and young adultsRET::CCDC6fusion (~ 60%)CCDC6at 10q21.2Can be detected by cytogeneticsAssociated with typical papillary growth and microcarcinomasTend to have more benign clinical courseRET::NCOA4fusion (~ 30%)NCOA4at 10q11.22Not detected by conventional cytogeneticsOften correlate with solid variant of PTC and with more aggressive clinical behaviorRET::PRKAR1Afusion (~ 5%)PRKAR1Aat 17q24.2",
                    "sub_points": [
                      "16 different partner genes are reported",
                      "Fusion of tyrosine kinase domain ofREToncogene (10q11.21) to 5' portion of partner genes",
                      "Present in 5-25% of PTCStrong association with radiation-related PTCCommon in tumors from children and young adults",
                      "Strong association with radiation-related PTC",
                      "Common in tumors from children and young adults",
                      "RET::CCDC6fusion (~ 60%)CCDC6at 10q21.2Can be detected by cytogeneticsAssociated with typical papillary growth and microcarcinomasTend to have more benign clinical course",
                      "CCDC6at 10q21.2",
                      "Can be detected by cytogenetics",
                      "Associated with typical papillary growth and microcarcinomas",
                      "Tend to have more benign clinical course",
                      "RET::NCOA4fusion (~ 30%)NCOA4at 10q11.22Not detected by conventional cytogeneticsOften correlate with solid variant of PTC and with more aggressive clinical behavior",
                      "NCOA4at 10q11.22",
                      "Not detected by conventional cytogenetics",
                      "Often correlate with solid variant of PTC and with more aggressive clinical behavior",
                      "RET::PRKAR1Afusion (~ 5%)PRKAR1Aat 17q24.2",
                      "PRKAR1Aat 17q24.2"
                    ]
                  },
                  {
                    "text": "BRAFrearrangementsPresent in ~ 2-3% of PTCDiverse gene partners, includingAKAP9andAGK",
                    "sub_points": [
                      "Present in ~ 2-3% of PTC",
                      "Diverse gene partners, includingAKAP9andAGK"
                    ]
                  },
                  {
                    "text": "PAX8::PPARGrearrangementMore common in EFV-PTC (~ 10%)PAX8at 2q13 fused withPPARGat 3p25",
                    "sub_points": [
                      "More common in EFV-PTC (~ 10%)",
                      "PAX8at 2q13 fused withPPARGat 3p25"
                    ]
                  },
                  {
                    "text": "NTRK1andNTRK3rearrangementsPresent in < 5% of PTCCommon fusion partners ofNTRK1includeTPM3,TPR, andTFGCommon fusion partner ofNTRK3isETV6Common in radiation-associated PTCAssociated with aggressive features",
                    "sub_points": [
                      "Present in < 5% of PTC",
                      "Common fusion partners ofNTRK1includeTPM3,TPR, andTFG",
                      "Common fusion partner ofNTRK3isETV6Common in radiation-associated PTC",
                      "Common in radiation-associated PTC",
                      "Associated with aggressive features"
                    ]
                  },
                  {
                    "text": "ALKrearrangementsReported in ~ 1-5% of PTCRearrangements includeSTRN::ALKandEML4::ALKPredominantly follicular infiltrative pattern and solid growthMay respond to ALK inhibitors (e.g., crizotinib)",
                    "sub_points": [
                      "Reported in ~ 1-5% of PTC",
                      "Rearrangements includeSTRN::ALKandEML4::ALK",
                      "Predominantly follicular infiltrative pattern and solid growth",
                      "May respond to ALK inhibitors (e.g., crizotinib)"
                    ]
                  },
                  {
                    "text": "MicroRNA dysregulationHigh levels of miR-146b, miR-221, and miR-222",
                    "sub_points": [
                      "High levels of miR-146b, miR-221, and miR-222"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Classic subtype shows characteristic papillary growth"
                  },
                  {
                    "text": "Papillae are usually complex, branching with central fibrovascular core, and randomly oriented"
                  },
                  {
                    "text": "Lined by neoplastic cells withGround-glass or optically clear nuclei (in formalin-fixed tissue only)Nuclear pseudoinclusionNuclear grooves (usually parallel to long axis)",
                    "sub_points": [
                      "Ground-glass or optically clear nuclei (in formalin-fixed tissue only)",
                      "Nuclear pseudoinclusion",
                      "Nuclear grooves (usually parallel to long axis)"
                    ]
                  },
                  {
                    "text": "Mitotic activity is rarely increased"
                  },
                  {
                    "text": "Psammoma bodies may be present in ~ 50% of PTC"
                  },
                  {
                    "text": "Lymphatic invasion is commonly present"
                  },
                  {
                    "text": "Extrathyroidal extension found in ~ 25% of PTC"
                  },
                  {
                    "text": "Involvement of cervical lymph nodes is very common (> 80%)"
                  },
                  {
                    "text": "Vascular (blood vessel) invasion is rare (up to 7%)"
                  }
                ],
                "Histologic Subtypes": [
                  {
                    "text": "Infiltrative follicular variant (IFVPTC)Infiltrative growth pattern of classic PTCPredominant follicular architecture with nuclear atypiaCommon molecular alterationsBRAFmutationsRETtranslocations,NTRKandALKfusions",
                    "sub_points": [
                      "Infiltrative growth pattern of classic PTC",
                      "Predominant follicular architecture with nuclear atypia",
                      "Common molecular alterationsBRAFmutationsRETtranslocations,NTRKandALKfusions",
                      "BRAFmutations",
                      "RETtranslocations,NTRKandALKfusions"
                    ]
                  },
                  {
                    "text": "EncapsulatedClassic PTC enveloped by thick, fibrous capsuleCapsule may be intact or infiltrated by tumor",
                    "sub_points": [
                      "Classic PTC enveloped by thick, fibrous capsule",
                      "Capsule may be intact or infiltrated by tumor"
                    ]
                  },
                  {
                    "text": "Tall cell and columnar cell variantTall cellsBasal nuclei with abundant eosinophilic cytoplasmTumor cell height at least 3x widthTall cells at least 30% of tumorStrongest association withBRAFmutations (up to 80%)TERTpromoter mutations frequently foundColumnar cellsLacks conventional nuclear features of PTC",
                    "sub_points": [
                      "Tall cellsBasal nuclei with abundant eosinophilic cytoplasmTumor cell height at least 3x widthTall cells at least 30% of tumorStrongest association withBRAFmutations (up to 80%)TERTpromoter mutations frequently found",
                      "Basal nuclei with abundant eosinophilic cytoplasm",
                      "Tumor cell height at least 3x width",
                      "Tall cells at least 30% of tumor",
                      "Strongest association withBRAFmutations (up to 80%)",
                      "TERTpromoter mutations frequently found",
                      "Columnar cellsLacks conventional nuclear features of PTC",
                      "Lacks conventional nuclear features of PTC"
                    ]
                  },
                  {
                    "text": "Diffuse sclerosing variantDiffuse lobular involvement, dense sclerosis, squamous metaplasia, and dense lymphocytic infiltratePsammoma bodies are abundantSolid or papillary growth with extensive lymphovascular invasionCommon nodal and distant metastasisRETrearrangements commonBRAFV600E mutations (20%)Disease-free survival rate lower than conventional PTC",
                    "sub_points": [
                      "Diffuse lobular involvement, dense sclerosis, squamous metaplasia, and dense lymphocytic infiltrate",
                      "Psammoma bodies are abundant",
                      "Solid or papillary growth with extensive lymphovascular invasionCommon nodal and distant metastasis",
                      "Common nodal and distant metastasis",
                      "RETrearrangements common",
                      "BRAFV600E mutations (20%)",
                      "Disease-free survival rate lower than conventional PTC"
                    ]
                  },
                  {
                    "text": "Other variantsHobnail, solid/trabecular, oncocytic, spindle cell, clear cell, Warthin-like",
                    "sub_points": [
                      "Hobnail, solid/trabecular, oncocytic, spindle cell, clear cell, Warthin-like"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Positive for pancytokeratin, CK19, PAX8, thyroglobulin, and TTF-1"
                  },
                  {
                    "text": "S100, vimentin, EMA, CA125, HBME-1, galectin-3 variably positive"
                  },
                  {
                    "text": "Galectin-3 and HBME-1 show higher specificity for PTC cells"
                  },
                  {
                    "text": "BRAF pV600 (VE1 clone) highly sensitive and specific for detection of mutation"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Papillary Hyperplasia in Graves Disease and Adenomatous Goiter": [
                  {
                    "text": "Lacks characteristic nuclear features of PTC"
                  }
                ],
                "Follicular Adenoma and Carcinoma": [
                  {
                    "text": "Frequently microfollicular pattern with thick, fibrous capsule"
                  },
                  {
                    "text": "Lacks characteristic nuclear features of PTC"
                  },
                  {
                    "text": "RAS-like molecular signature"
                  }
                ],
                "Medullary Carcinoma": [
                  {
                    "text": "May have papillary growth pattern"
                  },
                  {
                    "text": "Positive for calcitonin and neuroendocrine markers"
                  },
                  {
                    "text": "Amyloid deposits frequently present"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Oligodendroglioma, IDH Mutant, and 1p/19q Codeleted": {
            "name": "Oligodendroglioma, IDH Mutant, and 1p/19q Codeleted",
            "url": "https://app.pathprimer.com/document/c521024c-854a-4b3b-926f-b46e7e81e998/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Diffusely infiltrating glioma withIDH1orIDH2alterations and codeletion of chromosome arms 1p and 19q"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Adults (30-50 years of age)"
                  },
                  {
                    "text": "Frequently involve cerebral hemispheres"
                  },
                  {
                    "text": "Seizure common presenting symptom"
                  },
                  {
                    "text": "Surgery involves gross total resection when possible"
                  },
                  {
                    "text": "Most patients receive chemotherapy"
                  },
                  {
                    "text": "Clinical trials of IDH1 inhibitors and IDH1 vaccination inIDH1-mutant cases"
                  },
                  {
                    "text": "Average survival for WHO grade 2 is 10-15 years, with PCV chemotherapy, and 14 years in grade 3"
                  }
                ],
                "Imaging": [
                  {
                    "text": "Low-grade tumor typically nonenhancing"
                  },
                  {
                    "text": "T2 and FLAIR hyperintense"
                  },
                  {
                    "text": "Occasionally more circumscribed than infiltrating astrocytoma"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Balanced 1p19q (whole chromosome) codeletions"
                  },
                  {
                    "text": "IDH1andIDH2mutationsIdentified in all cases",
                    "sub_points": [
                      "Identified in all cases"
                    ]
                  },
                  {
                    "text": "CICandFUBP1mutations may indicate poor prognosis"
                  },
                  {
                    "text": "TERTpromoter region mutations"
                  },
                  {
                    "text": "Hypermethylation of multiple CpG islands, glioma CpG island methylator phenotype (G-CIMP)"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Round, uniform glial cells with perinuclear halos"
                  },
                  {
                    "text": "Microcalcifications common (albeit nondiagnostic)"
                  },
                  {
                    "text": "Minigemistocytes"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "IDH-R132H immunohistochemistry (+)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Oligodendroglioma, IDH mutant, 1p19q codeleted (WHO grade 2)"
                  },
                  {
                    "text": "Oligodendroglioma, IDH mutant (WHO grade 3)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Diffusely infiltrating glioma withIDH1orIDH2alterations and codeletion of chromosome arms 1p and 19q"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Age: Typically present at 30-50 years"
                  }
                ],
                "Incidence": [
                  {
                    "text": "Accounts for 15-20% of infiltrating gliomas"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Seizures most common; focal neurological deficits, focal deficits"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Aim is for complete resection when possible"
                  }
                ],
                "Drugs": [
                  {
                    "text": "Most patients receive chemotherapyTemozolomide is most commonly usedPCV (procarbazine, lomustine, vincristine)",
                    "sub_points": [
                      "Temozolomide is most commonly used",
                      "PCV (procarbazine, lomustine, vincristine)"
                    ]
                  },
                  {
                    "text": "IDH1 inhibitorsIn phase 1, clinical trials to evaluate suppression of 2-HG inIDH1-mutated gliomas",
                    "sub_points": [
                      "In phase 1, clinical trials to evaluate suppression of 2-HG inIDH1-mutated gliomas"
                    ]
                  },
                  {
                    "text": "IDH1 vaccinationIn phase 1, clinical trials to evaluate IDH1R132H 20-mer peptide vaccine in newly diagnosed patients",
                    "sub_points": [
                      "In phase 1, clinical trials to evaluate IDH1R132H 20-mer peptide vaccine in newly diagnosed patients"
                    ]
                  }
                ],
                "Radiation": [
                  {
                    "text": "Radiotherapy common with subtotal resection"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Average survival for WHO grade 2 is 10-15 years and even 14 years in grade with PCV chemotherapy"
                  },
                  {
                    "text": "Improved in younger patients and in treated patients with 1p and 19q codeletions"
                  }
                ]
              },
              "IMAGING": {
                "MR Findings": [
                  {
                    "text": "Low-grade tumors typically nonenhancing"
                  },
                  {
                    "text": "T2 and FLAIR hyperintense"
                  },
                  {
                    "text": "Occasionally more circumscribed than infiltrating astrocytoma"
                  }
                ],
                "CT Findings": [
                  {
                    "text": "May see calcifications"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Sometimes described as gelatinous or mucinous"
                  }
                ]
              },
              "MOLECULAR": {
                "Fluorescence In Situ Hybridization": [
                  {
                    "text": "1p and 19q codeletionsCharacteristic of oligodendrogliomasMaintained by balanced translocation, der(1;19)(q10;p10)",
                    "sub_points": [
                      "Characteristic of oligodendrogliomas",
                      "Maintained by balanced translocation, der(1;19)(q10;p10)"
                    ]
                  },
                  {
                    "text": "False-positives, less reliable than PCR"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "IDH1andIDH2mutationsDetected in all cases90% canonicalIDH1p.R132H mutation with moreIDH2mutations than in astrocytomas",
                    "sub_points": [
                      "Detected in all cases",
                      "90% canonicalIDH1p.R132H mutation with moreIDH2mutations than in astrocytomas"
                    ]
                  },
                  {
                    "text": "CICandFUBP1mutations are commonPoor prognostic indicator",
                    "sub_points": [
                      "Poor prognostic indicator"
                    ]
                  },
                  {
                    "text": "TERTpromoter region mutations stable throughout diseaseIDHmutant, Ip19q codeleted oligodendrogliomas in teenagers may lack pTERTmutations",
                    "sub_points": [
                      "IDHmutant, Ip19q codeleted oligodendrogliomas in teenagers may lack pTERTmutations"
                    ]
                  },
                  {
                    "text": "PIK3CA,PIK3R1,NOTCH1mutations"
                  },
                  {
                    "text": "HomozygousCDKN2Adeletion with tumor progression"
                  }
                ],
                "Epigenetic changes": [
                  {
                    "text": "Hypermethylation of multiple CpG islands, glioma CpG island methylator phenotype (G-CIMP)DNA methylation classifier differs from IDH mutant astrocytoma",
                    "sub_points": [
                      "DNA methylation classifier differs from IDH mutant astrocytoma"
                    ]
                  },
                  {
                    "text": "MGMTpromoter methylated in most oligodendrogliomas"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Cells infiltrate diffusely with perineuronal satellitosis, perivascular and subpial accumulations"
                  },
                  {
                    "text": "Round, uniform glial cells with artificial perinuclear halos giving fried egg appearance"
                  },
                  {
                    "text": "Microcalcifications not specific; sometimes (mini)gemistocytes"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "IDH-1(+)In ~ 90% of adults, but usually (-) in childrenNuclear and cytoplasmic staining",
                    "sub_points": [
                      "In ~ 90% of adults, but usually (-) in children",
                      "Nuclear and cytoplasmic staining"
                    ]
                  },
                  {
                    "text": "GFAP variable, Olig2 uniformly (+), synaptophysin (+) with neurocytic differentiation"
                  },
                  {
                    "text": "Lack strong nuclear p53(+) &/or loss of nuclear ATRX"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Central Neurocytoma": [
                  {
                    "text": "Typically intraventricular, often septum pellucidum"
                  },
                  {
                    "text": "Synaptophysin and NSE (+)"
                  },
                  {
                    "text": "Distinct DNA methylation cluster"
                  }
                ],
                "Clear Cell Ependymoma": [
                  {
                    "text": "FrequentZFTA(C11orf95) fusions"
                  },
                  {
                    "text": "Olig2(-) and IDH(-), EMA(+) dots"
                  }
                ],
                "Dysembryoplastic Neuroepithelial Tumor": [
                  {
                    "text": "Mucin-rich nodules containing floating neurons"
                  },
                  {
                    "text": "Classic (nodular) radiographic appearance often in mesial temporal lobe"
                  },
                  {
                    "text": "Younger age"
                  },
                  {
                    "text": "FGFR1 alterations"
                  }
                ],
                "Astrocytoma, IDH Mutant": [
                  {
                    "text": "ATRX nuclear loss, p53 accumulation"
                  },
                  {
                    "text": "Lack 1p19 codeletion"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Ewing Sarcoma": {
            "name": "Ewing Sarcoma",
            "url": "https://app.pathprimer.com/document/970cadd5-5394-43ed-a1cc-210ae83473ce/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Ewing sarcoma (ES): Peripheral neuroectodermal tumor"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "FET family gene fuses to ETS family gene, creating aberrant transcription factorFET gene family:EWSR1,FUS, andTAF15ETS gene family:FLI1,ERG,ETV1,ETV4, andFEV",
                    "sub_points": [
                      "FET gene family:EWSR1,FUS, andTAF15",
                      "ETS gene family:FLI1,ERG,ETV1,ETV4, andFEV"
                    ]
                  },
                  {
                    "text": "EWSR1::FLI1fusionEncodes protein that directly affects chromatin remodelingCauses widespread profound changes in gene expressionThis translocation is found in ~ 85% of ES",
                    "sub_points": [
                      "Encodes protein that directly affects chromatin remodeling",
                      "Causes widespread profound changes in gene expression",
                      "This translocation is found in ~ 85% of ES"
                    ]
                  },
                  {
                    "text": "White populations most commonly affected10x higher incidence of ES than in Black populationsWhite populations may have higher percentage of permissive GGAA microsatellite repeats in transcriptionally important sites",
                    "sub_points": [
                      "10x higher incidence of ES than in Black populations",
                      "White populations may have higher percentage of permissive GGAA microsatellite repeats in transcriptionally important sites"
                    ]
                  },
                  {
                    "text": "Cell of origin: Mesenchymal stem cell or neural crest stem cell"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "ES generally considered \"immune desert\" or \"cold\" tumor that provokes minimal immune response"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Major pathways disruptedEGFR pathwayIGF-1 (insulin-like growth factor type 1) pathwayPi3K/AKT/mTOR pathwayCell cycleDegree and variety of disruptions varies by patientTargeted therapy may require testing of each patient's tumor for specific alterations",
                    "sub_points": [
                      "EGFR pathway",
                      "IGF-1 (insulin-like growth factor type 1) pathway",
                      "Pi3K/AKT/mTOR pathway",
                      "Cell cycle",
                      "Degree and variety of disruptions varies by patient",
                      "Targeted therapy may require testing of each patient's tumor for specific alterations"
                    ]
                  },
                  {
                    "text": "Abnormal expression of various genes appear prognostic but not clinically validated"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Ewing sarcoma (ES)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Peripheral neuroectodermal tumor (PNET)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Primitive mesenchymal sarcomas of bone and soft tissue characterized bySmall round blue cell morphologyRearrangements of FET (TET) family gene with ETS family gene: FET::ETSMost common rearrangement:EWSR1::FLI1(70-80% of cases)Others:EWSR1/FUS::ERG(15%),EWSR1/FUS::FEV(5%), andEWSR1::ETV1/ETV4(1%)",
                    "sub_points": [
                      "Small round blue cell morphology",
                      "Rearrangements of FET (TET) family gene with ETS family gene: FET::ETSMost common rearrangement:EWSR1::FLI1(70-80% of cases)Others:EWSR1/FUS::ERG(15%),EWSR1/FUS::FEV(5%), andEWSR1::ETV1/ETV4(1%)",
                      "Most common rearrangement:EWSR1::FLI1(70-80% of cases)",
                      "Others:EWSR1/FUS::ERG(15%),EWSR1/FUS::FEV(5%), andEWSR1::ETV1/ETV4(1%)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Putative Cell of Origin": [
                  {
                    "text": "Mesenchymal stem cell or neural crest stem cell"
                  }
                ],
                "FET Family Gene Rearrangements": [
                  {
                    "text": "Rearrangements of FET family gene (most commonlyEWSR1) with ETS family gene (most commonlyFLI1)FET gene family:EWSR1,FUS, andTAF15ETS gene family:FLI1,ERG,ETV1,ETV4,FEV, E1AF, and 21 others",
                    "sub_points": [
                      "FET gene family:EWSR1,FUS, andTAF15",
                      "ETS gene family:FLI1,ERG,ETV1,ETV4,FEV, E1AF, and 21 others"
                    ]
                  },
                  {
                    "text": "Fusion protein acts as aberrant transcription factor to dysregulate numerous pathwaysCell differentiation is repressedCell cycle is disruptedCell migration and proliferation are disrupted",
                    "sub_points": [
                      "Cell differentiation is repressed",
                      "Cell cycle is disrupted",
                      "Cell migration and proliferation are disrupted"
                    ]
                  },
                  {
                    "text": "EWSR1::FLI1fusion proteinEncoded protein aberrantly affects chromatin remodelingCreates novel enhancers at GGAA repeatsAbnormally activates numerous genesRepresses normal enhancers by competing with ETS proteinsAbnormally represses numerous genesRepresses miRNAs including miRNA-145 low levels of which impair differentiation",
                    "sub_points": [
                      "Encoded protein aberrantly affects chromatin remodeling",
                      "Creates novel enhancers at GGAA repeatsAbnormally activates numerous genes",
                      "Abnormally activates numerous genes",
                      "Represses normal enhancers by competing with ETS proteinsAbnormally represses numerous genes",
                      "Abnormally represses numerous genes",
                      "Represses miRNAs including miRNA-145 low levels of which impair differentiation"
                    ]
                  }
                ],
                "Genetic Predisposition": [
                  {
                    "text": "Germline mutation ofPTPRDPTPRDencodes tyrosine phosphatase proteinNormally inhibitsSTAT3activationSTAT3highly overexpressed in ES",
                    "sub_points": [
                      "PTPRDencodes tyrosine phosphatase protein",
                      "Normally inhibitsSTAT3activationSTAT3highly overexpressed in ES",
                      "STAT3highly overexpressed in ES"
                    ]
                  },
                  {
                    "text": "NR0B1overexpressionSpecific susceptibility alleles at 1p36, 10q21, 15q15White populations show highest frequencyAssociated with mild increase in ES risk",
                    "sub_points": [
                      "Specific susceptibility alleles at 1p36, 10q21, 15q15White populations show highest frequencyAssociated with mild increase in ES risk",
                      "White populations show highest frequency",
                      "Associated with mild increase in ES risk"
                    ]
                  },
                  {
                    "text": "Inactivating variants or mutations in DNA damage repair genes found in ~ 13% of patients"
                  },
                  {
                    "text": "CD99germline polymorphisms reported to increase risk of developing ESEncodes CD99 protein",
                    "sub_points": [
                      "Encodes CD99 protein"
                    ]
                  },
                  {
                    "text": "6 candidate susceptibility loci identified by genome wide association studies (GWAS)Genes include some downstream targets ofEWSR1::FLI1fusion protein, genes involved in centrosome stabilization and in apoptosisMost risk alleles are more common in White populations",
                    "sub_points": [
                      "Genes include some downstream targets ofEWSR1::FLI1fusion protein, genes involved in centrosome stabilization and in apoptosis",
                      "Most risk alleles are more common in White populations"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Annual USA incidence: 250-400 patients (~ 3 patients/million/year)"
                  }
                ],
                "Age": [
                  {
                    "text": "Patients with bone tumors: 90% < 30 yearsPeak: 15 years",
                    "sub_points": [
                      "Peak: 15 years"
                    ]
                  },
                  {
                    "text": "Patients with soft tissue tumors: Broader age range than for primary bone ES"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "White populations most commonly affected10x higher incidence than Black populationsHigher percentage of permissive GGAA microsatellite repeats present in White populations increases risk for ES",
                    "sub_points": [
                      "10x higher incidence than Black populations",
                      "Higher percentage of permissive GGAA microsatellite repeats present in White populations increases risk for ES"
                    ]
                  }
                ],
                "Site": [
                  {
                    "text": "Bone (80%)Most common bone sitesLarge long bones: Metaphyseal &/or diaphyseal (~ 45%)Pelvic bones and ribs (~ 35%)",
                    "sub_points": [
                      "Most common bone sitesLarge long bones: Metaphyseal &/or diaphyseal (~ 45%)Pelvic bones and ribs (~ 35%)",
                      "Large long bones: Metaphyseal &/or diaphyseal (~ 45%)",
                      "Pelvic bones and ribs (~ 35%)"
                    ]
                  },
                  {
                    "text": "Soft tissue and skin (~ 20%)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Mass, usually painful, sometimes with systemic symptomsPain (~ 90% of patients)Mass (~ 60% of patients)Intermittent fever &/or anemia (~ 20% of patients)Pathologic fracture (~ 15% of patients)",
                    "sub_points": [
                      "Pain (~ 90% of patients)",
                      "Mass (~ 60% of patients)",
                      "Intermittent fever &/or anemia (~ 20% of patients)",
                      "Pathologic fracture (~ 15% of patients)"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "80% have localized disease~ 70% 5-year survival",
                    "sub_points": [
                      "~ 70% 5-year survival"
                    ]
                  },
                  {
                    "text": "20% have metastases~ 20% 5-year survivalPatients with isolated pulmonary metastases do better than patients with bone/bone marrow involvement",
                    "sub_points": [
                      "~ 20% 5-year survival",
                      "Patients with isolated pulmonary metastases do better than patients with bone/bone marrow involvement"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Complete surgical excision ± radiation ± intense induction chemotherapy for resectable tumorsMany regimens currently available or in trials",
                    "sub_points": [
                      "Many regimens currently available or in trials"
                    ]
                  },
                  {
                    "text": "Radiation ± chemotherapy for unresectable tumorsMany regimens currently available or in trials",
                    "sub_points": [
                      "Many regimens currently available or in trials"
                    ]
                  },
                  {
                    "text": "New treatment approachesImmunotherapyES generally considered \"immune desert\" or \"cold\" tumor that provokes minimal immune responseImmune checkpoint inhibitors, such as PD1 and PDL1, are only rarely expressedPhase I trials using CAR T cells and \"FANG\" autologous immunotherapy are ongoing (as of 2018)Targeted therapy to downstream effector proteins",
                    "sub_points": [
                      "ImmunotherapyES generally considered \"immune desert\" or \"cold\" tumor that provokes minimal immune responseImmune checkpoint inhibitors, such as PD1 and PDL1, are only rarely expressedPhase I trials using CAR T cells and \"FANG\" autologous immunotherapy are ongoing (as of 2018)",
                      "ES generally considered \"immune desert\" or \"cold\" tumor that provokes minimal immune response",
                      "Immune checkpoint inhibitors, such as PD1 and PDL1, are only rarely expressed",
                      "Phase I trials using CAR T cells and \"FANG\" autologous immunotherapy are ongoing (as of 2018)",
                      "Targeted therapy to downstream effector proteins"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Unfavorable prognostic indicators (representative)Metastatic disease is worst predictor of outcome1q gain (30% of patients)DTLpossibly responsibleTP53mutations (7-13% of patients): Controversial in terms of worsening prognosisCDKN2Adeletions (~ 12% of patients)HDGFoverexpressionSTAG2loss-of-function mutations (15-21% of patients)EWSR1::FLI1tumors arising by chromoplexy (up to 40% of ES) rather than reciprocal translocation (60% of ES)Detectable or high levels of circulating tumor DNA (ctDNA) may predict higher risk for relapse",
                    "sub_points": [
                      "Metastatic disease is worst predictor of outcome",
                      "1q gain (30% of patients)DTLpossibly responsible",
                      "DTLpossibly responsible",
                      "TP53mutations (7-13% of patients): Controversial in terms of worsening prognosis",
                      "CDKN2Adeletions (~ 12% of patients)",
                      "HDGFoverexpression",
                      "STAG2loss-of-function mutations (15-21% of patients)",
                      "EWSR1::FLI1tumors arising by chromoplexy (up to 40% of ES) rather than reciprocal translocation (60% of ES)",
                      "Detectable or high levels of circulating tumor DNA (ctDNA) may predict higher risk for relapse"
                    ]
                  },
                  {
                    "text": "Favorable prognostic indicators (representative)Few (< 3) to no copy number alterations (CNA)No CNA = 85% 5-year survival",
                    "sub_points": [
                      "Few (< 3) to no copy number alterations (CNA)No CNA = 85% 5-year survival",
                      "No CNA = 85% 5-year survival"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "Cytogenetics": [
                  {
                    "text": "Karyotype can detect translocations"
                  },
                  {
                    "text": "Additional chromosomal abnormalities often presentGains: Chromosome 8, chromosome 12, 1q",
                    "sub_points": [
                      "Gains: Chromosome 8, chromosome 12, 1q"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "CommercialEWSR1break-apart probe~ 90% of ES tumorsDetectsEWSR1translocation with any of ETS family genesSplit signal found in all tumors withEWSR1translocationsNot specific for ESMany other tumors besides ES family haveEWSR1rearrangementsMust correlate positive result with histology, clinical findings, imaging",
                    "sub_points": [
                      "~ 90% of ES tumors",
                      "DetectsEWSR1translocation with any of ETS family genes",
                      "Split signal found in all tumors withEWSR1translocations",
                      "Not specific for ESMany other tumors besides ES family haveEWSR1rearrangementsMust correlate positive result with histology, clinical findings, imaging",
                      "Many other tumors besides ES family haveEWSR1rearrangements",
                      "Must correlate positive result with histology, clinical findings, imaging"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Determines specific translocation partners"
                  },
                  {
                    "text": "Not typically used in clinical practiceMultiple probe sets requiredRNA preservation sometimes inadequate",
                    "sub_points": [
                      "Multiple probe sets required",
                      "RNA preservation sometimes inadequate"
                    ]
                  }
                ],
                "Chromosomal Microarray": [
                  {
                    "text": "~ 80% of ES have copy number alterations"
                  },
                  {
                    "text": "Gains: 1q (30%), 8 (35%), 12 (25%), 20q most commonPatients with 1q gains have inferior overall survival",
                    "sub_points": [
                      "Patients with 1q gains have inferior overall survival"
                    ]
                  },
                  {
                    "text": "Deletions/LOH: 10q, 11p, 16q, 17p most commonPatients with 16q loss have inferior survival",
                    "sub_points": [
                      "Patients with 16q loss have inferior survival"
                    ]
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Fusion of FET family member gene with ETS family member gene to create novelFET::ETSfusion proteinConfirms diagnosis if histology is also supportiveEWSR1is FET partner for ~ 99% of Ewing sarcoma gene fusions",
                    "sub_points": [
                      "Confirms diagnosis if histology is also supportive",
                      "EWSR1is FET partner for ~ 99% of Ewing sarcoma gene fusions"
                    ]
                  },
                  {
                    "text": "t(11;22)(q24;q12)EWSR1::FLI1Most common translocation found in ES (~ 85% of cases)Number of splice variants: Multiple (at least 18)Site of gene fusion not prognostic or predictiveCommon feature5' end ofEWSR1joined to 3' end ofFLI1or other ETS family gene membersExpression levels ofEWSR1::FLI1protein in individual tumor cells correlates with invasive capacityTumor cells with lower expression (minority of tumor) show enhanced migration, invasion, and metastasisBy contrast, tumor cells with higher expression (most of tumor) are more proliferative and show high cell-cell adhesion propensity",
                    "sub_points": [
                      "Most common translocation found in ES (~ 85% of cases)",
                      "Number of splice variants: Multiple (at least 18)Site of gene fusion not prognostic or predictive",
                      "Site of gene fusion not prognostic or predictive",
                      "Common feature5' end ofEWSR1joined to 3' end ofFLI1or other ETS family gene members",
                      "5' end ofEWSR1joined to 3' end ofFLI1or other ETS family gene members",
                      "Expression levels ofEWSR1::FLI1protein in individual tumor cells correlates with invasive capacityTumor cells with lower expression (minority of tumor) show enhanced migration, invasion, and metastasisBy contrast, tumor cells with higher expression (most of tumor) are more proliferative and show high cell-cell adhesion propensity",
                      "Tumor cells with lower expression (minority of tumor) show enhanced migration, invasion, and metastasis",
                      "By contrast, tumor cells with higher expression (most of tumor) are more proliferative and show high cell-cell adhesion propensity"
                    ]
                  },
                  {
                    "text": "Major genes upregulatedDKK2Acts as antagonist or agonist of WNT-β-catenin signaling pathwayERBB4Activates PI3K-AKT and FAK pathwaysMore highly expressed in metastatic ESIncreases survival of tumor cells detached from ECMOthers: CCND1,EZH2,SOX2,NKX2-2,VRK1,PTK2",
                    "sub_points": [
                      "DKK2Acts as antagonist or agonist of WNT-β-catenin signaling pathway",
                      "Acts as antagonist or agonist of WNT-β-catenin signaling pathway",
                      "ERBB4Activates PI3K-AKT and FAK pathwaysMore highly expressed in metastatic ESIncreases survival of tumor cells detached from ECM",
                      "Activates PI3K-AKT and FAK pathways",
                      "More highly expressed in metastatic ES",
                      "Increases survival of tumor cells detached from ECM",
                      "Others: CCND1,EZH2,SOX2,NKX2-2,VRK1,PTK2"
                    ]
                  },
                  {
                    "text": "Major genes downregulatedERRFI1,CABLES1,TGFβ1,SNAI2,TRPS1,NT5E,FOXO1,STAG2",
                    "sub_points": [
                      "ERRFI1,CABLES1,TGFβ1,SNAI2,TRPS1,NT5E,FOXO1,STAG2"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Major pathways disruptedEGFR pathwayIGF-1Pi3K/AKT/mTOR pathwayCell cyclep53 protein pathways",
                    "sub_points": [
                      "EGFR pathway",
                      "IGF-1",
                      "Pi3K/AKT/mTOR pathway",
                      "Cell cycle",
                      "p53 protein pathways"
                    ]
                  },
                  {
                    "text": "Degree of disruption varies among patientsTargeted therapy may require testing of each patient's tumor for specific alterations",
                    "sub_points": [
                      "Targeted therapy may require testing of each patient's tumor for specific alterations"
                    ]
                  }
                ],
                "Molecular Immunopathology": [
                  {
                    "text": "CTLA4polymorphisms associated with ESCTLA4 expressed on cytotoxic T lymphocytesReduces T-cell antitumor response by regulating effector T cellsCTLA449G/A genotype: ↑ risk and ↑ metastatic rateCorrelated with high expression of CTLA4 proteinAlso associated with other cancers and some autoimmune diseasesCD861057G/A genotype: ↑ riskCD86 is binding partner of CTLA4Also increases risk for osteosarcoma",
                    "sub_points": [
                      "CTLA4 expressed on cytotoxic T lymphocytesReduces T-cell antitumor response by regulating effector T cells",
                      "Reduces T-cell antitumor response by regulating effector T cells",
                      "CTLA449G/A genotype: ↑ risk and ↑ metastatic rateCorrelated with high expression of CTLA4 proteinAlso associated with other cancers and some autoimmune diseases",
                      "Correlated with high expression of CTLA4 protein",
                      "Also associated with other cancers and some autoimmune diseases",
                      "CD861057G/A genotype: ↑ riskCD86 is binding partner of CTLA4Also increases risk for osteosarcoma",
                      "CD86 is binding partner of CTLA4",
                      "Also increases risk for osteosarcoma"
                    ]
                  },
                  {
                    "text": "Immune suppressive myeloid cellsArise from myeloid-derived suppressor cells and ↑ in pediatric sarcomasPresent in peripheral blood and tumor microenvironmentExpress SMA and CD34, but not CD163, consistent with nascent fibrocyte phenotype",
                    "sub_points": [
                      "Arise from myeloid-derived suppressor cells and ↑ in pediatric sarcomasPresent in peripheral blood and tumor microenvironment",
                      "Present in peripheral blood and tumor microenvironment",
                      "Express SMA and CD34, but not CD163, consistent with nascent fibrocyte phenotype"
                    ]
                  }
                ],
                "Epigenetics": [
                  {
                    "text": "Differential expression of microRNAs (miRNAs)Tumor suppressor effect of miRNA-31Diminished due to ↓ expression in ES (1 study)Tumor suppressor effect of miRNA-34↓ expression in primary tumor of patients with metastasis at presentation or within 1 year of diagnosis",
                    "sub_points": [
                      "Tumor suppressor effect of miRNA-31Diminished due to ↓ expression in ES (1 study)",
                      "Diminished due to ↓ expression in ES (1 study)",
                      "Tumor suppressor effect of miRNA-34↓ expression in primary tumor of patients with metastasis at presentation or within 1 year of diagnosis",
                      "↓ expression in primary tumor of patients with metastasis at presentation or within 1 year of diagnosis"
                    ]
                  },
                  {
                    "text": "Hypermethylation of specific genes8 genes silenced in > 20% of cases testedCTHRC1,DNAJA4,ECHDC2,NEFH,NPTX2,PHF11,RARRES2,CEP41NPTX2orPHF11hypermethylation → ↓ prognosisMost of these genes also show > 20% hypermethylation frequency in osteosarcomasHypermethylation ofRASSF2",
                    "sub_points": [
                      "8 genes silenced in > 20% of cases testedCTHRC1,DNAJA4,ECHDC2,NEFH,NPTX2,PHF11,RARRES2,CEP41NPTX2orPHF11hypermethylation → ↓ prognosisMost of these genes also show > 20% hypermethylation frequency in osteosarcomas",
                      "CTHRC1,DNAJA4,ECHDC2,NEFH,NPTX2,PHF11,RARRES2,CEP41",
                      "NPTX2orPHF11hypermethylation → ↓ prognosis",
                      "Most of these genes also show > 20% hypermethylation frequency in osteosarcomas",
                      "Hypermethylation ofRASSF2"
                    ]
                  },
                  {
                    "text": "Abnormalities of long noncoding RNAs (lncRNAs)At least 12 lncRNAs reported to be abnormally upregulated in ESCould serve as druggable targets in ESOne lncRNA example:EWSAT1(Ewing sarcoma-associated transcript 1)Originally described in ESPromotes tumor proliferation",
                    "sub_points": [
                      "At least 12 lncRNAs reported to be abnormally upregulated in ESCould serve as druggable targets in ES",
                      "Could serve as druggable targets in ES",
                      "One lncRNA example:EWSAT1(Ewing sarcoma-associated transcript 1)Originally described in ESPromotes tumor proliferation",
                      "Originally described in ES",
                      "Promotes tumor proliferation"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Classic (conventional) ESArchitecture: Sheets to vague lobules ± prominent perivascular cuffing in areas of necrosisSmall round blue cells with round nuclei, inconspicuous nucleoli, low mitotic rateCytoplasm may be clear due to glycogen",
                    "sub_points": [
                      "Architecture: Sheets to vague lobules ± prominent perivascular cuffing in areas of necrosis",
                      "Small round blue cells with round nuclei, inconspicuous nucleoli, low mitotic rate",
                      "Cytoplasm may be clear due to glycogen"
                    ]
                  },
                  {
                    "text": "Tumors with neural differentiationSame features as classic ES but also with Homer Wright rosettesNeural markers positivePreviously called primitive neuroectodermal tumor (PNET)",
                    "sub_points": [
                      "Same features as classic ES but also with Homer Wright rosettes",
                      "Neural markers positive",
                      "Previously called primitive neuroectodermal tumor (PNET)"
                    ]
                  },
                  {
                    "text": "Atypical (large cell) ESArchitecture: Similar to classic ESCells: Larger than classic ES with more nuclear pleomorphism, vesicular nuclei ± macronucleoli, and ↑ mitoses",
                    "sub_points": [
                      "Architecture: Similar to classic ES",
                      "Cells: Larger than classic ES with more nuclear pleomorphism, vesicular nuclei ± macronucleoli, and ↑ mitoses"
                    ]
                  },
                  {
                    "text": "Unusual featuresArchitecture: Adamantinoma-like, sclerotic, hemangioendothelioma-likeExtensive component of spindled tumor cells",
                    "sub_points": [
                      "Architecture: Adamantinoma-like, sclerotic, hemangioendothelioma-like",
                      "Extensive component of spindled tumor cells"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD99Strong membranous reactivity in ~ 95% of ESCytoplasmic reactivity much less specific findingOther tumors can be CD99 positivee.g., rhabdomyosarcoma, synovial sarcoma, others",
                    "sub_points": [
                      "Strong membranous reactivity in ~ 95% of ESCytoplasmic reactivity much less specific finding",
                      "Cytoplasmic reactivity much less specific finding",
                      "Other tumors can be CD99 positivee.g., rhabdomyosarcoma, synovial sarcoma, others",
                      "e.g., rhabdomyosarcoma, synovial sarcoma, others"
                    ]
                  },
                  {
                    "text": "FLI-1Positive in most cases of ES, regardless of fusion typeNot specific antibody for ES",
                    "sub_points": [
                      "Positive in most cases of ES, regardless of fusion type",
                      "Not specific antibody for ES"
                    ]
                  },
                  {
                    "text": "ERGPositive in tumors withEWSR1::ERGfusions but expressed in multiple other non-Ewing sarcomas",
                    "sub_points": [
                      "Positive in tumors withEWSR1::ERGfusions but expressed in multiple other non-Ewing sarcomas"
                    ]
                  },
                  {
                    "text": "NKX2.2Highly sensitive but only moderately specific for ES",
                    "sub_points": [
                      "Highly sensitive but only moderately specific for ES"
                    ]
                  },
                  {
                    "text": "KeratinUsually focal, positive in ~ 33% of cases",
                    "sub_points": [
                      "Usually focal, positive in ~ 33% of cases"
                    ]
                  },
                  {
                    "text": "Neural differentiation markers: S100, NSE, CD57 (+/-)"
                  },
                  {
                    "text": "Desmin: Rarely positive"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Lymphoma": [
                  {
                    "text": "Different phenotype, including CD45 reactivityCD45 negative in ES",
                    "sub_points": [
                      "CD45 negative in ES"
                    ]
                  },
                  {
                    "text": "Lymphoblastic lymphomaOften negative for CD45, CD20, and CD3, like ESPositive for CD99 and FLI-1, like ESPositive for CD43, CD19, CD10, CD79A, and TdT; supports B lymphoblastic lymphomaNegative forEWSR1::FLI1rearrangements",
                    "sub_points": [
                      "Often negative for CD45, CD20, and CD3, like ES",
                      "Positive for CD99 and FLI-1, like ES",
                      "Positive for CD43, CD19, CD10, CD79A, and TdT; supports B lymphoblastic lymphoma",
                      "Negative forEWSR1::FLI1rearrangements"
                    ]
                  }
                ],
                "Mesenchymal Chondrosarcoma": [
                  {
                    "text": "Biphasic with small round blue cells and cartilage matrix"
                  },
                  {
                    "text": "CD99 can be positive"
                  },
                  {
                    "text": "SOX9 positive"
                  },
                  {
                    "text": "FLI-1, ERG negative"
                  },
                  {
                    "text": "FISH negative forEWSR1translocation"
                  }
                ],
                "Small Cell Osteosarcoma": [
                  {
                    "text": "Biphasic with small round blue cells and osteoid matrix"
                  },
                  {
                    "text": "CD99 can be positive"
                  },
                  {
                    "text": "FLI-1 negative"
                  },
                  {
                    "text": "FISH negative forEWSR1translocation"
                  }
                ],
                "Desmoplastic Small Round Cell Tumor": [
                  {
                    "text": "Soft tissue tumor composed of small round blue cells, epithelioid like areas, and sclerotic matrix"
                  },
                  {
                    "text": "IHCCD99 can be positivePolymorphous expression of keratins, desmin (paranuclear dot-like in many cases), WT1, and NSE",
                    "sub_points": [
                      "CD99 can be positive",
                      "Polymorphous expression of keratins, desmin (paranuclear dot-like in many cases), WT1, and NSE"
                    ]
                  },
                  {
                    "text": "FISH positive forEWSR1translocation"
                  }
                ],
                "Poorly Differentiated Synovial Sarcoma": [
                  {
                    "text": "Sheets of small round blue cells, but classic components often present"
                  },
                  {
                    "text": "IHCTLE-1 sensitive and relatively specific for synovial sarcomaFLI-1 and CD99 may be present in synovial sarcoma, and CD99 rarely can show membranous expression pattern, like ESSSX highly sensitive and specific for synovial sarcoma",
                    "sub_points": [
                      "TLE-1 sensitive and relatively specific for synovial sarcoma",
                      "FLI-1 and CD99 may be present in synovial sarcoma, and CD99 rarely can show membranous expression pattern, like ES",
                      "SSX highly sensitive and specific for synovial sarcoma"
                    ]
                  },
                  {
                    "text": "FISHPositive for t(X;18) in ~ 95% of casesNegative forEWSR1translocation",
                    "sub_points": [
                      "Positive for t(X;18) in ~ 95% of cases",
                      "Negative forEWSR1translocation"
                    ]
                  }
                ],
                "Rhabdomyosarcoma": [
                  {
                    "text": "Alveolar RMSAlveolar architecture may be absent or focalSmall round blue cells but also multinucleated tumor cells and positive rhabdomyoblastsIHCSimilar to ES: CD99 positive, keratins focally positiveDissimilar to ES: Positive for myogenin, MYOD1Desmin positive (rare in ES)FISHPositive forPAX3orPAX7translocationsNegative forEWSR1translocation",
                    "sub_points": [
                      "Alveolar architecture may be absent or focal",
                      "Small round blue cells but also multinucleated tumor cells and positive rhabdomyoblasts",
                      "IHCSimilar to ES: CD99 positive, keratins focally positiveDissimilar to ES: Positive for myogenin, MYOD1Desmin positive (rare in ES)",
                      "Similar to ES: CD99 positive, keratins focally positive",
                      "Dissimilar to ES: Positive for myogenin, MYOD1",
                      "Desmin positive (rare in ES)",
                      "FISHPositive forPAX3orPAX7translocationsNegative forEWSR1translocation",
                      "Positive forPAX3orPAX7translocations",
                      "Negative forEWSR1translocation"
                    ]
                  },
                  {
                    "text": "Embryonal RMSUsually spindled cells and rhabdomyoblastsIHCSimilar to ES: May be CD99 positiveDissimilar to ES: Myogenin, MYOD1 positiveFISHNegative forEWSR1translocation",
                    "sub_points": [
                      "Usually spindled cells and rhabdomyoblasts",
                      "IHCSimilar to ES: May be CD99 positiveDissimilar to ES: Myogenin, MYOD1 positive",
                      "Similar to ES: May be CD99 positive",
                      "Dissimilar to ES: Myogenin, MYOD1 positive",
                      "FISHNegative forEWSR1translocation",
                      "Negative forEWSR1translocation"
                    ]
                  }
                ],
                "Ewing-Like Sarcomas": [
                  {
                    "text": "May be histologically and clinically very similar"
                  },
                  {
                    "text": "IHC: CD99 often positive"
                  },
                  {
                    "text": "FISH: Negative forEWSR1translocation, except forEWSR1::NFATC2sarcoma andEWSR1::PATZ1sarcoma"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Synovial Sarcoma": {
            "name": "Synovial Sarcoma",
            "url": "https://app.pathprimer.com/document/989846e1-6c26-4b23-b0e2-0f292c2561fa/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "Key Facts": {
                "Macroscopic Features": [
                  {
                    "text": "Large, well-circumscribed, pleural-based mass"
                  },
                  {
                    "text": "May extend along pleural surface mimicking malignant mesothelioma"
                  },
                  {
                    "text": "May show cystic and hemorrhagic changes"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "May be biphasic or monophasic"
                  },
                  {
                    "text": "Biphasic tumors are composed of cleft-like and glandular structures with intraluminal eosinophilic proteinaceous material admixed with population of atypical spindle cells"
                  },
                  {
                    "text": "Monophasic tumors are composed of monotonous atypical spindle cell proliferation with herringbone, storiform, or hemangiopericytic growth patterns"
                  },
                  {
                    "text": "Variable mitotic activity (range: 2-10 mitoses per 10 high-power fields)"
                  },
                  {
                    "text": "Spindle cell population is very monotonous and uniform"
                  },
                  {
                    "text": "Absence of nuclear pleomorphism or prominent nucleoli"
                  },
                  {
                    "text": "Glands lined by tall columnar cells with abundant cytoplasm in biphasic type"
                  },
                  {
                    "text": "Focal (patchy) positivity for epithelial markers (cytokeratin and EMA)"
                  },
                  {
                    "text": "Strong positivity for Bcl-2 and CD99"
                  },
                  {
                    "text": "Shares many markers with malignant mesothelioma, including calretinin and HBME-1"
                  },
                  {
                    "text": "Some cases may be positive for CD34"
                  },
                  {
                    "text": "Characteristic chromosomal translocation, t(X;18)(SYT-SSX) seen in > 80% of cases"
                  },
                  {
                    "text": "Distinctive translocation may be assayed by FISH, PCR, or DNA in situ hybridization"
                  }
                ]
              },
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Synovial sarcoma (SS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Pleural malignant neoplasm composed of nonmesothelial cells showing epithelial differentiation with distinctive spindle cell pattern of growth and chromosomal translocation"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Pathogenesis": [
                  {
                    "text": "Unknown"
                  }
                ]
              },
              "Clinical Issues": {
                "Presentation": [
                  {
                    "text": "Pleural effusion"
                  },
                  {
                    "text": "Pleural-based mass on CT scan"
                  },
                  {
                    "text": "Age range: 10-50 years (average: 25 years)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Surgical excision, radiation therapy, chemotherapy"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Similar prognosis to soft tissue counterpart"
                  },
                  {
                    "text": "Aggressive behavior with local recurrence and metastases"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Large, well-circumscribed, pleural-based mass"
                  },
                  {
                    "text": "May extend along pleural surface mimicking malignant mesothelioma"
                  },
                  {
                    "text": "May infiltrate underlying structures"
                  },
                  {
                    "text": "May show cystic and hemorrhagic changes"
                  },
                  {
                    "text": "May attain large sizes (up to 16 cm in greatest dimension)"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "May be biphasic or monophasic"
                  },
                  {
                    "text": "Biphasic tumors are composed of cleft-like and glandular structures with intraluminal eosinophilic proteinaceous material admixed with population of atypical spindle cells"
                  },
                  {
                    "text": "Monophasic tumors are composed of monotonous atypical spindle cell proliferation with herringbone, storiform, or hemangiopericytic growth patterns"
                  },
                  {
                    "text": "Poorly differentiated variants are characterized by round epithelioid cells rather than spindle cells"
                  },
                  {
                    "text": "Variable mitotic activity (range: 2-10 mitoses per 10 high-power fields)"
                  },
                  {
                    "text": "May display hemorrhage and necrosis"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Spindle cell population is very monotonous and uniform"
                  },
                  {
                    "text": "Absence of nuclear pleomorphism or prominent nucleoli"
                  },
                  {
                    "text": "Glands lined by tall columnar cells with abundant cytoplasm in biphasic type"
                  },
                  {
                    "text": "Absence of fibrous stroma"
                  },
                  {
                    "text": "Absence of marked anaplasia or multinucleated tumor cells"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Focal (patchy) positivity for epithelial markers (cytokeratin and EMA)"
                  },
                  {
                    "text": "Strong positivity for Bcl-2 and CD99"
                  },
                  {
                    "text": "Shares many markers with malignant mesothelioma, including calretinin and HBME-1"
                  },
                  {
                    "text": "May also stain with calponin and CD117"
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "Characteristic chromosomal translocation, t(X;18)(SYT-SSX) seen in > 80% of cases"
                  },
                  {
                    "text": "Distinctive translocation may be demonstrated by FISH, PCR, or DNA in situ hybridization"
                  },
                  {
                    "text": "Distinctive translocation has not been recognized in other similar tumors"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Biphasic Malignant Mesothelioma": [
                  {
                    "text": "More intimate admixture between glandular structures and spindle cell component seen in synovial sarcoma"
                  },
                  {
                    "text": "Extensive overlap in results of immunohistochemical staining"
                  },
                  {
                    "text": "Both tumors share cytokeratin, EMA, calretinin, and HMBE-1 positivity"
                  },
                  {
                    "text": "WT1 is positive in mesothelioma but consistently negative in synovial sarcoma"
                  },
                  {
                    "text": "Cytogenetic studies demonstrate t(X;18) in all synovial sarcomas; translocation is negative in mesothelioma"
                  }
                ],
                "Sarcomatoid Malignant Mesothelioma": [
                  {
                    "text": "Can be confused for monophasic spindle cell variant of synovial sarcoma"
                  },
                  {
                    "text": "Cell population more uniform in synovial sarcoma than in sarcomatoid mesothelioma"
                  },
                  {
                    "text": "Spindle cells in sarcomatoid mesothelioma show marked nuclear pleomorphism"
                  },
                  {
                    "text": "Both can be negative for epithelial (keratin, EMA) and mesothelial (calretinin, WT1, HBME-1) markers"
                  },
                  {
                    "text": "Demonstration of t(X;18) is most reliable way for separating the two"
                  }
                ],
                "Solitary Fibrous Tumor/Malignant SFT": [
                  {
                    "text": "Both can show very similar morphologic features"
                  },
                  {
                    "text": "Bcl-2, CD99, and CD34 reactivity can be shared by both synovial sarcoma and sarcomatoid mesothelioma"
                  },
                  {
                    "text": "Focal keratin or EMA positivity favors synovial sarcoma"
                  },
                  {
                    "text": "Demonstration of t(X;18) can help make definitive diagnosis of synovial sarcoma in equivocal cases"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "More frequent in young adults than in mature or elderly patients"
                  },
                  {
                    "text": "Aggressive behavior with frequent recurrences and metastases"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Uniformity of spindle cell population is important key for diagnosis of synovial sarcoma"
                  },
                  {
                    "text": "Demonstration of t(X;18) by molecular techniques is of value in equivocal cases"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Urothelial Carcinoma": {
            "name": "Urothelial Carcinoma",
            "url": "https://app.pathprimer.com/document/f02cd47e-cb82-4d43-ad0a-040d789eefa6/lesson/0bb0f12a-1196-4925-9c8a-4a2a6ad0c0c6",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Malignant neoplasm derived from urothelium"
                  }
                ],
                "Molecular": [
                  {
                    "text": "2 important clinicopathologic categories of urothelial carcinomaNonmuscle invasive bladder cancerTends to recur rather than progressTypically associated with low-grade papillary histologyAssociated withFGFR3,HRAS, andPIK3CAmutations, and chromosome 9 lossesMuscle invasive bladder cancer (MIBC)Tends to progress and metastasizeUsually high-grade histologyHigh rate of mutations and genomic amplifications",
                    "sub_points": [
                      "Nonmuscle invasive bladder cancerTends to recur rather than progressTypically associated with low-grade papillary histologyAssociated withFGFR3,HRAS, andPIK3CAmutations, and chromosome 9 losses",
                      "Tends to recur rather than progress",
                      "Typically associated with low-grade papillary histology",
                      "Associated withFGFR3,HRAS, andPIK3CAmutations, and chromosome 9 losses",
                      "Muscle invasive bladder cancer (MIBC)Tends to progress and metastasizeUsually high-grade histologyHigh rate of mutations and genomic amplifications",
                      "Tends to progress and metastasize",
                      "Usually high-grade histology",
                      "High rate of mutations and genomic amplifications"
                    ]
                  },
                  {
                    "text": "Comprehensive genomic analysis of MIBC has shown dysregulation of several pathwaysp53/cell cycle regulation (89% of tumors), including alterations inTP53,CDKN2A,RB1,CDKN1A, andMDM2RTK/RAS/PI(3)K (71% of tumors), including mutations inFGFR3,EGFR,ERBB2,ERBB3,PIK3CA, andPTENChromatin modification pathways: Histone-modifying genes (52% of tumors), SWI/SNF complex (26%), including mutations inARID1A,KMT2D,KMT2C,KDM6A,EP300, andCREBBPDNA repair pathway (16% of tumors), including alterations inATM,ERCC2, andRAD51B",
                    "sub_points": [
                      "p53/cell cycle regulation (89% of tumors), including alterations inTP53,CDKN2A,RB1,CDKN1A, andMDM2",
                      "RTK/RAS/PI(3)K (71% of tumors), including mutations inFGFR3,EGFR,ERBB2,ERBB3,PIK3CA, andPTEN",
                      "Chromatin modification pathways: Histone-modifying genes (52% of tumors), SWI/SNF complex (26%), including mutations inARID1A,KMT2D,KMT2C,KDM6A,EP300, andCREBBP",
                      "DNA repair pathway (16% of tumors), including alterations inATM,ERCC2, andRAD51B"
                    ]
                  },
                  {
                    "text": "Mutational signatureMIBC has high somatic mutation rate, driven mainly by APOBEC-mediated mutagenesisTumors with profile of high APOBEC-signature mutagenesis, high mutational burden, and predicted high neoantigen load have 75% 5-year survival",
                    "sub_points": [
                      "MIBC has high somatic mutation rate, driven mainly by APOBEC-mediated mutagenesis",
                      "Tumors with profile of high APOBEC-signature mutagenesis, high mutational burden, and predicted high neoantigen load have 75% 5-year survival"
                    ]
                  },
                  {
                    "text": "International Consensus Molecular Classification combines expression profiling studies of MIBC to show 6 subtypes with biologic relevance: Luminal-papillary, luminal nonspecified, luminal-unstable, stroma-rich, basal/squamous, and neuroendocrine-like"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Transitional cell carcinoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Malignant neoplasm derived from urothelium2 important clinicopathological phenotypes of urothelial carcinomaSuperficial nonmuscle invasive bladder cancer (NMIBC)Muscle invasive bladder cancer (MIBC)",
                    "sub_points": [
                      "2 important clinicopathological phenotypes of urothelial carcinomaSuperficial nonmuscle invasive bladder cancer (NMIBC)Muscle invasive bladder cancer (MIBC)",
                      "Superficial nonmuscle invasive bladder cancer (NMIBC)",
                      "Muscle invasive bladder cancer (MIBC)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Tobacco smokeCarcinogens, such as 4-aminophenolSmokers have 2-5x increased riskEstimated to give rise to 30-50% of bladder cancers",
                    "sub_points": [
                      "Carcinogens, such as 4-aminophenol",
                      "Smokers have 2-5x increased risk",
                      "Estimated to give rise to 30-50% of bladder cancers"
                    ]
                  },
                  {
                    "text": "Occupational carcinogen exposureEspecially in rubber and dye industries with exposure to aniline dyes, β-naphthylamine, and benzidine",
                    "sub_points": [
                      "Especially in rubber and dye industries with exposure to aniline dyes, β-naphthylamine, and benzidine"
                    ]
                  },
                  {
                    "text": "DrugsCyclophosphamide, phenacetin",
                    "sub_points": [
                      "Cyclophosphamide, phenacetin"
                    ]
                  },
                  {
                    "text": "Arsenic in drinking water"
                  },
                  {
                    "text": "Pelvic radiation"
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "VirusesMay contribute to development of small percentage of bladder tumorsViral DNA and RNA transcripts described in 4-6% of casesViruses, including CMV, BK polyomavirus, and HPV-16",
                    "sub_points": [
                      "May contribute to development of small percentage of bladder tumorsViral DNA and RNA transcripts described in 4-6% of casesViruses, including CMV, BK polyomavirus, and HPV-16",
                      "Viral DNA and RNA transcripts described in 4-6% of cases",
                      "Viruses, including CMV, BK polyomavirus, and HPV-16"
                    ]
                  },
                  {
                    "text": "Schistosoma haematobiumParticularly associated with bladder squamous cell carcinoma",
                    "sub_points": [
                      "Particularly associated with bladder squamous cell carcinoma"
                    ]
                  }
                ],
                "Tumorigenic Pathways": [
                  {
                    "text": "Papillary pathway"
                  },
                  {
                    "text": "Flat, carcinoma in situ (CIS) pathway"
                  },
                  {
                    "text": "Invasive carcinoma can arise from both"
                  }
                ],
                "Pathogenic Role of APOBEC-Mediated Mutagenesis": [
                  {
                    "text": "High mutational load is driven mainly by APOBEC-signature mutagenesis"
                  },
                  {
                    "text": "Major driver of mutagenesis in both NMIBC and MIBC"
                  }
                ],
                "Hereditary Factors": [
                  {
                    "text": "In general, not major contributor"
                  },
                  {
                    "text": "Polymorphisms inNAT2andGSTM1(carcinogen detoxifying genes) genes may confer some increased risk"
                  },
                  {
                    "text": "Lynch syndrome associated with increased risk of urothelial cancer of ureter and renal pelvis (upper urinary tract)"
                  },
                  {
                    "text": "Costello syndrome (germlineHRASmutations): Increased risk of urothelial carcinoma in adolescents and young adults"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Geographic variabilityHighest incidence in Southern Europe and EgyptLowest incidence in Far East",
                    "sub_points": [
                      "Highest incidence in Southern Europe and Egypt",
                      "Lowest incidence in Far East"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "10th most common cancer worldwide"
                  },
                  {
                    "text": "200,000-220,000 deaths worldwide per year"
                  }
                ],
                "Age": [
                  {
                    "text": "Most diagnosed in 6th decade or older"
                  }
                ],
                "Sex": [
                  {
                    "text": "4x more common in men"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Painless gross or microscopic hematuria"
                  },
                  {
                    "text": "Bladder irritative symptoms including urinary frequency, urgency, dysuria"
                  },
                  {
                    "text": "Mass or obstructive symptoms"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Intravesical therapyChemotherapy (e.g., mitomycin C)Low- to intermediate-risk Ta papillary tumorsBacillus Calmette-Guérin (BCG) therapyIntermediate- to high-risk Ta tumors, T1 tumors, CIS",
                    "sub_points": [
                      "Chemotherapy (e.g., mitomycin C)Low- to intermediate-risk Ta papillary tumors",
                      "Low- to intermediate-risk Ta papillary tumors",
                      "Bacillus Calmette-Guérin (BCG) therapyIntermediate- to high-risk Ta tumors, T1 tumors, CIS",
                      "Intermediate- to high-risk Ta tumors, T1 tumors, CIS"
                    ]
                  },
                  {
                    "text": "Systemic chemotherapyCisplatin-based protocolsMetastatic diseaseNeoadjuvant therapy prior to cystectomy",
                    "sub_points": [
                      "Cisplatin-based protocolsMetastatic diseaseNeoadjuvant therapy prior to cystectomy",
                      "Metastatic disease",
                      "Neoadjuvant therapy prior to cystectomy"
                    ]
                  },
                  {
                    "text": "Immunotherapy with immune checkpoint inhibitorsMetastatic disease; possibly also in neoadjuvant setting",
                    "sub_points": [
                      "Metastatic disease; possibly also in neoadjuvant setting"
                    ]
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "Transurethral resectionNoninvasive papillary tumors (Ta), T1 tumors",
                    "sub_points": [
                      "Noninvasive papillary tumors (Ta), T1 tumors"
                    ]
                  },
                  {
                    "text": "CystectomyT2/T3 tumors, sometimes for T1/Ta tumors",
                    "sub_points": [
                      "T2/T3 tumors, sometimes for T1/Ta tumors"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "MIBCOverall 5-year cancer-specific survival rate: < 50%Stage is most important prognostic factorPrognosis worsens with increase in stage5-year survival with tumor spread to regional lymph nodes: ~ 34%5-year survival with distant metastasis: ~ 6%Certain histological subtypes have poorer outcome, including small cell, micropapillary, and sarcomatoidGrade is not as important prognostic factor after muscle invasion has occurred",
                    "sub_points": [
                      "Overall 5-year cancer-specific survival rate: < 50%",
                      "Stage is most important prognostic factorPrognosis worsens with increase in stage5-year survival with tumor spread to regional lymph nodes: ~ 34%5-year survival with distant metastasis: ~ 6%",
                      "Prognosis worsens with increase in stage",
                      "5-year survival with tumor spread to regional lymph nodes: ~ 34%",
                      "5-year survival with distant metastasis: ~ 6%",
                      "Certain histological subtypes have poorer outcome, including small cell, micropapillary, and sarcomatoid",
                      "Grade is not as important prognostic factor after muscle invasion has occurred"
                    ]
                  },
                  {
                    "text": "NMIBC5-year survival: ~ 90%Risk of recurrence: Up to 75%; progression: ~ 10-15%Risk increases with tumor size, number of tumors, grade, prior recurrence, presence of lamina propria invasion, and additional presence of CIS",
                    "sub_points": [
                      "5-year survival: ~ 90%",
                      "Risk of recurrence: Up to 75%; progression: ~ 10-15%",
                      "Risk increases with tumor size, number of tumors, grade, prior recurrence, presence of lamina propria invasion, and additional presence of CIS"
                    ]
                  }
                ],
                "AJCC TNM Staging Summary": [
                  {
                    "text": "T0: No evidence of primary tumor"
                  },
                  {
                    "text": "Ta: Noninvasive papillary carcinoma"
                  },
                  {
                    "text": "Tis: CIS (flat)"
                  },
                  {
                    "text": "T1: Tumor invades subepithelial connective tissue"
                  },
                  {
                    "text": "T2a: Tumor invades superficial muscularis propria"
                  },
                  {
                    "text": "T2b: Tumor invades deep muscularis propria"
                  },
                  {
                    "text": "T3a: Tumor invades perivesical tissue microscopically"
                  },
                  {
                    "text": "T3b: Tumor invades perivesical tissue macroscopically"
                  },
                  {
                    "text": "T4a: Tumor invades prostate stroma, seminal vesicles, uterus, vagina"
                  },
                  {
                    "text": "T4b: Tumor invades pelvic wall, abdominal wall"
                  },
                  {
                    "text": "N0: No lymph node metastasis"
                  },
                  {
                    "text": "N1: Single regional lymph node metastasis in true pelvis"
                  },
                  {
                    "text": "N2: Multiple regional lymph node metastases in true pelvis"
                  },
                  {
                    "text": "N3: Lymph node metastasis to common iliac lymph nodes"
                  },
                  {
                    "text": "M0: No distant metastasis"
                  },
                  {
                    "text": "M1: Distant metastasis"
                  }
                ]
              },
              "MOLECULAR": {
                "Cytogenetics": [
                  {
                    "text": "NMIBCChromosome 9 deletion in > 50%Appears to be early event in carcinogenesisGains of 3q, 7p, and 17q can be seenTesting (UroVysion) for these may provide diagnostic and prognostic informationOther early events include 9q, 9p, 11p deletionsOther later events include 8p, 17p, 11q deletions and gain of 20qFew genomic rearrangements and near diploid karyotype compared to MIBC",
                    "sub_points": [
                      "Chromosome 9 deletion in > 50%Appears to be early event in carcinogenesis",
                      "Appears to be early event in carcinogenesis",
                      "Gains of 3q, 7p, and 17q can be seenTesting (UroVysion) for these may provide diagnostic and prognostic information",
                      "Testing (UroVysion) for these may provide diagnostic and prognostic information",
                      "Other early events include 9q, 9p, 11p deletions",
                      "Other later events include 8p, 17p, 11q deletions and gain of 20q",
                      "Few genomic rearrangements and near diploid karyotype compared to MIBC"
                    ]
                  },
                  {
                    "text": "MIBCFrequently aneuploid with multiple alterations",
                    "sub_points": [
                      "Frequently aneuploid with multiple alterations"
                    ]
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "NMIBCFGFR3-activating point mutationsUp to 80% of Ta tumors, 10-30% of T1 tumorsHRASorKRAS10-15% of NMIBCMutually exclusive withFGFR3mutationsPIK3CA-inactivating point mutations40-50% of Ta tumors, 6-20% of T1 tumorsFrequently co-occur withFGFR3,HRAS, orKRASmutationsTERTpromoter mutationsMost common alteration in urothelial carcinoma, seen across grades, stages, and subtypes70-80% of Ta/T1 tumors, 65% of CISEarly event in tumorigenesisNot seen in benign entitiesSeen in majority of tumors withFGFR3mutationsCan be detected in urine samplesCCND1amplificationDetected in ~ 20%STAG2-inactivating mutationsTa tumors: 32-36%; T1 tumors: 18-27%Chromatin modifier genesMajority of tumors have inactivating (indel, nonsense, splice site) mutations in at least one of these genesKDM6A,KMT2A,KMT2C,KMT2D,ARID1A,EP300,CREBBPDNA damage repair genesSeen more commonly in high-grade Ta and T1 tumorsERCC2,ATR,ATM,FANCA,BRCA1,BRCA2,POLEOther mutated genes:TSC1,RHOB",
                    "sub_points": [
                      "FGFR3-activating point mutationsUp to 80% of Ta tumors, 10-30% of T1 tumors",
                      "Up to 80% of Ta tumors, 10-30% of T1 tumors",
                      "HRASorKRAS10-15% of NMIBCMutually exclusive withFGFR3mutations",
                      "10-15% of NMIBC",
                      "Mutually exclusive withFGFR3mutations",
                      "PIK3CA-inactivating point mutations40-50% of Ta tumors, 6-20% of T1 tumorsFrequently co-occur withFGFR3,HRAS, orKRASmutations",
                      "40-50% of Ta tumors, 6-20% of T1 tumors",
                      "Frequently co-occur withFGFR3,HRAS, orKRASmutations",
                      "TERTpromoter mutationsMost common alteration in urothelial carcinoma, seen across grades, stages, and subtypes70-80% of Ta/T1 tumors, 65% of CISEarly event in tumorigenesisNot seen in benign entitiesSeen in majority of tumors withFGFR3mutationsCan be detected in urine samples",
                      "Most common alteration in urothelial carcinoma, seen across grades, stages, and subtypes",
                      "70-80% of Ta/T1 tumors, 65% of CIS",
                      "Early event in tumorigenesis",
                      "Not seen in benign entities",
                      "Seen in majority of tumors withFGFR3mutations",
                      "Can be detected in urine samples",
                      "CCND1amplificationDetected in ~ 20%",
                      "Detected in ~ 20%",
                      "STAG2-inactivating mutationsTa tumors: 32-36%; T1 tumors: 18-27%",
                      "Ta tumors: 32-36%; T1 tumors: 18-27%",
                      "Chromatin modifier genesMajority of tumors have inactivating (indel, nonsense, splice site) mutations in at least one of these genesKDM6A,KMT2A,KMT2C,KMT2D,ARID1A,EP300,CREBBP",
                      "Majority of tumors have inactivating (indel, nonsense, splice site) mutations in at least one of these genesKDM6A,KMT2A,KMT2C,KMT2D,ARID1A,EP300,CREBBP",
                      "KDM6A,KMT2A,KMT2C,KMT2D,ARID1A,EP300,CREBBP",
                      "DNA damage repair genesSeen more commonly in high-grade Ta and T1 tumorsERCC2,ATR,ATM,FANCA,BRCA1,BRCA2,POLE",
                      "Seen more commonly in high-grade Ta and T1 tumors",
                      "ERCC2,ATR,ATM,FANCA,BRCA1,BRCA2,POLE",
                      "Other mutated genes:TSC1,RHOB"
                    ]
                  },
                  {
                    "text": "MIBCThe Cancer Genome Atlas (TCGA) 2017 project has shown deregulation of several pathwaysTP53/cell cycle pathway in 89%RTK/RAS/PI(3)K pathway in 71%Chromatin modification pathways: Histone modifiers (52%), SWI/SNF complex (26%)DNA repair pathway (16%)High level of genomic amplifications and deletions34 significantly amplified and 32 significantly deleted recurrent focal somatic copy number alterations (CNAs) in TCGA studyCDKN2Adeletion in 22%Other likely targeted deleted genes includeRB1,KDM6A,CREBBP,ARID1A,RAD51B,PTEN,PTPRB,NCOR1, andCDKN2BAmplified genes includeAHR,EGFR,GATA3,CCND1,PPARG,MDM2,E2F3,SOX4,ERBB2,YWHAZ,MYC,CCNE1,FGFR3,MYCL,ZNF703,BCL2L1,KRAS, andTERTGene fusions includeFGFR3::TACC3,TSEN2::PPARG, andMKRN2::PPARGMutation signaturesMIBC has high somatic mutation rate, driven mainly by APOBEC-mediated mutagenesisTumors with profile of high APOBEC-signature mutagenesis, high mutational burden, and predicted high neoantigen load have 75% 5-year survival> 50% of APOBEC-signature mutations are clonal, suggesting that they are generated early in tumorigenesisMutations includeTP53(48%),KMT2D(28%),KDM6A(26%),ARID1A(25%),PIK3CA(22%),KMT2C(18%),RB1(17%),EP300(15%),STAG2(14%),FGFR3(14%),ATM(14%),CREBBP(12%),ELF3(12%),FAT1(12%),SPTAN1(12%),ERBB2(12%),KMT2A(11%), andERBB3(10%)TERTpromoter mutations most common alteration in urothelial carcinoma (70-80%)Mutually exclusive mutations includeCDKN2AandTP53;CDKN2AandRB1;TP53andMDM2;FGFR3andTP53Co-occurring mutations includeTP53andRB1;TP53andE2F3;FGFR3andCDKN2A;FGFR3andSTAG2",
                    "sub_points": [
                      "The Cancer Genome Atlas (TCGA) 2017 project has shown deregulation of several pathwaysTP53/cell cycle pathway in 89%RTK/RAS/PI(3)K pathway in 71%Chromatin modification pathways: Histone modifiers (52%), SWI/SNF complex (26%)DNA repair pathway (16%)",
                      "TP53/cell cycle pathway in 89%",
                      "RTK/RAS/PI(3)K pathway in 71%",
                      "Chromatin modification pathways: Histone modifiers (52%), SWI/SNF complex (26%)",
                      "DNA repair pathway (16%)",
                      "High level of genomic amplifications and deletions34 significantly amplified and 32 significantly deleted recurrent focal somatic copy number alterations (CNAs) in TCGA studyCDKN2Adeletion in 22%Other likely targeted deleted genes includeRB1,KDM6A,CREBBP,ARID1A,RAD51B,PTEN,PTPRB,NCOR1, andCDKN2BAmplified genes includeAHR,EGFR,GATA3,CCND1,PPARG,MDM2,E2F3,SOX4,ERBB2,YWHAZ,MYC,CCNE1,FGFR3,MYCL,ZNF703,BCL2L1,KRAS, andTERT",
                      "34 significantly amplified and 32 significantly deleted recurrent focal somatic copy number alterations (CNAs) in TCGA study",
                      "CDKN2Adeletion in 22%",
                      "Other likely targeted deleted genes includeRB1,KDM6A,CREBBP,ARID1A,RAD51B,PTEN,PTPRB,NCOR1, andCDKN2B",
                      "Amplified genes includeAHR,EGFR,GATA3,CCND1,PPARG,MDM2,E2F3,SOX4,ERBB2,YWHAZ,MYC,CCNE1,FGFR3,MYCL,ZNF703,BCL2L1,KRAS, andTERT",
                      "Gene fusions includeFGFR3::TACC3,TSEN2::PPARG, andMKRN2::PPARG",
                      "FGFR3::TACC3,TSEN2::PPARG, andMKRN2::PPARG",
                      "Mutation signaturesMIBC has high somatic mutation rate, driven mainly by APOBEC-mediated mutagenesisTumors with profile of high APOBEC-signature mutagenesis, high mutational burden, and predicted high neoantigen load have 75% 5-year survival> 50% of APOBEC-signature mutations are clonal, suggesting that they are generated early in tumorigenesisMutations includeTP53(48%),KMT2D(28%),KDM6A(26%),ARID1A(25%),PIK3CA(22%),KMT2C(18%),RB1(17%),EP300(15%),STAG2(14%),FGFR3(14%),ATM(14%),CREBBP(12%),ELF3(12%),FAT1(12%),SPTAN1(12%),ERBB2(12%),KMT2A(11%), andERBB3(10%)TERTpromoter mutations most common alteration in urothelial carcinoma (70-80%)",
                      "MIBC has high somatic mutation rate, driven mainly by APOBEC-mediated mutagenesis",
                      "Tumors with profile of high APOBEC-signature mutagenesis, high mutational burden, and predicted high neoantigen load have 75% 5-year survival",
                      "> 50% of APOBEC-signature mutations are clonal, suggesting that they are generated early in tumorigenesis",
                      "Mutations includeTP53(48%),KMT2D(28%),KDM6A(26%),ARID1A(25%),PIK3CA(22%),KMT2C(18%),RB1(17%),EP300(15%),STAG2(14%),FGFR3(14%),ATM(14%),CREBBP(12%),ELF3(12%),FAT1(12%),SPTAN1(12%),ERBB2(12%),KMT2A(11%), andERBB3(10%)TERTpromoter mutations most common alteration in urothelial carcinoma (70-80%)",
                      "TP53(48%),KMT2D(28%),KDM6A(26%),ARID1A(25%),PIK3CA(22%),KMT2C(18%),RB1(17%),EP300(15%),STAG2(14%),FGFR3(14%),ATM(14%),CREBBP(12%),ELF3(12%),FAT1(12%),SPTAN1(12%),ERBB2(12%),KMT2A(11%), andERBB3(10%)",
                      "TERTpromoter mutations most common alteration in urothelial carcinoma (70-80%)",
                      "Mutually exclusive mutations includeCDKN2AandTP53;CDKN2AandRB1;TP53andMDM2;FGFR3andTP53",
                      "CDKN2AandTP53;CDKN2AandRB1;TP53andMDM2;FGFR3andTP53",
                      "Co-occurring mutations includeTP53andRB1;TP53andE2F3;FGFR3andCDKN2A;FGFR3andSTAG2",
                      "TP53andRB1;TP53andE2F3;FGFR3andCDKN2A;FGFR3andSTAG2"
                    ]
                  },
                  {
                    "text": "Alterations associated with histological subtypesPlasmacytoid subtypeSomaticCDH1-truncating mutations (84%) or promoter hypermethylation: Loss of E-cadherin expressionCDH1germline alterations not describedMicropapillary subtypeERBB2amplificationClusters with luminal nonspecified expression groupSmall cell/neuroendocrine carcinoma subtypeLoss of function ofTP53(90%) andRB1(87%)High rates ofTERTpromoter and chromatin remodeling gene alterations, similar to usual urothelial carcinomaUnlike usual urothelial carcinoma, generally lacks alterations inKDM6A,CDKN2A, andCCND1High genome instability: Whole-genome duplication in 72%Low rate of PD-L1 expressionNested subtypeHigh rates ofTERTpromoter mutations; may have mutations inTP53,JAK3, andCTNNB1Large nested subtype: Large majority haveFGFR3alterationsUsually show luminal expression markersSarcomatoid subtypeEnriched inTP53,RB1, andPIK3CAmutationsExpression features of basal molecular groupOverexpression of PD-L1Squamous differentiationClusters with basal/squamous molecular groupDownregulation of markers of urothelial differentiationGlandular differentiationHigh rates ofTERTpromoter and chromatin remodeling gene alterations, similar to usual urothelial carcinoma",
                    "sub_points": [
                      "Plasmacytoid subtypeSomaticCDH1-truncating mutations (84%) or promoter hypermethylation: Loss of E-cadherin expressionCDH1germline alterations not described",
                      "SomaticCDH1-truncating mutations (84%) or promoter hypermethylation: Loss of E-cadherin expression",
                      "CDH1germline alterations not described",
                      "Micropapillary subtypeERBB2amplificationClusters with luminal nonspecified expression group",
                      "ERBB2amplification",
                      "Clusters with luminal nonspecified expression group",
                      "Small cell/neuroendocrine carcinoma subtypeLoss of function ofTP53(90%) andRB1(87%)High rates ofTERTpromoter and chromatin remodeling gene alterations, similar to usual urothelial carcinomaUnlike usual urothelial carcinoma, generally lacks alterations inKDM6A,CDKN2A, andCCND1High genome instability: Whole-genome duplication in 72%Low rate of PD-L1 expression",
                      "Loss of function ofTP53(90%) andRB1(87%)",
                      "High rates ofTERTpromoter and chromatin remodeling gene alterations, similar to usual urothelial carcinoma",
                      "Unlike usual urothelial carcinoma, generally lacks alterations inKDM6A,CDKN2A, andCCND1",
                      "High genome instability: Whole-genome duplication in 72%",
                      "Low rate of PD-L1 expression",
                      "Nested subtypeHigh rates ofTERTpromoter mutations; may have mutations inTP53,JAK3, andCTNNB1Large nested subtype: Large majority haveFGFR3alterationsUsually show luminal expression markers",
                      "High rates ofTERTpromoter mutations; may have mutations inTP53,JAK3, andCTNNB1",
                      "Large nested subtype: Large majority haveFGFR3alterations",
                      "Usually show luminal expression markers",
                      "Sarcomatoid subtypeEnriched inTP53,RB1, andPIK3CAmutationsExpression features of basal molecular groupOverexpression of PD-L1",
                      "Enriched inTP53,RB1, andPIK3CAmutations",
                      "Expression features of basal molecular group",
                      "Overexpression of PD-L1",
                      "Squamous differentiationClusters with basal/squamous molecular groupDownregulation of markers of urothelial differentiation",
                      "Clusters with basal/squamous molecular group",
                      "Downregulation of markers of urothelial differentiation",
                      "Glandular differentiationHigh rates ofTERTpromoter and chromatin remodeling gene alterations, similar to usual urothelial carcinoma",
                      "High rates ofTERTpromoter and chromatin remodeling gene alterations, similar to usual urothelial carcinoma"
                    ]
                  },
                  {
                    "text": "Potentially predictive alterationsAlterations inERCC2and other DNA damage repair genes may predict better response to cisplatin-based regimens, immune checkpoint inhibitors, and radiation therapyTumors withFGFR3alterations may respond to anti-FGFR agentsTumor mutation burden, mismatch repair deficiency, and PD-L1 expression in tumor/immune cells help predict response to immune checkpoint inhibitor therapy",
                    "sub_points": [
                      "Alterations inERCC2and other DNA damage repair genes may predict better response to cisplatin-based regimens, immune checkpoint inhibitors, and radiation therapy",
                      "Tumors withFGFR3alterations may respond to anti-FGFR agents",
                      "Tumor mutation burden, mismatch repair deficiency, and PD-L1 expression in tumor/immune cells help predict response to immune checkpoint inhibitor therapy"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Classification of MIBC based on mRNA expression clusteringMay have predictive/prognostic and therapeutic implicationsSeveral partially overlapping classifications published",
                    "sub_points": [
                      "May have predictive/prognostic and therapeutic implications",
                      "Several partially overlapping classifications published"
                    ]
                  },
                  {
                    "text": "International Consensus Molecular Classification (Kamoun 2020): 6 consensus molecular classesEffort by Bladder Cancer Molecular Taxonomy Group to unify multiple existing classificationsReanalysis of 1,750 transcriptomic profiles from 18 data sets, including 6 existing classification systemsResulted in 6 consensus molecular classes, showing differences in oncogenic mechanism, histology, tumor microenvironment, and prognosis (worse survival: Neuroendocrine-like, basal/squamous, luminal unstable)",
                    "sub_points": [
                      "Effort by Bladder Cancer Molecular Taxonomy Group to unify multiple existing classifications",
                      "Reanalysis of 1,750 transcriptomic profiles from 18 data sets, including 6 existing classification systems",
                      "Resulted in 6 consensus molecular classes, showing differences in oncogenic mechanism, histology, tumor microenvironment, and prognosis (worse survival: Neuroendocrine-like, basal/squamous, luminal unstable)"
                    ]
                  },
                  {
                    "text": "Luminal-papillary (24% of cases)Enriched in papillary histology (59%); younger patients, lower stage, better prognosisStrongly associated with FGFR3 transcriptional activity signature and noninvasive Ta pathway signatureEnriched inFGFR3(55%) andKDM6A(38%) alterations, andCDKN2Adeletions (33%)Overexpression of urothelial differentiation gene signature",
                    "sub_points": [
                      "Enriched in papillary histology (59%); younger patients, lower stage, better prognosis",
                      "Strongly associated with FGFR3 transcriptional activity signature and noninvasive Ta pathway signature",
                      "Enriched inFGFR3(55%) andKDM6A(38%) alterations, andCDKN2Adeletions (33%)",
                      "Overexpression of urothelial differentiation gene signature"
                    ]
                  },
                  {
                    "text": "Luminal nonspecified (8%)Enriched in micropapillary subtype (36%); commonly associated with CIS, older patientsAssociated with fibroblastic, and B- and T-cell signaturesEnriched inELF3(33%) andPPARG(76%) alterationsOverexpression of urothelial differentiation gene signature",
                    "sub_points": [
                      "Enriched in micropapillary subtype (36%); commonly associated with CIS, older patients",
                      "Associated with fibroblastic, and B- and T-cell signatures",
                      "Enriched inELF3(33%) andPPARG(76%) alterations",
                      "Overexpression of urothelial differentiation gene signature"
                    ]
                  },
                  {
                    "text": "Luminal-unstable (15%)Higher cell cycle activity, most genomic alterations (highest somatic mutation load, most CNAs)Associated withPPARGalterations (89%),TP53(76%) andERCC2(22%) mutations, amplifications of 6p22.3 region (76%) andERBB2(22%)Overexpression of urothelial differentiation gene signature",
                    "sub_points": [
                      "Higher cell cycle activity, most genomic alterations (highest somatic mutation load, most CNAs)",
                      "Associated withPPARGalterations (89%),TP53(76%) andERCC2(22%) mutations, amplifications of 6p22.3 region (76%) andERBB2(22%)",
                      "Overexpression of urothelial differentiation gene signature"
                    ]
                  },
                  {
                    "text": "Stroma-rich (15%)Characterized by stromal (smooth muscle, endothelial, fibroblastic, and myofibroblastic) and immune (B- and T-cell) signaturesIntermediate levels of urothelial differentiation",
                    "sub_points": [
                      "Characterized by stromal (smooth muscle, endothelial, fibroblastic, and myofibroblastic) and immune (B- and T-cell) signatures",
                      "Intermediate levels of urothelial differentiation"
                    ]
                  },
                  {
                    "text": "Basal/squamous (35%)Enriched inTP53(58%) andRB1(20%) mutations (coexist in 14%), genomic deletion at 13p14.2 (49%)Associated with CD8 T- and NK-cell signaturesEnriched in squamous histology (42%), more common in women, higher stage, poorer prognosisAssociated withSTAT3,HIF1A,EGFRregulatory unit activityOverexpression of basal differentiation gene signature",
                    "sub_points": [
                      "Enriched inTP53(58%) andRB1(20%) mutations (coexist in 14%), genomic deletion at 13p14.2 (49%)",
                      "Associated with CD8 T- and NK-cell signatures",
                      "Enriched in squamous histology (42%), more common in women, higher stage, poorer prognosis",
                      "Associated withSTAT3,HIF1A,EGFRregulatory unit activity",
                      "Overexpression of basal differentiation gene signature"
                    ]
                  },
                  {
                    "text": "Neuroendocrine-like (3%)TP53andRB1in 90%Neuroendocrine histology in 72%Poor prognosisOverexpression of neuroendocrine differentiation gene signature",
                    "sub_points": [
                      "TP53andRB1in 90%",
                      "Neuroendocrine histology in 72%",
                      "Poor prognosis",
                      "Overexpression of neuroendocrine differentiation gene signature"
                    ]
                  },
                  {
                    "text": "Examples of molecular classes from 2017 The Cancer Genome Atlas (TCGA) project for MIBC (one of major studies subsumed into ICC)TCGA Luminal-papillary (35%)Enriched in tumors with papillary morphology, lower stageFGFR3,CDKN2A,STAG2alterationsLow CIS expression signatureMay have low risk for progressionTCGA luminal (6%)High expression of luminal markers (uroplakins,KRT20,SNX31)Enriched forTP53mutationsTCGA luminal-infiltrated (19%)Mesenchymal expression signature, myofibroblast and EMT markersMedium expression of immune markers:CD274(PD-L1),CTLA4Enriched forTP53mutation andCDKN2AlossMay be resistant to cisplatinMay be sensitive to immune checkpoint inhibitorsTCGA basal-squamous (35%)High expression of basal and stem-like markers (CD44,KRT14,KRT5,KRT6A)Enriched in squamous features and CIS gene signatureSubtype with strongest immune signature expression:CD274(PD-L1),CTLA4May respond to cisplatin and immune checkpoint inhibitorsHigher incidence in femalesTCGA neuronal (5%)Expression of neuroendocrine and neuronal genesHigh cell-cycle signatureMost are not morphologically neuroendocrineTP53andRB1mutations,E2F3amplification",
                    "sub_points": [
                      "TCGA Luminal-papillary (35%)Enriched in tumors with papillary morphology, lower stageFGFR3,CDKN2A,STAG2alterationsLow CIS expression signatureMay have low risk for progression",
                      "Enriched in tumors with papillary morphology, lower stage",
                      "FGFR3,CDKN2A,STAG2alterations",
                      "Low CIS expression signature",
                      "May have low risk for progression",
                      "TCGA luminal (6%)High expression of luminal markers (uroplakins,KRT20,SNX31)Enriched forTP53mutations",
                      "High expression of luminal markers (uroplakins,KRT20,SNX31)",
                      "Enriched forTP53mutations",
                      "TCGA luminal-infiltrated (19%)Mesenchymal expression signature, myofibroblast and EMT markersMedium expression of immune markers:CD274(PD-L1),CTLA4Enriched forTP53mutation andCDKN2AlossMay be resistant to cisplatinMay be sensitive to immune checkpoint inhibitors",
                      "Mesenchymal expression signature, myofibroblast and EMT markers",
                      "Medium expression of immune markers:CD274(PD-L1),CTLA4",
                      "Enriched forTP53mutation andCDKN2Aloss",
                      "May be resistant to cisplatin",
                      "May be sensitive to immune checkpoint inhibitors",
                      "TCGA basal-squamous (35%)High expression of basal and stem-like markers (CD44,KRT14,KRT5,KRT6A)Enriched in squamous features and CIS gene signatureSubtype with strongest immune signature expression:CD274(PD-L1),CTLA4May respond to cisplatin and immune checkpoint inhibitorsHigher incidence in females",
                      "High expression of basal and stem-like markers (CD44,KRT14,KRT5,KRT6A)",
                      "Enriched in squamous features and CIS gene signature",
                      "Subtype with strongest immune signature expression:CD274(PD-L1),CTLA4",
                      "May respond to cisplatin and immune checkpoint inhibitors",
                      "Higher incidence in females",
                      "TCGA neuronal (5%)Expression of neuroendocrine and neuronal genesHigh cell-cycle signatureMost are not morphologically neuroendocrineTP53andRB1mutations,E2F3amplification",
                      "Expression of neuroendocrine and neuronal genes",
                      "High cell-cycle signature",
                      "Most are not morphologically neuroendocrine",
                      "TP53andRB1mutations,E2F3amplification"
                    ]
                  },
                  {
                    "text": "NMIBCUROMOL study described 3 groups based on mRNA expression clusteringClass IEarly cell cycle genes, luminal expression patternBest prognosisClass IILate cell cycle genes, luminal expression patternEnriched with CIS, high-grade T1Most progression eventsClass IIIBasal differentiationLow cell cycle and metabolic activity",
                    "sub_points": [
                      "UROMOL study described 3 groups based on mRNA expression clustering",
                      "Class IEarly cell cycle genes, luminal expression patternBest prognosis",
                      "Early cell cycle genes, luminal expression pattern",
                      "Best prognosis",
                      "Class IILate cell cycle genes, luminal expression patternEnriched with CIS, high-grade T1Most progression events",
                      "Late cell cycle genes, luminal expression pattern",
                      "Enriched with CIS, high-grade T1",
                      "Most progression events",
                      "Class IIIBasal differentiationLow cell cycle and metabolic activity",
                      "Basal differentiation",
                      "Low cell cycle and metabolic activity"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Papillary lesionsPapilloma and papillary urothelial neoplasm of low malignant potential (PUNLMP)Hyperplastic and neoplastic urothelium thrown into papillary structures with central thin, fibrovascular coreUrothelium appears normal and hyperplastic, respectivelyLow-grade urothelial carcinomaLow-grade cytologic atypia; branching and fusion of papillaeHigh-grade urothelial carcinomaHigh-grade cytologic atypia, more branching and fusion of papillae, may have associated invasion",
                    "sub_points": [
                      "Papilloma and papillary urothelial neoplasm of low malignant potential (PUNLMP)Hyperplastic and neoplastic urothelium thrown into papillary structures with central thin, fibrovascular coreUrothelium appears normal and hyperplastic, respectively",
                      "Hyperplastic and neoplastic urothelium thrown into papillary structures with central thin, fibrovascular core",
                      "Urothelium appears normal and hyperplastic, respectively",
                      "Low-grade urothelial carcinomaLow-grade cytologic atypia; branching and fusion of papillae",
                      "Low-grade cytologic atypia; branching and fusion of papillae",
                      "High-grade urothelial carcinomaHigh-grade cytologic atypia, more branching and fusion of papillae, may have associated invasion",
                      "High-grade cytologic atypia, more branching and fusion of papillae, may have associated invasion"
                    ]
                  },
                  {
                    "text": "Flat lesionsCISNoninvasive, usually multifocalDisordered, mitotically active, cytologically high gradeSubepithelial proliferation of small capillaries common",
                    "sub_points": [
                      "CISNoninvasive, usually multifocalDisordered, mitotically active, cytologically high gradeSubepithelial proliferation of small capillaries common",
                      "Noninvasive, usually multifocal",
                      "Disordered, mitotically active, cytologically high grade",
                      "Subepithelial proliferation of small capillaries common"
                    ]
                  },
                  {
                    "text": "Invasive carcinomaTumor invades through basement membrane into lamina propria (T1) or muscularis propria (T2)Most are high grade, and most arise from dysplasia or CIS, or from high-grade papillary tumorsHistological subtypes include nested, micropapillary, plasmacytoid, small cell, and sarcomatoidAberrant differentiation, including squamous, glandular, trophoblastic, and müllerian, can occur",
                    "sub_points": [
                      "Tumor invades through basement membrane into lamina propria (T1) or muscularis propria (T2)",
                      "Most are high grade, and most arise from dysplasia or CIS, or from high-grade papillary tumors",
                      "Histological subtypes include nested, micropapillary, plasmacytoid, small cell, and sarcomatoid",
                      "Aberrant differentiation, including squamous, glandular, trophoblastic, and müllerian, can occur"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CIS (flat)Full-thickness staining for CK20; p53 nuclear staining",
                    "sub_points": [
                      "Full-thickness staining for CK20; p53 nuclear staining"
                    ]
                  },
                  {
                    "text": "Urothelial carcinomaFrequently positive for CK7 and CK20Positive for high-molecular-weight cytokeratins, p63, and GATA3PD-L1 expression in tumor and immune cells helps predict response to immune checkpoint inhibitor therapy",
                    "sub_points": [
                      "Frequently positive for CK7 and CK20",
                      "Positive for high-molecular-weight cytokeratins, p63, and GATA3",
                      "PD-L1 expression in tumor and immune cells helps predict response to immune checkpoint inhibitor therapy"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "UroVysionInterphase FISH-based assay testing for aneuploidy of chromosomes 3, 7, and 17, and for loss of 9q21 in urothelial cells in urineFDA approved for surveillance of recurrence in patients with previously diagnosed urothelial carcinomaAlso approved for screening of high-risk patients (smokers) with hematuriaImproves sensitivity of urine cytology for detection of urothelial carcinomaReported sensitivity: 69-87%; specificity: 89-96%May provide prognostic information for NMIBC recurrenceWhen performed after BCG therapy, may provide predictive information for therapy failure",
                    "sub_points": [
                      "Interphase FISH-based assay testing for aneuploidy of chromosomes 3, 7, and 17, and for loss of 9q21 in urothelial cells in urine",
                      "FDA approved for surveillance of recurrence in patients with previously diagnosed urothelial carcinoma",
                      "Also approved for screening of high-risk patients (smokers) with hematuria",
                      "Improves sensitivity of urine cytology for detection of urothelial carcinoma",
                      "Reported sensitivity: 69-87%; specificity: 89-96%",
                      "May provide prognostic information for NMIBC recurrence",
                      "When performed after BCG therapy, may provide predictive information for therapy failure"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Papillary/Polypoid Cystitis": [
                  {
                    "text": "Commonly associated with indwelling catheters"
                  },
                  {
                    "text": "Stromal edema and inflammation"
                  },
                  {
                    "text": "No significant cytologic atypia"
                  }
                ],
                "Pseudocarcinomatous Hyperplasia": [
                  {
                    "text": "Benign reactive epithelial proliferation"
                  },
                  {
                    "text": "Usually in setting of prior radiation or chemotherapy"
                  },
                  {
                    "text": "Inflammation and edema; may have atypia"
                  }
                ],
                "Nonurothelial Tumors": [
                  {
                    "text": "Local extension from tumors such as prostate, cervix, or other high-grade gynecologic carcinomas can mimic high-grade invasive urothelial carcinoma"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "PCR-Based Sequencing": {
        "name": "PCR-Based Sequencing",
        "url": "https://app.pathprimer.com/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
        "topics": {
          "BRAFMutations": {
            "name": "BRAFMutations",
            "url": "https://app.pathprimer.com/document/ab4b7a82-a8e8-44ac-b10d-158b43c2d8a5/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: B-Raf protooncogene, serine/threonine kinase"
                  },
                  {
                    "text": "Official symbol:BRAF"
                  },
                  {
                    "text": "HGNC ID: 1097"
                  },
                  {
                    "text": "Chromosomal location: 7q34"
                  },
                  {
                    "text": "Genomic location: Chr7:140,713,328-140,924,929 (GRCh38/hg38)"
                  },
                  {
                    "text": "Size: 766 amino acids"
                  },
                  {
                    "text": "Number of exons: 24"
                  },
                  {
                    "text": "Aliases: BRAF1, RAFB1, protooncogene B-RAF"
                  }
                ]
              },
              "STRUCTURE AND FUNCTIONS OF BRAF PROTEIN": {
                "Structure": [
                  {
                    "text": "BRAF protein is serine/threonine kinase"
                  },
                  {
                    "text": "Composed of 3 conserved regions (CR)CR1 and CR2 are regulatory domainsCR3 contains catalytic protein kinase domain",
                    "sub_points": [
                      "CR1 and CR2 are regulatory domains",
                      "CR3 contains catalytic protein kinase domain"
                    ]
                  }
                ],
                "Functions": [
                  {
                    "text": "Member of rapidly accelerated fibrosarcoma (RAF) kinase family of serine/threonine kinases (ARAF, BRAF, CRAF) involved in RAS/RAF/MEK/ERK pathwayActivated RAS proteins induce dimerization of RAF proteins, leading to cascade of kinase activation from MEK1/MEK2 to ERK1/ERK2, subsequently causing changes in gene expression",
                    "sub_points": [
                      "Activated RAS proteins induce dimerization of RAF proteins, leading to cascade of kinase activation from MEK1/MEK2 to ERK1/ERK2, subsequently causing changes in gene expression"
                    ]
                  },
                  {
                    "text": "Enzymatic activity of BRAF proteins in cytoplasm is tightly controlled in normal cells"
                  }
                ]
              },
              "BRAF GENE ALTERATIONS": {
                "BRAFSomatic Missense Mutations": [
                  {
                    "text": "Class I mutations (mutations in codon V600, independent of both upstream RAS activation and need for dimerization)Most commonly identifiedBRAFmutations in human cancersBRAFc.1799T>A, p.V600E mutation, 80-90% of all V600 codon mutationsc.1798_1799delGTinsAA, p.V600K in 5-12%c.1798_1799delGTinsAG, p.V600R in ~ 5%c.1799_1800delTGinsAT, p.V600D in ~ 1%c.1798G>A, p.V600M in < 1%",
                    "sub_points": [
                      "Most commonly identifiedBRAFmutations in human cancers",
                      "BRAFc.1799T>A, p.V600E mutation, 80-90% of all V600 codon mutations",
                      "c.1798_1799delGTinsAA, p.V600K in 5-12%",
                      "c.1798_1799delGTinsAG, p.V600R in ~ 5%",
                      "c.1799_1800delTGinsAT, p.V600D in ~ 1%",
                      "c.1798G>A, p.V600M in < 1%"
                    ]
                  },
                  {
                    "text": "Class II mutations (non-V600 mutations, inducing constitutive activation via Ras-independent dimerization)Substitutions atBRAFactivation segmentK601E, K601N, K601T, L597QSubstitutions within P loopG464, G469A, G469V, G469R",
                    "sub_points": [
                      "Substitutions atBRAFactivation segmentK601E, K601N, K601T, L597Q",
                      "K601E, K601N, K601T, L597Q",
                      "Substitutions within P loopG464, G469A, G469V, G469R",
                      "G464, G469A, G469V, G469R"
                    ]
                  },
                  {
                    "text": "Class III mutations (non-V600 mutations, lack or possess low kinase activity; increase signaling via enhanced RAS binding and enhancement of CRAF activation)G466V, G466E, N581S, D594N, D594G, G596D",
                    "sub_points": [
                      "G466V, G466E, N581S, D594N, D594G, G596D"
                    ]
                  }
                ],
                "Fusions": [
                  {
                    "text": "Function similarly to class II BRAF mutants"
                  },
                  {
                    "text": "C-terminal portion of BRAF is fused in-frame with another protein at N-terminus"
                  },
                  {
                    "text": "BRAFfusions cause autophosphorylation due to loss of regulatory domain of BRAF protein resulting in constitutively active BRAF dimers"
                  },
                  {
                    "text": "Found in various neoplasms, such asAGAP3::BRAF,AGK::BRAF,AKAP9::BRAF, andZNF767P::BRAFin melanomaAGK::BRAF,AKAP9::BRAF,KIAA1549::BRAF, andCCDC6::BRAFin gliomaZC3HAV1::BRAF,AGTRAP::BRAF, andMKRN1::BRAFin GI tract carcinomasSND1::BRAFandMYRIP::BRAFin pancreatic carcinomaBTF3L4::BRAF,NUP214::BRAF,ARMC10::BRAF, andNUP214::BRAFin lung carcinomaKLHL7::BRAF,RBMS3::BRAF, andTANK::BRAFin thyroid carcinomaMKRN1::BRAFin head and neck carcinomaNUB1::BRAFandSLC45A3::BRAFin prostate cancerKIAA1549::BRAFin metastatic breast carcinomaMIGA1::BRAFfusion in Langerhans cell histiocytosis",
                    "sub_points": [
                      "AGAP3::BRAF,AGK::BRAF,AKAP9::BRAF, andZNF767P::BRAFin melanoma",
                      "AGK::BRAF,AKAP9::BRAF,KIAA1549::BRAF, andCCDC6::BRAFin glioma",
                      "ZC3HAV1::BRAF,AGTRAP::BRAF, andMKRN1::BRAFin GI tract carcinomas",
                      "SND1::BRAFandMYRIP::BRAFin pancreatic carcinoma",
                      "BTF3L4::BRAF,NUP214::BRAF,ARMC10::BRAF, andNUP214::BRAFin lung carcinoma",
                      "KLHL7::BRAF,RBMS3::BRAF, andTANK::BRAFin thyroid carcinoma",
                      "MKRN1::BRAFin head and neck carcinoma",
                      "NUB1::BRAFandSLC45A3::BRAFin prostate cancer",
                      "KIAA1549::BRAFin metastatic breast carcinoma",
                      "MIGA1::BRAFfusion in Langerhans cell histiocytosis"
                    ]
                  }
                ],
                "BRAFGermline Mutations": [
                  {
                    "text": "Involved in developmental disorders and includeA246P, Q257R, G469E, L485F, K499E, E501K, and N581D, among others",
                    "sub_points": [
                      "A246P, Q257R, G469E, L485F, K499E, E501K, and N581D, among others"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Melanoma": [
                  {
                    "text": "BRAFsomatic missense mutations are most common oncogenic driver in melanomaDetected in ~ 60% of melanomas",
                    "sub_points": [
                      "Detected in ~ 60% of melanomas"
                    ]
                  },
                  {
                    "text": "BRAF inhibitorsSmall molecule that binds mutatedBRAFand renders BRAF protein inactivationFDA-approved inhibitors: Vemurafenib, dabrafenib, trametinib, cobimetinib, atezolizumabResistance to BRAF inhibitorsDevelops in almost all patients, usually within 1 yearThought to be due to alternative survival pathways, includingPDGFR,NRAS, andHGF",
                    "sub_points": [
                      "Small molecule that binds mutatedBRAFand renders BRAF protein inactivation",
                      "FDA-approved inhibitors: Vemurafenib, dabrafenib, trametinib, cobimetinib, atezolizumab",
                      "Resistance to BRAF inhibitorsDevelops in almost all patients, usually within 1 yearThought to be due to alternative survival pathways, includingPDGFR,NRAS, andHGF",
                      "Develops in almost all patients, usually within 1 year",
                      "Thought to be due to alternative survival pathways, includingPDGFR,NRAS, andHGF"
                    ]
                  }
                ],
                "Colorectal Carcinoma": [
                  {
                    "text": "BRAFmutations occurs in 6-15% of colorectal carcinoma (CRC)"
                  },
                  {
                    "text": "Sporadic CRC with microsatellite instability high (MSI-H) vs. hereditary nonpolyposis colorectal carcinoma (HNPCC)Majority of sporadic CRC with MSI-H haveBRAFmutationHNPCC patients almost never haveBRAFmutationTestingBRAFV600E status can avoid expense of full gene sequencing for mismatch repair genes",
                    "sub_points": [
                      "Majority of sporadic CRC with MSI-H haveBRAFmutation",
                      "HNPCC patients almost never haveBRAFmutation",
                      "TestingBRAFV600E status can avoid expense of full gene sequencing for mismatch repair genes"
                    ]
                  },
                  {
                    "text": "Resistance to EGFR-targeted therapy by cetuximab and panitumumab is common in CRC withBRAFmutations"
                  },
                  {
                    "text": "FDA has approved cetuximab + encorafenib for metastatic CRC withBRAFV600E mutation"
                  }
                ],
                "Papillary Thyroid Carcinoma": [
                  {
                    "text": "BRAFV600E mutation is most common genetic alteration~ 69% have V600E mutation; mainly in classic variant, rare in other variantsV600E is virtually absent in follicular, Hürthle cell carcinoma, medullary thyroid carcinomas, and in benign thyroid tumorsRecurrence, lymph node metastases, extrathyroidal extension, and advanced stage are common in tumors withBRAFV600E mutation",
                    "sub_points": [
                      "~ 69% have V600E mutation; mainly in classic variant, rare in other variants",
                      "V600E is virtually absent in follicular, Hürthle cell carcinoma, medullary thyroid carcinomas, and in benign thyroid tumors",
                      "Recurrence, lymph node metastases, extrathyroidal extension, and advanced stage are common in tumors withBRAFV600E mutation"
                    ]
                  }
                ],
                "Non-Small Cell Lung Cancer": [
                  {
                    "text": "1-4% haveBRAFsomatic mutations"
                  },
                  {
                    "text": "Types ofBRAFmutationsV600E in ~ 50%, G469A in 39%, and D594G in 11%",
                    "sub_points": [
                      "V600E in ~ 50%, G469A in 39%, and D594G in 11%"
                    ]
                  },
                  {
                    "text": "BRAFmutations are mutually exclusive withKRASandEGFRmutations"
                  }
                ],
                "Hairy Cell Leukemia": [
                  {
                    "text": "Nearly 100% of patients carryBRAFV600E mutation"
                  },
                  {
                    "text": "BRAFV600E typically negative in other B-cell lymphomas, includingSplenic marginal zone lymphomaHairy cell leukemia variantSplenic red pulp small B-cell lymphoma",
                    "sub_points": [
                      "Splenic marginal zone lymphoma",
                      "Hairy cell leukemia variant",
                      "Splenic red pulp small B-cell lymphoma"
                    ]
                  }
                ],
                "Langerhans Cell Histiocytosis": [
                  {
                    "text": "BRAFV600E mutation found in ~ 60%"
                  },
                  {
                    "text": "Increased risk of initial treatment failure in patients with this mutation"
                  },
                  {
                    "text": "Associated with 2x increased risk for recurrence or relapse"
                  },
                  {
                    "text": "Other isolated case reports of rare types ofBRAFmutationsBRAFexon 12 in-frame deletion,MIGA1::BRAFfusion",
                    "sub_points": [
                      "BRAFexon 12 in-frame deletion,MIGA1::BRAFfusion"
                    ]
                  }
                ],
                "Glioma": [
                  {
                    "text": "BRAFmutations are significant driver of disease in both pediatric and adult gliomas"
                  },
                  {
                    "text": "BRAFV600E is associated with improved survival overall in adults with glioma"
                  },
                  {
                    "text": "FDA-approved dabrafenib with trametinib for pediatric patients with low-grade glioma withBRAFV600E"
                  }
                ],
                "Cardiofaciocutaneous Syndrome, LEOPARD Syndrome, and Noonan Syndrome": [
                  {
                    "text": "All linked to gene alterations in RAS/RAF/MEK/ERK signaling pathway"
                  },
                  {
                    "text": "Different germlineBRAFmutations35-75% in cardiofaciocutaneous syndromeUp to 17% in LEOPARD syndrome~ 2% in Noonan syndrome",
                    "sub_points": [
                      "35-75% in cardiofaciocutaneous syndrome",
                      "Up to 17% in LEOPARD syndrome",
                      "~ 2% in Noonan syndrome"
                    ]
                  }
                ]
              },
              "DETECTION TECHNIQUES": {
                "Next-Generation Sequencing": [
                  {
                    "text": "Highly accurate due to much higher degree of sequence coverage"
                  },
                  {
                    "text": "Most ofBRAFmutations are covered in targeted NGS panels"
                  }
                ],
                "Pyrosequencing": [
                  {
                    "text": "Efficient method to detectBRAFmutations; commonly used in molecular diagnostics laboratoriesSimple, robust, and sensitive method with detection limit of ~ 5% mutant alleles",
                    "sub_points": [
                      "Simple, robust, and sensitive method with detection limit of ~ 5% mutant alleles"
                    ]
                  }
                ],
                "Digital PCR": [
                  {
                    "text": "Can accurately detect and quantify low nucleic acid targets"
                  },
                  {
                    "text": "High sensitivity and specificity"
                  }
                ],
                "Allele-Specific Real-Time PCR": [
                  {
                    "text": "Simple; high sensitivity and specificity"
                  },
                  {
                    "text": "Low-cost and fast diagnostic tool for accurate detection ofBRAFmutations"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "BRAFV600E mutation-specific antibody (VE1) is targeted to BRAF V600E proteinHas high concordance with DNA-based methods detectingBRAFV600E",
                    "sub_points": [
                      "Has high concordance with DNA-based methods detectingBRAFV600E"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Colorectal Adenocarcinoma and Precancerous Lesions": {
            "name": "Colorectal Adenocarcinoma and Precancerous Lesions",
            "url": "https://app.pathprimer.com/document/98cffb54-0064-4f07-96d7-25bcc829916a/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Colorectal adenocarcinoma (CRC) is malignant epithelial neoplasm of colon"
                  },
                  {
                    "text": "Colorectal precancerous lesions are dysplastic epithelial neoplasms that typically present as adenomatous polyps or flat dysplastic lesions"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "CRC arises from sequential genetic alterations through various carcinogenic pathways"
                  },
                  {
                    "text": "Risk involves environmental and genetic factors"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Molecular subtyping of CRC helps refine patient prognosisSporadic MSI-H CRC shows most favorable outcome, especially withBRAFwildtypeMSS,BRAF-mutated CRC shows worst prognosis",
                    "sub_points": [
                      "Sporadic MSI-H CRC shows most favorable outcome, especially withBRAFwildtype",
                      "MSS,BRAF-mutated CRC shows worst prognosis"
                    ]
                  },
                  {
                    "text": "Effectiveness of EGFR inhibition for advanced-stage disease depends on downstream mutationsKRAS,BRAF, andNRASmutations confer resistance to anti-EGFR therapy",
                    "sub_points": [
                      "KRAS,BRAF, andNRASmutations confer resistance to anti-EGFR therapy"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "Sporadic CRCMSI-H, CIMP-H,BRAF-mutated,MLH1promoter hypermethylated",
                    "sub_points": [
                      "MSI-H, CIMP-H,BRAF-mutated,MLH1promoter hypermethylated"
                    ]
                  },
                  {
                    "text": "LS-associated CRCMSI-H,BRAFwildtype, promoter nonmethylated, germline MMR gene mutation",
                    "sub_points": [
                      "MSI-H,BRAFwildtype, promoter nonmethylated, germline MMR gene mutation"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "KRAS,NRAS,BRAFgene mutation testing"
                  },
                  {
                    "text": "NGS panel may detect other clinically actionable mutations"
                  },
                  {
                    "text": "LS screen testingUniversal LS screening recommended in all patients with newly diagnosed CRCMSI by PCR, MMR by IHC or bothReflexBRAFV600 testingPerform if MSI-H &/or lacks MMR IHC expression (dMMR)ReflexMLH1promoter methylationPerform if MSI-H &/or lacks MLH1 IHC expressionLS positive screenMSI-H, dMMR IHC,BRAFwt,MLH1promoter nonmethylatedGenetics referral required for all LS positive screensEvaluation may include germline MMR gene mutation testing and genetic counseling",
                    "sub_points": [
                      "Universal LS screening recommended in all patients with newly diagnosed CRC",
                      "MSI by PCR, MMR by IHC or both",
                      "ReflexBRAFV600 testingPerform if MSI-H &/or lacks MMR IHC expression (dMMR)ReflexMLH1promoter methylationPerform if MSI-H &/or lacks MLH1 IHC expression",
                      "Perform if MSI-H &/or lacks MMR IHC expression (dMMR)",
                      "ReflexMLH1promoter methylationPerform if MSI-H &/or lacks MLH1 IHC expression",
                      "Perform if MSI-H &/or lacks MLH1 IHC expression",
                      "LS positive screenMSI-H, dMMR IHC,BRAFwt,MLH1promoter nonmethylatedGenetics referral required for all LS positive screensEvaluation may include germline MMR gene mutation testing and genetic counseling",
                      "MSI-H, dMMR IHC,BRAFwt,MLH1promoter nonmethylated",
                      "Genetics referral required for all LS positive screensEvaluation may include germline MMR gene mutation testing and genetic counseling",
                      "Evaluation may include germline MMR gene mutation testing and genetic counseling"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Colorectal adenocarcinoma (CRC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Malignant epithelial neoplasm of colon"
                  },
                  {
                    "text": "Colorectal precancerous lesions are epithelial-derived dysplastic epithelial changes that typically present as adenomatous polyps or flat dysplastic lesionsSome precancerous lesions progress to CRC",
                    "sub_points": [
                      "Some precancerous lesions progress to CRC"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Underlying Cause": [
                  {
                    "text": "CRC arises from sequential genetic alterations through various carcinogenic pathways"
                  },
                  {
                    "text": "Risk involves environmental and genetic factors"
                  }
                ],
                "Environmental Factors": [
                  {
                    "text": "Western diet with high calorie and animal fat content"
                  },
                  {
                    "text": "Alcohol, smoking, sedentary lifestyle"
                  },
                  {
                    "text": "Chronic inflammation: Increased incidence in inflammatory bowel disease"
                  },
                  {
                    "text": "Protective factors: Diet high in vegetables, fiber, whole grains, exercise, and prolonged NSAID use"
                  }
                ],
                "Carcinogenic Pathways of CRC and Precancerous Lesions": [
                  {
                    "text": "Chromosomal instability (CIN) pathwaySporadic and hereditaryAdenoma-carcinoma sequenceAccounts for ~ 60-70% of sporadic CRCInactivation ofAPCis initial mutation, present in 80% of adenomas and CRCActivating mutations inKRAS(early event)18q loss of heterozygosity: Loss ofDCC/SMAD4Inactivation ofTP53tumor suppressor geneSequential accumulation of mutations inKRAS,DCC,SMAD4, andTP53drives progression to CRC",
                    "sub_points": [
                      "Sporadic and hereditary",
                      "Adenoma-carcinoma sequenceAccounts for ~ 60-70% of sporadic CRCInactivation ofAPCis initial mutation, present in 80% of adenomas and CRCActivating mutations inKRAS(early event)18q loss of heterozygosity: Loss ofDCC/SMAD4Inactivation ofTP53tumor suppressor gene",
                      "Accounts for ~ 60-70% of sporadic CRC",
                      "Inactivation ofAPCis initial mutation, present in 80% of adenomas and CRC",
                      "Activating mutations inKRAS(early event)",
                      "18q loss of heterozygosity: Loss ofDCC/SMAD4",
                      "Inactivation ofTP53tumor suppressor gene",
                      "Sequential accumulation of mutations inKRAS,DCC,SMAD4, andTP53drives progression to CRC"
                    ]
                  },
                  {
                    "text": "Serrated adenoma/CpG island methylator phenotype (CIMP) pathwaySporadic and hereditaryMSI-high (MSI-H) or MSI-low (MSI-L)MSI-H tumors account for ~ 15% of all sporadic CRCBRAFV600E mutationCIMP-high (CIMP-H)Hypermethylation of promoterMLH1Loss of MLH1 leads to defective mismatch repairSessile serrated adenomas are precursors that progress to CRC",
                    "sub_points": [
                      "Sporadic and hereditary",
                      "MSI-high (MSI-H) or MSI-low (MSI-L)MSI-H tumors account for ~ 15% of all sporadic CRC",
                      "MSI-H tumors account for ~ 15% of all sporadic CRC",
                      "BRAFV600E mutation",
                      "CIMP-high (CIMP-H)Hypermethylation of promoterMLH1Loss of MLH1 leads to defective mismatch repair",
                      "Hypermethylation of promoterMLH1Loss of MLH1 leads to defective mismatch repair",
                      "Loss of MLH1 leads to defective mismatch repair",
                      "Sessile serrated adenomas are precursors that progress to CRC"
                    ]
                  },
                  {
                    "text": "Mismatch repair (MMR) pathwayHereditary Lynch syndrome (LS) tumors, 2-4% of all CRCMSI-HBRAFwildtype (wt) in almost all casesMLH1promoter methylation test more sensitive to separate hereditary from sporadic MSI-H casesMLH1promoter hypermethylated in sporadic cases and only rarely in LSMMR mutation results in defective DNA MMR proteinsResulting accumulation of other mutations drives progression to CRC",
                    "sub_points": [
                      "Hereditary Lynch syndrome (LS) tumors, 2-4% of all CRC",
                      "MSI-H",
                      "BRAFwildtype (wt) in almost all cases",
                      "MLH1promoter methylation test more sensitive to separate hereditary from sporadic MSI-H casesMLH1promoter hypermethylated in sporadic cases and only rarely in LS",
                      "MLH1promoter hypermethylated in sporadic cases and only rarely in LS",
                      "MMR mutation results in defective DNA MMR proteinsResulting accumulation of other mutations drives progression to CRC",
                      "Resulting accumulation of other mutations drives progression to CRC"
                    ]
                  },
                  {
                    "text": "Other pathway classification systemsCancer Genome Atlas Project3 groups: Chromosomal instability, hypermutated, and ultramutatedConsensus Molecular Subtypes Consortium5 groups: MSI, canonical, metabolic, mesenchymal, and mixed features",
                    "sub_points": [
                      "Cancer Genome Atlas Project3 groups: Chromosomal instability, hypermutated, and ultramutated",
                      "3 groups: Chromosomal instability, hypermutated, and ultramutated",
                      "Consensus Molecular Subtypes Consortium5 groups: MSI, canonical, metabolic, mesenchymal, and mixed features",
                      "5 groups: MSI, canonical, metabolic, mesenchymal, and mixed features"
                    ]
                  }
                ],
                "Precancerous Lesions": [
                  {
                    "text": "Tubular/tubulovillous adenoma (TA/TVA)Precursor polyps to conventional CRCInactivatingAPCmutationLeads to development of dysplasia in aberrant crypt foci and early adenomasSubsequent CIN pathway mutations drives progression to CRC",
                    "sub_points": [
                      "Precursor polyps to conventional CRC",
                      "InactivatingAPCmutationLeads to development of dysplasia in aberrant crypt foci and early adenomas",
                      "Leads to development of dysplasia in aberrant crypt foci and early adenomas",
                      "Subsequent CIN pathway mutations drives progression to CRC"
                    ]
                  },
                  {
                    "text": "Sessile serrated lesion (SSL)Precursor polyp to CIMP-H, MSI-H CRCInitiatingBRAFmutationProgressive CpG island hypermethylationMLH1promoter hypermethylation commonly seen with progression to cytologic dysplasia",
                    "sub_points": [
                      "Precursor polyp to CIMP-H, MSI-H CRC",
                      "InitiatingBRAFmutation",
                      "Progressive CpG island hypermethylation",
                      "MLH1promoter hypermethylation commonly seen with progression to cytologic dysplasia"
                    ]
                  },
                  {
                    "text": "Traditional serrated adenomaPoorly characterized compared to TA and SSLMolecularly diverseMay harborKRASorBRAFmutations as early eventsMay show low or high CIMP, or non-CIMPAssociated withMGMTpromoter methylationTypically do not showMLH1promoter hypermethylation or loss of MLH1 protein expression, and not associated with MSI-H CRCWNT pathway activating mutations (CTNNB1,APC,RNF43) can occur but appear to be late eventsMay give rise toBRAF- orKRAS-mutated MSS CRC",
                    "sub_points": [
                      "Poorly characterized compared to TA and SSL",
                      "Molecularly diverseMay harborKRASorBRAFmutations as early eventsMay show low or high CIMP, or non-CIMP",
                      "May harborKRASorBRAFmutations as early events",
                      "May show low or high CIMP, or non-CIMP",
                      "Associated withMGMTpromoter methylation",
                      "Typically do not showMLH1promoter hypermethylation or loss of MLH1 protein expression, and not associated with MSI-H CRC",
                      "WNT pathway activating mutations (CTNNB1,APC,RNF43) can occur but appear to be late events",
                      "May give rise toBRAF- orKRAS-mutated MSS CRC"
                    ]
                  },
                  {
                    "text": "Microvesicular hyperplastic polypBRAFmutations present in ~ 70%~ 47-73% are CIMP positiveSpeculation that these may be precursors to SSL",
                    "sub_points": [
                      "BRAFmutations present in ~ 70%",
                      "~ 47-73% are CIMP positive",
                      "Speculation that these may be precursors to SSL"
                    ]
                  },
                  {
                    "text": "Goblet cell-rich hyperplastic polypKRASmutations in ~ 50%",
                    "sub_points": [
                      "KRASmutations in ~ 50%"
                    ]
                  }
                ],
                "Genetic Factors and Hereditary CRC": [
                  {
                    "text": "Lynch syndromeAutosomal dominant (AD) with germline mutation in MMR genes:MSH2(50%),MLH1(30-40%),MSH6(~ 7-10%),PMS2(< 5%)2nd-hit somatic mutation leads to MMR deficiency (dMMR)70% lifetime risk of developing CRCMost common form of hereditary CRCAssociated with early-onset CRC",
                    "sub_points": [
                      "Autosomal dominant (AD) with germline mutation in MMR genes:MSH2(50%),MLH1(30-40%),MSH6(~ 7-10%),PMS2(< 5%)2nd-hit somatic mutation leads to MMR deficiency (dMMR)",
                      "2nd-hit somatic mutation leads to MMR deficiency (dMMR)",
                      "70% lifetime risk of developing CRC",
                      "Most common form of hereditary CRC",
                      "Associated with early-onset CRC"
                    ]
                  },
                  {
                    "text": "Serrated polyposis syndromeGenetic alterations similar to serrated pathway CRC~ 25-40% risk of of developing CRC",
                    "sub_points": [
                      "Genetic alterations similar to serrated pathway CRC",
                      "~ 25-40% risk of of developing CRC"
                    ]
                  },
                  {
                    "text": "Familial adenomatous polyposis (FAP)GermlineAPCmutation with 2nd-hit somatic mutation~ 90-100% risk of developing CRCOften thousands of colonic tubular adenomasAttenuated FAP has < 100 adenomas with ~ 70% risk for development of CRC",
                    "sub_points": [
                      "GermlineAPCmutation with 2nd-hit somatic mutation",
                      "~ 90-100% risk of developing CRC",
                      "Often thousands of colonic tubular adenomas",
                      "Attenuated FAP has < 100 adenomas with ~ 70% risk for development of CRC"
                    ]
                  },
                  {
                    "text": "MUTYH-associated polyposisMUTYHmutations result in heritable predisposition to colon and gastric cancerBiallelic mutations inMUTYHwith 35-53% risk of CRC in adulthood",
                    "sub_points": [
                      "MUTYHmutations result in heritable predisposition to colon and gastric cancer",
                      "Biallelic mutations inMUTYHwith 35-53% risk of CRC in adulthood"
                    ]
                  },
                  {
                    "text": "Juvenile polyposisGermline mutations inSMAD4orBMPR1Awith autosomal dominant patternPolyps appear benign, but patient has ~ 40% risk of developing CRC",
                    "sub_points": [
                      "Germline mutations inSMAD4orBMPR1Awith autosomal dominant pattern",
                      "Polyps appear benign, but patient has ~ 40% risk of developing CRC"
                    ]
                  },
                  {
                    "text": "Peutz-JegherssyndromeAD disorder with germline mutations inSTK11~ 40% risk of developing CRC",
                    "sub_points": [
                      "AD disorder with germline mutations inSTK11",
                      "~ 40% risk of developing CRC"
                    ]
                  },
                  {
                    "text": "PTENhamartoma tumor syndromesGermline mutations inPTENassociated with variety of syndromes, including Cowden, Bannayan-Riley-Ruvalcaba, and others~ 13-16% risk of developing CRC",
                    "sub_points": [
                      "Germline mutations inPTENassociated with variety of syndromes, including Cowden, Bannayan-Riley-Ruvalcaba, and others",
                      "~ 13-16% risk of developing CRC"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 1.9 million new cases per year worldwide and 150,000 new cases per year in United States"
                  },
                  {
                    "text": "3rd most common cancer worldwide"
                  }
                ],
                "Age": [
                  {
                    "text": "Median at diagnosis was 72 years in 2000, now is 66 years"
                  },
                  {
                    "text": "Early-onset cases (< 50 year) have steadily increased in past few decades and are projected to continue increasing"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Often asymptomatic, identified on screening"
                  },
                  {
                    "text": "Change in bowel habits"
                  },
                  {
                    "text": "Iron-deficiency anemia (right sided tumors)"
                  },
                  {
                    "text": "Hematochezia (left-sided tumors)"
                  },
                  {
                    "text": "Tenesmus (rectal tumors)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Surgical resection for stage I tumors"
                  },
                  {
                    "text": "Adjuvant chemotherapy after surgical resection for stage III CRC and high-risk stage II tumors"
                  },
                  {
                    "text": "Patients with stage II MSI-H CRC may not benefit from adjuvant 5-fluorouracil (5-FU)-based chemotherapy"
                  },
                  {
                    "text": "Targeted EGFR antibodies in advanced-stage disease with wildtypeKRAS,BRAF, andNRAS"
                  },
                  {
                    "text": "Immune checkpoint inhibitors are FDA approved for advanced dMMR/MSI-H tumors"
                  },
                  {
                    "text": "TRK inhibitors are a treatment option forNTRKfusion positive metastatic CRC"
                  },
                  {
                    "text": "Selpercatinib RET inhibitor is treatment option forRETfusion positive metastatic CRC"
                  },
                  {
                    "text": "Tucatinib and trastuzumab combination is now FDA approved forERBB2(HER2)-amplified CRC for some patients with advanced disease"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Association of molecular subtypes and patient survivalMSI-H CRC shows most favorable outcome, especially with wildtypeBRAFMSS,BRAF-mutated CRC shows worst prognosis",
                    "sub_points": [
                      "MSI-H CRC shows most favorable outcome, especially with wildtypeBRAF",
                      "MSS,BRAF-mutated CRC shows worst prognosis"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Exophytic, fungating mass"
                  },
                  {
                    "text": "Annular mass with circumferential mural growth (apple core lesion)"
                  },
                  {
                    "text": "MSI-H and MSS/CIMP-H tumors are frequently located in right colon"
                  },
                  {
                    "text": "MSS/CIMP-negative tumors are frequently located in left colon"
                  }
                ]
              },
              "MOLECULAR": {
                "Gene Mutations": [
                  {
                    "text": "KRASandNRASRASmutation testing mandatory for all patients who are candidates for anti-EGFR therapyActivating mutations in 40%-50% (KRAS) and 1-6% (NRAS) of CRC respectivelyPresence of mutation precludes treatment with anti-EGFR monoclonal antibodies (cetuximab and panitumumab)Significantly reduced response to EGFR blockade",
                    "sub_points": [
                      "RASmutation testing mandatory for all patients who are candidates for anti-EGFR therapy",
                      "Activating mutations in 40%-50% (KRAS) and 1-6% (NRAS) of CRC respectivelyPresence of mutation precludes treatment with anti-EGFR monoclonal antibodies (cetuximab and panitumumab)Significantly reduced response to EGFR blockade",
                      "Presence of mutation precludes treatment with anti-EGFR monoclonal antibodies (cetuximab and panitumumab)Significantly reduced response to EGFR blockade",
                      "Significantly reduced response to EGFR blockade"
                    ]
                  },
                  {
                    "text": "BRAFV600EMutually exclusive ofKRASmutation in most casesAssociated with reduced response to anti-EGFR targeted therapy in advanced CRC unless given with BRAF inhibitorInsufficient evidence to recommendBRAFmutational status as predictive test for EGFR blockadeIndicates poor prognosis in MSS or MSI-L CRCBRAFmutation analysis should be performed in select patients for prognostic stratification",
                    "sub_points": [
                      "Mutually exclusive ofKRASmutation in most cases",
                      "Associated with reduced response to anti-EGFR targeted therapy in advanced CRC unless given with BRAF inhibitorInsufficient evidence to recommendBRAFmutational status as predictive test for EGFR blockade",
                      "Insufficient evidence to recommendBRAFmutational status as predictive test for EGFR blockade",
                      "Indicates poor prognosis in MSS or MSI-L CRCBRAFmutation analysis should be performed in select patients for prognostic stratification",
                      "BRAFmutation analysis should be performed in select patients for prognostic stratification"
                    ]
                  },
                  {
                    "text": "ERBB2(HER2) amplificationDetected in ~ 3% of CRCAppears to exclusively occur in MSS,RAS/BRAFwt CRCAppears to correlate with resistance to EGFR blockade, but currently not recommended for determining patient eligibility for EGFR blockadeCombination of tucatinib and trastuzumab is now FDA-approved for some patients withERBB2(HER2)-amplified tumors and advanced disease",
                    "sub_points": [
                      "Detected in ~ 3% of CRC",
                      "Appears to exclusively occur in MSS,RAS/BRAFwt CRC",
                      "Appears to correlate with resistance to EGFR blockade, but currently not recommended for determining patient eligibility for EGFR blockade",
                      "Combination of tucatinib and trastuzumab is now FDA-approved for some patients withERBB2(HER2)-amplified tumors and advanced disease"
                    ]
                  },
                  {
                    "text": "PIK3CAActivating mutations in 10-30% of all CRCUnclear whether mutations are of prognostic significance, though poor survival inconsistently reported in resectable stage I-III CRCClinical effect ofPIK3CAmutations on response to anti-EGFR therapy has shown conflicting resultsInsufficient evidence to recommendPIK3CAmutational status for therapy selections outside of clinical trialRetrospective studies might suggest improve survival with postoperative aspirin use in patients with CRC harboringPIK3CAmutation",
                    "sub_points": [
                      "Activating mutations in 10-30% of all CRC",
                      "Unclear whether mutations are of prognostic significance, though poor survival inconsistently reported in resectable stage I-III CRC",
                      "Clinical effect ofPIK3CAmutations on response to anti-EGFR therapy has shown conflicting resultsInsufficient evidence to recommendPIK3CAmutational status for therapy selections outside of clinical trial",
                      "Insufficient evidence to recommendPIK3CAmutational status for therapy selections outside of clinical trial",
                      "Retrospective studies might suggest improve survival with postoperative aspirin use in patients with CRC harboringPIK3CAmutation"
                    ]
                  },
                  {
                    "text": "MMR genesMLH1,MSH2,MSH6, andPMS2Code for mismatch repair proteins responsible for DNA repairInactivated through germline mutations or methylationEPCAMDeletions of 3' end ofEPCAMin 1-3% of LSMutations result in epigenetic silencing ofMSH2and subsequent loss of MSH2/MSH6 protein expressionGermlineMSH2mutation analysis usually includes testing forEPCAMdeletions",
                    "sub_points": [
                      "MLH1,MSH2,MSH6, andPMS2Code for mismatch repair proteins responsible for DNA repair",
                      "Code for mismatch repair proteins responsible for DNA repair",
                      "Inactivated through germline mutations or methylation",
                      "EPCAMDeletions of 3' end ofEPCAMin 1-3% of LSMutations result in epigenetic silencing ofMSH2and subsequent loss of MSH2/MSH6 protein expressionGermlineMSH2mutation analysis usually includes testing forEPCAMdeletions",
                      "Deletions of 3' end ofEPCAMin 1-3% of LS",
                      "Mutations result in epigenetic silencing ofMSH2and subsequent loss of MSH2/MSH6 protein expression",
                      "GermlineMSH2mutation analysis usually includes testing forEPCAMdeletions"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Conventional CRCMost are well- to moderately differentiated~ 15% are poorly differentiated with solid growth",
                    "sub_points": [
                      "Most are well- to moderately differentiated",
                      "~ 15% are poorly differentiated with solid growth"
                    ]
                  },
                  {
                    "text": "Microscopic features characteristic of MSI-H CRCMucinous, medullary, poorly differentiated, and signet ring cell phenotypesAbundant tumor-infiltrating lymphocytesCrohn-like peritumoral lymphoid aggregates",
                    "sub_points": [
                      "Mucinous, medullary, poorly differentiated, and signet ring cell phenotypes",
                      "Abundant tumor-infiltrating lymphocytes",
                      "Crohn-like peritumoral lymphoid aggregates"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Gene mutation testingKRAS,NRAS,BRAFmutation by single gene or NGS panelNGS panel may detect other clinically actionable mutationsERBB2(HER2) amplification by IHC, FISH, or NGS inRAS/BRAFwildtype cases",
                    "sub_points": [
                      "KRAS,NRAS,BRAFmutation by single gene or NGS panel",
                      "NGS panel may detect other clinically actionable mutations",
                      "ERBB2(HER2) amplification by IHC, FISH, or NGS inRAS/BRAFwildtype cases"
                    ]
                  },
                  {
                    "text": "Lynch syndrome screen testingUniversal LS screening is recommended for all patients with newly diagnosed CRCMMR by IHC or MSI by PCR or both for sensitivity near 100%MMR IHC/MSI discordance rate: ~ 2%Discordant show normal MMR IHC/MSI-H, as some dMMR mutations do not result in loss of immunoreactivity or MSI-HMicrosatellite instability (MSI)80-90% sensitivity for identifying LSTest by PCR or NGSMSI-H: Changes in ≥ 40% or ≥ 2 of 5 National Cancer Institute (NCI)-designated or mononucleotide microsatellite markersMicrosatellite stable (MSS): No changes in microsatellite markersMMR IHC85% sensitivity for identifying LSShows MLH1, PMS2, MSH2, and MSH6 protein expression or loss",
                    "sub_points": [
                      "Universal LS screening is recommended for all patients with newly diagnosed CRC",
                      "MMR by IHC or MSI by PCR or both for sensitivity near 100%MMR IHC/MSI discordance rate: ~ 2%Discordant show normal MMR IHC/MSI-H, as some dMMR mutations do not result in loss of immunoreactivity or MSI-H",
                      "MMR IHC/MSI discordance rate: ~ 2%Discordant show normal MMR IHC/MSI-H, as some dMMR mutations do not result in loss of immunoreactivity or MSI-H",
                      "Discordant show normal MMR IHC/MSI-H, as some dMMR mutations do not result in loss of immunoreactivity or MSI-H",
                      "Microsatellite instability (MSI)80-90% sensitivity for identifying LSTest by PCR or NGSMSI-H: Changes in ≥ 40% or ≥ 2 of 5 National Cancer Institute (NCI)-designated or mononucleotide microsatellite markersMicrosatellite stable (MSS): No changes in microsatellite markers",
                      "80-90% sensitivity for identifying LS",
                      "Test by PCR or NGS",
                      "MSI-H: Changes in ≥ 40% or ≥ 2 of 5 National Cancer Institute (NCI)-designated or mononucleotide microsatellite markers",
                      "Microsatellite stable (MSS): No changes in microsatellite markers",
                      "MMR IHC85% sensitivity for identifying LSShows MLH1, PMS2, MSH2, and MSH6 protein expression or loss",
                      "85% sensitivity for identifying LS",
                      "Shows MLH1, PMS2, MSH2, and MSH6 protein expression or loss"
                    ]
                  },
                  {
                    "text": "MMRIHC interpretationMMR proficient (pMMR) tumorIntact nuclear expression of MLH1, PMS2, MSH2, and MSH6 proteinAssociated with sporadic tumorsUninterpretable IHCNegative staining with negative internal controlRequires repeat IHCMMR-deficient (dMMR) tumorNegative staining of tumor with positive internal control (nonneoplastic mononuclear and stromal cells)Lack of MSH2/MSH6, PMS2 or MSH6 expressionMutatedMSH2leads to loss of MSH2 and MSH6 expression but not vice versa for mutatedMSH6MutatedPMS2leads to loss of PMS2 expressionMutatedMSH6leads to loss of MSH6 expressionSeen in LS-associated CRCReflex toBRAFV600E and MSI testingLack of MLH1/PMS2 expressionMutated or methylatedMLH1leads to loss of MLH1 and PMS2 expression, but not vice versa for mutatedPMS2Seen in sporadic or LS-associated CRCReflex toMLH1promoter methylation testing &/orBRAFV600E mutation testingCaveats~ 30-60% of patients with loss of MSH2 expression may have biallelic somatic mutations (not LS)False-positive loss of MSH6 expression can occur in neoadjuvant-treated CRCRepeat IHC on pretreatment diagnostic biopsyMSI-H may not occur in CRC with germlineMSH6mutationReflex BRAF V600E testingPerform if MSI-H &/or lacks MMR IHC expression (dMMR)BRAFmutation is associated with sporadic CRCBRAFwildtype is associated with LSReflex MLH1 promoter methylation testingPerform if MSI-H &/or lacks MLH1 IHC expressionPresence ofMLH1promoter hypermethylation indicatesMLH1silencingTypically seen in MSI-H sporadic CRC and only rarely in LSLack of significant promoter methylation suggests germline mutations in the MMR geneMLH1Typically seen in LSLynch syndrome positive screenMSI-H, dMMR IHC,MLH1promoter nonmethylated",
                    "sub_points": [
                      "MMR proficient (pMMR) tumorIntact nuclear expression of MLH1, PMS2, MSH2, and MSH6 proteinAssociated with sporadic tumors",
                      "Intact nuclear expression of MLH1, PMS2, MSH2, and MSH6 protein",
                      "Associated with sporadic tumors",
                      "Uninterpretable IHCNegative staining with negative internal controlRequires repeat IHC",
                      "Negative staining with negative internal control",
                      "Requires repeat IHC",
                      "MMR-deficient (dMMR) tumorNegative staining of tumor with positive internal control (nonneoplastic mononuclear and stromal cells)Lack of MSH2/MSH6, PMS2 or MSH6 expressionMutatedMSH2leads to loss of MSH2 and MSH6 expression but not vice versa for mutatedMSH6MutatedPMS2leads to loss of PMS2 expressionMutatedMSH6leads to loss of MSH6 expressionSeen in LS-associated CRCReflex toBRAFV600E and MSI testingLack of MLH1/PMS2 expressionMutated or methylatedMLH1leads to loss of MLH1 and PMS2 expression, but not vice versa for mutatedPMS2Seen in sporadic or LS-associated CRCReflex toMLH1promoter methylation testing &/orBRAFV600E mutation testing",
                      "Negative staining of tumor with positive internal control (nonneoplastic mononuclear and stromal cells)",
                      "Lack of MSH2/MSH6, PMS2 or MSH6 expression",
                      "MutatedMSH2leads to loss of MSH2 and MSH6 expression but not vice versa for mutatedMSH6",
                      "MutatedPMS2leads to loss of PMS2 expression",
                      "MutatedMSH6leads to loss of MSH6 expression",
                      "Seen in LS-associated CRC",
                      "Reflex toBRAFV600E and MSI testing",
                      "Lack of MLH1/PMS2 expressionMutated or methylatedMLH1leads to loss of MLH1 and PMS2 expression, but not vice versa for mutatedPMS2Seen in sporadic or LS-associated CRCReflex toMLH1promoter methylation testing &/orBRAFV600E mutation testing",
                      "Mutated or methylatedMLH1leads to loss of MLH1 and PMS2 expression, but not vice versa for mutatedPMS2",
                      "Seen in sporadic or LS-associated CRC",
                      "Reflex toMLH1promoter methylation testing &/orBRAFV600E mutation testing",
                      "Caveats~ 30-60% of patients with loss of MSH2 expression may have biallelic somatic mutations (not LS)False-positive loss of MSH6 expression can occur in neoadjuvant-treated CRCRepeat IHC on pretreatment diagnostic biopsyMSI-H may not occur in CRC with germlineMSH6mutation",
                      "~ 30-60% of patients with loss of MSH2 expression may have biallelic somatic mutations (not LS)",
                      "False-positive loss of MSH6 expression can occur in neoadjuvant-treated CRCRepeat IHC on pretreatment diagnostic biopsy",
                      "Repeat IHC on pretreatment diagnostic biopsy",
                      "MSI-H may not occur in CRC with germlineMSH6mutation",
                      "Reflex BRAF V600E testingPerform if MSI-H &/or lacks MMR IHC expression (dMMR)BRAFmutation is associated with sporadic CRCBRAFwildtype is associated with LS",
                      "Perform if MSI-H &/or lacks MMR IHC expression (dMMR)BRAFmutation is associated with sporadic CRCBRAFwildtype is associated with LS",
                      "BRAFmutation is associated with sporadic CRC",
                      "BRAFwildtype is associated with LS",
                      "Reflex MLH1 promoter methylation testingPerform if MSI-H &/or lacks MLH1 IHC expressionPresence ofMLH1promoter hypermethylation indicatesMLH1silencingTypically seen in MSI-H sporadic CRC and only rarely in LSLack of significant promoter methylation suggests germline mutations in the MMR geneMLH1Typically seen in LS",
                      "Perform if MSI-H &/or lacks MLH1 IHC expression",
                      "Presence ofMLH1promoter hypermethylation indicatesMLH1silencingTypically seen in MSI-H sporadic CRC and only rarely in LS",
                      "Typically seen in MSI-H sporadic CRC and only rarely in LS",
                      "Lack of significant promoter methylation suggests germline mutations in the MMR geneMLH1Typically seen in LS",
                      "Typically seen in LS",
                      "Lynch syndrome positive screenMSI-H, dMMR IHC,MLH1promoter nonmethylated",
                      "MSI-H, dMMR IHC,MLH1promoter nonmethylated"
                    ]
                  },
                  {
                    "text": "Germline testingGenetics referral required for all LS-positive screens for further evaluationEvaluation may include germline MMR gene mutation testing and genetic counseling if indicated",
                    "sub_points": [
                      "Genetics referral required for all LS-positive screens for further evaluationEvaluation may include germline MMR gene mutation testing and genetic counseling if indicated",
                      "Evaluation may include germline MMR gene mutation testing and genetic counseling if indicated"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Metastatic Carcinomas": [
                  {
                    "text": "Lack or only weakly express CRC markers, such as CK20, CDX2, and SATB2"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Lynch Syndrome Screening Recommendations": [
                  {
                    "text": "Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommends LS screening for all patients with newly diagnosed CRCRevised Bethesda criteria may miss up to 25% of LS patientsMSI PCR has 80-90% sensitivity for identifying LSMMR IHC has 85% sensitivity for identifying LSNear 100% sensitivity for combined MSI PCR and MMR IHC testing",
                    "sub_points": [
                      "Revised Bethesda criteria may miss up to 25% of LS patients",
                      "MSI PCR has 80-90% sensitivity for identifying LS",
                      "MMR IHC has 85% sensitivity for identifying LS",
                      "Near 100% sensitivity for combined MSI PCR and MMR IHC testing"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "KITMutations": {
            "name": "KITMutations",
            "url": "https://app.pathprimer.com/document/b90d0be5-9e5c-4168-8b6e-bc069b45a529/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "KITOfficial name: KIT protooncogene receptor tyrosine kinasePrevious name: Feline sarcoma viral oncogene homolog v-kitHGNC ID: 6342Gene locus: 4q12Genomic positionCh4: 54,657,957-54,740,715 (GRCh38.p14)Number of exons: 21RefSeq: NG_007456.1Aliases: PBT, SCFR, C-kit, CD117, and MASTC",
                    "sub_points": [
                      "Official name: KIT protooncogene receptor tyrosine kinasePrevious name: Feline sarcoma viral oncogene homolog v-kit",
                      "Previous name: Feline sarcoma viral oncogene homolog v-kit",
                      "HGNC ID: 6342",
                      "Gene locus: 4q12",
                      "Genomic positionCh4: 54,657,957-54,740,715 (GRCh38.p14)Number of exons: 21",
                      "Ch4: 54,657,957-54,740,715 (GRCh38.p14)",
                      "Number of exons: 21",
                      "RefSeq: NG_007456.1",
                      "Aliases: PBT, SCFR, C-kit, CD117, and MASTC"
                    ]
                  },
                  {
                    "text": "KITLGOfficial name: KIT ligandHGNC ID: 6343Gene locus: 12q21.32Genomic positionCh12: 88,492,793-88,580,471Number of exons: 10RefSeq: NG_012098.2Aliases: MGF (mast cell growth factor), SCF (stem cell factor), SF, SLF, Kitl, KL-1, DFNA69, DCUA, SHEP7, FPHH, and FPH2",
                    "sub_points": [
                      "Official name: KIT ligand",
                      "HGNC ID: 6343",
                      "Gene locus: 12q21.32",
                      "Genomic positionCh12: 88,492,793-88,580,471Number of exons: 10",
                      "Ch12: 88,492,793-88,580,471",
                      "Number of exons: 10",
                      "RefSeq: NG_012098.2",
                      "Aliases: MGF (mast cell growth factor), SCF (stem cell factor), SF, SLF, Kitl, KL-1, DFNA69, DCUA, SHEP7, FPHH, and FPH2"
                    ]
                  }
                ],
                "KITFunction": [
                  {
                    "text": "Encodes type III receptor tyrosine kinaseFormerly known as PDGF (platelet-derived growth factor) receptor familyOther proteins in this category include PDGFRA, PDGFRB, CSF1R, and FLT3145 kDa protein (976 amino acids)Monomer in absence of bound ligandHomodimer in presence of ligand with further oligomerization forming heterotetramerExtracellular portion contains 5 immunoglobulin-like domains (positions 26-524)Hydrophobic transmembrane domain with 21 amino acids (positions 525-545)Intracellular portion with 2 tyrosine kinase domains separated by kinase insert region (positions 546-976)",
                    "sub_points": [
                      "Formerly known as PDGF (platelet-derived growth factor) receptor familyOther proteins in this category include PDGFRA, PDGFRB, CSF1R, and FLT3",
                      "Other proteins in this category include PDGFRA, PDGFRB, CSF1R, and FLT3",
                      "145 kDa protein (976 amino acids)Monomer in absence of bound ligandHomodimer in presence of ligand with further oligomerization forming heterotetramerExtracellular portion contains 5 immunoglobulin-like domains (positions 26-524)Hydrophobic transmembrane domain with 21 amino acids (positions 525-545)Intracellular portion with 2 tyrosine kinase domains separated by kinase insert region (positions 546-976)",
                      "Monomer in absence of bound ligand",
                      "Homodimer in presence of ligand with further oligomerization forming heterotetramer",
                      "Extracellular portion contains 5 immunoglobulin-like domains (positions 26-524)",
                      "Hydrophobic transmembrane domain with 21 amino acids (positions 525-545)",
                      "Intracellular portion with 2 tyrosine kinase domains separated by kinase insert region (positions 546-976)"
                    ]
                  },
                  {
                    "text": "KIT protein normal functionExpressed in hematopoietic stem cellsExpression lost with cell differentiationLinked to proliferation, survival, and migration of melanocytes from neural crest during embryogenesisNecessary for successful gametogenesis through PIK3/AKT in mTOR pathwayImportant for development of interstitial cells of Cajal in gastrointestinal tractAssociated with migration of neural stem cells to sites of injury in brainAssociated with spatial learning function in hippocampusInvolved in maintenance of vasculature and regulatory functions in angiogenesisPossible role in maintaining integrity of lung tissue",
                    "sub_points": [
                      "Expressed in hematopoietic stem cellsExpression lost with cell differentiation",
                      "Expression lost with cell differentiation",
                      "Linked to proliferation, survival, and migration of melanocytes from neural crest during embryogenesis",
                      "Necessary for successful gametogenesis through PIK3/AKT in mTOR pathway",
                      "Important for development of interstitial cells of Cajal in gastrointestinal tract",
                      "Associated with migration of neural stem cells to sites of injury in brain",
                      "Associated with spatial learning function in hippocampus",
                      "Involved in maintenance of vasculature and regulatory functions in angiogenesis",
                      "Possible role in maintaining integrity of lung tissue"
                    ]
                  },
                  {
                    "text": "Role of KIT in signaling pathwaysEffector ligand is KITLG (KIT ligand)In utero acts in germ cell and neural cell development, hematopoiesis, and cell migrationIn adults, has pleiotropic effects with broad expression across multiple tissue types and continued requirement in hematopoiesisActivation of KIT signaling pathwayResults in phosphorylation of numerous proteins, including PIK3R1, PLCG1, SH2B2, and CBLPromotes phosphorylation of many other protein phosphatases and transcription factorsKITLG binding activates several downstream signaling pathways, includingPI3K/AKT/mTORRAS/RAF/MEK/ERKSTAT3Associated pathways are involved in mediation of progrowth, prosurvival, and migration signaling",
                    "sub_points": [
                      "Effector ligand is KITLG (KIT ligand)In utero acts in germ cell and neural cell development, hematopoiesis, and cell migrationIn adults, has pleiotropic effects with broad expression across multiple tissue types and continued requirement in hematopoiesis",
                      "In utero acts in germ cell and neural cell development, hematopoiesis, and cell migration",
                      "In adults, has pleiotropic effects with broad expression across multiple tissue types and continued requirement in hematopoiesis",
                      "Activation of KIT signaling pathwayResults in phosphorylation of numerous proteins, including PIK3R1, PLCG1, SH2B2, and CBLPromotes phosphorylation of many other protein phosphatases and transcription factors",
                      "Results in phosphorylation of numerous proteins, including PIK3R1, PLCG1, SH2B2, and CBL",
                      "Promotes phosphorylation of many other protein phosphatases and transcription factors",
                      "KITLG binding activates several downstream signaling pathways, includingPI3K/AKT/mTORRAS/RAF/MEK/ERKSTAT3",
                      "PI3K/AKT/mTOR",
                      "RAS/RAF/MEK/ERK",
                      "STAT3",
                      "Associated pathways are involved in mediation of progrowth, prosurvival, and migration signaling"
                    ]
                  }
                ],
                "KITMutations": [
                  {
                    "text": "Variety of mutations are described throughoutKIT"
                  },
                  {
                    "text": "Oncogenic gain-of-function mutationsGenerally disrupt protein autoinhibitory mechanismsCommonly affected regions includeExon 8 (extracellular dimerization motif) and 9-10 (transmembrane region)Regions are involved in dimer interactions and stabilizationExon 11 juxtamembrane domainKey autoregulatory domain that stabilizes inactive protein conformationExons 17-18 kinase domain 2Includes activation loop of kinase domain",
                    "sub_points": [
                      "Generally disrupt protein autoinhibitory mechanisms",
                      "Commonly affected regions includeExon 8 (extracellular dimerization motif) and 9-10 (transmembrane region)Regions are involved in dimer interactions and stabilizationExon 11 juxtamembrane domainKey autoregulatory domain that stabilizes inactive protein conformationExons 17-18 kinase domain 2Includes activation loop of kinase domain",
                      "Exon 8 (extracellular dimerization motif) and 9-10 (transmembrane region)Regions are involved in dimer interactions and stabilization",
                      "Regions are involved in dimer interactions and stabilization",
                      "Exon 11 juxtamembrane domainKey autoregulatory domain that stabilizes inactive protein conformation",
                      "Key autoregulatory domain that stabilizes inactive protein conformation",
                      "Exons 17-18 kinase domain 2Includes activation loop of kinase domain",
                      "Includes activation loop of kinase domain"
                    ]
                  },
                  {
                    "text": "Loss-of-function mutations found in many regions, including exons 2-6, 11, 12-14, and 17-19"
                  }
                ],
                "Diseases Associated WithKITSomatic Mutations": [
                  {
                    "text": "Gastrointestinalstromaltumor (GIST)ActivatingKITmutations in ~ 80% of cases; 5-10% havePDGFRAalterationExon 11 mutations in ~ 70%Exon 9 mutations in ~ 10-15%Less common mutations in exons 10, 13, 14, and 17GIST lackingKITandPDGFRAmutation often has SDH deficiencyPresence and type ofKITandPDGFRAalterations not strongly correlated with prognosis or biologic potential of individual casesTumor mutation status linked to imatinib response ratesExon 11 mutation associated with better response rates and survival (median progression-free and overall) compared to exon 9 mutations or nonmutatedKITExon 9 mutations have lower response rates and progression-free survival than exon 11 mutated cases at 400 mg dailyHigher dosing (e.g., 400 mg 2x daily) in exon 9 mutated cases associated with better progression-free survivalCases with exon 11 deletions benefit from longer duration of therapyExon 11 deletions and exon 9 duplications associated with worse disease-free survivalPrior to targeted kinase inhibitor therapy, metastatic GIST was refractory to existing therapyPatients may acquire imatinib resistance due to 2nd mutation in primary mutant KIT alleleExon 17 mutations may confer resistance to tyrosine kinase inhibitors, including sunitinib",
                    "sub_points": [
                      "ActivatingKITmutations in ~ 80% of cases; 5-10% havePDGFRAalterationExon 11 mutations in ~ 70%Exon 9 mutations in ~ 10-15%Less common mutations in exons 10, 13, 14, and 17GIST lackingKITandPDGFRAmutation often has SDH deficiency",
                      "Exon 11 mutations in ~ 70%",
                      "Exon 9 mutations in ~ 10-15%",
                      "Less common mutations in exons 10, 13, 14, and 17",
                      "GIST lackingKITandPDGFRAmutation often has SDH deficiency",
                      "Presence and type ofKITandPDGFRAalterations not strongly correlated with prognosis or biologic potential of individual cases",
                      "Tumor mutation status linked to imatinib response ratesExon 11 mutation associated with better response rates and survival (median progression-free and overall) compared to exon 9 mutations or nonmutatedKITExon 9 mutations have lower response rates and progression-free survival than exon 11 mutated cases at 400 mg dailyHigher dosing (e.g., 400 mg 2x daily) in exon 9 mutated cases associated with better progression-free survivalCases with exon 11 deletions benefit from longer duration of therapy",
                      "Exon 11 mutation associated with better response rates and survival (median progression-free and overall) compared to exon 9 mutations or nonmutatedKIT",
                      "Exon 9 mutations have lower response rates and progression-free survival than exon 11 mutated cases at 400 mg daily",
                      "Higher dosing (e.g., 400 mg 2x daily) in exon 9 mutated cases associated with better progression-free survival",
                      "Cases with exon 11 deletions benefit from longer duration of therapy",
                      "Exon 11 deletions and exon 9 duplications associated with worse disease-free survival",
                      "Prior to targeted kinase inhibitor therapy, metastatic GIST was refractory to existing therapyPatients may acquire imatinib resistance due to 2nd mutation in primary mutant KIT alleleExon 17 mutations may confer resistance to tyrosine kinase inhibitors, including sunitinib",
                      "Patients may acquire imatinib resistance due to 2nd mutation in primary mutant KIT allele",
                      "Exon 17 mutations may confer resistance to tyrosine kinase inhibitors, including sunitinib"
                    ]
                  },
                  {
                    "text": "MelanomaKITactivating mutations found with variable incidence~ 10-15% in mucosal- and acral-based melanomas~ 2-3% in cases arising in chronic sun-damaged skinTypically absent in uveal melanomas and melanomas arising in non-sun-damaged skinKITmutations mutually exclusive ofBRAF,NRAS, and other driver mutationsMutations typically involve exons 11, 13, and 17Mutations found to cluster in 4 hotspotsL576 and W557-V560 of exon 11K642 of exon 13D816-A829 of exon 17Mutations generally confer imatinib sensitivityExon 17 mutations (e.g., D816V and A829P) are associated with resistance to imatinibMinimal or no sensitivity with KIT amplification",
                    "sub_points": [
                      "KITactivating mutations found with variable incidence~ 10-15% in mucosal- and acral-based melanomas~ 2-3% in cases arising in chronic sun-damaged skinTypically absent in uveal melanomas and melanomas arising in non-sun-damaged skin",
                      "~ 10-15% in mucosal- and acral-based melanomas",
                      "~ 2-3% in cases arising in chronic sun-damaged skin",
                      "Typically absent in uveal melanomas and melanomas arising in non-sun-damaged skin",
                      "KITmutations mutually exclusive ofBRAF,NRAS, and other driver mutations",
                      "Mutations typically involve exons 11, 13, and 17",
                      "Mutations found to cluster in 4 hotspotsL576 and W557-V560 of exon 11K642 of exon 13D816-A829 of exon 17",
                      "L576 and W557-V560 of exon 11",
                      "K642 of exon 13",
                      "D816-A829 of exon 17",
                      "Mutations generally confer imatinib sensitivityExon 17 mutations (e.g., D816V and A829P) are associated with resistance to imatinibMinimal or no sensitivity with KIT amplification",
                      "Exon 17 mutations (e.g., D816V and A829P) are associated with resistance to imatinib",
                      "Minimal or no sensitivity with KIT amplification"
                    ]
                  },
                  {
                    "text": "Systemicmastocytosis (SM)High-sensitivity, quantitative, PCR-based assays preferredNext-generation sequencing (NGS) panel testing may not be sufficiently sensitiveNeoplastic cell yield from blood may be lower; marrow preferable for testing, if availableTesting in skin or other solid tissue may be considered if marrow mast-cell burden is lowKITexon 17 D816V occurs in > 90% of SMPresence of D816V mutation is WHO-defined minor criterion for diagnosisMutations possible in non-mast-cell component of SM associated with hematologic malignanciesKITmutations are detected in ~ 75% of cutaneous mastocytosis with only ~ 1/3 harboring D816VLess common (< 5-10%) mutations may include V560G, D815K, D816Y, D816F, D816H, and D820GKITD816 mutations are resistant to imatinib at clinically achievable dosesMay reflect favored active protein conformation, to which imatinib cannot bindNilotinib may be effective in some cases, including those withKITD816V mutationRare cases with juxtamembrane domainKITmutations may respond to imatinibMidostaurin may be effective in mastocytosis harboringKITD816V mutationWell-differentiated SM (rare variant) often lacks D816V and has mutations in exons 10-11Exon 10-11 mutations may increase potential for responsiveness to imatinib",
                    "sub_points": [
                      "High-sensitivity, quantitative, PCR-based assays preferredNext-generation sequencing (NGS) panel testing may not be sufficiently sensitiveNeoplastic cell yield from blood may be lower; marrow preferable for testing, if availableTesting in skin or other solid tissue may be considered if marrow mast-cell burden is low",
                      "Next-generation sequencing (NGS) panel testing may not be sufficiently sensitive",
                      "Neoplastic cell yield from blood may be lower; marrow preferable for testing, if availableTesting in skin or other solid tissue may be considered if marrow mast-cell burden is low",
                      "Testing in skin or other solid tissue may be considered if marrow mast-cell burden is low",
                      "KITexon 17 D816V occurs in > 90% of SMPresence of D816V mutation is WHO-defined minor criterion for diagnosisMutations possible in non-mast-cell component of SM associated with hematologic malignanciesKITmutations are detected in ~ 75% of cutaneous mastocytosis with only ~ 1/3 harboring D816V",
                      "Presence of D816V mutation is WHO-defined minor criterion for diagnosis",
                      "Mutations possible in non-mast-cell component of SM associated with hematologic malignancies",
                      "KITmutations are detected in ~ 75% of cutaneous mastocytosis with only ~ 1/3 harboring D816V",
                      "Less common (< 5-10%) mutations may include V560G, D815K, D816Y, D816F, D816H, and D820G",
                      "KITD816 mutations are resistant to imatinib at clinically achievable dosesMay reflect favored active protein conformation, to which imatinib cannot bindNilotinib may be effective in some cases, including those withKITD816V mutation",
                      "May reflect favored active protein conformation, to which imatinib cannot bind",
                      "Nilotinib may be effective in some cases, including those withKITD816V mutation",
                      "Rare cases with juxtamembrane domainKITmutations may respond to imatinib",
                      "Midostaurin may be effective in mastocytosis harboringKITD816V mutation",
                      "Well-differentiated SM (rare variant) often lacks D816V and has mutations in exons 10-11Exon 10-11 mutations may increase potential for responsiveness to imatinib",
                      "Exon 10-11 mutations may increase potential for responsiveness to imatinib"
                    ]
                  },
                  {
                    "text": "Childhood-onsetmastocytosisSeen with germline or acquired activatingKITmutations~ 40% harbor exon 17 alterations at codon D816Other rare mutations associated with familial mastocytosis includeF522CA533DR634W (reported in 3 siblings with urticaria pigmentosa)",
                    "sub_points": [
                      "Seen with germline or acquired activatingKITmutations",
                      "~ 40% harbor exon 17 alterations at codon D816",
                      "Other rare mutations associated with familial mastocytosis includeF522CA533DR634W (reported in 3 siblings with urticaria pigmentosa)",
                      "F522C",
                      "A533D",
                      "R634W (reported in 3 siblings with urticaria pigmentosa)"
                    ]
                  },
                  {
                    "text": "Core-binding factor (CBF) acute myeloid leukemia (AML)KITmutations found in ~ 20-30% of CBF AMLAML with t(8;21)(q22;q22)AML with inv(16)(p13q22)/t(16;16)(p13;q22)KITmutations in CBF AMLNo impact on complete remission (CR)Higher incidence of relapse and decreased overall survival inKIT-mutated AML with t(8;21)Prognostic associations less clear in AML with inv(16)/t(16;16)Frequently involve exon 17 codon D816 (e.g., D816V, D816Y, D816H, etc.)Other exon 17 codons less frequently involvedInfrequent mutations involveKITexon 8Mutations in exon 8 include inframe indelsRare alterations also reported in exons 10 and 11ConcurrentKIT+FLT3mutations seen in ~ 6% of casesKITmutations are typically absent inKRAS-orNRAS-mutated casesMinimal residual disease (MRD) status stronger prognostic/risk factor for CBF-AML risk (AML clinical practice guidelines, NCCN, 2.2022)",
                    "sub_points": [
                      "KITmutations found in ~ 20-30% of CBF AMLAML with t(8;21)(q22;q22)AML with inv(16)(p13q22)/t(16;16)(p13;q22)",
                      "AML with t(8;21)(q22;q22)",
                      "AML with inv(16)(p13q22)/t(16;16)(p13;q22)",
                      "KITmutations in CBF AMLNo impact on complete remission (CR)Higher incidence of relapse and decreased overall survival inKIT-mutated AML with t(8;21)Prognostic associations less clear in AML with inv(16)/t(16;16)Frequently involve exon 17 codon D816 (e.g., D816V, D816Y, D816H, etc.)Other exon 17 codons less frequently involvedInfrequent mutations involveKITexon 8Mutations in exon 8 include inframe indelsRare alterations also reported in exons 10 and 11ConcurrentKIT+FLT3mutations seen in ~ 6% of casesKITmutations are typically absent inKRAS-orNRAS-mutated casesMinimal residual disease (MRD) status stronger prognostic/risk factor for CBF-AML risk (AML clinical practice guidelines, NCCN, 2.2022)",
                      "No impact on complete remission (CR)",
                      "Higher incidence of relapse and decreased overall survival inKIT-mutated AML with t(8;21)Prognostic associations less clear in AML with inv(16)/t(16;16)",
                      "Prognostic associations less clear in AML with inv(16)/t(16;16)",
                      "Frequently involve exon 17 codon D816 (e.g., D816V, D816Y, D816H, etc.)Other exon 17 codons less frequently involved",
                      "Other exon 17 codons less frequently involved",
                      "Infrequent mutations involveKITexon 8Mutations in exon 8 include inframe indels",
                      "Mutations in exon 8 include inframe indels",
                      "Rare alterations also reported in exons 10 and 11",
                      "ConcurrentKIT+FLT3mutations seen in ~ 6% of cases",
                      "KITmutations are typically absent inKRAS-orNRAS-mutated cases",
                      "Minimal residual disease (MRD) status stronger prognostic/risk factor for CBF-AML risk (AML clinical practice guidelines, NCCN, 2.2022)"
                    ]
                  },
                  {
                    "text": "Germcell tumorsActivatingKITmutations in ~ 8% of germ cell tumorsMutations arise in juxtamembrane domain, tyrosine kinase 2 domain, and tyrosine kinase 1 domainMajority arise in seminomas/dysgerminomasKIT-mutated seminoma has distinct DNA methylation and immune infiltration profilesAlso described in extragonadal sites, such as mediastinumFocal amplifications ofKITalso describedKITmutations do not appear to be increased risk factor for bilateral gonadal involvement",
                    "sub_points": [
                      "ActivatingKITmutations in ~ 8% of germ cell tumorsMutations arise in juxtamembrane domain, tyrosine kinase 2 domain, and tyrosine kinase 1 domainMajority arise in seminomas/dysgerminomasKIT-mutated seminoma has distinct DNA methylation and immune infiltration profilesAlso described in extragonadal sites, such as mediastinum",
                      "Mutations arise in juxtamembrane domain, tyrosine kinase 2 domain, and tyrosine kinase 1 domain",
                      "Majority arise in seminomas/dysgerminomasKIT-mutated seminoma has distinct DNA methylation and immune infiltration profiles",
                      "KIT-mutated seminoma has distinct DNA methylation and immune infiltration profiles",
                      "Also described in extragonadal sites, such as mediastinum",
                      "Focal amplifications ofKITalso described",
                      "KITmutations do not appear to be increased risk factor for bilateral gonadal involvement"
                    ]
                  }
                ],
                "Disease Associated With Germline Mutations": [
                  {
                    "text": "Piebaldism (partial albinism)Loss-of-function mutationsAutosomal dominant inheritance patternDefective melanocytes migration characterized by congenital areas of unpigmented skin and hairOther genes may also modify expressed phenotype",
                    "sub_points": [
                      "Loss-of-function mutations",
                      "Autosomal dominant inheritance pattern",
                      "Defective melanocytes migration characterized by congenital areas of unpigmented skin and hair",
                      "Other genes may also modify expressed phenotype"
                    ]
                  }
                ],
                "Detection Methods": [
                  {
                    "text": "Sequencing modalities commonly usedHigh-sensitivity, allele-specific oligonucleotide (ASO)-PCR, digital droplet PCR, etc.NGSLess sensitive than ASO-PCR but can interrogate multiple exon targets at onceLimitations in identifying larger deletions",
                    "sub_points": [
                      "High-sensitivity, allele-specific oligonucleotide (ASO)-PCR, digital droplet PCR, etc.",
                      "NGSLess sensitive than ASO-PCR but can interrogate multiple exon targets at onceLimitations in identifying larger deletions",
                      "Less sensitive than ASO-PCR but can interrogate multiple exon targets at once",
                      "Limitations in identifying larger deletions"
                    ]
                  },
                  {
                    "text": "Nonsequencing molecular techniques, such as allelic discrimination assays, fragment analysis, or high-resolution melting curve analysis may be usedFurther direct sequencing may be required to identify specific mutationsThese may target only specific variants and may not exclude otherKITalteration",
                    "sub_points": [
                      "Further direct sequencing may be required to identify specific mutations",
                      "These may target only specific variants and may not exclude otherKITalteration"
                    ]
                  },
                  {
                    "text": "No correlation between immunohistochemical expression of CD117 andKITmutations"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Immunoglobulin Heavy (IGH) Chain Gene Rearrangements": {
            "name": "Immunoglobulin Heavy (IGH) Chain Gene Rearrangements",
            "url": "https://app.pathprimer.com/document/a20f0f36-cbce-4ac7-b049-79dc3d7f36d4/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Immunoglobulin heavy locus (IGH)HGNC ID: 5477Chromosomal location: 14q32.33Genomic positionCh14: 105,586,437-106,879,844Includes variable (VH), diversity (DH), joining (JH), and constant (CH) gene segments",
                    "sub_points": [
                      "HGNC ID: 5477",
                      "Chromosomal location: 14q32.33",
                      "Genomic positionCh14: 105,586,437-106,879,844",
                      "Ch14: 105,586,437-106,879,844",
                      "Includes variable (VH), diversity (DH), joining (JH), and constant (CH) gene segments"
                    ]
                  },
                  {
                    "text": "Immunoglobulin kappa (IGK) and lambda (IGL) lociChromosomal location: 2p11.2 and 22q11.22, respectivelyHGNC ID forIGK: 5715HGNC ID forIGL: 5853Include variable (V), joining (J), and constant (C) gene segmentsIGKalso includes immunoglobulin kappa deleting element (IGKDE)",
                    "sub_points": [
                      "Chromosomal location: 2p11.2 and 22q11.22, respectivelyHGNC ID forIGK: 5715HGNC ID forIGL: 5853",
                      "HGNC ID forIGK: 5715",
                      "HGNC ID forIGL: 5853",
                      "Include variable (V), joining (J), and constant (C) gene segments",
                      "IGKalso includes immunoglobulin kappa deleting element (IGKDE)"
                    ]
                  }
                ]
              },
              "Immunoglobulin Structure": {
                "Immunoglobulin Heavy Chain": [
                  {
                    "text": "Y-shaped molecule composed of 2 heavy and 2 light chains connected by disulfide bondsFragment antigen-binding (Fab) portion at tip of Ig molecule contains antigen-binding siteFragment crystallizable (Fc) portion interacts with complement system and Fc receptors on certain cells",
                    "sub_points": [
                      "Fragment antigen-binding (Fab) portion at tip of Ig molecule contains antigen-binding site",
                      "Fragment crystallizable (Fc) portion interacts with complement system and Fc receptors on certain cells"
                    ]
                  },
                  {
                    "text": "5 different types of heavy chains exist: α, δ, ε, γ, and μHeavy chain type corresponds to specific class of Ig: IgA, IgD, IgE, IgG, and IgMConsist of variable and constant regionsVariable region is encoded by VH, DH, and JH gene segmentsIncludes conserved sequences that constitute 4 framework regions (FR1, FR2, FR3, and FR4)Between FRs are 3 hypervariable complementarity determining regions (CDR1, CDR2, and CDR3) involved in antigen bindingCDR3 is most variable regionConstant region is encoded by CH segment",
                    "sub_points": [
                      "Heavy chain type corresponds to specific class of Ig: IgA, IgD, IgE, IgG, and IgM",
                      "Consist of variable and constant regions",
                      "Variable region is encoded by VH, DH, and JH gene segmentsIncludes conserved sequences that constitute 4 framework regions (FR1, FR2, FR3, and FR4)Between FRs are 3 hypervariable complementarity determining regions (CDR1, CDR2, and CDR3) involved in antigen bindingCDR3 is most variable region",
                      "Includes conserved sequences that constitute 4 framework regions (FR1, FR2, FR3, and FR4)",
                      "Between FRs are 3 hypervariable complementarity determining regions (CDR1, CDR2, and CDR3) involved in antigen binding",
                      "CDR3 is most variable region",
                      "Constant region is encoded by CH segment"
                    ]
                  }
                ],
                "Immunoglobulin Light Chains": [
                  {
                    "text": "Light chains include κ and λ"
                  },
                  {
                    "text": "Similar structure to heavy chain exceptVariable region encoded byIGKorIGLV and J gene segmentsNo D segments inIGKandIGLShorter constant region",
                    "sub_points": [
                      "Variable region encoded byIGKorIGLV and J gene segments",
                      "No D segments inIGKandIGL",
                      "Shorter constant region"
                    ]
                  },
                  {
                    "text": "Immunoglobulins are seen in 2 physical formsSoluble form secreted by plasma cells and present in peripheral blood, body fluids, and secretionsMembrane-bound form found on surface of B cells and referred to as surface Ig (sIg)sIg (IgM or IgD) is main component of B-cell receptor (BCR)CD79A/CD79B heterodimer is BCR 2nd component",
                    "sub_points": [
                      "Soluble form secreted by plasma cells and present in peripheral blood, body fluids, and secretions",
                      "Membrane-bound form found on surface of B cells and referred to as surface Ig (sIg)sIg (IgM or IgD) is main component of B-cell receptor (BCR)CD79A/CD79B heterodimer is BCR 2nd component",
                      "sIg (IgM or IgD) is main component of B-cell receptor (BCR)",
                      "CD79A/CD79B heterodimer is BCR 2nd component"
                    ]
                  },
                  {
                    "text": "Steps involved in generation of diversity are similar in both BCR and T-cell receptor (TCR)Somatic hypermutations are unique to Ig genes",
                    "sub_points": [
                      "Somatic hypermutations are unique to Ig genes"
                    ]
                  }
                ]
              },
              "Overview of B-Cell Development": {
                "Antigen-Independent Stages": [
                  {
                    "text": "Occur in bone marrow, progress throughIGHandIGK/IGLrearrangements, and lead to surface BCR assembly"
                  },
                  {
                    "text": "IGH,IGK, andIGLare in germline configuration in hematopoietic stem cells"
                  },
                  {
                    "text": "Early and late progenitor B cells (pro B cells)IGHundergoes DH to JH rearrangement followed by VH to DH-JH rearrangement",
                    "sub_points": [
                      "IGHundergoes DH to JH rearrangement followed by VH to DH-JH rearrangement"
                    ]
                  },
                  {
                    "text": "Large precursor B cells (pre B cells)Express surface pre B-cell receptor composed of μ heavy chain and surrogate light chainSuccessful assembly triggers allelic exclusion to preventIGHrearrangements on 2nd alleleNonproductive rearrangements of bothIGHalleles lead to cell death",
                    "sub_points": [
                      "Express surface pre B-cell receptor composed of μ heavy chain and surrogate light chain",
                      "Successful assembly triggers allelic exclusion to preventIGHrearrangements on 2nd allele",
                      "Nonproductive rearrangements of bothIGHalleles lead to cell death"
                    ]
                  },
                  {
                    "text": "Small precursor B cells (pre B cells)IGKundergoes Vκ to Jκ rearrangementIfIGKrearrangements are unproductive on both alleles, thenIGLundergoes rearrangements",
                    "sub_points": [
                      "IGKundergoes Vκ to Jκ rearrangement",
                      "IfIGKrearrangements are unproductive on both alleles, thenIGLundergoes rearrangements"
                    ]
                  },
                  {
                    "text": "Immature B cellsAssemble BCR composed of μ heavy chain (IgM), and κ or λ light chain on cell surface",
                    "sub_points": [
                      "Assemble BCR composed of μ heavy chain (IgM), and κ or λ light chain on cell surface"
                    ]
                  },
                  {
                    "text": "Mature naive B cellsEnter peripheral circulation and migrate to secondary lymphoid tissuesExpress surface IgM and IgD through alternative splicing",
                    "sub_points": [
                      "Enter peripheral circulation and migrate to secondary lymphoid tissues",
                      "Express surface IgM and IgD through alternative splicing"
                    ]
                  }
                ],
                "Antigen-Dependent Stages": [
                  {
                    "text": "T-cell independent B-cell reaction in paracortexSome antigens may activate B cells directly without T-cell cooperation in paracortex of lymph node; consequently, mature naive B cells transform into proliferating extrafollicular B blastsTheir progeny can mature into short-lived plasma cells secreting low-affinity IgMNo memory B cells are generated",
                    "sub_points": [
                      "Some antigens may activate B cells directly without T-cell cooperation in paracortex of lymph node; consequently, mature naive B cells transform into proliferating extrafollicular B blastsTheir progeny can mature into short-lived plasma cells secreting low-affinity IgMNo memory B cells are generated",
                      "Their progeny can mature into short-lived plasma cells secreting low-affinity IgM",
                      "No memory B cells are generated"
                    ]
                  },
                  {
                    "text": "T-cell dependent B-cell reaction in germinal centerProliferating blasts migrate to primary follicles, form germinal centers (GC), and become centroblastsSelected cells with BCRs to specific antigen present in GC survive and continue to proliferateCentroblasts undergosomatic hypermutations (SHM)that introduce point mutations in variable regions of heavy and light chainsCentroblasts mature into nonproliferating centrocytes and then undergo selection processCells capable of producing high-affinity Ig are \"rescued\" from apoptosisAffinity maturationis direct result of SHM and selection processSubset of centrocytes undergoclass switch recombination (CSR)to produce IgG, IgA, or, rarely, IgE, instead of IgMCSR changes Ig functional characteristics but does not affect antigen specificityDifferentiation into effector cells (post-GC step)Memory B cells are detectable in peripheral blood and marginal zone of lymphoid tissues and include IgM and class-switched subsetsLong-lived plasma cells secrete Ig of all classes and can be found in lymph node medulla, splenic cords, and bone marrowIn adults, new B cells are continuously produced in bone marrow",
                    "sub_points": [
                      "Proliferating blasts migrate to primary follicles, form germinal centers (GC), and become centroblastsSelected cells with BCRs to specific antigen present in GC survive and continue to proliferate",
                      "Selected cells with BCRs to specific antigen present in GC survive and continue to proliferate",
                      "Centroblasts undergosomatic hypermutations (SHM)that introduce point mutations in variable regions of heavy and light chains",
                      "Centroblasts mature into nonproliferating centrocytes and then undergo selection processCells capable of producing high-affinity Ig are \"rescued\" from apoptosisAffinity maturationis direct result of SHM and selection process",
                      "Cells capable of producing high-affinity Ig are \"rescued\" from apoptosis",
                      "Affinity maturationis direct result of SHM and selection process",
                      "Subset of centrocytes undergoclass switch recombination (CSR)to produce IgG, IgA, or, rarely, IgE, instead of IgMCSR changes Ig functional characteristics but does not affect antigen specificity",
                      "CSR changes Ig functional characteristics but does not affect antigen specificity",
                      "Differentiation into effector cells (post-GC step)Memory B cells are detectable in peripheral blood and marginal zone of lymphoid tissues and include IgM and class-switched subsetsLong-lived plasma cells secrete Ig of all classes and can be found in lymph node medulla, splenic cords, and bone marrow",
                      "Memory B cells are detectable in peripheral blood and marginal zone of lymphoid tissues and include IgM and class-switched subsets",
                      "Long-lived plasma cells secrete Ig of all classes and can be found in lymph node medulla, splenic cords, and bone marrow",
                      "In adults, new B cells are continuously produced in bone marrow"
                    ]
                  }
                ]
              },
              "IGH Rearrangements": {
                "Overview": [
                  {
                    "text": "Sequence of somatic recombination events occurring at pro B-cell stages in B-cell lineage precursorsJoins gene segments that are spatially separated in germline configuration",
                    "sub_points": [
                      "Joins gene segments that are spatially separated in germline configuration"
                    ]
                  },
                  {
                    "text": "General order of Ig gene rearrangementsIGH1st followed byIGK, followed byIGLif rearrangedIGKin both alleles is nonproductive",
                    "sub_points": [
                      "IGH1st followed byIGK, followed byIGLif rearrangedIGKin both alleles is nonproductive"
                    ]
                  }
                ],
                "IGHLocus": [
                  {
                    "text": "IGHvariable region gene cluster contains comparable number of V segments toIGK,IGL,TRA, andTRBlociNumbers of V segments vary between individualsOf ~ 123-139 VH segments, only 46-52 are functionalBelong to 7 V families based on homologySeveral VH segments are considered pseudogenes",
                    "sub_points": [
                      "Numbers of V segments vary between individuals",
                      "Of ~ 123-139 VH segments, only 46-52 are functionalBelong to 7 V families based on homologySeveral VH segments are considered pseudogenes",
                      "Belong to 7 V families based on homology",
                      "Several VH segments are considered pseudogenes"
                    ]
                  },
                  {
                    "text": "Additionally,IGHlocus contains 26 DH segments, 9 JH segments, and 11 CH segments"
                  }
                ],
                "Recombination Process": [
                  {
                    "text": "Requires many enzymes and other proteinsEnzymes expressed only in developing lymphocytesRAG1 and RAG2 encoded by recombination activating genes are key componentsTerminal deoxynucleotidyl transferase (TdT)Ubiquitously expressed DNA-modifying proteins normally involved in DNA repair and other cellular processesKu70:Ku80 heterodimer, DNA dependent protein kinase, Artemis nuclease, DNA ligase IV",
                    "sub_points": [
                      "Enzymes expressed only in developing lymphocytesRAG1 and RAG2 encoded by recombination activating genes are key componentsTerminal deoxynucleotidyl transferase (TdT)",
                      "RAG1 and RAG2 encoded by recombination activating genes are key components",
                      "Terminal deoxynucleotidyl transferase (TdT)",
                      "Ubiquitously expressed DNA-modifying proteins normally involved in DNA repair and other cellular processesKu70:Ku80 heterodimer, DNA dependent protein kinase, Artemis nuclease, DNA ligase IV",
                      "Ku70:Ku80 heterodimer, DNA dependent protein kinase, Artemis nuclease, DNA ligase IV"
                    ]
                  },
                  {
                    "text": "Recombination proceeds in regulated stepwise fashionBegins with RAG complex recognizing and cutting DNA at recombination signal sequences (RSS)RSS located immediately downstream of VH segments, at both sides of DH segments and upstream of JH segmentsRSS are composed of conserved heptamer, 12 or 23 bp spacer, and conserved nonamer sequencesSegments with RSS having 12 bp and 23 bp spacers (12/23 rule) are usually joined (to prevent nonproductive rearrangements, e.g., VH to VH)Next step involves formation of hairpin structure (stem loop) at ends of coding segmentsBlunt ends of RSS are ligated together into circular DNA containing all intervening sequencesOther proteins bind to and open hairpin at random site to yield single-stranded DNA endsPalindromic (P) nucleotides originate from complementary strand of hairpin that is asymmetrically openedExonuclease and TdT randomly cleave and add nontemplated nucleotides (N), resulting in junctional diversityFinally, DNA ligase joins rearranging gene segmentsDH to JH rearrangement is followed by VH to DH-JH rearrangement to form recombined complete VDJRepertoire of inherited gene segments accounts for Ig combinatorial diversityCombinatorial and junctional diversitytogether create essentially limitless repertoire of variable region sequences",
                    "sub_points": [
                      "Begins with RAG complex recognizing and cutting DNA at recombination signal sequences (RSS)RSS located immediately downstream of VH segments, at both sides of DH segments and upstream of JH segmentsRSS are composed of conserved heptamer, 12 or 23 bp spacer, and conserved nonamer sequencesSegments with RSS having 12 bp and 23 bp spacers (12/23 rule) are usually joined (to prevent nonproductive rearrangements, e.g., VH to VH)",
                      "RSS located immediately downstream of VH segments, at both sides of DH segments and upstream of JH segments",
                      "RSS are composed of conserved heptamer, 12 or 23 bp spacer, and conserved nonamer sequences",
                      "Segments with RSS having 12 bp and 23 bp spacers (12/23 rule) are usually joined (to prevent nonproductive rearrangements, e.g., VH to VH)",
                      "Next step involves formation of hairpin structure (stem loop) at ends of coding segmentsBlunt ends of RSS are ligated together into circular DNA containing all intervening sequences",
                      "Blunt ends of RSS are ligated together into circular DNA containing all intervening sequences",
                      "Other proteins bind to and open hairpin at random site to yield single-stranded DNA endsPalindromic (P) nucleotides originate from complementary strand of hairpin that is asymmetrically openedExonuclease and TdT randomly cleave and add nontemplated nucleotides (N), resulting in junctional diversity",
                      "Palindromic (P) nucleotides originate from complementary strand of hairpin that is asymmetrically opened",
                      "Exonuclease and TdT randomly cleave and add nontemplated nucleotides (N), resulting in junctional diversity",
                      "Finally, DNA ligase joins rearranging gene segments",
                      "DH to JH rearrangement is followed by VH to DH-JH rearrangement to form recombined complete VDJRepertoire of inherited gene segments accounts for Ig combinatorial diversityCombinatorial and junctional diversitytogether create essentially limitless repertoire of variable region sequences",
                      "Repertoire of inherited gene segments accounts for Ig combinatorial diversity",
                      "Combinatorial and junctional diversitytogether create essentially limitless repertoire of variable region sequences"
                    ]
                  },
                  {
                    "text": "Transcription step is followed by RNA splicing, leading to joining of V region to neighboring C segmentAlternative RNA splicing results in expression of μ or δ heavy chainsClass-switch recombination is required for α, ε, and γ heavy chain expressionSwitch from membrane-bound to soluble Ig also occurs at RNA processing step via alternate splicing",
                    "sub_points": [
                      "Alternative RNA splicing results in expression of μ or δ heavy chainsClass-switch recombination is required for α, ε, and γ heavy chain expression",
                      "Class-switch recombination is required for α, ε, and γ heavy chain expression",
                      "Switch from membrane-bound to soluble Ig also occurs at RNA processing step via alternate splicing"
                    ]
                  },
                  {
                    "text": "Translation and Ig assembly are final steps"
                  },
                  {
                    "text": "All Ig and TCR gene rearrangements follow similar steps and use same enzymes and cellular machineryRearrangedIGK/IGLhave reduced junctional diversity compared toIGH",
                    "sub_points": [
                      "RearrangedIGK/IGLhave reduced junctional diversity compared toIGH"
                    ]
                  }
                ],
                "Other Related Processes": [
                  {
                    "text": "Both SHM and CSR also result in somatic changes to germline sequence of Ig genes"
                  },
                  {
                    "text": "Utilize different enzymes and cellular mechanismsActivation-induced cytidine deaminase is important enzyme in this process",
                    "sub_points": [
                      "Activation-induced cytidine deaminase is important enzyme in this process"
                    ]
                  }
                ]
              },
              "Clonality Testing": {
                "General Comments": [
                  {
                    "text": "Clonality does not equal malignancyBenign and reactive conditions can produce clonal patterns due to antigen-driven lymphocyte expansions",
                    "sub_points": [
                      "Benign and reactive conditions can produce clonal patterns due to antigen-driven lymphocyte expansions"
                    ]
                  },
                  {
                    "text": "Clonal rearrangements are not lineage specificB-cell malignancies (especially of B-cell precursors) often have clonal T-cell receptor gene rearrangementsT-cell malignancies can have clonal Ig gene rearrangements",
                    "sub_points": [
                      "B-cell malignancies (especially of B-cell precursors) often have clonal T-cell receptor gene rearrangements",
                      "T-cell malignancies can have clonal Ig gene rearrangements"
                    ]
                  },
                  {
                    "text": "Results of clonality testing should always be interpreted within appropriate clinical context and in conjunction with morphologic findings"
                  }
                ],
                "Antibody-Based Methods": [
                  {
                    "text": "Based on evaluation of light chain restriction in B cells &/or plasma cellsRatio of κ to λ is calculated/estimatedResults outside of established normal range are indicative of clonality",
                    "sub_points": [
                      "Ratio of κ to λ is calculated/estimatedResults outside of established normal range are indicative of clonality",
                      "Results outside of established normal range are indicative of clonality"
                    ]
                  },
                  {
                    "text": "Flow cytometry (FC), in situ hybridization (ISH), and immunohistochemistry (IHC) can be usedSeveral limitations existFresh tissue requirement for FC, inability to evaluate light chain restriction in majority of B cells by IHC/ISH",
                    "sub_points": [
                      "Several limitations existFresh tissue requirement for FC, inability to evaluate light chain restriction in majority of B cells by IHC/ISH",
                      "Fresh tissue requirement for FC, inability to evaluate light chain restriction in majority of B cells by IHC/ISH"
                    ]
                  }
                ],
                "Nucleic Acid-Based Methods": [
                  {
                    "text": "Southern blot hybridizationUsed to be gold standard for clonality analysis in old days, now largely replaced by PCR-based approachesBased on principle that antigen receptor gene rearrangements alter restriction-digested DNA fragments compared with germline DNAGenes with significant combinatorial diversity, such asIGH,IGK, andTRB, are suitable targets for analysisRequires significant amount of high-quality DNASensitivity of this method is ~ 5-10%ProtocolGenomic DNA digestion by restriction enzymesSize fractionation by gel electrophoresisTransfer to membrane and hybridization with labeled DNA probes targeting J or C regionWash and visualization stepIndividual gene rearrangements are not detected unless they are overrepresented at ≥ 5% in background lymphoid cellsPolyclonal sample appears as germline bands onlyClonal rearrangements appear as novel bands",
                    "sub_points": [
                      "Used to be gold standard for clonality analysis in old days, now largely replaced by PCR-based approaches",
                      "Based on principle that antigen receptor gene rearrangements alter restriction-digested DNA fragments compared with germline DNAGenes with significant combinatorial diversity, such asIGH,IGK, andTRB, are suitable targets for analysis",
                      "Genes with significant combinatorial diversity, such asIGH,IGK, andTRB, are suitable targets for analysis",
                      "Requires significant amount of high-quality DNA",
                      "Sensitivity of this method is ~ 5-10%",
                      "ProtocolGenomic DNA digestion by restriction enzymesSize fractionation by gel electrophoresisTransfer to membrane and hybridization with labeled DNA probes targeting J or C regionWash and visualization step",
                      "Genomic DNA digestion by restriction enzymes",
                      "Size fractionation by gel electrophoresis",
                      "Transfer to membrane and hybridization with labeled DNA probes targeting J or C region",
                      "Wash and visualization step",
                      "Individual gene rearrangements are not detected unless they are overrepresented at ≥ 5% in background lymphoid cellsPolyclonal sample appears as germline bands onlyClonal rearrangements appear as novel bands",
                      "Polyclonal sample appears as germline bands only",
                      "Clonal rearrangements appear as novel bands"
                    ]
                  },
                  {
                    "text": "PCR-based approachesCurrent gold standard for clonality analysisBased on principle that somatic Ig gene rearrangements bring V, (D), and J segments together, enabling their PCR amplificationEach rearrangement is unique in length and sequence due to combinatorial and junctional diversityIGHandIGKare usually testedTestingIGLadds little to overall ability to detect clonal rearrangements and is not widely usedCan be performed on variety of specimen types, including formalin-fixed, paraffin-embedded tissueTissues exposed to strong acid-based decalcification solutions are not suitable for PCR amplificationTissues exposed to heparin-based decalcification solution are suitable for PCR amplificationPCR protocolGenomic DNA is extracted andIGHandIGKCDR3 regions are PCR amplifiedBIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is most commonly usedCommercial kits are available (e.g., IGH + IGK B-cell clonality assay from Invivoscribe)ForIGH,primers targeting multiple VH families within FR1, 2, and 3 plus single consensus primer for JH segment (3 separate reactions) are usedSHM can interfere with primers bindingIGKtube A includes 6 Vκ primers plus 2 Jκ primersIGKtube B includes 6 Vκ primers and Jκ-Cκ intron primer plus 1 IGKDE primer (to detect rearrangements involving IGKDE)Not affected by SHM (main advantage)Fractionation by capillary electrophoresis (CE)One of PCR primers requires fluorescent labelingSeparates amplicons based on length onlyConventional gel electrophoresis can also be used as alternative, but it is more labor intensive and time consuming with lesser resolutionInterpretation should be assay and specimen specificPolyclonal B cells generate normal (Gaussian) distribution of amplicon of different sizesClonal B cells produce 1 or 2 prominent amplicons within diminished polyclonal backgroundGenerally not suitable for minimal residual disease (MRD) monitoring, unless specific primers for patient-specific clone are designed",
                    "sub_points": [
                      "Current gold standard for clonality analysis",
                      "Based on principle that somatic Ig gene rearrangements bring V, (D), and J segments together, enabling their PCR amplificationEach rearrangement is unique in length and sequence due to combinatorial and junctional diversityIGHandIGKare usually testedTestingIGLadds little to overall ability to detect clonal rearrangements and is not widely used",
                      "Each rearrangement is unique in length and sequence due to combinatorial and junctional diversity",
                      "IGHandIGKare usually tested",
                      "TestingIGLadds little to overall ability to detect clonal rearrangements and is not widely used",
                      "Can be performed on variety of specimen types, including formalin-fixed, paraffin-embedded tissueTissues exposed to strong acid-based decalcification solutions are not suitable for PCR amplificationTissues exposed to heparin-based decalcification solution are suitable for PCR amplification",
                      "Tissues exposed to strong acid-based decalcification solutions are not suitable for PCR amplification",
                      "Tissues exposed to heparin-based decalcification solution are suitable for PCR amplification",
                      "PCR protocol",
                      "Genomic DNA is extracted andIGHandIGKCDR3 regions are PCR amplifiedBIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is most commonly usedCommercial kits are available (e.g., IGH + IGK B-cell clonality assay from Invivoscribe)ForIGH,primers targeting multiple VH families within FR1, 2, and 3 plus single consensus primer for JH segment (3 separate reactions) are usedSHM can interfere with primers bindingIGKtube A includes 6 Vκ primers plus 2 Jκ primersIGKtube B includes 6 Vκ primers and Jκ-Cκ intron primer plus 1 IGKDE primer (to detect rearrangements involving IGKDE)Not affected by SHM (main advantage)",
                      "BIOMED-2 (from European BIOMED-2 collaborative study) primer strategy is most commonly usedCommercial kits are available (e.g., IGH + IGK B-cell clonality assay from Invivoscribe)",
                      "Commercial kits are available (e.g., IGH + IGK B-cell clonality assay from Invivoscribe)",
                      "ForIGH,primers targeting multiple VH families within FR1, 2, and 3 plus single consensus primer for JH segment (3 separate reactions) are usedSHM can interfere with primers binding",
                      "SHM can interfere with primers binding",
                      "IGKtube A includes 6 Vκ primers plus 2 Jκ primers",
                      "IGKtube B includes 6 Vκ primers and Jκ-Cκ intron primer plus 1 IGKDE primer (to detect rearrangements involving IGKDE)Not affected by SHM (main advantage)",
                      "Not affected by SHM (main advantage)",
                      "Fractionation by capillary electrophoresis (CE)One of PCR primers requires fluorescent labelingSeparates amplicons based on length onlyConventional gel electrophoresis can also be used as alternative, but it is more labor intensive and time consuming with lesser resolution",
                      "One of PCR primers requires fluorescent labeling",
                      "Separates amplicons based on length only",
                      "Conventional gel electrophoresis can also be used as alternative, but it is more labor intensive and time consuming with lesser resolution",
                      "Interpretation should be assay and specimen specificPolyclonal B cells generate normal (Gaussian) distribution of amplicon of different sizesClonal B cells produce 1 or 2 prominent amplicons within diminished polyclonal background",
                      "Polyclonal B cells generate normal (Gaussian) distribution of amplicon of different sizes",
                      "Clonal B cells produce 1 or 2 prominent amplicons within diminished polyclonal background",
                      "Generally not suitable for minimal residual disease (MRD) monitoring, unless specific primers for patient-specific clone are designed"
                    ]
                  },
                  {
                    "text": "Next-generation sequencing approachesHigh throughput sequencing may identifies MRD deeper than conventional clinical cutoff of 0.01 by flow cytometryHigh specificity attributable to resolution of rearrangements by size and sequenceHigh sensitivity suitable for MRD monitoringClaimed to have lower false-negative rate compared to flow cytometry",
                    "sub_points": [
                      "High throughput sequencing may identifies MRD deeper than conventional clinical cutoff of 0.01 by flow cytometry",
                      "High specificity attributable to resolution of rearrangements by size and sequence",
                      "High sensitivity suitable for MRD monitoring",
                      "Claimed to have lower false-negative rate compared to flow cytometry"
                    ]
                  },
                  {
                    "text": "IGHrearrangements analysis using RNA sequencing (RNAseq)Patient's specificIGHrearrangements is identified in initial presentation for MRD monitoring in lymphoblastic leukemia patientsRNAseq data is generated using antigen receptor research tool (ARResT): http://bat.infspire.orgTool is built within EuroClonality NGS Working GroupRNAseq data is analyzed using ARResT to interrogate and identify possible MRD markersSimilar strategy can be employed for disease monitoring in other lymphomas and multiple myeloma",
                    "sub_points": [
                      "Patient's specificIGHrearrangements is identified in initial presentation for MRD monitoring in lymphoblastic leukemia patients",
                      "RNAseq data is generated using antigen receptor research tool (ARResT): http://bat.infspire.orgTool is built within EuroClonality NGS Working Group",
                      "Tool is built within EuroClonality NGS Working Group",
                      "RNAseq data is analyzed using ARResT to interrogate and identify possible MRD markers",
                      "Similar strategy can be employed for disease monitoring in other lymphomas and multiple myeloma"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Wilms Tumor": {
            "name": "Wilms Tumor",
            "url": "https://app.pathprimer.com/document/189aa7f7-49d9-4d25-8171-2428f80b140b/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Wilms tumor (WT): Malignant nephroblastic tumor, often with multiphasic differentiation"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Syndromic associations in 10%WT,aniridia,genitourinary abnormalities, mentalrestriction (WAGR) syndrome, sporadic aniridiaDenys-Drash and Frasier syndromesBeckwith-Wiedemann syndromeFamilial nephroblastomaOther syndromes include Bloom, Perlman, Li-Fraumeni, Sotos, Simpson-Golabi-Behmel, trisomy 18, CLOVES",
                    "sub_points": [
                      "WT,aniridia,genitourinary abnormalities, mentalrestriction (WAGR) syndrome, sporadic aniridia",
                      "Denys-Drash and Frasier syndromes",
                      "Beckwith-Wiedemann syndrome",
                      "Familial nephroblastoma",
                      "Other syndromes include Bloom, Perlman, Li-Fraumeni, Sotos, Simpson-Golabi-Behmel, trisomy 18, CLOVES"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most common pediatric renal tumor"
                  },
                  {
                    "text": "5-10% have bilateral or multicentric tumors"
                  },
                  {
                    "text": "~ 75% of cases < 5 years of age"
                  }
                ],
                "Molecular": [
                  {
                    "text": "WT1deletions or mutationsGermline: WAGR syndrome, sporadic aniridia, Denys-Drash syndrome, sporadic tumorsSomatic mutations occur in 12% of tumors",
                    "sub_points": [
                      "Germline: WAGR syndrome, sporadic aniridia, Denys-Drash syndrome, sporadic tumors",
                      "Somatic mutations occur in 12% of tumors"
                    ]
                  },
                  {
                    "text": "WT2locus alterationsGermline alterations in Beckwith-Wiedemann syndromeSomatic loss of heterozygosity (LOH) and loss of imprinting (LOI) at 11p15 in 70% of tumors",
                    "sub_points": [
                      "Germline alterations in Beckwith-Wiedemann syndrome",
                      "Somatic loss of heterozygosity (LOH) and loss of imprinting (LOI) at 11p15 in 70% of tumors"
                    ]
                  },
                  {
                    "text": "Other mutated genes includeCTNNB1,AMER1,TP53, and microRNA processing genes"
                  },
                  {
                    "text": "Gain of 1q: Strongest predictor of adverse outcome"
                  },
                  {
                    "text": "If 1q normal, LOH at 1p and 16q predicts relapse in favorable histology WT"
                  },
                  {
                    "text": "WT1mutation and LOH/LOI at 11p15Predict recurrence in very low-risk WT with surgery only",
                    "sub_points": [
                      "Predict recurrence in very low-risk WT with surgery only"
                    ]
                  },
                  {
                    "text": "TP53mutations or loss at 17p13 associated with anaplasia and worse prognosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Wilms tumor (WT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Nephroblastoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Malignant renal tumor from nephrogenic blastema, typically with multiphasic differentiation"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Developmental Anomaly": [
                  {
                    "text": "WT: Syndromic/congenital anomaly associations in 10-15%Can be grouped into nonovergrowth and overgrowth phenotypes based on absence or presence of overgrowth of somatic tissuesRenal ultrasound surveillance recommended every 3 months from birth/diagnosis until at least age 8 years in predisposing syndromes",
                    "sub_points": [
                      "Can be grouped into nonovergrowth and overgrowth phenotypes based on absence or presence of overgrowth of somatic tissues",
                      "Renal ultrasound surveillance recommended every 3 months from birth/diagnosis until at least age 8 years in predisposing syndromes"
                    ]
                  },
                  {
                    "text": "Nonovergrowth phenotype syndromes withWT1inactivation mutationsWilms tumor,aniridia,genitourinary anomalies, developmental delay (restriction) (WAGR) syndromeDeletions of several contiguous genes, includingPAX6in addition toWT1Denys-Drash syndrome, Frasier syndrome, isolated genitourinary abnormalities, and sporadic aniridiaAll associated withWT1mutations and predisposition to WT developmentSporadic aniridia associated with WT; precise mapping of breakpoint needed to determine ifWT1is involvedOther syndromes associated with predisposition for WT developmentLi-Fraumeni syndrome, Bloom syndrome, Fanconi anemia with biallelic mutations inBRCA2orPALB2, trisomy 18 (Edwards syndrome)",
                    "sub_points": [
                      "Wilms tumor,aniridia,genitourinary anomalies, developmental delay (restriction) (WAGR) syndromeDeletions of several contiguous genes, includingPAX6in addition toWT1",
                      "Deletions of several contiguous genes, includingPAX6in addition toWT1",
                      "Denys-Drash syndrome, Frasier syndrome, isolated genitourinary abnormalities, and sporadic aniridiaAll associated withWT1mutations and predisposition to WT developmentSporadic aniridia associated with WT; precise mapping of breakpoint needed to determine ifWT1is involved",
                      "All associated withWT1mutations and predisposition to WT development",
                      "Sporadic aniridia associated with WT; precise mapping of breakpoint needed to determine ifWT1is involved",
                      "Other syndromes associated with predisposition for WT developmentLi-Fraumeni syndrome, Bloom syndrome, Fanconi anemia with biallelic mutations inBRCA2orPALB2, trisomy 18 (Edwards syndrome)",
                      "Li-Fraumeni syndrome, Bloom syndrome, Fanconi anemia with biallelic mutations inBRCA2orPALB2, trisomy 18 (Edwards syndrome)"
                    ]
                  },
                  {
                    "text": "Overgrowth phenotype syndromes with predisposition to WT developmentBeckwith-Wiedemann syndrome (BWS)WT2mutations linked to predisposition to WTPerlman syndrome withDIS3L2mutationsAssociated with high risk of WT development9q22.3 microdeletion syndromeDeletion invariably encompassesPTCH1Isolated hemihypertrophyCongenital lipomatous overgrowth, epidermal nevi, scoliosis and spinal deformities (CLOVES) syndrome with somaticPIK3CAmutationsOther syndromes with predisposition to WT include Sotos syndrome and Simpson-Golabi-Behmel syndrome",
                    "sub_points": [
                      "Beckwith-Wiedemann syndrome (BWS)WT2mutations linked to predisposition to WT",
                      "WT2mutations linked to predisposition to WT",
                      "Perlman syndrome withDIS3L2mutationsAssociated with high risk of WT development",
                      "Associated with high risk of WT development",
                      "9q22.3 microdeletion syndromeDeletion invariably encompassesPTCH1",
                      "Deletion invariably encompassesPTCH1",
                      "Isolated hemihypertrophy",
                      "Congenital lipomatous overgrowth, epidermal nevi, scoliosis and spinal deformities (CLOVES) syndrome with somaticPIK3CAmutations",
                      "Other syndromes with predisposition to WT include Sotos syndrome and Simpson-Golabi-Behmel syndrome"
                    ]
                  },
                  {
                    "text": "Familial WT1-2% of patients with WT have 1 or more relatives with isolated WTFamilial cases show higher rate of bilateral tumors and earlier age of diagnosisGenetic linkage has identified several candidate genes/loci, including loci at 17q12-q21 and 19q13.4Rare mutations inWT1,BRCA2, andCTR9in familial WT",
                    "sub_points": [
                      "1-2% of patients with WT have 1 or more relatives with isolated WT",
                      "Familial cases show higher rate of bilateral tumors and earlier age of diagnosis",
                      "Genetic linkage has identified several candidate genes/loci, including loci at 17q12-q21 and 19q13.4",
                      "Rare mutations inWT1,BRCA2, andCTR9in familial WT"
                    ]
                  }
                ],
                "Nephrogenic Rests": [
                  {
                    "text": "Abnormal clusters of embryonic kidney cells that persist into postnatal lifeThought to be WT precursors",
                    "sub_points": [
                      "Thought to be WT precursors"
                    ]
                  },
                  {
                    "text": "Perilobular nephrogenic rests (PLNR)Located at periphery of renal lobule; may be multifocalIGF2dysregulated WT often associated with PLNR (including with hemihypertrophy and overgrowth syndromes)Well-circumscribed, blastemal-predominant histology",
                    "sub_points": [
                      "Located at periphery of renal lobule; may be multifocal",
                      "IGF2dysregulated WT often associated with PLNR (including with hemihypertrophy and overgrowth syndromes)",
                      "Well-circumscribed, blastemal-predominant histology"
                    ]
                  },
                  {
                    "text": "Intralobular nephrogenic rests (ILNR)Located within renal lobule, usually isolated lesionsWT1mutated WT often associated with ILNR PLNR (including with WAGR and Denys-Drash syndromes)Irregular, stromal-predominant histology",
                    "sub_points": [
                      "Located within renal lobule, usually isolated lesions",
                      "WT1mutated WT often associated with ILNR PLNR (including with WAGR and Denys-Drash syndromes)",
                      "Irregular, stromal-predominant histology"
                    ]
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Pathways involved in development of WT includeIGF2overexpression (70%, including alterations atWT2locus), abnormalities inWNTsignaling (30%, including mutations inWT1,CTNNB1, andAMER1), and abnormalities in microRNA processing (20%)"
                  },
                  {
                    "text": "Later events: 1p/16q loss, 1q gain,TP53mutations"
                  },
                  {
                    "text": "> 40 genes somatically mutated in WT"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Most common pediatric renal tumor> 95% of pediatric renal tumors~ 7 cases per million < 15 years of age",
                    "sub_points": [
                      "> 95% of pediatric renal tumors",
                      "~ 7 cases per million < 15 years of age"
                    ]
                  },
                  {
                    "text": "5-10% have bilateral or multicentric tumors"
                  },
                  {
                    "text": "Average age at presentation42-47 months for unilateral tumors30-33 months for bilateral tumors",
                    "sub_points": [
                      "42-47 months for unilateral tumors",
                      "30-33 months for bilateral tumors"
                    ]
                  },
                  {
                    "text": "~ 75% of cases present in patients < 5 years of age; 98% in patients < 10 years of age; peak incidence at 2-3 years of age"
                  },
                  {
                    "text": "Rare cases may occur in adults"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Usually abdominal mass noted by parent"
                  },
                  {
                    "text": "Pain, malaise, hematuria, hypertension (20-30%)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Multimodal therapy, including surgery, chemotherapy, and radiotherapy"
                  },
                  {
                    "text": "Differences between treatment protocols in North America vs. Europe, but both have excellent results"
                  },
                  {
                    "text": "SurgeryChildren's Oncology Group (COG) in North America recommends nephrectomy at time of diagnosis, followed by chemotherapy and radiotherapy in some patientsInternational Society of Pediatric Oncology (SIOP) in Europe advocates preoperative chemotherapy prior to nephrectomyNephron-sparing surgery considered for bilateral tumorsSurgery only may be considered in very low-risk WT",
                    "sub_points": [
                      "Children's Oncology Group (COG) in North America recommends nephrectomy at time of diagnosis, followed by chemotherapy and radiotherapy in some patients",
                      "International Society of Pediatric Oncology (SIOP) in Europe advocates preoperative chemotherapy prior to nephrectomy",
                      "Nephron-sparing surgery considered for bilateral tumors",
                      "Surgery only may be considered in very low-risk WT"
                    ]
                  },
                  {
                    "text": "Chemotherapy following nephrectomy at diagnosis (COG protocols in North America)Depends on factors, such as stage, tumor weight, and presence of anaplasiaIncludes agents, such as vincristine, dactinomycin, doxorubicin, etoposide, and cyclophosphamideWT with unfavorable histology (diffuse anaplasia) treated more aggressivelyFavorable histology WT (FHWT) with combined loss of heterozygosity (LOH) of 1p and 16q may be treated more aggressivelyStage III/IV tumors with LOH of 1p and 16q may be treated more aggressivelyOther markers that may allow risk stratification of otherwise very low-risk WT include 11p15 methylation status,WT1mutations, LOH at 11p15",
                    "sub_points": [
                      "Depends on factors, such as stage, tumor weight, and presence of anaplasia",
                      "Includes agents, such as vincristine, dactinomycin, doxorubicin, etoposide, and cyclophosphamide",
                      "WT with unfavorable histology (diffuse anaplasia) treated more aggressively",
                      "Favorable histology WT (FHWT) with combined loss of heterozygosity (LOH) of 1p and 16q may be treated more aggressively",
                      "Stage III/IV tumors with LOH of 1p and 16q may be treated more aggressively",
                      "Other markers that may allow risk stratification of otherwise very low-risk WT include 11p15 methylation status,WT1mutations, LOH at 11p15"
                    ]
                  },
                  {
                    "text": "Radiation therapyUsed postoperatively in high-stage tumors and tumors with anaplasia",
                    "sub_points": [
                      "Used postoperatively in high-stage tumors and tumors with anaplasia"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Overall survival: > 90%"
                  },
                  {
                    "text": "Unfavorable factors include high stage, unfavorable histology (diffuse anaplasia)"
                  },
                  {
                    "text": "Stage at diagnosis, tumor weight, patient age, and histology used to stratify patients into risk groupsVery low risk, low risk, standard risk, favorable histology, and high risk",
                    "sub_points": [
                      "Very low risk, low risk, standard risk, favorable histology, and high risk"
                    ]
                  },
                  {
                    "text": "Molecular alterations help further risk stratificationsGain of 1q is strongest predictor of poorer survival in unilateral FHWTIf 1q is normal, 1p/16q LOH may predict worse outcome11p15 LOH and methylation status predict recurrence in very low-risk WT treated by surgery aloneTP53mutations or loss at 17p13 associated with anaplasia and worse prognosisLOH at 4q, 14q, 11q associated with anaplasia and worse prognosisMYCNamplification andMYCNP44L mutation associated with poor prognosis",
                    "sub_points": [
                      "Gain of 1q is strongest predictor of poorer survival in unilateral FHWT",
                      "If 1q is normal, 1p/16q LOH may predict worse outcome",
                      "11p15 LOH and methylation status predict recurrence in very low-risk WT treated by surgery alone",
                      "TP53mutations or loss at 17p13 associated with anaplasia and worse prognosis",
                      "LOH at 4q, 14q, 11q associated with anaplasia and worse prognosis",
                      "MYCNamplification andMYCNP44L mutation associated with poor prognosis"
                    ]
                  },
                  {
                    "text": "Study of relapse samples in FHWT (from umbrella AREN03B2 study) showed following findings75% of relapse samples show gain of 1q40% contain mutations inSIX1andMYCNnetwork genesRecurrent mutations inDISC3andTERT",
                    "sub_points": [
                      "75% of relapse samples show gain of 1q",
                      "40% contain mutations inSIX1andMYCNnetwork genes",
                      "Recurrent mutations inDISC3andTERT"
                    ]
                  }
                ],
                "COG Staging (Conceptual Summary)": [
                  {
                    "text": "Stage I: Tumor limited to kidney and completely resected"
                  },
                  {
                    "text": "Stage II: Tumor with regional extension but completely resected"
                  },
                  {
                    "text": "Stage III: Residual tumor after surgery but confined to abdomen"
                  },
                  {
                    "text": "Stage IV: Hematogenous metastases, positive lymph nodes beyond abdomen/pelvis"
                  },
                  {
                    "text": "Stage V: Bilateral kidney tumors at time of diagnosis"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Minority of tumors are multicentric or bilateral"
                  },
                  {
                    "text": "Clearly demarcated, often encapsulated"
                  },
                  {
                    "text": "May have hemorrhage and necrosis"
                  }
                ]
              },
              "MOLECULAR": {
                "Cytogenetics": [
                  {
                    "text": "Partial gains of 1q"
                  },
                  {
                    "text": "Partial losses of 1p, 1q, 4q, 11q, 14q, 16q, and 22q"
                  },
                  {
                    "text": "Complete loss of chromosomes 22, 16, 11, and 12"
                  },
                  {
                    "text": "Trisomy of chromosomes 12, 18, 13, and 8"
                  },
                  {
                    "text": "Rearrangements and deletions of 11p13 may occur"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "WT1mutationsBoth somatic and germlineWT1mutations occur in WTSomaticWT1inactivating mutations or deletions in 12%GermlineWT1mutations occur in association with syndromes and with sporadic WTMutations in WAGR syndromeContiguous gene deletion syndrome involving multiple genes, includingWT1andPAX6~ 50% of patients with WAGR syndrome develop WTSporadic aniridiaResults from deletion that involvesPAX6and may include part or all ofWT1Risk of WT is 40-50% if deletion involvesWT1WT and isolated genitourinary anomaliesWT1deletions, frameshift and nonsense mutationsDenys-Drash syndromeMost have germline missense mutations in exon 8 or 9 ofWT1Risk for WT: > 90%Frasier syndromePoint mutation inWT1intron 9 donor splice siteRare cases with WTIsolated WT without syndromic findingsGermlineWT1mutations can be found in 2% of casesTumors withWT1mutations usually have stromal-predominant histology and muscle differentiationTumors withWT1mutations are often associated with mutations inCTNNB1",
                    "sub_points": [
                      "Both somatic and germlineWT1mutations occur in WT",
                      "SomaticWT1inactivating mutations or deletions in 12%",
                      "GermlineWT1mutations occur in association with syndromes and with sporadic WT",
                      "Mutations in WAGR syndromeContiguous gene deletion syndrome involving multiple genes, includingWT1andPAX6~ 50% of patients with WAGR syndrome develop WT",
                      "Contiguous gene deletion syndrome involving multiple genes, includingWT1andPAX6",
                      "~ 50% of patients with WAGR syndrome develop WT",
                      "Sporadic aniridiaResults from deletion that involvesPAX6and may include part or all ofWT1Risk of WT is 40-50% if deletion involvesWT1",
                      "Results from deletion that involvesPAX6and may include part or all ofWT1",
                      "Risk of WT is 40-50% if deletion involvesWT1",
                      "WT and isolated genitourinary anomaliesWT1deletions, frameshift and nonsense mutations",
                      "WT1deletions, frameshift and nonsense mutations",
                      "Denys-Drash syndromeMost have germline missense mutations in exon 8 or 9 ofWT1Risk for WT: > 90%",
                      "Most have germline missense mutations in exon 8 or 9 ofWT1",
                      "Risk for WT: > 90%",
                      "Frasier syndromePoint mutation inWT1intron 9 donor splice siteRare cases with WT",
                      "Point mutation inWT1intron 9 donor splice site",
                      "Rare cases with WT",
                      "Isolated WT without syndromic findingsGermlineWT1mutations can be found in 2% of cases",
                      "GermlineWT1mutations can be found in 2% of cases",
                      "Tumors withWT1mutations usually have stromal-predominant histology and muscle differentiation",
                      "Tumors withWT1mutations are often associated with mutations inCTNNB1"
                    ]
                  },
                  {
                    "text": "WT2alterationsWT2locus maps to 11p15.5 and includesH19-ICR(imprinting control region) withIGF2andH19, andCDKN1CandKCNQ1OT1IGF2codes for growth factor;H19produces noncoding RNA tumor suppressorNormally, inH19-ICR, bothIGF2andH19are imprinted with paternal allele-onlyIGF2expression and maternal allele-only expression ofH19Loss of imprinting (LOI) as result of hypermethylation ofH19-ICRresults in aberrant biallelic expression ofIGF2and decreased expression ofH19from maternal alleleOther functional abnormalities atWT2locus seen in WT and BWS include LOH, mutations, paternal uniparental disomy (UPD), microdeletions, microduplications, and microinsertionsBoth somatic and germline alterations inWT2occur in WTAlterations inWT2, including LOH and LOI, occur as somatic change in 70%Germline alterations inWT2occur in BWS and in sporadic tumorsBeckwith-Wiedemann syndrome is associated with several abnormalities atWT2locus, includingMicrodeletions, hypermethylation atH19-ICRMutation ofCDKN1C, microduplication at imprinting center 2Paternal UPD of 11p15Sporadic tumors without syndromic findings may show constitutional alterations atWT2locus, includingHypermethylation atH19-ICRPaternal UPD of 11p15Microdeletion and microinsertionTumors with LOI are usually stroma poor",
                    "sub_points": [
                      "WT2locus maps to 11p15.5 and includesH19-ICR(imprinting control region) withIGF2andH19, andCDKN1CandKCNQ1OT1IGF2codes for growth factor;H19produces noncoding RNA tumor suppressorNormally, inH19-ICR, bothIGF2andH19are imprinted with paternal allele-onlyIGF2expression and maternal allele-only expression ofH19Loss of imprinting (LOI) as result of hypermethylation ofH19-ICRresults in aberrant biallelic expression ofIGF2and decreased expression ofH19from maternal allele",
                      "H19-ICR(imprinting control region) withIGF2andH19, andCDKN1CandKCNQ1OT1",
                      "IGF2codes for growth factor;H19produces noncoding RNA tumor suppressor",
                      "Normally, inH19-ICR, bothIGF2andH19are imprinted with paternal allele-onlyIGF2expression and maternal allele-only expression ofH19",
                      "Loss of imprinting (LOI) as result of hypermethylation ofH19-ICRresults in aberrant biallelic expression ofIGF2and decreased expression ofH19from maternal allele",
                      "Other functional abnormalities atWT2locus seen in WT and BWS include LOH, mutations, paternal uniparental disomy (UPD), microdeletions, microduplications, and microinsertions",
                      "Both somatic and germline alterations inWT2occur in WTAlterations inWT2, including LOH and LOI, occur as somatic change in 70%Germline alterations inWT2occur in BWS and in sporadic tumors",
                      "Alterations inWT2, including LOH and LOI, occur as somatic change in 70%",
                      "Germline alterations inWT2occur in BWS and in sporadic tumors",
                      "Beckwith-Wiedemann syndrome is associated with several abnormalities atWT2locus, includingMicrodeletions, hypermethylation atH19-ICRMutation ofCDKN1C, microduplication at imprinting center 2Paternal UPD of 11p15",
                      "Microdeletions, hypermethylation atH19-ICR",
                      "Mutation ofCDKN1C, microduplication at imprinting center 2",
                      "Paternal UPD of 11p15",
                      "Sporadic tumors without syndromic findings may show constitutional alterations atWT2locus, includingHypermethylation atH19-ICRPaternal UPD of 11p15Microdeletion and microinsertion",
                      "Hypermethylation atH19-ICR",
                      "Paternal UPD of 11p15",
                      "Microdeletion and microinsertion",
                      "Tumors with LOI are usually stroma poor"
                    ]
                  },
                  {
                    "text": "AMER1mutationsSomatic mutations in ~ 15-20% of WTGermline mutations do not predispose to WTAssociated with epigenetic abnormalities at 11p15",
                    "sub_points": [
                      "Somatic mutations in ~ 15-20% of WT",
                      "Germline mutations do not predispose to WT",
                      "Associated with epigenetic abnormalities at 11p15"
                    ]
                  },
                  {
                    "text": "CTNNB1mutationsSomatic mutations in ~ 15% of WTAlmost always seen in association with mutations in eitherWT1, orAMER1, orMLLT1Late event (not seen in nephrogenic rests)",
                    "sub_points": [
                      "Somatic mutations in ~ 15% of WT",
                      "Almost always seen in association with mutations in eitherWT1, orAMER1, orMLLT1",
                      "Late event (not seen in nephrogenic rests)"
                    ]
                  },
                  {
                    "text": "TP53mutationMissense mutation or loss of copy number in 5% of WT, usually somaticStrongly associated with unfavorable histologyUp to 75% of anaplastic WT harborTP53mutations",
                    "sub_points": [
                      "Missense mutation or loss of copy number in 5% of WT, usually somatic",
                      "Strongly associated with unfavorable histologyUp to 75% of anaplastic WT harborTP53mutations",
                      "Up to 75% of anaplastic WT harborTP53mutations"
                    ]
                  },
                  {
                    "text": "MYCNalterationsMutations inMYCNreported in WT, including P44L, which is also seen in some neuroblastomasCopy number gain and high expression seen in WT and associated with diffuse anaplasia",
                    "sub_points": [
                      "Mutations inMYCNreported in WT, including P44L, which is also seen in some neuroblastomas",
                      "Copy number gain and high expression seen in WT and associated with diffuse anaplasia"
                    ]
                  },
                  {
                    "text": "Mutations in miRNA processing genesSeen in ~ 20% of WT, generally mutually exclusiveGermline mutations inDICER1(DICER1 syndrome) andDIS3L2(Perlman syndrome) predispose to WTSporadic mutations in WT includeDROSHA,DICER1,DIS3L2,XPO5,DGCR8, andTARBP2",
                    "sub_points": [
                      "Seen in ~ 20% of WT, generally mutually exclusive",
                      "Germline mutations inDICER1(DICER1 syndrome) andDIS3L2(Perlman syndrome) predispose to WT",
                      "Sporadic mutations in WT includeDROSHA,DICER1,DIS3L2,XPO5,DGCR8, andTARBP2"
                    ]
                  },
                  {
                    "text": "FBXW7mutationsSomatic deletions or mutations found in 4% of WT",
                    "sub_points": [
                      "Somatic deletions or mutations found in 4% of WT"
                    ]
                  },
                  {
                    "text": "CTR9mutationsGermline inactivating mutations predispose to WT",
                    "sub_points": [
                      "Germline inactivating mutations predispose to WT"
                    ]
                  },
                  {
                    "text": "PTCH1alterationsVirtually all 9q22.3 microdeletion syndrome cases have deletion of 1 copy ofPTCH1Associated with increased risk for WT development",
                    "sub_points": [
                      "Virtually all 9q22.3 microdeletion syndrome cases have deletion of 1 copy ofPTCH1",
                      "Associated with increased risk for WT development"
                    ]
                  },
                  {
                    "text": "MLLT1mutationsSeen in 4% of WT; associated withCTNNB1mutations",
                    "sub_points": [
                      "Seen in 4% of WT; associated withCTNNB1mutations"
                    ]
                  },
                  {
                    "text": "RESTmutationsGermline and sporadic mutations described",
                    "sub_points": [
                      "Germline and sporadic mutations described"
                    ]
                  },
                  {
                    "text": "SIX1andSIX2mutationsSporadic mutations seen; associated with microRNA processing gene mutations",
                    "sub_points": [
                      "Sporadic mutations seen; associated with microRNA processing gene mutations"
                    ]
                  },
                  {
                    "text": "BRAFp.V600E mutationSubset of epithelial-predominant WT in adults and childrenMorphologic overlap with metanephric adenomaMay respond to BRAF targeted therapy",
                    "sub_points": [
                      "Subset of epithelial-predominant WT in adults and children",
                      "Morphologic overlap with metanephric adenoma",
                      "May respond to BRAF targeted therapy"
                    ]
                  },
                  {
                    "text": "TRIM28mutationsGermline or somatic mutations associated with WT with monomorphic epithelial histologySeen in young children, very good prognosis",
                    "sub_points": [
                      "Germline or somatic mutations associated with WT with monomorphic epithelial histology",
                      "Seen in young children, very good prognosis"
                    ]
                  },
                  {
                    "text": "Additional mutations uncovered by whole genomic sequencing includeBCOR,BCORL1,NONO,MAX,COL6A3,ASXL1,MAP3K4, andARID1A",
                    "sub_points": [
                      "BCOR,BCORL1,NONO,MAX,COL6A3,ASXL1,MAP3K4, andARID1A"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "WT typically shows triphasic appearance with mixture of blastema, epithelial, and stromal elements"
                  },
                  {
                    "text": "Only 1 or 2 components may be present in some cases"
                  },
                  {
                    "text": "BlastemaDensely packed small round cells with little cytoplasm, darkly staining nuclei, and inconspicuous nucleoliUsually numerous mitosesDiffuse, nodular, and serpiginous growth patterns",
                    "sub_points": [
                      "Densely packed small round cells with little cytoplasm, darkly staining nuclei, and inconspicuous nucleoli",
                      "Usually numerous mitoses",
                      "Diffuse, nodular, and serpiginous growth patterns"
                    ]
                  },
                  {
                    "text": "Epithelial componentsTypically tubules, cysts, or glomeruloid structures lined by cuboidal or columnar cellsMay see squamous, mucinous, or other epithelial differentiationPoorly formed rosette structures may be seen",
                    "sub_points": [
                      "Typically tubules, cysts, or glomeruloid structures lined by cuboidal or columnar cells",
                      "May see squamous, mucinous, or other epithelial differentiation",
                      "Poorly formed rosette structures may be seen"
                    ]
                  },
                  {
                    "text": "Stromal componentsUsually fibroblastic or myxoid spindle cellsHeterologous differentiation may be present: Skeletal and smooth muscle, fat, bone, cartilage, neural elements",
                    "sub_points": [
                      "Usually fibroblastic or myxoid spindle cells",
                      "Heterologous differentiation may be present: Skeletal and smooth muscle, fat, bone, cartilage, neural elements"
                    ]
                  },
                  {
                    "text": "WT with predominant skeletal muscle differentiation termed \"fetal rhabdomyomatous nephroblastoma\"Relatively chemoresistant but has good prognosis",
                    "sub_points": [
                      "Relatively chemoresistant but has good prognosis"
                    ]
                  },
                  {
                    "text": "WT with predominance of heterologous stromal and epithelial differentiation termed \"teratomatous WT\""
                  },
                  {
                    "text": "If chemotherapy precedes surgery, tumor may be completely necrotic, there may be accumulations of foamy macrophages, and there may be increased squamous and mucinous epithelial differentiation"
                  },
                  {
                    "text": "AnaplasiaAreas of tumor with definitely hyperchromatic large cells (3x diameter of blastemal cells in 2 axes) and large multipolar mitoses\"Focal anaplasia\" includes being confined to 1 or few discrete loci within primary tumor with no anaplasia or marked nuclear atypia elsewhere\"Diffuse anaplasia\" includes more extensive anaplasia, anaplastic tumor at margin, intravascular anaplastic tumor, or anaplastic tumor at extrarenal siteDiffuse anaplasia in WT is unfavorable histology",
                    "sub_points": [
                      "Areas of tumor with definitely hyperchromatic large cells (3x diameter of blastemal cells in 2 axes) and large multipolar mitoses",
                      "\"Focal anaplasia\" includes being confined to 1 or few discrete loci within primary tumor with no anaplasia or marked nuclear atypia elsewhere",
                      "\"Diffuse anaplasia\" includes more extensive anaplasia, anaplastic tumor at margin, intravascular anaplastic tumor, or anaplastic tumor at extrarenal site",
                      "Diffuse anaplasia in WT is unfavorable histology"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "WT1 expressed in blastemal and epithelial components"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Germline testingMay be indicated depending on clinical findings",
                    "sub_points": [
                      "May be indicated depending on clinical findings"
                    ]
                  },
                  {
                    "text": "Tumor testingGain of 1q: Strongest predictor of adverse outcomeLOH at 1p and 16q: If 1q normal, predicts poor outcomeLOH or LOI at 11p15,WT1mutations: Worse prognosis in very low-risk WTTP53mutation or 17p13 LOH,MYCNamplification or mutation: Worse prognosis",
                    "sub_points": [
                      "Gain of 1q: Strongest predictor of adverse outcome",
                      "LOH at 1p and 16q: If 1q normal, predicts poor outcome",
                      "LOH or LOI at 11p15,WT1mutations: Worse prognosis in very low-risk WT",
                      "TP53mutation or 17p13 LOH,MYCNamplification or mutation: Worse prognosis"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Clear Cell Sarcoma": [
                  {
                    "text": "Delicate fibrovascular septa"
                  },
                  {
                    "text": "WT1 negative, cyclin-D1 positive"
                  }
                ],
                "Rhabdoid Tumor": [
                  {
                    "text": "SMARCB1 (INI1) negative, WT1 negative"
                  }
                ],
                "Other Small Round Blue Cell Tumors": [
                  {
                    "text": "NeuroblastomaNeuroendocrine markers positive, WT1 negative",
                    "sub_points": [
                      "Neuroendocrine markers positive, WT1 negative"
                    ]
                  },
                  {
                    "text": "Ewing sarcomaCD99 and NKX2.2 positive, WT1 negative",
                    "sub_points": [
                      "CD99 and NKX2.2 positive, WT1 negative"
                    ]
                  }
                ],
                "Metanephric Adenoma": [
                  {
                    "text": "CD57 positive, WT1 negative or weak"
                  }
                ],
                "Papillary Renal Cell Carcinoma": [
                  {
                    "text": "CK7 and AMACR positive, WT1 negative"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Preneoplastic Conditions, Cervix/Vulva/Vagina": {
            "name": "Preneoplastic Conditions, Cervix/Vulva/Vagina",
            "url": "https://app.pathprimer.com/document/38801038-79ff-477f-b34a-f97e1a250ea3/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Cervix, vagina, and vulva (HPV-associated, HPV-A)Persistent high-risk (HR)-HPV infection is single most important factor in development of precancerous lesionsHR-HPV in high-grade squamous intraepithelial lesion (HSIL) and most low-grade squamous intraepithelial lesions (LSIL)",
                    "sub_points": [
                      "Persistent high-risk (HR)-HPV infection is single most important factor in development of precancerous lesions",
                      "HR-HPV in high-grade squamous intraepithelial lesion (HSIL) and most low-grade squamous intraepithelial lesions (LSIL)"
                    ]
                  },
                  {
                    "text": "Viral integration into host genome often present in HSILDegrades p53 and RB1; p16 overexpressedUpregulates genes in S-phase progression and cellular proliferation",
                    "sub_points": [
                      "Degrades p53 and RB1; p16 overexpressed",
                      "Upregulates genes in S-phase progression and cellular proliferation"
                    ]
                  },
                  {
                    "text": "Endocervical adenocarcinoma in situ (AIS)HR-HPV infection in ~ 80-90% with increased HPV-18",
                    "sub_points": [
                      "HR-HPV infection in ~ 80-90% with increased HPV-18"
                    ]
                  },
                  {
                    "text": "Differentiated vulvar intraepithelial neoplasm (HPV-independent HPV-I)TP53mutations detectable in most cases",
                    "sub_points": [
                      "TP53mutations detectable in most cases"
                    ]
                  },
                  {
                    "text": "Extramammary Paget disease10-20% associated with adenocarcinoma from Bartholin gland or skin adnexa20% associated with invasive adenocarcinoma elsewhere",
                    "sub_points": [
                      "10-20% associated with adenocarcinoma from Bartholin gland or skin adnexa",
                      "20% associated with invasive adenocarcinoma elsewhere"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Prevention of HPV-A diseasePrimary prevention with nonavalent HPV vaccine for protection against HSIL and genital wartsPap or primary HPV for initial screening options",
                    "sub_points": [
                      "Primary prevention with nonavalent HPV vaccine for protection against HSIL and genital warts",
                      "Pap or primary HPV for initial screening options"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "Common technique used for HR-HPV detection"
                  },
                  {
                    "text": "Signal amplification hybridization, real-time PCR, methylation status, amplification E6/E7 mRNA transcripts"
                  },
                  {
                    "text": "Extended genotyping of HR-HPV genotyping for assessment of squamous cell carcinoma risk"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunostain for p16 of value for histologic diagnosis of HSIL and adenocarcinoma in situ"
                  },
                  {
                    "text": "Cytology dual stain with CINtech Plus (p16 and Ki-67) for HSIL"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Intraepithelial lesions of lower female genital tract in squamous and glandular mucosa of cervix, vagina, and vulva"
                  },
                  {
                    "text": "ClassificationsLower anogenital squamous terminology (LAST): Low- and high-grade squamous intraepithelial lesions (LSIL/HSIL) with intraepithelial neoplasia (WHO-IN)Site-specific intraepithelial neoplasia (WHO)Cervical intraepithelial neoplasia (CIN) 1-3Vaginal intraepithelial neoplasia (VaIN) 1-3Vulvar intraepithelial neoplasia (VIN) 1-3",
                    "sub_points": [
                      "Lower anogenital squamous terminology (LAST): Low- and high-grade squamous intraepithelial lesions (LSIL/HSIL) with intraepithelial neoplasia (WHO-IN)",
                      "Site-specific intraepithelial neoplasia (WHO)Cervical intraepithelial neoplasia (CIN) 1-3Vaginal intraepithelial neoplasia (VaIN) 1-3Vulvar intraepithelial neoplasia (VIN) 1-3",
                      "Cervical intraepithelial neoplasia (CIN) 1-3",
                      "Vaginal intraepithelial neoplasia (VaIN) 1-3",
                      "Vulvar intraepithelial neoplasia (VIN) 1-3"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Cervix, Vagina, Vulva (HPV-Associated, HPV-A)": [
                  {
                    "text": "Persistent oncogenic high-risk HPV (HR-HPV) infection is single most important factor in development of precancerous lesions"
                  },
                  {
                    "text": "HR-HPV in HSIL and most LSILHPV-16, -18, -45, and -31 highest riskViral integration into host genome often present in HSILHPV proteins E6 and E7 overexpressed and degrade tumor suppressor proteins p53 and pRB1E6 upregulates telomerase with loss of replicative senescenceE7 upregulates genes necessary for S-phase progression and cellular proliferation; p16 overexpressedAltered regulation of apoptosis-related factorsBCL2, FasL, survivin, MDM, TP53, BAX, and caspase-3",
                    "sub_points": [
                      "HPV-16, -18, -45, and -31 highest risk",
                      "Viral integration into host genome often present in HSILHPV proteins E6 and E7 overexpressed and degrade tumor suppressor proteins p53 and pRB1E6 upregulates telomerase with loss of replicative senescence",
                      "HPV proteins E6 and E7 overexpressed and degrade tumor suppressor proteins p53 and pRB1",
                      "E6 upregulates telomerase with loss of replicative senescence",
                      "E7 upregulates genes necessary for S-phase progression and cellular proliferation; p16 overexpressed",
                      "Altered regulation of apoptosis-related factorsBCL2, FasL, survivin, MDM, TP53, BAX, and caspase-3",
                      "BCL2, FasL, survivin, MDM, TP53, BAX, and caspase-3"
                    ]
                  },
                  {
                    "text": "Cervical adenocarcinoma in situ (AIS)HPV infection in ~ 80-90% with increased HPV-18",
                    "sub_points": [
                      "HPV infection in ~ 80-90% with increased HPV-18"
                    ]
                  },
                  {
                    "text": "Other risk factors and cofactorsCigarette smoking, nutritional deficiencies, other sexually transmitted infections, early sexual debut, high parity, lack of Pap screeningImmunosuppression (HIV, posttransplant)",
                    "sub_points": [
                      "Cigarette smoking, nutritional deficiencies, other sexually transmitted infections, early sexual debut, high parity, lack of Pap screening",
                      "Immunosuppression (HIV, posttransplant)"
                    ]
                  },
                  {
                    "text": "VaIN and VIN risk factorsPrevious WHO-IN, previous pelvic irradiation (VAIN)",
                    "sub_points": [
                      "Previous WHO-IN, previous pelvic irradiation (VAIN)"
                    ]
                  }
                ],
                "Vulva (HPV-Independent, HPV-I)": [
                  {
                    "text": "Differentiated VIN (D-VIN)High-grade squamous dysplasia associated with lichen sclerosus in postmenopausal womenTP53mutations detectable in most casesSome cases associated with autoimmune disease",
                    "sub_points": [
                      "High-grade squamous dysplasia associated with lichen sclerosus in postmenopausal women",
                      "TP53mutations detectable in most cases",
                      "Some cases associated with autoimmune disease"
                    ]
                  },
                  {
                    "text": "Extramammary Paget disease (EPD)Primary type originates from pluripotent epidermal stem cells of skin or skin adnexaHigh frequency of mutations occurs in key genes of RAS/RAF and PI3K/AKT pathwaysSecondary type (20%) associated with metastatic adenocarcinoma (e.g., bowel, urogenital tract, breast)",
                    "sub_points": [
                      "Primary type originates from pluripotent epidermal stem cells of skin or skin adnexa",
                      "High frequency of mutations occurs in key genes of RAS/RAF and PI3K/AKT pathways",
                      "Secondary type (20%) associated with metastatic adenocarcinoma (e.g., bowel, urogenital tract, breast)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Cervix~ 200,000 cases of HSIL diagnosed by Pap yearly per CDC (2022)~ 0.6 cases/100,000 endocervical AIS",
                    "sub_points": [
                      "~ 200,000 cases of HSIL diagnosed by Pap yearly per CDC (2022)",
                      "~ 0.6 cases/100,000 endocervical AIS"
                    ]
                  },
                  {
                    "text": "Vagina~ 0.2 cases/100,000 VaIN among White women; ~ 0.3 cases/100,000 among Black women",
                    "sub_points": [
                      "~ 0.2 cases/100,000 VaIN among White women; ~ 0.3 cases/100,000 among Black women"
                    ]
                  },
                  {
                    "text": "VulvaEPD primarily presents in postmenopausal women of European descent",
                    "sub_points": [
                      "EPD primarily presents in postmenopausal women of European descent"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Average: 25 years for CIN; peak at 25-34 years"
                  },
                  {
                    "text": "Mean age of endocervical AIS: ~ 38 years"
                  },
                  {
                    "text": "Mean age for VaIN: 53 years; peak at 60-70 years"
                  },
                  {
                    "text": "4th-5th decade for VIN; 7th-8th decade for D-VIN"
                  },
                  {
                    "text": "After 4th decade for EPD, peak at 65 years"
                  }
                ],
                "Presentation": [
                  {
                    "text": "HSILAsymptomatic with abnormal squamous cells on PapColposcopy: Acetowhite lesions, abnormal vessels, and mosaicism",
                    "sub_points": [
                      "Asymptomatic with abnormal squamous cells on Pap",
                      "Colposcopy: Acetowhite lesions, abnormal vessels, and mosaicism"
                    ]
                  },
                  {
                    "text": "Endocervical AISAsymptomatic with abnormal glandular cells on PapColposcopy: Acetowhite to red lesions and abnormal vessels; concurrent SIL 50-70%",
                    "sub_points": [
                      "Asymptomatic with abnormal glandular cells on Pap",
                      "Colposcopy: Acetowhite to red lesions and abnormal vessels; concurrent SIL 50-70%"
                    ]
                  },
                  {
                    "text": "VaINAsymptomatic with normal or abnormal Pap test, sometimes vaginal bleedingColposcopy: Acetowhite to pink, raised lesions with abnormal vessels; upper 1/3 posterior wall50% multifocal, coexistent CIN or VIN in 10-30%",
                    "sub_points": [
                      "Asymptomatic with normal or abnormal Pap test, sometimes vaginal bleeding",
                      "Colposcopy: Acetowhite to pink, raised lesions with abnormal vessels; upper 1/3 posterior wall",
                      "50% multifocal, coexistent CIN or VIN in 10-30%"
                    ]
                  },
                  {
                    "text": "HPV-A VINVulvar irritation, pruritus, maculopapular or plaque, acetowhite to pigmented lesionsFound primarily on labia minora; 70% multifocal",
                    "sub_points": [
                      "Vulvar irritation, pruritus, maculopapular or plaque, acetowhite to pigmented lesions",
                      "Found primarily on labia minora; 70% multifocal"
                    ]
                  },
                  {
                    "text": "D-VINSymptomatic with pruritus in distribution of lichen sclerosus, dermatitis, eczema, and leukoplakia",
                    "sub_points": [
                      "Symptomatic with pruritus in distribution of lichen sclerosus, dermatitis, eczema, and leukoplakia"
                    ]
                  },
                  {
                    "text": "EPDSymptomatic with pruritus, pain, erythematous or eczematous lesion, and moist, weepy surfaceLocalized to widespread; may involve perianus",
                    "sub_points": [
                      "Symptomatic with pruritus, pain, erythematous or eczematous lesion, and moist, weepy surface",
                      "Localized to widespread; may involve perianus"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "HSILLaser electrocautery excision procedure (LEEP), cryotherapy, laser ablation, cold knife cone, observation if young",
                    "sub_points": [
                      "Laser electrocautery excision procedure (LEEP), cryotherapy, laser ablation, cold knife cone, observation if young"
                    ]
                  },
                  {
                    "text": "Endocervical AISCold knife cone, trachelectomy, or hysterectomy",
                    "sub_points": [
                      "Cold knife cone, trachelectomy, or hysterectomy"
                    ]
                  },
                  {
                    "text": "VaINExcision, partial vaginectomy, laser ablation, or topical 5-fluorouracil for VaIN 2-3",
                    "sub_points": [
                      "Excision, partial vaginectomy, laser ablation, or topical 5-fluorouracil for VaIN 2-3"
                    ]
                  },
                  {
                    "text": "VINTopical imiquimod for VIN 1, local excision, partial superficial vulvectomy, LEEP, or laser ablation for VIN 2-3",
                    "sub_points": [
                      "Topical imiquimod for VIN 1, local excision, partial superficial vulvectomy, LEEP, or laser ablation for VIN 2-3"
                    ]
                  },
                  {
                    "text": "EPDWide local excision or vulvectomy, topical 5-fluorouracil, laser ablation, or systemic retinoids",
                    "sub_points": [
                      "Wide local excision or vulvectomy, topical 5-fluorouracil, laser ablation, or systemic retinoids"
                    ]
                  },
                  {
                    "text": "PreventionPrimary: nonavalent HPV vaccine offers protection against HSIL and genital warts (HPV-16, -18, -31, -33, -45, -52, -58, -6, and -11)Secondary: Screening by Pap test at 21-25 years or primary HPV test at 25 years; cotesting 30-65 years",
                    "sub_points": [
                      "Primary: nonavalent HPV vaccine offers protection against HSIL and genital warts (HPV-16, -18, -31, -33, -45, -52, -58, -6, and -11)",
                      "Secondary: Screening by Pap test at 21-25 years or primary HPV test at 25 years; cotesting 30-65 years"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "CINLSIL: ~ 62% of LSIL regress in 24 months, 22% persist as LSIL, and 16% progress to HSILHSIL: ~ 50% of CIN 2 regress in 24 monthsHSIL: ~ 20% of CIN 3 progress to squamous cell carcinoma (SCC) if untreated",
                    "sub_points": [
                      "LSIL: ~ 62% of LSIL regress in 24 months, 22% persist as LSIL, and 16% progress to HSIL",
                      "HSIL: ~ 50% of CIN 2 regress in 24 months",
                      "HSIL: ~ 20% of CIN 3 progress to squamous cell carcinoma (SCC) if untreated"
                    ]
                  },
                  {
                    "text": "VaIN~ 5-10% of VaIN 3 progress to SCC after treatment",
                    "sub_points": [
                      "~ 5-10% of VaIN 3 progress to SCC after treatment"
                    ]
                  },
                  {
                    "text": "VIN~ 10% of HPV-related VIN 3 progress to SCC untreated~ 80-90% of differentiated VIN progresses to SCC",
                    "sub_points": [
                      "~ 10% of HPV-related VIN 3 progress to SCC untreated",
                      "~ 80-90% of differentiated VIN progresses to SCC"
                    ]
                  },
                  {
                    "text": "EPDMay persist for years as noninvasive lesion10-20% progress to invasive adenocarcinomaPoor prognosis if metastatic from other sites",
                    "sub_points": [
                      "May persist for years as noninvasive lesion",
                      "10-20% progress to invasive adenocarcinoma",
                      "Poor prognosis if metastatic from other sites"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "In Situ Hybridization": [
                  {
                    "text": "Tissue detection of HPV E6 and E7 mRNA (IS-HPV)"
                  }
                ],
                "PCR": [
                  {
                    "text": "RT-PCR detects specific viral RNA and multiple HPV types"
                  },
                  {
                    "text": "Extended genotyping for risk stratificationHPV-16, -18, -31, -45, -51, and -52; 35/39/68; 56/59/66; 33/58",
                    "sub_points": [
                      "HPV-16, -18, -31, -45, -51, and -52; 35/39/68; 56/59/66; 33/58"
                    ]
                  },
                  {
                    "text": "Methylation status by pyrosequencing or methylation-specific PCREPB41L3/L1,L2,CADM1/MAL,MAL/miR-124-2,FAM19A4/miR-124-2;SOX14",
                    "sub_points": [
                      "EPB41L3/L1,L2,CADM1/MAL,MAL/miR-124-2,FAM19A4/miR-124-2;SOX14"
                    ]
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "For HPV variants, novel HPV types, and integration sites"
                  },
                  {
                    "text": "LINC00290,LINC02500, andLENG9as possible driver genes"
                  }
                ],
                "mRNA E6/E7 Oncoprotein Overexpression": [
                  {
                    "text": "Upregulation of E6/E7 proteins with increased risk of SCC"
                  }
                ],
                "Signal Amplification Hybridization": [
                  {
                    "text": "DNA hybridization by hybrid capture or invader chemistry"
                  }
                ],
                "Lateral Flow Immunochromatographic Test": [
                  {
                    "text": "E6 protein from HPV-16, -18, and -45 detected in HSIL, AIS"
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Upregulation ofMCM,E2F1, and DNA repair genesBRCA2-BRIP1,FANCA, andCMYC"
                  },
                  {
                    "text": "MAPK, JAK-STAT, transcriptional misregulation pathways"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "HPV-A cervical, vaginal, and vulva show similar histologic findingsLSILExpanded basal layer and surface with enlarged, irregular, hyperchromatic, and crowded nucleiMitotic figures in lower 1/3 of epitheliumHSILNear- to full-thickness epithelium with enlarged, irregular, hyperchromatic cells, increased N:C ratioMitotic figures in all levels of epitheliumEndocervical AISHyperchromatic, pseudostratified nuclei, mitoses, apoptotic bodies, HSIL also seen in 50%Subtypes: Intestinal, endometrioid, gastric, tubal",
                    "sub_points": [
                      "LSILExpanded basal layer and surface with enlarged, irregular, hyperchromatic, and crowded nucleiMitotic figures in lower 1/3 of epithelium",
                      "Expanded basal layer and surface with enlarged, irregular, hyperchromatic, and crowded nuclei",
                      "Mitotic figures in lower 1/3 of epithelium",
                      "HSILNear- to full-thickness epithelium with enlarged, irregular, hyperchromatic cells, increased N:C ratioMitotic figures in all levels of epithelium",
                      "Near- to full-thickness epithelium with enlarged, irregular, hyperchromatic cells, increased N:C ratio",
                      "Mitotic figures in all levels of epithelium",
                      "Endocervical AISHyperchromatic, pseudostratified nuclei, mitoses, apoptotic bodies, HSIL also seen in 50%Subtypes: Intestinal, endometrioid, gastric, tubal",
                      "Hyperchromatic, pseudostratified nuclei, mitoses, apoptotic bodies, HSIL also seen in 50%",
                      "Subtypes: Intestinal, endometrioid, gastric, tubal"
                    ]
                  },
                  {
                    "text": "D-VINMarked nuclear atypia in basal layer with some superficial maturation and differentiationBasal nuclei with pleomorphism, dispersed chromatin, eosinophilic cytoplasm, prominent nucleoli, and mitoses",
                    "sub_points": [
                      "Marked nuclear atypia in basal layer with some superficial maturation and differentiation",
                      "Basal nuclei with pleomorphism, dispersed chromatin, eosinophilic cytoplasm, prominent nucleoli, and mitoses"
                    ]
                  },
                  {
                    "text": "EPDIntraepithelial proliferation of atypical cells with enlarged nuclei, prominent nucleoli, and abundant cytoplasm",
                    "sub_points": [
                      "Intraepithelial proliferation of atypical cells with enlarged nuclei, prominent nucleoli, and abundant cytoplasm"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Cervix, vagina, and vulva HR-HPV-A lesionsp16 strongly and diffusely (+), CINtec PLUS (+) (p16 and Ki-67), ProExC (+) (Top2a and MCM2), IS-HPV",
                    "sub_points": [
                      "p16 strongly and diffusely (+), CINtec PLUS (+) (p16 and Ki-67), ProExC (+) (Top2a and MCM2), IS-HPV"
                    ]
                  },
                  {
                    "text": "Endocervical AISp16 strongly and diffusely (+); CEA (+), ProExC (+), Ki-67 (+) > 75%; ER (-), vimentin (-)Intestinal type CDX2 (+), may be p16 (-)",
                    "sub_points": [
                      "p16 strongly and diffusely (+); CEA (+), ProExC (+), Ki-67 (+) > 75%; ER (-), vimentin (-)",
                      "Intestinal type CDX2 (+), may be p16 (-)"
                    ]
                  },
                  {
                    "text": "EPDPrimary: CK7, CEA, GCDFP-15, GATA3, and BerEp4 (+)ER, PR, HMB-45, and MART1/Melan-A (-)Secondary: Shows site of origin-specific staining",
                    "sub_points": [
                      "Primary: CK7, CEA, GCDFP-15, GATA3, and BerEp4 (+)ER, PR, HMB-45, and MART1/Melan-A (-)",
                      "ER, PR, HMB-45, and MART1/Melan-A (-)",
                      "Secondary: Shows site of origin-specific staining"
                    ]
                  },
                  {
                    "text": "Differentiated VINp53 (+) in basal layer in > 50%, Ki-67 (+) over background, p16 (-), HR-HPV (-)",
                    "sub_points": [
                      "p53 (+) in basal layer in > 50%, Ki-67 (+) over background, p16 (-), HR-HPV (-)"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Atrophy, Reactive and Radiation Atypia": [
                  {
                    "text": "Nuclear enlargement and atypia similar to CIN, VaIN, VIN"
                  },
                  {
                    "text": "All are negative for p16, IS-HPV"
                  }
                ],
                "Mesonephric Remnants": [
                  {
                    "text": "Glandular proliferation in deep lateral cervical wall"
                  },
                  {
                    "text": "PAS (+) luminal material, GATA3 (+), p16 (-), HR-HPV (-)"
                  }
                ],
                "Tubal Metaplasia": [
                  {
                    "text": "Endocervical glands with cilia, bland nuclei lacking mitoses"
                  },
                  {
                    "text": "ER/PR (+), p16 patchy (+), BCL2 (+), vimentin (+), and HPV (-)"
                  }
                ],
                "Endometriosis": [
                  {
                    "text": "Presence of endometrial glands and stroma in cervix"
                  },
                  {
                    "text": "ER, PR, BCL2, and vimentin (+), stroma CD10 (+), and p16 (-)"
                  }
                ],
                "Melanoma, In Situ and Superficial Spreading": [
                  {
                    "text": "Atypical basal cells with prominent nucleoli ± pigmented"
                  },
                  {
                    "text": "S100, A103, HMB45, MART1, and SOX10 (+)"
                  },
                  {
                    "text": "Cytokeratin (-) and GCDFP15 (-) help differentiate EPD"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "BCR::ABL1Fusion": {
            "name": "BCR::ABL1Fusion",
            "url": "https://app.pathprimer.com/document/f9a013ff-5e25-4889-8fb8-7ce2dec987c9/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Philadelphia (Ph) chromosomeTerminology extensively used forBCR::ABL1fusion",
                    "sub_points": [
                      "Terminology extensively used forBCR::ABL1fusion"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "BCR::ABL1fusion due to reciprocal translocation involving long arms of chromosomes 9 and 22"
                  }
                ],
                "Historical View": [
                  {
                    "text": "1960: Discovered and named Ph-chromosome by Nowell and HungerfordCalled aberrant acrocentric chromosome 22 in 7 patients with chronic myeloid leukemia (CML)1st recurrent chromosomal abnormality linked to human malignancy",
                    "sub_points": [
                      "Called aberrant acrocentric chromosome 22 in 7 patients with chronic myeloid leukemia (CML)",
                      "1st recurrent chromosomal abnormality linked to human malignancy"
                    ]
                  },
                  {
                    "text": "1973: Janet Rowley utilized chromosomal banding techniques to demonstrate underlying t(9;22)(q34.1;q11.2)"
                  },
                  {
                    "text": "1998: Imatinib (Gleevec) targeted therapy introduced"
                  },
                  {
                    "text": "2001: Imatinib approved as 1st-line therapy for CML2nd- (dasatinib, nilotinib, bosutinib) and 3rd- (ponatinib) generation tyrosine kinase inhibitor (TKI) therapies also availableAllosteric inhibitors ofBCR::ABL1kinase activity (asciminib) and plant alkaloid derived pharmaceuticals (omacetaxine) are other approved treatments",
                    "sub_points": [
                      "2nd- (dasatinib, nilotinib, bosutinib) and 3rd- (ponatinib) generation tyrosine kinase inhibitor (TKI) therapies also available",
                      "Allosteric inhibitors ofBCR::ABL1kinase activity (asciminib) and plant alkaloid derived pharmaceuticals (omacetaxine) are other approved treatments"
                    ]
                  }
                ],
                "Normal Function ofBCR": [
                  {
                    "text": "Localizes to chromosome 22q11.2"
                  },
                  {
                    "text": "Protein with regulatory activities toward small GTP-binding proteins through GTPase activity modulation, including RAC1"
                  },
                  {
                    "text": "Amino terminus contains intrinsic kinase activity"
                  }
                ],
                "Normal Function ofABL1": [
                  {
                    "text": "Localizes to chromosome 9q34.1"
                  },
                  {
                    "text": "Protooncogene involved in variety of cellular processes, including cell division, adhesion, differentiation, and stress responses"
                  },
                  {
                    "text": "Encodes cytoplasmic and nuclear nonreceptor tyrosine kinase"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "t(9;22)(q34.1;q11.2)": [
                  {
                    "text": "Reciprocal translocation following breakpoints withinBCRandABL1lociEncodes oncogenicBCR::ABL1fusion proteinTranslocation is balanced in majority of casesLoss of portion of reciprocalABL1::BCRfound in derivative chromosome 9 in ~ 10% of CML cases",
                    "sub_points": [
                      "Encodes oncogenicBCR::ABL1fusion protein",
                      "Translocation is balanced in majority of cases",
                      "Loss of portion of reciprocalABL1::BCRfound in derivative chromosome 9 in ~ 10% of CML cases"
                    ]
                  },
                  {
                    "text": "t(9;22)(q34.1;q11.2) fuses 3' sequences fromABL1to 5' sequences fromBCR"
                  },
                  {
                    "text": "ABL1breakpoint typically between exons 1-2 (a2)RareABL1breakpoints occur between exons 2-3 (a3)Known a3 fusions include e13a3, e14a3, and e1a3",
                    "sub_points": [
                      "RareABL1breakpoints occur between exons 2-3 (a3)",
                      "Known a3 fusions include e13a3, e14a3, and e1a3"
                    ]
                  },
                  {
                    "text": "BCRwith at least 3 different breakpoint regionsMajor breakpoint cluster region (M-BCR)Breakpoints occur in region spanning exon 12-16 (a.k.a. exons b1-b5)Mostly between exons 13-14 or exons 14-15Fusions withABL1 a2lead to mRNA products referred to as e13a2 or e14a2Result in 210 kDa fusion protein (p210)Minor breakpoint cluster region (m-BCR)Arise 5' of M-BCR between exons 1-2 (e1)Fusion withABL1 a2results in e1a2 transcriptsResults in 190 kDa fusion protein (p190)Micro breakpoint cluster region (μ-BCR)RareBCRbreakpoint between exons 17-20Results in 230 kDa fusion protein (p230)",
                    "sub_points": [
                      "Major breakpoint cluster region (M-BCR)Breakpoints occur in region spanning exon 12-16 (a.k.a. exons b1-b5)Mostly between exons 13-14 or exons 14-15Fusions withABL1 a2lead to mRNA products referred to as e13a2 or e14a2Result in 210 kDa fusion protein (p210)",
                      "Breakpoints occur in region spanning exon 12-16 (a.k.a. exons b1-b5)Mostly between exons 13-14 or exons 14-15",
                      "Mostly between exons 13-14 or exons 14-15",
                      "Fusions withABL1 a2lead to mRNA products referred to as e13a2 or e14a2Result in 210 kDa fusion protein (p210)",
                      "Result in 210 kDa fusion protein (p210)",
                      "Minor breakpoint cluster region (m-BCR)Arise 5' of M-BCR between exons 1-2 (e1)Fusion withABL1 a2results in e1a2 transcriptsResults in 190 kDa fusion protein (p190)",
                      "Arise 5' of M-BCR between exons 1-2 (e1)",
                      "Fusion withABL1 a2results in e1a2 transcriptsResults in 190 kDa fusion protein (p190)",
                      "Results in 190 kDa fusion protein (p190)",
                      "Micro breakpoint cluster region (μ-BCR)RareBCRbreakpoint between exons 17-20Results in 230 kDa fusion protein (p230)",
                      "RareBCRbreakpoint between exons 17-20",
                      "Results in 230 kDa fusion protein (p230)"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Chronic Myeloid Leukemia": [
                  {
                    "text": "BCR::ABL1is required to diagnose CMLFISH &/or RT-PCR must be performed in suspected cases with negative cytogeneticsFISH &/or RT-PCR may identify cryptic fusions missed by conventional karyotypingVery rare cryptic fusions may also be missed by FISH but can be detected by RT-PCR",
                    "sub_points": [
                      "FISH &/or RT-PCR must be performed in suspected cases with negative cytogeneticsFISH &/or RT-PCR may identify cryptic fusions missed by conventional karyotypingVery rare cryptic fusions may also be missed by FISH but can be detected by RT-PCR",
                      "FISH &/or RT-PCR may identify cryptic fusions missed by conventional karyotyping",
                      "Very rare cryptic fusions may also be missed by FISH but can be detected by RT-PCR"
                    ]
                  },
                  {
                    "text": "Multipotent hematopoietic progenitor is affectedFusion gene present in all stages of granulocytic, erythroid, and megakaryocytic lineages",
                    "sub_points": [
                      "Fusion gene present in all stages of granulocytic, erythroid, and megakaryocytic lineages"
                    ]
                  },
                  {
                    "text": "Major breakpoint cluster region (M-BCR, p210 transcripts) involved in ~ 99% of CML cases"
                  },
                  {
                    "text": "Primary fusion involving minor breakpoint cluster region (m-BCR, p190 transcripts) in only 1% of CML"
                  },
                  {
                    "text": "> 90% of cases with p210 will have low-level p190 transcripts detectable at initial diagnosisLow-level p190 due to alternative splicing ofBCR",
                    "sub_points": [
                      "Low-level p190 due to alternative splicing ofBCR"
                    ]
                  },
                  {
                    "text": "Primary micro breakpoint cluster region fusions (μ-BCR, p230 transcripts) are rareCases with p230 show prominent mature neutrophilia &/or conspicuous thrombocytosis",
                    "sub_points": [
                      "Cases with p230 show prominent mature neutrophilia &/or conspicuous thrombocytosis"
                    ]
                  }
                ],
                "B-Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "~ 25% of adult B-ALL cases areBCR::ABL1-positive~ 60% of Ph(+) cases involve m-BCR (p190)Remaining 40% involve M-BCR (p210)",
                    "sub_points": [
                      "~ 60% of Ph(+) cases involve m-BCR (p190)",
                      "Remaining 40% involve M-BCR (p210)"
                    ]
                  },
                  {
                    "text": "~ 2-4% of childhood B-ALL areBCR::ABL1-positive~ 90% of cases involve m-BCR (p190)",
                    "sub_points": [
                      "~ 90% of cases involve m-BCR (p190)"
                    ]
                  },
                  {
                    "text": "WHO 5th edition classification for B-ALL withBCR::ABL1is unchanged from prior edition"
                  },
                  {
                    "text": "International Consensus Classification (ICC) system dividesBCR::ABL1-positive ALL into 2 biologically distinct subsetsOne subset is biologically closer to CML presenting in lymphoid blast phaseDistinguished by detection ofBCR::ABL1fusion in both leukemic lymphoblasts and non-ALL lymphocytes/granulocytesSuggests multipotent hematopoietic progenitor is affected byBCR::ABL1fusionThis subset is distinguished on basis of FISH analysis and is not identifiable byBCR::ABL1fusion transcript analysisMay require cell sorting or granulocyte enrichment step prior to FISH to obtain sufficient cells for analysisWill demonstrate higherBCR::ABL1fusion levels thanIGH/TCRrearrangements when monitoring for minimal residual disease (MRD)2nd subset is closer to more conventional lymphoblastic leukemia/lymphomaBCR::ABL1fusion is present only in lymphoblasts",
                    "sub_points": [
                      "One subset is biologically closer to CML presenting in lymphoid blast phaseDistinguished by detection ofBCR::ABL1fusion in both leukemic lymphoblasts and non-ALL lymphocytes/granulocytesSuggests multipotent hematopoietic progenitor is affected byBCR::ABL1fusionThis subset is distinguished on basis of FISH analysis and is not identifiable byBCR::ABL1fusion transcript analysisMay require cell sorting or granulocyte enrichment step prior to FISH to obtain sufficient cells for analysisWill demonstrate higherBCR::ABL1fusion levels thanIGH/TCRrearrangements when monitoring for minimal residual disease (MRD)",
                      "Distinguished by detection ofBCR::ABL1fusion in both leukemic lymphoblasts and non-ALL lymphocytes/granulocytesSuggests multipotent hematopoietic progenitor is affected byBCR::ABL1fusionThis subset is distinguished on basis of FISH analysis and is not identifiable byBCR::ABL1fusion transcript analysisMay require cell sorting or granulocyte enrichment step prior to FISH to obtain sufficient cells for analysisWill demonstrate higherBCR::ABL1fusion levels thanIGH/TCRrearrangements when monitoring for minimal residual disease (MRD)",
                      "Suggests multipotent hematopoietic progenitor is affected byBCR::ABL1fusion",
                      "This subset is distinguished on basis of FISH analysis and is not identifiable byBCR::ABL1fusion transcript analysis",
                      "May require cell sorting or granulocyte enrichment step prior to FISH to obtain sufficient cells for analysis",
                      "Will demonstrate higherBCR::ABL1fusion levels thanIGH/TCRrearrangements when monitoring for minimal residual disease (MRD)",
                      "2nd subset is closer to more conventional lymphoblastic leukemia/lymphomaBCR::ABL1fusion is present only in lymphoblasts",
                      "BCR::ABL1fusion is present only in lymphoblasts"
                    ]
                  }
                ],
                "Acute Myeloid Leukemia WithBCR::ABL1": [
                  {
                    "text": "Rare acute myeloid leukemia (AML) subtype (< 1%) recognized by both WHO 5th edition and ICC systemsDe novo AML with no evidence of prior CMLMost cases involve M-BCR (p210)≥ 20% blasts required for diagnosis by both WHO and ICCVariable anemia and thrombocytopeniaLower peripheral blood basophilia (usually < 2%)",
                    "sub_points": [
                      "De novo AML with no evidence of prior CML",
                      "Most cases involve M-BCR (p210)",
                      "≥ 20% blasts required for diagnosis by both WHO and ICC",
                      "Variable anemia and thrombocytopenia",
                      "Lower peripheral blood basophilia (usually < 2%)"
                    ]
                  }
                ],
                "Mixed Phenotype Acute Leukemia WithBCR::ABL1": [
                  {
                    "text": "p190 transcript is more common than p210 transcript"
                  },
                  {
                    "text": "If p210 transcript detected, CML in mixed blast crisis should be considered; especially if 2 distinct myeloid and lymphoid blast populations are present"
                  }
                ]
              },
              "Methods of Detection": {
                "Conventional Cytogenetics": [
                  {
                    "text": "Detects t(9;22)(q34.1;q11.2) in ~ 95% of casesPresumptive evidence forBCR::ABL1fusion gene",
                    "sub_points": [
                      "Presumptive evidence forBCR::ABL1fusion gene"
                    ]
                  },
                  {
                    "text": "Also identifies variant t(9;22) translocations as well as other chromosomal aberrancies if present"
                  },
                  {
                    "text": "Cryptic translocations are not detected"
                  },
                  {
                    "text": "Inappropriate for disease monitoring; low detection sensitivity (~ 5%)Not useful for MRD detection",
                    "sub_points": [
                      "Not useful for MRD detection"
                    ]
                  }
                ],
                "FISH": [
                  {
                    "text": "IdentifiesBCR::ABL1fusion in > 95% of casesDetects most cryptic rearrangementsRare cryptic rearrangements may be missed",
                    "sub_points": [
                      "Detects most cryptic rearrangements",
                      "Rare cryptic rearrangements may be missed"
                    ]
                  },
                  {
                    "text": "More sensitive than conventional cytogenetics but insufficient for MRD or early relapse detection"
                  },
                  {
                    "text": "Cannot differentiate between various fusion transcripts"
                  }
                ],
                "Quantitative Real-Time PCR": [
                  {
                    "text": "Reliably determines type ofBCR::ABL1transcript"
                  },
                  {
                    "text": "More accurately quantifiesBCR::ABL1transcripts"
                  },
                  {
                    "text": "Standard for monitoring treatment response, MRD, and early relapse detection"
                  },
                  {
                    "text": "International Scale was developed to standardize inter-laboratory quantitative reporting of transcript levels"
                  },
                  {
                    "text": "Basic principles for quantitative real-time PCRRNA extraction from fresh blood, bone marrow, or other involved sitesReverse transcription to convert RNA to cDNAReal-time PCR amplification using primer sets to cover desiredBCR::ABL1fusionsSmall probes of ~ 25 bases in lengthMany laboratories in USA use \"European network probes\" complementary to portion ofABL1sequences in proximity of fusion withBCRSimultaneous PCR amplification of internal control gene, such asABL1,B2M,GUSB, or other genesInclusion of serially diluted positive cell line/plasmid controls",
                    "sub_points": [
                      "RNA extraction from fresh blood, bone marrow, or other involved sites",
                      "Reverse transcription to convert RNA to cDNA",
                      "Real-time PCR amplification using primer sets to cover desiredBCR::ABL1fusions",
                      "Small probes of ~ 25 bases in lengthMany laboratories in USA use \"European network probes\" complementary to portion ofABL1sequences in proximity of fusion withBCR",
                      "Many laboratories in USA use \"European network probes\" complementary to portion ofABL1sequences in proximity of fusion withBCR",
                      "Simultaneous PCR amplification of internal control gene, such asABL1,B2M,GUSB, or other genes",
                      "Inclusion of serially diluted positive cell line/plasmid controls"
                    ]
                  }
                ],
                "Digital Droplet PCR": [
                  {
                    "text": "May be feasible alternate to quantitative real-time PCR"
                  },
                  {
                    "text": "Returns absolute quantification, which may also be expressed as percentage on IS"
                  }
                ]
              },
              "Disease Monitoring in CML and Ph(+) B-ALL": {
                "Detection of Minimal Residual Disease and Treatment Response in Chronic Myeloid Leukemia": [
                  {
                    "text": "Quantitative real-time PCR is recommended at diagnosis and for monitoring"
                  },
                  {
                    "text": "Level ofBCR::ABL1transcripts can be expressed using 2 different methodsRatio ofBCR::ABL1toABL1internal control gene (or other selected internal control gene) methodRatios of ≥ 0.1 are typically present at diagnosis and indicate high copy numbers of transcriptsMajor molecular response (MMR) is defined asBCR::ABL1toABL1ratio with ≥ 3 log reduction from baselineDisease burden as determined by International Standard (IS) methodTranscript levels at initial diagnosis set as 100% ISMajor molecular response (≥ 3 log reduction, MR3.0) defined as IS value of ≤ 0.1%Ongoing lack of consensus regarding levels for deep molecular response (DMR)MR4.0 (IS ≤ 0.01%) and MR4.5 (IS ≤ 0.0032%) both in useAchieving and maintaining DMR required for consideration of discontinuing TKI therapy",
                    "sub_points": [
                      "Ratio ofBCR::ABL1toABL1internal control gene (or other selected internal control gene) methodRatios of ≥ 0.1 are typically present at diagnosis and indicate high copy numbers of transcriptsMajor molecular response (MMR) is defined asBCR::ABL1toABL1ratio with ≥ 3 log reduction from baseline",
                      "Ratios of ≥ 0.1 are typically present at diagnosis and indicate high copy numbers of transcripts",
                      "Major molecular response (MMR) is defined asBCR::ABL1toABL1ratio with ≥ 3 log reduction from baseline",
                      "Disease burden as determined by International Standard (IS) methodTranscript levels at initial diagnosis set as 100% ISMajor molecular response (≥ 3 log reduction, MR3.0) defined as IS value of ≤ 0.1%Ongoing lack of consensus regarding levels for deep molecular response (DMR)MR4.0 (IS ≤ 0.01%) and MR4.5 (IS ≤ 0.0032%) both in useAchieving and maintaining DMR required for consideration of discontinuing TKI therapy",
                      "Transcript levels at initial diagnosis set as 100% IS",
                      "Major molecular response (≥ 3 log reduction, MR3.0) defined as IS value of ≤ 0.1%",
                      "Ongoing lack of consensus regarding levels for deep molecular response (DMR)MR4.0 (IS ≤ 0.01%) and MR4.5 (IS ≤ 0.0032%) both in useAchieving and maintaining DMR required for consideration of discontinuing TKI therapy",
                      "MR4.0 (IS ≤ 0.01%) and MR4.5 (IS ≤ 0.0032%) both in use",
                      "Achieving and maintaining DMR required for consideration of discontinuing TKI therapy"
                    ]
                  },
                  {
                    "text": "Peripheral blood is suitable for monitoring diseaseBCR::ABL1transcripts are present in all myeloid lineages, including in segmented neutrophils",
                    "sub_points": [
                      "BCR::ABL1transcripts are present in all myeloid lineages, including in segmented neutrophils"
                    ]
                  },
                  {
                    "text": "Bone marrow specimen is not typically needed for disease monitoring"
                  }
                ],
                "Detection of Treatment Response and Early Relapse in Ph(+) ALL": [
                  {
                    "text": "Quantitative real-time PCR is recommended test for disease monitoringTherapeutic aim is complete molecular response with attainment of negativity forBCR::ABL1transcriptsDetection of low-levelBCR::ABL1transcripts following complete molecular response predicts recurrent disease at early molecular relapse stageIS reporting is not applicable to Ph(+) B-ALL",
                    "sub_points": [
                      "Therapeutic aim is complete molecular response with attainment of negativity forBCR::ABL1transcriptsDetection of low-levelBCR::ABL1transcripts following complete molecular response predicts recurrent disease at early molecular relapse stageIS reporting is not applicable to Ph(+) B-ALL",
                      "Detection of low-levelBCR::ABL1transcripts following complete molecular response predicts recurrent disease at early molecular relapse stage",
                      "IS reporting is not applicable to Ph(+) B-ALL"
                    ]
                  },
                  {
                    "text": "Bone marrow preferred for disease monitoring in Ph(+) B-ALLIn contrast to CML,BCR::ABL1transcripts may be limited to B lymphoblastsPeripheral blood has low detection sensitivity for patients in morphologic remission",
                    "sub_points": [
                      "In contrast to CML,BCR::ABL1transcripts may be limited to B lymphoblasts",
                      "Peripheral blood has low detection sensitivity for patients in morphologic remission"
                    ]
                  }
                ]
              },
              "BCR::ABL1-Resistant Mutations": {
                "Mutations inABL1Kinase Domain": [
                  {
                    "text": "Most common cause of acquired tyrosine kinase inhibitor (TKI) resistance"
                  },
                  {
                    "text": "> 80 mutations reported, mostly single nucleotide substitutionsMutations at G250, Y253, E255, T315, M351, F359, and H396 codons account for ~ 60% of all mutationsT315I/A and mutations in codon F317 and V299 associated with dasatinib resistanceY253H, E255K/V, T315I, and F359C/V/I mutations are associated with nilotinib resistanceL248V, G250E, V299L, T315I, F317L, and F359C mutations are associated with bosutinib resistancePonatinib (3rd-generation kinase inhibitor), asciminib (allosteric inhibitor), and omacetaxine may be used in some treatment-resistant CML cases with any mutations, including T315I",
                    "sub_points": [
                      "Mutations at G250, Y253, E255, T315, M351, F359, and H396 codons account for ~ 60% of all mutations",
                      "T315I/A and mutations in codon F317 and V299 associated with dasatinib resistance",
                      "Y253H, E255K/V, T315I, and F359C/V/I mutations are associated with nilotinib resistance",
                      "L248V, G250E, V299L, T315I, F317L, and F359C mutations are associated with bosutinib resistance",
                      "Ponatinib (3rd-generation kinase inhibitor), asciminib (allosteric inhibitor), and omacetaxine may be used in some treatment-resistant CML cases with any mutations, including T315I"
                    ]
                  },
                  {
                    "text": "Analysis of RNA required to ensureABL1kinase domain mutation is within fusion transcript"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "EGFRMutations": {
            "name": "EGFRMutations",
            "url": "https://app.pathprimer.com/document/24987eb1-b769-4f7e-8549-e75e11105c38/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Official name: Epidermal growth factor receptor"
                  },
                  {
                    "text": "Official symbol:EGFR"
                  },
                  {
                    "text": "HGNC ID: 3236"
                  },
                  {
                    "text": "Chromosomal location: 7p11.2"
                  },
                  {
                    "text": "Genomic location: Chr7:55,019,017-55,211,628 (GRCh38/hg38)"
                  },
                  {
                    "text": "Size: 1,210 amino acids"
                  },
                  {
                    "text": "Number of exons: 28"
                  },
                  {
                    "text": "Aliases: Receptor tyrosine-protein kinase ErbB-1, ERBB1, ERBB, ERRP, HER1"
                  }
                ]
              },
              "STRUCTURE AND FUNCTIONS OF EGFR PROTEIN": {
                "EGFR Structure": [
                  {
                    "text": "Plasma transmembrane glycoprotein composed ofExtracellular ligand-binding domains with 2 cysteine-rich regionsSingle transmembrane helix domainIntracellular region containing tyrosine kinase domain and autophosphorylation regions",
                    "sub_points": [
                      "Extracellular ligand-binding domains with 2 cysteine-rich regions",
                      "Single transmembrane helix domain",
                      "Intracellular region containing tyrosine kinase domain and autophosphorylation regions"
                    ]
                  },
                  {
                    "text": "Ligands of EGFR7 ligands binding EGFREpidermal growth factor (EGF), transforming growth factor alpha (TGFA), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), and epigenIn general, EGFR ligands are synthesized as type 1 transmembrane precursors that undergo extracellular domain cleavage to release soluble ligands",
                    "sub_points": [
                      "7 ligands binding EGFREpidermal growth factor (EGF), transforming growth factor alpha (TGFA), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), and epigen",
                      "Epidermal growth factor (EGF), transforming growth factor alpha (TGFA), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), and epigen",
                      "In general, EGFR ligands are synthesized as type 1 transmembrane precursors that undergo extracellular domain cleavage to release soluble ligands"
                    ]
                  }
                ],
                "EGFR Functions": [
                  {
                    "text": "Binding of ligand to extracellular domain results in activation ofEGFRpathway"
                  },
                  {
                    "text": "Activation of downstream pathways leads to cell proliferation, differentiation, migration/motility, adhesion, protection from apoptosis, and transformation"
                  }
                ]
              },
              "EGFR ALTERATIONS": {
                "Extracellular Domain Mutations": [
                  {
                    "text": "EGFRvariant III: Most common type of extracellular domain mutationDeletion of exons 2-7 ofEGFRin extracellular domainRenders mutant receptor incapable of binding any known ligandsDisplays low-level constitutive EGFR activityDrives tumor progression and correlates with poor prognosisMainly occur in glioblastoma multiforme (GBM) (~ 60%)Rarely occur in epithelial neoplasms, including breast, prostate, ovarian, and non-small cell lung carcinoma (NSCLC)",
                    "sub_points": [
                      "Deletion of exons 2-7 ofEGFRin extracellular domain",
                      "Renders mutant receptor incapable of binding any known ligands",
                      "Displays low-level constitutive EGFR activity",
                      "Drives tumor progression and correlates with poor prognosis",
                      "Mainly occur in glioblastoma multiforme (GBM) (~ 60%)",
                      "Rarely occur in epithelial neoplasms, including breast, prostate, ovarian, and non-small cell lung carcinoma (NSCLC)"
                    ]
                  },
                  {
                    "text": "Deletion of amino acids 521-603 in extracellular domain: Much less common thanEGFRvariant III"
                  }
                ],
                "Intracellular Kinase Domain Mutations": [
                  {
                    "text": "Most are activating mutations affecting exons 18-21"
                  },
                  {
                    "text": "Mutations result in constitutive activation of EGFR protein and subsequent oncogenesis"
                  },
                  {
                    "text": "Majority of mutations show enhanced sensitivity to 1st-generation tyrosine kinase inhibitors (TKIs)"
                  },
                  {
                    "text": "Found in NSCLC with adenocarcinoma histology~ 10-15% of NSCLC patients in western nations harborEGFRmutations~ 40% of NSCLC in Asian populations harborEGFRmutationsMore common in female patients who are nonsmokers or light smokers",
                    "sub_points": [
                      "~ 10-15% of NSCLC patients in western nations harborEGFRmutations",
                      "~ 40% of NSCLC in Asian populations harborEGFRmutations",
                      "More common in female patients who are nonsmokers or light smokers"
                    ]
                  },
                  {
                    "text": "SpecificEGFRmutations in tyrosine kinase domainExon 18 mutationsAccount for ~ 5% ofEGFRmutationsRelatively common mutations include G719C, G719S, and G719A; less common mutations include V689M, E709K, E709Q, and N700DExon 19 mutationsDeletion mutations, 9-18 bp deletions in exon 19Account for ~ 45% ofEGFRmutations; most frequent is p.E746_A750delD761Y (< 1%) is associated with resistance to TKIsExon 20 mutationsT790MConfers resistance to 1st- and 2nd-generation TKIsAccounts for ~ 50% of resistance-associated mutations to TKIsDevelops post EGFR TKI treatment in NSCLCCan also be primary event before drug exposureExon 20 in-frame insertion mutationsHeterogeneous in-frame insertions of 1-7 amino acids within D761-C775 in exon 20Results in constitutive activation of EGFR proteinAssociated with de novo resistance to targeted EGFR inhibitors and correlated with poor prognosise.g., D770-N771insX, V769-D770insX, H773-V774insX, P772-H773insX, N771-P772insXExon 21 mutationsAccount for 40-45% ofEGFRmutationsL858R is most common point mutation inEGFR",
                    "sub_points": [
                      "Exon 18 mutationsAccount for ~ 5% ofEGFRmutationsRelatively common mutations include G719C, G719S, and G719A; less common mutations include V689M, E709K, E709Q, and N700D",
                      "Account for ~ 5% ofEGFRmutations",
                      "Relatively common mutations include G719C, G719S, and G719A; less common mutations include V689M, E709K, E709Q, and N700D",
                      "Exon 19 mutationsDeletion mutations, 9-18 bp deletions in exon 19Account for ~ 45% ofEGFRmutations; most frequent is p.E746_A750delD761Y (< 1%) is associated with resistance to TKIs",
                      "Deletion mutations, 9-18 bp deletions in exon 19Account for ~ 45% ofEGFRmutations; most frequent is p.E746_A750del",
                      "Account for ~ 45% ofEGFRmutations; most frequent is p.E746_A750del",
                      "D761Y (< 1%) is associated with resistance to TKIs",
                      "Exon 20 mutationsT790MConfers resistance to 1st- and 2nd-generation TKIsAccounts for ~ 50% of resistance-associated mutations to TKIsDevelops post EGFR TKI treatment in NSCLCCan also be primary event before drug exposureExon 20 in-frame insertion mutationsHeterogeneous in-frame insertions of 1-7 amino acids within D761-C775 in exon 20Results in constitutive activation of EGFR proteinAssociated with de novo resistance to targeted EGFR inhibitors and correlated with poor prognosise.g., D770-N771insX, V769-D770insX, H773-V774insX, P772-H773insX, N771-P772insX",
                      "T790MConfers resistance to 1st- and 2nd-generation TKIsAccounts for ~ 50% of resistance-associated mutations to TKIsDevelops post EGFR TKI treatment in NSCLCCan also be primary event before drug exposure",
                      "Confers resistance to 1st- and 2nd-generation TKIs",
                      "Accounts for ~ 50% of resistance-associated mutations to TKIs",
                      "Develops post EGFR TKI treatment in NSCLC",
                      "Can also be primary event before drug exposure",
                      "Exon 20 in-frame insertion mutationsHeterogeneous in-frame insertions of 1-7 amino acids within D761-C775 in exon 20Results in constitutive activation of EGFR proteinAssociated with de novo resistance to targeted EGFR inhibitors and correlated with poor prognosise.g., D770-N771insX, V769-D770insX, H773-V774insX, P772-H773insX, N771-P772insX",
                      "Heterogeneous in-frame insertions of 1-7 amino acids within D761-C775 in exon 20",
                      "Results in constitutive activation of EGFR protein",
                      "Associated with de novo resistance to targeted EGFR inhibitors and correlated with poor prognosis",
                      "e.g., D770-N771insX, V769-D770insX, H773-V774insX, P772-H773insX, N771-P772insX",
                      "Exon 21 mutationsAccount for 40-45% ofEGFRmutationsL858R is most common point mutation inEGFR",
                      "Account for 40-45% ofEGFRmutations",
                      "L858R is most common point mutation inEGFR"
                    ]
                  },
                  {
                    "text": "EGFRmutations in exons 18, 19, 20, and 21 are mutually exclusive withKRASandBRAFmutations"
                  }
                ],
                "EGFRAmplification": [
                  {
                    "text": "CNS tumorsGlioblastoma, IDH-wildtype~ 50% of tumors showEGFRamplificationPresent solely in IDH-wildtype gliomas (26%) andTERT-mutated gliomas (27%)Diffuse pediatric type high-grade glioma, IDH-wildtypeEGFRamplification occurs in ~ 50% patients",
                    "sub_points": [
                      "Glioblastoma, IDH-wildtype~ 50% of tumors showEGFRamplificationPresent solely in IDH-wildtype gliomas (26%) andTERT-mutated gliomas (27%)",
                      "~ 50% of tumors showEGFRamplification",
                      "Present solely in IDH-wildtype gliomas (26%) andTERT-mutated gliomas (27%)",
                      "Diffuse pediatric type high-grade glioma, IDH-wildtypeEGFRamplification occurs in ~ 50% patients",
                      "EGFRamplification occurs in ~ 50% patients"
                    ]
                  },
                  {
                    "text": "Lung cancerEGFRamplification is more prevalent in squamous cell carcinoma than adenocarcinomaNSCLC withEGFRamplification may respond to TKIs",
                    "sub_points": [
                      "EGFRamplification is more prevalent in squamous cell carcinoma than adenocarcinoma",
                      "NSCLC withEGFRamplification may respond to TKIs"
                    ]
                  },
                  {
                    "text": "Breast cancer~ 6% showEGFRamplificationEGFRamplification can coexist withERRB2(HER2) amplificationMetaplastic breast carcinoma has highestEGFRamplification rate (~ 70%)",
                    "sub_points": [
                      "~ 6% showEGFRamplification",
                      "EGFRamplification can coexist withERRB2(HER2) amplification",
                      "Metaplastic breast carcinoma has highestEGFRamplification rate (~ 70%)"
                    ]
                  },
                  {
                    "text": "Ovarian cancerEGFRamplification and high polysomy present in 20% of primary and recurrent ovarian carcinomasEGFRmutation is extremely rare in ovarian cancer",
                    "sub_points": [
                      "EGFRamplification and high polysomy present in 20% of primary and recurrent ovarian carcinomas",
                      "EGFRmutation is extremely rare in ovarian cancer"
                    ]
                  },
                  {
                    "text": "Gastroesophageal adenocarcinomaEGFR-amplified tumors are associated with higher stage, more poorly differentiated histology, increased vascular invasion, and potentially shorter survival",
                    "sub_points": [
                      "EGFR-amplified tumors are associated with higher stage, more poorly differentiated histology, increased vascular invasion, and potentially shorter survival"
                    ]
                  },
                  {
                    "text": "Metastatic colorectal carcinoma (mCRC)EGFR amplification occurs in ~ 1% of mCRCMostEGFR-amplified tumors are microsatellite stable and HER2 nonamplified",
                    "sub_points": [
                      "EGFR amplification occurs in ~ 1% of mCRC",
                      "MostEGFR-amplified tumors are microsatellite stable and HER2 nonamplified"
                    ]
                  }
                ],
                "EGFR Small Molecule Inhibitors": [
                  {
                    "text": "1st-generation EGFR TKIs include erlotinib and gefitinib"
                  },
                  {
                    "text": "2nd-generation EGFR TKIs include neratinib, dacomitinib, and afatinib"
                  },
                  {
                    "text": "3rd-generation EGFR TKIs include rociletinib and osimertinib"
                  },
                  {
                    "text": "EGFRmutation testing should be used to select patients for EGFR-targeted TKI therapy"
                  }
                ],
                "Anti-EGFR Monoclonal Antibodies for Chemotherapy-Refectory Metastatic Colorectal Carcinoma": [
                  {
                    "text": "Cetuximab (Erbitux) and panitumumab (Vectibix)"
                  },
                  {
                    "text": "Resistance to EGFR blockade in mCRC with constitutive activation mutation inKRAS,NRAS, orBRAF"
                  },
                  {
                    "text": "Recommend testingKRAS,NRAS, andBRAFmutation status before treatment"
                  },
                  {
                    "text": "Mutation status ofEGFRcatalytic domain does not correlate with disease response with anti-EGFR monoclonal antibodies"
                  }
                ]
              },
              "DETECTION OF EGFR GENE ALTERATIONS": {
                "Detection of Gene Mutations": [
                  {
                    "text": "Next-generation sequencing (NGS)EGFRmutations are typically included in targeted gene panel; commonly used in clinical laboratoriesHighly sensitive and accurate when adequate sequencing depth of coverage present",
                    "sub_points": [
                      "EGFRmutations are typically included in targeted gene panel; commonly used in clinical laboratories",
                      "Highly sensitive and accurate when adequate sequencing depth of coverage present"
                    ]
                  },
                  {
                    "text": "Sanger sequencingUsed in some clinical laboratories to detectEGFRmutationsCan reliably detect many possible mutationsLess sensitive compared to NGSRequires 20-25% mutant alleles in background of wildtype alleles for reliable detection of mutations",
                    "sub_points": [
                      "Used in some clinical laboratories to detectEGFRmutations",
                      "Can reliably detect many possible mutations",
                      "Less sensitive compared to NGSRequires 20-25% mutant alleles in background of wildtype alleles for reliable detection of mutations",
                      "Requires 20-25% mutant alleles in background of wildtype alleles for reliable detection of mutations"
                    ]
                  }
                ],
                "Detection ofEGFRAmplification": [
                  {
                    "text": "Fluorescence in situ hybridization (FISH)Standard method for detectingEGFRamplificationDetectsEGFRgene copy number gain, high degrees of polysomy",
                    "sub_points": [
                      "Standard method for detectingEGFRamplification",
                      "DetectsEGFRgene copy number gain, high degrees of polysomy"
                    ]
                  },
                  {
                    "text": "Digital PCR (dPCR)Can accurately detect and quantify low nucleic acid targetsHighly sensitive and high specificity",
                    "sub_points": [
                      "Can accurately detect and quantify low nucleic acid targets",
                      "Highly sensitive and high specificity"
                    ]
                  },
                  {
                    "text": "NGSCan be used to detectEGFRamplificationCommonly included in targeted solid tumor panels",
                    "sub_points": [
                      "Can be used to detectEGFRamplification",
                      "Commonly included in targeted solid tumor panels"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryUsed to detect EGFR protein overexpression",
                    "sub_points": [
                      "Used to detect EGFR protein overexpression"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lobular Carcinoma": {
            "name": "Lobular Carcinoma",
            "url": "https://app.pathprimer.com/document/f8374211-6ae4-4880-baa7-2bc4a91d09c0/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Group of invasive carcinomas with loss of normal cell adhesion and dysregulation of actin cytoskeleton"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "E-cadherin plays functional role in intercellular adhesion and cell polarityLoss of E-cadherin expression (~ 85% of ILC)1 allele on 16q inactive by mutation (50-60% of ILC)2nd allele is inactivated by either loss of heterozygosity or by promoter hypermethylation",
                    "sub_points": [
                      "Loss of E-cadherin expression (~ 85% of ILC)",
                      "1 allele on 16q inactive by mutation (50-60% of ILC)",
                      "2nd allele is inactivated by either loss of heterozygosity or by promoter hypermethylation"
                    ]
                  },
                  {
                    "text": "Loss of E-cadherin affects cellular adhesion, cell motility, and possible cell division"
                  },
                  {
                    "text": "Responsible for characteristic morphology; plays role in detachment and invasion of neoplastic cells"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Prognosis for ILC similar to carcinomas of no special type if matched for grade and stage"
                  },
                  {
                    "text": "High-grade forms of ILC have more aggressive behavior"
                  }
                ],
                "Molecular": [
                  {
                    "text": "ILC has fewer chromosomal abnormalities than carcinomas of no special typeFrequent and consistent changes in all ILC types have been describedLoss at 16q at location ofCDH1(E-cadherin) at 6q22.1",
                    "sub_points": [
                      "Frequent and consistent changes in all ILC types have been described",
                      "Loss at 16q at location ofCDH1(E-cadherin) at 6q22.1"
                    ]
                  },
                  {
                    "text": "Majority of ILC are ER positive and of luminal molecular subtypeShow gene expression related to cell adhesion, cell-to-cell signaling, and actin cytoskeleton signaling",
                    "sub_points": [
                      "Show gene expression related to cell adhesion, cell-to-cell signaling, and actin cytoskeleton signaling"
                    ]
                  },
                  {
                    "text": "Hereditary diffuse gastric cancer syndrome is due to germline mutation inCDH1(E-cadherin)Risk of ILC for women is 40-50% by age 80Risk of gastric carcinoma is 40-80% by age 80",
                    "sub_points": [
                      "Risk of ILC for women is 40-50% by age 80",
                      "Risk of gastric carcinoma is 40-80% by age 80"
                    ]
                  },
                  {
                    "text": "ILC of all grades are more similar to each other than to other breast cancer types"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Invasive lobular carcinoma (ILC)"
                  },
                  {
                    "text": "Lobular carcinoma in situ (LCIS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "ILC is group of invasive carcinomas characterized by loss of normal cell adhesion and dysregulation of actin cytoskeletonCarcinomas show specific morphologic appearance, typically diffuse tissue infiltration and single-file growthPattern seen in breast and distant metastatic sites",
                    "sub_points": [
                      "Carcinomas show specific morphologic appearance, typically diffuse tissue infiltration and single-file growthPattern seen in breast and distant metastatic sites",
                      "Pattern seen in breast and distant metastatic sites"
                    ]
                  }
                ],
                "Classification": [
                  {
                    "text": "ILC originally defined as carcinoma having specific architectural and cytologic features (classic ILC)Architecture: Single-file invasion of stroma (1 or 2 cells wide)Comprise at least 80% of invasive tumorCytologic grade 1 or 2 nuclei",
                    "sub_points": [
                      "Architecture: Single-file invasion of stroma (1 or 2 cells wide)",
                      "Comprise at least 80% of invasive tumor",
                      "Cytologic grade 1 or 2 nuclei"
                    ]
                  },
                  {
                    "text": "Later recognized that other invasive carcinomas not included in this definition also lacked cellular cohesionMolecular studies support these carcinomas as part of family of lobular neoplasiaThese carcinomas are classified as variants of ILC",
                    "sub_points": [
                      "Molecular studies support these carcinomas as part of family of lobular neoplasia",
                      "These carcinomas are classified as variants of ILC"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Cell Adhesion Protein Expression": [
                  {
                    "text": "Characteristic dyscohesive growth pattern of ILC results from targeted disruption of E-cadherin"
                  },
                  {
                    "text": "Loss of E-cadherin gene (CDH1) expression in ~ 85% of ILCSimilar changes have been described in classic and variant forms of ILC",
                    "sub_points": [
                      "Similar changes have been described in classic and variant forms of ILC"
                    ]
                  },
                  {
                    "text": "E-cadherin is calcium-dependent transmembrane protein; has functional role in intercellular adhesion and cell polarityBinds actin cytoskeleton through interactions with p120, α-, β-, and γ-catenin",
                    "sub_points": [
                      "Binds actin cytoskeleton through interactions with p120, α-, β-, and γ-catenin"
                    ]
                  },
                  {
                    "text": "Loss of E-cadherin affects cellular adhesion, cell motility, and possible cell divisionPlays role in detachment and invasion of neoplastic cellsLeads to loss of α-, β-, and γ-cateninLeads to upregulation of p120 catenin and relocalization of protein from membrane to cytoplasm of tumor cellsRelocalization enables anoikis resistance of tumor cells, allowing survival independent from attachmentPromotes anchorage-independent growth and cell migration through Rho/Rock signalingE-cadherin functions as negative regulator of insulin-like growth factor receptor 1 (IGF1R)E-cadherin loss in ILC may sensitize cells to growth factor signaling and alter sensitivity to growth factor signaling inhibitorsCell lines withCDH1knock-out and ILC patient-derived organoids show increased sensitivity to IGFR1, PI3K, AKT, and MEK inhibitorsThese targets require further exploration, as potential ILC treatment andCDH1loss may be biomarker of response for patient stratificationLoss of E-cadherin promotes expression of DNA binding 2 (Id2), mediator of cell cycle progression in ILCId2 is essential for anchorage-independent survivalLoss of E-cadherin and subsequent expression of Id2 may contribute to indolence and dissemination of ILC",
                    "sub_points": [
                      "Plays role in detachment and invasion of neoplastic cells",
                      "Leads to loss of α-, β-, and γ-catenin",
                      "Leads to upregulation of p120 catenin and relocalization of protein from membrane to cytoplasm of tumor cellsRelocalization enables anoikis resistance of tumor cells, allowing survival independent from attachmentPromotes anchorage-independent growth and cell migration through Rho/Rock signaling",
                      "Relocalization enables anoikis resistance of tumor cells, allowing survival independent from attachment",
                      "Promotes anchorage-independent growth and cell migration through Rho/Rock signaling",
                      "E-cadherin functions as negative regulator of insulin-like growth factor receptor 1 (IGF1R)E-cadherin loss in ILC may sensitize cells to growth factor signaling and alter sensitivity to growth factor signaling inhibitorsCell lines withCDH1knock-out and ILC patient-derived organoids show increased sensitivity to IGFR1, PI3K, AKT, and MEK inhibitorsThese targets require further exploration, as potential ILC treatment andCDH1loss may be biomarker of response for patient stratification",
                      "E-cadherin loss in ILC may sensitize cells to growth factor signaling and alter sensitivity to growth factor signaling inhibitors",
                      "Cell lines withCDH1knock-out and ILC patient-derived organoids show increased sensitivity to IGFR1, PI3K, AKT, and MEK inhibitors",
                      "These targets require further exploration, as potential ILC treatment andCDH1loss may be biomarker of response for patient stratification",
                      "Loss of E-cadherin promotes expression of DNA binding 2 (Id2), mediator of cell cycle progression in ILCId2 is essential for anchorage-independent survivalLoss of E-cadherin and subsequent expression of Id2 may contribute to indolence and dissemination of ILC",
                      "Id2 is essential for anchorage-independent survival",
                      "Loss of E-cadherin and subsequent expression of Id2 may contribute to indolence and dissemination of ILC"
                    ]
                  },
                  {
                    "text": "Defect in cellular adhesion responsible for morphologic appearance of cellsCells are rounded and dyscohesiveCannot form cribriform spaces, tubules, or papillaeCells infiltrate along path of least resistance between collagen bundles and along blood vesselsPhenotype in turn attributable to reduced stromal-epithelial crosstalk by transforming growth factor β",
                    "sub_points": [
                      "Cells are rounded and dyscohesiveCannot form cribriform spaces, tubules, or papillaeCells infiltrate along path of least resistance between collagen bundles and along blood vessels",
                      "Cannot form cribriform spaces, tubules, or papillae",
                      "Cells infiltrate along path of least resistance between collagen bundles and along blood vessels",
                      "Phenotype in turn attributable to reduced stromal-epithelial crosstalk by transforming growth factor β"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "ILC is most common special histologic typeRepresents 5-15% of all invasive carcinomasILC variants are only 20-30% of all ILC",
                    "sub_points": [
                      "Represents 5-15% of all invasive carcinomas",
                      "ILC variants are only 20-30% of all ILC"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatment of all ILC and variants depends on tumor stage and receptor status, similar to treatment for invasive ductal carcinoma (IDC)Majority are ER(+), and adjuvant endocrine therapy is usually recommendedHER2 overexpression can be seen in high-grade variant forms; patients are candidates for targeted therapy",
                    "sub_points": [
                      "Majority are ER(+), and adjuvant endocrine therapy is usually recommended",
                      "HER2 overexpression can be seen in high-grade variant forms; patients are candidates for targeted therapy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Prognosis for ILC is similar to that for carcinomas of no special type if matched for grade and stageMost studies suggest that classic ILC has better prognosis than variant forms of ILCPatients with stage I classic ILC may show better recurrence-free survivalTrend toward late recurrence for ILCHistologic grading (Nottingham grading) is recommended for all breast cancer, including ILC and variantsHistologic grade provides strong predictor of outcome for ILC and variantsHigh-grade forms of ILC have more aggressive behaviorPublished studies show that histologic grading of ILC is associated with other prognostic markers",
                    "sub_points": [
                      "Most studies suggest that classic ILC has better prognosis than variant forms of ILCPatients with stage I classic ILC may show better recurrence-free survivalTrend toward late recurrence for ILC",
                      "Patients with stage I classic ILC may show better recurrence-free survival",
                      "Trend toward late recurrence for ILC",
                      "Histologic grading (Nottingham grading) is recommended for all breast cancer, including ILC and variantsHistologic grade provides strong predictor of outcome for ILC and variants",
                      "Histologic grade provides strong predictor of outcome for ILC and variants",
                      "High-grade forms of ILC have more aggressive behavior",
                      "Published studies show that histologic grading of ILC is associated with other prognostic markers"
                    ]
                  },
                  {
                    "text": "ILC has distinctive patterns of metastatic spreadSerosal and mucosal involvement of GI and gynecologic tract and retroperitoneumMetastatic ILC can occasionally be seen in GI mucosal biopsies and endometrial curettingLeptomeninges and cerebrospinal fluid involvementCarcinomatous meningitis is typically due to ILCBone metastasesMetastatic ILC can be very difficult to detect in bone marrow; may resemble hematopoietic cellsIHC for keratin can be very helpful to determine presence and extent of involvementPleural and pulmonary metastases are less common than for other histologic types of carcinoma",
                    "sub_points": [
                      "Serosal and mucosal involvement of GI and gynecologic tract and retroperitoneumMetastatic ILC can occasionally be seen in GI mucosal biopsies and endometrial curetting",
                      "Metastatic ILC can occasionally be seen in GI mucosal biopsies and endometrial curetting",
                      "Leptomeninges and cerebrospinal fluid involvementCarcinomatous meningitis is typically due to ILC",
                      "Carcinomatous meningitis is typically due to ILC",
                      "Bone metastasesMetastatic ILC can be very difficult to detect in bone marrow; may resemble hematopoietic cellsIHC for keratin can be very helpful to determine presence and extent of involvement",
                      "Metastatic ILC can be very difficult to detect in bone marrow; may resemble hematopoietic cells",
                      "IHC for keratin can be very helpful to determine presence and extent of involvement",
                      "Pleural and pulmonary metastases are less common than for other histologic types of carcinoma"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "Mechanism of Loss of E-Cadherin": [
                  {
                    "text": "E-cadherin plays functional role in intercellular adhesion and cell polarity"
                  },
                  {
                    "text": "1 allele on 16q is inactivated by mutation (50-60% of ILC)Most somaticCDH1mutations in ILC are frameshiftResults in truncated, nonfunctional E-cadherin proteinCDH1mutations are present in up to 80% of cases of ILC by whole-exome sequencing",
                    "sub_points": [
                      "Most somaticCDH1mutations in ILC are frameshiftResults in truncated, nonfunctional E-cadherin protein",
                      "Results in truncated, nonfunctional E-cadherin protein",
                      "CDH1mutations are present in up to 80% of cases of ILC by whole-exome sequencing"
                    ]
                  },
                  {
                    "text": "2nd allele is inactivated by either loss of heterozygosity or by promoter hypermethylationLeads to loss of E-cadherin protein expression, which can be detected by IHC",
                    "sub_points": [
                      "Leads to loss of E-cadherin protein expression, which can be detected by IHC"
                    ]
                  },
                  {
                    "text": "Expression of E-cadherin but loss of other catenin complex proteins occurs in ~ 10-15% of ILCIf E-cadherin is expressed, then 1 or more catenins will show abnormal expressionp120 catenin will show abnormal cytoplasmic localization",
                    "sub_points": [
                      "If E-cadherin is expressed, then 1 or more catenins will show abnormal expression",
                      "p120 catenin will show abnormal cytoplasmic localization"
                    ]
                  },
                  {
                    "text": "Some E-cadherin (+) ILC harborCDH1mutations, which preserve epitope recognized by commercial anti-E-cadherin antibodies"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "ILC more likely to be diploid than ductal tumors"
                  },
                  {
                    "text": "ILC has fewer chromosomal abnormalities than carcinomas of no special type3 frequent and consistent changes in all ILC types have been describedLoss at 16q at location of E-cadherin gene (CDH1) at 16q22.1, 16p, 17p, and 22qGains at 1q and 16q",
                    "sub_points": [
                      "3 frequent and consistent changes in all ILC types have been describedLoss at 16q at location of E-cadherin gene (CDH1) at 16q22.1, 16p, 17p, and 22qGains at 1q and 16q",
                      "Loss at 16q at location of E-cadherin gene (CDH1) at 16q22.1, 16p, 17p, and 22q",
                      "Gains at 1q and 16q"
                    ]
                  },
                  {
                    "text": "Poorly differentiated variant forms of ILC show additional genomic changesTP53mutationsAmplifications ofERBB2(HER2),MYC, andMDM2Mutations may help explain higher grade features and more aggressive clinical behaviorPleomorphic ILC may demonstrate amplifications at loci 8q24, 17q12, and 20q13These findings are also characteristic of high-grade invasive carcinomas of no special type",
                    "sub_points": [
                      "TP53mutations",
                      "Amplifications ofERBB2(HER2),MYC, andMDM2Mutations may help explain higher grade features and more aggressive clinical behavior",
                      "Mutations may help explain higher grade features and more aggressive clinical behavior",
                      "Pleomorphic ILC may demonstrate amplifications at loci 8q24, 17q12, and 20q13These findings are also characteristic of high-grade invasive carcinomas of no special type",
                      "These findings are also characteristic of high-grade invasive carcinomas of no special type"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Majority of ILC are ER(+) and luminal subtypeILC of all grades are more similar to each other than to other breast cancer typesSimilar expression patterns related to cell adhesion, cell-to-cell signaling, and actin cytoskeleton signalingGrade 1 and 2 ILC have distinct gene expression patterns compared to grade 1 and 2 carcinomas of no special type",
                    "sub_points": [
                      "ILC of all grades are more similar to each other than to other breast cancer typesSimilar expression patterns related to cell adhesion, cell-to-cell signaling, and actin cytoskeleton signaling",
                      "Similar expression patterns related to cell adhesion, cell-to-cell signaling, and actin cytoskeleton signaling",
                      "Grade 1 and 2 ILC have distinct gene expression patterns compared to grade 1 and 2 carcinomas of no special type"
                    ]
                  },
                  {
                    "text": "Variant ILC can be in luminal, molecular apocrine, orERBB2-enriched subgroups by gene expression profilingBasal-like subgroup is very rare",
                    "sub_points": [
                      "Basal-like subgroup is very rare"
                    ]
                  },
                  {
                    "text": "Functional gene groups distinctive for lobular tumorsAdhesion; transforming growth factor β signaling; cell communication and trafficking; actin remodeling; lipid/prostaglandin synthesis",
                    "sub_points": [
                      "Adhesion; transforming growth factor β signaling; cell communication and trafficking; actin remodeling; lipid/prostaglandin synthesis"
                    ]
                  },
                  {
                    "text": "32-87% of ILC belong to luminal molecular subtype of breast cancer, and 50% are low risk by Oncotype DXLower percentage of patients with ILC vs. invasive ductal carcinoma (IDC) have high-risk Oncotype DX score (6.6% vs. 16%)ILC patient with high-risk Oncotype DX appear to benefit from chemotherapy11% of ILC patients are classified as high genomic risk by 70-gene signature test",
                    "sub_points": [
                      "Lower percentage of patients with ILC vs. invasive ductal carcinoma (IDC) have high-risk Oncotype DX score (6.6% vs. 16%)",
                      "ILC patient with high-risk Oncotype DX appear to benefit from chemotherapy",
                      "11% of ILC patients are classified as high genomic risk by 70-gene signature test"
                    ]
                  }
                ],
                "Germline Mutations ofCDH1(E-Cadherin)": [
                  {
                    "text": "Hereditary diffuse gastric cancer syndrome is due to germline mutation inCDH1Risk of gastric carcinoma is 40-80% by age 80Risk of ILC for women is 40-50% by age 80",
                    "sub_points": [
                      "Risk of gastric carcinoma is 40-80% by age 80",
                      "Risk of ILC for women is 40-50% by age 80"
                    ]
                  },
                  {
                    "text": "Gastric signet-ring cell carcinomas and ILC are morphologically similarBoth lack expression of E-cadherin proteinCarcinomas have organ-specific gene expression patterns that differ between 2 sites",
                    "sub_points": [
                      "Both lack expression of E-cadherin protein",
                      "Carcinomas have organ-specific gene expression patterns that differ between 2 sites"
                    ]
                  },
                  {
                    "text": "Some affected families are detected by predominance of cases of ILC"
                  },
                  {
                    "text": "Vast majority of women with ILC do not carry germline mutation inCDH1"
                  },
                  {
                    "text": "Possibility of germline mutations in other cytoskeletal protein genes is under investigation"
                  }
                ],
                "Precursor Lesion: LCIS": [
                  {
                    "text": "LCIS is known risk factor of invasive carcinomaIncreasing data suggest nonobligate precursor relationship between LCIS and ILCLCIS confers 8-10x increase in relative risk for subsequently developing invasive carcinomaAnnual rate of developing carcinoma is 2% with cumulative cancer incidence of 26% at 15 yearsCancers occurred in ipsilateral breast in 63%, contralateral breast in 25%, and in bilateral breasts in 12% of casesLCIS and ILC are phenotypically and genetically similarMost LCIS and ILC are luminal A molecular subtype, harboring recurrent gains of 1q and loss of 16qSequencing analyses focused on paired LCIS and ILC demonstrated comparable shared somatic mutations inCDH1,PIK3CA, andCBFB70-80% incidence of LCIS associated with cases of ILCSimilar to association between ductal carcinoma in situ and IDCInvasive carcinoma arising in women with history of LCIS are 3x more likely to be ILCGene expression profiling studies separate classic LCIS into 2 groupsDifferences between groups based on genes involved in proliferation,TGFB1, TP53, actin cytoskeleton, apoptosis, and Wnt signalingAdditional candidate precursor genes may play role in disease progression",
                    "sub_points": [
                      "Increasing data suggest nonobligate precursor relationship between LCIS and ILCLCIS confers 8-10x increase in relative risk for subsequently developing invasive carcinomaAnnual rate of developing carcinoma is 2% with cumulative cancer incidence of 26% at 15 yearsCancers occurred in ipsilateral breast in 63%, contralateral breast in 25%, and in bilateral breasts in 12% of casesLCIS and ILC are phenotypically and genetically similarMost LCIS and ILC are luminal A molecular subtype, harboring recurrent gains of 1q and loss of 16qSequencing analyses focused on paired LCIS and ILC demonstrated comparable shared somatic mutations inCDH1,PIK3CA, andCBFB",
                      "LCIS confers 8-10x increase in relative risk for subsequently developing invasive carcinomaAnnual rate of developing carcinoma is 2% with cumulative cancer incidence of 26% at 15 yearsCancers occurred in ipsilateral breast in 63%, contralateral breast in 25%, and in bilateral breasts in 12% of cases",
                      "Annual rate of developing carcinoma is 2% with cumulative cancer incidence of 26% at 15 years",
                      "Cancers occurred in ipsilateral breast in 63%, contralateral breast in 25%, and in bilateral breasts in 12% of cases",
                      "LCIS and ILC are phenotypically and genetically similar",
                      "Most LCIS and ILC are luminal A molecular subtype, harboring recurrent gains of 1q and loss of 16q",
                      "Sequencing analyses focused on paired LCIS and ILC demonstrated comparable shared somatic mutations inCDH1,PIK3CA, andCBFB",
                      "70-80% incidence of LCIS associated with cases of ILCSimilar to association between ductal carcinoma in situ and IDC",
                      "Similar to association between ductal carcinoma in situ and IDC",
                      "Invasive carcinoma arising in women with history of LCIS are 3x more likely to be ILC",
                      "Gene expression profiling studies separate classic LCIS into 2 groupsDifferences between groups based on genes involved in proliferation,TGFB1, TP53, actin cytoskeleton, apoptosis, and Wnt signalingAdditional candidate precursor genes may play role in disease progression",
                      "Differences between groups based on genes involved in proliferation,TGFB1, TP53, actin cytoskeleton, apoptosis, and Wnt signaling",
                      "Additional candidate precursor genes may play role in disease progression"
                    ]
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "Technologic advances have led to ability to interrogate individual tumor genomesExome sequencing of ILC have demonstrated recurrent mutations inCDH1andPIK3CAPIK3CAmutation rate is similar to that observed overall in ER(+) breast cancersActivation ofPIK3CAby somatic mutations present in 30-50% of ILC",
                    "sub_points": [
                      "Exome sequencing of ILC have demonstrated recurrent mutations inCDH1andPIK3CAPIK3CAmutation rate is similar to that observed overall in ER(+) breast cancersActivation ofPIK3CAby somatic mutations present in 30-50% of ILC",
                      "PIK3CAmutation rate is similar to that observed overall in ER(+) breast cancers",
                      "Activation ofPIK3CAby somatic mutations present in 30-50% of ILC"
                    ]
                  },
                  {
                    "text": "Somatic mutations inERBB2are generally rare in breast cancerERBB2mutations are significantly enriched in ILCActivatingERBB2somatic mutations associated with poorly differentiated, pleomorphic, and recurrent ILCERBB2mutations preferentially affected tyrosine kinase activity domainFrequent targetableERBB2mutation is p.L755S (57%)ERBB2is important clinically actionable targetTargeted sequencing analysis may aid in management of patient when planning therapy in futureERBB2mutation testing should be considered in all ILC with nuclear grade 3",
                    "sub_points": [
                      "ERBB2mutations are significantly enriched in ILC",
                      "ActivatingERBB2somatic mutations associated with poorly differentiated, pleomorphic, and recurrent ILCERBB2mutations preferentially affected tyrosine kinase activity domainFrequent targetableERBB2mutation is p.L755S (57%)",
                      "ERBB2mutations preferentially affected tyrosine kinase activity domain",
                      "Frequent targetableERBB2mutation is p.L755S (57%)",
                      "ERBB2is important clinically actionable targetTargeted sequencing analysis may aid in management of patient when planning therapy in futureERBB2mutation testing should be considered in all ILC with nuclear grade 3",
                      "Targeted sequencing analysis may aid in management of patient when planning therapy in future",
                      "ERBB2mutation testing should be considered in all ILC with nuclear grade 3"
                    ]
                  },
                  {
                    "text": "IDC and ILC are characterized by different mutational landscapeEnrichment forCDH1,TBX3,FOXA1,AKT1,ERBB2, andERBB3mutations seen in lobular tumorsPTENloss associated with increased AKT phosphorylation was highest in ILC among all breast cancer subtypesProliferation and immune-related signatures determine 3 ILC transcriptional subtypes associated with survivalMixed IDC/ILC cases are molecularly classified as ILC-like and IDC-like with no true hybrid features",
                    "sub_points": [
                      "Enrichment forCDH1,TBX3,FOXA1,AKT1,ERBB2, andERBB3mutations seen in lobular tumors",
                      "PTENloss associated with increased AKT phosphorylation was highest in ILC among all breast cancer subtypes",
                      "Proliferation and immune-related signatures determine 3 ILC transcriptional subtypes associated with survival",
                      "Mixed IDC/ILC cases are molecularly classified as ILC-like and IDC-like with no true hybrid features"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "ILC has distinctive cytologic featuresCells are round in shape due to lack of cohesionNuclear grade can vary from grade 1 to grade 3Cytoplasmic mucin vacuoles may be presentProminent cells with signet-ring appearance have single vacuole with mucin dropletSignet-ring cells of GI tract more typically have multiple vacuoles, foamy cytoplasmSignet-ring cells can also be seen in breast carcinomas of no special type",
                    "sub_points": [
                      "Cells are round in shape due to lack of cohesion",
                      "Nuclear grade can vary from grade 1 to grade 3",
                      "Cytoplasmic mucin vacuoles may be presentProminent cells with signet-ring appearance have single vacuole with mucin dropletSignet-ring cells of GI tract more typically have multiple vacuoles, foamy cytoplasmSignet-ring cells can also be seen in breast carcinomas of no special type",
                      "Prominent cells with signet-ring appearance have single vacuole with mucin droplet",
                      "Signet-ring cells of GI tract more typically have multiple vacuoles, foamy cytoplasm",
                      "Signet-ring cells can also be seen in breast carcinomas of no special type"
                    ]
                  },
                  {
                    "text": "ILC has distinctive growth patternsClassic growth pattern: Linear arrangement of dyscohesive cells in single file between collagenInfiltration by bands of > 2 neoplastic cells across has been termed \"trabecular\" ILCSingle cells may be presentInfiltrating tumor cells may be oriented in circular fashion around normal ducts (concentric or bull's-eye appearance)Skip lesions or patchy growth frequentDesmoplastic stromal reaction may be absentCorrelates with absence of discrete mass by palpation or imaging in some cases",
                    "sub_points": [
                      "Classic growth pattern: Linear arrangement of dyscohesive cells in single file between collagenInfiltration by bands of > 2 neoplastic cells across has been termed \"trabecular\" ILC",
                      "Infiltration by bands of > 2 neoplastic cells across has been termed \"trabecular\" ILC",
                      "Single cells may be present",
                      "Infiltrating tumor cells may be oriented in circular fashion around normal ducts (concentric or bull's-eye appearance)",
                      "Skip lesions or patchy growth frequent",
                      "Desmoplastic stromal reaction may be absentCorrelates with absence of discrete mass by palpation or imaging in some cases",
                      "Correlates with absence of discrete mass by palpation or imaging in some cases"
                    ]
                  },
                  {
                    "text": "ILCclassictype (55% of cases)Linear, single-file, invasive growth patternSingle-file growth no more than 1-2 cells wideConcentric pattern of growth around ductsFocal alveolar or solid area may be present; should be < 20% of tumorNuclear grade 1 or 2 in vast majority of cases",
                    "sub_points": [
                      "Linear, single-file, invasive growth patternSingle-file growth no more than 1-2 cells wideConcentric pattern of growth around ductsFocal alveolar or solid area may be present; should be < 20% of tumor",
                      "Single-file growth no more than 1-2 cells wide",
                      "Concentric pattern of growth around ducts",
                      "Focal alveolar or solid area may be present; should be < 20% of tumor",
                      "Nuclear grade 1 or 2 in vast majority of cases"
                    ]
                  },
                  {
                    "text": "Architectural variantsVariants of ILC with distinctive tissue architecture and growth patternsSolid variant (5-10% of cases)Tumor forms large, usual circumscribed nests or sheets of poorly cohesive cellsSingle-file growth may be present at periphery55% grade 3, 40% grade 2, 5% grade 1Appearance may mimic lymphoma or melanomaAlveolar variant (5-20% of ILC)Smaller, rounded aggregates of tumor cells arranged in clusters90% grade 2, 10% grade 3Some cases may resemble LCIS but lack surrounding myoepithelial cell layerTubulolobular variant (< 1%)Consists of classic ILC combined and intermixed with small, round tubulesCells are low grade, positive for E-cadherin and ERILC with extracellular mucin (ILCEM)Rare histologic subtype demonstrating lobular morphology, extracellular mucin, and absent or reduced E-cadherin expressionILCEM is typically moderate to poorly differentiated and frequently exhibits variant morphologyDistinct variant that often presents with higher grade and is associated with aggressive clinical course",
                    "sub_points": [
                      "Variants of ILC with distinctive tissue architecture and growth patterns",
                      "Solid variant (5-10% of cases)Tumor forms large, usual circumscribed nests or sheets of poorly cohesive cellsSingle-file growth may be present at periphery55% grade 3, 40% grade 2, 5% grade 1Appearance may mimic lymphoma or melanoma",
                      "Tumor forms large, usual circumscribed nests or sheets of poorly cohesive cells",
                      "Single-file growth may be present at periphery",
                      "55% grade 3, 40% grade 2, 5% grade 1",
                      "Appearance may mimic lymphoma or melanoma",
                      "Alveolar variant (5-20% of ILC)Smaller, rounded aggregates of tumor cells arranged in clusters90% grade 2, 10% grade 3Some cases may resemble LCIS but lack surrounding myoepithelial cell layer",
                      "Smaller, rounded aggregates of tumor cells arranged in clusters",
                      "90% grade 2, 10% grade 3",
                      "Some cases may resemble LCIS but lack surrounding myoepithelial cell layer",
                      "Tubulolobular variant (< 1%)Consists of classic ILC combined and intermixed with small, round tubulesCells are low grade, positive for E-cadherin and ER",
                      "Consists of classic ILC combined and intermixed with small, round tubules",
                      "Cells are low grade, positive for E-cadherin and ER",
                      "ILC with extracellular mucin (ILCEM)Rare histologic subtype demonstrating lobular morphology, extracellular mucin, and absent or reduced E-cadherin expressionILCEM is typically moderate to poorly differentiated and frequently exhibits variant morphologyDistinct variant that often presents with higher grade and is associated with aggressive clinical course",
                      "Rare histologic subtype demonstrating lobular morphology, extracellular mucin, and absent or reduced E-cadherin expression",
                      "ILCEM is typically moderate to poorly differentiated and frequently exhibits variant morphology",
                      "Distinct variant that often presents with higher grade and is associated with aggressive clinical course"
                    ]
                  },
                  {
                    "text": "CytologicvariantsSignet-ring cell variantSignet-ring cell morphology is prominent in ILCHistiocytoid variantCells have abundant foamy cytoplasm and can closely resemble histocytesPleomorphic variantCells have large, irregular nuclei (grade 2 or 3)May have eosinophilic cytoplasm (apocrine)Pleomorphic variant typically presents with greater tumor size, stage, fewer ER(+) and more HER2(+) cases",
                    "sub_points": [
                      "Signet-ring cell variantSignet-ring cell morphology is prominent in ILC",
                      "Signet-ring cell morphology is prominent in ILC",
                      "Histiocytoid variantCells have abundant foamy cytoplasm and can closely resemble histocytes",
                      "Cells have abundant foamy cytoplasm and can closely resemble histocytes",
                      "Pleomorphic variantCells have large, irregular nuclei (grade 2 or 3)May have eosinophilic cytoplasm (apocrine)Pleomorphic variant typically presents with greater tumor size, stage, fewer ER(+) and more HER2(+) cases",
                      "Cells have large, irregular nuclei (grade 2 or 3)",
                      "May have eosinophilic cytoplasm (apocrine)",
                      "Pleomorphic variant typically presents with greater tumor size, stage, fewer ER(+) and more HER2(+) cases"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Ductal Carcinomas": {
            "name": "Ductal Carcinomas",
            "url": "https://app.pathprimer.com/document/e9b77ac9-bc69-4d47-8958-a723361d49b6/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Invasive ductal carcinoma (IDC) is heterogeneous group of carcinomas with regards to clinical presentation, pathologic features, prognosis, clinical outcomes, and response to therapyMultiple different treatment options available, including targeted therapiesIncreasingly, clinical decisions on treatment options and targeted therapies require assessment of underlying tumor",
                    "sub_points": [
                      "Multiple different treatment options available, including targeted therapies",
                      "Increasingly, clinical decisions on treatment options and targeted therapies require assessment of underlying tumor"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Technical advances have made it possible to study tumor biology in clinical breast cancer samples"
                  },
                  {
                    "text": "Tumor tissue can be analyzed for DNA changes, gene expression profiling, and patterns of protein expression"
                  },
                  {
                    "text": "Clinically useful for breast cancer classification to help inform optimal patient management"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Molecular or intrinsic types of IDCGlobal expression patterns can be used to group tumors into classes or groups with similar findings",
                    "sub_points": [
                      "Global expression patterns can be used to group tumors into classes or groups with similar findings"
                    ]
                  },
                  {
                    "text": "ER(+) luminal cancers (ER expression)Luminal A (lower grade, low proliferation, indolent course) and luminal B (higher grade, more aggressive)Most benefit from hormonal treatment; luminal B tumors may benefit from adding chemotherapy",
                    "sub_points": [
                      "Luminal A (lower grade, low proliferation, indolent course) and luminal B (higher grade, more aggressive)",
                      "Most benefit from hormonal treatment; luminal B tumors may benefit from adding chemotherapy"
                    ]
                  },
                  {
                    "text": "HER2-enriched cancer (HER2 overexpression)Unfavorable prognosis; however, great benefit from chemotherapy and HER2-targeted therapy",
                    "sub_points": [
                      "Unfavorable prognosis; however, great benefit from chemotherapy and HER2-targeted therapy"
                    ]
                  },
                  {
                    "text": "Basal-like carcinomas (triple-negative breast carcinoma)Unfavorable prognosis but subset have good response to adjuvant or neoadjuvant chemotherapy",
                    "sub_points": [
                      "Unfavorable prognosis but subset have good response to adjuvant or neoadjuvant chemotherapy"
                    ]
                  },
                  {
                    "text": "Numerous multigene assays to predict prognosis and treatment benefit have been developed"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Invasive ductal carcinoma (IDC)IDC of no special type (IDCNST)",
                    "sub_points": [
                      "IDC of no special type (IDCNST)"
                    ]
                  },
                  {
                    "text": "Basal-like carcinoma (BLC)"
                  },
                  {
                    "text": "Triple-negative breast carcinoma (TNBC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "IDC includes all adenocarcinomas of breast that are not classified as special histologic typeHeterogeneous group of carcinomas with regards to clinical presentation, pathologic features, prognosis, clinical outcomes, and response to therapyMultiple different treatment options available, including targeted therapiesIncreasingly, clinical decisions on treatment options and targeted therapies require assessment of tumor biology/molecular drivers of disease progressionNeed for clinically useful classification scheme to help assess prognosis, aid treatment decisionsAdvances in molecular analysis that can be performed on clinical breast tumor tissue samples can help address these questionsProvides more comprehensive assessment of biologic characteristic of tumor tissue from clinical samplesTechnologies are robust and reproducibleCan identify therapeutic targets in subsets of patients that could benefit from specific targeted therapiesAnalysis serves as adjunct to standard clinical and pathologic assessmentClassification should help distinguish different prognostic groups among patients with similar featuresShould help predict response and benefit from different therapies (endocrine, chemotherapy, targeted therapy)Clinically useful breast cancer classification will help to inform optimal patient management",
                    "sub_points": [
                      "Heterogeneous group of carcinomas with regards to clinical presentation, pathologic features, prognosis, clinical outcomes, and response to therapyMultiple different treatment options available, including targeted therapiesIncreasingly, clinical decisions on treatment options and targeted therapies require assessment of tumor biology/molecular drivers of disease progression",
                      "Multiple different treatment options available, including targeted therapies",
                      "Increasingly, clinical decisions on treatment options and targeted therapies require assessment of tumor biology/molecular drivers of disease progression",
                      "Need for clinically useful classification scheme to help assess prognosis, aid treatment decisionsAdvances in molecular analysis that can be performed on clinical breast tumor tissue samples can help address these questionsProvides more comprehensive assessment of biologic characteristic of tumor tissue from clinical samplesTechnologies are robust and reproducibleCan identify therapeutic targets in subsets of patients that could benefit from specific targeted therapiesAnalysis serves as adjunct to standard clinical and pathologic assessment",
                      "Advances in molecular analysis that can be performed on clinical breast tumor tissue samples can help address these questions",
                      "Provides more comprehensive assessment of biologic characteristic of tumor tissue from clinical samples",
                      "Technologies are robust and reproducible",
                      "Can identify therapeutic targets in subsets of patients that could benefit from specific targeted therapies",
                      "Analysis serves as adjunct to standard clinical and pathologic assessment",
                      "Classification should help distinguish different prognostic groups among patients with similar featuresShould help predict response and benefit from different therapies (endocrine, chemotherapy, targeted therapy)Clinically useful breast cancer classification will help to inform optimal patient management",
                      "Should help predict response and benefit from different therapies (endocrine, chemotherapy, targeted therapy)",
                      "Clinically useful breast cancer classification will help to inform optimal patient management"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Breast Cancer Biology and Classification": [
                  {
                    "text": "Technical advances have made it possible to study tumor biology in clinical breast cancer samplesTumor tissue can be analyzed for DNA changes, gene expression profiling (GEP), and patterns of protein expressionEach of these approaches can be used to classify tumors into different biologic subsetsEach approach has different specimen requirementsMost molecular studies have been adapted for use in formalin-fixed, paraffin-embedded tissue (FFPE)",
                    "sub_points": [
                      "Tumor tissue can be analyzed for DNA changes, gene expression profiling (GEP), and patterns of protein expressionEach of these approaches can be used to classify tumors into different biologic subsetsEach approach has different specimen requirementsMost molecular studies have been adapted for use in formalin-fixed, paraffin-embedded tissue (FFPE)",
                      "Each of these approaches can be used to classify tumors into different biologic subsets",
                      "Each approach has different specimen requirements",
                      "Most molecular studies have been adapted for use in formalin-fixed, paraffin-embedded tissue (FFPE)"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "Gene Expression Profiling": [
                  {
                    "text": "Molecular or intrinsic types of IDC"
                  },
                  {
                    "text": "It has long been known that ER(+) and ER(-) cancers are fundamentally distinct tumorsDiffer in risk factors, peak age incidence, histologic appearance, association with germline mutations, somatic mutations, patterns of metastasis, response to therapy, and clinical outcome",
                    "sub_points": [
                      "Differ in risk factors, peak age incidence, histologic appearance, association with germline mutations, somatic mutations, patterns of metastasis, response to therapy, and clinical outcome"
                    ]
                  },
                  {
                    "text": "GEP (mRNA) can be used to identify biologically distinct groups of carcinomasGlobal expression patterns can be used to group tumors into classes or groups with similar findingsIdentification of these subtypes is important, as they vary in morphology, expression of tumor markers, natural history, response to therapy, and prognosis",
                    "sub_points": [
                      "Global expression patterns can be used to group tumors into classes or groups with similar findings",
                      "Identification of these subtypes is important, as they vary in morphology, expression of tumor markers, natural history, response to therapy, and prognosis"
                    ]
                  },
                  {
                    "text": "ER(+) luminal cancers(ER expression)Luminal A: Refers to most well-differentiated carcinomas of this group with low proliferationLuminal B: Refers to higher grade carcinomas within this group with high proliferationGradation of proliferation and genomic changes with no discrete separation of A and B groupsSome luminal B cancers are HER2(+) (luminal HER2)Chromosomal instability is strongly correlated with metastatic burden in ER(+)/HER2(+) tumors",
                    "sub_points": [
                      "Luminal A: Refers to most well-differentiated carcinomas of this group with low proliferation",
                      "Luminal B: Refers to higher grade carcinomas within this group with high proliferationGradation of proliferation and genomic changes with no discrete separation of A and B groupsSome luminal B cancers are HER2(+) (luminal HER2)Chromosomal instability is strongly correlated with metastatic burden in ER(+)/HER2(+) tumors",
                      "Gradation of proliferation and genomic changes with no discrete separation of A and B groups",
                      "Some luminal B cancers are HER2(+) (luminal HER2)",
                      "Chromosomal instability is strongly correlated with metastatic burden in ER(+)/HER2(+) tumors"
                    ]
                  },
                  {
                    "text": "HER2-enriched cancer (HER2 overexpression)Overall gene expression pattern is more similar to luminal cancers than to basal-like cancersHER2-enriched carcinomas identified by GEP are typically ER(-)ERBB2(HER2) amplification drives protein receptor overexpression, which in turn drives proliferation and more aggressive clinical courseHER2 overexpression can be effectively targeted by drugs like trastuzumab, pertuzumab, and TDM1",
                    "sub_points": [
                      "Overall gene expression pattern is more similar to luminal cancers than to basal-like cancersHER2-enriched carcinomas identified by GEP are typically ER(-)",
                      "HER2-enriched carcinomas identified by GEP are typically ER(-)",
                      "ERBB2(HER2) amplification drives protein receptor overexpression, which in turn drives proliferation and more aggressive clinical course",
                      "HER2 overexpression can be effectively targeted by drugs like trastuzumab, pertuzumab, and TDM1"
                    ]
                  },
                  {
                    "text": "BLCs (TNBC)GEP dominated by proliferation, angiogenesis, expression of basal cytokeratinsPattern of mutations is similar to that seen in high-grade serous ovarian carcinomas",
                    "sub_points": [
                      "GEP dominated by proliferation, angiogenesis, expression of basal cytokeratinsPattern of mutations is similar to that seen in high-grade serous ovarian carcinomas",
                      "Pattern of mutations is similar to that seen in high-grade serous ovarian carcinomas"
                    ]
                  }
                ],
                "Germline Mutations": [
                  {
                    "text": "Inherited mutations can markedly elevate risk of developing breast cancerBRCA1andBRCA2most common genes with highest riskTP53,CHEK2,PTEN,STK11, andATMmutations elevate risk to lesser degree",
                    "sub_points": [
                      "BRCA1andBRCA2most common genes with highest risk",
                      "TP53,CHEK2,PTEN,STK11, andATMmutations elevate risk to lesser degree"
                    ]
                  },
                  {
                    "text": "These genes function in DNA repair and maintaining genomic integrity"
                  },
                  {
                    "text": "All of these mutations combined account for < 10% of all breast carcinomas"
                  },
                  {
                    "text": "Majority of resulting carcinomas are IDC"
                  }
                ],
                "Multigene Assays": [
                  {
                    "text": "Assessment for hormonal and HER2-targeted therapy is based on biomarker evaluation for ER/PR and HER2Indication for adding chemotherapy to patients adjuvant treatment regimen is more challengingClinical tumor characteristics (size, grade, nodal involvement) are used to predict risk of recurrence and are considered in chemotherapy decisionRisk of recurrence is weighed against potential benefit (improved outcome) and drug toxicityMolecular analysis of clinical samples provides new conceptual approach for evaluating risk and guiding chemotherapy decisionsInitial studies based on gene expression analysis but have been translated into RT-PCR multigene tests and other molecular methodologies",
                    "sub_points": [
                      "Indication for adding chemotherapy to patients adjuvant treatment regimen is more challengingClinical tumor characteristics (size, grade, nodal involvement) are used to predict risk of recurrence and are considered in chemotherapy decisionRisk of recurrence is weighed against potential benefit (improved outcome) and drug toxicity",
                      "Clinical tumor characteristics (size, grade, nodal involvement) are used to predict risk of recurrence and are considered in chemotherapy decision",
                      "Risk of recurrence is weighed against potential benefit (improved outcome) and drug toxicity",
                      "Molecular analysis of clinical samples provides new conceptual approach for evaluating risk and guiding chemotherapy decisionsInitial studies based on gene expression analysis but have been translated into RT-PCR multigene tests and other molecular methodologies",
                      "Initial studies based on gene expression analysis but have been translated into RT-PCR multigene tests and other molecular methodologies"
                    ]
                  },
                  {
                    "text": "Oncotype DX assayValidated 21-gene quantitative RT-PCR assayDeveloped for use in ER(+) breast cancer utilizing FFPE samplesQuantitatively measures 16 cancer genes and 5 housekeeping genes to check RNA integrityGene expression levels are used in algorithm to calculated numerical recurrence score (RS)RS is heavily weighted for proliferation genes as well as activated ER and HER2 pathwaysRS is divided into low, intermediate, and high recurrence risk categoriesIndependently predictive of recurrence in multiple published studiesHas been show to be prognostic (predicts likelihood of recurrence at 10 years) and predictive of chemotherapy benefit for patient with high RSUsed clinically to help decide which ER(+) breast cancers need or can be spared adjuvant chemotherapyTest was validated for ER(+)/node (-) tumor; may be informative for node (+) patientsAssay offered clinically as reference test by Genomic Health IncorporatedTAILORx clinical trial demonstrated that adjuvant endocrine and chemoendocrine had similar efficacy in women with midrange Oncotype DX assay scoresFound benefit of chemotherapy for some women ≤ 50 years of age with midrange scoreRxPONDER trial shows no benefit for adjuvant chemotherapy + endocrine therapy for postmenopausal women with 1-3 positive lymph nodes and RS < 25",
                    "sub_points": [
                      "Validated 21-gene quantitative RT-PCR assayDeveloped for use in ER(+) breast cancer utilizing FFPE samplesQuantitatively measures 16 cancer genes and 5 housekeeping genes to check RNA integrityGene expression levels are used in algorithm to calculated numerical recurrence score (RS)RS is heavily weighted for proliferation genes as well as activated ER and HER2 pathways",
                      "Developed for use in ER(+) breast cancer utilizing FFPE samples",
                      "Quantitatively measures 16 cancer genes and 5 housekeeping genes to check RNA integrity",
                      "Gene expression levels are used in algorithm to calculated numerical recurrence score (RS)",
                      "RS is heavily weighted for proliferation genes as well as activated ER and HER2 pathways",
                      "RS is divided into low, intermediate, and high recurrence risk categoriesIndependently predictive of recurrence in multiple published studiesHas been show to be prognostic (predicts likelihood of recurrence at 10 years) and predictive of chemotherapy benefit for patient with high RSUsed clinically to help decide which ER(+) breast cancers need or can be spared adjuvant chemotherapyTest was validated for ER(+)/node (-) tumor; may be informative for node (+) patients",
                      "Independently predictive of recurrence in multiple published studies",
                      "Has been show to be prognostic (predicts likelihood of recurrence at 10 years) and predictive of chemotherapy benefit for patient with high RS",
                      "Used clinically to help decide which ER(+) breast cancers need or can be spared adjuvant chemotherapy",
                      "Test was validated for ER(+)/node (-) tumor; may be informative for node (+) patients",
                      "Assay offered clinically as reference test by Genomic Health Incorporated",
                      "TAILORx clinical trial demonstrated that adjuvant endocrine and chemoendocrine had similar efficacy in women with midrange Oncotype DX assay scoresFound benefit of chemotherapy for some women ≤ 50 years of age with midrange score",
                      "Found benefit of chemotherapy for some women ≤ 50 years of age with midrange score",
                      "RxPONDER trial shows no benefit for adjuvant chemotherapy + endocrine therapy for postmenopausal women with 1-3 positive lymph nodes and RS < 25"
                    ]
                  },
                  {
                    "text": "MammaPrint assayInvolves gene expression analysis using microarray technology; has been adapted for FFPE tissue70-gene classifier is used to stratify patient into low-risk and high-risk categories for distant recurrenceValidation studies have shown that patient with good prognostic signature had < 15% risk of recurrence at 10 yearsPatients with poor prognostic signature had 50% risk for distant metastasesStudies showed that risk predicted by MammaPrint is most likely associated with early recurrenceOriginally required fresh or frozen tumor tissue, but test has been adapted for formalin-fixed samplesFunction of 70 genes assayed is related to cellular pathways involving apoptosis, growth signaling, limitless potential to replicate, tissue invasion, and angiogenesisSeveral clinical validation studies of MammaPrint have been conductedMost of these studies have been retrospective or nonrandomized, limiting predictive ability for chemotherapy benefitMetaanalysis showed that MammaPrint is also predictive for chemotherapy benefitMicroarray in node (-) and 1-3 (+) lymph node disease may avoid chemotherapy (MINDACT randomized/prospective trial)Randomized based on discordant risk assessment from MammaPrint vs. clinical risk based on Adjuvant! OnlinePatients with high clinical risk but low genomic risk receiving no chemotherapy had 5-year survival that was 1.5% lower that those receiving chemotherapyConcluded that ~ 46% of women at high clinical risk but low genomic risk based on MammaPrint might not require chemotherapy",
                    "sub_points": [
                      "Involves gene expression analysis using microarray technology; has been adapted for FFPE tissue70-gene classifier is used to stratify patient into low-risk and high-risk categories for distant recurrenceValidation studies have shown that patient with good prognostic signature had < 15% risk of recurrence at 10 yearsPatients with poor prognostic signature had 50% risk for distant metastasesStudies showed that risk predicted by MammaPrint is most likely associated with early recurrenceOriginally required fresh or frozen tumor tissue, but test has been adapted for formalin-fixed samplesFunction of 70 genes assayed is related to cellular pathways involving apoptosis, growth signaling, limitless potential to replicate, tissue invasion, and angiogenesis",
                      "70-gene classifier is used to stratify patient into low-risk and high-risk categories for distant recurrenceValidation studies have shown that patient with good prognostic signature had < 15% risk of recurrence at 10 yearsPatients with poor prognostic signature had 50% risk for distant metastasesStudies showed that risk predicted by MammaPrint is most likely associated with early recurrence",
                      "Validation studies have shown that patient with good prognostic signature had < 15% risk of recurrence at 10 years",
                      "Patients with poor prognostic signature had 50% risk for distant metastases",
                      "Studies showed that risk predicted by MammaPrint is most likely associated with early recurrence",
                      "Originally required fresh or frozen tumor tissue, but test has been adapted for formalin-fixed samples",
                      "Function of 70 genes assayed is related to cellular pathways involving apoptosis, growth signaling, limitless potential to replicate, tissue invasion, and angiogenesis",
                      "Several clinical validation studies of MammaPrint have been conductedMost of these studies have been retrospective or nonrandomized, limiting predictive ability for chemotherapy benefitMetaanalysis showed that MammaPrint is also predictive for chemotherapy benefit",
                      "Most of these studies have been retrospective or nonrandomized, limiting predictive ability for chemotherapy benefit",
                      "Metaanalysis showed that MammaPrint is also predictive for chemotherapy benefit",
                      "Microarray in node (-) and 1-3 (+) lymph node disease may avoid chemotherapy (MINDACT randomized/prospective trial)Randomized based on discordant risk assessment from MammaPrint vs. clinical risk based on Adjuvant! OnlinePatients with high clinical risk but low genomic risk receiving no chemotherapy had 5-year survival that was 1.5% lower that those receiving chemotherapyConcluded that ~ 46% of women at high clinical risk but low genomic risk based on MammaPrint might not require chemotherapy",
                      "Randomized based on discordant risk assessment from MammaPrint vs. clinical risk based on Adjuvant! Online",
                      "Patients with high clinical risk but low genomic risk receiving no chemotherapy had 5-year survival that was 1.5% lower that those receiving chemotherapy",
                      "Concluded that ~ 46% of women at high clinical risk but low genomic risk based on MammaPrint might not require chemotherapy"
                    ]
                  },
                  {
                    "text": "Prosigna Breast Cancer Prognostic Gene Signature assayRT-PCR assay measuring expression levels of 50 genesResults can classify breast tumors into intrinsic subtypes [luminal A and B, HER2(+), basal-like]Risk of RS incorporates clinical treatment score data with gene expression dataTranslates prognostic information from intrinsic subtypes into prognostic scoreUseful for predicting late recurrence in ER(+) patients treated with endocrine therapyUseful in identifying ER(+) patients with excellent outcome who may not benefit from chemotherapy",
                    "sub_points": [
                      "RT-PCR assay measuring expression levels of 50 genesResults can classify breast tumors into intrinsic subtypes [luminal A and B, HER2(+), basal-like]",
                      "Results can classify breast tumors into intrinsic subtypes [luminal A and B, HER2(+), basal-like]",
                      "Risk of RS incorporates clinical treatment score data with gene expression dataTranslates prognostic information from intrinsic subtypes into prognostic scoreUseful for predicting late recurrence in ER(+) patients treated with endocrine therapyUseful in identifying ER(+) patients with excellent outcome who may not benefit from chemotherapy",
                      "Translates prognostic information from intrinsic subtypes into prognostic score",
                      "Useful for predicting late recurrence in ER(+) patients treated with endocrine therapy",
                      "Useful in identifying ER(+) patients with excellent outcome who may not benefit from chemotherapy"
                    ]
                  },
                  {
                    "text": "EndoPredictMultigene classifier to assess prognosis in ER(+)/HER2(-) cancer treated with endocrine therapyGene expression measured for 11 genes (8 cancer genes, 3 control genes)Gene panel assesses proliferation and hormone receptor activity (does not include ER, PR, or HER2)Results useful for low and high risk for recurrenceEndoPredict score significantly correlates with both early and late distant disease recurrenceUseful for assessing prognosis in ER(+)/HER2(-)/node (-) or node (+) postmenopausal cancer",
                    "sub_points": [
                      "Multigene classifier to assess prognosis in ER(+)/HER2(-) cancer treated with endocrine therapyGene expression measured for 11 genes (8 cancer genes, 3 control genes)Gene panel assesses proliferation and hormone receptor activity (does not include ER, PR, or HER2)Results useful for low and high risk for recurrence",
                      "Gene expression measured for 11 genes (8 cancer genes, 3 control genes)",
                      "Gene panel assesses proliferation and hormone receptor activity (does not include ER, PR, or HER2)",
                      "Results useful for low and high risk for recurrence",
                      "EndoPredict score significantly correlates with both early and late distant disease recurrenceUseful for assessing prognosis in ER(+)/HER2(-)/node (-) or node (+) postmenopausal cancer",
                      "Useful for assessing prognosis in ER(+)/HER2(-)/node (-) or node (+) postmenopausal cancer"
                    ]
                  }
                ],
                "Next-Generation Sequencing": [
                  {
                    "text": "Permits simultaneous interrogation of genomic alterations present in panel of cancer genes, whole exomes, or entire genomeMost recurrently mutate genes in breast cancer:PIK3CAandTP53(30%)CCND1,FGFR1mutations, andHER2amplification (15%)Majority of other cancer genes and new potential driver mutations mutated at frequencies of < 5%Mutations inGATA3andRBFOX1appear to be confined to ER(+) diseaseInvasive ductal and lobular carcinomas characterized by different mutational landscapesEnrichment ofCDH1,TBX3,FOXA1, andERBB2mutations in lobular carcinomasSequencing studies highlight important genomic diversity among breast tumors",
                    "sub_points": [
                      "Most recurrently mutate genes in breast cancer:PIK3CAandTP53(30%)",
                      "CCND1,FGFR1mutations, andHER2amplification (15%)",
                      "Majority of other cancer genes and new potential driver mutations mutated at frequencies of < 5%",
                      "Mutations inGATA3andRBFOX1appear to be confined to ER(+) disease",
                      "Invasive ductal and lobular carcinomas characterized by different mutational landscapesEnrichment ofCDH1,TBX3,FOXA1, andERBB2mutations in lobular carcinomas",
                      "Enrichment ofCDH1,TBX3,FOXA1, andERBB2mutations in lobular carcinomas",
                      "Sequencing studies highlight important genomic diversity among breast tumors"
                    ]
                  },
                  {
                    "text": "Genomic characterization of circulating tumor DNA (ctDNA) released from tumor cells shows promise for clinical applicationsNoninvasive tumor genotypingSurveillance and monitoring treatment responseIdentification of residual disease in early-stage cancersIdentification of resistance-associated mutations, such asESR1mutations, and endocrine resistance",
                    "sub_points": [
                      "Noninvasive tumor genotyping",
                      "Surveillance and monitoring treatment response",
                      "Identification of residual disease in early-stage cancers",
                      "Identification of resistance-associated mutations, such asESR1mutations, and endocrine resistance"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Histologic gradeElston and Ellis modification of Scarff-Bloom-Richardson histologic grade divides breast cancers into groups with different natural histories and biologic characteristicsGrading based on tumor differentiation and proliferationGrade 1: Well differentiated; 20%; incidence higher in older womenGrade 2: Moderately differentiated; 30-35%Grade 3: Poorly differentiated; 45-50%; incidence higher in younger womenHistologic grade is strongly correlated with breast cancer-specific survival and disease-free survivalSignificant association between grade and survival holds true for different tumor subgroups (tumor size and lymph node stages)Grade correlates with overall length of survival regardless of clinical stage",
                    "sub_points": [
                      "Elston and Ellis modification of Scarff-Bloom-Richardson histologic grade divides breast cancers into groups with different natural histories and biologic characteristicsGrading based on tumor differentiation and proliferationGrade 1: Well differentiated; 20%; incidence higher in older womenGrade 2: Moderately differentiated; 30-35%Grade 3: Poorly differentiated; 45-50%; incidence higher in younger womenHistologic grade is strongly correlated with breast cancer-specific survival and disease-free survivalSignificant association between grade and survival holds true for different tumor subgroups (tumor size and lymph node stages)Grade correlates with overall length of survival regardless of clinical stage",
                      "Grading based on tumor differentiation and proliferationGrade 1: Well differentiated; 20%; incidence higher in older womenGrade 2: Moderately differentiated; 30-35%Grade 3: Poorly differentiated; 45-50%; incidence higher in younger women",
                      "Grade 1: Well differentiated; 20%; incidence higher in older women",
                      "Grade 2: Moderately differentiated; 30-35%",
                      "Grade 3: Poorly differentiated; 45-50%; incidence higher in younger women",
                      "Histologic grade is strongly correlated with breast cancer-specific survival and disease-free survivalSignificant association between grade and survival holds true for different tumor subgroups (tumor size and lymph node stages)Grade correlates with overall length of survival regardless of clinical stage",
                      "Significant association between grade and survival holds true for different tumor subgroups (tumor size and lymph node stages)",
                      "Grade correlates with overall length of survival regardless of clinical stage"
                    ]
                  },
                  {
                    "text": "Grade and genomic grade index (GGI)Developed using GEP comparing low- and high-grade carcinomas97-gene panel discriminates reproducibly between 2 ER(+) subgroups that correlate with grade and significantly different clinical outcomeGGI driven by proliferation and cell cycle-related genesOnly informative in ER(+), HER2(-) luminal tumorsAssociated with prognosis and tumor gradeGrade 1 tumors: 85% low GGI; grade 3 tumors: 90% high GGI; grade 2 tumors: Split into low and high GGI categoriesPredictive for recurrence in endocrine- and chemotherapy-treated patients and prognostic for neoadjuvant chemotherapy",
                    "sub_points": [
                      "Developed using GEP comparing low- and high-grade carcinomas97-gene panel discriminates reproducibly between 2 ER(+) subgroups that correlate with grade and significantly different clinical outcomeGGI driven by proliferation and cell cycle-related genesOnly informative in ER(+), HER2(-) luminal tumorsAssociated with prognosis and tumor gradeGrade 1 tumors: 85% low GGI; grade 3 tumors: 90% high GGI; grade 2 tumors: Split into low and high GGI categoriesPredictive for recurrence in endocrine- and chemotherapy-treated patients and prognostic for neoadjuvant chemotherapy",
                      "97-gene panel discriminates reproducibly between 2 ER(+) subgroups that correlate with grade and significantly different clinical outcome",
                      "GGI driven by proliferation and cell cycle-related genes",
                      "Only informative in ER(+), HER2(-) luminal tumors",
                      "Associated with prognosis and tumor gradeGrade 1 tumors: 85% low GGI; grade 3 tumors: 90% high GGI; grade 2 tumors: Split into low and high GGI categories",
                      "Grade 1 tumors: 85% low GGI; grade 3 tumors: 90% high GGI; grade 2 tumors: Split into low and high GGI categories",
                      "Predictive for recurrence in endocrine- and chemotherapy-treated patients and prognostic for neoadjuvant chemotherapy"
                    ]
                  },
                  {
                    "text": "Grade and DNA changesNumber and pattern of genomic copy number alterations differ significantly when stratified by histologic gradeAverage number of chromosomal changes increases with increasing gradeHigh-grade tumors: High genomic instability (gains at 5p, 8q, 10p, 17q12, and 19; losses at 3q, 4, 5q proximal, 9p, 11p, 18q, and 21)Low-grade tumors: Low level of instability, deletion 16q and gain of 1q (80%)Gains and losses occur at loci harboring oncogenes and tumor suppressor genesClose correlation between DNA copy number changes and mRNA expression levelsGene amplification may be common mechanism for driving GEP in breast carcinoma",
                    "sub_points": [
                      "Number and pattern of genomic copy number alterations differ significantly when stratified by histologic gradeAverage number of chromosomal changes increases with increasing gradeHigh-grade tumors: High genomic instability (gains at 5p, 8q, 10p, 17q12, and 19; losses at 3q, 4, 5q proximal, 9p, 11p, 18q, and 21)Low-grade tumors: Low level of instability, deletion 16q and gain of 1q (80%)",
                      "Average number of chromosomal changes increases with increasing grade",
                      "High-grade tumors: High genomic instability (gains at 5p, 8q, 10p, 17q12, and 19; losses at 3q, 4, 5q proximal, 9p, 11p, 18q, and 21)",
                      "Low-grade tumors: Low level of instability, deletion 16q and gain of 1q (80%)",
                      "Gains and losses occur at loci harboring oncogenes and tumor suppressor genes",
                      "Close correlation between DNA copy number changes and mRNA expression levels",
                      "Gene amplification may be common mechanism for driving GEP in breast carcinoma"
                    ]
                  },
                  {
                    "text": "IHC and breast cancer subtypesGroups similar to those defined by GEP can be defined based on expression of ER, PR, HER2, and proliferation index (IHC surrogate)Subtypes defined by GEP and IHC overlap by 80-85%Groups were originally defined by GEP; helpful to use same names to describe similar groups of cancers defined by IHCClassification by IHC has advantage of organizing cancers according to therapeutic targets and likely response to chemotherapy",
                    "sub_points": [
                      "Groups similar to those defined by GEP can be defined based on expression of ER, PR, HER2, and proliferation index (IHC surrogate)",
                      "Subtypes defined by GEP and IHC overlap by 80-85%Groups were originally defined by GEP; helpful to use same names to describe similar groups of cancers defined by IHCClassification by IHC has advantage of organizing cancers according to therapeutic targets and likely response to chemotherapy",
                      "Groups were originally defined by GEP; helpful to use same names to describe similar groups of cancers defined by IHC",
                      "Classification by IHC has advantage of organizing cancers according to therapeutic targets and likely response to chemotherapy"
                    ]
                  },
                  {
                    "text": "ER(+), HER2(-), low proliferation (luminal A)Invasive tumor: Well-formed tubules, cribriform nestMajority are grade 1 or 2, small- to moderate-sized nuclei, minute or absent nucleoliMitotic figures are absentER and PR generally present and highly expressedPIK3CAmutations (~ 35%);TP53mutations rareFavorable prognosis; most benefit from hormonal treatment; little benefit from chemotherapy",
                    "sub_points": [
                      "Invasive tumor: Well-formed tubules, cribriform nestMajority are grade 1 or 2, small- to moderate-sized nuclei, minute or absent nucleoliMitotic figures are absentER and PR generally present and highly expressed",
                      "Majority are grade 1 or 2, small- to moderate-sized nuclei, minute or absent nucleoli",
                      "Mitotic figures are absent",
                      "ER and PR generally present and highly expressed",
                      "PIK3CAmutations (~ 35%);TP53mutations rare",
                      "Favorable prognosis; most benefit from hormonal treatment; little benefit from chemotherapy"
                    ]
                  },
                  {
                    "text": "ER(+), HER2(+/-), high proliferation (luminal B)Poor acini formation; may invade as nests and sheetsMajority are grade 2 or 3; nuclei typically high grade with prominent nucleoliMitotic figures present and may be prominentER is present but may be at low levels; PR may be absent; may be HER2(+)Complex genomic changes, genetic instability, deletion 16q and gain 1q (50%); may haveTP53mutationsLess favorable prognosis, may benefit from endocrine and chemotherapy",
                    "sub_points": [
                      "Poor acini formation; may invade as nests and sheetsMajority are grade 2 or 3; nuclei typically high grade with prominent nucleoliMitotic figures present and may be prominentER is present but may be at low levels; PR may be absent; may be HER2(+)",
                      "Majority are grade 2 or 3; nuclei typically high grade with prominent nucleoli",
                      "Mitotic figures present and may be prominent",
                      "ER is present but may be at low levels; PR may be absent; may be HER2(+)",
                      "Complex genomic changes, genetic instability, deletion 16q and gain 1q (50%); may haveTP53mutations",
                      "Less favorable prognosis, may benefit from endocrine and chemotherapy"
                    ]
                  },
                  {
                    "text": "ER(-), HER2(+) (HER2enriched)Usually invade as nests or sheets of cellsMajority are grade 3; prominent nucleoli; may have abundant cytoplasm with apocrine featuresMitotic figure present and may be frequentMay show necrosis (40%), lymphocytic infiltrates (60%), lymphatic invasion (45%)Amplification ofERBB2(HER2) and surrounding genesTP53mutations are commonUnfavorable prognosis; however, great benefit from chemotherapy and HER2-targeted therapy",
                    "sub_points": [
                      "Usually invade as nests or sheets of cellsMajority are grade 3; prominent nucleoli; may have abundant cytoplasm with apocrine featuresMitotic figure present and may be frequentMay show necrosis (40%), lymphocytic infiltrates (60%), lymphatic invasion (45%)",
                      "Majority are grade 3; prominent nucleoli; may have abundant cytoplasm with apocrine features",
                      "Mitotic figure present and may be frequent",
                      "May show necrosis (40%), lymphocytic infiltrates (60%), lymphatic invasion (45%)",
                      "Amplification ofERBB2(HER2) and surrounding genes",
                      "TP53mutations are common",
                      "Unfavorable prognosis; however, great benefit from chemotherapy and HER2-targeted therapy"
                    ]
                  },
                  {
                    "text": "ER(-), HER2(-) (basal-like, TNBC)Circumscribed border, syncytial-like growthMost grade 3, pleomorphic nuclei, prominent nucleoliMitotic figures frequent, may be prominentCentral fibrosis &/or geographic necrosis frequentLymphocytic infiltrates and lymphatic invasion commonGenome highly unstable; numerous copy number changes; loss of function of DNA repair genes; majority haveTP53mutationsUnfavorable prognosis but subset has good response to adjuvant or neoadjuvant chemotherapy",
                    "sub_points": [
                      "Circumscribed border, syncytial-like growthMost grade 3, pleomorphic nuclei, prominent nucleoliMitotic figures frequent, may be prominentCentral fibrosis &/or geographic necrosis frequentLymphocytic infiltrates and lymphatic invasion common",
                      "Most grade 3, pleomorphic nuclei, prominent nucleoli",
                      "Mitotic figures frequent, may be prominent",
                      "Central fibrosis &/or geographic necrosis frequent",
                      "Lymphocytic infiltrates and lymphatic invasion common",
                      "Genome highly unstable; numerous copy number changes; loss of function of DNA repair genes; majority haveTP53mutations",
                      "Unfavorable prognosis but subset has good response to adjuvant or neoadjuvant chemotherapy"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Breast cancer predictive assay used in clinical practice"
                  },
                  {
                    "text": "ERRegulates growth and development of breast and other hormonally responsive tissuesAfter binding to its ligand (estrogen), ER is transported to nucleus where it functions as transcription factorER regulates expression of genes that are important in development and physiologic function, including proliferation70-80% of all invasive breast cancers express ERER drives tumor cell proliferation and disease progression in these tumorsER expression in breast cancer can be detected by IHCTumor is considered ER(+) if as few as 1% of invasive tumor cells show moderate nuclear stainingMost low-grade breast cancers should be ER(+)ER expression in breast cancer predicts clinical benefit from hormonal therapiesEndocrine therapies: Tamoxifen (ER antagonist) and aromatase inhibitors (block local estrogen production)",
                    "sub_points": [
                      "Regulates growth and development of breast and other hormonally responsive tissuesAfter binding to its ligand (estrogen), ER is transported to nucleus where it functions as transcription factorER regulates expression of genes that are important in development and physiologic function, including proliferation70-80% of all invasive breast cancers express ERER drives tumor cell proliferation and disease progression in these tumors",
                      "After binding to its ligand (estrogen), ER is transported to nucleus where it functions as transcription factor",
                      "ER regulates expression of genes that are important in development and physiologic function, including proliferation",
                      "70-80% of all invasive breast cancers express ER",
                      "ER drives tumor cell proliferation and disease progression in these tumors",
                      "ER expression in breast cancer can be detected by IHCTumor is considered ER(+) if as few as 1% of invasive tumor cells show moderate nuclear stainingMost low-grade breast cancers should be ER(+)ER expression in breast cancer predicts clinical benefit from hormonal therapiesEndocrine therapies: Tamoxifen (ER antagonist) and aromatase inhibitors (block local estrogen production)",
                      "Tumor is considered ER(+) if as few as 1% of invasive tumor cells show moderate nuclear staining",
                      "Most low-grade breast cancers should be ER(+)",
                      "ER expression in breast cancer predicts clinical benefit from hormonal therapies",
                      "Endocrine therapies: Tamoxifen (ER antagonist) and aromatase inhibitors (block local estrogen production)"
                    ]
                  },
                  {
                    "text": "HER2Transmembrane growth factor receptor that regulates normal cell growth and developmentERBB2(HER2) located on chromosome 17, amplified (early oncogenic event) in 12-18% of invasive beast carcinomasGene amplification drives HER2 overexpression, increasing receptor activation and signalingActivation of HER2 signaling drives proliferation, angiogenesis, and enhances cell survival pathwaysHER2-driven breast cancers are more aggressive with higher recurrence rates and mortalityHER2 can be assessed by IHC or in situ hybridization in clinical samples from breast cancerPatients who test as HER2(+) are candidates for targeted therapies against HER2HER2-targeted therapies include antibodies (trastuzumab, pertuzumab, and TDM1) and small molecule inhibitors (lapatinib)HER2-targeted therapies are effective in metastatic, adjuvant, and neoadjuvant settings",
                    "sub_points": [
                      "Transmembrane growth factor receptor that regulates normal cell growth and development",
                      "ERBB2(HER2) located on chromosome 17, amplified (early oncogenic event) in 12-18% of invasive beast carcinomasGene amplification drives HER2 overexpression, increasing receptor activation and signalingActivation of HER2 signaling drives proliferation, angiogenesis, and enhances cell survival pathwaysHER2-driven breast cancers are more aggressive with higher recurrence rates and mortality",
                      "Gene amplification drives HER2 overexpression, increasing receptor activation and signaling",
                      "Activation of HER2 signaling drives proliferation, angiogenesis, and enhances cell survival pathways",
                      "HER2-driven breast cancers are more aggressive with higher recurrence rates and mortality",
                      "HER2 can be assessed by IHC or in situ hybridization in clinical samples from breast cancerPatients who test as HER2(+) are candidates for targeted therapies against HER2HER2-targeted therapies include antibodies (trastuzumab, pertuzumab, and TDM1) and small molecule inhibitors (lapatinib)HER2-targeted therapies are effective in metastatic, adjuvant, and neoadjuvant settings",
                      "Patients who test as HER2(+) are candidates for targeted therapies against HER2",
                      "HER2-targeted therapies include antibodies (trastuzumab, pertuzumab, and TDM1) and small molecule inhibitors (lapatinib)",
                      "HER2-targeted therapies are effective in metastatic, adjuvant, and neoadjuvant settings"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Invasive Ductal Carcinoma of No Special Type With Medullary Features": {
            "name": "Invasive Ductal Carcinoma of No Special Type With Medullary Features",
            "url": "https://app.pathprimer.com/document/5eff86f9-05af-4548-a821-ce27130f35b9/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Historically described as medullary carcinoma, atypical medullary carcinoma, or carcinoma with medullary features"
                  },
                  {
                    "text": "In most recent WHO classification (5th edition), this entity is not considered separate histologic subtype and is now regarded as type of tumor-infiltrating lymphocyte (TIL)-rich invasive ductal carcinoma"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Targeted FDA-approved immunotherapy in breast cancer is attractive option for these patients given predictive role PD-L1 plays in triple-negative breast cancer (TNBC)"
                  },
                  {
                    "text": "Medullary pattern reported in 30-60% of breast tumor arising in patients withBRCA1germline mutationsPatients with germline BRCA mutations are candidates for treatment with PARP inhibitors",
                    "sub_points": [
                      "Patients with germline BRCA mutations are candidates for treatment with PARP inhibitors"
                    ]
                  },
                  {
                    "text": "Historically reported favorable prognosis is now considered to be secondary to TILs present in these tumors"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Invasive ductal carcinomas that display following featuresProminent lymphoplasmacytic infiltratesCohesive, expansile syncytial growth with circumscribed or pushing borderHigh-grade histology and proliferation",
                    "sub_points": [
                      "Prominent lymphoplasmacytic infiltrates",
                      "Cohesive, expansile syncytial growth with circumscribed or pushing border",
                      "High-grade histology and proliferation"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunohistochemistryTriple-negative profile in > 90% of cases",
                    "sub_points": [
                      "Triple-negative profile in > 90% of cases"
                    ]
                  },
                  {
                    "text": "Molecular geneticsMost tumors withBRCA1germline mutations have medullary pattern",
                    "sub_points": [
                      "Most tumors withBRCA1germline mutations have medullary pattern"
                    ]
                  },
                  {
                    "text": "Gene expression profiling95% of cases exhibit basal-like phenotype",
                    "sub_points": [
                      "95% of cases exhibit basal-like phenotype"
                    ]
                  },
                  {
                    "text": "TP53mutations are most common"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Invasive ductal carcinoma, medullary pattern (IDC-MP)"
                  },
                  {
                    "text": "Triple-negative breast cancer (TNBC)"
                  },
                  {
                    "text": "Tumor-infiltrating lymphocytes (TILs)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Historically described as medullary carcinoma, atypical medullary carcinoma, or carcinoma with medullary featuresIn most recent WHO classification (5th edition), this entity is not considered separate histologic subtype and is now regarded as type of TIL-rich invasive ductal carcinoma",
                    "sub_points": [
                      "In most recent WHO classification (5th edition), this entity is not considered separate histologic subtype and is now regarded as type of TIL-rich invasive ductal carcinoma"
                    ]
                  },
                  {
                    "text": "Typically has TNBC biomarker profile"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "IDC-MP": [
                  {
                    "text": "Basal-like molecular profile"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Association withBRCA1Medullary pattern reported in 30-60% of breast cancer arising in patients withBRCA1germline mutationsMedullary pattern reported in 25% of tumors withBRCA1somatic mutations",
                    "sub_points": [
                      "Medullary pattern reported in 30-60% of breast cancer arising in patients withBRCA1germline mutations",
                      "Medullary pattern reported in 25% of tumors withBRCA1somatic mutations"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Most commonly observed in younger women"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Rapidly enlarging, palpable breast mass"
                  },
                  {
                    "text": "Axillary lymph nodes commonly enlargedNodal enlargement can be secondary to reactive lymphoid hyperplasia",
                    "sub_points": [
                      "Nodal enlargement can be secondary to reactive lymphoid hyperplasia"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treated similar to TNBCTargeted FDA-approved immunotherapy in breast cancer is attractive option for these patients given predictive role PD-L1 plays in TNBCPatients with germline BRCA mutations are candidates for treatment with PARP inhibitors",
                    "sub_points": [
                      "Targeted FDA-approved immunotherapy in breast cancer is attractive option for these patients given predictive role PD-L1 plays in TNBC",
                      "Patients with germline BRCA mutations are candidates for treatment with PARP inhibitors"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Historically reported favorable prognosis is now considered to be secondary to TILs present in these tumors"
                  },
                  {
                    "text": "Dependent on stage of tumor like other TNBC"
                  },
                  {
                    "text": "TILsCan be used both as prognostic and predictive immuno-oncologic biomarkerPredicts better response to chemotherapy (both in neoadjuvant and adjuvant setting)Higher TILs in postneoadjuvant residual disease in TNBC are important independent predictor of improved survivalImproved metastasis-free survival and overall survival reported in postneoadjuvant TNBC patients with high TILs (> 60%)",
                    "sub_points": [
                      "Can be used both as prognostic and predictive immuno-oncologic biomarker",
                      "Predicts better response to chemotherapy (both in neoadjuvant and adjuvant setting)",
                      "Higher TILs in postneoadjuvant residual disease in TNBC are important independent predictor of improved survivalImproved metastasis-free survival and overall survival reported in postneoadjuvant TNBC patients with high TILs (> 60%)",
                      "Improved metastasis-free survival and overall survival reported in postneoadjuvant TNBC patients with high TILs (> 60%)"
                    ]
                  },
                  {
                    "text": "PD-L1 expression in TNBCCompared to normal breast tissue, PD-L1 expression is upregulated in 38% of basal-like carcinomas (BLC)Expression can serve significant prognostic biomarker of breast cancerHigh PD-L1(+) TILs score (> 50%) is independently associated with better outcome in TNBCPathologic complete response after neoadjuvant chemotherapy is higher in case of PD-L1 upregulationCan serve as important predictive biomarkerPD-L1 inhibitors + chemotherapy can prolong progression-free and overall survival among patients with metastatic TNBC",
                    "sub_points": [
                      "Compared to normal breast tissue, PD-L1 expression is upregulated in 38% of basal-like carcinomas (BLC)",
                      "Expression can serve significant prognostic biomarker of breast cancer",
                      "High PD-L1(+) TILs score (> 50%) is independently associated with better outcome in TNBC",
                      "Pathologic complete response after neoadjuvant chemotherapy is higher in case of PD-L1 upregulation",
                      "Can serve as important predictive biomarkerPD-L1 inhibitors + chemotherapy can prolong progression-free and overall survival among patients with metastatic TNBC",
                      "PD-L1 inhibitors + chemotherapy can prolong progression-free and overall survival among patients with metastatic TNBC"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Invasive ductal carcinomas that display following featuresProminent intratumoral and peritumoral lymphoplasmacytic cell infiltratesStromal and occasionally intratumoralOften involve periphery of tumorTend to involve distant benign ducts and lobules",
                    "sub_points": [
                      "Prominent intratumoral and peritumoral lymphoplasmacytic cell infiltratesStromal and occasionally intratumoralOften involve periphery of tumorTend to involve distant benign ducts and lobules",
                      "Stromal and occasionally intratumoral",
                      "Often involve periphery of tumor",
                      "Tend to involve distant benign ducts and lobules"
                    ]
                  },
                  {
                    "text": "Cohesive, expansile syncytial growth with circumscribed or pushing border"
                  },
                  {
                    "text": "High-grade histology and proliferation"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Prognostic and predictive biomarkers~ 90% of cases negative for ER, PR, and HER2 (triple-negative profile)Can be focal weak positive for hormone receptors",
                    "sub_points": [
                      "~ 90% of cases negative for ER, PR, and HER2 (triple-negative profile)Can be focal weak positive for hormone receptors",
                      "Can be focal weak positive for hormone receptors"
                    ]
                  },
                  {
                    "text": "Basal-like immunophenotypeCK5/6(+) in up to 94%CK14(+) in ~ 12%SMA(+) in up to 34%EGFR(+) in up to 71%S100(+) in ~ 44%P-cadherin (+) in ~ 87%",
                    "sub_points": [
                      "CK5/6(+) in up to 94%",
                      "CK14(+) in ~ 12%",
                      "SMA(+) in up to 34%",
                      "EGFR(+) in up to 71%",
                      "S100(+) in ~ 44%",
                      "P-cadherin (+) in ~ 87%"
                    ]
                  },
                  {
                    "text": "p53High rate of expressionRange: 46-87%",
                    "sub_points": [
                      "High rate of expressionRange: 46-87%",
                      "Range: 46-87%"
                    ]
                  },
                  {
                    "text": "Lymphoid infiltratesIncreased CD8(+) cytotoxic T lymphocytesIncreased activated HLA-DR-positive T cellsMay explain in part favorable prognosis",
                    "sub_points": [
                      "Increased CD8(+) cytotoxic T lymphocytes",
                      "Increased activated HLA-DR-positive T cells",
                      "May explain in part favorable prognosis"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Most tumors withBRCA1germline mutations have IDC-MP"
                  },
                  {
                    "text": "TP53mutations most common"
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Segregate for BLC in 95% of casesBelongs to immunomodulatory (IM) subgroup in original 6-class system of TNBC and to BL1 subgroup in 4-class system",
                    "sub_points": [
                      "Belongs to immunomodulatory (IM) subgroup in original 6-class system of TNBC and to BL1 subgroup in 4-class system"
                    ]
                  },
                  {
                    "text": "Overexpressed genes are related to immune responseB-cell/plasma-cell metageneGenes involved in extrinsic apoptosis pathwayGenes involved in antigen processing and presentationGenes located in 12p13 and 6p21.3 regionsLong isoform transcript ofBCL2L14more frequently expressed",
                    "sub_points": [
                      "B-cell/plasma-cell metagene",
                      "Genes involved in extrinsic apoptosis pathway",
                      "Genes involved in antigen processing and presentation",
                      "Genes located in 12p13 and 6p21.3 regionsLong isoform transcript ofBCL2L14more frequently expressed",
                      "Long isoform transcript ofBCL2L14more frequently expressed"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Intramammary Nodal Metastasis": [
                  {
                    "text": "Metastases to intramammary lymph node may be difficult to distinguish from IDC-MP in come casesResidual benign lymph node architecture usually presentPresence of primary tumor mass elsewhere in breast may favor metastasisNo surrounding breast parenchymaNo surrounding in situ carcinoma",
                    "sub_points": [
                      "Residual benign lymph node architecture usually present",
                      "Presence of primary tumor mass elsewhere in breast may favor metastasis",
                      "No surrounding breast parenchyma",
                      "No surrounding in situ carcinoma"
                    ]
                  }
                ],
                "Lymphoma": [
                  {
                    "text": "Lacks typical syncytial sheets of epithelial cell"
                  },
                  {
                    "text": "Negative for cytokeratin markers"
                  },
                  {
                    "text": "Positive for CD45 and lymphoid-associated markers"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Prostatic Adenocarcinoma, Acinar Type and High-Grade Prostatic Intraepithelial Neoplasia": {
            "name": "Prostatic Adenocarcinoma, Acinar Type and High-Grade Prostatic Intraepithelial Neoplasia",
            "url": "https://app.pathprimer.com/document/4ea1c220-b22b-4fe4-b018-829bbaec7373/lesson/3cd1c2f1-0e2b-4434-bf96-2598369107a8",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Prostatic adenocarcinoma, acinar type (PCa)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Combination of genetic and environmental factors"
                  },
                  {
                    "text": "High-grade prostatic intraepithelial neoplasia (HG-PIN) shares multiple molecular genetic abnormalities with invasive acinar adenocarcinoma"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most frequent noncutaneous malignancy in men, 2nd most common cause of cancer deaths among men in USA"
                  },
                  {
                    "text": "Heterogeneous disease with highly variable clinical course"
                  }
                ],
                "Molecular": [
                  {
                    "text": "TMPRSS2fusion with member of ETS transcription factor family in ~ 50% of cases"
                  },
                  {
                    "text": "ETS fusion-positive tumors appear biologically distinct from ETS-negative PCas"
                  },
                  {
                    "text": "Mutations inSPOP,FLI1,FOXA1, andIDH1mutually exclusive with ETS rearrangement and with each other"
                  },
                  {
                    "text": "SPOPmutations andCHD1deletions may be driver mutations in ETS-negative tumors"
                  },
                  {
                    "text": "Alterations in androgen receptor gene and pathway in hormone-refractory PCa"
                  },
                  {
                    "text": "Chromothripsis and chromoplexy common"
                  },
                  {
                    "text": "Other genetic alterations common inMYC,PTEN,TP53, andNKX3-1"
                  },
                  {
                    "text": "Alterations in PI3K-AKT-mTOR pathway more common in advanced tumors"
                  },
                  {
                    "text": "PCA3overexpressed in > 90% of prostate cancers"
                  },
                  {
                    "text": "Epigenetic changes common with hypermethylation of many genes, includingGSTP1"
                  },
                  {
                    "text": "Mutations in DNA repair genes involved in homologous recombination repair or in mismatch repair in up to 20% of metastatic carcinomas"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "NKX3.1, prostein, PSA, PSAP, and AMACR positive"
                  },
                  {
                    "text": "Invasive carcinoma lacks staining for basal cell markers p63, CK5, and 34βE12"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Prostatic adenocarcinoma, acinar type (PCa)"
                  },
                  {
                    "text": "High-grade prostatic intraepithelial neoplasia (HG-PIN)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Acinar adenocarcinomaMalignant neoplasm of prostatic epithelial origin",
                    "sub_points": [
                      "Malignant neoplasm of prostatic epithelial origin"
                    ]
                  },
                  {
                    "text": "HG-PINNoninvasive epithelial proliferation in preexisting acini and ducts with neoplastic cytologic features",
                    "sub_points": [
                      "Noninvasive epithelial proliferation in preexisting acini and ducts with neoplastic cytologic features"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiologic and Pathogenetic Factors": [
                  {
                    "text": "Acinar adenocarcinomaCombination of genetic and environmental factorsWell-documented familial associationRole of infection &/or inflammation remains unclear",
                    "sub_points": [
                      "Combination of genetic and environmental factors",
                      "Well-documented familial association",
                      "Role of infection &/or inflammation remains unclear"
                    ]
                  },
                  {
                    "text": "HG-PINCommonly associated with invasive PCaShares multiple molecular genetic abnormalities with invasive carcinomaConsidered preinvasive neoplasm",
                    "sub_points": [
                      "Commonly associated with invasive PCa",
                      "Shares multiple molecular genetic abnormalities with invasive carcinomaConsidered preinvasive neoplasm",
                      "Considered preinvasive neoplasm"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Acinar adenocarcinomaMost frequent noncutaneous malignancy in men2nd most common cause of cancer deaths among men in USA",
                    "sub_points": [
                      "Most frequent noncutaneous malignancy in men",
                      "2nd most common cause of cancer deaths among men in USA"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Acinar adenocarcinomaSerum PSA screening remains 1st-line biomarkerLacks high sensitivity and specificityLeads to overdetection of indolent disease and may lead to overtreatment in many casesPSA indices include free PSA, PSA density, and PSA velocity",
                    "sub_points": [
                      "Serum PSA screening remains 1st-line biomarkerLacks high sensitivity and specificityLeads to overdetection of indolent disease and may lead to overtreatment in many cases",
                      "Lacks high sensitivity and specificity",
                      "Leads to overdetection of indolent disease and may lead to overtreatment in many cases",
                      "PSA indices include free PSA, PSA density, and PSA velocity"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Acinar adenocarcinomaActive surveillance (watchful waiting) with repeat biopsy in patients with low-grade, low-volume diseaseRadical prostatectomyBrachytherapy or external beam radiationAndrogen-deprivation therapy for systemic diseaseBilateral orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonists, antiandrogens, or LHRH antagonistsDocetaxel or cabazitaxel chemotherapyPalliative transurethral resection to relieve obstructive symptoms",
                    "sub_points": [
                      "Active surveillance (watchful waiting) with repeat biopsy in patients with low-grade, low-volume disease",
                      "Radical prostatectomy",
                      "Brachytherapy or external beam radiation",
                      "Androgen-deprivation therapy for systemic diseaseBilateral orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonists, antiandrogens, or LHRH antagonists",
                      "Bilateral orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonists, antiandrogens, or LHRH antagonists",
                      "Docetaxel or cabazitaxel chemotherapy",
                      "Palliative transurethral resection to relieve obstructive symptoms"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Acinar adenocarcinomaHeterogeneous disease with highly variable clinical courseMany patients have indolent disease that will not threaten their health during lifetimeOther patients have aggressive disease with progression and metastasesEstablished prognostic factorsPreoperative serum PSA levels, histologic grade (Gleason score, grade group), tumor volume, pathologic stage, surgical margin statusPrognosis of hormone-refractory prostate cancer is poor with survival ~ 1 yearDevelopment of new prognostic and predictive markers is major goal of ongoing researchSeveral proprietary molecular tests commercially available with goal to aid in clinical decision making",
                    "sub_points": [
                      "Heterogeneous disease with highly variable clinical courseMany patients have indolent disease that will not threaten their health during lifetimeOther patients have aggressive disease with progression and metastases",
                      "Many patients have indolent disease that will not threaten their health during lifetime",
                      "Other patients have aggressive disease with progression and metastases",
                      "Established prognostic factorsPreoperative serum PSA levels, histologic grade (Gleason score, grade group), tumor volume, pathologic stage, surgical margin status",
                      "Preoperative serum PSA levels, histologic grade (Gleason score, grade group), tumor volume, pathologic stage, surgical margin status",
                      "Prognosis of hormone-refractory prostate cancer is poor with survival ~ 1 year",
                      "Development of new prognostic and predictive markers is major goal of ongoing research",
                      "Several proprietary molecular tests commercially available with goal to aid in clinical decision making"
                    ]
                  }
                ],
                "Risk Factors": [
                  {
                    "text": "Acinar adenocarcinomaPositive family historyRisk low < age 50, rises steeply with older ageEthnicity: Risk higher in Black populations with greater mortality, lower in Asian populations",
                    "sub_points": [
                      "Positive family history",
                      "Risk low < age 50, rises steeply with older age",
                      "Ethnicity: Risk higher in Black populations with greater mortality, lower in Asian populations"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "Molecular Genetics": [
                  {
                    "text": "Acinar adenocarcinomaFusion of androgen-regulatedTMPRSS2with member of ETS family of transcription factors, includingERGor, less commonly,ETV1,ETV4,ETV5, andFLI1Detected in ~ 50% of casesTMPRSS2::ERGfusion by far most common, leads to ERG protein overexpressionGene fusions detectable by break-apart FISH assayETS family fusion-positive tumors appear biologically distinct from ETS-negative PCaETS-positive tumors are enriched in mutations or deletions ofPTENandTP53Mutations inSPOP,FLI1,FOXA1,IDH1mutually exclusive with ETS rearrangement and with each otherSPOPmutations detected in 5-15% of primary PCaMutually exclusive with ETS gene rearrangementsMutually exclusive withTP53andPTENalterationsSPOP-mutant tumors show distinct pattern of genomic alteration, specifically deletions ofCHD1SPOP-mutant tumors lack alterations in PI3K pathwayCHD1deletions in 10-25% of PCaSPOPmutations andCHD1deletions may be driver mutations in ETS-negative tumorsSPINK1overexpression in ~ 10% of ETS-negative tumors, associated with aggressive diseaseOther molecular genetic abnormalitiesAlterations in androgen receptor gene (AR) and pathway in hormone-refractory PCas includeARamplification (~ 40%), point mutations (~ 10%), and splice variantsTypically absent in clinically localized cancers but emerge during androgen-deprivation therapyIfARis not altered, genes that modulate AR function may be dysregulatedChromothripsis (shattering and subsequent complex rearrangement of chromosomes) found in 20-23% of clinically significant PCaChromoplexy (balanced interweaving of interchromosomal translocations) in 50% of PCaLoss ofPTENby deletion or mutation in ~ 40% of primary PCa, associated with higher Gleason score and poor prognosisPTENgenomic deletions and inactivating mutationsInactivating mutations in 5-10%Deletions occur in ~ 40% of primary PCaDysregulation ofPTENis often late event in tumor progression and associated with poor prognosisTP53point mutations in up to 40%, deletions in 25-40% of PCaPoint mutations in up to 40%Deletions ofTP53locus in 25-40% of PCa25-30% of clinically localized cancers harborTP53alterations, suggesting that alterations are not exclusively late eventsTP53alterations in 25-30% of clinically localized PCa, suggesting they are not exclusively late eventsPoint mutations in 5-40%Deletions ofTP53locus in 25-40% of PCaMYCis commonly amplified &/or overexpressedMay be present in high-grade and hormone-refractory diseaseNKX3-1deleted in 10-40% of casesRecurrent mutations inFOXA1,CUL3,IDH1found in < 10% of casesAmplification ofPIK3CAin ~ 25% of PCaAlterations in PI3K-AKT-mTOR pathway more common in metastatic &/or hormone-refractory casesGenomic alterations in WNT/β-catenin pathway in ~ 10%RAS-RAF-MAPK signaling pathway alterations in ~ 5%Allelic loss ofNKX3-1tumor suppressor geneLoss ofCDKN1Bassociated with poor prognosisPCA3overexpressed in > 90% of PCa but not expressed in benign prostateEZH2has critical role in chromatin regulation, is overexpressed in PCa, associated with aggressive diseaseEpigenetic changes common with hypermethylation of many genes, includingGSTP1Common with hypermethylation of many genesRecurrent mutations in epigenetic regulators and chromatin remodelersGenome-wide association studies identified > 100 PCa susceptibility lociGermline variations at 8q24 contribute to PCa riskLocus at 19q13 associated with aggressive PCaGenome-wide association studiesIdentified multiple single-nucleotide polymorphisms (SNPs) associated with familial PCaGermline or somatic mutations in DNA repair genes involved in homologous recombination repair (HRR) or in mismatch repair found in up to 20% of metastatic carcinomasHRR defects may be associated with sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitorsDNA mismatch repair defects may be associated with sensitivity to immune checkpoint inhibitorsGermline &/or somatic testing for DNA repair defects recommended for aggressive primary and for metastatic tumorsMost common actionable mutations in DNA repair genes inBRCA2,ATM,CHEK2, andBRCA1Germline DNA repair gene mutations identified in ~ 12% of metastatic PCa, more often in metastatic than in localized PCaBRCA2most common gene affected",
                    "sub_points": [
                      "Fusion of androgen-regulatedTMPRSS2with member of ETS family of transcription factors, includingERGor, less commonly,ETV1,ETV4,ETV5, andFLI1Detected in ~ 50% of casesTMPRSS2::ERGfusion by far most common, leads to ERG protein overexpressionGene fusions detectable by break-apart FISH assayETS family fusion-positive tumors appear biologically distinct from ETS-negative PCaETS-positive tumors are enriched in mutations or deletions ofPTENandTP53",
                      "Detected in ~ 50% of cases",
                      "TMPRSS2::ERGfusion by far most common, leads to ERG protein overexpression",
                      "Gene fusions detectable by break-apart FISH assay",
                      "ETS family fusion-positive tumors appear biologically distinct from ETS-negative PCa",
                      "ETS-positive tumors are enriched in mutations or deletions ofPTENandTP53",
                      "Mutations inSPOP,FLI1,FOXA1,IDH1mutually exclusive with ETS rearrangement and with each other",
                      "SPOPmutations detected in 5-15% of primary PCaMutually exclusive with ETS gene rearrangementsMutually exclusive withTP53andPTENalterationsSPOP-mutant tumors show distinct pattern of genomic alteration, specifically deletions ofCHD1SPOP-mutant tumors lack alterations in PI3K pathway",
                      "Mutually exclusive with ETS gene rearrangements",
                      "Mutually exclusive withTP53andPTENalterations",
                      "SPOP-mutant tumors show distinct pattern of genomic alteration, specifically deletions ofCHD1",
                      "SPOP-mutant tumors lack alterations in PI3K pathway",
                      "CHD1deletions in 10-25% of PCa",
                      "SPOPmutations andCHD1deletions may be driver mutations in ETS-negative tumors",
                      "SPINK1overexpression in ~ 10% of ETS-negative tumors, associated with aggressive disease",
                      "Other molecular genetic abnormalitiesAlterations in androgen receptor gene (AR) and pathway in hormone-refractory PCas includeARamplification (~ 40%), point mutations (~ 10%), and splice variantsTypically absent in clinically localized cancers but emerge during androgen-deprivation therapyIfARis not altered, genes that modulate AR function may be dysregulatedChromothripsis (shattering and subsequent complex rearrangement of chromosomes) found in 20-23% of clinically significant PCaChromoplexy (balanced interweaving of interchromosomal translocations) in 50% of PCaLoss ofPTENby deletion or mutation in ~ 40% of primary PCa, associated with higher Gleason score and poor prognosisPTENgenomic deletions and inactivating mutationsInactivating mutations in 5-10%Deletions occur in ~ 40% of primary PCaDysregulation ofPTENis often late event in tumor progression and associated with poor prognosisTP53point mutations in up to 40%, deletions in 25-40% of PCaPoint mutations in up to 40%Deletions ofTP53locus in 25-40% of PCa25-30% of clinically localized cancers harborTP53alterations, suggesting that alterations are not exclusively late eventsTP53alterations in 25-30% of clinically localized PCa, suggesting they are not exclusively late eventsPoint mutations in 5-40%Deletions ofTP53locus in 25-40% of PCaMYCis commonly amplified &/or overexpressedMay be present in high-grade and hormone-refractory diseaseNKX3-1deleted in 10-40% of casesRecurrent mutations inFOXA1,CUL3,IDH1found in < 10% of casesAmplification ofPIK3CAin ~ 25% of PCaAlterations in PI3K-AKT-mTOR pathway more common in metastatic &/or hormone-refractory casesGenomic alterations in WNT/β-catenin pathway in ~ 10%RAS-RAF-MAPK signaling pathway alterations in ~ 5%Allelic loss ofNKX3-1tumor suppressor geneLoss ofCDKN1Bassociated with poor prognosisPCA3overexpressed in > 90% of PCa but not expressed in benign prostateEZH2has critical role in chromatin regulation, is overexpressed in PCa, associated with aggressive diseaseEpigenetic changes common with hypermethylation of many genes, includingGSTP1Common with hypermethylation of many genesRecurrent mutations in epigenetic regulators and chromatin remodelersGenome-wide association studies identified > 100 PCa susceptibility lociGermline variations at 8q24 contribute to PCa riskLocus at 19q13 associated with aggressive PCaGenome-wide association studiesIdentified multiple single-nucleotide polymorphisms (SNPs) associated with familial PCaGermline or somatic mutations in DNA repair genes involved in homologous recombination repair (HRR) or in mismatch repair found in up to 20% of metastatic carcinomasHRR defects may be associated with sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitorsDNA mismatch repair defects may be associated with sensitivity to immune checkpoint inhibitorsGermline &/or somatic testing for DNA repair defects recommended for aggressive primary and for metastatic tumorsMost common actionable mutations in DNA repair genes inBRCA2,ATM,CHEK2, andBRCA1Germline DNA repair gene mutations identified in ~ 12% of metastatic PCa, more often in metastatic than in localized PCaBRCA2most common gene affected",
                      "Alterations in androgen receptor gene (AR) and pathway in hormone-refractory PCas includeARamplification (~ 40%), point mutations (~ 10%), and splice variantsTypically absent in clinically localized cancers but emerge during androgen-deprivation therapyIfARis not altered, genes that modulate AR function may be dysregulated",
                      "Typically absent in clinically localized cancers but emerge during androgen-deprivation therapy",
                      "IfARis not altered, genes that modulate AR function may be dysregulated",
                      "Chromothripsis (shattering and subsequent complex rearrangement of chromosomes) found in 20-23% of clinically significant PCa",
                      "Chromoplexy (balanced interweaving of interchromosomal translocations) in 50% of PCa",
                      "Loss ofPTENby deletion or mutation in ~ 40% of primary PCa, associated with higher Gleason score and poor prognosis",
                      "PTENgenomic deletions and inactivating mutationsInactivating mutations in 5-10%Deletions occur in ~ 40% of primary PCaDysregulation ofPTENis often late event in tumor progression and associated with poor prognosis",
                      "Inactivating mutations in 5-10%",
                      "Deletions occur in ~ 40% of primary PCa",
                      "Dysregulation ofPTENis often late event in tumor progression and associated with poor prognosis",
                      "TP53point mutations in up to 40%, deletions in 25-40% of PCaPoint mutations in up to 40%Deletions ofTP53locus in 25-40% of PCa25-30% of clinically localized cancers harborTP53alterations, suggesting that alterations are not exclusively late events",
                      "Point mutations in up to 40%",
                      "Deletions ofTP53locus in 25-40% of PCa",
                      "25-30% of clinically localized cancers harborTP53alterations, suggesting that alterations are not exclusively late events",
                      "TP53alterations in 25-30% of clinically localized PCa, suggesting they are not exclusively late eventsPoint mutations in 5-40%Deletions ofTP53locus in 25-40% of PCa",
                      "Point mutations in 5-40%",
                      "Deletions ofTP53locus in 25-40% of PCa",
                      "MYCis commonly amplified &/or overexpressedMay be present in high-grade and hormone-refractory disease",
                      "May be present in high-grade and hormone-refractory disease",
                      "NKX3-1deleted in 10-40% of cases",
                      "Recurrent mutations inFOXA1,CUL3,IDH1found in < 10% of cases",
                      "Amplification ofPIK3CAin ~ 25% of PCaAlterations in PI3K-AKT-mTOR pathway more common in metastatic &/or hormone-refractory cases",
                      "Alterations in PI3K-AKT-mTOR pathway more common in metastatic &/or hormone-refractory cases",
                      "Genomic alterations in WNT/β-catenin pathway in ~ 10%",
                      "RAS-RAF-MAPK signaling pathway alterations in ~ 5%",
                      "Allelic loss ofNKX3-1tumor suppressor gene",
                      "Loss ofCDKN1Bassociated with poor prognosis",
                      "PCA3overexpressed in > 90% of PCa but not expressed in benign prostate",
                      "EZH2has critical role in chromatin regulation, is overexpressed in PCa, associated with aggressive disease",
                      "Epigenetic changes common with hypermethylation of many genes, includingGSTP1Common with hypermethylation of many genesRecurrent mutations in epigenetic regulators and chromatin remodelers",
                      "Common with hypermethylation of many genes",
                      "Recurrent mutations in epigenetic regulators and chromatin remodelers",
                      "Genome-wide association studies identified > 100 PCa susceptibility lociGermline variations at 8q24 contribute to PCa riskLocus at 19q13 associated with aggressive PCa",
                      "Germline variations at 8q24 contribute to PCa risk",
                      "Locus at 19q13 associated with aggressive PCa",
                      "Genome-wide association studiesIdentified multiple single-nucleotide polymorphisms (SNPs) associated with familial PCa",
                      "Identified multiple single-nucleotide polymorphisms (SNPs) associated with familial PCa",
                      "Germline or somatic mutations in DNA repair genes involved in homologous recombination repair (HRR) or in mismatch repair found in up to 20% of metastatic carcinomasHRR defects may be associated with sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitorsDNA mismatch repair defects may be associated with sensitivity to immune checkpoint inhibitorsGermline &/or somatic testing for DNA repair defects recommended for aggressive primary and for metastatic tumorsMost common actionable mutations in DNA repair genes inBRCA2,ATM,CHEK2, andBRCA1",
                      "HRR defects may be associated with sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors",
                      "DNA mismatch repair defects may be associated with sensitivity to immune checkpoint inhibitors",
                      "Germline &/or somatic testing for DNA repair defects recommended for aggressive primary and for metastatic tumors",
                      "Most common actionable mutations in DNA repair genes inBRCA2,ATM,CHEK2, andBRCA1",
                      "Germline DNA repair gene mutations identified in ~ 12% of metastatic PCa, more often in metastatic than in localized PCaBRCA2most common gene affected",
                      "BRCA2most common gene affected"
                    ]
                  },
                  {
                    "text": "HG-PINTMPRSS2fusion with member of ETS transcription factor family detected in ~ 20%Most often in HG-PIN adjacent to invasive PCaSPOPmutations found in ETS-negative casesETS-rearrangements andSPOPmutations likely are mutually exclusive early eventsMYCoverexpression commonHypermethylation ofGSTP1",
                    "sub_points": [
                      "TMPRSS2fusion with member of ETS transcription factor family detected in ~ 20%Most often in HG-PIN adjacent to invasive PCa",
                      "Most often in HG-PIN adjacent to invasive PCa",
                      "SPOPmutations found in ETS-negative cases",
                      "ETS-rearrangements andSPOPmutations likely are mutually exclusive early events",
                      "MYCoverexpression common",
                      "Hypermethylation ofGSTP1"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Acinar adenocarcinomaTypically located in peripheral zoneMultifocal growth commonCombination of architectural and cytologic featuresArchitectural featuresHaphazard growth of crowded acinar glandsInfiltrative pattern often with irregular gland outlines and sharp luminal bordersBasal cell layer absentCharacteristic but not diagnostic features include luminal blue mucin, pink amorphous luminal secretions, bright eosinophilic crystalloidsFeatures diagnostic of carcinoma are perineural invasion, mucinous fibroplasia, and glomerulationsCytologic featuresAmphophilic cytoplasm, nuclear enlargement with nuclear overlap, prominent nucleoliGleason grading system based on architectural featuresGrade of primary and secondary patterns added to obtain Gleason scoreGleason patterns 1 and 2 rareCircumscribed nodule of closely packed oval glandsGleason pattern 2 (uncommon)Oval to round glands form circumscribed noduleGleason pattern 3Small acinar glands infiltrate haphazardly between normal glandsInvasive glands vary in size and shape, often have angular shapesGleason pattern 4Poorly defined fused glands, cribriform fused glands, or glomeruloid architectureGleason pattern 5Absence of glandular lumina; grows as solid sheets, strands, or single cellsGrade groups 1-5 are reported in conjunction with Gleason scoresHistologic variants include foamy gland variant, mucinous (colloid), signet-ring cell, atrophic, and pseudohyperplastic",
                    "sub_points": [
                      "Typically located in peripheral zone",
                      "Multifocal growth common",
                      "Combination of architectural and cytologic features",
                      "Architectural featuresHaphazard growth of crowded acinar glandsInfiltrative pattern often with irregular gland outlines and sharp luminal bordersBasal cell layer absentCharacteristic but not diagnostic features include luminal blue mucin, pink amorphous luminal secretions, bright eosinophilic crystalloidsFeatures diagnostic of carcinoma are perineural invasion, mucinous fibroplasia, and glomerulations",
                      "Haphazard growth of crowded acinar glands",
                      "Infiltrative pattern often with irregular gland outlines and sharp luminal borders",
                      "Basal cell layer absent",
                      "Characteristic but not diagnostic features include luminal blue mucin, pink amorphous luminal secretions, bright eosinophilic crystalloids",
                      "Features diagnostic of carcinoma are perineural invasion, mucinous fibroplasia, and glomerulations",
                      "Cytologic featuresAmphophilic cytoplasm, nuclear enlargement with nuclear overlap, prominent nucleoli",
                      "Amphophilic cytoplasm, nuclear enlargement with nuclear overlap, prominent nucleoli",
                      "Gleason grading system based on architectural featuresGrade of primary and secondary patterns added to obtain Gleason score",
                      "Grade of primary and secondary patterns added to obtain Gleason score",
                      "Gleason patterns 1 and 2 rareCircumscribed nodule of closely packed oval glands",
                      "Circumscribed nodule of closely packed oval glands",
                      "Gleason pattern 2 (uncommon)Oval to round glands form circumscribed nodule",
                      "Oval to round glands form circumscribed nodule",
                      "Gleason pattern 3Small acinar glands infiltrate haphazardly between normal glandsInvasive glands vary in size and shape, often have angular shapes",
                      "Small acinar glands infiltrate haphazardly between normal glands",
                      "Invasive glands vary in size and shape, often have angular shapes",
                      "Gleason pattern 4Poorly defined fused glands, cribriform fused glands, or glomeruloid architecture",
                      "Poorly defined fused glands, cribriform fused glands, or glomeruloid architecture",
                      "Gleason pattern 5Absence of glandular lumina; grows as solid sheets, strands, or single cells",
                      "Absence of glandular lumina; grows as solid sheets, strands, or single cells",
                      "Grade groups 1-5 are reported in conjunction with Gleason scores",
                      "Histologic variants include foamy gland variant, mucinous (colloid), signet-ring cell, atrophic, and pseudohyperplastic"
                    ]
                  },
                  {
                    "text": "HG-PINAcini and ducts lined by cells with neoplastic cytologic featuresEnlarged, hyperchromatic nuclei with coarse chromatin and prominent nucleoli4 architectural patternsFlat, tufting, micropapillary, and cribriform",
                    "sub_points": [
                      "Acini and ducts lined by cells with neoplastic cytologic featuresEnlarged, hyperchromatic nuclei with coarse chromatin and prominent nucleoli",
                      "Enlarged, hyperchromatic nuclei with coarse chromatin and prominent nucleoli",
                      "4 architectural patternsFlat, tufting, micropapillary, and cribriform",
                      "Flat, tufting, micropapillary, and cribriform"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Acinar adenocarcinomaNKX3.1, prostein (P501S), PSA, PSAP, AMACR (P504S), and MYC positive; subset positive for ERG or SPINK1Absent staining for basal cell markers p63, CK5, and 34βE12 (CK903)",
                    "sub_points": [
                      "NKX3.1, prostein (P501S), PSA, PSAP, AMACR (P504S), and MYC positive; subset positive for ERG or SPINK1",
                      "Absent staining for basal cell markers p63, CK5, and 34βE12 (CK903)"
                    ]
                  },
                  {
                    "text": "HG-PINLuminal cells positive for AMACR (P504S) and MYCBasal cells positive for p63, CK5, and 34βE12 (CK903)",
                    "sub_points": [
                      "Luminal cells positive for AMACR (P504S) and MYC",
                      "Basal cells positive for p63, CK5, and 34βE12 (CK903)"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Low-Grade Prostatic Intraepithelial Neoplasia": [
                  {
                    "text": "Lacks nuclear features of HG-PIN, including pseudostratification, hyperchromasia, and nucleoli"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Cancer Syndromes": {
        "name": "Cancer Syndromes",
        "url": "https://app.pathprimer.com/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
        "topics": {
          "Pathology of Familial Tumor Syndromes": {
            "name": "Pathology of Familial Tumor Syndromes",
            "url": "https://app.pathprimer.com/document/4b07c103-e068-4c64-b50b-4496bb4f12dc/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "Introduction": {
                "Hereditary Syndromes: Practical Guide to Pathological Recognition": [
                  {
                    "text": "Diverse neoplasias are a common finding in patients with a genetic predisposition to cancer"
                  },
                  {
                    "text": "It is becoming increasingly well recognized that a given familial tumor syndrome may be very heterogeneous in clinical appearance"
                  },
                  {
                    "text": "Patients without overt clinical signs of their underlying syndrome may present initially for treatment of a tumor"
                  },
                  {
                    "text": "As molecular diagnostic testing for these familial diseases has become more readily available, the heterogeneous clinical appearance seen in many syndromes has become better recognized"
                  },
                  {
                    "text": "Awareness of important manifestations associated with each syndrome that might provide additional clues to a hereditary/familial neoplasia syndrome is also important"
                  },
                  {
                    "text": "Identification of hereditary cases and early diagnosis makes preventive surgery and adequate treatment possible"
                  },
                  {
                    "text": "Most of the patients with familial disease are asymptomatic and are discovered through genetic screening in predisposing families"
                  },
                  {
                    "text": "All patients identified as having  familial tumors should then be screened for the familial disease's associated mutation"
                  },
                  {
                    "text": "Vast majority of tumors occurring in a familial setting are multiple, bilateral, and involve multiple organs"
                  },
                  {
                    "text": "Many surgical specimens are received from patients who have a known syndrome diagnosis at time of surgeryPathologist may be 1st physician to suggest possibility of a syndromic association based on presence of unique pathologic findings in a tumor resection specimen",
                    "sub_points": [
                      "Pathologist may be 1st physician to suggest possibility of a syndromic association based on presence of unique pathologic findings in a tumor resection specimen"
                    ]
                  },
                  {
                    "text": "Gross and histological features that are evaluated in routine tumor resection specimens might suggest each individual syndrome"
                  },
                  {
                    "text": "In their pathological examinations, it is important for surgical pathologists to be aware of specific gross and microscopic findings that suggest a possible syndromic association"
                  },
                  {
                    "text": "Some tumors frequently display characteristic clinical, biochemical, and histopathological features that, although not pathognomonic, can be helpful in suggesting an inherited disease as the underlying etiology and distinguishing these tumors from sporadic cases"
                  }
                ],
                "Recognition of Morphological Characteristics That Indicate Familial Tumor Syndrome": [
                  {
                    "text": "Awareness of pathologic features of neoplasms seen in a variety of hereditary/familial neoplasia syndromes is crucial for diagnosis"
                  },
                  {
                    "text": "Pathological findings suggestive of a familial or inherited tumor syndromes or findings specific for a syndrome areTumors occurring at a younger age than the sporadic counterpartMultiple tumorsBilateral tumorsTumors involving multiple organs and systemsTumors associated with multiple lesionsTumors associated with multiple hamartomatous lesionsSpecific location of a tumorUnique morphological features of a tumorPresence of precursor lesionsPresence of multiple benign lesions",
                    "sub_points": [
                      "Tumors occurring at a younger age than the sporadic counterpart",
                      "Multiple tumors",
                      "Bilateral tumors",
                      "Tumors involving multiple organs and systems",
                      "Tumors associated with multiple lesions",
                      "Tumors associated with multiple hamartomatous lesions",
                      "Specific location of a tumor",
                      "Unique morphological features of a tumor",
                      "Presence of precursor lesions",
                      "Presence of multiple benign lesions"
                    ]
                  },
                  {
                    "text": "Characteristic and distinct pathology findings in some of these syndromes should alert the pathologist of a possible familial cancer syndromeCorrect histologic interpretation may lead to further molecular genetic evaluation of patient and family members",
                    "sub_points": [
                      "Correct histologic interpretation may lead to further molecular genetic evaluation of patient and family members"
                    ]
                  }
                ],
                "Pathology Reporting": [
                  {
                    "text": "If the constellation of pathology findings strongly suggests a potential syndromic associationConsult medical records for the diagnosis of a potential syndromeContact clinician to discuss possibility of a genetic syndromePathologists should notify clinicians about this possibility, considering appropriate molecular testing",
                    "sub_points": [
                      "Consult medical records for the diagnosis of a potential syndrome",
                      "Contact clinician to discuss possibility of a genetic syndrome",
                      "Pathologists should notify clinicians about this possibility, considering appropriate molecular testing"
                    ]
                  },
                  {
                    "text": "For reporting purposes, diagnosis of a lesion or a neoplasm should use same criteria and terminology as for sporadic lesions and tumorsComment suggesting a possible association with a genetic disease is recommendedTo document possibility of specific genetic association",
                    "sub_points": [
                      "Comment suggesting a possible association with a genetic disease is recommendedTo document possibility of specific genetic association",
                      "To document possibility of specific genetic association"
                    ]
                  },
                  {
                    "text": "Final diagnostic commentary to highlight differential diagnostic issues that frequently arise when these diagnoses are considered"
                  }
                ]
              },
              "Hereditary Syndromes Known to Be Associated With Neoplasia": {
                "Hereditary Syndromes": [
                  {
                    "text": "Some hereditary syndromes are known to be associated with neoplasia and have unique &/or characteristic pathological features"
                  },
                  {
                    "text": "Characteristic and distinct pathology findings in some of these syndromes should alert the pathologist of a possible familial cancer syndrome"
                  }
                ]
              },
              "Endocrine System": {
                "Hereditary Syndromes Known to be Associated With Thyroid Neoplasia": [
                  {
                    "text": "Medullary thyroid carcinoma (MTC)Multiple endocrine neoplasia 2A (MEN2A)Multiple endocrine neoplasia 2B (MEN2B)Familial medullary thyroid carcinoma (FMTC)",
                    "sub_points": [
                      "Multiple endocrine neoplasia 2A (MEN2A)",
                      "Multiple endocrine neoplasia 2B (MEN2B)",
                      "Familial medullary thyroid carcinoma (FMTC)"
                    ]
                  },
                  {
                    "text": "Cribriform morular papillary thyroid carcinomaFamilial adenomatous polyposis (FAP) syndromeCribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) was described originally as FAP-associated thyroid carcinoma",
                    "sub_points": [
                      "Familial adenomatous polyposis (FAP) syndromeCribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) was described originally as FAP-associated thyroid carcinoma",
                      "Cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) was described originally as FAP-associated thyroid carcinoma"
                    ]
                  },
                  {
                    "text": "Numerous adenomatous nodules, follicular adenomas, and follicular carcinomaPTEN-hamartoma tumor syndrome (PHTS)/Cowden diseasePresence of numerous multiple adenomatous nodules (MANs) or follicular thyroid carcinoma (FC) in younger patients should raise suspicion for diagnosis of PHTSCarney complex",
                    "sub_points": [
                      "PTEN-hamartoma tumor syndrome (PHTS)/Cowden diseasePresence of numerous multiple adenomatous nodules (MANs) or follicular thyroid carcinoma (FC) in younger patients should raise suspicion for diagnosis of PHTS",
                      "Presence of numerous multiple adenomatous nodules (MANs) or follicular thyroid carcinoma (FC) in younger patients should raise suspicion for diagnosis of PHTS",
                      "Carney complex"
                    ]
                  },
                  {
                    "text": "Oncocytic tumorsLi-Fraumeni syndromeFamilial oncocytic neoplasmsMcCune-Albright syndromeTuberous sclerosis complex",
                    "sub_points": [
                      "Li-Fraumeni syndrome",
                      "Familial oncocytic neoplasms",
                      "McCune-Albright syndrome",
                      "Tuberous sclerosis complex"
                    ]
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Adrenal Neoplasia": [
                  {
                    "text": "Adrenal cortical tumorsBeckwith-Wiedemann syndromeLi-Fraumeni syndromeMultiple endocrine neoplasia 1Carney complexLynch syndromeCongenital adrenal hyperplasia",
                    "sub_points": [
                      "Beckwith-Wiedemann syndrome",
                      "Li-Fraumeni syndrome",
                      "Multiple endocrine neoplasia 1",
                      "Carney complex",
                      "Lynch syndrome",
                      "Congenital adrenal hyperplasia"
                    ]
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Parathyroid Neoplasia": [
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  },
                  {
                    "text": "Hereditary hyperparathyroidism-jaw tumor syndrome"
                  },
                  {
                    "text": "Familial isolated hyperparathyroidism syndrome"
                  },
                  {
                    "text": "Multiple endocrine neoplasia 2A"
                  },
                  {
                    "text": "Neonatal severe primary hyperparathyroidism"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Pituitary Neoplasia": [
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  },
                  {
                    "text": "Familial pituitary adenoma syndrome"
                  },
                  {
                    "text": "Familial isolated pituitary adenoma syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Endocrine Pancreas Neoplasia": [
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Von Hippel-Lindau syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With PGL/PCC": [
                  {
                    "text": "Multiple endocrine neoplasia 2A"
                  },
                  {
                    "text": "Multiple endocrine neoplasia 2B"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Neurofibromatosis 1"
                  },
                  {
                    "text": "Familial paraganglioma type 1 (PGL1)"
                  },
                  {
                    "text": "Familial PGL2"
                  },
                  {
                    "text": "Familial PGL3"
                  },
                  {
                    "text": "Familial PGL4"
                  },
                  {
                    "text": "Carney-Stratakis syndrome"
                  },
                  {
                    "text": "Familial pheochromocytoma (PCC) 2q"
                  },
                  {
                    "text": "MAX-related"
                  },
                  {
                    "text": "SDHA-related"
                  }
                ]
              },
              "Genitourinary Tract": {
                "Hereditary Syndromes Known to be Associated With Renal Neoplasia": [
                  {
                    "text": "von Hippel-Lindau"
                  },
                  {
                    "text": "Hereditary papillary renal cell carcinoma (RCC)"
                  },
                  {
                    "text": "Hereditary leiomyomatosis RCC"
                  },
                  {
                    "text": "Birt-Hogg-Dubé"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Succinate dehydrogenase (SDH) germline mutation"
                  },
                  {
                    "text": "Lynch syndrome"
                  },
                  {
                    "text": "Heritable sickle cell hemoglobinopathy and medullary carcinoma of kidney"
                  },
                  {
                    "text": "Hyperparathyroidism-jaw tumor syndrome"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Constitutional chromosome 3 translocation"
                  },
                  {
                    "text": "Wilms tumor syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Testicle Neoplasia": [
                  {
                    "text": "Carney complex"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Renal cell carcinoma and leiomyomas"
                  },
                  {
                    "text": "Xeroderma pigmentosus"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Bladder and Ureter Neoplasia": [
                  {
                    "text": "Lynch syndrome"
                  }
                ]
              },
              "Gastrointestinal Tract": {
                "Hereditary Syndromes Known to be Associated With Esophagus, Stomach, and Intestinal Neoplasia": [
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Juvenile polyposis"
                  },
                  {
                    "text": "Familial gastrointestinal stromal tumor"
                  },
                  {
                    "text": "Hereditary diffuse gastric cancer"
                  },
                  {
                    "text": "MYH-associated polyposis"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Breast/ovarianBRCA1andBRCA2"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Bloom syndrome"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Gastrointestinal stromal tumor syndrome"
                  },
                  {
                    "text": "Neurofibromatosis 1"
                  },
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Pancreas Neoplasia": [
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Breast/ovarianBRCA1andBRCA2"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Juvenile polyposis"
                  },
                  {
                    "text": "Familial melanoma"
                  },
                  {
                    "text": "Multiple endocrine neoplasia 1"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Carney complex"
                  },
                  {
                    "text": "Tuberous sclerosis"
                  },
                  {
                    "text": "Hereditary pancreatic cancer syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Liver Neoplasia": [
                  {
                    "text": "Breast/ovarianBRCA2"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Beckwith-Wiedemann syndrome"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Lynch syndrome"
                  }
                ]
              },
              "Central Nervous System": {
                "Hereditary Syndromes Known to be Associated With CNS Neoplasia": [
                  {
                    "text": "Neurofibromatosis 1"
                  },
                  {
                    "text": "Neurofibromatosis 2"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Gorlin syndrome"
                  },
                  {
                    "text": "Lynch syndrome"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Constitutional mismatch repair"
                  },
                  {
                    "text": "Melanoma astrocytoma syndrome"
                  },
                  {
                    "text": "Familial uveal melanoma"
                  },
                  {
                    "text": "Rhabdoid predisposition syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Multiple meningoma syndrome"
                  },
                  {
                    "text": "Pleuropulmonary blastoma"
                  }
                ]
              },
              "Skin": {
                "Hereditary Syndromes Known to be Associated With Skin Neoplasia": [
                  {
                    "text": "Carney complex"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Basal cell nevus syndrome"
                  },
                  {
                    "text": "Beckwith-Wiedemann syndrome"
                  },
                  {
                    "text": "Birt-Hogg-Dubé syndrome"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Hereditary multiple melanoma"
                  },
                  {
                    "text": "Howell-Evans syndrome"
                  },
                  {
                    "text": "Melanoma pancreatic carcinoma syndrome"
                  },
                  {
                    "text": "Werner syndrome"
                  }
                ]
              },
              "Breast": {
                "Hereditary Syndromes Known to be Associated With Breast Neoplasia": [
                  {
                    "text": "BRCA1hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "BRCA2hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Familial gastric cancer and breast lobular cancer syndrome"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Ataxia-telangiectasia syndrome"
                  }
                ]
              },
              "Gynecologic": {
                "Hereditary Syndromes Known to be Associated With Uterine Neoplasia": [
                  {
                    "text": "BRCA1hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "BRCA2hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "Lynch syndrome"
                  },
                  {
                    "text": "PTEN-hamartoma tumor syndrome"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Hereditary leiomyomatosis and renal cell carcinoma"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Ovarian Neoplasia": [
                  {
                    "text": "BRCA1hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "BRCA2hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  },
                  {
                    "text": "Lynch syndrome"
                  }
                ]
              },
              "Lung": {
                "Hereditary Syndromes Known to be Associated With Lung Neoplasia": [
                  {
                    "text": "BRCA2hereditary breast &/or ovarian cancer syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma syndrome"
                  },
                  {
                    "text": "Familial pleuropulmonary blastoma"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Carney triad"
                  },
                  {
                    "text": "Bloom syndrome"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Xeroderma pigmentosum"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome"
                  }
                ]
              },
              "Head and Neck": {
                "Hereditary Syndromes Known to be Associated With Head and Neck Neoplasia": [
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Fanconi anemia"
                  },
                  {
                    "text": "Xeroderma pigmentosum"
                  },
                  {
                    "text": "Bloom syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma"
                  },
                  {
                    "text": "Neurofibromatosis 2"
                  },
                  {
                    "text": "Basal cell nevus syndrome/Gorlin syndrome"
                  },
                  {
                    "text": "Hyperparathyroidism-jaw tumor syndrome"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "von Hippel-Lindau"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Salivary Gland Neoplasia": [
                  {
                    "text": "von Hippel-Lindau syndrome"
                  },
                  {
                    "text": "Ataxia-telangiectasia syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma syndrome"
                  },
                  {
                    "text": "Brooke-Spiegler syndrome and familial cylindromatosis"
                  }
                ]
              },
              "Bone and Soft Tissue": {
                "Hereditary Syndromes Known to be Associated With Bone Neoplasia": [
                  {
                    "text": "Hereditary multiple exostosis"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma"
                  },
                  {
                    "text": "Familial chordoma syndrome"
                  },
                  {
                    "text": "Tuberous sclerosis complex"
                  },
                  {
                    "text": "Hyperparathyroidism-jaw tumor syndrome"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Soft Tissue Neoplasia": [
                  {
                    "text": "Basal cell nevus syndrome"
                  },
                  {
                    "text": "Li-Fraumeni syndrome"
                  },
                  {
                    "text": "Hereditary retinoblastoma"
                  },
                  {
                    "text": "Hereditary multiple exostosis"
                  },
                  {
                    "text": "Familial adenomatous polyposis"
                  },
                  {
                    "text": "Renal carcinoma with leiomyomas"
                  },
                  {
                    "text": "Neurofibromatosis 1"
                  },
                  {
                    "text": "Neurofibromatosis 2"
                  },
                  {
                    "text": "Carney complex"
                  },
                  {
                    "text": "Beckwith-Wiedemann syndrome"
                  }
                ]
              },
              "Hematology": {
                "Hereditary Syndromes Known to be Associated With Blood and Bone Marrow Neoplasia": [
                  {
                    "text": "Congenital amegakaryocytic thrombocytopenia"
                  },
                  {
                    "text": "Diamond-Blackfan anemia"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Severe congenital neutropenia"
                  },
                  {
                    "text": "Shwachman-Diamond syndrome"
                  },
                  {
                    "text": "Fanconi anemia"
                  }
                ],
                "Hereditary Syndromes Known to be Associated With Lymphoma/Leukemia": [
                  {
                    "text": "Familial non-Hodgkin lymphoma"
                  },
                  {
                    "text": "Familial acute myeloid leukemia"
                  },
                  {
                    "text": "Familial chronic lymphocytic leukemia"
                  },
                  {
                    "text": "Familial Hodgkin lymphoma"
                  },
                  {
                    "text": "Fanconi anemia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Clinical Diagnosis and Management of Familial/Hereditary Tumor Syndromes": {
            "name": "Clinical Diagnosis and Management of Familial/Hereditary Tumor Syndromes",
            "url": "https://app.pathprimer.com/document/8031e4eb-2a97-4a3c-8bcb-95af4c22580a/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "Introduction": {
                "Hereditary Cancer": [
                  {
                    "text": "Characterized by mutations associated with a high probability of cancer development, vertical transmission through parents, and an association with other types of tumors"
                  },
                  {
                    "text": "Often have early age of onset"
                  },
                  {
                    "text": "Usually multiple and involve multiple organs"
                  },
                  {
                    "text": "Familial cancers may be associated with (or by combination of these)Chance of clustering of sporadic cancer cases within a familyGenetic variation in lower penetrance genesShared environment",
                    "sub_points": [
                      "Chance of clustering of sporadic cancer cases within a family",
                      "Genetic variation in lower penetrance genes",
                      "Shared environment"
                    ]
                  },
                  {
                    "text": "Molecular genetics have identified a number of genes associated with inherited susceptibility to a specific cancerAlso provides a means of characterizing  specific gene mutation or mutations present in certain individuals and families exhibiting an increased risk of cancer",
                    "sub_points": [
                      "Also provides a means of characterizing  specific gene mutation or mutations present in certain individuals and families exhibiting an increased risk of cancer"
                    ]
                  }
                ],
                "Background": [
                  {
                    "text": "~ 10% of all cancers are attributable to a cancer predisposition gene"
                  },
                  {
                    "text": "Learning the clinical features that suggest possibility of an underlying genetic predisposition to cancer is another easily mastered diagnostic toolIt is crucial to raise awareness among oncologists and other health care providers about the importance of inherited cancer risk in the practice of oncology and cancer prevention",
                    "sub_points": [
                      "It is crucial to raise awareness among oncologists and other health care providers about the importance of inherited cancer risk in the practice of oncology and cancer prevention"
                    ]
                  },
                  {
                    "text": "Study of rare familial clusters became a remarkably productive scientific and clinical enterpriseThese data haveIdentified multiple new susceptibility genesInformed understanding of pathogenesis of hereditary and nonhereditary cancers at individual, population, and laboratory levelsDefined clinical phenotypes of specific disorders more preciselyMuch of the data that form basis of understanding of hereditary cancer syndromes are derived from evaluation of highly selected familiesSingle-gene hereditary syndromes account for only a small fraction of familial clustering on a population basisAccuracy of reports from 1st-degree relatives is substantially better than for 2nd-degree relatives",
                    "sub_points": [
                      "These data haveIdentified multiple new susceptibility genesInformed understanding of pathogenesis of hereditary and nonhereditary cancers at individual, population, and laboratory levelsDefined clinical phenotypes of specific disorders more precisely",
                      "Identified multiple new susceptibility genes",
                      "Informed understanding of pathogenesis of hereditary and nonhereditary cancers at individual, population, and laboratory levels",
                      "Defined clinical phenotypes of specific disorders more precisely",
                      "Much of the data that form basis of understanding of hereditary cancer syndromes are derived from evaluation of highly selected families",
                      "Single-gene hereditary syndromes account for only a small fraction of familial clustering on a population basis",
                      "Accuracy of reports from 1st-degree relatives is substantially better than for 2nd-degree relatives"
                    ]
                  },
                  {
                    "text": "Diagnosis accuracy varies considerably, depending onAge, gender, and cancer status of individualPrimary site of cancer originDegree of relatedness between individual and relativeVital status of affected relativeRecentness of reported cancer diagnosis",
                    "sub_points": [
                      "Age, gender, and cancer status of individual",
                      "Primary site of cancer origin",
                      "Degree of relatedness between individual and relative",
                      "Vital status of affected relative",
                      "Recentness of reported cancer diagnosis"
                    ]
                  },
                  {
                    "text": "Need has never been greater for clinicians to be well groundedIn knowledge of biological and molecular bases of diseases they encounterTo become familiar with related new clinical issues, including predictive risk assessment, genetic counseling, and germline mutation testing for clinical decision makingTo warn at-risk relatives vs. their high-risk patients' right to privacy and confidentiality, and the need for evidence-based, safe, and effective management recommendations for high-risk individuals",
                    "sub_points": [
                      "In knowledge of biological and molecular bases of diseases they encounter",
                      "To become familiar with related new clinical issues, including predictive risk assessment, genetic counseling, and germline mutation testing for clinical decision making",
                      "To warn at-risk relatives vs. their high-risk patients' right to privacy and confidentiality, and the need for evidence-based, safe, and effective management recommendations for high-risk individuals"
                    ]
                  }
                ],
                "Identification of At-Risk Individuals": [
                  {
                    "text": "Accurate identification of patients at increased risk for developing cancer is essential"
                  },
                  {
                    "text": "Assessment of an individual's risk of familial or hereditary cancer is based on a thorough evaluation of the family history"
                  },
                  {
                    "text": "In the process of focusing on molecular biology of human cancer susceptibility, importance of taking a thoughtful family history cannot be emphasized sufficientlyRecording an appropriately focused family history must be performed in course of daily practice",
                    "sub_points": [
                      "Recording an appropriately focused family history must be performed in course of daily practice"
                    ]
                  },
                  {
                    "text": "It is now increasingly routine to undertake a cancer genetics risk assessment, which includes the option of germline mutation testing for 1 or more relevant genes"
                  },
                  {
                    "text": "Identification of individuals at risk for cancer has become an integral part of medicineWill allow health care providers to intervene with appropriateCounseling and educationIncreased cancer surveillanceCancer prevention",
                    "sub_points": [
                      "Will allow health care providers to intervene with appropriateCounseling and educationIncreased cancer surveillanceCancer prevention",
                      "Counseling and education",
                      "Increased cancer surveillance",
                      "Cancer prevention"
                    ]
                  },
                  {
                    "text": "Genetic risk assessment in the context of childhood cancer represents a specific settingMeticulous clinical evaluation often provides essential information upon which to base a syndromic diagnosis",
                    "sub_points": [
                      "Meticulous clinical evaluation often provides essential information upon which to base a syndromic diagnosis"
                    ]
                  },
                  {
                    "text": "The National Comprehensive Cancer Network (NCCN) has established criteria for those individuals who need further genetic risk assessmentMultiple algorithmic approach for tumor syndromes are available at their websitehttp://www.nccn.org/professionals/physician_gls/pdf/genetics_screening",
                    "sub_points": [
                      "Multiple algorithmic approach for tumor syndromes are available at their websitehttp://www.nccn.org/professionals/physician_gls/pdf/genetics_screening",
                      "http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening"
                    ]
                  }
                ]
              },
              "Cancer Susceptibility Testing": {
                "American Society of Clinical Oncology (ASCO): Indications for Testing": [
                  {
                    "text": "ASCO recommends that genetic testing be offered whenIndividual has personal or family history features suggestive of a genetic cancer susceptibility conditionTest can be adequately interpreted, andResults will aid in diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk of cancer",
                    "sub_points": [
                      "Individual has personal or family history features suggestive of a genetic cancer susceptibility condition",
                      "Test can be adequately interpreted, and",
                      "Results will aid in diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk of cancer"
                    ]
                  },
                  {
                    "text": "ASCO recommends that genetic testing only be done in setting of pre- and post-test counseling, which should include discussion of possible risks and benefits of early cancer detection and prevention modalities"
                  }
                ],
                "ASCO: Policy Statement": [
                  {
                    "text": "Advent of syndrome-specific germline mutation testing represents a major advance in the care of cancer-prone individuals"
                  },
                  {
                    "text": "ASCO reaffirms its commitment to integrating cancer risk assessment and management, including molecular analysis of cancer predisposition genes, into the practice of oncology and preventive medicineGenetic testing for cancer susceptibility has become an accepted part of oncologic careAccording to ASCO guidelinesGermline testing for inherited predisposition is well established as part of the care of individuals who may be at hereditary risk for cancers of the breast, ovary, colon, stomach, uterus, thyroid, and other primary sitesGermline genetic testing is distinct from somatic genetic profiling of cancer tissue to predict prognosis or treatment responseGermline testing involves analysis of DNA from blood or saliva for inherited mutations in specific genes that are associated with the type of cancer seen in the individual or family seeking assessmentWhen identified, such high-penetrance mutations usually result in a significant alteration in the function of the corresponding gene product and are associated with large increases in cancer riskOther mutations result in less dramatic increases in risk (intermediate penetrance)Identification of a high-penetrance mutation often justifies an adjustment of clinical care through the modification of surveillance or through preventive surgeryGermline testing for certain high-penetrance predispositions is now part of clinical guidelines and is reimbursed by most 3rd-party payersImpact of intermediate penetrance mutations on clinical care is less clear",
                    "sub_points": [
                      "Genetic testing for cancer susceptibility has become an accepted part of oncologic careAccording to ASCO guidelinesGermline testing for inherited predisposition is well established as part of the care of individuals who may be at hereditary risk for cancers of the breast, ovary, colon, stomach, uterus, thyroid, and other primary sitesGermline genetic testing is distinct from somatic genetic profiling of cancer tissue to predict prognosis or treatment responseGermline testing involves analysis of DNA from blood or saliva for inherited mutations in specific genes that are associated with the type of cancer seen in the individual or family seeking assessmentWhen identified, such high-penetrance mutations usually result in a significant alteration in the function of the corresponding gene product and are associated with large increases in cancer riskOther mutations result in less dramatic increases in risk (intermediate penetrance)Identification of a high-penetrance mutation often justifies an adjustment of clinical care through the modification of surveillance or through preventive surgeryGermline testing for certain high-penetrance predispositions is now part of clinical guidelines and is reimbursed by most 3rd-party payersImpact of intermediate penetrance mutations on clinical care is less clear",
                      "According to ASCO guidelines",
                      "Germline testing for inherited predisposition is well established as part of the care of individuals who may be at hereditary risk for cancers of the breast, ovary, colon, stomach, uterus, thyroid, and other primary sites",
                      "Germline genetic testing is distinct from somatic genetic profiling of cancer tissue to predict prognosis or treatment response",
                      "Germline testing involves analysis of DNA from blood or saliva for inherited mutations in specific genes that are associated with the type of cancer seen in the individual or family seeking assessment",
                      "When identified, such high-penetrance mutations usually result in a significant alteration in the function of the corresponding gene product and are associated with large increases in cancer risk",
                      "Other mutations result in less dramatic increases in risk (intermediate penetrance)",
                      "Identification of a high-penetrance mutation often justifies an adjustment of clinical care through the modification of surveillance or through preventive surgery",
                      "Germline testing for certain high-penetrance predispositions is now part of clinical guidelines and is reimbursed by most 3rd-party payers",
                      "Impact of intermediate penetrance mutations on clinical care is less clear"
                    ]
                  }
                ],
                "ASCO: Clinical Utility of Genetic Testing": [
                  {
                    "text": "Genetic tests may benefit individuals by providing deeper self-knowledge and motivation to pursue healthy behaviors, even if the results do not inform clinical decision making"
                  },
                  {
                    "text": "Tests for high-penetrance mutations in appropriate populations have clinical utility, meaning that they inform clinical decision making and facilitate the prevention or amelioration of adverse health outcomes"
                  },
                  {
                    "text": "Genetic tests for intermediate-penetrance mutations and genomic profiles of SNPS linked to low-penetrance variants are of uncertain clinical utility"
                  }
                ],
                "ASCO: Informed Consent": [
                  {
                    "text": "Proposed elements of informed consent related to testing for inherited cancer susceptibility are set forth"
                  },
                  {
                    "text": "Basic elements of informed consent for cancer susceptibility testingInformation on specific genetic mutation(s) or genomic variant(s) being tested, including whether range of risk associated with variant will impact medical careImplications of a positive and negative resultPossibility that test will not be informativeOptions for risk estimation without genetic or genomic testingRisk of passing a genetic variant to childrenTechnical accuracy of the test including, where required by law, licensure of the testing laboratoryFees involved in testing and counseling and, for direct-to-consumer (DTC) testing, whether the counselor is employed by the testing companyPsychological implications of test results (benefits and risks)Risks and protections against genetic discrimination by employers or insurersConfidentiality issues, including, for DTC testing companies, policies related to privacy and data securityPossible use of DNA testing samples in future researchOptions and limitations of medical surveillance and strategies for prevention after genetic or genomic testingImportance of sharing genetic and genomic test results with at-risk relatives so that they may benefit from this informationPlans for follow-up after testing",
                    "sub_points": [
                      "Information on specific genetic mutation(s) or genomic variant(s) being tested, including whether range of risk associated with variant will impact medical care",
                      "Implications of a positive and negative result",
                      "Possibility that test will not be informative",
                      "Options for risk estimation without genetic or genomic testing",
                      "Risk of passing a genetic variant to children",
                      "Technical accuracy of the test including, where required by law, licensure of the testing laboratory",
                      "Fees involved in testing and counseling and, for direct-to-consumer (DTC) testing, whether the counselor is employed by the testing company",
                      "Psychological implications of test results (benefits and risks)",
                      "Risks and protections against genetic discrimination by employers or insurers",
                      "Confidentiality issues, including, for DTC testing companies, policies related to privacy and data security",
                      "Possible use of DNA testing samples in future research",
                      "Options and limitations of medical surveillance and strategies for prevention after genetic or genomic testing",
                      "Importance of sharing genetic and genomic test results with at-risk relatives so that they may benefit from this information",
                      "Plans for follow-up after testing"
                    ]
                  }
                ],
                "Special Issues Related to Genetic Testing Research": [
                  {
                    "text": "Prospective clinical trials, large registries, and retrospective reviews are the most accurate methods forDeriving relative risks of genetic variantsMeasuring response to and effectiveness of clinical interventions based on genetic cancer risk assessment",
                    "sub_points": [
                      "Deriving relative risks of genetic variants",
                      "Measuring response to and effectiveness of clinical interventions based on genetic cancer risk assessment"
                    ]
                  },
                  {
                    "text": "Tests with uncertain clinical utility become commercially availableIt will be crucial to establish an evidence-based algorithm for clinically responsible use of these testsFor patient safety and effectiveness",
                    "sub_points": [
                      "It will be crucial to establish an evidence-based algorithm for clinically responsible use of these testsFor patient safety and effectiveness",
                      "For patient safety and effectiveness"
                    ]
                  },
                  {
                    "text": "Wherever possible, genetic tests with uncertain clinical utility should be administered in the context of clinical trials"
                  },
                  {
                    "text": "Research should include basic studies of the functional significance of the genetic variants linked to disease riskAs well as prospective, randomized controlled trials of individual genomic markers",
                    "sub_points": [
                      "As well as prospective, randomized controlled trials of individual genomic markers"
                    ]
                  },
                  {
                    "text": "At a translational level, it is important to establish criteria for technologic assessment of genetic and other diagnostic tests"
                  },
                  {
                    "text": "Research should focus on the extent to which personal benefits accrue to individuals who receive tests that have uncertain clinical utilityAs well as the appropriate mechanism for measuring personal utility",
                    "sub_points": [
                      "As well as the appropriate mechanism for measuring personal utility"
                    ]
                  },
                  {
                    "text": "Establishing an evidence-based test for personal utility is particularly important for tests that would not be recommended based on clinical utility"
                  },
                  {
                    "text": "Research is also needed to demonstrate validity and reproducibility of some commercially available tests"
                  },
                  {
                    "text": "Because the algorithms used to convert genotypes into absolute risk estimates are empirically derived, prospective research is needed to confirm calibration of these estimates and to measure the effectiveness of interventions based on individual genomic profiling"
                  },
                  {
                    "text": "If genetic and genomic tests for cancer risk are going to be offered or justified on basis of personal utility, an effort should be made to establish evidence-based tests for these claims"
                  }
                ],
                "Genetic Counseling": [
                  {
                    "text": "Genetic testing should be conducted only in the setting of pre- and post-test counselingPretest counselingAllows for advance consideration of medical options and the impact test results may have on family membersPost-test counselingProvides a valuable opportunity for health care providers to interpret test results, recommend appropriate follow-up, and emphasize the importance of continuing regular prevention activities",
                    "sub_points": [
                      "Pretest counselingAllows for advance consideration of medical options and the impact test results may have on family members",
                      "Allows for advance consideration of medical options and the impact test results may have on family members",
                      "Post-test counseling",
                      "Provides a valuable opportunity for health care providers to interpret test results, recommend appropriate follow-up, and emphasize the importance of continuing regular prevention activities"
                    ]
                  }
                ]
              },
              "Diagnosis": {
                "Established Diagnostic Criteria": [
                  {
                    "text": "Some examples of diagnostic criteria to characterize a syndrome present in individuals with multiple lesions and tumors"
                  },
                  {
                    "text": "Diagnostic criteria for basal cell nevus syndrome"
                  },
                  {
                    "text": "Diagnosis is established if 2 major or 1 major and 2 minor criteria are metMultiple (> 2) basal cell carcinomas, or 1 basal cell carcinoma in patient < 30 years, or > 10 basal cell nevi",
                    "sub_points": [
                      "Multiple (> 2) basal cell carcinomas, or 1 basal cell carcinoma in patient < 30 years, or > 10 basal cell nevi"
                    ]
                  },
                  {
                    "text": "Major criteriaAny odontogenic keratocyst (proven on histology) or polyostotic bone cystPalmar or plantar pits (≥ 3)Ectopic calcification; lamellar or early (patient < 20 years) falx calcificationFamily history of  basal cell nevus syndrome (BCNS)Minor criteriaCongenital skeletal anomaly: Bifid, fused, splayed, or missing rib; or bifid, wedged, or fused vertebraeHead circumference > 97th percentile, with frontal bossingCardiac or ovarian fibromaMedulloblastoma (primitive neuroectodermal tumor [PNET], most often of desmoplastic histology)Lymphomesenteric or pleural cystsCongenital malformation: Cleft lip &/or palate, polydactyly, eye anomaly (cataract, coloboma, microphthalmia)",
                    "sub_points": [
                      "Any odontogenic keratocyst (proven on histology) or polyostotic bone cyst",
                      "Palmar or plantar pits (≥ 3)Ectopic calcification; lamellar or early (patient < 20 years) falx calcificationFamily history of  basal cell nevus syndrome (BCNS)",
                      "Ectopic calcification; lamellar or early (patient < 20 years) falx calcification",
                      "Family history of  basal cell nevus syndrome (BCNS)",
                      "Minor criteriaCongenital skeletal anomaly: Bifid, fused, splayed, or missing rib; or bifid, wedged, or fused vertebraeHead circumference > 97th percentile, with frontal bossingCardiac or ovarian fibromaMedulloblastoma (primitive neuroectodermal tumor [PNET], most often of desmoplastic histology)Lymphomesenteric or pleural cystsCongenital malformation: Cleft lip &/or palate, polydactyly, eye anomaly (cataract, coloboma, microphthalmia)",
                      "Congenital skeletal anomaly: Bifid, fused, splayed, or missing rib; or bifid, wedged, or fused vertebrae",
                      "Head circumference > 97th percentile, with frontal bossing",
                      "Cardiac or ovarian fibroma",
                      "Medulloblastoma (primitive neuroectodermal tumor [PNET], most often of desmoplastic histology)",
                      "Lymphomesenteric or pleural cysts",
                      "Congenital malformation: Cleft lip &/or palate, polydactyly, eye anomaly (cataract, coloboma, microphthalmia)"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria for von Hippel-Lindau(VHL) syndromeDiagnosis is established if there areVHLmutation≥ 2 CNS or retinal hemangioblastomas orSingle CNS or retinal hemangioblastoma, plus 1 of the followingMultiple renal, pancreatic, or hepatic cystsPheochromocytoma (any location)Renal cancerEndolymphatic sac tumor of inner earPapillary cystadenoma of the epididymis or broad ligamentNeuroendocrine tumor of the pancreas orDefinite family history of VHL plus 1 of the followingCNS or retinal hemangioblastomaMultiple renal, pancreatic, or hepatic cystsPheochromocytomaRenal cancer < age 60 yearsEpididymal cystadenomaKey diagnostic pointsMultiple retinal and CNS hemangioblastomasMultiple clear cell RCCs (bilateral), multiple renal cysts (bilateral) with clear cell lining, multiple pancreatic and hepatic cystsMay suspect possibility of syndrome based on constellation of pathologic findings",
                    "sub_points": [
                      "Diagnosis is established if there are",
                      "VHLmutation",
                      "≥ 2 CNS or retinal hemangioblastomas or",
                      "Single CNS or retinal hemangioblastoma, plus 1 of the followingMultiple renal, pancreatic, or hepatic cystsPheochromocytoma (any location)Renal cancerEndolymphatic sac tumor of inner earPapillary cystadenoma of the epididymis or broad ligamentNeuroendocrine tumor of the pancreas or",
                      "Multiple renal, pancreatic, or hepatic cysts",
                      "Pheochromocytoma (any location)",
                      "Renal cancer",
                      "Endolymphatic sac tumor of inner ear",
                      "Papillary cystadenoma of the epididymis or broad ligament",
                      "Neuroendocrine tumor of the pancreas or",
                      "Definite family history of VHL plus 1 of the followingCNS or retinal hemangioblastomaMultiple renal, pancreatic, or hepatic cystsPheochromocytomaRenal cancer < age 60 yearsEpididymal cystadenoma",
                      "CNS or retinal hemangioblastoma",
                      "Multiple renal, pancreatic, or hepatic cysts",
                      "Pheochromocytoma",
                      "Renal cancer < age 60 years",
                      "Epididymal cystadenoma",
                      "Key diagnostic pointsMultiple retinal and CNS hemangioblastomasMultiple clear cell RCCs (bilateral), multiple renal cysts (bilateral) with clear cell lining, multiple pancreatic and hepatic cystsMay suspect possibility of syndrome based on constellation of pathologic findings",
                      "Multiple retinal and CNS hemangioblastomas",
                      "Multiple clear cell RCCs (bilateral), multiple renal cysts (bilateral) with clear cell lining, multiple pancreatic and hepatic cysts",
                      "May suspect possibility of syndrome based on constellation of pathologic findings"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria for Carney complexPRKAR1Agene mutationPatient must have at least 2 of the followingSpotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)Myxoma (cutaneous: Often on the eyelid, external ear, nipple)Cardiac myxomaBreast myxomatosis or fat-suppressed MR findings suggestive of this diagnosisPrimary pigmented nodular adrenocortical disease or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during Liddle diagnostic test for Cushing syndromeAcromegaly due to GH-producing adenoma (somatotropinomas)Large-cell calcifying Sertoli cell tumor of testis or characteristic calcification on testicular ultrasonographyThyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patientPsammomatous melanotic schwannomaBlue nevus, epithelioid blue nevus (multiple)Breast ductal adenoma (multiple) (or mammary tumor with intraductal papilloma)Osteochondromyxoma of bone (histological diagnosis)Diagnostic criteria is also satisfied in a patient meeting any of these criteria and having either affected 1st-degree relative or inactivating mutation ofPRKAR1Agene",
                    "sub_points": [
                      "PRKAR1Agene mutation",
                      "Patient must have at least 2 of the followingSpotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)Myxoma (cutaneous: Often on the eyelid, external ear, nipple)Cardiac myxomaBreast myxomatosis or fat-suppressed MR findings suggestive of this diagnosisPrimary pigmented nodular adrenocortical disease or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during Liddle diagnostic test for Cushing syndromeAcromegaly due to GH-producing adenoma (somatotropinomas)Large-cell calcifying Sertoli cell tumor of testis or characteristic calcification on testicular ultrasonographyThyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patientPsammomatous melanotic schwannomaBlue nevus, epithelioid blue nevus (multiple)Breast ductal adenoma (multiple) (or mammary tumor with intraductal papilloma)Osteochondromyxoma of bone (histological diagnosis)",
                      "Spotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)",
                      "Myxoma (cutaneous: Often on the eyelid, external ear, nipple)",
                      "Cardiac myxoma",
                      "Breast myxomatosis or fat-suppressed MR findings suggestive of this diagnosis",
                      "Primary pigmented nodular adrenocortical disease or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during Liddle diagnostic test for Cushing syndrome",
                      "Acromegaly due to GH-producing adenoma (somatotropinomas)",
                      "Large-cell calcifying Sertoli cell tumor of testis or characteristic calcification on testicular ultrasonography",
                      "Thyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patient",
                      "Psammomatous melanotic schwannoma",
                      "Blue nevus, epithelioid blue nevus (multiple)",
                      "Breast ductal adenoma (multiple) (or mammary tumor with intraductal papilloma)",
                      "Osteochondromyxoma of bone (histological diagnosis)",
                      "Diagnostic criteria is also satisfied in a patient meeting any of these criteria and having either affected 1st-degree relative or inactivating mutation ofPRKAR1Agene"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria forneurofibromatosistype 1 (NF1)NF1mutationDiagnosis requires 2 or more of the followingCafé au lait maculesIn children, ≥ 5  that are ≥ 0.5 cm in diameterIn adults, ≥ 6 that are ≥ 1.5 cm in diameter≥ 2 neurofibromas of any type or 1 plexiform neurofibromaMultiple axillary or inguinal frecklesSphenoid wing dysplasia or congenital bowing or thinning of long bone cortex (± pseudoarthrosis)Bilateral optic nerve gliomas≥ 2 iris Lisch nodules (iris hamartomas)1st-degree relative with NF1 by these criteria",
                    "sub_points": [
                      "NF1mutation",
                      "Diagnosis requires 2 or more of the following",
                      "Café au lait maculesIn children, ≥ 5  that are ≥ 0.5 cm in diameterIn adults, ≥ 6 that are ≥ 1.5 cm in diameter",
                      "In children, ≥ 5  that are ≥ 0.5 cm in diameter",
                      "In adults, ≥ 6 that are ≥ 1.5 cm in diameter",
                      "≥ 2 neurofibromas of any type or 1 plexiform neurofibroma",
                      "Multiple axillary or inguinal freckles",
                      "Sphenoid wing dysplasia or congenital bowing or thinning of long bone cortex (± pseudoarthrosis)",
                      "Bilateral optic nerve gliomas",
                      "≥ 2 iris Lisch nodules (iris hamartomas)",
                      "1st-degree relative with NF1 by these criteria"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria for neurofibromatosis type 2 (NF2)NF2mutationRequires 1 of the following 2 major criteria to be metBilateral 8th nerve masses seen by MR with gadolinium or1st-degree relative with NF2 plus 1 of the followingCT or MR evidence of an unilateral 8th nerve massImaging evidence of intracranial or spinal cord tumorPosterior subcapsular cataract at a young ageGliomas (≥ 2)Neurofibromas (≥ 2)Meningioma (≥ 2)",
                    "sub_points": [
                      "NF2mutation",
                      "Requires 1 of the following 2 major criteria to be met",
                      "Bilateral 8th nerve masses seen by MR with gadolinium or",
                      "1st-degree relative with NF2 plus 1 of the followingCT or MR evidence of an unilateral 8th nerve massImaging evidence of intracranial or spinal cord tumorPosterior subcapsular cataract at a young ageGliomas (≥ 2)Neurofibromas (≥ 2)Meningioma (≥ 2)",
                      "CT or MR evidence of an unilateral 8th nerve mass",
                      "Imaging evidence of intracranial or spinal cord tumor",
                      "Posterior subcapsular cataract at a young age",
                      "Gliomas (≥ 2)",
                      "Neurofibromas (≥ 2)",
                      "Meningioma (≥ 2)"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria for Li-Fraumeni syndrome (LFS)Population to be screenedWhen strict criteria are met,TP53mutations are found in 60-80%If less strict criteria are used (Li-Fraumeni-like [LFL]),TP53mutations are found in up to 40%Chompret criteria for screeningIndividual (proband) must have 1 of the following tumors before age 46: Sarcoma, osteosarcoma, premenopausal breast cancer, brain tumor, adrenal cortical carcinoma, leukemia, or lung lepidic pattern carcinoma, and at least 1 of following 3 criteriaAt least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumorsBreast cancer is not included if proband has breast cancerMultiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred < age 46Adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history30% of individuals fulfilling these criteria have a germlineTP53mutation",
                    "sub_points": [
                      "Population to be screenedWhen strict criteria are met,TP53mutations are found in 60-80%If less strict criteria are used (Li-Fraumeni-like [LFL]),TP53mutations are found in up to 40%",
                      "When strict criteria are met,TP53mutations are found in 60-80%",
                      "If less strict criteria are used (Li-Fraumeni-like [LFL]),TP53mutations are found in up to 40%",
                      "Chompret criteria for screening",
                      "Individual (proband) must have 1 of the following tumors before age 46: Sarcoma, osteosarcoma, premenopausal breast cancer, brain tumor, adrenal cortical carcinoma, leukemia, or lung lepidic pattern carcinoma, and at least 1 of following 3 criteriaAt least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumorsBreast cancer is not included if proband has breast cancerMultiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred < age 46Adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history",
                      "At least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumors",
                      "Breast cancer is not included if proband has breast cancer",
                      "Multiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred < age 46",
                      "Adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history",
                      "30% of individuals fulfilling these criteria have a germlineTP53mutation"
                    ]
                  },
                  {
                    "text": "Diagnostic criteria forLynch syndromeMutations in genes coding for mismatch repair proteins (MLH1, PMS2, MSH2, MSH6)Clinical featuresMultiple epithelial cancers occur at average age of ~ 20 years younger than expectedSeveral guidelines have been proposed to help identify patients who should be tested for Lynch syndromeAmsterdam criteria II≥ 3 relatives with a Lynch-associated cancer≥ 2 successive generations affected≥ 1 relative diagnosed < age 501 should be a 1st-degree relative of the other 2Familial adenomatous polyposis must be excludedRevised Bethesda guidelinesColorectal carcinoma (CRC) diagnosed prior to age 50Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of ageCRC with histologic features suggestive of microsatellite instability in patient < age 60CRC diagnosed in ≥ 1 first-degree relative with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50CRC diagnosed in ≥ 2 first-degree or second-degree relatives with Lynch-associated tumors, regardless of ageNeither of these guidelines is foolproof; hence, many studies recommend testing all CRCs for Lynch syndrome",
                    "sub_points": [
                      "Mutations in genes coding for mismatch repair proteins (MLH1, PMS2, MSH2, MSH6)",
                      "Clinical featuresMultiple epithelial cancers occur at average age of ~ 20 years younger than expected",
                      "Multiple epithelial cancers occur at average age of ~ 20 years younger than expected",
                      "Several guidelines have been proposed to help identify patients who should be tested for Lynch syndromeAmsterdam criteria II≥ 3 relatives with a Lynch-associated cancer≥ 2 successive generations affected≥ 1 relative diagnosed < age 501 should be a 1st-degree relative of the other 2Familial adenomatous polyposis must be excludedRevised Bethesda guidelinesColorectal carcinoma (CRC) diagnosed prior to age 50Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of ageCRC with histologic features suggestive of microsatellite instability in patient < age 60CRC diagnosed in ≥ 1 first-degree relative with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50CRC diagnosed in ≥ 2 first-degree or second-degree relatives with Lynch-associated tumors, regardless of age",
                      "Amsterdam criteria II",
                      "≥ 3 relatives with a Lynch-associated cancer",
                      "≥ 2 successive generations affected",
                      "≥ 1 relative diagnosed < age 50",
                      "1 should be a 1st-degree relative of the other 2",
                      "Familial adenomatous polyposis must be excluded",
                      "Revised Bethesda guidelines",
                      "Colorectal carcinoma (CRC) diagnosed prior to age 50",
                      "Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of age",
                      "CRC with histologic features suggestive of microsatellite instability in patient < age 60",
                      "CRC diagnosed in ≥ 1 first-degree relative with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50",
                      "CRC diagnosed in ≥ 2 first-degree or second-degree relatives with Lynch-associated tumors, regardless of age",
                      "Neither of these guidelines is foolproof; hence, many studies recommend testing all CRCs for Lynch syndrome"
                    ]
                  }
                ],
                "Future Perspectives": [
                  {
                    "text": "Progress of recent years in understanding pathogenesis of familial tumor syndromes is expected to continue to improve patient screeningAlso become, in the long term, a catalyst for development of new therapeutic options for surgically untreatable tumors",
                    "sub_points": [
                      "Also become, in the long term, a catalyst for development of new therapeutic options for surgically untreatable tumors"
                    ]
                  },
                  {
                    "text": "With the fast-moving field, a new syndrome is frequently identified"
                  },
                  {
                    "text": "Awareness of possible syndromes when dealing with patients is critical for proper patient management"
                  },
                  {
                    "text": "Hereditary cancer syndromes in children and adolescents are becoming more recognized in the field of pediatric hematology/oncology"
                  },
                  {
                    "text": "Recently, germline mutations ofDICER1have been identified in patients with rare neoplasms, suggesting existence of a discovered syndrome involving cancer predispositionFamilial pleuropulmonary blastoma tumor predisposition (DICER1) syndromeDICER1mutations were identified in patients with familial pleuropulmonary blastomaAdditional manifestations of syndrome have been identified, including cystic nephroma, medulloepithelioma, Sertoli-Leydig cell tumor, and others",
                    "sub_points": [
                      "Familial pleuropulmonary blastoma tumor predisposition (DICER1) syndrome",
                      "DICER1mutations were identified in patients with familial pleuropulmonary blastoma",
                      "Additional manifestations of syndrome have been identified, including cystic nephroma, medulloepithelioma, Sertoli-Leydig cell tumor, and others"
                    ]
                  },
                  {
                    "text": "Familial pheochromocytoma and paraganglioma (PCC/PGL) syndromes form a heterogeneous group of tumorsExtensive genetic heterogeneity of these tumors came to light the identification of multiple susceptibility genesAt least 13 PPC/PGL syndromes are hereditaryMutations account for at least 30% of these tumors, the highest inheritable proportion of any known human tumor",
                    "sub_points": [
                      "Extensive genetic heterogeneity of these tumors came to light the identification of multiple susceptibility genes",
                      "At least 13 PPC/PGL syndromes are hereditary",
                      "Mutations account for at least 30% of these tumors, the highest inheritable proportion of any known human tumor"
                    ]
                  },
                  {
                    "text": "Importance of learning about them for the practicing physicians"
                  },
                  {
                    "text": "Of particular use for identification of genetic testing resources and regularly updated clinical management information for many of these disorders"
                  },
                  {
                    "text": "There are now a number of additional online resources available that provide more comprehensive information about these conditionsGeneTests website, a resource to those seeing individuals with genetic disorders: http://www. genetests.org/",
                    "sub_points": [
                      "GeneTests website, a resource to those seeing individuals with genetic disorders: http://www. genetests.org/"
                    ]
                  },
                  {
                    "text": "Pathologist plays a crucial role; important for surgical pathologists to be aware of specific pathology findings that suggest a possible tumor syndrome"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Multiple Endocrine Neoplasia Type 1": {
            "name": "Multiple Endocrine Neoplasia Type 1",
            "url": "https://app.pathprimer.com/document/fa6d39e9-4818-4e76-a1c8-1f5b840d941b/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Multiple endocrine neoplasia type 1 (MEN1)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Wermer syndrome"
                  },
                  {
                    "text": "Multiple endocrine adenomatosis type 1"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Rare autosomal dominant disease resulting in proliferative lesions of multiple endocrine organs involving mainly parathyroid, endocrine pancreas/duodenum, and pituitary glands"
                  }
                ]
              },
              "Epidemiology": {
                "Etiology": [
                  {
                    "text": "Caused by mutations inMEN1gene"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "MEN1gene is a 10 exon gene that encodes 610-amino acid protein menin"
                  },
                  {
                    "text": "Function is unknown; may act as regulator of gene transcription, cell proliferation, apoptosis, and genome stability"
                  }
                ],
                "Incidence": [
                  {
                    "text": "1:20,000-50,000"
                  }
                ],
                "Age": [
                  {
                    "text": "Penetrance increases with age"
                  }
                ],
                "Gender": [
                  {
                    "text": "1:1 sex distribution"
                  }
                ]
              },
              "Genetics": {
                "MEN1Gene": [
                  {
                    "text": "Located on chromosome 11q13"
                  },
                  {
                    "text": "Consists of 10 exons and encodes menin"
                  }
                ],
                "Mutation Spectrum": [
                  {
                    "text": "> 1,300 different mutations ofMEN1gene have been characterized"
                  },
                  {
                    "text": "Penetrance ofMEN1mutations is high: 45% by age 30, 82% by age 50, 96% by age 70"
                  },
                  {
                    "text": "Spread over entire coding and intronic sequence> 60% truncating mutation, 20% missense mutation, 10% in frame deletions or insertions, 10% others",
                    "sub_points": [
                      "> 60% truncating mutation, 20% missense mutation, 10% in frame deletions or insertions, 10% others"
                    ]
                  },
                  {
                    "text": "Most are inactivating mutations, consistent with those expected in tumor suppressor genePrecise role of menin in tumor suppression remains elusive",
                    "sub_points": [
                      "Precise role of menin in tumor suppression remains elusive"
                    ]
                  },
                  {
                    "text": "Clinical recommendation cannot be based on genotypeTruncating mutations: Increased risk of pancreatic endocrine tumorFrameshift mutations in exon 2: Increased incidence of pituitary tumor",
                    "sub_points": [
                      "Truncating mutations: Increased risk of pancreatic endocrine tumor",
                      "Frameshift mutations in exon 2: Increased incidence of pituitary tumor"
                    ]
                  },
                  {
                    "text": "5-25% of patients with MEN1 may not harbor germline mutation inMEN1gene-coding regionWhole or partial deletions or mutations in promoter region",
                    "sub_points": [
                      "Whole or partial deletions or mutations in promoter region"
                    ]
                  }
                ],
                "Testing": [
                  {
                    "text": "MEN1mutational analysis should be undertaken inIndex case with 2 or more MEN1-associated endocrine tumorsAsymptomatic 1st-degree relative1st-degree relative ofMEN1mutation carrierPatients with suspicious or atypical MEN1",
                    "sub_points": [
                      "Index case with 2 or more MEN1-associated endocrine tumors",
                      "Asymptomatic 1st-degree relative",
                      "1st-degree relative ofMEN1mutation carrier",
                      "Patients with suspicious or atypical MEN1"
                    ]
                  },
                  {
                    "text": "Genetic counseling useful for individuals and families with nonclassic MEN1 presentations"
                  },
                  {
                    "text": "Testing should be undertaken as soon as possible, even before the age of 5"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Presentation": [
                  {
                    "text": "Hyperparathyroidism(HPT)Present in > 90% of MEN1 patientsOccurs at younger ages (19 years)  than sporadic counterpart (50 years)Percentage of patients who develop biochemical evidence of hyperparathyroidism increases with age43% and 94% at age 20 and 50 years, respectivelyMost are asymptomatic, severe cases with \"moans, groans, bones, and stones\"  as hallmarks of hypercalcemiaMultiglandular disorderHigh recurrence rate",
                    "sub_points": [
                      "Present in > 90% of MEN1 patientsOccurs at younger ages (19 years)  than sporadic counterpart (50 years)",
                      "Occurs at younger ages (19 years)  than sporadic counterpart (50 years)",
                      "Percentage of patients who develop biochemical evidence of hyperparathyroidism increases with age43% and 94% at age 20 and 50 years, respectively",
                      "43% and 94% at age 20 and 50 years, respectively",
                      "Most are asymptomatic, severe cases with \"moans, groans, bones, and stones\"  as hallmarks of hypercalcemia",
                      "Multiglandular disorder",
                      "High recurrence rate"
                    ]
                  },
                  {
                    "text": "Pituitary tumorsFound in 10-60% of MEN1 patients; mean age 38Initial clinical manifestation of MEN1 in 10% and 20% of familial and sporadic cases, respectivelyMEN1 pituitary adenomas tend to be larger and more aggressive than sporadic counterpartsProlactinomas (PRL) (60%), growth hormone (GH) secreting adenoma (10%), adrenocorticotrophin (ACTH) secreting (5%), and nonsecreting adenomas (15%)Women with PRL adenoma: Major clinical signs are amenorrhea, infertility, galactorrheaMen with PRL adenoma: HypogonadismGH adenoma: AcromegalyACTH-secreting adenoma: Cushing disease",
                    "sub_points": [
                      "Found in 10-60% of MEN1 patients; mean age 38",
                      "Initial clinical manifestation of MEN1 in 10% and 20% of familial and sporadic cases, respectively",
                      "MEN1 pituitary adenomas tend to be larger and more aggressive than sporadic counterparts",
                      "Prolactinomas (PRL) (60%), growth hormone (GH) secreting adenoma (10%), adrenocorticotrophin (ACTH) secreting (5%), and nonsecreting adenomas (15%)Women with PRL adenoma: Major clinical signs are amenorrhea, infertility, galactorrheaMen with PRL adenoma: HypogonadismGH adenoma: AcromegalyACTH-secreting adenoma: Cushing disease",
                      "Women with PRL adenoma: Major clinical signs are amenorrhea, infertility, galactorrhea",
                      "Men with PRL adenoma: Hypogonadism",
                      "GH adenoma: Acromegaly",
                      "ACTH-secreting adenoma: Cushing disease"
                    ]
                  },
                  {
                    "text": "Endocrine pancreatic/duodenal tumorsFamilial Zollinger-Ellison syndrome (ZES)Most frequent clinical manifestation related to duodenal &/or pancreatic gastrinoma observed in MEN1 patientsInitial symptoms, such as abdominal pain or gastroesophageal reflux disease, caused by gastric acid hypersecretionSevere complications include bleeding, perforation, and esophageal stricturesIn 90% of MEN1 patients with ZES, lesions are often multiple, small, and located in duodenumInsulinomas2nd most frequent pancreatic tumor in setting of MEN1HypoglycemiaGlucagonoma, VIPoma, and other pancreatic endocrine tumorsOccur in < 5% of MEN1 patients~ 80% of glucagonomas and 40% of VIPomas are malignantGlucagonomas induce necrolytic migratory erythema associated with diabetes mellitus, which is secondary to abnormal glucagon secretionVIPomas induce classical Verner-Morrison syndrome associated with watery diarrhea, hypokalemia, and achlorhydriaNonfunctioning pancreatic endocrine tumors20-40% of MEN1 patientsWhen misdiagnosed, often discovered after local compression &/or hepatic metastases",
                    "sub_points": [
                      "Familial Zollinger-Ellison syndrome (ZES)Most frequent clinical manifestation related to duodenal &/or pancreatic gastrinoma observed in MEN1 patientsInitial symptoms, such as abdominal pain or gastroesophageal reflux disease, caused by gastric acid hypersecretionSevere complications include bleeding, perforation, and esophageal stricturesIn 90% of MEN1 patients with ZES, lesions are often multiple, small, and located in duodenum",
                      "Most frequent clinical manifestation related to duodenal &/or pancreatic gastrinoma observed in MEN1 patients",
                      "Initial symptoms, such as abdominal pain or gastroesophageal reflux disease, caused by gastric acid hypersecretion",
                      "Severe complications include bleeding, perforation, and esophageal strictures",
                      "In 90% of MEN1 patients with ZES, lesions are often multiple, small, and located in duodenum",
                      "Insulinomas2nd most frequent pancreatic tumor in setting of MEN1Hypoglycemia",
                      "2nd most frequent pancreatic tumor in setting of MEN1",
                      "Hypoglycemia",
                      "Glucagonoma, VIPoma, and other pancreatic endocrine tumorsOccur in < 5% of MEN1 patients~ 80% of glucagonomas and 40% of VIPomas are malignantGlucagonomas induce necrolytic migratory erythema associated with diabetes mellitus, which is secondary to abnormal glucagon secretionVIPomas induce classical Verner-Morrison syndrome associated with watery diarrhea, hypokalemia, and achlorhydria",
                      "Occur in < 5% of MEN1 patients",
                      "~ 80% of glucagonomas and 40% of VIPomas are malignant",
                      "Glucagonomas induce necrolytic migratory erythema associated with diabetes mellitus, which is secondary to abnormal glucagon secretion",
                      "VIPomas induce classical Verner-Morrison syndrome associated with watery diarrhea, hypokalemia, and achlorhydria",
                      "Nonfunctioning pancreatic endocrine tumors20-40% of MEN1 patientsWhen misdiagnosed, often discovered after local compression &/or hepatic metastases",
                      "20-40% of MEN1 patients",
                      "When misdiagnosed, often discovered after local compression &/or hepatic metastases"
                    ]
                  },
                  {
                    "text": "OthersAdrenal cortical lesionsObserved in 20-40% of MEN1 patientsOften detected about 7 years after diagnosis of MEN1Most are adenomas and may produce aldosterone and cortisolOften small, benign, and nonfunctionalSurgery for lesions < 3 cmGastric ECLomasThought to originate from proliferation of enterochromaffin-like (ECL) cells in gastric mucosaOften small and multipleCan be treated with endoscopic polypectomy if lesion is < 1 cmGood prognosisThymic and bronchial neuroendocrine tumorObserved in 5-10% of MEN1 patientsThymic carcinoids are predominantly in malesPoor prognosis with local invasion, recurrence, and distant metastasisCutaneous proliferationsPresent in 40-80% of MEN1 patientsNodular lipomas (30%)Collagenomas (5%)Angiofibromas are multiple and often on face (75%)Soft tissue tumorsEsophageal leiomyomaRenal angiomyolipomaMalignant gastrointestinal stromal tumorsCentral nervous system tumorsSpinal ependymomas, meningioma, and astrocytoma have been described in MEN1 cases",
                    "sub_points": [
                      "Adrenal cortical lesionsObserved in 20-40% of MEN1 patientsOften detected about 7 years after diagnosis of MEN1Most are adenomas and may produce aldosterone and cortisolOften small, benign, and nonfunctionalSurgery for lesions < 3 cm",
                      "Observed in 20-40% of MEN1 patients",
                      "Often detected about 7 years after diagnosis of MEN1",
                      "Most are adenomas and may produce aldosterone and cortisol",
                      "Often small, benign, and nonfunctional",
                      "Surgery for lesions < 3 cm",
                      "Gastric ECLomasThought to originate from proliferation of enterochromaffin-like (ECL) cells in gastric mucosaOften small and multipleCan be treated with endoscopic polypectomy if lesion is < 1 cmGood prognosis",
                      "Thought to originate from proliferation of enterochromaffin-like (ECL) cells in gastric mucosa",
                      "Often small and multiple",
                      "Can be treated with endoscopic polypectomy if lesion is < 1 cm",
                      "Good prognosis",
                      "Thymic and bronchial neuroendocrine tumorObserved in 5-10% of MEN1 patientsThymic carcinoids are predominantly in malesPoor prognosis with local invasion, recurrence, and distant metastasis",
                      "Observed in 5-10% of MEN1 patients",
                      "Thymic carcinoids are predominantly in males",
                      "Poor prognosis with local invasion, recurrence, and distant metastasis",
                      "Cutaneous proliferationsPresent in 40-80% of MEN1 patientsNodular lipomas (30%)Collagenomas (5%)Angiofibromas are multiple and often on face (75%)",
                      "Present in 40-80% of MEN1 patients",
                      "Nodular lipomas (30%)",
                      "Collagenomas (5%)",
                      "Angiofibromas are multiple and often on face (75%)",
                      "Soft tissue tumorsEsophageal leiomyomaRenal angiomyolipomaMalignant gastrointestinal stromal tumors",
                      "Esophageal leiomyoma",
                      "Renal angiomyolipoma",
                      "Malignant gastrointestinal stromal tumors",
                      "Central nervous system tumorsSpinal ependymomas, meningioma, and astrocytoma have been described in MEN1 cases",
                      "Spinal ependymomas, meningioma, and astrocytoma have been described in MEN1 cases"
                    ]
                  }
                ]
              },
              "Clinical Diagnosis": {
                "Basis for MEN1 Diagnosis": [
                  {
                    "text": "Diagnosis of MEN1 may be established by 1 of 3 criteria"
                  },
                  {
                    "text": "ClinicalOccurrence of 2 or more primary MEN1-associated endocrine tumors: Parathyroid adenoma, enteropancreatic tumor, and pituitary adenoma",
                    "sub_points": [
                      "Occurrence of 2 or more primary MEN1-associated endocrine tumors: Parathyroid adenoma, enteropancreatic tumor, and pituitary adenoma"
                    ]
                  },
                  {
                    "text": "FamilialOccurrence of 1 MEN1-associated tumor in 1st-degree relative of patient with clinical diagnosis of MEN1",
                    "sub_points": [
                      "Occurrence of 1 MEN1-associated tumor in 1st-degree relative of patient with clinical diagnosis of MEN1"
                    ]
                  },
                  {
                    "text": "GeneticIdentification of germlineMEN1mutation in an individual who may be asymptomatic and has not yet developed serum biochemical or radiological abnormalities is indicative of tumor development",
                    "sub_points": [
                      "Identification of germlineMEN1mutation in an individual who may be asymptomatic and has not yet developed serum biochemical or radiological abnormalities is indicative of tumor development"
                    ]
                  }
                ],
                "Diagnostic Criteria": [
                  {
                    "text": "Presence of ≥ 2 of the followingPrimary hyperparathyroidism with multiglandular hyperplasia &/or adenoma or recurrent primary hyperparathyroidismDuodenal &/or pancreatic endocrine tumors, gastric enterochromaffin-like tumorsBoth functioning and nonfunctioning or multisecreting tumorAnterior pituitary adenomaFunctioning (GH-secreting tumor, prolactinoma)Nonfunctioning or multisecretingAdrenal cortical tumorBoth functioning and nonfunctioningThymic &/or bronchial endocrine tumors (foregut carcinoids)1st-degree relative with MEN1",
                    "sub_points": [
                      "Primary hyperparathyroidism with multiglandular hyperplasia &/or adenoma or recurrent primary hyperparathyroidism",
                      "Duodenal &/or pancreatic endocrine tumors, gastric enterochromaffin-like tumorsBoth functioning and nonfunctioning or multisecreting tumor",
                      "Both functioning and nonfunctioning or multisecreting tumor",
                      "Anterior pituitary adenomaFunctioning (GH-secreting tumor, prolactinoma)Nonfunctioning or multisecreting",
                      "Functioning (GH-secreting tumor, prolactinoma)",
                      "Nonfunctioning or multisecreting",
                      "Adrenal cortical tumorBoth functioning and nonfunctioning",
                      "Both functioning and nonfunctioning",
                      "Thymic &/or bronchial endocrine tumors (foregut carcinoids)",
                      "1st-degree relative with MEN1"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Pituitary adenoma can express 1 or several hormonesProlactin, ACTH, HGH, LH, FSH, TSH",
                    "sub_points": [
                      "Prolactin, ACTH, HGH, LH, FSH, TSH"
                    ]
                  },
                  {
                    "text": "Pancreatic endocrine tumor can express 1 or several hormonesInsulin, gastrin, glucagon, pancreatic polypeptide, VIP, somatostatin, or serotonin",
                    "sub_points": [
                      "Insulin, gastrin, glucagon, pancreatic polypeptide, VIP, somatostatin, or serotonin"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Screening": [
                  {
                    "text": "Optimal screening age, test, and frequencies not established, but recommend starting annual biochemical test by 5 yearsFor known carriers ofMEN1mutationsGlucose, insulin, prolactin, and IGF-1 levels",
                    "sub_points": [
                      "For known carriers ofMEN1mutationsGlucose, insulin, prolactin, and IGF-1 levels",
                      "Glucose, insulin, prolactin, and IGF-1 levels"
                    ]
                  },
                  {
                    "text": "Finding of MEN1 in a patient has important implications for family members1st-degree relatives have 50% risk of developing disease and can often be identified byMEN1mutational analysis",
                    "sub_points": [
                      "1st-degree relatives have 50% risk of developing disease and can often be identified byMEN1mutational analysis"
                    ]
                  },
                  {
                    "text": "Serologic testsStarting at age 8: PTH and calcium levelsStarting at age 20: Fasting serum gastrin, pancreatic polypeptide, VIP, and glucagonRecommended serologic testsSerum Ca, PTH: HyperparathyroidismPRL, GH, ACTH, others: Pituitary adenomaGastrin, insulin, glucagon, pancreatic polypeptide, and serum chromogranin-A: GI neuroendocrine tumorsOther markers: 5-HIAA, calcitonin",
                    "sub_points": [
                      "Starting at age 8: PTH and calcium levels",
                      "Starting at age 20: Fasting serum gastrin, pancreatic polypeptide, VIP, and glucagon",
                      "Recommended serologic testsSerum Ca, PTH: HyperparathyroidismPRL, GH, ACTH, others: Pituitary adenomaGastrin, insulin, glucagon, pancreatic polypeptide, and serum chromogranin-A: GI neuroendocrine tumorsOther markers: 5-HIAA, calcitonin",
                      "Serum Ca, PTH: Hyperparathyroidism",
                      "PRL, GH, ACTH, others: Pituitary adenoma",
                      "Gastrin, insulin, glucagon, pancreatic polypeptide, and serum chromogranin-A: GI neuroendocrine tumors",
                      "Other markers: 5-HIAA, calcitonin"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Pituitary adenomaMedical and surgical treatment for prolactin or GH-producing tumors",
                    "sub_points": [
                      "Medical and surgical treatment for prolactin or GH-producing tumors"
                    ]
                  },
                  {
                    "text": "Endocrine pancreatic/duodenal tumorsSurgery in most cases",
                    "sub_points": [
                      "Surgery in most cases"
                    ]
                  },
                  {
                    "text": "HyperparathyroidismTotal parathyroidectomy with autotransplantation or subtotal resection",
                    "sub_points": [
                      "Total parathyroidectomy with autotransplantation or subtotal resection"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "MEN1 patients have decreased life expectancy, and outcomes of current treatments are not as successful  due toMultiple tumorsTumors may be larger, more aggressive, and resistant to treatmentConcurrence of metastases",
                    "sub_points": [
                      "Multiple tumorsTumors may be larger, more aggressive, and resistant to treatment",
                      "Tumors may be larger, more aggressive, and resistant to treatment",
                      "Concurrence of metastases"
                    ]
                  },
                  {
                    "text": "Same prognosis for pituitary adenoma in MEN1 as in sporadic counterparts"
                  },
                  {
                    "text": "Malignancy of duodenal and pancreatic endocrine tumorsGastrinomas > 40%, glucagonoma > 80%, VIPoma > 40%, nonfunctioning tumor > 70%",
                    "sub_points": [
                      "Gastrinomas > 40%, glucagonoma > 80%, VIPoma > 40%, nonfunctioning tumor > 70%"
                    ]
                  },
                  {
                    "text": "Prognosis for MEN1 patients might be improved by presymptomatic tumor detection"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Multiple Endocrine Neoplasia Type 2/Familial Medullary Thyroid Carcinoma": {
            "name": "Multiple Endocrine Neoplasia Type 2/Familial Medullary Thyroid Carcinoma",
            "url": "https://app.pathprimer.com/document/9e5e0292-b6b0-4769-aa4e-b905c78f3a01/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Multiple endocrine neoplasia type 2 (MEN2)Multiple endocrine neoplasia type 2A (MEN2A)Multiple endocrine neoplasia type 2B (MEN2B)",
                    "sub_points": [
                      "Multiple endocrine neoplasia type 2A (MEN2A)",
                      "Multiple endocrine neoplasia type 2B (MEN2B)"
                    ]
                  },
                  {
                    "text": "Familial medullary thyroid carcinoma (FMTC)"
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "MEN2Overall incidence is 1 in 30,000 live birthsHereditary medullary thyroid carcinoma (MTC) accounts for 25% of all MTC",
                    "sub_points": [
                      "Overall incidence is 1 in 30,000 live birthsHereditary medullary thyroid carcinoma (MTC) accounts for 25% of all MTC",
                      "Hereditary medullary thyroid carcinoma (MTC) accounts for 25% of all MTC"
                    ]
                  },
                  {
                    "text": "MEN2AUnknown; estimated 1.25-7.5 per 10 million per yearPrevalence is 1 per 35,000",
                    "sub_points": [
                      "Unknown; estimated 1.25-7.5 per 10 million per year",
                      "Prevalence is 1 per 35,000"
                    ]
                  },
                  {
                    "text": "MEN2BComprises about 5% of cases of MEN2",
                    "sub_points": [
                      "Comprises about 5% of cases of MEN2"
                    ]
                  },
                  {
                    "text": "FMTCComprises about 10-20% of cases with MEN2",
                    "sub_points": [
                      "Comprises about 10-20% of cases with MEN2"
                    ]
                  },
                  {
                    "text": "Overall incidence of MTC in patients with familial disease is 25%This group represents ~ 5% of all thyroid tumors and ~ 15% of all thyroid cancer-related deaths",
                    "sub_points": [
                      "This group represents ~ 5% of all thyroid tumors and ~ 15% of all thyroid cancer-related deaths"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "MEN2AIn late adolescence or early adulthoodPeak incidence of medullary carcinoma in these patients is in 4th decade",
                    "sub_points": [
                      "In late adolescence or early adulthood",
                      "Peak incidence of medullary carcinoma in these patients is in 4th decade"
                    ]
                  },
                  {
                    "text": "MEN2BPatients usually develop medullary carcinoma early in life, diagnosed in infancy or early childhood",
                    "sub_points": [
                      "Patients usually develop medullary carcinoma early in life, diagnosed in infancy or early childhood"
                    ]
                  },
                  {
                    "text": "FMTCInherited medullary carcinoma without associated endocrinopathiesSimilar to other types of thyroid cancers, peak incidence is between age 40 and 50 years",
                    "sub_points": [
                      "Inherited medullary carcinoma without associated endocrinopathiesSimilar to other types of thyroid cancers, peak incidence is between age 40 and 50 years",
                      "Similar to other types of thyroid cancers, peak incidence is between age 40 and 50 years"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "MEN2F:M = 1:1",
                    "sub_points": [
                      "F:M = 1:1"
                    ]
                  }
                ]
              },
              "Genetics": {
                "RETProto-Oncogene": [
                  {
                    "text": "Maps to chromosome 10q11.2 and encodes a receptor tyrosine kinase called \"rearranged during transfection\"Tyrosine kinase plays integral role in transducing signals for growth and differentiation in tissues derived from neural crest",
                    "sub_points": [
                      "Tyrosine kinase plays integral role in transducing signals for growth and differentiation in tissues derived from neural crest"
                    ]
                  },
                  {
                    "text": "MEN2A:RETmutation in > 98% of cases"
                  },
                  {
                    "text": "MEN2B:RETmutation in 100% of cases"
                  },
                  {
                    "text": "FMTC:RETmutation in > 85% of cases"
                  },
                  {
                    "text": "MEN2 is caused by gain-of-function mutations that produce constitutively active protein or ↓ substrate specificity"
                  },
                  {
                    "text": "In contrast, loss-of-function mutations are associated with a subset of Hirschsprung disease (HSCR)"
                  },
                  {
                    "text": "Pathologic allelic variants: Major disease-causing mutations are nonconservative gain-of-function substitutions located in 1 of 6 cysteine codons in extracellular domain of encoded proteinInclude codons 609, 611, 618, and 620 in exon 10 and codons 630 and 634 in exon 11All of these variants have been identified in families with MEN2A, and some have been identified in families with FMTCMutations in these sites have been detected in 98% of families with MEN2A~ 95% of all individuals with MEN2B have single-point mutation at codon 918 in exon 162nd point mutation at codon 883 in exon 15 has been found in 3-5% of individuals with MEN2B",
                    "sub_points": [
                      "Include codons 609, 611, 618, and 620 in exon 10 and codons 630 and 634 in exon 11",
                      "All of these variants have been identified in families with MEN2A, and some have been identified in families with FMTCMutations in these sites have been detected in 98% of families with MEN2A",
                      "Mutations in these sites have been detected in 98% of families with MEN2A",
                      "~ 95% of all individuals with MEN2B have single-point mutation at codon 918 in exon 16",
                      "2nd point mutation at codon 883 in exon 15 has been found in 3-5% of individuals with MEN2B"
                    ]
                  },
                  {
                    "text": "For families in which MEN2A and HSCR cosegregate, models to explain how same mutation can cause gain of function and loss of function have been proposed"
                  }
                ],
                "Genotype-Phenotype Correlations": [
                  {
                    "text": "1st clear genotype-phenotype associations to be found in inherited neoplasia syndromes:RETgenotype- and MEN2-phenotype correlations"
                  },
                  {
                    "text": "Most striking observation: Gain-of-function mutations affected several hotspot codons, with great majority mutating cysteine residues in exons 10 and 11"
                  },
                  {
                    "text": "Notably, mutations of codon 634 in exon 11 are highly associated with full-blown phenotype of MEN2A, i.e., with high prevalence of pheochromocytoma and hyperparathyroidismAssociated fulminant course with p.C634R, which is associated with higher probability of having metastases at diagnosis of MTC than other codon 634 mutationsAlthough 25% of FMTC kindreds harbor a mutation in codon 634 (most commonly p.C634Y), p.C634R mutations are virtually absent in this subtypeCodon 634 mutations are also associated with development of cutaneous lichen amyloidosis (36%)",
                    "sub_points": [
                      "Associated fulminant course with p.C634R, which is associated with higher probability of having metastases at diagnosis of MTC than other codon 634 mutations",
                      "Although 25% of FMTC kindreds harbor a mutation in codon 634 (most commonly p.C634Y), p.C634R mutations are virtually absent in this subtype",
                      "Codon 634 mutations are also associated with development of cutaneous lichen amyloidosis (36%)"
                    ]
                  },
                  {
                    "text": "RETgermline p.M918T mutations are associated only with MEN2BSomatic mutations at this codon are frequently observed in MTC in individuals with no known family history of MTCOverrepresented in individuals with sporadic MTC who have particular germlineRETvariant, c.2439C/T",
                    "sub_points": [
                      "Somatic mutations at this codon are frequently observed in MTC in individuals with no known family history of MTCOverrepresented in individuals with sporadic MTC who have particular germlineRETvariant, c.2439C/T",
                      "Overrepresented in individuals with sporadic MTC who have particular germlineRETvariant, c.2439C/T"
                    ]
                  },
                  {
                    "text": "Genotype-phenotype correlations suggest that exon 10 codon mutations, in particular at codons 609 and 611, have incidence of MTC in 77%, pheochromocytoma in 17%, and HPT in 3%"
                  },
                  {
                    "text": "Mutations involving cysteine codons 609, 618, and 620 in exon 10 ofRETare associated with MEN2A or FMTC cosegregating with HSCR"
                  },
                  {
                    "text": "Mutations at codons 768, 804, and 891 are associated with FMTC and in rare families with MEN2A"
                  },
                  {
                    "text": "Mutations in codons 790 or 804 may be associated with papillary thyroid carcinoma (PTC) as well as MTC40% of family members with p.V804M mutation had concomitant medullary and PTC",
                    "sub_points": [
                      "40% of family members with p.V804M mutation had concomitant medullary and PTC"
                    ]
                  },
                  {
                    "text": "American Thyroid Association Guidelines Task Force has classified mutations based on risk for aggressive MTCMay be used in predicting phenotype and recommendations for age at which to perform prophylactic thyroidectomy and to begin biochemical screening for pheochromocytoma and hyperparathyroidism",
                    "sub_points": [
                      "May be used in predicting phenotype and recommendations for age at which to perform prophylactic thyroidectomy and to begin biochemical screening for pheochromocytoma and hyperparathyroidism"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Presentation": [
                  {
                    "text": "MEN2A, FMTC, and MEN2B can all be diagnosed based on clinical features"
                  },
                  {
                    "text": "With advances ofRETtesting, genotype-specific risks, and management, molecular genetic testing is virtually mandatoryMost often used to distinguish sporadic from hereditary MTC",
                    "sub_points": [
                      "Most often used to distinguish sporadic from hereditary MTC"
                    ]
                  },
                  {
                    "text": "MEN2ADiagnosed clinically by occurrence of ≥ 2 specific endocrine tumors (MTC, pheochromocytoma, or parathyroid adenoma/hyperplasia) in single individual or in close relativesMakes up ~ 70-80% of cases of MEN2~ 100% of individuals with MEN2A develop MTC10-60% develop pheochromocytoma and 10-30% develop hyperparathyroidism",
                    "sub_points": [
                      "Diagnosed clinically by occurrence of ≥ 2 specific endocrine tumors (MTC, pheochromocytoma, or parathyroid adenoma/hyperplasia) in single individual or in close relatives",
                      "Makes up ~ 70-80% of cases of MEN2",
                      "~ 100% of individuals with MEN2A develop MTC",
                      "10-60% develop pheochromocytoma and 10-30% develop hyperparathyroidism"
                    ]
                  },
                  {
                    "text": "MEN2BDiagnosed clinically by presence of mucosal neuromas of lips and tongue, as well as medullated corneal nerve fibers, distinctive facies with enlarged lips, asthenic \"Marfanoid\" body habitus, and MTCComprises ~ 5% of cases of MEN2Characterized by early development of aggressive form of MTC associated with C-cell hyperplasia (CCH)50% develop pheochromocytoma60-90% have ganglioneuromatosisPresence of mucosal neuromas is identified early in life~ 100% have asthenic \"Marfanoid\" body habitus",
                    "sub_points": [
                      "Diagnosed clinically by presence of mucosal neuromas of lips and tongue, as well as medullated corneal nerve fibers, distinctive facies with enlarged lips, asthenic \"Marfanoid\" body habitus, and MTC",
                      "Comprises ~ 5% of cases of MEN2",
                      "Characterized by early development of aggressive form of MTC associated with C-cell hyperplasia (CCH)",
                      "50% develop pheochromocytoma",
                      "60-90% have ganglioneuromatosis",
                      "Presence of mucosal neuromas is identified early in life",
                      "~ 100% have asthenic \"Marfanoid\" body habitus"
                    ]
                  },
                  {
                    "text": "FMTCHistorically, operationally diagnosed in families with ≥ 4 cases of MTC in absence of pheochromocytoma or parathyroid adenoma/hyperplasiaBecauseRETmutation accounts for all clinical subtypes of MEN2, FMTC may be viewed as MEN2A with reduced organ-specific penetranceComprises 10-20% of cases of MEN2MTC is the only clinical manifestation of FMTC",
                    "sub_points": [
                      "Historically, operationally diagnosed in families with ≥ 4 cases of MTC in absence of pheochromocytoma or parathyroid adenoma/hyperplasia",
                      "BecauseRETmutation accounts for all clinical subtypes of MEN2, FMTC may be viewed as MEN2A with reduced organ-specific penetrance",
                      "Comprises 10-20% of cases of MEN2",
                      "MTC is the only clinical manifestation of FMTC"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "MTC: In provocative testing, plasma calcitonin concentration is measured before (basal levels) as well as 2 and 5 minutes after intravenous administration of calcium (stimulated level)Other calcitonin secretagogues, e.g., pentagastrin, are also usedReference levels for basal calcitonin vary across laboratories: < 10 pg/mL for adult males and < 5 pg/mL for adult females are typically considered normalBasal or stimulated calcitonin level of ≥ 100 pg/mL is indication for surgeryCaution should be used when interpreting calcitonin levels in children younger than 5 years",
                    "sub_points": [
                      "Other calcitonin secretagogues, e.g., pentagastrin, are also used",
                      "Reference levels for basal calcitonin vary across laboratories: < 10 pg/mL for adult males and < 5 pg/mL for adult females are typically considered normal",
                      "Basal or stimulated calcitonin level of ≥ 100 pg/mL is indication for surgeryCaution should be used when interpreting calcitonin levels in children younger than 5 years",
                      "Caution should be used when interpreting calcitonin levels in children younger than 5 years"
                    ]
                  },
                  {
                    "text": "Pheochromocytomais suspected when biochemical screening reveals elevated secretion of catecholamines and catecholamine metabolitesIn MEN2, pheochromocytomas consistently produce epinephrine or both epinephrine and norepinephrine",
                    "sub_points": [
                      "In MEN2, pheochromocytomas consistently produce epinephrine or both epinephrine and norepinephrine"
                    ]
                  },
                  {
                    "text": "Diagnosis ofparathyroid abnormalitiesis made when biochemical screening reveals simultaneously elevated serum concentrations of calcium and elevated or high to normal parathyroid hormone"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "MTC: Calcitonin, calcitonin gene-related peptide (CGRP), chromogranin, and CEA"
                  },
                  {
                    "text": "Pheochromocytoma (PCC): Neuroendocrine markers; RET staining is not helpful to distinguish MEN2-associated PCC from sporadic counterpart"
                  }
                ],
                "Imaging Features": [
                  {
                    "text": "May be used in predicting phenotype and recommendations for age at which to perform prophylactic thyroidectomy and to begin biochemical screening for pheochromocytoma and hyperparathyroidismMR is more sensitive than CT in detection of pheochromocytoma",
                    "sub_points": [
                      "MR is more sensitive than CT in detection of pheochromocytoma"
                    ]
                  },
                  {
                    "text": "18F-fluorodopamine positron emission tomography (PET) is best overall imaging modality in localization of pheochromocytomas"
                  },
                  {
                    "text": "Postoperative parathyroid localizing studies with Tc-99m sestamibi scintigraphy may be helpful if HPT recurs"
                  },
                  {
                    "text": "For preoperative adenoma localization, 3D single-photon emission CT may also be used"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Precursor Lesions": [
                  {
                    "text": "Neoplastic C-cell hyperplasia (NCCH)NCCH is precursor lesion in hereditary MTCClusters should have > 50 C cellsa.k.a. C-cell carcinoma in situ or medullary carcinoma in situThese lesions harbor germlineRETmutationsPostulated that CCH progresses to medullary microcarcinoma (MMC) and eventually to MTCFound in vicinity of medullary carcinomasDistinguishing CCH from MMC or intrathyroid spread of MTC may be difficult",
                    "sub_points": [
                      "NCCH is precursor lesion in hereditary MTC",
                      "Clusters should have > 50 C cells",
                      "a.k.a. C-cell carcinoma in situ or medullary carcinoma in situ",
                      "These lesions harbor germlineRETmutations",
                      "Postulated that CCH progresses to medullary microcarcinoma (MMC) and eventually to MTC",
                      "Found in vicinity of medullary carcinomas",
                      "Distinguishing CCH from MMC or intrathyroid spread of MTC may be difficult"
                    ]
                  },
                  {
                    "text": "Adrenal medullary hyperplasia (AMH)Common in multiple endocrine neoplasia 2A and 2B; absent or very rare in other pheochromocytoma/paraganglioma syndromesAdrenals removed for pheochromocytoma should be carefully examined for additional nodules as a clue to presence of MEN2AMH may present with signs of catecholamine excess or be discovered incidentally after adrenalectomy for pheochromocytomaAdrenal medulla normally confined to central region (\"body\") of glandAMH often identifiable by gross extension of gray medullary tissue into alae and tailNodules often superimposed on diffuse hyperplasia",
                    "sub_points": [
                      "Common in multiple endocrine neoplasia 2A and 2B; absent or very rare in other pheochromocytoma/paraganglioma syndromes",
                      "Adrenals removed for pheochromocytoma should be carefully examined for additional nodules as a clue to presence of MEN2",
                      "AMH may present with signs of catecholamine excess or be discovered incidentally after adrenalectomy for pheochromocytoma",
                      "Adrenal medulla normally confined to central region (\"body\") of glandAMH often identifiable by gross extension of gray medullary tissue into alae and tailNodules often superimposed on diffuse hyperplasia",
                      "AMH often identifiable by gross extension of gray medullary tissue into alae and tail",
                      "Nodules often superimposed on diffuse hyperplasia"
                    ]
                  }
                ],
                "Medullary Thyroid Carcinoma": [
                  {
                    "text": "Often presents as painless \"cold\" noduleUp to 50% have nodal metastasesUp to 20% may present with distant metastasesSymptoms of carcinoid and Cushing syndromes may be present",
                    "sub_points": [
                      "Up to 50% have nodal metastases",
                      "Up to 20% may present with distant metastases",
                      "Symptoms of carcinoid and Cushing syndromes may be present"
                    ]
                  },
                  {
                    "text": "Typically at junction of upper and middle 1/3 of lobeHereditary tumors are usually multicentric and bilateralSporadic tumors tend to present as solitary mass ± lymph node involvementAlways associated with C-cell hyperplasia in MEN2",
                    "sub_points": [
                      "Hereditary tumors are usually multicentric and bilateralSporadic tumors tend to present as solitary mass ± lymph node involvement",
                      "Sporadic tumors tend to present as solitary mass ± lymph node involvement",
                      "Always associated with C-cell hyperplasia in MEN2"
                    ]
                  }
                ],
                "Pheochromocytoma": [
                  {
                    "text": "≥ 30% of PCCs/paraganglioma are hereditary tumors~ 1/3 of these are MEN2 patientsOccult germline mutations of susceptibility genes are common in patients with apparently sporadic pheochromocytomas",
                    "sub_points": [
                      "~ 1/3 of these are MEN2 patients",
                      "Occult germline mutations of susceptibility genes are common in patients with apparently sporadic pheochromocytomas"
                    ]
                  },
                  {
                    "text": "Affected by genotypeMultiple tumors or tumors presenting in children suggest hereditary diseaseSporadic tumors are solitary, usually in adultsTumors withRETmutations are almost always intraadrenal",
                    "sub_points": [
                      "Multiple tumors or tumors presenting in children suggest hereditary diseaseSporadic tumors are solitary, usually in adults",
                      "Sporadic tumors are solitary, usually in adults",
                      "Tumors withRETmutations are almost always intraadrenal"
                    ]
                  }
                ],
                "Parathyroid Hyperplasia and Adenoma": [
                  {
                    "text": "20-30% of MEN2A are associated with parathyroid hyperplasia or adenoma"
                  },
                  {
                    "text": "Almost never initial presentation of MEN2AIn contrast, hyperparathyroidism is common presentation in MEN1 (> 80%)",
                    "sub_points": [
                      "In contrast, hyperparathyroidism is common presentation in MEN1 (> 80%)"
                    ]
                  }
                ],
                "Ganglioneuroma of Gastrointestinal Tract": [
                  {
                    "text": "~ 40% of MEN2B-affected individuals have diffuse intestinal ganglioneuromatosis"
                  }
                ],
                "Mucosal Neuroma": [
                  {
                    "text": "May be identified in infancy and early childhood"
                  },
                  {
                    "text": "On palate, anterior dorsal surface of tongue, or pharynx"
                  },
                  {
                    "text": "Neuromas in eyelids"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Genetic Testing, MEN2": [
                  {
                    "text": "RETis the only gene known to be associated with MEN2"
                  },
                  {
                    "text": "RETmolecular genetic testing is indicated in all individuals with diagnosis of MTC, clinical diagnosis of MEN2, or primary CCH"
                  },
                  {
                    "text": "Algorithm for testing is summarized in most recent American Thyroid Association MTC Practice GuidelinesYoung age of onset, significant CCH, &/or multifocal disease suggest inherited disorderAll individuals with MTC, regardless of other features or family history, and those with clinical features suspicious for MEN2 &/or with family history suspicious of MEN2 should be offered germlineRETtesting for exons 10, 11, and 13-16",
                    "sub_points": [
                      "Young age of onset, significant CCH, &/or multifocal disease suggest inherited disorder",
                      "All individuals with MTC, regardless of other features or family history, and those with clinical features suspicious for MEN2 &/or with family history suspicious of MEN2 should be offered germlineRETtesting for exons 10, 11, and 13-16"
                    ]
                  },
                  {
                    "text": "MEN2A: 98% of families haveRETmutation in exon 10 or 11"
                  },
                  {
                    "text": "Families with FMTC:RETmutation in > 85%"
                  },
                  {
                    "text": "Individuals with features suggestive of MEN2B: Mutation analysis or sequencing of exons 16 and 15 to detect p.M918T and p.A883F mutationsIf mutation negative, testing for p.V804M in exon 14 followed by sequencing of entireRETcoding region should be performedAlthough isolated p.V804M mutation is associated with FMTC, p.V804M co-occurring with 2ndRETvariant seems to result in MEN2BThis strategy will detect > 98% of mutations in individuals with MEN2B",
                    "sub_points": [
                      "If mutation negative, testing for p.V804M in exon 14 followed by sequencing of entireRETcoding region should be performed",
                      "Although isolated p.V804M mutation is associated with FMTC, p.V804M co-occurring with 2ndRETvariant seems to result in MEN2B",
                      "This strategy will detect > 98% of mutations in individuals with MEN2B"
                    ]
                  },
                  {
                    "text": "RETmolecular genetic testing may be warranted in subsets of individuals presenting with apparently isolated adrenal pheochromocytomaOther differential diagnoses, such as VHL and succinate dehydrogenase-associated pheochromocytoma, should also be consideredTesting algorithms for genes associated with paraganglioma and pheochromocytoma have been proposed based on age of onset, location, laterality, malignancy, and family historyUnexpected germlineRETmutations are rarely (if ever) found in head and neck paraganglioma in absence of other features of MEN2 or family history of MEN2 phenotype",
                    "sub_points": [
                      "Other differential diagnoses, such as VHL and succinate dehydrogenase-associated pheochromocytoma, should also be considered",
                      "Testing algorithms for genes associated with paraganglioma and pheochromocytoma have been proposed based on age of onset, location, laterality, malignancy, and family history",
                      "Unexpected germlineRETmutations are rarely (if ever) found in head and neck paraganglioma in absence of other features of MEN2 or family history of MEN2 phenotype"
                    ]
                  },
                  {
                    "text": "Other clinical presentations may prompt consideration of genetic testingExon 10 sequencing should be considered in individuals with HSCR",
                    "sub_points": [
                      "Exon 10 sequencing should be considered in individuals with HSCR"
                    ]
                  },
                  {
                    "text": "Differential diagnosis in persons with intestinal ganglioneuromatosis should include MEN2B, and RET testing may be considered"
                  },
                  {
                    "text": "Rarely, germlineRETmutation may not be detected in family with clinical diagnosis of MEN2A, MEN2B, or FMTC"
                  }
                ],
                "Genetic Testing, FMTC": [
                  {
                    "text": "Germline point mutation inRETgene on chromosome 10q11.2 is responsible for hereditary MTC"
                  }
                ],
                "Testing of Relatives at Risk": [
                  {
                    "text": "At-risk relatives should be periodically screened forMTC with neck ultrasound examination and basal &/or stimulated calcitonin measurementsHPT with albumin-corrected calcium or ionized calciumPCC with measurement of plasma or 24-hour urine metanephrine and normetanephrine",
                    "sub_points": [
                      "MTC with neck ultrasound examination and basal &/or stimulated calcitonin measurements",
                      "HPT with albumin-corrected calcium or ionized calcium",
                      "PCC with measurement of plasma or 24-hour urine metanephrine and normetanephrine"
                    ]
                  },
                  {
                    "text": "RETmolecular genetic testing should be offered to probands with any MEN2 subtype and to all at-risk kindreds when a germlineRETmutation has been identified in an affected family member"
                  },
                  {
                    "text": "American Society of Clinical Oncologists identifies MEN2 as group 1 disorder, i.e., well-defined hereditary cancer syndrome for which genetic testing is considered part of standard management for at-risk family members"
                  },
                  {
                    "text": "RETmolecular genetic testing should be performed as soon as possible after birth in all children known to be at risk for MEN2B"
                  },
                  {
                    "text": "In families with MEN2A or FMTC, molecular genetic testing should be offered to at-risk children by age 5 years, as MTC has been documented in childhood"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Familial Adenomatous Polyposis": {
            "name": "Familial Adenomatous Polyposis",
            "url": "https://app.pathprimer.com/document/2297b31e-4183-465a-aa01-ec0b55c33776/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Familial adenomatous polyposis (FAP)"
                  },
                  {
                    "text": "Attenuated familial adenomatous polyposis (AFAP)"
                  },
                  {
                    "text": "Congenital hypertrophy of retinal pigment epithelium (CHRPE)"
                  },
                  {
                    "text": "Colorectal carcinoma (CRC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Adenomatous polyposis coli (APC), familial polyposis coli, Gardner syndrome, Turcot syndrome, Crail syndrome, Bussey-Gardner polyposis"
                  }
                ]
              },
              "Epidemiology": {
                "Age Range": [
                  {
                    "text": "1st adenomas detected between ages 10 and 20 years"
                  },
                  {
                    "text": "Mean age of diagnosis: 34-36 years if not in a known kindred undergoing screening"
                  },
                  {
                    "text": "Mean age of CRC: 40-42 years, but can occur in teenagers"
                  }
                ],
                "Incidence": [
                  {
                    "text": "0.003-0.015% of population"
                  },
                  {
                    "text": "Most common genetic polyposis syndromeFAP accounts for < 1% of all CRCs",
                    "sub_points": [
                      "FAP accounts for < 1% of all CRCs"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Adenomas increase in size and number with agePolyp count and patient age predict cancer riskAs in sporadic adenomas, only a small percentage progress to cancer",
                    "sub_points": [
                      "Polyp count and patient age predict cancer risk",
                      "As in sporadic adenomas, only a small percentage progress to cancer"
                    ]
                  },
                  {
                    "text": "AFAP: Fewer adenomas at a later onset (~ 15 years later than FAP)Upper GI lesions almost always present, but extraintestinal manifestations rareLower risk of developing CRCPhenotype identical toMYH-associated polyposis, which is autosomal recessiveRequires genetic testing to differentiate the 2",
                    "sub_points": [
                      "Upper GI lesions almost always present, but extraintestinal manifestations rare",
                      "Lower risk of developing CRC",
                      "Phenotype identical toMYH-associated polyposis, which is autosomal recessiveRequires genetic testing to differentiate the 2",
                      "Requires genetic testing to differentiate the 2"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "M = F"
                  }
                ]
              },
              "Genetics": {
                "Germline Mutation inAPCGene": [
                  {
                    "text": "Tumor suppressor gene that downregulates β-catenin (Wnt signaling pathway)Controls cell cycle and stabilizes microtubules",
                    "sub_points": [
                      "Controls cell cycle and stabilizes microtubules"
                    ]
                  },
                  {
                    "text": "Located on chromosome 5q21-22"
                  },
                  {
                    "text": "SpecificAPCmutations correlate with phenotypesAFAP associated with mutations at 3' and 5' ends ofAPCgene, whereas CHRPEs, osteomas, desmoids, and epidermal cysts are associated with mutations in middle of geneHot spot for severe polyposis phenotype at codon 1309More polyps and earlier onset of CRC in families with mutations near this hot spot",
                    "sub_points": [
                      "AFAP associated with mutations at 3' and 5' ends ofAPCgene, whereas CHRPEs, osteomas, desmoids, and epidermal cysts are associated with mutations in middle of gene",
                      "Hot spot for severe polyposis phenotype at codon 1309More polyps and earlier onset of CRC in families with mutations near this hot spot",
                      "More polyps and earlier onset of CRC in families with mutations near this hot spot"
                    ]
                  },
                  {
                    "text": "30-40% of FAP cases arise de novo (no family history)Cause of these spontaneous mutations unknown",
                    "sub_points": [
                      "Cause of these spontaneous mutations unknown"
                    ]
                  },
                  {
                    "text": "APCI1307K mutationAutosomal dominant mutation that imparts a 10-20% lifetime CRC riskNo polyposis or extracolonic manifestationsAffects 6% of Ashkenazi JewsRendersAPCgene susceptible to further mutations that lead to CRC",
                    "sub_points": [
                      "Autosomal dominant mutation that imparts a 10-20% lifetime CRC risk",
                      "No polyposis or extracolonic manifestations",
                      "Affects 6% of Ashkenazi Jews",
                      "RendersAPCgene susceptible to further mutations that lead to CRC"
                    ]
                  }
                ]
              },
              "Clinical Implications": {
                "Clinical Presentation": [
                  {
                    "text": "Rectal bleeding, diarrhea, colicky abdominal pain, mucous discharge, intussusception"
                  },
                  {
                    "text": "Rarely, severe electrolyte depletion can occur with diffuse polyposis"
                  },
                  {
                    "text": "Acute pancreatitis due to adenoma obstructing ampulla/pancreatic duct"
                  }
                ],
                "Imaging Findings": [
                  {
                    "text": "Polyps can be detected in both upper GI and lower GI locations, especially with fluoroscopic-guided barium enema"
                  },
                  {
                    "text": "Osteomas of jaw in Gardner syndrome can be identified on radiographs"
                  },
                  {
                    "text": "Desmoid tumors in Gardner syndrome can be identified on CT"
                  }
                ]
              },
              "Macroscopic Findings": {
                "General Features": [
                  {
                    "text": "Diagnostic criteria for FAP (any of the following)≥ 100 colorectal adenomas (classical FAP)< 100 colorectal adenomas in AFAPGermlineAPCmutationFamily history of FAP plus at least 1 of the followingEpidermoid cyst, osteoma, desmoid",
                    "sub_points": [
                      "≥ 100 colorectal adenomas (classical FAP)",
                      "< 100 colorectal adenomas in AFAP",
                      "GermlineAPCmutation",
                      "Family history of FAP plus at least 1 of the followingEpidermoid cyst, osteoma, desmoid",
                      "Epidermoid cyst, osteoma, desmoid"
                    ]
                  }
                ],
                "Endoscopic Findings": [
                  {
                    "text": "Hundreds of small sessile adenomas carpet the colonSimilar location as in sporadic adenomas with predilection for rectosigmoidSome larger pedunculated polypsMay have rectal sparing in AFAP",
                    "sub_points": [
                      "Similar location as in sporadic adenomas with predilection for rectosigmoid",
                      "Some larger pedunculated polyps",
                      "May have rectal sparing in AFAP"
                    ]
                  },
                  {
                    "text": "CRC distribution follows adenomas (70-80% left-sided)Often multiple CRCs, either synchronous or metachronous",
                    "sub_points": [
                      "Often multiple CRCs, either synchronous or metachronous"
                    ]
                  }
                ],
                "Specimen Handling": [
                  {
                    "text": "Total resectionAside from taking sections of all large polyps to look for invasive carcinoma, face-down sections of the flat mucosa can be taken to show unicryptal adenomas that are pathognomonic of FAP (so-called Bussey section)",
                    "sub_points": [
                      "Aside from taking sections of all large polyps to look for invasive carcinoma, face-down sections of the flat mucosa can be taken to show unicryptal adenomas that are pathognomonic of FAP (so-called Bussey section)"
                    ]
                  }
                ]
              },
              "Microscopic Findings": {
                "General Features": [
                  {
                    "text": "Colonic adenomas look identical to sporadic counterparts"
                  },
                  {
                    "text": "Presence of unicryptal adenomas in flat mucosa diagnostic of FAP"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Other GI (Extracolonic Lesions)": [
                  {
                    "text": "Small intestineMostly duodenal/ampullary adenomasPossible cocarcinogenic effect of bile10-15 years later than colonic adenomas but 30 years earlier than general population50-100% of FAP patients have these on routine screening (50-100%)Cumulative cancer risk: 2-10%Common cause of death in patients who have had a prophylactic colectomy (20%)",
                    "sub_points": [
                      "Mostly duodenal/ampullary adenomasPossible cocarcinogenic effect of bile10-15 years later than colonic adenomas but 30 years earlier than general population50-100% of FAP patients have these on routine screening (50-100%)Cumulative cancer risk: 2-10%Common cause of death in patients who have had a prophylactic colectomy (20%)",
                      "Possible cocarcinogenic effect of bile",
                      "10-15 years later than colonic adenomas but 30 years earlier than general population",
                      "50-100% of FAP patients have these on routine screening (50-100%)",
                      "Cumulative cancer risk: 2-10%",
                      "Common cause of death in patients who have had a prophylactic colectomy (20%)"
                    ]
                  },
                  {
                    "text": "StomachMostly fundic gland polyps (40-60%)More numerous, occurring at a younger age, and more likely to have dysplasia (up to 25%) than sporadicAntral adenomas (6%)Gastric cancer is rare, but cases have been reported",
                    "sub_points": [
                      "Mostly fundic gland polyps (40-60%)More numerous, occurring at a younger age, and more likely to have dysplasia (up to 25%) than sporadic",
                      "More numerous, occurring at a younger age, and more likely to have dysplasia (up to 25%) than sporadic",
                      "Antral adenomas (6%)",
                      "Gastric cancer is rare, but cases have been reported"
                    ]
                  },
                  {
                    "text": "LiverIncreasing rate of hepatoblastomas in male infantsRare hepatic adenomas and hepatocellular carcinomasRare malignant embryonal tumor",
                    "sub_points": [
                      "Increasing rate of hepatoblastomas in male infants",
                      "Rare hepatic adenomas and hepatocellular carcinomas",
                      "Rare malignant embryonal tumor"
                    ]
                  },
                  {
                    "text": "PancreasAdenocarcinomaRare reports of intraductal mucinous neoplasms",
                    "sub_points": [
                      "Adenocarcinoma",
                      "Rare reports of intraductal mucinous neoplasms"
                    ]
                  },
                  {
                    "text": "Biliary tractAdenocarcinoma and dysplasia of bile ducts and gallbladder",
                    "sub_points": [
                      "Adenocarcinoma and dysplasia of bile ducts and gallbladder"
                    ]
                  }
                ],
                "Extraintestinal Manifestations": [
                  {
                    "text": "Soft tissue (10-30% of FAP patients)Fibromatosis (desmoid tumors)Locally aggressive (even fatal) but \"benign\" tumors: Do not metastasize2nd most common cause of death in FAP patients (after CRC)UnencapsulatedHereditary desmoid disease: RareAPCmutation that causes multiple desmoids and other extraintestinal manifestations without colonic diseaseMost common in small bowel mesenteryOften post surgery/traumaHormones may affect growth (pregnancy, estrogen); tamoxifen sometimes used for treatment",
                    "sub_points": [
                      "Fibromatosis (desmoid tumors)Locally aggressive (even fatal) but \"benign\" tumors: Do not metastasize2nd most common cause of death in FAP patients (after CRC)UnencapsulatedHereditary desmoid disease: RareAPCmutation that causes multiple desmoids and other extraintestinal manifestations without colonic diseaseMost common in small bowel mesenteryOften post surgery/traumaHormones may affect growth (pregnancy, estrogen); tamoxifen sometimes used for treatment",
                      "Locally aggressive (even fatal) but \"benign\" tumors: Do not metastasize",
                      "2nd most common cause of death in FAP patients (after CRC)",
                      "Unencapsulated",
                      "Hereditary desmoid disease: RareAPCmutation that causes multiple desmoids and other extraintestinal manifestations without colonic disease",
                      "Most common in small bowel mesentery",
                      "Often post surgery/trauma",
                      "Hormones may affect growth (pregnancy, estrogen); tamoxifen sometimes used for treatment"
                    ]
                  },
                  {
                    "text": "BonesMultiple osteomas of the skull, long bones, and mandible",
                    "sub_points": [
                      "Multiple osteomas of the skull, long bones, and mandible"
                    ]
                  },
                  {
                    "text": "Teeth (70-80% of FAP patients)Impaction, supernumerary/absent, abnormal roots",
                    "sub_points": [
                      "Impaction, supernumerary/absent, abnormal roots"
                    ]
                  },
                  {
                    "text": "Eye (75-90% of FAP patients)Congenital hypertrophy of retinal pigment epithelium (CHRPE)Pigmented fundus lesionEarliest manifestation of FAP; can be seen in young infants",
                    "sub_points": [
                      "Congenital hypertrophy of retinal pigment epithelium (CHRPE)Pigmented fundus lesionEarliest manifestation of FAP; can be seen in young infants",
                      "Pigmented fundus lesion",
                      "Earliest manifestation of FAP; can be seen in young infants"
                    ]
                  },
                  {
                    "text": "SkinMultiple epidermal inclusion cysts of face and scalpLipomas, fibromas, sebaceous cysts",
                    "sub_points": [
                      "Multiple epidermal inclusion cysts of face and scalp",
                      "Lipomas, fibromas, sebaceous cysts"
                    ]
                  },
                  {
                    "text": "Endocrine systemPapillary thyroid carcinoma, cribriform morular variant, in womenAdrenal cortical neoplasmsPancreatic islet cell neoplasmsRare reports of parathyroid and pituitary adenomas",
                    "sub_points": [
                      "Papillary thyroid carcinoma, cribriform morular variant, in women",
                      "Adrenal cortical neoplasms",
                      "Pancreatic islet cell neoplasms",
                      "Rare reports of parathyroid and pituitary adenomas"
                    ]
                  },
                  {
                    "text": "Brain (Turcot syndrome)Hereditary CRC & brain tumorFAP patients: MedulloblastomasLynch patients: Gliomas",
                    "sub_points": [
                      "Hereditary CRC & brain tumorFAP patients: MedulloblastomasLynch patients: Gliomas",
                      "FAP patients: Medulloblastomas",
                      "Lynch patients: Gliomas"
                    ]
                  },
                  {
                    "text": "Head and neckNasopharyngeal angiofibroma",
                    "sub_points": [
                      "Nasopharyngeal angiofibroma"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Surgery": [
                  {
                    "text": "Prophylactic colectomy with ileoanal pouch anastomosis is surgical treatment of choice"
                  },
                  {
                    "text": "Goal is to do this when patient is in their teens (if diagnosis can be established this early)"
                  },
                  {
                    "text": "Patients will still require surveillance of pouch to remove adenomas"
                  },
                  {
                    "text": "Upper endoscopy with biopsy of gastric and duodenal polypsMost duodenal/ampullary adenomas can be excised endoscopically, but some may require a Whipple procedure",
                    "sub_points": [
                      "Most duodenal/ampullary adenomas can be excised endoscopically, but some may require a Whipple procedure"
                    ]
                  },
                  {
                    "text": "Surgical excision of desmoids (when possible)"
                  }
                ],
                "Medical Management": [
                  {
                    "text": "Chemoprevention of polyps with indomethacin and other NSAIDs"
                  },
                  {
                    "text": "Medical treatment of desmoids includes hormonal therapy, imatinib, and NSAIDs"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Protein truncation test (PTT)Looks for abnormally shortened APC protein in exon 15",
                    "sub_points": [
                      "Looks for abnormally shortened APC protein in exon 15"
                    ]
                  },
                  {
                    "text": "Gene sequencingAPCgene is very large; hence, sequencing is difficultSequencing is done to try and predict phenotype of affected family members (likelihood of desmoids or severe phenotype)Latest techniques are about 95% sensitive in detecting mutations in classic FAP, < 30% in AFAPImportant to test forMYH-associated polyposis if these tests are negativeMultiplex ligation probe amplification (MLPA) is used to look for large deletions and duplications",
                    "sub_points": [
                      "APCgene is very large; hence, sequencing is difficultSequencing is done to try and predict phenotype of affected family members (likelihood of desmoids or severe phenotype)",
                      "Sequencing is done to try and predict phenotype of affected family members (likelihood of desmoids or severe phenotype)",
                      "Latest techniques are about 95% sensitive in detecting mutations in classic FAP, < 30% in AFAPImportant to test forMYH-associated polyposis if these tests are negative",
                      "Important to test forMYH-associated polyposis if these tests are negative",
                      "Multiplex ligation probe amplification (MLPA) is used to look for large deletions and duplications"
                    ]
                  },
                  {
                    "text": "Sequencing of exons 1-14 coupled with PTT of exon 15 is one commonly used testing strategyIf PTT is positive, then exon 15 can be sequenced",
                    "sub_points": [
                      "If PTT is positive, then exon 15 can be sequenced"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Peutz-Jeghers Syndrome": {
            "name": "Peutz-Jeghers Syndrome",
            "url": "https://app.pathprimer.com/document/c784c769-a626-40b7-b60d-f69180a34efe/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Peutz-Jeghers syndrome (PJS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "PJS is characterized byPigmented melanotic lesions around lips, oral cavity, and genitalsHamartomatous polyposis of gastrointestinal (GI) tractIncreased risk of cancers in the GI tract, pancreas, gynecologic tract, testis, breast, lung, and thyroidAutosomal dominant inheritance25% of cases appear de novo",
                    "sub_points": [
                      "Pigmented melanotic lesions around lips, oral cavity, and genitals",
                      "Hamartomatous polyposis of gastrointestinal (GI) tract",
                      "Increased risk of cancers in the GI tract, pancreas, gynecologic tract, testis, breast, lung, and thyroid",
                      "Autosomal dominant inheritance25% of cases appear de novo",
                      "25% of cases appear de novo"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Prevalence": [
                  {
                    "text": "Exact prevalence is unknown; estimates range from 1 in 8,500 to 1 in 300,000 live births"
                  },
                  {
                    "text": "No gender or racial predominance"
                  }
                ]
              },
              "Genetics": {
                "LKB1Gene": [
                  {
                    "text": "Also known asSTK11"
                  },
                  {
                    "text": "Serine-threonine kinase that is thought to behave like a tumor suppressor gene"
                  },
                  {
                    "text": "Important in controlling cell proliferation"
                  },
                  {
                    "text": "Regulates mTOR pathwayClinical trials using mTOR pathway inhibitors (rapamycin analogues) for chemoprevention are currently underway in PJS patients and have shown promising early results",
                    "sub_points": [
                      "Clinical trials using mTOR pathway inhibitors (rapamycin analogues) for chemoprevention are currently underway in PJS patients and have shown promising early results"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Presentation": [
                  {
                    "text": "Pigmentation of lips and oral and genital mucosa seen in infancy and early childhoodLips most common site (> 95%)Pigmentation may fade with age",
                    "sub_points": [
                      "Lips most common site (> 95%)",
                      "Pigmentation may fade with age"
                    ]
                  },
                  {
                    "text": "GI tract symptomsAbdominal pain due to obstruction/intussusceptionPolyps arise in stomach (50%), small bowel (65%), and colon (50%)Anemia due to occult or frank GI tract bleedingHematemesis in patients with gastric and duodenal polyposisProlapse of rectal polyps",
                    "sub_points": [
                      "Abdominal pain due to obstruction/intussusceptionPolyps arise in stomach (50%), small bowel (65%), and colon (50%)",
                      "Polyps arise in stomach (50%), small bowel (65%), and colon (50%)",
                      "Anemia due to occult or frank GI tract bleedingHematemesis in patients with gastric and duodenal polyposis",
                      "Hematemesis in patients with gastric and duodenal polyposis",
                      "Prolapse of rectal polyps"
                    ]
                  },
                  {
                    "text": "Associated skeletal abnormalitiesClub foot and scoliosis",
                    "sub_points": [
                      "Club foot and scoliosis"
                    ]
                  }
                ],
                "Diagnostic Criteria": [
                  {
                    "text": "≥ 2 histologically confirmed Peutz-Jeghers polyps (PJPs)Even patients with only a single PJP seem to have an increased risk of cancer",
                    "sub_points": [
                      "Even patients with only a single PJP seem to have an increased risk of cancer"
                    ]
                  },
                  {
                    "text": "Any number of PJPs in a patient with a family history of PJS"
                  },
                  {
                    "text": "Any number of PJPs in a patient with mucocutaneous pigmentation"
                  },
                  {
                    "text": "Mucocutaneous pigmentation in a patient with a family history of PJS"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Sequencing theLKB1gene identifies a mutation in 50-70% of casesNeed to look for both protein-truncating mutations as well as large deletions",
                    "sub_points": [
                      "Need to look for both protein-truncating mutations as well as large deletions"
                    ]
                  },
                  {
                    "text": "Gene inactivation theorized in cases that test negative"
                  }
                ]
              },
              "Associated Neoplasms": {
                "GI Tract Neoplasms": [
                  {
                    "text": "Adenocarcinoma of small bowelCumulative risk: 13%",
                    "sub_points": [
                      "Cumulative risk: 13%"
                    ]
                  },
                  {
                    "text": "Adenocarcinoma of colonCumulative risk: 39%Mean age of diagnosis: ~ 46 years",
                    "sub_points": [
                      "Cumulative risk: 39%",
                      "Mean age of diagnosis: ~ 46 years"
                    ]
                  },
                  {
                    "text": "Adenocarcinoma of pancreasCumulative risk: 36% (100x risk in general population)",
                    "sub_points": [
                      "Cumulative risk: 36% (100x risk in general population)"
                    ]
                  },
                  {
                    "text": "Adenocarcinoma of stomachCumulative risk: 29%",
                    "sub_points": [
                      "Cumulative risk: 29%"
                    ]
                  }
                ],
                "Other Neoplasms": [
                  {
                    "text": "Carcinoma of breastAbsolute risk: ~ 54%",
                    "sub_points": [
                      "Absolute risk: ~ 54%"
                    ]
                  },
                  {
                    "text": "Ovarian sex cord tumors with annular tubules"
                  },
                  {
                    "text": "Adenoma malignum of cervix"
                  },
                  {
                    "text": "Mucinous tumors of ovaries and fallopian tubesAbsolute risk: 10%",
                    "sub_points": [
                      "Absolute risk: 10%"
                    ]
                  },
                  {
                    "text": "Bronchioalveolar carcinomas of lung"
                  },
                  {
                    "text": "Testicular sex cord and Sertoli cell tumorsAbsolute risk: 9%",
                    "sub_points": [
                      "Absolute risk: 9%"
                    ]
                  },
                  {
                    "text": "Papillary thyroid cancer"
                  },
                  {
                    "text": "Overall cumulative cancer risk: 93% at age 65"
                  }
                ]
              },
              "Microscopic Findings": {
                "Hamartomatous Polyps": [
                  {
                    "text": "Polyps classically have arborizing bands of smooth muscle with a papillary architectureBest seen in small bowel polyps; stomach and colon polyps may lack classic features and thus can be difficult to diagnose",
                    "sub_points": [
                      "Best seen in small bowel polyps; stomach and colon polyps may lack classic features and thus can be difficult to diagnose"
                    ]
                  },
                  {
                    "text": "Epithelium is nonneoplastic and has a lobular growth patternEpithelium frequently is trapped in bands of smooth muscle; do not overinterpret this finding as carcinomaDysplasia has hardly ever been found in PJPs, suggesting that cancer may arise by a different mechanism",
                    "sub_points": [
                      "Epithelium frequently is trapped in bands of smooth muscle; do not overinterpret this finding as carcinoma",
                      "Dysplasia has hardly ever been found in PJPs, suggesting that cancer may arise by a different mechanism"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Endoscopic Surveillance": [
                  {
                    "text": "Baseline upper and lower endoscopy at age 8, to be repeated every 2-3 years"
                  },
                  {
                    "text": "Endoscopic removal of small polypsSurgery may be necessary for obstructing polyps or intussusception",
                    "sub_points": [
                      "Surgery may be necessary for obstructing polyps or intussusception"
                    ]
                  }
                ],
                "Radiologic Surveillance": [
                  {
                    "text": "Transvaginal ultrasound, serum CA-125, and Pap smears annually beginning between age 20 and 25 for gynecologic (GYN) tumors"
                  },
                  {
                    "text": "Endoscopic ultrasound, abdominal CT, and CA-19-9 every 1-2 years starting between age 25 and 30 for pancreas tumors"
                  },
                  {
                    "text": "Mammography or MR annually starting at age 25 for breast cancer"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Gastrointestinal Stromal Tumor": {
            "name": "Gastrointestinal Stromal Tumor",
            "url": "https://app.pathprimer.com/document/f8f5c44e-60d6-49e2-8bc0-2eee3f5ec09e/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Mural-based mesenchymal tumor of gastrointestinal (GI) tract with differentiation toward interstitial cells of Cajal and characteristic histologic, immunohistochemical, and molecular features"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Acquired mutually exclusiveKITorPDGFRAmutations in most casesKITsomatic mutation in 75% of casesPDGFRAsomatic mutation in 10% of casesPromotes ligand-independent cell proliferation",
                    "sub_points": [
                      "KITsomatic mutation in 75% of cases",
                      "PDGFRAsomatic mutation in 10% of cases",
                      "Promotes ligand-independent cell proliferation"
                    ]
                  },
                  {
                    "text": "KITandPDGFRAwildtype GISTMost demonstrate lack of function of succinate dehydrogenase (SDH) complex (SDH-deficient GIST)Comprise 8% of all gastric GISTBRAFmutationActivation of RAS/RAF/MEK pathway",
                    "sub_points": [
                      "Most demonstrate lack of function of succinate dehydrogenase (SDH) complex (SDH-deficient GIST)Comprise 8% of all gastric GIST",
                      "Comprise 8% of all gastric GIST",
                      "BRAFmutationActivation of RAS/RAF/MEK pathway",
                      "Activation of RAS/RAF/MEK pathway"
                    ]
                  },
                  {
                    "text": "Genetic factors and syndrome associationsNeurofibromatosis type 1 (NF1)Familial GIST syndromeCarney-Stratakis dyadCarney triad",
                    "sub_points": [
                      "Neurofibromatosis type 1 (NF1)",
                      "Familial GIST syndrome",
                      "Carney-Stratakis dyad",
                      "Carney triad"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most common GI mesenchymal neoplasm"
                  },
                  {
                    "text": "Nonspecific symptoms at presentation"
                  },
                  {
                    "text": "Tumor behavior is primarily determined by location, size, mitotic rate, and mutation status"
                  },
                  {
                    "text": "Specific mutations render important information regarding treatment options"
                  },
                  {
                    "text": "Primary treatment consists of surgery and tyrosine kinase inhibitors (TKIs)"
                  },
                  {
                    "text": "Imatinib TKITumor response depends on specific mutationAcquired resistance may occur due to secondary resistance-associated mutations",
                    "sub_points": [
                      "Tumor response depends on specific mutation",
                      "Acquired resistance may occur due to secondary resistance-associated mutations"
                    ]
                  },
                  {
                    "text": "2nd generation TKIsMultikinase inhibitors, which act on other tyrosine kinases, such as VEGFR in addition to PDGFRA and KITUsed to overcome imatinib TKI resistance",
                    "sub_points": [
                      "Multikinase inhibitors, which act on other tyrosine kinases, such as VEGFR in addition to PDGFRA and KIT",
                      "Used to overcome imatinib TKI resistance"
                    ]
                  },
                  {
                    "text": "TRK inhibitors: Entrectinib/larotrectinibFor GIST withNTRK1/NTRK2/NTRK3fusions",
                    "sub_points": [
                      "For GIST withNTRK1/NTRK2/NTRK3fusions"
                    ]
                  },
                  {
                    "text": "BRAF inhibitors: Dabrafenib/trametinibFor GIST withBRAFV600E mutation",
                    "sub_points": [
                      "For GIST withBRAFV600E mutation"
                    ]
                  }
                ],
                "Molecular": [
                  {
                    "text": "Morphologic-molecular associationsSpindle cell GIST is typicallyKITmutatedAdult gastric epithelioid GIST:PDGFRAmutatedPediatric gastric epithelioid GIST: SDH deficient",
                    "sub_points": [
                      "Spindle cell GIST is typicallyKITmutated",
                      "Adult gastric epithelioid GIST:PDGFRAmutated",
                      "Pediatric gastric epithelioid GIST: SDH deficient"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunohistochemistryCD117Positive in > 90% of GIST, including nearly allKIT-mutated tumorsPositive in SDH-deficient andBRAF-mutated GISTDOG1Usually captures CD117-negative GISTPDGFRAExpressed in GIST of any typeSDHBBest stain for identifying SDH-deficient GISTSDHALoss of expression reliably predicts tumor and subsequent germlineSDHAmutation",
                    "sub_points": [
                      "CD117Positive in > 90% of GIST, including nearly allKIT-mutated tumorsPositive in SDH-deficient andBRAF-mutated GIST",
                      "Positive in > 90% of GIST, including nearly allKIT-mutated tumors",
                      "Positive in SDH-deficient andBRAF-mutated GIST",
                      "DOG1Usually captures CD117-negative GIST",
                      "Usually captures CD117-negative GIST",
                      "PDGFRAExpressed in GIST of any type",
                      "Expressed in GIST of any type",
                      "SDHBBest stain for identifying SDH-deficient GIST",
                      "Best stain for identifying SDH-deficient GIST",
                      "SDHALoss of expression reliably predicts tumor and subsequent germlineSDHAmutation",
                      "Loss of expression reliably predicts tumor and subsequent germlineSDHAmutation"
                    ]
                  },
                  {
                    "text": "Gene mutation testingKIT,PDGFRA,BRAF,NF1,NTRK1/NTRK2/NTRK3, andFGFRanalysis by NGS panelGenetics referral required for the followingKIT,PDGFRA, and SDHB IHC negative tumorsNF1mutation-positive tumorsEvaluation may include germline mutation analysis",
                    "sub_points": [
                      "KIT,PDGFRA,BRAF,NF1,NTRK1/NTRK2/NTRK3, andFGFRanalysis by NGS panel",
                      "Genetics referral required for the followingKIT,PDGFRA, and SDHB IHC negative tumorsNF1mutation-positive tumorsEvaluation may include germline mutation analysis",
                      "KIT,PDGFRA, and SDHB IHC negative tumors",
                      "NF1mutation-positive tumors",
                      "Evaluation may include germline mutation analysis"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Gastrointestinal stromal tumor (GIST)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Mural-based mesenchymal tumor of gastrointestinal (GI) tract with differentiation toward interstitial cells of Cajal and characteristic histologic, immunohistochemical, and molecular featuresComposed of spindled &/or epithelioid cellsCD117 &/or DOG1 immunohistochemical positivity",
                    "sub_points": [
                      "Composed of spindled &/or epithelioid cells",
                      "CD117 &/or DOG1 immunohistochemical positivity"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Underlying Cause of GIST": [
                  {
                    "text": "Acquired mutually exclusiveKITorPDGFRAmutations in most casesKITsomatic mutation in 75% of casesPDGFRAsomatic mutation in 10% of casesPromotes ligand-independent cell proliferation",
                    "sub_points": [
                      "KITsomatic mutation in 75% of cases",
                      "PDGFRAsomatic mutation in 10% of cases",
                      "Promotes ligand-independent cell proliferation"
                    ]
                  },
                  {
                    "text": "KITandPDGFRAwildtype GISTMost show lack of function of succinate dehydrogenase (SDH) complex (SDH-deficient GIST)SDH subunit gene mutation in ~ 60% of casesSDHCgene promoter hypermethylation in ~ 40% of casesComprise 8% of all gastric GISTBRAF/KRASmutationsActivation of RAS/RAF/MEK pathwayComprise 7-13% of all wildtype GIST in stomach and small intestine",
                    "sub_points": [
                      "Most show lack of function of succinate dehydrogenase (SDH) complex (SDH-deficient GIST)SDH subunit gene mutation in ~ 60% of casesSDHCgene promoter hypermethylation in ~ 40% of casesComprise 8% of all gastric GIST",
                      "SDH subunit gene mutation in ~ 60% of cases",
                      "SDHCgene promoter hypermethylation in ~ 40% of cases",
                      "Comprise 8% of all gastric GIST",
                      "BRAF/KRASmutationsActivation of RAS/RAF/MEK pathwayComprise 7-13% of all wildtype GIST in stomach and small intestine",
                      "Activation of RAS/RAF/MEK pathway",
                      "Comprise 7-13% of all wildtype GIST in stomach and small intestine"
                    ]
                  },
                  {
                    "text": "Genetic factors and syndrome associationsNeurofibromatosis type 1 (NF1)Inactivating germline mutations inNF1Constitutes 1-2% of all GISTMultifocal, most commonly involves small bowelFamilial GIST syndromeGermline mutations inKIT or PDGFRAMultiple GIST along GI tractAssociated with aggressive behaviorCarney-Stratakis dyadAD disorder with germline mutations inSDHGIST in pediatric, adolescent, and young adult patientsGIST and paragangliomasCarney triadSDH-deficiency bySDHCgene promoter hypermethylationPredominantly affects young womenGIST, pulmonary chondroma, and paraganglioma",
                    "sub_points": [
                      "Neurofibromatosis type 1 (NF1)Inactivating germline mutations inNF1Constitutes 1-2% of all GISTMultifocal, most commonly involves small bowel",
                      "Inactivating germline mutations inNF1",
                      "Constitutes 1-2% of all GIST",
                      "Multifocal, most commonly involves small bowel",
                      "Familial GIST syndromeGermline mutations inKIT or PDGFRAMultiple GIST along GI tractAssociated with aggressive behavior",
                      "Germline mutations inKIT or PDGFRA",
                      "Multiple GIST along GI tract",
                      "Associated with aggressive behavior",
                      "Carney-Stratakis dyadAD disorder with germline mutations inSDHGIST in pediatric, adolescent, and young adult patientsGIST and paragangliomas",
                      "AD disorder with germline mutations inSDH",
                      "GIST in pediatric, adolescent, and young adult patients",
                      "GIST and paragangliomas",
                      "Carney triadSDH-deficiency bySDHCgene promoter hypermethylationPredominantly affects young womenGIST, pulmonary chondroma, and paraganglioma",
                      "SDH-deficiency bySDHCgene promoter hypermethylation",
                      "Predominantly affects young women",
                      "GIST, pulmonary chondroma, and paraganglioma"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Most common GI mesenchymal neoplasm"
                  },
                  {
                    "text": "10-20 per million annually"
                  },
                  {
                    "text": "Subclinical GIST more commonUp to 25% incidence of small incidental gastric GIST seen at autopsy",
                    "sub_points": [
                      "Up to 25% incidence of small incidental gastric GIST seen at autopsy"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Older adults inKITandPDGFRA-mutated GIST (median: 60-65 years)"
                  },
                  {
                    "text": "Young adults and children in SDH-deficient GISTNearly all gastric GIST in patients < 21 years of age SDH deficient",
                    "sub_points": [
                      "Nearly all gastric GIST in patients < 21 years of age SDH deficient"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "No sex preference for adult GIST"
                  },
                  {
                    "text": "Strong female predilection for pediatric SDH-deficient GIST"
                  }
                ],
                "Site": [
                  {
                    "text": "Stomach: ~ 60%"
                  },
                  {
                    "text": "Jejunum/ileum: ~ 30%"
                  },
                  {
                    "text": "Duodenum: ~ 5%"
                  },
                  {
                    "text": "Rectum: < 5%"
                  },
                  {
                    "text": "Very rare in esophagus and appendix"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Nonspecific symptomsGastric discomfortGI obstructionGI bleedingAsymptomatic abdominal mass",
                    "sub_points": [
                      "Gastric discomfort",
                      "GI obstruction",
                      "GI bleeding",
                      "Asymptomatic abdominal mass"
                    ]
                  }
                ],
                "Endoscopic Findings": [
                  {
                    "text": "Round, mural, nonmucosal-based mass"
                  },
                  {
                    "text": "Small GIST usually found incidentally"
                  }
                ],
                "Treatment": [],
                "Options, risks, complications": [
                  {
                    "text": "Primary treatment consists of surgery and tyrosine kinase inhibitors (TKIs)"
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "Wedge resection for single gastric GIST < 5 cm"
                  },
                  {
                    "text": "Distal gastrectomy for large GIST involving pylorus or lesser curvature"
                  },
                  {
                    "text": "Total gastrectomy for large, multiple, or recurrent GIST"
                  },
                  {
                    "text": "Segmental resection for intestinal GIST"
                  },
                  {
                    "text": "Risk of peritoneal seeding with extensive tumor manipulation and rupture"
                  }
                ],
                "Drugs": [
                  {
                    "text": "Imatinib (Gleevec) TKIInhibits receptor tyrosine kinases, including KITTumor response depends on specific mutationNeoadjuvant therapy to shrink GIST before surgery1st-line drug of choice to prevent recurrence in high-risk resected tumorsAcquired resistance may occur due to secondary resistance-associated mutations",
                    "sub_points": [
                      "Inhibits receptor tyrosine kinases, including KIT",
                      "Tumor response depends on specific mutation",
                      "Neoadjuvant therapy to shrink GIST before surgery",
                      "1st-line drug of choice to prevent recurrence in high-risk resected tumors",
                      "Acquired resistance may occur due to secondary resistance-associated mutations"
                    ]
                  },
                  {
                    "text": "2nd-generation TKIsMultikinase inhibitors, which act on other tyrosine kinases, such as VEGFR in addition to PDGFRA and KITUsed to overcome imatinib resistanceAvapritinibFDA-approved for GIST withPDGFRAexon 18 or D842V mutationSunitinib, regorafenib, and pazopanibFor unresectable SDH-deficient GISTRipretinib for patients already treated with ≥ 3 TKIs",
                    "sub_points": [
                      "Multikinase inhibitors, which act on other tyrosine kinases, such as VEGFR in addition to PDGFRA and KIT",
                      "Used to overcome imatinib resistance",
                      "AvapritinibFDA-approved for GIST withPDGFRAexon 18 or D842V mutation",
                      "FDA-approved for GIST withPDGFRAexon 18 or D842V mutation",
                      "Sunitinib, regorafenib, and pazopanibFor unresectable SDH-deficient GIST",
                      "For unresectable SDH-deficient GIST",
                      "Ripretinib for patients already treated with ≥ 3 TKIs"
                    ]
                  },
                  {
                    "text": "TRK inhibitors: Entrectinib/larotrectinibFor GIST withNTRK1/NTRK2/NTRK3fusionsNCCN recommends as preferred 1st-line treatment",
                    "sub_points": [
                      "For GIST withNTRK1/NTRK2/NTRK3fusions",
                      "NCCN recommends as preferred 1st-line treatment"
                    ]
                  },
                  {
                    "text": "BRAF inhibitors: Dabrafenib/trametinibFor GIST withBRAFV600E mutation",
                    "sub_points": [
                      "For GIST withBRAFV600E mutation"
                    ]
                  },
                  {
                    "text": "Other drugs under investigationTemozolomide for SDH-deficient GIST",
                    "sub_points": [
                      "Temozolomide for SDH-deficient GIST"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Risk stratificationMalignant potential determined by anatomic site, tumor size, and mitotic rate per 50 HPF forKIT-andPDGFRA-mutated GIST",
                    "sub_points": [
                      "Malignant potential determined by anatomic site, tumor size, and mitotic rate per 50 HPF forKIT-andPDGFRA-mutated GIST"
                    ]
                  },
                  {
                    "text": "Mutation statusKIT-mutated GIST more aggressive thanPDGFRA-mutated or triple-negative (KIT/PDGFRA/BRAF) GISTPDGFRAexon 12,BRAF, andKITexon 11 mutations associated with most favorable outcomeKITexon 9 andPDGFRAexon 18 (non-D842V) mutations have worst outcome",
                    "sub_points": [
                      "KIT-mutated GIST more aggressive thanPDGFRA-mutated or triple-negative (KIT/PDGFRA/BRAF) GIST",
                      "PDGFRAexon 12,BRAF, andKITexon 11 mutations associated with most favorable outcome",
                      "KITexon 9 andPDGFRAexon 18 (non-D842V) mutations have worst outcome"
                    ]
                  },
                  {
                    "text": "Less aggressive behavior seen inGastric GISTPDGFRA-mutated GIST",
                    "sub_points": [
                      "Gastric GIST",
                      "PDGFRA-mutated GIST"
                    ]
                  },
                  {
                    "text": "Intestinal and SDH-deficient GIST much less predictable thanKIT-/PDGFRA-mutated GIST with same prognostic factorsLifelong follow-up required due to 20-25% risk of liver metastases and risk of developing other syndrome-related tumorsLonger survival with metastatic disease compared toKIT-mutated GISTTendency toward lymph node metastases (up to 10%) compared to other GIST, though this does not adversely affect prognosisMore prone to recurrence compared toKIT- andPDGFRA-mutated GIST",
                    "sub_points": [
                      "Lifelong follow-up required due to 20-25% risk of liver metastases and risk of developing other syndrome-related tumors",
                      "Longer survival with metastatic disease compared toKIT-mutated GIST",
                      "Tendency toward lymph node metastases (up to 10%) compared to other GIST, though this does not adversely affect prognosis",
                      "More prone to recurrence compared toKIT- andPDGFRA-mutated GIST"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "MR Findings": [
                  {
                    "text": "T1WILow signal intensity in solid componentGadolinium enhancement occurs, usually at tumor periphery",
                    "sub_points": [
                      "Low signal intensity in solid component",
                      "Gadolinium enhancement occurs, usually at tumor periphery"
                    ]
                  },
                  {
                    "text": "T2WIHigh signal intensity in solid component",
                    "sub_points": [
                      "High signal intensity in solid component"
                    ]
                  }
                ],
                "CT Findings": [
                  {
                    "text": "Peripheral contrast enhancement most common"
                  },
                  {
                    "text": "Homogeneous enhancement uncommon"
                  },
                  {
                    "text": "Central low attenuation corresponds to hemorrhage and necrosis"
                  },
                  {
                    "text": "Rare calcification"
                  }
                ],
                "Endoscopic Ultrasound": [
                  {
                    "text": "Muscularis propria-based tumor"
                  },
                  {
                    "text": "Homogeneous, hypoechoic, round lesion with smooth margins"
                  },
                  {
                    "text": "Features more common in aggressive tumorsHeterogeneous, cystic, irregular borders, and size > 3 cm",
                    "sub_points": [
                      "Heterogeneous, cystic, irregular borders, and size > 3 cm"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Well-defined, round to oval tumor in muscularis propria"
                  },
                  {
                    "text": "Firm to fleshy or gelatinous cut surface"
                  },
                  {
                    "text": "Hemorrhage and cystic degeneration in large tumors"
                  },
                  {
                    "text": "Tumor necrosis uncommon (poor prognostic factor)"
                  }
                ],
                "Size": [
                  {
                    "text": "Range from submillimeter to > 20 cm"
                  }
                ]
              },
              "MOLECULAR": {
                "KITMutations": [
                  {
                    "text": "Relative frequency: 75-80%"
                  },
                  {
                    "text": "Exon 11Highest imatinib response rateFound in 70% of GISTCommon in gastric GISTMutations include deletions, insertions, and substitutionsIsolated inframe deletions most common and usually involve 5' end between codons 550-560557 and 558 deletions associated with aggressive behavior compared to other exon 11 mutations in gastric GISTPoint mutations usually associated with benign behaviorProbability of primary resistance (defined as tumor progression within first 6 months) to imatinib is ~ 5%",
                    "sub_points": [
                      "Highest imatinib response rate",
                      "Found in 70% of GISTCommon in gastric GIST",
                      "Common in gastric GIST",
                      "Mutations include deletions, insertions, and substitutions",
                      "Isolated inframe deletions most common and usually involve 5' end between codons 550-560557 and 558 deletions associated with aggressive behavior compared to other exon 11 mutations in gastric GIST",
                      "557 and 558 deletions associated with aggressive behavior compared to other exon 11 mutations in gastric GIST",
                      "Point mutations usually associated with benign behavior",
                      "Probability of primary resistance (defined as tumor progression within first 6 months) to imatinib is ~ 5%"
                    ]
                  },
                  {
                    "text": "Exon 9Found in 10-15% of GIST, more common in jejunum/ileum6 bp insertion/duplication of AY residues encoded by codons 502-503 (most common)Probability of primary resistance: ~ 16%Shorter progression-free and overall survival compared to imatinib-treated exon 11-mutated GISTMore responsive to treatment with sunitinib",
                    "sub_points": [
                      "Found in 10-15% of GIST, more common in jejunum/ileum",
                      "6 bp insertion/duplication of AY residues encoded by codons 502-503 (most common)",
                      "Probability of primary resistance: ~ 16%",
                      "Shorter progression-free and overall survival compared to imatinib-treated exon 11-mutated GIST",
                      "More responsive to treatment with sunitinib"
                    ]
                  },
                  {
                    "text": "Exon 13 and 17Each found in ~ 1-2% of GISTPoint mutations most commonK642E in exon 13N822K in exon 17Exon 13 mutations may indicate poor prognosis in gastric GISTNo prognostic significance for exon 17 mutationsVariably sensitive to imatinib",
                    "sub_points": [
                      "Each found in ~ 1-2% of GIST",
                      "Point mutations most commonK642E in exon 13N822K in exon 17",
                      "K642E in exon 13",
                      "N822K in exon 17",
                      "Exon 13 mutations may indicate poor prognosis in gastric GIST",
                      "No prognostic significance for exon 17 mutations",
                      "Variably sensitive to imatinib"
                    ]
                  }
                ],
                "PDGFRAMutations": [
                  {
                    "text": "Relative frequency: ~ 10%"
                  },
                  {
                    "text": "Lower malignant potential thanKIT-mutated GIST"
                  },
                  {
                    "text": "Exon 18D842V most commonPDGFRAmutationFound in 5% of GISTStrongly resistant to imatinibResponds to avapritinib",
                    "sub_points": [
                      "D842V most commonPDGFRAmutation",
                      "Found in 5% of GIST",
                      "Strongly resistant to imatinib",
                      "Responds to avapritinib"
                    ]
                  },
                  {
                    "text": "Other exon 18 mutations (deletions and substitutions) uncommonFound in 1% of GISTVariable mutation-specific response to imatinib",
                    "sub_points": [
                      "Found in 1% of GIST",
                      "Variable mutation-specific response to imatinib"
                    ]
                  },
                  {
                    "text": "Exon 12V561D common, followed by insertions and deletionsFound in 1% of GISTMost respond to imatinib",
                    "sub_points": [
                      "V561D common, followed by insertions and deletions",
                      "Found in 1% of GIST",
                      "Most respond to imatinib"
                    ]
                  },
                  {
                    "text": "Exon 14N659K commonFound in < 1% of GISTNo data on imatinib response",
                    "sub_points": [
                      "N659K common",
                      "Found in < 1% of GIST",
                      "No data on imatinib response"
                    ]
                  }
                ],
                "SDH Deficiency": [
                  {
                    "text": "Relative frequency: ~ 8%"
                  },
                  {
                    "text": "SDH-deficient GIST has lack of function of SDH complexComplex consists of 4 subunits encoded by similarly named genes (SDHA,SDHB,SDHC, andSDHD)",
                    "sub_points": [
                      "Complex consists of 4 subunits encoded by similarly named genes (SDHA,SDHB,SDHC, andSDHD)"
                    ]
                  },
                  {
                    "text": "Inactivated bySDHCgene promoter hypermethylation or SDH subunit mutationsMutations include substitutions (majority), deletions, splice-site, frameshift, and duplicationsNo significant prognostic differences among various SDH mutations",
                    "sub_points": [
                      "Mutations include substitutions (majority), deletions, splice-site, frameshift, and duplications",
                      "No significant prognostic differences among various SDH mutations"
                    ]
                  },
                  {
                    "text": "SDHAis most commonly mutated gene (~ 35% frequency)Usually germline mutations with low disease penetranceSo far not associated with familial tumor syndromesOccurs in older patients (median age: 34 years)",
                    "sub_points": [
                      "Usually germline mutations with low disease penetrance",
                      "So far not associated with familial tumor syndromes",
                      "Occurs in older patients (median age: 34 years)"
                    ]
                  },
                  {
                    "text": "SDHB,SDHC, andSDHDmutations (~ 20-30% frequency)Usually germline mutations",
                    "sub_points": [
                      "Usually germline mutations"
                    ]
                  },
                  {
                    "text": "Most SDH-deficient GIST not associated with known syndrome"
                  },
                  {
                    "text": "10-20% SDH-deficient GIST associated with Carney triad or Carney-Stratakis syndrome"
                  },
                  {
                    "text": "Resistant to imatinib"
                  },
                  {
                    "text": "Potentially better efficacy with 2nd- and 3rd-generation tyrosine kinase inhibitors with anti-VEGFR activity"
                  }
                ],
                "BRAFV600E Mutation": [
                  {
                    "text": "Prognostic significance still unclear"
                  },
                  {
                    "text": "Candidate for therapy withBRAF-targeted drugs"
                  },
                  {
                    "text": "Show predilection for small bowel location"
                  }
                ],
                "Secondary Mutations": [
                  {
                    "text": "Lead to development of imatinib resistance (secondary resistance-associated mutations)"
                  },
                  {
                    "text": "Secondary resistance defined as tumor progression 12-36 months following period of good response or stable disease"
                  },
                  {
                    "text": "Seen in 44-83% of GIST that progress after imatinib treatment"
                  },
                  {
                    "text": "KITexons 13, 14, 17, and 18 are common targetsSunitinib effective against secondary exon 13 and 14 mutationsRegorafenib effective 3rd-line therapy for exon 17 and 18 mutations",
                    "sub_points": [
                      "Sunitinib effective against secondary exon 13 and 14 mutations",
                      "Regorafenib effective 3rd-line therapy for exon 17 and 18 mutations"
                    ]
                  },
                  {
                    "text": "SecondaryPDGFRAmutations less frequentUsually in exons 14 and 18",
                    "sub_points": [
                      "Usually in exons 14 and 18"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features Indicating Aggressive Behavior for all GIST": [
                  {
                    "text": "High mitotic rate"
                  },
                  {
                    "text": "Tumor necrosis"
                  },
                  {
                    "text": "Hypercellularity and sarcomatous appearanceEpithelioid sarcomatous tumors have slightly better prognosis than spindle cell counterparts",
                    "sub_points": [
                      "Epithelioid sarcomatous tumors have slightly better prognosis than spindle cell counterparts"
                    ]
                  },
                  {
                    "text": "Tumor extension into mucosa"
                  }
                ],
                "KIT-Mutated GIST": [
                  {
                    "text": "Spindle cell type most common; epithelioid and mixed types also occur"
                  },
                  {
                    "text": "Spindle cells arranged in fascicles or nodules"
                  },
                  {
                    "text": "Eosinophilic cytoplasm"
                  },
                  {
                    "text": "Elongated nuclei with vesicular chromatin and inconspicuous nucleoli"
                  },
                  {
                    "text": "Paranuclear vacuoles (artifact of fixation)"
                  },
                  {
                    "text": "Nuclear palisades in gastric tumors"
                  },
                  {
                    "text": "Skeinoid fibers in benign small intestinal tumors"
                  }
                ],
                "PDGFRA-Mutated GIST": [
                  {
                    "text": "Commonly epithelioid type"
                  },
                  {
                    "text": "Round to polygonal cells with distinct cell borders or with syncytial appearance"
                  },
                  {
                    "text": "Eosinophilic to pale or clear cytoplasm"
                  },
                  {
                    "text": "May have stromal sclerosis, myxoid change, or scant interstitial matrix"
                  },
                  {
                    "text": "Rhabdoid and plasmacytoid forms, binucleate and multinucleated giant cells"
                  }
                ],
                "SDH-Deficient GIST": [
                  {
                    "text": "Usually pure epithelioid type, less commonly mixed spindle/epithelioid"
                  },
                  {
                    "text": "Often multinodular or plexiform growth patternMost characteristic feature",
                    "sub_points": [
                      "Most characteristic feature"
                    ]
                  },
                  {
                    "text": "Hypercellularity is common"
                  },
                  {
                    "text": "Pleomorphism and tumor necrosis are rare"
                  },
                  {
                    "text": "Lymphovascular invasion seen in up to 50% of cases"
                  }
                ],
                "BRAFV600E-Mutated GIST": [
                  {
                    "text": "No known distinguishing histologic features"
                  }
                ],
                "Features Described Following Imatinib Treatment": [
                  {
                    "text": "Hypocellularity"
                  },
                  {
                    "text": "Stromal hyalinization, fibrosis, &/or myxoid change"
                  },
                  {
                    "text": "Necrosis"
                  },
                  {
                    "text": "Rhabdomyoblastic differentiation"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD117Positive in > 90% of GIST, including nearly allKIT-mutated tumorsUsually diffuse cytoplasmic positivity but may show membranous and perinuclear dot-like positivityStaining patterns and extent of staining do not correlate with type ofKITmutation or response to imatinibCD117 negative or only weakly positive GIST are usually epithelioid withPDGFRAmutationsPositive in SDH-deficient andBRAF-mutated GIST",
                    "sub_points": [
                      "Positive in > 90% of GIST, including nearly allKIT-mutated tumors",
                      "Usually diffuse cytoplasmic positivity but may show membranous and perinuclear dot-like positivity",
                      "Staining patterns and extent of staining do not correlate with type ofKITmutation or response to imatinib",
                      "CD117 negative or only weakly positive GIST are usually epithelioid withPDGFRAmutations",
                      "Positive in SDH-deficient andBRAF-mutated GIST"
                    ]
                  },
                  {
                    "text": "DOG1Highly sensitive and specific marker for GISTPositive in > 95% of tumorsUsually captures CD117-negative GISTSmall bowel tumors are negative, usually CD117 positive",
                    "sub_points": [
                      "Highly sensitive and specific marker for GIST",
                      "Positive in > 95% of tumors",
                      "Usually captures CD117-negative GIST",
                      "Small bowel tumors are negative, usually CD117 positive"
                    ]
                  },
                  {
                    "text": "PDGFRAExpressed in GIST of any typeNot surrogate marker forPDGFRAmutationAlso expressed in other tumors",
                    "sub_points": [
                      "Expressed in GIST of any typeNot surrogate marker forPDGFRAmutationAlso expressed in other tumors",
                      "Not surrogate marker forPDGFRAmutation",
                      "Also expressed in other tumors"
                    ]
                  },
                  {
                    "text": "SDHBExpression lost inallSDH-deficient GIST regardless of specific subunit alterationBest stain for identifying SDH-deficient GISTNo genotype/phenotype correlation",
                    "sub_points": [
                      "Expression lost inallSDH-deficient GIST regardless of specific subunit alterationBest stain for identifying SDH-deficient GISTNo genotype/phenotype correlation",
                      "Best stain for identifying SDH-deficient GIST",
                      "No genotype/phenotype correlation"
                    ]
                  },
                  {
                    "text": "SDHALoss of expression reliably predicts tumor and subsequent germlineSDHAmutationGood genotype/phenotype correlation",
                    "sub_points": [
                      "Loss of expression reliably predicts tumor and subsequent germlineSDHAmutationGood genotype/phenotype correlation",
                      "Good genotype/phenotype correlation"
                    ]
                  },
                  {
                    "text": "CD34Positive in 70% of all GIST, but not specificConsistently expressed in gastric spindle cell GISTNegative in non-SDH-deficient gastric epithelioid GIST",
                    "sub_points": [
                      "Positive in 70% of all GIST, but not specificConsistently expressed in gastric spindle cell GISTNegative in non-SDH-deficient gastric epithelioid GIST",
                      "Consistently expressed in gastric spindle cell GIST",
                      "Negative in non-SDH-deficient gastric epithelioid GIST"
                    ]
                  },
                  {
                    "text": "SMANegative or only focally positive in ~ 19-30% of GISTAlmost never expressed in SDH-deficient GIST",
                    "sub_points": [
                      "Negative or only focally positive in ~ 19-30% of GIST",
                      "Almost never expressed in SDH-deficient GIST"
                    ]
                  },
                  {
                    "text": "DesminUsually negativeFocally expressed in 5% of epithelioid type tumorsExpressed in imatinib-treated tumors with rhabdomyoblastic differentiation",
                    "sub_points": [
                      "Usually negative",
                      "Focally expressed in 5% of epithelioid type tumors",
                      "Expressed in imatinib-treated tumors with rhabdomyoblastic differentiation"
                    ]
                  },
                  {
                    "text": "S100Usually negativeFocally expressed in < 1% of epithelioid-type tumors",
                    "sub_points": [
                      "Usually negative",
                      "Focally expressed in < 1% of epithelioid-type tumors"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Gene mutation testingKIT,PDGFRA,BRAF,NF1, andFGFRmutations andNTRK1/NTRK2/NTRK3fusions by NGS panelGenetics referral required for the followingKIT,PDGFRA, and SDHB IHC-negative tumorsNF1mutation-positive tumorsEvaluation may include germline mutation analysis",
                    "sub_points": [
                      "KIT,PDGFRA,BRAF,NF1, andFGFRmutations andNTRK1/NTRK2/NTRK3fusions by NGS panel",
                      "Genetics referral required for the followingKIT,PDGFRA, and SDHB IHC-negative tumorsNF1mutation-positive tumorsEvaluation may include germline mutation analysis",
                      "KIT,PDGFRA, and SDHB IHC-negative tumors",
                      "NF1mutation-positive tumors",
                      "Evaluation may include germline mutation analysis"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Leiomyoma": [
                  {
                    "text": "Intersecting fascicles of brightly eosinophilic spindle cells"
                  },
                  {
                    "text": "Nuclei with blunted ends"
                  },
                  {
                    "text": "SMA(+), desmin (+), CD117(-), and DOG1(-)Potential pitfall: CD117 and DOG1 may stain colonizing Cajal cells interspersed among smooth muscle bundles",
                    "sub_points": [
                      "Potential pitfall: CD117 and DOG1 may stain colonizing Cajal cells interspersed among smooth muscle bundles"
                    ]
                  }
                ],
                "Schwannoma": [
                  {
                    "text": "Prominent lymphoid cuff"
                  },
                  {
                    "text": "Gastric schwannomas lack features of soft tissue counterpartsVerocay bodies, hyalinized vessels, and encapsulation",
                    "sub_points": [
                      "Verocay bodies, hyalinized vessels, and encapsulation"
                    ]
                  },
                  {
                    "text": "S100(+), CD117(-), and DOG1(-)"
                  }
                ],
                "Fibromatosis": [
                  {
                    "text": "Arises in mesentery and extends into muscularis propria"
                  },
                  {
                    "text": "Poorly circumscribed with infiltrative growth pattern"
                  },
                  {
                    "text": "Sweeping fascicles of uniform spindle cells within collagenous stroma"
                  },
                  {
                    "text": "Bipolar cells with pale cytoplasm, open chromatin, and prominent nucleoli"
                  },
                  {
                    "text": "Nuclear β-catenin (+), CD34(-), DOG1(-), and CD117 usually negative"
                  }
                ],
                "Inflammatory Fibroid Polyp": [
                  {
                    "text": "Submucosal lesion, not centered in muscularis propria"
                  },
                  {
                    "text": "Bland spindle cells within loose collagenous stroma"
                  },
                  {
                    "text": "Spindle cells cuff blood vessels (onion skinning)"
                  },
                  {
                    "text": "Numerous stromal eosinophils"
                  },
                  {
                    "text": "PDGFRAmutations and CD34(+) overlap with GIST"
                  },
                  {
                    "text": "CD117(-) and DOG1(-)"
                  }
                ],
                "Glomus Tumor": [
                  {
                    "text": "Rare in GI tract"
                  },
                  {
                    "text": "May mimic epithelioid GISTRound, sharply demarcated cells with cytoplasmic clearingMay be multiple, mimicking SDH-deficient epithelioid GIST, but median age is 55 years",
                    "sub_points": [
                      "Round, sharply demarcated cells with cytoplasmic clearing",
                      "May be multiple, mimicking SDH-deficient epithelioid GIST, but median age is 55 years"
                    ]
                  },
                  {
                    "text": "Positive for smooth muscle markers (SMA, H-caldesmon, and calponin), but desmin (-), CD117(-), and DOG1(-)"
                  }
                ],
                "Clear Cell Sarcoma-Like Tumor of GI Tract": [
                  {
                    "text": "Sheet-like or nested epithelioid or spindle cells with eosinophilic to clear cytoplasm"
                  },
                  {
                    "text": "Eccentric nuclei may impart plasmacytoid appearance"
                  },
                  {
                    "text": "S100(+), CD56(+/-), synaptophysin (+/-), CD117(-), DOG1(-), and CD34(-)"
                  },
                  {
                    "text": "EWSR1::ATF1orEWSR1::CREB1fusions"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "KIT- andPDGFRA-mutated GISTTumor behavior determined by location, size, and mitotic rateSpecific mutations render important information regarding treatment options and response to imatinib",
                    "sub_points": [
                      "Tumor behavior determined by location, size, and mitotic rate",
                      "Specific mutations render important information regarding treatment options and response to imatinib"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "General morphologic-molecular associationsSpindle cell GIST typicallyKITmutatedGastric epithelioid GISTIn adult patient, typicallyPDGFRAmutatedIn pediatric patient, typically SDH deficient",
                    "sub_points": [
                      "Spindle cell GIST typicallyKITmutated",
                      "Gastric epithelioid GISTIn adult patient, typicallyPDGFRAmutatedIn pediatric patient, typically SDH deficient",
                      "In adult patient, typicallyPDGFRAmutated",
                      "In pediatric patient, typically SDH deficient"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lynch Syndrome": {
            "name": "Lynch Syndrome",
            "url": "https://app.pathprimer.com/document/b7d29fde-d617-473b-b83d-b28e9d2af083/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "Hereditary nonpolyposis colorectal cancer (HNPCC) (old term for Lynch syndrome)"
                  }
                ]
              },
              "Epidemiology": {
                "Prevalence": [
                  {
                    "text": "Lynch syndrome is most common heritable cause of cancer"
                  },
                  {
                    "text": "~ 3% of all colorectal cancers (CRCs)"
                  }
                ]
              },
              "Genetics": {
                "Lynch Syndrome": [
                  {
                    "text": "Autosomal dominant"
                  },
                  {
                    "text": "Mutations in genes coding for mismatch repair proteins (MLH1, PMS2, MSH2, MSH6)Mutation inEPCAM(a gene immediately adjacent toMSH2) leads to epigenetic silencing ofMSH2Immunostains for MSH2 and MSH6 will be negative, implying anMSH2mutation, but sequencing will not findMSH2mutation",
                    "sub_points": [
                      "Mutation inEPCAM(a gene immediately adjacent toMSH2) leads to epigenetic silencing ofMSH2Immunostains for MSH2 and MSH6 will be negative, implying anMSH2mutation, but sequencing will not findMSH2mutation",
                      "Immunostains for MSH2 and MSH6 will be negative, implying anMSH2mutation, but sequencing will not findMSH2mutation"
                    ]
                  }
                ],
                "Constitutional Mismatch Repair-Deficiency (CMMR-D) Syndrome": [
                  {
                    "text": "Autosomal recessive (very rare)Patient inherits a mutated copy of mismatch repair gene from each parent (biallelic mutation)",
                    "sub_points": [
                      "Patient inherits a mutated copy of mismatch repair gene from each parent (biallelic mutation)"
                    ]
                  },
                  {
                    "text": "Early childhood cancers (lymphoma/leukemia plus Lynch-associated solid tumors)Café au lait spots similar to neurofibromatosis type 1",
                    "sub_points": [
                      "Café au lait spots similar to neurofibromatosis type 1"
                    ]
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Clinical Features": [
                  {
                    "text": "Multiple epithelial cancers occur at average age of ~ 20 years younger than expected"
                  },
                  {
                    "text": "Several guidelines have been proposed to help identify patients who should be tested for Lynch syndromeAmsterdam criteria IIAt least 3 relatives with a Lynch-associated cancer2 or more successive generations affected1 or more relatives diagnosed before age 501 should be a 1st-degree relative of the other 2Familial adenomatous polyposis must be excludedRevised Bethesda guidelinesCRC diagnosed prior to age 50Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of ageCRC with histologic features suggestive of microsatellite instability (MSI) in patients < age 60CRC diagnosed in 1 or more 1st-degree relatives with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50CRC diagnosed in 2 or more 1st-degree or 2nd-degree relatives with Lynch-associated tumors, regardless of age",
                    "sub_points": [
                      "Amsterdam criteria IIAt least 3 relatives with a Lynch-associated cancer2 or more successive generations affected1 or more relatives diagnosed before age 501 should be a 1st-degree relative of the other 2Familial adenomatous polyposis must be excluded",
                      "At least 3 relatives with a Lynch-associated cancer",
                      "2 or more successive generations affected",
                      "1 or more relatives diagnosed before age 50",
                      "1 should be a 1st-degree relative of the other 2",
                      "Familial adenomatous polyposis must be excluded",
                      "Revised Bethesda guidelinesCRC diagnosed prior to age 50Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of ageCRC with histologic features suggestive of microsatellite instability (MSI) in patients < age 60CRC diagnosed in 1 or more 1st-degree relatives with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50CRC diagnosed in 2 or more 1st-degree or 2nd-degree relatives with Lynch-associated tumors, regardless of age",
                      "CRC diagnosed prior to age 50",
                      "Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of age",
                      "CRC with histologic features suggestive of microsatellite instability (MSI) in patients < age 60",
                      "CRC diagnosed in 1 or more 1st-degree relatives with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50",
                      "CRC diagnosed in 2 or more 1st-degree or 2nd-degree relatives with Lynch-associated tumors, regardless of age"
                    ]
                  },
                  {
                    "text": "Neither of these guidelines is foolproof; hence, many studies recommend testing all CRCs for Lynch syndrome"
                  }
                ],
                "Immunohistochemistry (IHC)": [
                  {
                    "text": "Immunostains for MLH1, PMS2, MSH2, and MSH6 have become fairly routine5-10% false-negative rate, as protein may be antigenic but still not function due to mutationAdvantage of IHC over microsatellite instability (MSI-H) testing is that IHC reveals which gene is mutated",
                    "sub_points": [
                      "5-10% false-negative rate, as protein may be antigenic but still not function due to mutation",
                      "Advantage of IHC over microsatellite instability (MSI-H) testing is that IHC reveals which gene is mutated"
                    ]
                  }
                ],
                "Microsatellite Instability": [
                  {
                    "text": "Mutations in proofreading genes lead to replication errors in DNAThese replication errors can be detected in short DNA repeats called microsatellites~ 95% of all Lynch syndrome colorectal cancers have MSI-HCan be tested easily using formalin-fixed paraffin-embedded tissueNeed both normal and neoplastic tissue for comparison",
                    "sub_points": [
                      "These replication errors can be detected in short DNA repeats called microsatellites",
                      "~ 95% of all Lynch syndrome colorectal cancers have MSI-HCan be tested easily using formalin-fixed paraffin-embedded tissueNeed both normal and neoplastic tissue for comparison",
                      "Can be tested easily using formalin-fixed paraffin-embedded tissue",
                      "Need both normal and neoplastic tissue for comparison"
                    ]
                  },
                  {
                    "text": "MSI-H is also seen in 10-15% of sporadic colon cancers (not specific for Lynch syndrome)Sporadic tumors often haveBRAF V600Emutations &/or methylation ofMLH1Neither of these are present in Lynch tumors",
                    "sub_points": [
                      "Sporadic tumors often haveBRAF V600Emutations &/or methylation ofMLH1Neither of these are present in Lynch tumors",
                      "Neither of these are present in Lynch tumors"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Gastrointestinal Tract Tumors": [
                  {
                    "text": "Colorectal cancer80% lifetime riskHistologic features are often characteristicIncreased numbers of tumor-infiltrating lymphocytes and a Crohn-like reaction around edge of tumorMore likely to be well or poorly differentiatedMore likely to have mucinous differentiation and lack dirty necrosisMore often right sidedMore likely to have a circumscribed growth pattern and to exhibit histologic heterogeneity",
                    "sub_points": [
                      "80% lifetime risk",
                      "Histologic features are often characteristicIncreased numbers of tumor-infiltrating lymphocytes and a Crohn-like reaction around edge of tumorMore likely to be well or poorly differentiatedMore likely to have mucinous differentiation and lack dirty necrosisMore often right sidedMore likely to have a circumscribed growth pattern and to exhibit histologic heterogeneity",
                      "Increased numbers of tumor-infiltrating lymphocytes and a Crohn-like reaction around edge of tumor",
                      "More likely to be well or poorly differentiated",
                      "More likely to have mucinous differentiation and lack dirty necrosis",
                      "More often right sided",
                      "More likely to have a circumscribed growth pattern and to exhibit histologic heterogeneity"
                    ]
                  },
                  {
                    "text": "Adenocarcinoma of stomach, small bowel, appendix, ampulla, and biliary treeMay share some of histologic features listed above for colon cancers",
                    "sub_points": [
                      "May share some of histologic features listed above for colon cancers"
                    ]
                  }
                ],
                "Nongastrointestinal Tract Tumors": [
                  {
                    "text": "Endometrium40-60% lifetime riskEndometrioid carcinomas with mucinous differentiation, histologic heterogeneity, dedifferentiation, and increased host response",
                    "sub_points": [
                      "40-60% lifetime risk",
                      "Endometrioid carcinomas with mucinous differentiation, histologic heterogeneity, dedifferentiation, and increased host response"
                    ]
                  },
                  {
                    "text": "Ovaries4-12% lifetime riskClear cell and endometrioid carcinomas",
                    "sub_points": [
                      "4-12% lifetime risk",
                      "Clear cell and endometrioid carcinomas"
                    ]
                  },
                  {
                    "text": "AdrenalAs many as 5% of adrenal cortical carcinomas may be associated with Lynch syndrome",
                    "sub_points": [
                      "As many as 5% of adrenal cortical carcinomas may be associated with Lynch syndrome"
                    ]
                  },
                  {
                    "text": "ProstateLynch patients have 2x the risk of prostate cancer as general population",
                    "sub_points": [
                      "Lynch patients have 2x the risk of prostate cancer as general population"
                    ]
                  },
                  {
                    "text": "Kidney, ureters, bladderUrothelial carcinomasMSH2mutations may selectively increase risk of bladder cancers compared to other mismatch repair gene mutations",
                    "sub_points": [
                      "Urothelial carcinomasMSH2mutations may selectively increase risk of bladder cancers compared to other mismatch repair gene mutations",
                      "MSH2mutations may selectively increase risk of bladder cancers compared to other mismatch repair gene mutations"
                    ]
                  },
                  {
                    "text": "SkinSebaceous neoplasms and multiple keratoacanthomas = Muir-Torre syndromeCafé au lait spots in CMMR-D syndrome",
                    "sub_points": [
                      "Sebaceous neoplasms and multiple keratoacanthomas = Muir-Torre syndrome",
                      "Café au lait spots in CMMR-D syndrome"
                    ]
                  },
                  {
                    "text": "BrainGlioblastoma in Turcot syndrome variant of Lynch syndrome",
                    "sub_points": [
                      "Glioblastoma in Turcot syndrome variant of Lynch syndrome"
                    ]
                  },
                  {
                    "text": "Leukemia/lymphomaOccurs in patients with CMMR-D",
                    "sub_points": [
                      "Occurs in patients with CMMR-D"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Surveillance Endoscopy": [
                  {
                    "text": "Every 1-2 years starting between ages 20 and 25"
                  }
                ],
                "Surgery": [
                  {
                    "text": "Prophylactic colectomy is an option, but most patients opt for colonoscopic surveillance"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Carney Complex": {
            "name": "Carney Complex",
            "url": "https://app.pathprimer.com/document/7af07825-9173-44d3-955c-c3759ee12b97/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Carney complex (CNC)"
                  },
                  {
                    "text": "Lentigines, atrial myxomas, mucocutaneous myxomas, and blue nevi syndrome  (LAMB)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Nevi, atrial myxoma, myxoid neurofibroma, and ephelides (NAME) syndrome"
                  },
                  {
                    "text": "Carney syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Multiple neoplasia syndrome featuring cardiac, endocrine, cutaneous, and neural tumors, as well as variety of pigmented lesions of skin and mucosae"
                  },
                  {
                    "text": "CNC may simultaneously involve multiple endocrine glands, as in classic multiple endocrine neoplasia syndromes 1 and 2"
                  }
                ]
              },
              "Epidemiology": {
                "Age Range": [
                  {
                    "text": "Mean age at diagnosis is 10-20 years"
                  }
                ],
                "Gender": [
                  {
                    "text": "M = F"
                  }
                ],
                "Incidence": [
                  {
                    "text": "> 400 patients have been diagnosed with CNC"
                  },
                  {
                    "text": "Cardiac myxomas are most common primary cardiac tumor and occur in 7 per 10,000 individuals"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Etiology": [
                  {
                    "text": "Autosomal dominant disorder characterized by complex of myxomas, spotty pigmentation, and endocrine overactivitySeveral patients described in earlier years under acronyms NAME and LAMB probably had CNCCNC is not only multiple neoplasia syndrome but also causes variety of pigmented lesions of skin and mucosae",
                    "sub_points": [
                      "Several patients described in earlier years under acronyms NAME and LAMB probably had CNC",
                      "CNC is not only multiple neoplasia syndrome but also causes variety of pigmented lesions of skin and mucosae"
                    ]
                  },
                  {
                    "text": "Genetic mutation inPRKAR1Agene (17q22-24) and chromosome 2p16PRKAR1Aencodes regulatory R1 α-subunit of protein kinase A",
                    "sub_points": [
                      "PRKAR1Aencodes regulatory R1 α-subunit of protein kinase A"
                    ]
                  }
                ]
              },
              "Clinical Implications": {
                "Clinical Presentation": [
                  {
                    "text": "SkinMultiple facial lentigines and mucosal labial pigmentationSubcutaneous myxoid neurofibromasEpithelioid blue nevus",
                    "sub_points": [
                      "Multiple facial lentigines and mucosal labial pigmentation",
                      "Subcutaneous myxoid neurofibromas",
                      "Epithelioid blue nevus"
                    ]
                  },
                  {
                    "text": "Endocrine organsAdrenalPrimary pigmented nodular adrenocortical disease (PPNAD)Cushing syndromeThyroidThyroid nodulesPituitary adenomaAcromegaly/gigantism or galactorrhea, depending on tumor type",
                    "sub_points": [
                      "AdrenalPrimary pigmented nodular adrenocortical disease (PPNAD)Cushing syndrome",
                      "Primary pigmented nodular adrenocortical disease (PPNAD)",
                      "Cushing syndrome",
                      "ThyroidThyroid nodules",
                      "Thyroid nodules",
                      "Pituitary adenomaAcromegaly/gigantism or galactorrhea, depending on tumor type",
                      "Acromegaly/gigantism or galactorrhea, depending on tumor type"
                    ]
                  },
                  {
                    "text": "HeartAtrial myxomas are most common primary tumor of heartMajority of tumors arise from left atrial septum near fossa ovalisLesions arising from right atrium or in young adults are more likely to be associated with familial syndromeMay present with tumor emboli",
                    "sub_points": [
                      "Atrial myxomas are most common primary tumor of heart",
                      "Majority of tumors arise from left atrial septum near fossa ovalis",
                      "Lesions arising from right atrium or in young adults are more likely to be associated with familial syndrome",
                      "May present with tumor emboli"
                    ]
                  },
                  {
                    "text": "TestisLarge cell calcifying Sertoli cell tumor (LCCSCT), often bilateral",
                    "sub_points": [
                      "Large cell calcifying Sertoli cell tumor (LCCSCT), often bilateral"
                    ]
                  },
                  {
                    "text": "Gastrointestinal tractPsammomatous melanotic schwannoma in esophagus and stomach",
                    "sub_points": [
                      "Psammomatous melanotic schwannoma in esophagus and stomach"
                    ]
                  },
                  {
                    "text": "Psammomatous melanotic schwannomas"
                  },
                  {
                    "text": "Breast ductal adenoma"
                  },
                  {
                    "text": "Osteochondromyxoma"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Depends on main pathologyBilateral adrenalectomyRemoval of cardiac myxomasSurgery with removal of testicular tumorsSurgery with removal of other tumors",
                    "sub_points": [
                      "Bilateral adrenalectomy",
                      "Removal of cardiac myxomas",
                      "Surgery with removal of testicular tumors",
                      "Surgery with removal of other tumors"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Most tumors associated with CNC are slow growing with no malignant potential"
                  },
                  {
                    "text": "Sudden death due to cardiac myxoma may occurDecreased lifespan expected",
                    "sub_points": [
                      "Decreased lifespan expected"
                    ]
                  },
                  {
                    "text": "Complications of Cushing syndrome"
                  }
                ]
              },
              "Macroscopic Findings": {
                "Atrial Myxoma": [
                  {
                    "text": "Mobile, pedunculated, ball-shaped mass"
                  }
                ],
                "PPNAD": [
                  {
                    "text": "Small to normal-sized adrenal glands"
                  },
                  {
                    "text": "Multiple bilateral, small cortical nodules (0.1-0.3 cm)May be pigmented, brown, or black; some may be pale to bright yellow",
                    "sub_points": [
                      "May be pigmented, brown, or black; some may be pale to bright yellow"
                    ]
                  }
                ],
                "Large Cell Calcifying Sertoli Cell Tumor": [
                  {
                    "text": "Ranges in size from microscopic to large tumor replacing entire testis"
                  },
                  {
                    "text": "Usually multicentric, bilateral, and calcified"
                  }
                ],
                "Psammomatous Melanotic Schwannoma": [
                  {
                    "text": "Black, multiple nodules that occur simultaneously or asynchronously at different sites"
                  }
                ]
              },
              "Microscopic Findings": {
                "Histologic Features": [
                  {
                    "text": "Atrial myxomaComposed of plump, stellate, or spindled cells arranged in cords and primitive-appearing vessels in loose, myxoid stromaStroma often contains hemorrhage or hemosiderin with variable numbers of inflammatory cellsHeterologous elements such as glands or extramedullary hematopoiesis can be found in small minority of cases (2%)",
                    "sub_points": [
                      "Composed of plump, stellate, or spindled cells arranged in cords and primitive-appearing vessels in loose, myxoid stromaStroma often contains hemorrhage or hemosiderin with variable numbers of inflammatory cells",
                      "Stroma often contains hemorrhage or hemosiderin with variable numbers of inflammatory cells",
                      "Heterologous elements such as glands or extramedullary hematopoiesis can be found in small minority of cases (2%)"
                    ]
                  },
                  {
                    "text": "PPNADNodules composed of cells with compact eosinophilic cytoplasm, with abundant brown granular pigment (lipofuscin)Cell nuclei are vesicular and may contain prominent nucleoliIntervening cortical tissue is atrophic",
                    "sub_points": [
                      "Nodules composed of cells with compact eosinophilic cytoplasm, with abundant brown granular pigment (lipofuscin)",
                      "Cell nuclei are vesicular and may contain prominent nucleoli",
                      "Intervening cortical tissue is atrophic"
                    ]
                  },
                  {
                    "text": "Large cell calcifying Sertoli cell tumorTumor has ill-defined peripheryMultiple cellular arrangement patterns of distribution: Usually solid or trabecularLarge tumor cells with abundant granular and eosinophilic cytoplasmLaminated calcospherites are characteristicMay be only few or multiple, and often with confluenceMitoses are rareNeutrophilic infiltration is usually present",
                    "sub_points": [
                      "Tumor has ill-defined periphery",
                      "Multiple cellular arrangement patterns of distribution: Usually solid or trabecular",
                      "Large tumor cells with abundant granular and eosinophilic cytoplasm",
                      "Laminated calcospherites are characteristicMay be only few or multiple, and often with confluence",
                      "May be only few or multiple, and often with confluence",
                      "Mitoses are rare",
                      "Neutrophilic infiltration is usually present"
                    ]
                  },
                  {
                    "text": "Pituitary adenomaAdenoma with solid growth patternRound and polygonal cells with granular eosinophilic cytoplasm and round to oval nucleiUsually growth hormone (GH) &/or prolactin-producing tumors",
                    "sub_points": [
                      "Adenoma with solid growth pattern",
                      "Round and polygonal cells with granular eosinophilic cytoplasm and round to oval nuclei",
                      "Usually growth hormone (GH) &/or prolactin-producing tumors"
                    ]
                  },
                  {
                    "text": "Psammomatous melanotic schwannomaPeripheral nerve sheath tumor affecting posterior spinal nerve roots, alimentary tract, bone, and skinSpindle and epithelioid cells intermixed with melanin, psammoma bodies, and adipose tissue~ 10% are malignant and metastasize",
                    "sub_points": [
                      "Peripheral nerve sheath tumor affecting posterior spinal nerve roots, alimentary tract, bone, and skin",
                      "Spindle and epithelioid cells intermixed with melanin, psammoma bodies, and adipose tissue",
                      "~ 10% are malignant and metastasize"
                    ]
                  }
                ]
              },
              "Diagnosis": {
                "Criteria": [
                  {
                    "text": "Definite diagnosis of CNC is given if 2 or more major manifestations are present"
                  },
                  {
                    "text": "Major diagnostic criteria for CNCSpotty skin pigmentation with typical distribution on such sites as the lips, conjunctiva and inner or outer canthi, or vaginal and penile mucosaMyxoma (cutaneous and mucosal)Cardiac myxomaBreast myxomatosis or fat-suppressed MR imaging findings are suggestivePPNAD or paradoxical positive response of urinary glucocorticosteroid excretion to dexamethasone administration during Liddle testAcromegaly due to GH-producing adenomaLarge cell calcifying Sertoli cell tumorThyroid carcinoma or multiple adenomatous nodules in young patientPsammomatous melanotic schwannomasBlue nevus, epithelioid blue nevusBreast ductal adenomaOsteochondromyxoma",
                    "sub_points": [
                      "Spotty skin pigmentation with typical distribution on such sites as the lips, conjunctiva and inner or outer canthi, or vaginal and penile mucosa",
                      "Myxoma (cutaneous and mucosal)",
                      "Cardiac myxoma",
                      "Breast myxomatosis or fat-suppressed MR imaging findings are suggestive",
                      "PPNAD or paradoxical positive response of urinary glucocorticosteroid excretion to dexamethasone administration during Liddle test",
                      "Acromegaly due to GH-producing adenoma",
                      "Large cell calcifying Sertoli cell tumor",
                      "Thyroid carcinoma or multiple adenomatous nodules in young patient",
                      "Psammomatous melanotic schwannomas",
                      "Blue nevus, epithelioid blue nevus",
                      "Breast ductal adenoma",
                      "Osteochondromyxoma"
                    ]
                  },
                  {
                    "text": "Supplementary criteriaAffected 1st-degree relativeInactivating mutation ofPRKAR1Agene",
                    "sub_points": [
                      "Affected 1st-degree relative",
                      "Inactivating mutation ofPRKAR1Agene"
                    ]
                  },
                  {
                    "text": "Cutaneous manifestations constitute 3 of the major disease manifestationsCutaneous or mucosal myxomaBlue nevi (multiple) or epithelioid blue nevus",
                    "sub_points": [
                      "Cutaneous or mucosal myxoma",
                      "Blue nevi (multiple) or epithelioid blue nevus"
                    ]
                  },
                  {
                    "text": "Findings suggestive of,or possibly associated with CNC, but not diagnosticIntense freckling (without darkly pigmented spots or typical distribution)Multiple blue nevi of common typeCafé au lait spots or other birthmarksElevated IGF1 levels, abnormal GTT, or paradoxical GH response to TRH testing in absence of clinical acromegalyCardiomyopathyPilonidal sinusHistory of Cushing syndrome, acromegaly, or sudden death in extended familyMultiple skin tags or other skin lesions, including lipomas and angiofibromasColonic polyps (usually in association with acromegaly)Hyperprolactinemia (usually mild and almost always combined with clinical or subclinical acromegaly)Single, benign thyroid nodule in young patient; multiple thyroid nodules in older patient (detected on ultrasound)Family history of carcinoma, particularly of thyroid, colon, pancreas, and ovary; other multiple benign or malignant tumorsRelationship between cutaneous and noncutaneous manifestations of CNC appears to be essential clue to molecular etiology> 1/2 of CNC patients present with both characteristic dermatological and endocrine signsSignificant number of patients present with skin lesions that are only suggestive, not characteristic, of CNC",
                    "sub_points": [
                      "Intense freckling (without darkly pigmented spots or typical distribution)",
                      "Multiple blue nevi of common type",
                      "Café au lait spots or other birthmarks",
                      "Elevated IGF1 levels, abnormal GTT, or paradoxical GH response to TRH testing in absence of clinical acromegaly",
                      "Cardiomyopathy",
                      "Pilonidal sinus",
                      "History of Cushing syndrome, acromegaly, or sudden death in extended family",
                      "Multiple skin tags or other skin lesions, including lipomas and angiofibromas",
                      "Colonic polyps (usually in association with acromegaly)",
                      "Hyperprolactinemia (usually mild and almost always combined with clinical or subclinical acromegaly)",
                      "Single, benign thyroid nodule in young patient; multiple thyroid nodules in older patient (detected on ultrasound)",
                      "Family history of carcinoma, particularly of thyroid, colon, pancreas, and ovary; other multiple benign or malignant tumors",
                      "Relationship between cutaneous and noncutaneous manifestations of CNC appears to be essential clue to molecular etiology",
                      "> 1/2 of CNC patients present with both characteristic dermatological and endocrine signsSignificant number of patients present with skin lesions that are only suggestive, not characteristic, of CNC",
                      "Significant number of patients present with skin lesions that are only suggestive, not characteristic, of CNC"
                    ]
                  },
                  {
                    "text": "Classification based on both dermatological and endocrine markers has subgrouped CNC patients asMultisymptomatic (with extensive endocrine and skin signs)Intermediate (with few dermatological and endocrine manifestations)Paucisymptomatic (with isolated PPNAD and no cutaneous signs)",
                    "sub_points": [
                      "Multisymptomatic (with extensive endocrine and skin signs)",
                      "Intermediate (with few dermatological and endocrine manifestations)",
                      "Paucisymptomatic (with isolated PPNAD and no cutaneous signs)"
                    ]
                  }
                ],
                "Diagnostic Criteria for Clinical Diagnosis": [
                  {
                    "text": "Patient must have ≥ 2 of the followingSpotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)Myxoma (cutaneous: Often on the eyelid, external ear, nipple)Cardiac myxomaBreast myxomatosis or fat-suppressed MR findings suggestive of this diagnosisAcromegaly due to GH-producing adenoma (somatotropinoma)PPNAD or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during diagnostic test for Cushing syndromeThyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patientLCCSCT of testis or characteristic calcification on testicular ultrasonographyPsammomatous melanotic schwannomaBlue nevus, epithelioid blue nevus (multiple)Breast ductal adenoma, or mammary tumor with intraductal papillomaOsteochondromyxoma of boneAdditionally, criteria is satisfied by a patient meeting only 1 of these criteria, but having eitherAffected 1st-degree relative orInactivating mutation of thePRKAR1Agene",
                    "sub_points": [
                      "Spotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)",
                      "Myxoma (cutaneous: Often on the eyelid, external ear, nipple)",
                      "Cardiac myxoma",
                      "Breast myxomatosis or fat-suppressed MR findings suggestive of this diagnosis",
                      "Acromegaly due to GH-producing adenoma (somatotropinoma)",
                      "PPNAD or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during diagnostic test for Cushing syndrome",
                      "Thyroid carcinoma or multiple hypoechoic nodules on thyroid ultrasonography in a young patient",
                      "LCCSCT of testis or characteristic calcification on testicular ultrasonography",
                      "Psammomatous melanotic schwannoma",
                      "Blue nevus, epithelioid blue nevus (multiple)",
                      "Breast ductal adenoma, or mammary tumor with intraductal papilloma",
                      "Osteochondromyxoma of bone",
                      "Additionally, criteria is satisfied by a patient meeting only 1 of these criteria, but having eitherAffected 1st-degree relative orInactivating mutation of thePRKAR1Agene",
                      "Affected 1st-degree relative or",
                      "Inactivating mutation of thePRKAR1Agene"
                    ]
                  }
                ],
                "Similar Clinical and Pathological Features": [
                  {
                    "text": "Peutz-Jeghers syndrome (PJS), with which it shares mucosal lentiginosis and unusual gonadal tumor, and large cell calcifying Sertoli cell tumor"
                  },
                  {
                    "text": "McCune-Albright syndrome: Sporadic condition also characterized by multiple endocrine and nonendocrine tumors"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Atrial myxomaCells stain positive for CD34, CD31, and S100Calretinin is positive in 74-100% of cases and can be useful to distinguish this lesion from myxoid thrombus",
                    "sub_points": [
                      "Cells stain positive for CD34, CD31, and S100",
                      "Calretinin is positive in 74-100% of cases and can be useful to distinguish this lesion from myxoid thrombus"
                    ]
                  },
                  {
                    "text": "PPNADIncreased expression of glucocorticoid receptor",
                    "sub_points": [
                      "Increased expression of glucocorticoid receptor"
                    ]
                  },
                  {
                    "text": "Large cell calcifying Sertoli cell tumorPositive for vimentin, inhibin-α, NSE, S100, desmin, and smooth muscle actinNegative for α-fetoprotein, HCG, PLAP, podoplanin, OCT3/4, and cytokeratin (may be focally positive)",
                    "sub_points": [
                      "Positive for vimentin, inhibin-α, NSE, S100, desmin, and smooth muscle actin",
                      "Negative for α-fetoprotein, HCG, PLAP, podoplanin, OCT3/4, and cytokeratin (may be focally positive)"
                    ]
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Genetic heterogeneity with ≥ 2 main loci for candidate genesChromosome 2 locus at 2p15-16Mutations ofPRKAR1Agene on chromosome 17 (17q22-24)",
                    "sub_points": [
                      "Chromosome 2 locus at 2p15-16",
                      "Mutations ofPRKAR1Agene on chromosome 17 (17q22-24)"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Other Syndromes": [
                  {
                    "text": "Share clinical features and molecular pathways with several other familial lentiginosis syndromes, such asMcCune-Albright syndromePeutz-Jeghers syndromeLEOPARD (multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness)Noonan syndromePTEN-hamartoma tumor syndromes (e.g., Cowden disease [CD] and Bannayan-Ruvalcaba-Riley syndrome [BRRS])In all of these conditions, skin lesions accompany underlying endocrine &/or other abnormalities, and, similarly to CNC, are considered important diagnostic sign",
                    "sub_points": [
                      "McCune-Albright syndrome",
                      "Peutz-Jeghers syndrome",
                      "LEOPARD (multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness)",
                      "Noonan syndrome",
                      "PTEN-hamartoma tumor syndromes (e.g., Cowden disease [CD] and Bannayan-Ruvalcaba-Riley syndrome [BRRS])",
                      "In all of these conditions, skin lesions accompany underlying endocrine &/or other abnormalities, and, similarly to CNC, are considered important diagnostic sign"
                    ]
                  }
                ],
                "McCune-Albright Syndrome": [
                  {
                    "text": "Probably the closest to CNC in terms of molecular pathway link"
                  },
                  {
                    "text": "Patients have characteristic lesions that affect predominantly 3 systems: Skin, endocrine system, and skeleton"
                  },
                  {
                    "text": "Café au lait spots in McCune-Albright syndrome patients are similar to those observed in CNCTend to be more intensely pigmented",
                    "sub_points": [
                      "Tend to be more intensely pigmented"
                    ]
                  },
                  {
                    "text": "Caused by post-zygotic activating mutations ofGNAS1"
                  }
                ],
                "Peutz-Jeghers Syndrome": [
                  {
                    "text": "Autosomal dominant familial lentiginosis syndrome characterized by melanocytic macules of lips, buccal mucosa, and digits, multiple gastrointestinal hamartomatous polyps, and increased risk of various neoplasms"
                  },
                  {
                    "text": "Lentigines observed in Peutz-Jeghers syndrome patients show similar density and distribution to those in CNC patients"
                  },
                  {
                    "text": "Peutz-Jeghers syndrome was first mapped to chromosome 19p13.3, and gene-encoding serine threonine kinase 11 (STK11a.k.a.LKB1) was found to be mutated in most patients"
                  }
                ],
                "LEOPARD": [
                  {
                    "text": "Multiplelentigines,electrocardiographic conduction abnormalities,ocular hypertelorism,pulmonic stenosis,abnormal genitalia,retardation of growth, and sensorineuraldeafness"
                  }
                ],
                "Cowden Disease and Bannayan-Ruvalcaba-Riley Syndrome (PTEN-Hamartoma Tumor Syndromes)": [
                  {
                    "text": "Cowden disease and BRRS share clinical characteristics, such as mucocutaneous lesions, hamartomatous polyps of gastrointestinal tract, and increased risk of developing neoplasms"
                  },
                  {
                    "text": "Both conditions are caused by mutations inPTENgenePTENis located on 10q23.31 and encodes phosphatidylinositol-3,4,5-triphosphate 3-phosphataseTumor suppressor gene that has been found mutated in a number of tumors",
                    "sub_points": [
                      "PTENis located on 10q23.31 and encodes phosphatidylinositol-3,4,5-triphosphate 3-phosphataseTumor suppressor gene that has been found mutated in a number of tumors",
                      "Tumor suppressor gene that has been found mutated in a number of tumors"
                    ]
                  },
                  {
                    "text": "Thyroid is usually affected by numerous adenomatous nodules, follicular adenomas, and follicular carcinomaFindings are similar to those familial syndromes characterized by predominance of nonthyroidal tumorsPTEN-hamartoma tumor syndrome, Carney complex, Werner syndrome, and Pendred syndrome",
                    "sub_points": [
                      "Findings are similar to those familial syndromes characterized by predominance of nonthyroidal tumorsPTEN-hamartoma tumor syndrome, Carney complex, Werner syndrome, and Pendred syndrome",
                      "PTEN-hamartoma tumor syndrome, Carney complex, Werner syndrome, and Pendred syndrome"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Gorlin Syndrome": {
            "name": "Gorlin Syndrome",
            "url": "https://app.pathprimer.com/document/39f55623-ba03-4885-8353-443c0140233d/lesson/551b91f9-3977-47fe-bff2-df65caa70b2b",
            "content": {
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "Nevoid basal cell carcinoma syndrome"
                  },
                  {
                    "text": "Basal cell carcinoma nevus syndrome"
                  },
                  {
                    "text": "Gorlin-Goltz syndrome"
                  }
                ]
              },
              "Epidemiology": {
                "Age at Presentation": [
                  {
                    "text": "From birth (may not be detected until later)Bony abnormalities",
                    "sub_points": [
                      "Bony abnormalities"
                    ]
                  },
                  {
                    "text": "1st decadeJaw cysts (of mandible/maxilla)",
                    "sub_points": [
                      "Jaw cysts (of mandible/maxilla)"
                    ]
                  },
                  {
                    "text": "2nd decadePalmoplantar pitting",
                    "sub_points": [
                      "Palmoplantar pitting"
                    ]
                  },
                  {
                    "text": "Childhood but more often late puberty/adulthoodBasal cell carcinomas (sometimes resembling skin tags)",
                    "sub_points": [
                      "Basal cell carcinomas (sometimes resembling skin tags)"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "~ 1 in 19,000 births"
                  }
                ]
              },
              "Genetics": {
                "Inheritance": [
                  {
                    "text": "Autosomal dominant"
                  }
                ],
                "PTCH1Gene": [
                  {
                    "text": "Mutations in this gene found in ~ 60-75% of those tested"
                  },
                  {
                    "text": "PTCH1Located on chromosome 9qPart of sonic hedgehog pathwayPTCH1encodes patched proteinPatched protein inhibits smoothenedMutatedPTCH1leads to disinhibition of smoothened and tumor growth",
                    "sub_points": [
                      "Located on chromosome 9q",
                      "Part of sonic hedgehog pathway",
                      "PTCH1encodes patched protein",
                      "Patched protein inhibits smoothened",
                      "MutatedPTCH1leads to disinhibition of smoothened and tumor growth"
                    ]
                  },
                  {
                    "text": "No clear genotype/phenotype correlation"
                  }
                ]
              },
              "Clinical Implications and Imaging Findings": {
                "Clinical Findings": [
                  {
                    "text": "Triggers that should prompt evaluation for Gorlin syndromeKeratocystic odontogenic tumor if age < 20 years oldBasal cell carcinoma if age < 20 years oldPalmar or plantar pitsLamellar calcification of falx cerebriMedulloblastoma, desmoplastic",
                    "sub_points": [
                      "Keratocystic odontogenic tumor if age < 20 years old",
                      "Basal cell carcinoma if age < 20 years old",
                      "Palmar or plantar pits",
                      "Lamellar calcification of falx cerebri",
                      "Medulloblastoma, desmoplastic"
                    ]
                  },
                  {
                    "text": "Characteristic faciesFrontal bossingHypoplastic maxillaBroad nasal root (and hypertelorism)",
                    "sub_points": [
                      "Frontal bossing",
                      "Hypoplastic maxilla",
                      "Broad nasal root (and hypertelorism)"
                    ]
                  }
                ],
                "Imaging Findings": [
                  {
                    "text": "HeadCalcification ofFalx, tentorium cerebelli, sella turcicaJaw cystsPanorex (digital if possible)Cleft lip/palate",
                    "sub_points": [
                      "Calcification ofFalx, tentorium cerebelli, sella turcica",
                      "Falx, tentorium cerebelli, sella turcica",
                      "Jaw cystsPanorex (digital if possible)",
                      "Panorex (digital if possible)",
                      "Cleft lip/palate"
                    ]
                  },
                  {
                    "text": "TrunkRibsBifid, missing, splayedSpineScoliosis, vertebral anomalies",
                    "sub_points": [
                      "RibsBifid, missing, splayed",
                      "Bifid, missing, splayed",
                      "SpineScoliosis, vertebral anomalies",
                      "Scoliosis, vertebral anomalies"
                    ]
                  },
                  {
                    "text": "Long bonesBone cysts",
                    "sub_points": [
                      "Bone cysts"
                    ]
                  },
                  {
                    "text": "Hands/feetFlame-shaped lucencies",
                    "sub_points": [
                      "Flame-shaped lucencies"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Skin": [
                  {
                    "text": "Basal cell carcinomaMay look like skin tags in childrenOften sun-exposed skinMay be non-sun-exposed areasTypical clinical morphologyPearly, pink, telangiectatic papules or nodulesErythematous, scaly, thin macules or plaquesMay be eroded/ulceratedAll histopathologic subtypesSuperficial multicentric with buds of basaloid islands off epidermal baseNodular with islands of basaloid cells with peripheral palisading in dermisMay be pigmentedMicronodular, morpheaform, infiltrative, infundibulocystic, etc.",
                    "sub_points": [
                      "May look like skin tags in children",
                      "Often sun-exposed skin",
                      "May be non-sun-exposed areas",
                      "Typical clinical morphologyPearly, pink, telangiectatic papules or nodulesErythematous, scaly, thin macules or plaquesMay be eroded/ulcerated",
                      "Pearly, pink, telangiectatic papules or nodules",
                      "Erythematous, scaly, thin macules or plaques",
                      "May be eroded/ulcerated",
                      "All histopathologic subtypesSuperficial multicentric with buds of basaloid islands off epidermal baseNodular with islands of basaloid cells with peripheral palisading in dermisMay be pigmentedMicronodular, morpheaform, infiltrative, infundibulocystic, etc.",
                      "Superficial multicentric with buds of basaloid islands off epidermal base",
                      "Nodular with islands of basaloid cells with peripheral palisading in dermis",
                      "May be pigmented",
                      "Micronodular, morpheaform, infiltrative, infundibulocystic, etc."
                    ]
                  },
                  {
                    "text": "Palmoplantar pitsSeveral millimeters in diameterPink in colorHistopathology: Basaloid proliferation",
                    "sub_points": [
                      "Several millimeters in diameter",
                      "Pink in color",
                      "Histopathology: Basaloid proliferation"
                    ]
                  },
                  {
                    "text": "Epidermal inclusion cyst/milium"
                  }
                ],
                "Musculoskeletal": [
                  {
                    "text": "Odontogenic keratocystMay become secondarily infectedThin capsule with lining of stratified squamous epitheliumSitesMandibular molar/ramus (~ 40%)Mandibular canine/incisor (~ 20%)Maxillary molar tuberosity (~ 10%)",
                    "sub_points": [
                      "May become secondarily infected",
                      "Thin capsule with lining of stratified squamous epithelium",
                      "SitesMandibular molar/ramus (~ 40%)Mandibular canine/incisor (~ 20%)Maxillary molar tuberosity (~ 10%)",
                      "Mandibular molar/ramus (~ 40%)",
                      "Mandibular canine/incisor (~ 20%)",
                      "Maxillary molar tuberosity (~ 10%)"
                    ]
                  }
                ],
                "Central Nervous System": [
                  {
                    "text": "MedulloblastomaEspecially desmoplastic",
                    "sub_points": [
                      "Especially desmoplastic"
                    ]
                  },
                  {
                    "text": "MeningiomaMay be consequence of radiation treatment of medulloblastoma",
                    "sub_points": [
                      "May be consequence of radiation treatment of medulloblastoma"
                    ]
                  }
                ],
                "Genitourinary": [
                  {
                    "text": "Ovarian fibroma/fibrosarcoma"
                  }
                ],
                "Cardiac": [
                  {
                    "text": "Fibroma"
                  }
                ]
              },
              "Cancer Risk Management": {
                "Multidisciplinary Care": [
                  {
                    "text": "Dermatology, surgery, dental/oral medicine, orthopaedics, ophthalmology, neurology, genetics"
                  },
                  {
                    "text": "Regular skin examinations necessaryEvery 6 months to 1 year (every 4 months in adults)",
                    "sub_points": [
                      "Every 6 months to 1 year (every 4 months in adults)"
                    ]
                  },
                  {
                    "text": "MedulloblastomaBaseline MR of brain with contrast and epilepsy protocolAnnually until age 8",
                    "sub_points": [
                      "Baseline MR of brain with contrast and epilepsy protocolAnnually until age 8",
                      "Annually until age 8"
                    ]
                  },
                  {
                    "text": "Minimize ionizing radiation exposure, as it can induce basal cell carcinomasConsider MR over serial CT scans",
                    "sub_points": [
                      "Consider MR over serial CT scans"
                    ]
                  },
                  {
                    "text": "Treatments/interventions to prevent new basal cell carcinomasOral retinoidsSun avoidance/sun protection",
                    "sub_points": [
                      "Oral retinoids",
                      "Sun avoidance/sun protection"
                    ]
                  },
                  {
                    "text": "PTCH1gene testing: Not mandatory for diagnosisScenarios in which testing is recommendedPrenatal testing if known mutation within familyCases highly suspicious for Gorlin syndrome but not yet meeting criteriaPredictive testing for patients with affected family member",
                    "sub_points": [
                      "Scenarios in which testing is recommendedPrenatal testing if known mutation within familyCases highly suspicious for Gorlin syndrome but not yet meeting criteriaPredictive testing for patients with affected family member",
                      "Prenatal testing if known mutation within family",
                      "Cases highly suspicious for Gorlin syndrome but not yet meeting criteria",
                      "Predictive testing for patients with affected family member"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Early Onset Basal Cell Carcinomas (Sporadic)": [
                  {
                    "text": "Increasingly, patients < age 40 are developing basal cell carcinomaMay be linked to tanning",
                    "sub_points": [
                      "May be linked to tanning"
                    ]
                  },
                  {
                    "text": "No other stigmata of Gorlin syndrome"
                  }
                ],
                "Bazex-Dupré-Christol Syndrome": [
                  {
                    "text": "Similarities to Gorlin syndromeMultiple basal cell carcinomas (may have earlier onset than in Gorlin syndrome)Milia",
                    "sub_points": [
                      "Multiple basal cell carcinomas (may have earlier onset than in Gorlin syndrome)",
                      "Milia"
                    ]
                  },
                  {
                    "text": "Distinguishing features from Gorlin syndromeX-linked dominant inheritanceHypotrichosisFollicular atrophodermaHypohidrosis",
                    "sub_points": [
                      "X-linked dominant inheritance",
                      "Hypotrichosis",
                      "Follicular atrophoderma",
                      "Hypohidrosis"
                    ]
                  }
                ],
                "Rombo Syndrome": [
                  {
                    "text": "Reported in 1 large Swedish family"
                  },
                  {
                    "text": "Similarities to Gorlin syndromeMultiple basal cell carcinomasMilia",
                    "sub_points": [
                      "Multiple basal cell carcinomas",
                      "Milia"
                    ]
                  },
                  {
                    "text": "Distinguishing features from Gorlin syndromeMultiple trichoepitheliomasAtrophoderma vermiculataAcral cyanosis",
                    "sub_points": [
                      "Multiple trichoepitheliomas",
                      "Atrophoderma vermiculata",
                      "Acral cyanosis"
                    ]
                  }
                ],
                "Brooke-Spiegler Syndrome": [
                  {
                    "text": "Multiple facial papules, often clustered on central face (previously termed multiple trichoepitheliomas)"
                  },
                  {
                    "text": "Papulonodules may predominate on scalp (previously termed cylindromatosis)"
                  },
                  {
                    "text": "HistopathologyTrichoepithelioma (not basal cell carcinomas)Basaloid islands, often with advanced follicular differentiation (e.g., horn cysts)Peripheral palisadingClefts between fibrotic stroma and unaffected dermisCylindromaJigsaw puzzle arrangement of islands with ductal differentiation surrounded by thickened basement membraneSpiradenomaBlue islands in dermis with alternating pattern of light and dark cells",
                    "sub_points": [
                      "Trichoepithelioma (not basal cell carcinomas)Basaloid islands, often with advanced follicular differentiation (e.g., horn cysts)Peripheral palisadingClefts between fibrotic stroma and unaffected dermis",
                      "Basaloid islands, often with advanced follicular differentiation (e.g., horn cysts)",
                      "Peripheral palisading",
                      "Clefts between fibrotic stroma and unaffected dermis",
                      "CylindromaJigsaw puzzle arrangement of islands with ductal differentiation surrounded by thickened basement membrane",
                      "Jigsaw puzzle arrangement of islands with ductal differentiation surrounded by thickened basement membrane",
                      "SpiradenomaBlue islands in dermis with alternating pattern of light and dark cells",
                      "Blue islands in dermis with alternating pattern of light and dark cells"
                    ]
                  }
                ],
                "Familial Multiple Basaloid Follicular Hamartomas": [
                  {
                    "text": "Multiple facial papules"
                  },
                  {
                    "text": "Presenting in childhood"
                  },
                  {
                    "text": "HistopathologyBasaloid follicular hamartoma (not basal cell carcinoma)Interconnecting cells with squamoid appearance with interspersed horn cysts, mucinous stromaCK20(+) cells present",
                    "sub_points": [
                      "Basaloid follicular hamartoma (not basal cell carcinoma)Interconnecting cells with squamoid appearance with interspersed horn cysts, mucinous stromaCK20(+) cells present",
                      "Interconnecting cells with squamoid appearance with interspersed horn cysts, mucinous stroma",
                      "CK20(+) cells present"
                    ]
                  }
                ],
                "Generalized Basaloid Follicular Hamartoma Syndrome": [
                  {
                    "text": "Reported in 1 large North Carolina family"
                  },
                  {
                    "text": "Similarities to Gorlin syndromePalmoplantar pitting",
                    "sub_points": [
                      "Palmoplantar pitting"
                    ]
                  },
                  {
                    "text": "Distinguishing features from Gorlin syndromeNo basal cell carcinomasNo jaw cystsMultiple basaloid follicular hamartomasDepicted in this syndrome as buds of basaloid islands arranged around 1 follicle or small cystic structure",
                    "sub_points": [
                      "No basal cell carcinomas",
                      "No jaw cysts",
                      "Multiple basaloid follicular hamartomasDepicted in this syndrome as buds of basaloid islands arranged around 1 follicle or small cystic structure",
                      "Depicted in this syndrome as buds of basaloid islands arranged around 1 follicle or small cystic structure"
                    ]
                  }
                ],
                "Hereditary Infundibulocystic Basal Cell Carcinoma": [
                  {
                    "text": "Distinguishing features from Gorlin syndromeMultiple small papules on central faceAbsence of palmar pitsNo jaw cystsHistopathology shows infundibulocystic basal cell carcinomaSquamoid, ramifying appearance superficially, often with more typical nodular basal cell carcinoma at base",
                    "sub_points": [
                      "Multiple small papules on central face",
                      "Absence of palmar pits",
                      "No jaw cysts",
                      "Histopathology shows infundibulocystic basal cell carcinomaSquamoid, ramifying appearance superficially, often with more typical nodular basal cell carcinoma at base",
                      "Squamoid, ramifying appearance superficially, often with more typical nodular basal cell carcinoma at base"
                    ]
                  }
                ],
                "Other Syndromes With Basal Cell Carcinoma": [
                  {
                    "text": "Defective DNA repair syndromes (e.g., xeroderma pigmentosum)"
                  }
                ]
              },
              "Criteria for Diagnosis": {
                "Major Criteria": [
                  {
                    "text": "Basal cell carcinoma1 if patient < 20 years of age2 or more if patient > 20 years of age",
                    "sub_points": [
                      "1 if patient < 20 years of age",
                      "2 or more if patient > 20 years of age"
                    ]
                  },
                  {
                    "text": "Palmoplantar pitting3 or more",
                    "sub_points": [
                      "3 or more"
                    ]
                  },
                  {
                    "text": "Odontogenic keratocystPatient age: < 20 years",
                    "sub_points": [
                      "Patient age: < 20 years"
                    ]
                  },
                  {
                    "text": "Calcification of falx cerebriSometimes the tentorium cerebelli or sella turcicaPatient age: < 20 years",
                    "sub_points": [
                      "Sometimes the tentorium cerebelli or sella turcica",
                      "Patient age: < 20 years"
                    ]
                  },
                  {
                    "text": "Family history of Gorlin syndrome"
                  },
                  {
                    "text": "Medulloblastoma (primitive neuroectodermal tumor)Patient age: ≤ 2 years",
                    "sub_points": [
                      "Patient age: ≤ 2 years"
                    ]
                  }
                ],
                "Minor Criteria": [
                  {
                    "text": "TumorsCardiac fibromaOvarian fibromaLymphomesenteric cysts",
                    "sub_points": [
                      "Cardiac fibroma",
                      "Ovarian fibroma",
                      "Lymphomesenteric cysts"
                    ]
                  },
                  {
                    "text": "Skeletal/developmental abnormalitiesBifid/fused/splayed/missing ribBifid/wedged/fused vertebra, kyphoscoliosisShort 4th metacarpal, postaxial polydactylyMacrocephalyCleft lip/palate",
                    "sub_points": [
                      "Bifid/fused/splayed/missing rib",
                      "Bifid/wedged/fused vertebra, kyphoscoliosis",
                      "Short 4th metacarpal, postaxial polydactyly",
                      "Macrocephaly",
                      "Cleft lip/palate"
                    ]
                  },
                  {
                    "text": "Ocular abnormalitiesStrabismusCongenital cataractHypertelorismGlaucomaColoboma",
                    "sub_points": [
                      "Strabismus",
                      "Congenital cataract",
                      "Hypertelorism",
                      "Glaucoma",
                      "Coloboma"
                    ]
                  }
                ],
                "Number of Criteria Needed": [
                  {
                    "text": "2 major,or"
                  },
                  {
                    "text": "1 major and 2 minor,or"
                  },
                  {
                    "text": "1 major and molecular confirmation"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      }
    }
  }
}